Therapeutic compounds and related methods of use

ABSTRACT

Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are de-scribed herein. Exemplary disorders include schizophrenia and cognitive deficit.

RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application Ser. Nos. 61/291,544, entitled “Therapeutic Compounds and Related Methods of Use” filed on Dec. 31, 2009; 61/291,550, entitled “Therapeutic Compounds and Related Methods of Use” filed on Dec. 31, 2009; and 61/291,554, entitled “Therapeutic Compounds and Related Methods of Use” filed on Dec. 31, 2009, all of which are herein incorporated by reference in their entireties.

BACKGROUND OF INVENTION

Tyrosine phosphorylation of synaptic receptors and signaling molecules regulates synaptic activity. A number of protein tyrosine phosphatases specifically expressed within the brain have been identified, including STEP (for STriatal-Enriched tyrosine Phosphatase, also known as PTPN5). Recent evidence suggests that STEP plays an important role in synaptic plasticity, for review see (Braithwaite S P. et al., (2006), Trends Neurosci, 29 (8): 452; Baum M L, et al., (2010), Commun Integr Biol, 3 (5): 419) STEP is specifically expressed within neurons of the central nervous system. As its name indicates, the highest expression level is within the striatum. However, more recent work has found that it is expressed at lower levels in multiple brain regions including the neocortex, amygdala, hippocampus, and embryonic spinal cord.

Four groups of proteins that STEP regulates have been identified: the mitogen-activated protein kinases (MAPKs), the tyrosine kinase Fyn, the N-methyl-D-aspartate (NMDA) receptor complex (specifically the NR2B subunit) and AMPA receptors (specifically, GluR2, (Zhang Y, et al., (2008), J Neurosci, 28 (42): 10561)). Three additional new substrates for STEP have also been recently discovered; proline-rich tyrosine kinase 2 (Pyk2; Xu J, et al., (2010), Abstracts of the Society for Neuroscience Meetings), the fragile X mental retardation protein (FMRP) (Goebel-Goody S M, et al., (2010), Abstracts of the Society for Neuroscience Meetings) and the cell-death mediator Bak (Fox J L, et al., (2010), EMBO J, 29 (22): 3853). Tyrosine phosphorylation of one member of the MAPK family, the extracellular signal regulated kinase (ERK), is necessary for the expression and maintenance of synaptic plasticity in many brain regions, and disruption of the ERK pathway leads to a disruption of learning and memory. One of the functions of these src and Pyk2 kinases is to phosphorylate NMDA receptors, thereby modulating their channel conductance properties and facilitating their movement toward the surface of neuronal plasma membranes, Pyk2 and Fyn tyrosine kinases are activated by phosphorylation on tyrosine residues. NR2B phosphorylation on Tyrosine 1452 inhibits the receptor endocytosis. STEP acts as direct or indirect brake of NMDAR mediated signaling by either respectively dephosphorylating NR2B or its associated kinases, Pyk2 and Fyn. Activation of AMPA, NMDA receptors and MAPKs are required for the induction of several forms of long-term potentiation (LTP) and long-term depression (LTD). Hippocampal LTP is increased in transgenic mice model of Alzheimer lacking STEP (Zhang Y, et al., (2010), Proc Natl Acad Sci USA, 107 (44): 19014). NR2B and AMPA receptor surface expression is increased in STEP KO mice. AMPA receptor endocytosis in group I metabotropic glutamate receptor I (mGluR) mediated LTD is mediated by a tyrosine phosphatase. AMPA receptor endocytosis induced by activation of group I mGLuR is blocked in STEP KO mice suggesting that STEP might also control mGluR mediated LTD.

Compounds that inhibit STEP activity should mimic the effects observed with the STEP KO and may be useful for treating conditions mediated by abnormal NMDA-receptor (NMDA-Rs) and/or MAP kinase pathway signaling. Both may mediate cognition, learning and memory, neurogenesis, and may also affect neuronal plasticity, pain perception, mood and anxiety, and neuroendocrine regulation.

Modulation of NMDA-Rs:

STEP decreases the tyrosine phosphorylation level of NMDA-Rs. Less phosphorylated NMDA-Rs have lower conductance states and thus will allow less current and fewer ions to pass. The NMDA-Rs will therefore be functionally less active (Alvestad K M, et al., (2003), J Biol Chem, 278 (13): 11020), which can lead to schizophrenic symptoms. Hypofunction of NMDA-Rs has been liked to schizophrenia. For example, phencyclidine, ketamine, and other noncompetitive antagonists at NMDA-type glutamate receptors can exacerbate symptoms in patients (Lahti A C, et al., (1995), Neuropsychopharmacology, 13 (1): 9) and may produce a range of psychotic symptoms in volunteers that are similar to those of schizophrenic patients. NMDA-R hypofunction is also linked to psychosis and drug addiction (Javitt D C and Zukin S R, (1991), Am J Psychiatry, 148 (10): 1301). Chronic treatment of atypical antipsychotic clozapine and risperidone in mice result in significant increase of phosphorylation of ERK, NR2B and Pyk2 on tyrosine residues recognized by STEP (Carry N C, et al., (2010), Abstracts of the Society for Neuroscience Meetings). Treatment of these anti-psychotics also enhances cAMP and STEP phosphorylation. Since PKA mediated phosphorylation of STEP is know to inactivate STEP, these results suggest that STEP inhibition mediates the beneficial effect of antipsychotic drugs. Recent studies have linked abnormal NMDA-R activity and expression of STEP to the cognitive decline observed in Alzheimer's disease or transgenic mice expressing mutant APP (Tg2576 mice) (Snyder E M, et al., (2005), Nat Neurosci, 8 (8): 1051; Hynd M R, et al., (2004), J Neurochem, 90 (4): 913; Kurup P, et al., (2010), Channels (Austin), 4 (5)). More specifically, STEP KO mice are less susceptible to PCP-induced hyperlocomotion and PCP-induced cognitive deficits in the object recognition tasks (Carty N C, et al., (2010), Abstracts of the Society for Neuroscience Meetings). Compared to the Tg2576 mice expressing STEP, Tg2576 lacking STEP gene showed rescue in their deficits in hyppocampal LTP and in different behavioral cognitive tasks. Altogether, these results suggest that STEP inhibitors might represent a novel class of drugs that can treat both positive symptoms and cognitive deficit associated with schizophrenia.

Medications that modulate glutamatergic neurotransmission via NMDA-Rs may be also effective in treatment for mood and anxiety disorders. Administration of NMDA-R antagonists has anxiolytic effects in rodent models of anxiety (Falls W A, et al., (1992), J Neurosci, 12 (3): 854; Miserendino M J, et al., (1990), Nature, 345 (6277): 716). NMDA-Rs antagonist like ketamine has been shown to be effective in drug-resistant unipolar depression (Machado-Vieira R, et al., (2009), Pharmacol Ther, 123 (2): 143).

Abnormal balance between the activity of NMDA receptors at synaptic (prosurvival linked to ERK activation) and extrasynaptic (proapoptotic linked to p38 activation) sites has been proposed in cellular and mouse model of Huntington Disease (HD) (Milnerwood A J, et al., Neuron, 65 (2): 178). YAC128 mouse model (containing high number of glutanmine repeat on huntingtin) of HD showed an increased activity of extrasynaptic NMDA receptors (NR2B subunit) and require p38 and caspase-6 cleavage activation. In YAC128 mice, NR2B synaptic expression is associated with high STEP expression and activity and a reduction in NR2B expression and phosphorylation (Gladding C M, et al., (2010), Abstracts of the Society for Neuroscience Meetings). Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP and activation of p38 (Xu J, et al., (2009), J Neurosci, 29 (29): 9330). Inhibiting STEP activity might therefore shift the balance toward the NMDA receptor/ERK synaptic prosurvival signaling pathway.

Modulation of ERK Pathway:

STEP inhibition may translate into activation of ERK1/2 kinases, for example, in the central nervous system (CNS). Activation of the ERK pathway in the CNS can mediate neurotrophic pathways involved in cellular resilience. ERK signaling directly affects Bak phosphorylation through inhibition of STEP to promote cell survival (Fox J L, et al., (2010), EMBO J, 29 (22): 3853). BDNF and other neurotrophins can block apoptosis and increase cell survival of different type of CNS neurons in vitro and in vivo via stimulation of the ERK pathway. Mood stabilizers effective in bipolar disorder like valproate and lithium may be potent activators of ERK activity. This effect on ERK activation is believed to be responsible for the neurotrophic effects of mood stabilizers observed in vitro or in brains of treated patients with bipolar disorder, for review see (Engel S R, et al., (2009), Mol Psychiatry, 14 (4): 448; Chen G and Manji H K, (2006), Curr Opin Psychiatry, 19 (3): 313; Machado-Vieira R, et al., (2009), Bipolar Disord, 11 Suppl 2 92). In vivo disruption of STEP activity was shown to activate MAPK pathway, leading to significant rescue from neuronal cell death after pilocarpine-induced status epilepticus (Choi Y S, et al., (2007), J Neurosci, 27 (11): 2999). Increasing cellular resilience could therefore limit or reduce neuronal loss in several neurologic disorders. Recent work has suggested a positive role for STEP inhibition in fragile X syndrome (FXS). This disorder results from the mutation of fmr1 gene coding for the fragile X mental retardation protein (FMRP). STEP binds to FMRP and its expression is dysregulated in FXS. FMR KO mice model displayed audiogenic seizures. FMR KO mice lacking STEP gene show a significant reduction of these seizures (Goebel-Goody S M, et al., (2010), Abstracts of the Society for Neuroscience Meetings), suggesting that STEP modulators might be therapeutic approach for FXS.

Various substituted heterocyclic compounds are disclosed in the art. For example, WO 02/062767 discloses quinazoline derivatives; WO 03/000188 discloses quinazolines and uses thereof; WO 2005/042501 discloses norepinephrine reuptake inhibitors for the treatment of central nervous system disorders; WO2006/058201 discloses heterocyclic and bicyclic compounds, compositions and methods; WO 2007/104560 discloses substituted 4-amino-quinazoline derivatives as regulators of metabotropic glutamate receptors and their use for producing drugs; WO 2007/133773 discloses CDKI pathway inhibitors; WO 2008/009078 discloses 4,6-DL- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections; WO 2009/000085 discloses quinoline and quinazoline derivatives useful as modulators of gated ion channels; US 2009/0143399 discloses protein kinase inhibitors; and Japan Publication Number 2007-084494A discloses substituted bicyclic compounds.

SUMMARY OF INVENTION

Described herein are compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat a disorder, e.g., schizophrenia or cognitive deficit, in a subject. The compounds disclosed herein include quinoline- and quinazoline-containing compounds that modulate (e.g., inhibit) the activity of STEP.

The present invention provides therapeutic compounds, pharmaceutical composition comprising said compounds, use of said compounds and method for treating or preventing a disorder as described in items 1 to 42 below.

-   Item 1. A compound of formula (I):

or a salt thereof,

wherein:

A is CR⁴ or N;

B is aryl, cyclyl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3, 4 or 5;

E is aryl or a 5-membered heteroaryl;

n is 0, 1, 2, 3 or 4;

when E is aryl, n is 0, 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3;

L is NR⁵, S, O or a direct bond;

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, silylalkoxy, silylalkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(c) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and one R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(c) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(c) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁹;

each R⁹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a)—C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(c) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2 and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy or silylalkoxyalkyl;

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; and

when B is phenyl, R² is not

a compound of formula (II):

or a salt thereof,

wherein:

L is CR⁴R⁵, O, C(O), NR⁶C(O) or NR⁷;

A is N;

each X¹, X², X³, X and X⁵ is independently CH or N, provided that at least two of X¹, X², X³, X⁴ and X⁵ are N;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2 or 3;

R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₅ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl or heterocyclylalkyl, each of which is optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ is optionally taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached, to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each of which is optionally substituted with 1-3 R¹¹;

each R⁴, R⁵, R⁶ and R⁷ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;

wherein, two R⁹, two R¹⁰ or two R¹¹ is optionally taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R¹² is —OR^(d);

Y is O or S;

q is 1 or 2 and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl and a compound of formula (III):

or a salt thereof,

wherein:

A is CH or N;

L is O, a direct bond or NR⁶;

one of X¹, X², X³, X⁴ and X⁵ is N and the others are CH;

m is 1, or 3;

n is 1, 2, 3 or 4;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, heteroaryl, heteroarylalkyl, arylalkyl, —C(Y)R^(e), cyclyl, cyclylalkyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷;

R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰;

R⁶ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R¹¹;

each R⁷, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₁-C₈ alkynyl, aryl, hetero aryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷, two R⁹ or two R¹⁰ are optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R¹¹ and R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, haloalkyl, halo, heterocyclyl, cyclyl, oxo or —C(Y)NR^(b)R^(b′);

Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, haloalkyl alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl;

with proviso R⁹ is not

-   Item 2. The compound according to item 1 represented by general     formula (I) or a salt thereof,

wherein:

A is CR⁴ or N:

B is aryl, cyclyl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3, 4 or 5;

n is 0, 1, 2, 3 or 4;

E is aryl or a 5-membered heteroaryl;

when E is aryl, n is 0, 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3;

L is NR⁵, S, O or a direct bond:

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, silylalkoxy, silylalkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and one R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —C(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁹;

each R⁹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy or silylalkoxyalkyl;

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; and

when B is phenyl, R² is not

-   Item 3. The compound according to item 2 represented by general     formula (I) or a salt thereof,

wherein:

A is CH or N;

B is aryl, cyclyl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3 or 4;

E is aryl or a 5-membered heteroaryl;

n is 0, 1 or 2;

when E is aryl, n is 0, 1 or 2 and when E is a 5-membered heteroaryl, n is 0 or 1;

p is 0, 1 or 2;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), C(Y)R^(c) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R⁶ is independently C₁-C₈ alkyl, heterocyclyl, heterocyclylalkyl, hydroxyalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R, —NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁷;

each R⁷ is oxo; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, haloalkyl, dialkylaminoalkyl, hydroxyalkyl or alkoxyalkyl.

-   Item 4. The compound according to item 3 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroquinoxalinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, quinolyl, isoquinolinyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, dihydroisobenzofuranyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, dihydrocyclopentathiophenyl, tetrahydrobenzothiophenyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyrrolyl or pyridyl;

E is phenyl, thienyl or pyrrolyl;

when E is phenyl, n is 1 or 2; and when E is thienyl, n is 0 or 1;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyrrolyl, oxadiazolyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, oxazolyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidyl, pyrrolidinyl, morpholinyl, dioxolanyl, phenylalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperidylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, oxo, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

each R⁶ is independently C₁-C₈ alkyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, morpholinylalkyl, dialkylaminoalkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —NR^(c)C(Y)R^(c′), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), alkoxyalkyl, —OR^(d) or —C(Y)R^(e); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₅ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, pyridyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, furylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, thiazolylalkyl, pyrazolylalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolylalkyl, dihydrobenzodioxinylalkyl, benzothienylalkyl, C₃-C₈ cycloalkylalkyl, oxazolidinylalkyl, haloalkyl or alkoxyalkyl.

-   Item 5. The compound according to item 3 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroquinoxalinyl, tetrahydroisoquinolyl, tetrahydroquinolinyl, dihydroquinolyl, quinolyl, isoquinolyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, dihydroisobenzofuranyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, dihydrocyclopentathiophenyl, tetrahydrobenzothienyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyrrolyl or pyridyl;

E is phenyl, thienyl or pyrrolyl;

when E is phenyl, n is 0, 1 or 2; and when E is thienyl, n is 0 or 1;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidyl, pyrrolidinyl, morpholinyl, dioxolanyl, phenylalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperidylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, oxo, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —OC(O)NR^(b)R^(b′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

each R⁶ is independently C₁-C₈ alkyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, morpholinylalkyl, dialkylaminoalkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —NR^(c)C(Y)R^(c′), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), alkoxyalkyl, —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁷;

R⁷ is oxo; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, pyridyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, furylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, thiazolylalkyl, pyrazolylalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolilalkyl, dihydrobenzodioxiyalkyl, benznylalkyl, benzothienylalkyl, C₃-C₈ cycloalkylalkyl, oxazolidinylalkyl, haloalkyl, or alkoxyalkyl.

-   Item 6. The compound according to item 5 represented by general     formula (I) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl, thienyl, pyrrolyl, oxazolyl, C₃-C₈ cycloalkyl, dioxolanyl, phenylalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

R² is C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, pyrrolidinyl, morpholinyl thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperiridylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁶;

R³ is C₁-C₈ alkyl, halo, haloalkyl, —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R⁶.

-   Item 7. The compound according to item 4 or 6 represented by general     formula (I) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl, thienyl, pyrrolyl, oxazolyl, C₃-C₈ cycloalkyl, dioxolanyl, phenylalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

R² is C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperiridinylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —OR^(d), —C(Y)R^(e) or —S(O)_(q)R^(f);

R³ is C₁-C₈ alkyl, halo, haloalkyl, —NR^(b)R^(b′) or —OR^(d).

-   Item 8. The compound according to item 7 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroisoquinolyl, tetrahydroquinolinyl, dihydroquinolyl, quinolyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, tetrahydrobenzothienyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, thiadiazolyl or pyridyl:

m is 1, 2, 3 or 4;

R¹ is C₁-C₈ alkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), or —S(O)_(q)R^(f);

R² is C₁-C₈ alkyl, C₃-C₈ cycloalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₁-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolilalkyl, dihydrobenzodioxinylalkyl, C₃-C₈ cycloalkylalkyl, haloalkyl or alkoxyalkyl.

-   Item 9. The compound according to item 1 represented by general     formula (II) or a salt thereof,

wherein:

L is CR⁴R⁵, O, C(O), NR⁶C(O) or NR⁷;

A is N;

each X¹, X², X³, X⁴ and X⁵ is independently CH or N, provided that at least two of X¹, X², X³, X⁴, and X⁵ are N;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2 or 3;

R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl or heterocyclylalkyl, each of which is optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ is optionally taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹¹;

each R⁴, R⁵, R⁶ and R⁷ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁸, two R⁹, two R¹⁰ or two R¹¹ is optionally taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R¹² is —OR^(d);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen,

C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl, or heteroarylalkyl.

-   Item 10. The compound according to item 9 represented by general     formula (II) or a salt thereof,

L is NR⁷;

n is 0, 1 or 2;

p is 0;

R¹ is C₁-C₈ alkyl, aryl or heteroaryl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, aryl, halo, heterocyclylalkyl, —NR^(c)C(Y)R^(c), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

R⁷ is hydrogen; and

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, heterocyclyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(c);

Y is O;

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, cyclyl, heterocyclyl, aryl, or heteroaryl.

-   Item 11. The compound according to item 10 represented by general     formula (II) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl or benzodioxolyl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(C), —NR^(b)R^(b′) or —OR^(d);

R⁹ is independently C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(c); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, tetrahydropyranyl, phenyl, or pyridyl.

-   Item 12. The compound according to item 10 represented by general     formula (II) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl or benzodioxolyl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, tetrahydropyranyl, phenyl, or pyridyl.

-   Item 13. The compound according to item 12 represented by general     formula (II) or a salt thereof, wherein:

R² is C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

R³ is hydrogen;

R⁹ is halo, haloalkoxy, —CN, —C(O)OR^(a) or —C(Y)NR^(b)R^(b′); and

R¹¹ is C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, —CN, —OR^(d) or —C(Y)R^(e);

-   Item 14. The compound according to idem 11 or 13 represented by     general formula (II) or a salt thereof, wherein:

R² is C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d);

R³ is hydrogen; and

R⁹ is halo, haloalkoxy, —CN, —C(O)OR^(a) or —C(Y)NR^(b)R^(b′).

-   Item 15. The compound according to item 1 represented by general     formula (III) or a salt thereof,

wherein:

A is CH or N;

L is O, a direct bond or NH;

one of X¹, X², X³, X⁴ and X⁵ is N and the others are CH;

m is 1, or 3:

n is 1, 2, 3 or 4;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, heteroaryl, heteroarylalkyl, arylalkyl, —C(Y)R^(e), cyclyl, cyclylalkyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷;

R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d), —C(Y)R^(c) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰;

each R⁷, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷ or two R⁹ are optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, haloalkyl, halo, heterocyclyl, cyclyl, oxo or —C(Y)NR^(b)R^(b′);

Y is or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, haloalkyl, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl.

-   Item 16. The compound according to item 15 represented by general     formula (III) or a salt thereof,

wherein:

m is 1;

n is 1;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, heteroaryl, heterocyclyl, arylalkyl, cyclylalkyl, heteroarylalkyl, alkoxyalkyl, hydroxyalkyl or —C(O)R^(e), each of which is optionally substituted with 1-3 R⁷;

R² is aryl, heteroaryl or benzofuryl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d);

R⁶ is hydrogen or C₁-C₈ alkyl;

each R⁷ and R⁹ is independently C₁-C₈ alkyl, aryl, heteroaryl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —N, —NO, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;

R¹² is independently C₁-C₈ alkyl, oxo, halo, haloalkyl, —CN, —C(O)NR^(b)R^(b′) or —C(O)R^(e) each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, halo or heterocyclyl; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, cyclyl, heterocyclyl, arylalkyl, alkoxyalkyl, heterocyclylalkyl, heteroarylalkyl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 17. The compound according to Item 16 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, thiazolidinyl isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, naphthyl, benzofuryl, indazolyl, benzothienyl, pyridyl, pyrimidinyl, dihydrobenzodioxinyl, benzodioxolyl, benzoimidazolyl, isoxazolyl, pyrazolyl, indolinyl or benzoisoxazolyl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d):

R⁶ is hydrogen or C₁-C₈ alkyl;

each R⁷ and R⁹ is independently C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 18. The compound according to item 16 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, furylalkyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, thiazolidinyl, isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, naphthyl, benzofuryl, indazolyl, benzothienyl, pyridyl, pyrimidinyl, dihydrobenzodioxinyl, benzodioxolyl, benzoimidazolyl, isoxazolyl, pyrazolyl, indolinyl or benzisoxazolyl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d);

R⁶ is hydrogen or C₁-C₈ alkyl;

each R⁷ and R⁹ is independently C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;

R¹² is independently C₁-C₈ alkyl, oxo, halo, haloalkyl, —CN, —C(O)NR^(b)R^(b′) or —C(O)R^(e), each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, halo or pyrrolidinyl; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 19. The compound according to idem 18 represented by general     formula (III) or a salt thereof,

wherein:

A is N;

R³ is hydrogen, C₁-C₈ alkyl, halo, haloalkyl, or —OR^(d);

R⁴ is hydrogen, C₁-C₈ alkyl, halo, or —OR^(d);

R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d) each of which is optionally substituted with 1-3 R¹²;

R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, tetrahydrofurylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 20. The compound according to item 17 or 19 represented by     general formula (III) or a salt thereof,

wherein:

A is N;

R³ is hydrogen, C₁-C₈ alkyl, halo, haloalkyl, or —OR^(d);

R⁴ is hydrogen, C₁-C₈ alkyl, halo, or —OR^(d);

R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d);

R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, dihydrobenzoxazinylalkyl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 21. The compound according to item 20 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, furylalkyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, which is optionally substituted with 1-5 R⁹; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, pyrrolidinyl, morpholinyl, tetrahydropyranyl, alkoxyalkyl, morpholinylalkyl, tetrahydropyranylalkyl, pyridylalkyl, thiazolylalkyl, pyrrolylalkyl, tetrahydrofuryl, alkylaminoalkyl or phenyl.

-   Item 22. A pharmaceutical composition comprising the compound     according to any one of items 1 to 21 or a salt thereof as an active     ingredient and a pharmaceutically acceptable carrier. -   Item 23. The pharmaceutical composition according to item 2 for     preventing or treating central nervous system diseases. -   Item 24. The pharmaceutical composition according to item 23 for     treating or preventing central nervous system disorders selected     from the group consisting of schizophrenia; refractory, intractable     or chronic schizophrenia; emotional disturbance; psychotic disorder;     mood disorder; bipolar I type disorder; bipolar II type disorder;     depression; endogenous depression; major depression; melancholy and     refractory depression; dysthymic disorder; cyclothymic disorder;     panic attack; panic disorder; agoraphobia; social phobia;     obsessive-compulsive disorder; post-traumatic stress disorder;     generalized anxiety disorder; acute stress disorder; hysteria;     somatization disorder; conversion disorder; pain disorder;     hypochondriasis; factitious disorder; dissociative disorder; sexual     dysfunction; sexual desire disorder; sexual arousal disorder;     erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep     disorder; adjustment disorder; alcohol abuse; alcohol intoxication;     drug addiction; stimulant intoxication; narcotism; anhedonia;     iatrogenic anhedonia; anhedonia of a psychic or mental cause;     anhedonia associated with depression; anhedonia associated with     schizophrenia; delirium; cognitive impairment; cognitive impairment     associated with Alzheimer's disease, Parkinson's disease and other     neurodegenerative diseases; cognitive impairment caused by     Alzheimer's disease; Parkinson's disease and associated     neurodegenerative diseases; cognitive impairment of schizophrenia;     cognitive impairment caused by refractory, intractable or chronic     schizophrenia; vomiting; motion sickness: obesity; migraine; pain     (ache); mental retardation; autism disorder (autism); Tourette's     disorder; tic disorder; attention-deficit/hyperactivity disorder;     conduct disorder; and Down's syndrome. -   Item 25. A process for producing a pharmaceutical composition     comprising mixing a compound of the formula (I), (II), or (III) or a     salt thereof according to any one of items 1 to 21 with a     pharmaceutically acceptable carrier. -   Item 26. Use of a compound of the formula (I), (II) or (III) or a     salt thereof according to any one of items 1 to 21 as a drug. -   Item 27. Use of the compound according to any one of items 1 to 21     represented by general formula (I), (II) or (III) or a salt thereof     as a STEP inhibitor. -   Item 28. A method of treating a disorder that would benefit by the     modulation of STEP (e.g., by activation of inhibition of STEP) in a     subject, the method comprising administering to a compound of     formula (I), (II) or (III) or a salt thereof according to any one of     items 1 to 21. -   Item 29. The method of item 28, wherein the disorder is     schizophrenia. -   Item 30. The method of item 28, wherein the disorder is cognitive     deficit. -   Item 31. The method of item 28, wherein the compound of formula (I),     (II), or (III) is administered in combination with an additional     therapeutic agent. -   Item 32. The method of item 28, wherein the additional therapeutic     agent is an atypical antipsychotic. -   Item 33. The method of item 28, wherein the additional therapeutic     agent is selected from the group consisting of aripiprazole,     clozapine, ziprasidone, risperidone, quetiapine, olanzapine,     amisulpride, asenapine, iloperidone, melperone, paliperidone,     perospirone, sertindole and sulpiride. -   Item 34. The method of item 28, wherein the additional therapeutic     agent is a typical antipsychotic. -   Item 35. The method of item 28, wherein the additional therapeutic     agent is selected from the group consisting of haloperidol,     molindone, loxapine, thioridazine, molindone, thiothixene, pimozide,     fluphenazine, trifluoperazine, mesoridazine, chlorprothixene,     chlorpromazine, perphenazine, triflupromazine and zuclopenthixol. -   Item 36. A kit comprising a composition comprising a compound of     formula (I), (II), or (III) or a salt thereof according to any one     of items 1 to 21 and an acceptable carrier, -   Item 37. A kit comprising a pharmaceutical composition comprising a     compound of formula (I), (II), or (III) or a salt thereof according     to any one of items 1 to 21 and a pharmaceutically acceptable     carrier. -   Item 38. A compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5- or 6-membered heteroaryl:

m is 0, 1, 2, 3, 4 or 5:

E is aryl or a 5-membered heteroaryl;

when E is aryl, n is 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3;

L is NR⁵ or O;

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when in is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₁-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(a), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(d), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶, wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring;

or a pharmaceutically acceptable derivative or prodrug thereof,

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring;

when B is phenyl, R² is not

and where in the compound is not:

-   Item 39. A compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5-membered heteroaryl;

E is aryl or a 5-membered heteroaryl;

L is NR⁵ or O;

one of X and Z is N and the other is CH;

m is 0, 1, 2, 3, 4 or 5;

n is 1, 2, 3 or 4;

p is, 1, 2, 3 or 4;

each R¹ and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, or aryl ring;

each R² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the carbons to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR, —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₁-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)(C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally further substituted with 1-3 R⁶, wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring;

wherein when 13 is phenyl, two R¹ are not taken together to form a pyrazole ring; and

when B is phenyl, R² is not

-   Item 40. A compound of formula (V):

wherein:

L is CR⁴R⁵, O, C(O), NR⁶C(O), or NR⁷;

A is CR⁸, CH or N;

each X¹, X², X³, X⁴ and X⁵ is independently CH or N, provided that at least two of X¹, X², X², X⁴ and X⁵ are N:

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2 or 3;

R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl or heterocyclylalkyl, each of which may be optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ may optionally be taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached, to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰;

each R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each of which is optionally substituted with 1-3 R¹¹;

each R⁴, R⁵, R⁶ and R⁷ is independently H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R⁸, R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally further substituted; wherein two R⁸, two R⁹, two R¹⁰ or two R¹¹ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁸,

or a pharmaceutically acceptable derivative or prodrug thereof.

-   Item 41. A compound of formula (VI):

wherein:

A is CR⁵, CH or N;

L is O or NR⁶;

1, 2 or 3 of X¹, X², X³, X⁴ and X⁵ are N and the others are CH;

m is 0, 1, 2 or 3;

n is 0, 1, 2, 3 or 4;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷; or when L is NR⁶, R¹ or R⁷ may be taken together with R⁶ and the atoms to which they are attached to form a heterocyclyl or heteroaryl ring that is optionally substituted with 1-3 R⁸;

R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹;

each R³, R⁴ and R⁵ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclyalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰;

R⁶ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R¹¹;

each R⁷, R⁸, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷, two R⁸, two R⁹ or two R¹⁰ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R¹¹ and R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′, —NR) ^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁷;

or a pharmaceutically acceptable derivative or prodrug thereof,

wherein when R¹ is cyclopropyl, R⁹ is not:

-   Item 42. A compound of formula (VI):

wherein:

A is CR⁵, CH or N;

L is O or NR⁶;

1, 2 or 3 of X¹, X², X³, X⁴ and X⁵ are N and the others are CH;

m is 0, 1, 2 or 3;

n is 0, 1, 2, 3 or 4;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷; or when L is NR⁶, R¹ or R⁷ may be taken together with R⁶ and the atoms to which they are attached to form a heterocyclyl or heteroaryl ring that is optionally substituted with 1-3 R⁸;

R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹;

each R³, R⁴ and R¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹¹;

R⁶ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R¹¹;

each R⁷, R⁸, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷, two R⁸, two R⁹ or two R¹⁰ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R¹¹ and R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁷;

wherein R⁹ is not:

Compounds of Formula (I)

The following aspects and embodiments relate to compounds of formula (I).

-   Item 2. The compound according to item 1 represented by general     formula (I) or a salt thereof,

wherein:

A is CR⁴ or N;

B is aryl, cyclyl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3, 4 or 5;

n is 0, 1, 2, 3 or 4;

E is aryl or a 5-membered heteroaryl;

when E is aryl, n is 0, 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3;

L is NR⁵, S, O or a direct bond;

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, silylalkoxy, silylalkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and one R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁹;

each R⁹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy or silylalkoxyalkyl;

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; and

when B is phenyl, R² is not

-   Item 3. The compound according to item 2 represented by general     formula (I) or a salt thereof,

wherein:

A is CH or N;

B is aryl, cyclyl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3 or 4;

E is aryl or a 5-membered heteroaryl;

n is 0, 1 or 2;

when E is aryl, n is 0, 1 or 2 and when E is a 5-membered heteroaryl, n is 0 or 1;

p is 0, 1 or 2;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R⁶ is independently C₁-C₈ alkyl, heterocyclyl, heterocyclylalkyl, hydroxyalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(C′), —NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁷;

each R⁷ is oxo; and

each R^(A), R^(b), R^(B′), R^(C), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, haloalkyl, dialkylaminoalkyl, hydroxyalkyl or alkoxyalkyl.

-   Item 4. The compound according to item 3 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroquinoxalinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, quinolyl, isoquinolinyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, dihydroisobenzofuranyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, dihydrocyclopentathiophenyl, tetrahydrobenzothiophenyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyrrolyl or pyridyl;

E is phenyl, thienyl or pyrrolyl;

when E is phenyl, n is 1 or 2; and when E is thienyl, n is 0 or 1;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyrrolyl, oxadiazolyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, oxazolyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidyl, pyrrolidinyl, morpholinyl, dioxolanyl, phenylalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperidylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, oxo, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

each R⁶ is independently C₁-C₈ alkyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, morpholinylalkyl, dialkylaminoalkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —NR^(c)C(Y)R^(c′), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), alkoxyalkyl, —OR^(d) or —C(Y)R^(e); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, pyridyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, furylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, thiazolylalkyl, pyrazolylalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolylalkyl, dihydrobenzodioxinylalkyl, benzothienylalkyl, C₃-C₈ cycloalkylalkyl, oxazolidinylalkyl, haloalkyl, or alkoxyalkyl.

-   Item 5. The compound according to item 3 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroquinoxalinyl, tetrahydroisoquinolyl, tetrahydroquinolinyl, dihydroquinolyl, quinolyl, isoquinolyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, dihydroisobenzofuranyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, dihydrocyclopentathiophenyl, tetrahydrobenzothienyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyrrolyl or pyridyl;

E is phenyl, thienyl or pyrrolyl;

when E is phenyl, n is 0, 1 or 2; and when E is thienyl, n is 0 or 1;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidyl, pyrrolidinyl, morpholinyl, dioxolanyl, phenylalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperidylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, oxo, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), O—C(O)NR^(b)R^(b′), SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

each R⁶ is independently C₁-C₈ alkyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, morpholinylalkyl, dialkylaminoalkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —NR^(c)C(Y)R^(c′), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), alkoxyalkyl, —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁷;

R⁷ is oxo; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, pyridyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, furylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, thiazolylalkyl, pyrazolylalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolilalkyl, dihydrobenzodioxinylalkyl, benzothienylalkyl, C₃-C₈ cycloalkylalkyl, oxazolidinylalkyl, haloalkyl, or alkoxyalkyl.

-   Item 6. The compound according to item 5 represented by general     formula (I) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl, thienyl, pyrrolyl, oxazolyl, C₃-C₈ cycloalkyl, dioxolanyl, phenylalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

R² is C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, pyrrolidinyl, morpholinyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperiridylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁶;

R³ is C₁-C₈ alkyl, halo, haloalkyl, —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R⁶.

-   Item 7. The compound according to item 4 or 6 represented by general     formula (I) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl, thienyl, pyrrolyl, oxazolyl, C₃-C₈ cycloalkyl, dioxolanyl, phenylalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

R² is C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperidinylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —OR^(d), —C(Y)R^(e) or —S(O)_(q)R^(f);

R³ is C₁-C₈ alkyl, halo, haloalkyl, —NR^(b)R^(b′) or —OR^(d).

-   Item 8. The compound according to item 7 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroisoquinolyl, tetrahydroquinolinyl, dihydroquinolyl, quinolyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, tetrahydrobenzothienyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, thiadiazolyl or pyridyl;

n is 1, 2, 3 or 4;

R¹ is C₁-C₈ alkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), or —S(O)_(q)R^(f);

R² is C₁-C₈ alkyl, C₃-C₈ cycloalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, —CN, —NO, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolilalkyl, dihydrobenzodioxinylalkyl, C₃-C₈ cycloalkylalkyl, haloalkyl or alkoxyalkyl.

In some embodiments, A is N. In some embodiments, A is CH. In some embodiments, A is CR⁴.

In some embodiments, B is aryl (e.g., phenyl).

In some embodiments, m is 0.

In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.

In some embodiments, R¹ is in the ortho position. In some embodiments, R¹ is in the meta position. In some embodiments, R¹ is in the para position.

In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl or tert-butyl). In some embodiments, R¹ is heteroaryl (e.g., oxazolyl, oxadiazolyl or quinazolinyl).

In some embodiments, R¹ is heteroaryl substituted with 1-3 R⁶ (e.g., 1 R⁶).

In some embodiments, R¹ is oxadiazolyl substituted with 1 R⁶. some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is heteroaryl substituted with 2 R⁶. In some embodiments, R¹ is quinazolinyl substituted with 2 R⁶. In some embodiments, one R⁶ is halo (e.g., bromo) and the other is heteroaryl (e.g., pyridyl).

In some embodiments, m is 1 and R¹ is halo (e.g., fluoro, chloro or bromo).

In some embodiments, m is 2 and each R¹ is halo (e.g., fluoro, chloro or bromo). In some embodiments, m is 3 and each R¹ is halo (e.g., fluoro, chloro or bromo). In some embodiments, R¹ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R¹ is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, R¹ is haloalkoxy substituted with 1 R⁶. In some embodiments, R¹ is —O—CF₂—R⁶. In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O, R^(b) is hydrogen and R^(b′) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R¹ is —O—CF₂—CH₂—R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino).

In some embodiments, R¹ is aminoalkyl. In some embodiments, R¹ is —CH₂NH₂. In some embodiments, R¹ is alkylaminoalkyl. In some embodiments, R¹ is —CH₂NHCH₂CH₂CH₃. In some embodiments, R¹ is dialkylaminoalkyl. In some embodiments, R¹ is —CH₂N(CH(CH₃)₂)₂.

In some embodiments, R¹ is hydroxyalkyl. In some embodiments, R¹ is —CH₂OH.

In some embodiments, R¹ is —CN.

In some embodiments, R¹ is —NO₂.

In some embodiments, R¹ is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen. In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R¹ is —NR^(c)C(Y)R^(c′). In some embodiments, one of R^(c) and R^(c′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R¹ is —SO₂NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, R¹ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(e) is heterocyclyl (e.g., pyrrolidinyl, piperidinyl or morpholino).

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is S. In some embodiments, Y is O, In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) is hydrogen. In some embodiments, R^(b) is hydrogen and R^(b′) is aralkyl. In some embodiments, R^(b) is hydrogen and R^(b′) is optionally substituted benzyl. In some embodiments, R^(b) is C₁-C₈ alkyl, e.g., methyl, ethyl, C₃ alkyl (e.g., n-propyl or isopropyl), C₄ alkyl (e.g., n-butyl, sec-butyl or tert-butyl), C₅ alkyl (e.g., n-pentyl, isopentyl or pentan-3-yl), C₆ alkyl (e.g., n-hexyl or 3,3-dimethylbutan-2-yl), or C₇ alkyl (e.g., n-heptyl or 2-heptyl).

In some embodiments, R^(b′) is bicyclyl (e.g., indanyl). In some embodiments, R^(b′) is heterocyclyl, e.g., a 6-membered heterocyclyl. In some embodiments, R^(b′) is a 6-membered oxygen-containing heterocyclyl (e.g., tetrahydropyranyl). In some embodiments, R^(b′) is a 6-membered nitrogen-containing heterocyclyl (e.g., piperidinyl).

In some embodiments, R^(b′) is aralkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂, C₃ or C₄ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the aryl is phenyl. In some embodiments, R^(b′) is benzyl. In some embodiments, R^(b′) is phenylethyl.

In some embodiments, R^(b′) is heteroaralkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂ or C₃ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the heteroaryl is pyridyl. In some embodiments, the heteroaryl is furanyl. In some embodiments, the heteroaryl is thiazolyl. In some embodiments, the heteroaryl is thienyl.

In some embodiments, R^(b′) is cyclylalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁ alkyl). In some embodiments, the cyclyl group is cyclopropyl. In some embodiments, the cyclyl group is cyclopentyl. In some embodiments, the cyclyl group is a bicyclic group. In some embodiments, the bicyclic group is indanyl. In some embodiments, R^(b′) is heterocyclylalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁ alkyl). In some embodiments, the heterocyclyl group is tetrahydropyranyl.

In some embodiments, R^(b′) is haloalkyl (e.g., fluoroethyl, difluoroethyl, trifluoroethyl or trifluoropropyl).

In some embodiments, R^(b′) is alkoxyalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂, C₃ or C₄ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the alkoxy is methoxy.

In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl, both ethyl, or both isopropyl).

In some embodiments, two R¹ and B are taken together to form a bicyclic heteroaryl or heterocyclic ring.

In some embodiments, two R¹ and B are taken together to form

In some embodiments, R¹ is halo. In some embodiments, R¹ is at the 6, 7, or 8 position.

In some embodiments, two R¹ and B are taken together to form a group selected from:

In some embodiments, R² is aryl.

In some embodiments, each R¹ is independently C₁-C₈ alkyl (e.g., each R¹ is methyl). In some embodiments, each R¹ is independently halo (e.g., each R¹ is fluoro or each R¹ is chloro). In some embodiments, one R¹ is fluoro and the other is chloro. In some embodiments, one R¹ is chloro and the other is bromo.

In some embodiments, each R¹ is independently —OR^(d). In some embodiments, each R^(d) is independently C₁-C₈ alkyl (e.g., each R^(d) is methyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one R¹ is halo (e.g., fluoro) and the other is heterocyclylalkyl (e.g., —CH₂-heterocyclyl). In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is piperazinyl. In some embodiments, the piperazinyl is substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is haloalkyl (e.g., trifluoromethyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen.

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —NR^(c)C(Y)R^(c′). In some embodiments, Y is O. In some embodiments, R^(c) is hydrogen and R^(c′) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —CN.

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —NO₂.

In some embodiments, one R¹ is —C(O)OR^(d) and the other is —NO₂. In some embodiments, R^(a) is hydrogen.

In some embodiments, one R¹ is —C(O)OR^(a) and the other is —OR^(d). In some embodiments, each R^(a) and R^(d) is hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is haloalkyl (e.g., trifluoromethyl). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is haloalkoxy (e.g. trifluoromethoxy). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is —S(O)_(q)R^(f). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(f) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is —CN. In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is haloalkyl (e.g., trifluoromethyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is —C(O)OR^(a). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(a) is hydrogen. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is —NR^(c)C(O)R^(c′). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(c) is hydrogen and R^(c′) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is haloalkyl (e.g., trifluoromethyl) and the other is —CN.

In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a cyclyl ring (e.g., a substituted cyclyl ring). In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a heterocyclyl ring (e.g., a substituted heterocyclyl ring). In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a heteroaryl ring (e.g., a substituted heteroaryl ring).

In some embodiments, two R¹ and ring B are taken together to form a group selected from:

In some embodiments, R² is aryl.

In some embodiments, each R¹ is independently halo (e.g., all three R¹ are fluoro or all three R¹ are chloro).

In some embodiments, two R¹ are independently halo (e.g., both are chloro) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, two R¹ are independently halo (e.g., both are chloro) and the other is heteroaryl (e.g., pyrrolyl).

In some embodiments, two R¹ are independently halo (e.g., both are fluoro) and the other is —C(Y)NR^(b)R^(b′) (e.g., —C(O)NH₂). In some embodiments, two R¹ are independently C₁-C₈ alkyl (e.g., both are methyl) and the other is halo (e.g., chloro or bromo).

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl), and two R¹, together with the atoms to which they are attached, are taken together to form a heterocyclyl ring.

In some embodiments, one R¹ is —OR^(d), and two R¹, together with the atoms to which they are attached, are taken together to form a heterocyclyl ring. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, three R¹ and ring B are taken together to form a group selected from:

In some embodiments, B is a 6-membered heteroaryl.

In some embodiments, B is pyridyl. In some embodiments, B is 3-pyridyl. In some embodiments, in is 2. In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form an aryl ring (e.g., a phenyl ring). In some embodiments, m is 3. In some embodiments, one R¹ is —OR^(d), and two R¹, together with the atoms to which they are attached, are taken together to form an aryl ring (e.g., a phenyl ring). In some embodiments, R^(d) is hydrogen.

In some embodiments, B is pyrazolyl. In some embodiments, m is 2. In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a cyclyl ring (e.g., a cyclohexyl ring).

In some embodiments, B is selected from:

In some embodiments, B is a 5-membered heteroaryl (e.g., pyrazolyl).

In some embodiments, m is 1.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, R¹ is phenyl substituted with 1 R⁶.

In some embodiments, R⁶ is halo (e.g., chloro). In some embodiments, R¹ is selected from:

In some embodiments, m is 2.

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl) and the other is aryl (e.g., phenyl). In some embodiments, the aryl is phenyl substituted with 1 R⁶. In some embodiments, R⁶ is halo (e.g., chloro). In some embodiments, R¹ is:

In some embodiments, B is thienyl. In some embodiments, B is selected from:

In some embodiments, m is 1. In some embodiments, in is 2. In some embodiments m is 2 and two R¹, together with the atoms to which they are attached, form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring

In some embodiments, R¹ is —C(O)OR^(a). In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., ethyl). In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, m is 2.

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl) and the other is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(h) and R^(b′) are both hydrogen.

In some embodiments, B is thiazolyl.

In some embodiments, in is 1.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, m is 2.

In some embodiments, two R¹, together with the atoms to which they are attached, form an aryl ring. In some embodiments, the aryl ring is substituted with —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, B is:

In some embodiments, B is:

In some embodiments, E is aryl (e.g., phenyl).

In some embodiments, n is 1.

In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is C₁-C₈ alkyl substituted with 1-3 R⁶. In some embodiments, R² is C₁ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl, or R^(b) and R^(b′) are both ethyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is haloalkyl (e.g., trifluoroethyl).

In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is cyclyl (e.g., cyclopentyl). In some embodiments, R^(d) is heterocyclylalkyl (e.g., —CH₂-tetrahydropyranyl).

In some embodiments, R² is C₂ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino or thiomorpholino). In some embodiments, R^(e) is thiomorpholino substituted with 2 R⁷. In some embodiments, each R⁷ is oxo. In some embodiments, R^(e) is:

In some embodiments, R² is C₃ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R⁶ is —NR^(c)C(Y)R^(c′). In some embodiments, Y is O. In some embodiments, R^(c) and R^(c′) are each independently C₁-C₈ alkyl (e.g., R^(c) and R^(c′) are both methyl).

In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R⁶ is silyloxy (e.g., tert-butyldimethylsilyloxy).

In some embodiments, R⁶ is —C(Y)R^(c). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, R² is C₂-C₈ alkynyl. In some embodiments, R² is C₂-C₈ alkynyl substituted with 1 R⁶ (e.g., C₃ alkynyl substituted with 1 R⁶). In some embodiments, R² is —C≡C—CH₂—R⁶. In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R⁶ is silyloxy (e.g., tert-butyldimethylsilyloxy). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino or thiomorpholino). In some embodiments, R⁶ is thiomorpholino substituted with 2 R⁷. In some embodiments, each R⁷ is oxo. In some embodiments, R⁶ is:

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is unsubstituted phenyl.

In some embodiments, R² is phenyl substituted with 1 R⁶.

In some embodiments, R⁶ is heterocyclylalkyl (e.g., —CH₂-morpholino). In some embodiments, R⁶ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R⁶ is —CN. In some embodiments. R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is —C(Y)R^(c). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, R² is phenyl substituted with 2 R⁶.

In some embodiments, each R⁶ is independently —OR^(d). In some embodiments, each R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one R⁶ is halo (e.g., fluoro) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one R⁶ is —C(O)OR^(a) and the other is —OR^(d). In some embodiments, R^(a) and R^(d) are each independently C₁-C₈ alkyl (e.g., R^(a) and R^(d) are both methyl).

In some embodiments, R² is heteroaryl.

In some embodiments, R² is isoxazolyl. In some embodiments, R² is isoxazolyl substituted with 2 R⁶. In some embodiments, each R⁶ is independently C₁-C₈ alkyl (e.g., R⁶ is methyl),

In some embodiments, R² is pyrazolyl. In some embodiments, R² is pyrazolyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is pyridyl. In some embodiments, R² is unsubstituted pyridyl. In some embodiments, R¹ is pyridyl substituted with 1 R⁶. In some embodiments, R⁶ is halo (e.g., fluoro). In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each hydrogen. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino or piperazinyl). In some embodiments, R⁶ is piperazinyl substituted with 1 R⁷. In some embodiments, R⁷ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is pyrimidinyl.

In some embodiments, R² is pyridazinyl.

In some embodiments, R² is cyclyl (e.g., cyclopropyl).

In some embodiments, R² is heterocyclyl (e.g., morpholino or pyrrolidinyl).

In some embodiments, R² is aralkyl (e.g., benzyl).

In some embodiments, R² is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the heterocyclyl is piperidinyl. In some embodiments, the heterocyclyl is piperazinyl. In some embodiments, the heterocyclyl is piperazinyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is thiomorpholino. In some embodiments, the heterocyclyl is thiomorpholino substituted with 2 R⁶. In some embodiments, each R⁶ is oxo. In some embodiments, the heterocyclyl is:

In some embodiments, R² is halo (e.g., fluoro, chloro, bromo or iodo).

In some embodiments, R² is haloalkyl (e.g., trifluoromethyl).

In some embodiments, R² is haloalkoxy (e.g., trifluoromethoxy).

In some embodiments, R² is —CN.

In some embodiments, R² is —NO₂.

In some embodiments, R² is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen. In some embodiments, R^(a) is C₁-C₈, alkyl (e.g., methyl).

In some embodiments, R² is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are each hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl or ethyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclylalkyl (e.g., —CH₂—CH₂-morpholino). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is haloalkyl (e.g., trifluoroethyl).

In some embodiments, R² is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclyl (e.g., tetrahydropyranyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is tetrahydrofuranyl. In some embodiments, the heterocyclyl is tetrahydropyranyl. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is hydroxyalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is alkoxyalkyl. In some embodiments, the alkyl is C₂ alkyl, In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkoxy is methoxy. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(e) is heterocyclyl. In some embodiments, R^(e) is tetrahydropyranyl.

In some embodiments, R² is —OR^(d).

In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is ethyl. In some embodiments, R^(d) is C₃ alkyl (e.g., isopropyl or n-propyl). In some embodiments, R^(d) is optionally substituted heteroaralkyl. In some embodiments, R^(d) is optionally substituted pyrindinalkyl.

In some embodiments, R^(d) is n-propyl. In some embodiments, R^(d) is cyclyl (e.g., cyclopentyl).

In some embodiments, R^(d) is heteroaralkyl (e.g., —CH₂-pyridyl).

In some embodiments, R^(d) is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkyl is C₄ alkyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is piperidyl. In some embodiments, the heterocyclyl is tetrahydrofuranyl. In some embodiments, R^(d) is cyclylalkyl (e.g., —CH₂-cyclobutyl).

In some embodiments, R^(d) is alkoxyalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkoxy is methoxy.

In some embodiments, R^(d) is dialkylaminoalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the dialkylamino is dimethylamino.

In some embodiments, R² is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl. In some embodiments, R^(e) is piperidyl. In some embodiments, R^(e) is pyrrolidinyl. In some embodiments, R^(e) is piperazinyl. In some embodiments, R^(e) is morpholino. In some embodiments, R^(e) is thiomorpholino.

In some embodiments, n is 2.

In some embodiments, each R² is independently halo (e.g., each R² is chloro).

In some embodiments, each R² is independently —OR^(d).

In some embodiments, each R^(d) is C₁-C₈ alkyl.

In some embodiments, each R² is methoxy. In some embodiments, one R² is methoxy and the other is ethoxy. In some embodiments, one R² is methoxy and the other is propoxy. In some embodiments, one R² is methoxy and the other is isopropoxy.

In some embodiments, one R² is methoxy and the other is ethoxy substituted with 1 R⁶. In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is methoxy and the other is propoxy substituted with 1 R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, one R² is —OR^(d) and the other is halo (e.g., chloro). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is —CN. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g. methyl).

In some embodiments, one R² is —OR^(d) and the other is —C(O)OR^(a). In some embodiments, R^(d) and R^(a) are both hydrogen.

In some embodiments, one R² is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is —C(Y)R^(e). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, one R² is halo (e.g., chloro or bromo) and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is —CN.

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is heteroaryl (e.g., pyridyl). In some embodiments, the pyridyl is substituted with 1 R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is heterocyclylalkyl (e.g., —CH₂-morpholino).

In some embodiments, p is 0.

In some embodiments, p is 1.

In some embodiments, R³ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R³ is halo (e.g., chloro). In some embodiments, R³ is haloalkyl (e.g., trifluoromethyl). In some embodiments R³ is oxo.

In some embodiments, R³ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R³ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R³ is heterocyclyl (e.g., piperazinyl). In some embodiments, R³ is piperazinyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, E is a 5-membered heteroaryl ring.

In some embodiments, E is a thiophene ring.

In some embodiments, E is a pyrrole ring.

In some embodiments, n is 1. In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl). In some embodiments, E is an N-methylpyrrole ring.

In some embodiments, L is NR⁵. In some embodiments, R⁵ is hydrogen.

In some embodiments, L is O.

In some embodiments, the compound is:

In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, R¹ is —C(Y)NR^(b)R^(b′).

In some embodiments, the compound is:

In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, R¹ is —C(Y)NR^(b)R^(b′).

In some embodiments,

In some embodiments,

In some embodiments, L is NH, and

is selected from

In some embodiments R⁶ is halo.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —-C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, in is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

Compounds of Formula (II)

The following aspects and embodiments relate to compounds of formula (II).

-   Item 9. The compound according to item 1 represented by general     formula (II) or a salt thereof,

wherein:

L is CR⁴R⁵, O, C(O), NR⁶C(O) or NR⁷;

A is N;

each X¹, X², X³, X and X⁵ is independently CH or N, provided that at least two of X¹, X², X³, X⁴ and X⁵ are N;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2 or 3

R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl or heterocyclylalkyl, each of which is optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ is optionally taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹¹;

each R⁴, R⁵, R⁶ and R⁷ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR, —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁸, two R⁹, two R¹⁰ or two R¹¹ is optionally taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R¹² is —OR^(d);

Y is C or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl, or heteroarylalkyl.

-   Item 10. The compound according to item 9 represented by general     formula (II) or a salt thereof,

L is NR⁷;

n is 0, 1 or 2;

p is 0;

R¹ is C₁-C₈ alkyl, aryl or heteroaryl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, aryl, halo, heterocyclylalkyl, —NR^(c)C(Y)R^(c), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

R⁷ is hydrogen; and

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, heterocyclyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e);

Y is O;

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, cyclyl, heterocyclyl, aryl or heteroaryl.

-   Item 11. The compound according to item 10 represented by general     formula (II) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl or benzodioxolyl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c), —NR^(b)R^(b′) or —OR^(d);

R⁹ is independently C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, tetrahydropyranyl, phenyl or pyridyl.

-   Item 12. The compound according to item 10 represented by general     formula (II) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl or benzodioxolyl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, tetrahydropyranyl, phenyl, or pyridyl.

-   Item 13. The compound according to item 12 represented by general     formula (II) or a salt thereof, wherein:

R² is C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

R³ is hydrogen;

R⁹ is halo, haloalkoxy, —CN, —C(O)OR^(a) or —C(Y)NR^(b)R^(b′); and

R¹¹ is C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, —CN, —OR^(d) or —C(Y)R^(e);

-   Item 14. The compound according to item 11 or 13 represented by     general formula (II) or a salt thereof, wherein:

R² is C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d);

R³ is hydrogen; and

R⁹ is halo, haloalkoxy, —CN, —C(O)OR^(a) or —C(Y)NR^(b)R^(b′).

In some embodiments, A is CH. In some embodiments, A is N.

In some embodiments, L is NR⁷. In some embodiments, R⁷ is H.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, R¹ is phenyl substituted with 1 R⁹. In some embodiments, R¹ is phenyl substituted with 1 R⁹ in the ortho position. In some embodiments, R¹ is phenyl substituted with 1 R⁹ in the meta position. In some embodiments, R⁹ is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy). In some embodiments, R⁹ is —CN. In some embodiments, R⁹ is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen. In some embodiments, R⁹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R¹ is:

In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is phenyl substituted with 2 R⁹. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is fluoro or each R⁹ is chloro). In some embodiments, one R⁹ is fluoro and the other is chloro. In some embodiments, one R⁹ is halo (e.g., chloro) and the other is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, 2 R⁹ are taken together with the atoms to which they are attached to form a heterocyclyl ring, e.g., a 5-membered heterocyclyl ring (e.g., a dioxole ring). In some embodiments, the dioxole ring is unsubstituted. In some embodiments, the dioxole ring is substituted. In some embodiments, the dioxole ring is substituted with two fluoro substituents. In some embodiments, R¹ is selected from:

In some embodiments, R¹ is aralkyl (e.g., benzyl). In some embodiments, R¹ is aralkyl substituted with 2 R⁹ (e.g., benzyl substituted with 2 R⁹). In some embodiments, 2 R⁹ substituents are on the phenyl ring. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is chloro).

In some embodiments, R¹ is alkyl (e.g., methyl).

In some embodiments, n is 0.

In some embodiments, n is 1.

In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is C₁-C₈ alkyl substituted with 1 R¹¹ (e.g., methyl substituted with 1 R¹¹). In some embodiments, R¹¹ is heterocyclyl (e.g., morpholino).

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is phenyl substituted with 1 R¹¹. In some embodiments, R¹¹ is —CN. In some embodiments, R¹¹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments. R¹¹ is halo.

In some embodiments, R² is halo (e.g., fluoro, chloro, bromo or iodo).

In some embodiments, R² is —NR^(c)C(Y)R^(c′). In some embodiments, R^(c) is hydrogen. In some embodiments, Y is O. In some embodiments, R^(c′) is alkyl (e.g., methyl). In some embodiments, R^(c′) is aryl (e.g., phenyl). In some embodiments, R^(c′) is phenyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is heteroaryl. In some embodiments, R^(c′) is furanyl. In some embodiments, R^(c′) is pyridyl. In some embodiments, R^(c′) is pyridyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is cyclyl (e.g., cyclohexyl). In some embodiments, R^(c′) is cyclohexyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d) in some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is heterocyclyl (e.g., tetrahydropyranyl).

In some embodiments, R² is —NR^(b)R^(b′) in some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl).

In some embodiments, R¹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl or ethyl). In some embodiments, R^(d) is ethyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R¹ is —OCH₂CH₂OCH₃. In some embodiments, R² is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R² is —OCH₂CH₂OCH₂CH₂CH₂OCH₃.

In some embodiments, n is 2.

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl) and the other is halo (e.g., chloro).

In some embodiments, one R² is —OR^(d) and the other is halo (e.g., chloro). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, X¹ and X⁴ are N and X², X³ and X⁵ are CH.

In some embodiments, X¹ and X³ are N and X², X⁴ and X⁵ are CH.

In some embodiments, X² and X³ are N and X¹, X⁴ and X⁵ are CH.

In some embodiments, X² and X⁴ are N and X¹, X³ and X⁵ are CH.

In some embodiments, the compound is:

wherein s is 0, 1, 2, 3 or 4.

In some embodiments, R⁹ is —C(O)NH₂, C₁-C₄ alkoxy, or substituted C₁-C₄ alkoxy. In some embodiments, R⁹ is halo,

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments. R¹ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments. R¹¹ is —OCH₂CH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

Compounds of Formula (III)

The following aspects and embodiments relate to compounds of formula (III).

-   Item 15. The compound according to item 1 represented by general     formula (III) or a salt thereof,

wherein:

A is CH or N;

L is O, a direct bond or NH;

one of X¹, X², X³, X⁴ and X⁵ is N and the others are CH;

m is 1, 2 or 3;

n is 1, 2, 3 or 4;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₅ alkynyl, alkoxyalkyl, hydroxyalkyl, heteroaryl, heteroarylalkyl, arylalkyl, —C(Y)R^(e), cyclyl, cyclylalkyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷;

R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d′), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰;

each R⁷, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷ or two R⁹ are optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, haloalkyl, halo, heterocyclyl, cyclyl, oxo or —C(Y)NR^(b)R^(b′);

Y is O or S

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, haloalkyl, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl.

-   Item 16. The compound according to item 15 represented by general     formula (III) or a salt thereof,

wherein:

m is 1;

n is 1;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, heteroaryl, heterocyclyl, arylalkyl, cyclylalkyl, heteroarylalkyl, alkoxyalkyl, hydroxyalkyl or —C(O)R^(e), each of which is optionally substituted with 1-3 R⁷;

R² is aryl, heteroaryl or benzofuryl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d);

R⁶ is hydrogen or C₁-C₈ alkyl;

each R⁷ and R⁹ is independently C₁-C₈ alkyl, aryl, heteroaryl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;

R¹² is independently C₁-C₈ alkyl, oxo, halo, haloalkyl, —CN, —C(O)NR^(b)R^(b′) or —C(O)R^(e) each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, halo or heterocyclyl; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₃ alkyl, cyclyl, heterocyclyl, arylalkyl, alkoxyalkyl, heterocyclylalkyl, heteroarylalkyl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 17. The compound according to Item 16 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₄ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, thiazolidinyl isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, naphthyl, benzofuryl, indazolyl, benzothienyl, pyridyl, pyrimidinyl, dihydrobenzodioxinyl, benzodioxolyl, benzoimidazolyl, isoxazolyl, pyrazolyl, indolinyl or benzoisoxazolyl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₅ alkyl, halo, haloalkyl or —OR^(d);

R⁶ is hydrogen or C₁-C₈ alkyl;

each R⁷ and R⁹ is independently C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 18. The compound according to item 16 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, furylalkyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, thiazolidinyl, isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, naphthyl, benzofuryl, indazolyl, benzothienyl, pyridyl, pyrimidinyl, dihydrobenzodioxinyl, benzodioxolyl, benzoimidazolyl, isoxazolyl, pyrazolyl, indolinyl or benzisoxazolyl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d);

R⁶ is hydrogen or C₁-C₈ alkyl;

each R⁷ and R⁹ is independently C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;

R¹² is independently C₁-C₈ alkyl, oxo, halo, haloalkyl, —CN, —C(O)NR^(b)R^(b′) or —C(O)R^(e), each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₃-C₈ alkyl, halo or pyrrolidinyl; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′, R) ^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 19. The compound according to item 18 represented by general     formula (III) or a salt thereof,

wherein:

A is N;

R³ is hydrogen, C₁-C₈ alkyl, halo, haloalkyl, or —OR^(d);

R⁴ is hydrogen, C₁-C₈ alkyl, halo, or —OR^(d);

R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d) each of which is optionally substituted with 1-3 R¹²;

R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, tetrahydrofurylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 20. The compound according to item 17 or 19 represented by     general formula (III) or a salt thereof,

wherein:

A is N;

R³ is hydrogen, C₁-C₈ alkyl, halo, haloalkyl, or —OR^(d);

R⁴ is hydrogen, C₁-C₈ alkyl, halo, or —OR^(d);

R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d);

R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂—C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, dihydrobenzoxazinylalkyl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 21. The compound according to item 20 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, furylalkyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, isoindolyl, —C(O)R^(c), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, which is optionally substituted with 1-5 R⁹; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, pyrrolidinyl, morpholinyl, tetrahydropyranyl, alkoxyalkyl, morpholinylalkyl, tetrahydropyranylalkyl, pyridylalkyl, thiazolylalkyl, pyrrolylalkyl, tetrahydrofuryl, alkylaminoalkyl or phenyl.

In some embodiments, R¹ is C₁-C₈ alkyl, which is optionally substituted with 1-3 R⁷; or when L is NR⁶, R¹ and R⁶ may be taken together with the atoms to which they are attached to form a heterocyclyl or heteroaryl ring that is optionally substituted with 1-3 R⁸.

In some embodiments, A is CH. In some embodiments, A is N.

In some embodiments, L is NR⁶. In some embodiments, R⁶ is hydrogen.

In some embodiments, R¹ is C₁-C₈ alkyl, e.g., methyl, ethyl, C₃ alkyl (e.g., n-propyl or isopropyl), C₄ alkyl (e.g., n-butyl, isobutyl or tert-butyl), or C₅ alkyl (e.g., pentan-3-yl).

In some embodiments, R¹ is C₁-C₈ alkyl substituted with 1-3 R⁷ (e.g., C₁-C₈ alkyl substituted with 1 R⁷). In some embodiments, R¹ is methyl substituted with 1 R⁷. In some embodiments, R¹ is cyclyl (e.g., cyclopropyl). In some embodiments, R⁷ is aryl (e.g., phenyl).

In some embodiments, R¹ is ethyl substituted with 1 R⁷. In some embodiments, R⁷ is aryl (e.g., phenyl). In some embodiments, R⁷ is —OR^(d). In some embodiments, R^(d) is aryl (e.g., phenyl).

In some embodiments, R¹ is n-propyl substituted with 1 R⁷. In some embodiments, R¹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., C₃ alkyl, e.g., n-propyl).

In some embodiments, R¹ is C₁-C₈ alkyl substituted with 3 R⁷. In some embodiments, R¹ is ethyl substituted with 3 R⁷. In some embodiments, each R⁷ is independently halo (e.g., each R⁷ is fluoro). In some embodiments, R¹ is 2,2,2-trifluoroethyl.

In some embodiments, R¹ is C₂-C₈ alkenyl, e.g., C₃ alkenyl (e.g., —CH₂—CH═CH₂).

In some embodiments, R¹ is C₂-C₈ alkynyl, e.g., C₃ alkynyl (e.g. —CH₂—C≡CH).

In some embodiments, R¹ is cyclyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl). In some embodiments, the cyclyl group is a bicyclic group (e.g., indanyl).

In some embodiments, R¹ is heterocyclyl (e.g., piperidyl). In some embodiments, R¹ is piperidyl substituted with 1 R⁷. In some embodiments, R¹ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R¹ is —OR^(d).

In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ and R⁶ are taken together with the atoms to which they are attached to form a heterocyclyl ring (e.g. a pyrrolidine ring).

In some embodiments, R¹ and R⁶ are taken together with the atoms to which they are attached to form a heteroaryl ring (e.g., an imidazole ring).

In some embodiments, L is O.

In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is unsubstituted phenyl. In some embodiments, R² is phenyl substituted with 1-3 R⁹. In some embodiments, R¹ is phenyl substituted with 1 R⁹.

In some embodiments, R² is:

In some embodiments, R⁹ is halo (e.g., fluoro or chloro). In some embodiments, R⁹ is —CN. In some embodiments, R⁹ is —NO₂. In some embodiments, R⁹ is haloalkoxy (e.g., trifluoroethoxy). In some embodiments, R⁹ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl).

In some embodiments, R⁹ is —OR^(d). In some embodiments, R⁹ is —OCH₂CH₂OCH₃. In some embodiments, R⁹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R⁹ is —OCH₂CH₂OCH₂CH₂OCH₃. In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is ethyl.

In some embodiments, R⁹ is hydroxyalkyl (e.g., —CH₂OH). In some embodiments, R⁹ is alkoxyalkyl (e.g., —CH—O—CH₃). In some embodiments, R⁹ is —C(O)R^(e). In some embodiments, R^(e) is heterocyclyl (e.g., morpholino). In some embodiments, R⁹ is —S(O)_(q)R^(f). In some embodiments, q is 1. In some embodiments, R^(f) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is phenyl substituted with 2 R⁹. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is fluoro). In some embodiments, each R⁹ is independently —OR^(d). In some embodiments, each R^(d) is independently C₁-C₈ alkyl (e.g., each R^(d) is methyl).

In some embodiments, R² is heteroaryl. In some embodiments, R² is a 6-membered heteroaryl. In some embodiments, R² is a 6-membered nitrogen-containing heteroaryl, e.g., pyridyl. In some embodiments, R² is unsubstituted pyridyl.

In some embodiments, R² is pyridyl substituted with 1 R⁹. In some embodiments, R⁹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is a 5-membered heteroaryl. In some embodiments, R² is a 5-membered nitrogen-containing heteroaryl (e.g., pyrrolyl or oxazolyl).

In some embodiments, m is 0.

In some embodiments, m is 1.

In some embodiments, R⁴ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁴ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁴ is halo. In some embodiments, R⁴ is methoxy. In some embodiments, R^(d) is C₁-C₈ alkyl.

In some embodiments, the compound has the following structure:

wherein one of X¹ and X² is N and the other is CH.

In some embodiments, X¹ is CH and X² is N. In some embodiments, X¹ is N and X² is CH. In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

wherein R¹ is C₁-C₈ alkyl, which is optionally substituted with 1-3 R⁷.

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments R¹ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is

In some embodiments, the compound has the following structure:

wherein p is 1, 2, 3, 4 or 5.

In some embodiments, L is NR⁶. In some embodiments, L is O. In some embodiments, R¹ is hydrogen or C₁-C₈ alkyl. In some embodiments, R¹ is cyclyl or heterocyclyl. In some embodiments, R¹ is aralkyl or heteroaralkyl. In some embodiments, R¹ is methyl, cyclohexyl, t-butyl, or

In some embodiments, R⁶ is hydrogen or C₁-C₈ alkyl. In some embodiments, R⁹ is C₁-C₈ alkyl, halo, —CN, or —OR^(d). In some embodiments, R³ is hydrogen.

In some embodiments, the compound has the following structure:

wherein p is 1, 2, 3, 4 or 5.

In some embodiments, L is NR⁶. In some embodiments, L is O. In some embodiments, R¹ is hydrogen or C₁-C₈ alkyl. In some embodiments, R¹ is cyclyl or heterocyclyl. In some embodiments, R¹ is aralkyl or heteroaralkyl. In some embodiments, R¹ is methyl, cyclohexyl, t-butyl, or

In some embodiments, R¹ is hydrogen or C₁-C₈ alkyl. In some embodiments, R⁹ is C₁-C₈ alkyl, halo, —CN, or —OR^(d). In some embodiments, R³ is hydrogen.

Compounds of Formula (IV)

The following aspects and embodiments relate to compounds of formula (IV), corresponding to formula (I) of U.S. Provisional Patent Application No. 61/291,544, entitled “Therapeutic Compounds and Related Methods of Use” filed on Dec. 31, 2009, and incorporated herein by reference in its entirety.

-   Item 38. A compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3, 4 or 5;

E is aryl or a 5-membered heteroaryl;

when E is aryl, n is 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3:

L is NR⁵ or O;

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when in is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d)—SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₁-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(v′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶, wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring;

or a pharmaceutically acceptable derivative or prodrug thereof,

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; when B is phenyl, R² is not

and where in the compound is not:

In some embodiments, when B is phenyl, R² is not a substituted pyridyl. In some embodiments, when B is phenyl and n=1, R² is not a substituted pyridyl.

In some embodiments, when X is N, B is not 4-pyridyl.

In some embodiments, each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶.

In some embodiments, B is aryl.

-   Item 39. A compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5-membered heteroaryl;

m is 0, 1, 2, 3, 4 or 5;

E is aryl or a 5-membered heteroaryl;

when E is aryl, n is 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3;

L is NR⁵ or O;

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR, —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring:

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, aralkyl, heteroalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d) SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶ wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring;

or a pharmaceutically acceptable derivative or prodrug thereof,

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; and

when B is phenyl, R² is not

In some embodiments, each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶.

In some embodiments, when B is phenyl, R¹ is not a substituted pyridyl. In some embodiments, when B is phenyl and n=1, R² is not a substituted pyridyl.

In one aspect, the invention features a compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5-membered heteroaryl;

E is aryl or a 5-membered heteroaryl;

L is NR⁵ or O;

one of X and Z is N and the other is CH;

m is 0, 1, 2, 3, 4 or 5;

n is 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

each R¹ and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the carbons to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′, —SO) ₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally further substituted with 1-3 R⁶ wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring;

or a pharmaceutically acceptable derivative or prodrug thereof,

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring.

In some embodiments, each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶.

In one aspect, the invention features a compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5-membered heteroaryl;

E is aryl or a 5-membered heteroaryl;

L is NR⁵ or O:

one of X and Z is N and the other is CH;

m is 0, 1, 2, 3, 4 or 5;

n is 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

each R¹ and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, or aryl ring;

each R² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the carbons to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO, —C(O)OR, —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂—C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR³C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally further substituted with 1-3 R⁶, wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring;

In some embodiments, A is N. In some embodiments, A is CH. In some embodiments, A is CR⁴.

In some embodiments, B is aryl (e.g., phenyl).

In some embodiments, m is 0.

In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.

In some embodiments, R¹ is in the ortho position. In some embodiments, R¹ is in the meta position. In some embodiments, R¹ is in the para position.

In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl or tert-butyl). In some embodiments, R¹ is heteroaryl (e.g., oxazolyl, oxadiazolyl or quinazolinyl).

In some embodiments, R¹ is heteroaryl substituted with 1-3 R⁶ (e.g., 1 R⁶).

In some embodiments, R¹ is oxadiazolyl substituted with 1 R⁶. some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is heteroaryl substituted with 2 R⁶. In some embodiments, R¹ is quinazolinyl substituted with 2 R⁶. In some embodiments, one R⁶ is halo (e.g., bromo) and the other is heteroaryl (e.g., pyridyl).

In some embodiments, m is 1 and R¹ is halo (e.g., fluoro, chloro or bromo). In some embodiments, m is 2 and each R¹ is halo (e.g., fluoro, chloro or bromo). In some embodiments, m is 3 and each R¹ is halo (e.g., fluoro, chloro or bromo). In some embodiments, R¹ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R¹ is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, R¹ is haloalkoxy substituted with 1 R⁶. In some embodiments, R¹ is —O—CF₂—R⁶. In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O, R^(b) is hydrogen and R^(1b) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R¹ is —O—CF, —CH₂—R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino).

In some embodiments, R¹ is aminoalkyl. In some embodiments, R¹ is —CH₂NH₂. In some embodiments, R¹ is alkylaminoalkyl. In some embodiments, R¹ is —CH₂ NHCH₂CH₂CH₃. In some embodiments, R¹ is dialkylaminoalkyl. In some embodiments, R¹ is —CH₂N(CH(CH₃)₂)₂.

In some embodiments, R¹ is hydroxyalkyl. In some embodiments, R¹ is —CH₂OH.

In some embodiments, R¹ is —CN.

In some embodiments, R¹ is —NO.

In some embodiments, R¹ is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen. In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R¹ is —NR^(c)C(Y)R^(c′). In some embodiments, one of R^(c) and R^(c′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R¹ is —SO₂NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, R¹ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(e) is heterocyclyl (e.g., pyrrolidinyl, piperidinyl or morpholino).

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is S. In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) is hydrogen. In some embodiments, R^(b) is hydrogen and R^(b′) is aralkyl. In some embodiments, R^(b) is hydrogen and R^(b′) is optionally substituted benzyl. In some embodiments, R^(b′) is C₁-C₈ alkyl, e.g., methyl, ethyl, C₃ alkyl (e.g., n-propyl or isopropyl), C₄ alkyl (e.g., n-butyl, sec-butyl or tert-butyl), C₅ alkyl (e.g., n-pentyl, isopentyl or pentan-3-yl), C₆ alkyl (e.g., n-hexyl or 3,3-dimethylbutan-2-yl), or C₇ alkyl (e.g., n-heptyl or 2-heptyl).

In some embodiments, R^(b′) is C₁-C₈ alkyl substituted with 1 R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is aryl (e.g., phenyl). In some embodiments, R^(b′) is C₂-C₈ alkenyl, e.g., C alkenyl (e.g., —CH₂—CH═CH₂). In some embodiments, R^(b′) is C₂-C₈ alkynyl, e.g., C₃ alkenyl (e.g., —CH₂—C≡CH).

In some embodiments, R^(b′) is aryl (e.g., phenyl). In some embodiments, R^(b′) is aryl substituted with 1 R⁶ (e.g., phenyl substituted with 1 R⁶). In some embodiments, R⁶ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R^(b′) is cyclyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl). In some embodiments, R^(b′) is cyclyl substituted with 1 R⁶ (e.g., cyclopropyl substituted with 1 R⁶ or cyclopentyl substituted with 1 R⁶). In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is aralkyl (e.g., benzyl).

In some embodiments, R^(b′) is cyclohexyl substituted with 1 R⁶. In some embodiments, R⁶ is —C(O)OR^(a). In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(b′) is bicyclyl (e.g., indanyl). In some embodiments, R^(b′) is heterocyclyl, e.g., a 6-membered heterocyclyl. In some embodiments, R^(b′) is a 6-membered oxygen-containing heterocyclyl (e.g., tetrahydropyranyl). In some embodiments, R^(b′) is a 6-membered nitrogen-containing heterocyclyl (e.g., piperidinyl).

In some embodiments, R^(b) is heterocyclyl substituted with 1 R⁶ (e.g., piperidinyl substituted with 1 R⁶). In some embodiments, R⁶ is —C(O)OR^(a). In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., ethyl). In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R^(b′) is aralkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂, C₃ or C₄ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the aryl is phenyl. In some embodiments, R^(b′) is benzyl. In some embodiments, R¹ is phenylethyl. In some embodiments, the aryl is substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is halo (e.g., fluoro or chloro). In some embodiments, R⁶ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, the aryl is substituted with 2 R⁶. In some embodiments, each R⁶ is independently —OR^(d). In some embodiments, each R^(d) is independently C₁-C₈ alkyl (e.g., each R^(d) is methyl). In some embodiments, each R⁶ is independently halo (e.g., each R⁶ is fluoro).

In some embodiments, R^(b′) is heteroaralkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂ or C₃ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the heteroaryl is pyridyl. In some embodiments, the heteroaryl is furanyl. In some embodiments, the heteroaryl is thiazolyl. In some embodiments, the heteroaryl is thienyl. In some embodiments, the heteroaryl is substituted with 1 R⁶.

In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is haloalkyl (e.g., trifluoromethyl).

In some embodiments, R^(b′) is cyclylalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁ alkyl). In some embodiments, the cyclyl group is cyclopropyl. In some embodiments, the cyclyl group is cyclopentyl. In some embodiments, the cyclyl group is a bicyclic group. In some embodiments, the bicyclic group is indanyl. In some embodiments, R^(b′) is cyclylalkyl substituted with 1 R⁶. In some embodiments, R⁶ is aryl (e.g., phenyl).

In some embodiments, R^(b) is heterocyclylalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁ alkyl). In some embodiments, the heterocyclyl group is tetrahydropyranyl.

In some embodiments, R^(b′) is haloalkyl (e.g., fluoroethyl, difluoroethyl, trifluoroethyl or trifluoropropyl).

In some embodiments, R^(b′) is alkoxyalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂, C₃ or C₄ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the alkoxy is methoxy.

In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl, both ethyl or both isopropyl).

In some embodiments, R¹ and R⁵, together with the atoms to which they are attached, form a heteroaryl ring (e.g., a substituted heteroaryl ring). In some embodiments, R¹ and R⁵, together with the atoms to which they are attached, form a heterocyclyl ring (e.g., a substituted heterocyclyl ring).

In some embodiments, R¹, R⁵, B and L are taken together to form a bicyclic heteroaryl or heterocyclic ring.

In some embodiments, R¹, R⁵, B and L are taken together to form

In some embodiments, R⁶ is halo. In some embodiments, R⁶ is at the 6, 7, or 8 position.

In some embodiments, R¹, R⁵, B and L are taken together to form a group selected from:

In some embodiments, R² is aryl.

In some embodiments, each R¹ is independently C₁-C₈ alkyl (e.g., each R¹ is methyl). In some embodiments, each R¹ is independently halo (e.g., each R¹ is fluoro or each R¹ is chloro). In some embodiments, one R¹ is fluoro and the other is chloro. In some embodiments, one R¹ is chloro and the other is bromo.

In some embodiments, each R¹ is independently —OR^(d). In some embodiments, each R¹ is independently C₁-C₈ alkyl (e.g., each R^(d) is methyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is C₃-C₈ alkyl (e.g., methyl). In some embodiments, one R¹ is halo (e.g., fluoro) and the other is heterocyclylalkyl (e.g., —CH₂-heterocyclyl). In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is piperazinyl. In some embodiments, the piperazinyl is substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is haloalkyl (e.g., trifluoromethyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen.

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —NR^(c)C(Y)R^(c′). In some embodiments, Y is O. In some embodiments, R^(c) is hydrogen and R^(c′) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —CN.

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —NO₂.

In some embodiments, one R¹ is —C(O)OR^(a) and the other is —NO₂. In some embodiments, R^(a) is hydrogen.

In some embodiments, one R¹ is —C(O)O(R¹ and the other is —OR^(d). In some embodiments, each R^(a) and R^(d) is hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is haloalkyl (e.g., trifluoromethyl). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is haloalkoxy (e.g., trifluoromethoxy). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is —S(O)_(q)R^(f). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(f) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is —CN. In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is haloalkyl (e.g., trifluoromethyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is —C(O)OR^(a). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(a) is hydrogen. In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is —NR^(c)C(O)R^(c′). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(c) is hydrogen and R^(c′) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is haloalkyl (e.g., trifluoromethyl) and the other is —CN.

In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a cyclyl ring (e.g., a substituted cyclyl ring). In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a heterocyclyl ring (e.g., a substituted heterocyclyl ring). In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a heteroaryl ring (e.g., a substituted heteroaryl ring).

In some embodiments, two R¹ and ring B are taken together to form a group selected from:

In some embodiments, R² is aryl.

In some embodiments, each R¹ is independently halo (e.g., all three R¹ are fluoro or all three R¹ are chloro).

In some embodiments, two R^(j) are independently halo (e.g., both are chloro) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, two R¹ are independently halo (e.g., both are chloro) and the other is heteroaryl (e.g., pyrrolyl). In some embodiments, two R¹ are independently halo (e.g., both are fluoro) and the other is —C(Y)NR^(b)R^(b′) (e.g., —C(O)NH₂). In some embodiments, two R¹ are independently C₁-C₈ alkyl (e.g., both are methyl) and the other is halo (e.g., chloro or bromo).

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl), and two R¹, together with the atoms to which they are attached, are taken together to form a heterocyclyl ring.

In some embodiments, one R¹ is —OR^(d), and two R¹, together with the atoms to which they are attached, are taken together to form a heterocycyl ring. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, three R¹ and ring B are taken together to form a group selected from:

In some embodiments, B is a 6-membered heteroaryl.

In some embodiments, B is pyridyl. In some embodiments, B is 3-pyridyl. In some embodiments, m is 2. In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form an aryl ring (e.g., a phenyl ring). In some embodiments, in is 3. In some embodiments, one R¹ is —OR^(d), and two R¹, together with the atoms to which they are attached, are taken together to form an aryl ring (e.g., a phenyl ring). In some embodiments, R^(d) is hydrogen.

In some embodiments, B is pyrazolyl. In some embodiments, m is 2. In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a cyclyl ring (e.g., a cyclohexyl ring),

In some embodiments, B is selected from:

In some embodiments, B is a 5-membered heteroaryl (e.g., pyrazolyl).

In some embodiments, m is 1.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, R¹ is phenyl substituted with 1 R⁶.

In some embodiments, R⁶ is halo (e.g., chloro). In some embodiments, R¹ is selected from:

In some embodiments, in is 2.

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl) and the other is aryl (e.g., phenyl). In some embodiments, the aryl is phenyl substituted with 1 R⁶. In some embodiments, R⁶ is halo (e.g., chloro). In some embodiments, R¹ is:

In some embodiments, B is thienyl. In some embodiments, B is selected from:

In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments m is 2 and two R¹, together with the atoms to which they are attached, form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring

In some embodiments, R¹ is —C(O)OR_(a). In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., ethyl).

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, m is 2.

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl) and the other is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, B is thiazolyl.

In some embodiments, m is 1.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, in is 2.

In some embodiments, two R¹, together with the atoms to which they are attached, form an aryl ring. In some embodiments, the aryl ring is substituted with —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, B is:

In some embodiments, B is:

In some embodiments, E is aryl (e.g., phenyl).

In some embodiments, n is 1.

In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is C₁-C₈ alkyl substituted with 1-3 R⁶. In some embodiments, R² is C₁ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl, or R^(b) and R^(b′) are both ethyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is haloalkyl (e.g., trifluoroethyl).

In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is cyclyl (e.g., cyclopentyl). In some embodiments, R^(d) is heterocyclylalkyl (e.g., —CH₂-tetrahydropyranyl).

In some embodiments, R² is C₂ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino or thiomorpholino). In some embodiments, R^(e) is thiomorpholino substituted with 2 R⁶. In some embodiments, each R⁶ is oxo. In some embodiments, R^(e) is:

In some embodiments, R² is C₃ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R⁶ is —NR^(c)C(Y)R^(c′). In some embodiments, Y is O. In some embodiments, R^(c) and R^(c′) are each independently C₁-C₈ alkyl (e.g., R^(c) and R^(c′) are both methyl).

In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R⁶ is silyloxy (e.g., tert-butyldimethylsilyloxy).

In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments. Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, R² is (C₂-C₈ alkynyl. In some embodiments, R² is C₂-C₈ alkynyl substituted with 1 R⁶ (e.g., C₃ alkynyl substituted with 1 R⁶). In some embodiments, R² is —C≡C—CH₂—R⁶. In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R⁶ is silyloxy (e.g., tert-butyldimethylsilyloxy). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino or thiomorpholino). In some embodiments, R⁶ is thiomorpholino substituted with 2 R⁷. In some embodiments, each R⁷ is oxo. In some embodiments, R⁶ is:

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is unsubstituted phenyl.

In some embodiments, R² is phenyl substituted with 1 R⁶.

In some embodiments, R⁶ is heterocyclylalkyl (e.g., —CH₂-morpholino). In some embodiments, R⁶ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R⁶ is —CN. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, R² is phenyl substituted with 2 R⁶.

In some embodiments, each R⁶ is independently —OR^(d). In some embodiments, each R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one R⁶ is halo (e.g., fluoro) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one R⁶ is —C(O)OR^(a) and the other is —OR^(d). In some embodiments, R^(a) and R^(d) are each independently C₁-C₈ alkyl (e.g., R^(a) and R^(d) are both methyl).

In some embodiments, R² is heteroaryl.

In some embodiments, R² is isoxazolyl. In some embodiments, R² is isoxazolyl substituted with 2 R⁶. In some embodiments, each R⁶ is independently C₁-C₈ alkyl (e.g., R⁶ is methyl).

In some embodiments, R² is pyrazolyl. In some embodiments, R² is pyrazolyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is pyridyl. In some embodiments, R⁶ is unsubstituted pyridyl. In some embodiments, R² is pyridyl substituted with 1 R⁶. In some embodiments, R⁶ is halo (e.g., fluoro). In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each hydrogen. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino or piperazinyl). In some embodiments, R⁶ is piperazinyl substituted with 1 R⁷. In some embodiments, R⁷ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is pyrimidinyl.

In some embodiments, R² is pyridazinyl.

In some embodiments, R² is cyclyl (e.g., cyclopropyl).

In some embodiments, R² is heterocyclyl (e.g., morpholino or pyrrolidinyl).

In some embodiments, R² is aralkyl (e.g., benzyl).

In some embodiments, R² is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the heterocyclyl is piperidinyl. In some embodiments, the heterocyclyl is piperazinyl. In some embodiments, the heterocyclyl is piperazinyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is thiomorpholino. In some embodiments, the heterocyclyl is thiomorpholino substituted with 2 R⁶. In some embodiments, each R⁶ is oxo. In some embodiments, the heterocyclyl is:

In some embodiments, R² is halo (e.g., fluoro, chloro, bromo or iodo).

In some embodiments, R² is haloalkyl (e.g., trifluoromethyl).

In some embodiments, R² is haloalkoxy (e.g., trifluoromethoxy).

In some embodiments, R² is —CN.

In some embodiments, R² is —NO₂.

In some embodiments, R² is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen. In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are each hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl or ethyl). In some embodiments, the C₁-C₈ alkyl is ethyl substituted with 2 R⁶. In some embodiments, each R¹ is independently —OR^(d). In some embodiments, each R^(d) is C₁-C₈ alkyl (e.g., each R^(d) is methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclylalkyl (e.g., —CH₂—CH₂-morpholino). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is haloalkyl (e.g., trifluoroethyl).

In some embodiments, R² is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclyl (e.g., tetrahydropyranyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is tetrahydrofuranyl. In some embodiments, the heterocyclyl is tetrahydropyranyl. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is hydroxyalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is alkoxyalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkoxy is methoxy. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(e) is heterocyclyl. In some embodiments, R^(e) is tetrahydropyranyl.

In some embodiments, R² is —OR^(d),

In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is methyl substituted with 1 R⁶. In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino). In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl or R^(b) and R^(b′) are both ethyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R^(d) is ethyl. In some embodiments, R^(d) is C₃ alkyl (e.g., isopropyl or n-propyl). In some embodiments, R^(d) is optionally substituted heteroaralkyl. In some embodiments, R^(d) is optionally substituted pyrindinalkyl.

In some embodiments, R^(d) is n-propyl substituted with 1 R⁶. In some embodiments, R⁶ is —NR^(c)C(Y)R^(c′). In some embodiments, Y is O. In some embodiments, R^(c) and R^(c′) are each independently C₁-C₈ alkyl (e.g., R^(c) and R^(c′) are both methyl). In some embodiments, R^(d) is cyclyl (e.g., cyclopentyl).

In some embodiments, R^(d) is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, the pyridyl is substituted with 1 R^(d). In some embodiments, R⁶ is alkyl (e.g., methyl) or haloalkyl (e.g., CF). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(d) is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkyl is C₄ alkyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is piperidinyl. In some embodiments, the heterocyclyl is tetrahydrofuranyl. In some embodiments, R^(d) is cyclylalkyl (e.g., —CH₂-cyclobutyl).

In some embodiments, R^(d) is alkoxyalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkoxy is methoxy.

In some embodiments, R^(d) is dialkylaminoalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the dialkylamino is dimethylamino.

In some embodiments, R² is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl. In some embodiments, R^(e) is piperidinyl. In some embodiments, R^(e) is pyrrolidinyl. In some embodiments, R^(e) is piperazinyl. In some embodiments, R^(e) is piperazinyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(e) is morpholino. In some embodiments, R^(e) is thiomorpholino. In some embodiments, R^(e) is thiomorpholino substituted with 2 R⁶. In some embodiments, each R⁶ is oxo. In some embodiments, R^(e) is:

In some embodiments, n is 2.

In some embodiments, each R² is independently halo (e.g., each R² is chloro).

In some embodiments, each R² is independently —OR^(d).

In some embodiments, each R^(d) is C₁-C₈ alkyl.

In some embodiments, each R² is methoxy. In some embodiments, one R² is methoxy and the other is ethoxy. In some embodiments, one R² is methoxy and the other is propoxy. In some embodiments, one R² is methoxy and the other is isopropoxy.

In some embodiments, one R² is methoxy and the other is ethoxy substituted with 1 R⁶. In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is methoxy and the other is propoxy substituted with 1 R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, one R² is —OR^(d) and the other is halo (e.g., chloro). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is —CN. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is —C(O)OR^(a). In some embodiments, R^(d) and R^(a) are both hydrogen.

In some embodiments, one R² is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is —C(Y)R^(e). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, one R² is halo (e.g., chloro or bromo) and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is —CN.

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is heteroaryl (e.g., pyridyl). In some embodiments, the pyridyl is substituted with 1 R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is heterocyclylalkyl (e.g., —CH₂-morpholino).

In some embodiments, p is 0.

In some embodiments, p is 1.

In some embodiments, R³ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R³ is halo (e.g., chloro). In some embodiments, R³ is haloalkyl (e.g., trifluoromethyl). In some embodiments. R³ is oxo.

In some embodiments, R³ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R³ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R³ is heterocyclyl (e.g., piperazinyl). In some embodiments, R³ is piperazinyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, E is a 5-membered heteroaryl ring.

In some embodiments, E is a thiophene ring.

In some embodiments, E is a pyrrole ring.

In some embodiments, n is 1. In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl). In some embodiments, E is an N-methylpyrrole ring.

In some embodiments, L is NR⁵. In some embodiments, R⁵ is hydrogen.

In some embodiments, L is O.

In some embodiments, the compound is:

In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, R¹ is —C(Y)NR^(b)R^(b′),

In some embodiments, the compound is:

In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, R¹ is —C(Y)NR^(b)R^(b′).

In some embodiments, L and

In some embodiments, L and

In some embodiments, L is NH, and

is selected from

In some embodiments R⁶ is halo. In some embodiments, R^(b) or R^(b′) are disubstituted with R⁶ (e.g., dichloro, 4-fluoro, 3-chloro, or difluoro).

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, in is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —-C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₇—(C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

Compounds of Formula (V)

The following aspects and embodiments relate to compounds of formula (V), corresponding to formula (I) of U.S. Provisional Patent Application No. 61/291,550, entitled “Therapeutic Compounds and Related Methods of Use” filed on Dec. 31, 2009, and incorporated herein by reference in its entirety.

-   Item 40, A compound of formula (V):

wherein:

L is CR⁴R⁵, O, C(O), NR⁶C(O), or NR⁷;

A is CR⁸, CH or N;

each X¹, X², X³, X⁴ and X is independently CH or N, provided that at least two of X¹, X², X³, X⁴ and X⁵ are N;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2 or 3;

R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl or heterocyclylalkyl, each of which may be optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ may optionally be taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached, to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰;

each R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each of which is optionally substituted with 1-3 R¹¹;

each R⁴, R⁵, R⁶ and R⁷ is independently H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R⁴, R⁵, R⁶ and R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally further substituted; wherein two R⁸, two R⁹, two R¹⁰ or two R¹¹ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁸,

or a pharmaceutically acceptable derivative or prodrug thereof.

In some embodiments, A is CH. In some embodiments, A is N.

In some embodiments, L is NR⁷. In some embodiments, R⁷ is H.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, R¹ is phenyl substituted with 1 R⁹. In some embodiments, R¹ is phenyl substituted with 1 R⁹ in the ortho position. In some embodiments, R¹ is phenyl substituted with 1 R⁹ in the meta position. In some embodiments, R⁹ is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy). In some embodiments, R⁹ is —CN. In some embodiments, R⁹ is —C(O)OR^(a). In some embodiments, R¹ is hydrogen. In some embodiments, R⁹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R¹ is:

In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl),

In some embodiments, R¹ is phenyl substituted with 2 R⁹. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is fluoro or each R⁹ is chloro). In some embodiments, one R⁹ is fluoro and the other is chloro. In some embodiments, one R⁹ is halo (e.g., chloro) and the other is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, 2 R⁹ are taken together with the atoms to which they are attached to form a heterocyclyl ring, e.g., a 5-membered heterocyclyl ring (e.g., a dioxole ring). In some embodiments, the dioxole ring is unsubstituted. In some embodiments, the dioxole ring is substituted. In some embodiments, the dioxole ring is substituted with two fluoro substituents. In some embodiments, R¹ is selected from:

In some embodiments, R¹ is aralkyl (e.g., benzyl). In some embodiments, R¹ is aralkyl substituted with 2 R⁹ (e.g., benzyl substituted with 2 R⁹). In some embodiments, 2 R⁹ substituents are on the phenyl ring. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is chloro).

In some embodiments, R¹ is alkyl (e.g., methyl).

In some embodiments, n is 0.

In some embodiments, n is 1.

In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is C₁-C₈ alkyl substituted with 1 R¹¹ (e.g., methyl substituted with 1 R¹¹). In some embodiments, R¹¹ is heterocyclyl (e.g., morpholino).

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is phenyl substituted with 1 R¹¹. In some embodiments, R¹¹ is —CN. In some embodiments, R¹¹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R¹¹ is halo.

In some embodiments, R² is halo (e.g., fluoro, chloro, bromo or iodo).

In some embodiments, R² is —NR^(c)C(Y)R^(c′). In some embodiments, R^(c) is hydrogen. In some embodiments, Y is O. In some embodiments, R^(c′) is alkyl (e.g., methyl). In some embodiments, R^(c′) is aryl (e.g., phenyl). In some embodiments, R^(c′) is phenyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is heteroaryl. In some embodiments, R^(c′) is furanyl. In some embodiments, R^(c) is pyridyl. In some embodiments, R^(c′) is pyridyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is cyclyl (e.g., cyclohexyl). In some embodiments, R^(c′) is cyclohexyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is heterocyclyl (e.g., tetrahydropyranyl).

In some embodiments, R¹ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl).

In some embodiments, R² is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl or ethyl). In some embodiments, R^(d) is ethyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is —OCH₂CH₂OCH₃. In some embodiments, R² is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R² is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, n is 2.

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is halo (e.g., chloro).

In some embodiments, one R² is —OR^(d) and the other is halo (e.g., chloro). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, X¹ and X⁴ are N and X², X³ and X⁵ are CH.

In some embodiments, X¹ and X³ are N and X², X⁴ and X⁵ are CH.

In some embodiments, X² and X³ are N and X¹, X⁴ and X⁵ are CH.

In some embodiments, X² and X⁴ are N and X¹, X³ and X⁵ are CH.

In some embodiments, the compound is:

wherein s is 0, 1, 2, 3 or 4.

In some embodiments, R⁹ is —C(O)NH₂, C₁-C₄ alkoxy, or substituted C₁-C₄ alkoxy. In some embodiments, R⁹ is halo,

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

N wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

Compounds of Formula (VI)

The following aspects and embodiments relate to compounds of formula (VI) corresponding to formula (I) of U.S. Provisional Patent Application No. 61/291,554, entitled “Therapeutic Compounds and Related Methods of Use” filed on Dec. 31, 2009, and incorporated herein by reference in its entirety.

-   Item 41. A compound of formula (VI):

wherein:

A is CR⁵, CH or N;

L is O or NR⁶;

1, 2 or 3 of X¹, X², X³, X⁴ and X⁵ are N and the others are CH;

m is 0, 1, 2 or 3;

n is 0, 1, 2, 3 or 4;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷; or when L is NR⁶, R¹ or R⁷ may be taken together with R⁶ and the atoms to which they are attached to form a heterocyclyl or heteroaryl ring that is optionally substituted with 1-3 R⁸;

R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹;

each R³, R⁴ and R⁵ is independently C₁-C₈ alkyl, C₁-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰;

R⁶ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R¹¹;

each R⁷, R⁸, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷, two R⁸, two R⁹ or two R¹⁰ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R¹¹ and R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁷;

or a pharmaceutically acceptable derivative or prodrug thereof, wherein when R¹ is cyclopropyl, R⁹ is not

In some embodiments, R⁷ is not:

In some embodiments, R¹ is C₁-C₈ alkyl, which is optionally substituted with 1-3 R⁷; or when L is NR⁶, R¹ and R⁶ may be taken together with the atoms to which they are attached to form a heterocyclyl or heteroaryl ring that is optionally substituted with 1-3 R⁸.

In some embodiments, A is CH. In some embodiments, A is N.

In some embodiments, L is NR⁶. In some embodiments, R⁶ is hydrogen.

In some embodiments, R¹ is C₁-C₈ alkyl, e.g., methyl, ethyl, C₃ alkyl (e.g., n-propyl or isopropyl), C₄ alkyl (e.g., n-butyl, isobutyl or tert-butyl), or C₅ alkyl (e.g., pentan-3-yl).

In some embodiments, R¹ is C₁-C₈ alkyl substituted with 1-3 R⁷ (e.g., C₁-C₈ s alkyl substituted with 1 R⁷). In some embodiments, R¹ is methyl substituted with 1 R⁷. In some embodiments, R⁷ is cyclyl (e.g., cyclopropyl). In some embodiments, R⁷ is aryl (e.g., phenyl).

In some embodiments, R¹ is ethyl substituted with 1 R⁷. In some embodiments, R⁷ is aryl (e.g., phenyl). In some embodiments, R⁷ is —OR^(d). In some embodiments, R^(d) is aryl (e.g., phenyl).

In some embodiments, R¹ is n-propyl substituted with 1 R⁷. In some embodiments, R¹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., C₃ alkyl, e.g., n-propyl).

In some embodiments, R¹ is C₁-C₈ alkyl substituted with 3 R⁷. In some embodiments, R¹ is ethyl substituted with 3 R⁷. In some embodiments, each R¹ is independently halo (e.g., each R¹ is fluoro). In some embodiments, R¹ is 2,2,2-trifluoroethyl.

In some embodiments, R¹ is C₂-C₈ alkenyl, e.g., C₃ alkenyl (e.g., —CH₂—CH═CH₂).

In some embodiments, R¹ is C₂-C₈ alkynyl, e.g., C₃ alkynyl (e.g. —CH₂—C≡CH).

In some embodiments, R¹ is cyclyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl). In some embodiments, the cyclyl group is a bicyclic group (e.g., indanyl).

In some embodiments, R¹ is heterocyclyl (e.g., piperidyl). In some embodiments, R¹ is piperidyl substituted with 1 R⁷. In some embodiments, R⁷ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R¹ is —OR^(d).

In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ and R⁶ are taken together with the atoms to which they are attached to form a heterocyclyl ring (e.g., a pyrrolidine ring).

In some embodiments, R¹ and R⁶ are taken together with the atoms to which they are attached to form a heteroaryl ring (e.g., an imidazole ring).

In some embodiments, L is O.

In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is unsubstituted phenyl. In some embodiments, R² is phenyl substituted with 1-3 R⁹. In some embodiments, R² is phenyl substituted with 1 R⁹.

In some embodiments, R² is:

In some embodiments, R⁹ is halo (e.g., fluoro or chloro). In some embodiments, R⁹ is —CN. In some embodiments, R⁹ is —NO₂. In some embodiments, R⁹ is haloalkoxy (e.g., trifluoroethoxy). In some embodiments, R⁹ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl).

In some embodiments, R⁹ is —OR^(d). In some embodiments, R⁹ is —OCH₂CH₂OCH₃. In some embodiments, R⁹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R⁹ is —OCH₂CH₂OCH₂CH₂OCH₃. In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₅ alkyl (e.g., methyl). In some embodiments, R^(d) is methyl substituted with 1 R⁷. In some embodiments, R⁷ is —CYNR^(b)R^(b′). In some embodiments, Y is O and R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b) are both methyl). In some embodiments, R^(d) is ethyl. In some embodiments, R^(d) is ethyl substituted with 1 R⁷. In some embodiments, R¹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁷ is heterocyclyl (e.g., morpholino).

In some embodiments, R⁹ is hydroxyalkyl (e.g., —CH₂OH). In some embodiments, R⁹ is alkoxyalkyl (e.g., —CH₂—O—CH₃). In some embodiments, R⁹ is —C(O)R^(e). In some embodiments, R^(e) is heterocyclyl (e.g., morpholino). In some embodiments, R⁹ is —S(O)_(q)R^(f). In some embodiments, q is 1. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is phenyl substituted with 2 R⁹. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is fluoro). In some embodiments, each R⁹ is independently —OR^(d). In some embodiments, each R^(d) is independently C₁-C₈ alkyl (e.g., each R^(d) is methyl).

In some embodiments, R² is heteroaryl. In some embodiments, R² is a 6-membered heteroaryl. In some embodiments, R² is a 6-membered nitrogen-containing heteroaryl, e.g., pyridyl. In some embodiments, R² is unsubstituted pyridyl.

In some embodiments, R² is pyridyl substituted with 1 R⁹. In some embodiments, R⁹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is a 5-membered heteroaryl. In some embodiments, R² is a 5-membered nitrogen-containing heteroaryl (e.g., pyrrolyl or oxazolyl).

In some embodiments, m is 0.

In some embodiments, in is 1.

In some embodiments, R⁴ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁴ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁴ is halo. In some embodiments, R⁴ is methoxy. In some embodiments, R^(d) is C₁-C₈ alkyl.

In some embodiments, the compound has the following structure:

wherein one of X¹ and X² is N and the other is CHI.

In some embodiments, X¹ is CH and X² is N. In some embodiments, X¹ is N and X² is CH. In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

wherein R¹ is C₁-C₈ alkyl, which is optionally substituted with 1-3 R⁷.

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments R¹ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is

In some embodiments, the compound has the following structure:

wherein p is 1, 2, 3, 4 or 5,

In some embodiments, L is NR⁶. In some embodiments, L is O. In some embodiments, R¹ is hydrogen or C₁-C₈ alkyl. In some embodiments, R^(j) is cyclyl or heterocyclyl. In some embodiments, R¹ is aralkyl or heteroaralkyl. In some embodiments, R¹ is methyl, cyclohexyl, t-butyl, or

In some embodiments, R¹ is hydrogen or C₁-C₈ alkyl. In some embodiments, R⁹ is C₁-C₈ alkyl, halo, —CN, or —OR^(d). In some embodiments, R³ is hydrogen.

In some embodiments, the compound has the following structure:

wherein p is 1, 2, 3, 4 or 5.

In some embodiments, L is NR⁶. In some embodiments, L is O. In some embodiments, R¹ is hydrogen or C₁-C₈ alkyl. In some embodiments, R¹ is cyclyl or heterocyclyl. In some embodiments, R¹ is aralkyl or heteroaralkyl. In some embodiments, R¹ is methyl, cyclohexyl, t-butyl, or

In some embodiments, R⁶ is hydrogen or C₁-C₈ alkyl. In some embodiments, R⁹ is C₁-C₈ alkyl, halo, —CN, or —OR^(d). In some embodiments, R³ is hydrogen.

Aspects and Embodiments of Compounds of Formulas (I) (II), (III), (IV), (V), and (VI)

In one aspect, the invention features a composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and an acceptable carrier.

In one aspect, the invention features a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and a pharmaceutically acceptable carrier.

In one aspect, the invention features a kit comprising a composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and an acceptable carrier.

In one aspect, the invention features a kit comprising a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and a pharmaceutically acceptable carrier.

In one aspect, the invention features a dosage form comprising a composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and an acceptable carrier.

In one aspect, the invention features a dosage form comprising a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and a pharmaceutically acceptable carrier.

In one aspect, the invention features a method of treating a disorder that would benefit by the modulation of STEP (e.g., by activation or inhibition of STEP) in a subject, the method comprising administering to a subject in need thereof a compound of formula (I), (II), (III), (IV), (V), or (VI). In one aspect, the invention features a method of treating a disorder that would benefit by the inhibition of STEP, the method comprising administering to a subject in need thereof a compound of formula (I), (II), (III), (IV), (V), or (VI). In some embodiments, the disorder is selected from schizophrenia, schizoaffective disorder, bipolar disorder, manic-depressive disorder, psychosis, mood and anxiety disorders, mania, drug or substance addiction, cognition disorders, learning disabilities, learning and memory disorders, aging and neurologic disorders associated with or linked with cognitive impairments; mild cognitive impairments (MCI), Alzheimer's disease, Alzheimer-related cognition disorders, Huntington's disease, Parkinson's disease, CADASIL syndrome (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), amnesia, Wernicke-Korsakoff syndrome, Korsakoff syndrome, mild traumatic head injury (MBTI), traumatic head injury (TBI), fragile X syndrome, stroke, attention-deficit and hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), loss of concentration, autism, cerebral palsy, encephalopathy, and narcolepsy. In some embodiments, the disorder affects learning and memory, neurogenesis, neuronal plasticity, pain perception, mood and anxiety, or neuroendocrine regulation. In some embodiments, the disorder is a cognitive deficit disorder. In some embodiments, the disorder involves pain perception or neuroendocrine regulation. In some embodiments, the disorder affects the central nervous system. In some embodiments the disorder is selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar II type disorder; depression; endogenous depression; major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; agoraphobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; generalized anxiety disorder; acute stress disorder; hysteria; somatization disorder; conversion disorder; pain disorder; hypochondriasis; factitious disorder; dissociative disorder; sexual dysfunction; sexual desire disorder; sexual arousal disorder; erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep disorder; adjustment disorder; alcohol abuse; alcohol intoxication; drug addiction; stimulant intoxication; narcotism; anhedonia; iatrogenic anhedonia; anhedonia of a psychic or mental cause; anhedonia associated with depression; anhedonia associated with schizophrenia; delirium; cognitive impairment; cognitive impairment associated with Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases; cognitive impairment caused by Alzheimer's disease; Parkinson's disease and associated neurodegenerative diseases; cognitive impairment of schizophrenia; cognitive impairment caused by refractory, intractable or chronic schizophrenia; vomiting; motion sickness; obesity; migraine; pain (ache); mental retardation; autism disorder (autism); Tourette's disorder; tic disorder; attention-deficit/hyperactivity disorder; conduct disorder; and Down's syndrome.

In one aspect, the invention features a method of treating a condition that would benefit by the modulation of STEP (e.g., by activation or inhibition of STEP) in a subject, the method comprising administering to a subject in need thereof a compound of formula (I), (II), (III), (IV), (V), or (VI). In some embodiments, the condition is selected from decreased neurogenesis, cell resilience, or neuronal plasticity due to normal aging, neurodegenerative disorders of the CNS; Alzheimer's disease, Huntington's disease, fragile X syndrome, amyotrophic lateral sclerosis/Lou Gehrig's disease, stroke, Parkinson's disease, parkinsonism, dementia, Pick disease, Corticobasal degeneration, Multiple system atrophy, Progressive supranuclear palsy, traumatic brain injury, head trauma, mild traumatic head injury (MBTI), traumatic head injury (TBI), encephalopathy, intoxication related to ethanol, alcoholism, fetal alcohol syndrome, drug addiction or drug abuse.

In some embodiments, a compound of formula (I), (II), (III), (IV), (V), or (VI) is administered in combination with an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an atypical antipsychotic. In some embodiments, the additional therapeutic agent is selected from the group consisting of aripiprazole, clozapine, ziprasidone, risperidone, quetiapine, olanzapine, amisulpride, asenapine, iloperidone, melperone, paliperidone, perospirone, sertindole and sulpiride. In some embodiments, the additional therapeutic agent is a typical antipsychotic. In some embodiments, the additional therapeutic agent is selected from the group consisting of haloperidol, molindone, loxapine, thioridazine, molindone, thiothixene, pimozide, fluphenazine, trifluoperazine, mesoridazine, chlorprothixene, chlorpromazine, perphenazine, triflupromazine and zuclopenthixol.

DETAILED DESCRIPTION

A compound or composition described herein can be used, e.g., in a method of treating schizophrenia or cognitive deficit. Many of the compounds described herein modulate STEP activity and can be used, e.g., to reduce or inhibit STEP activity, e.g., in a subject.

DEFINITIONS

The term “acyl” refers to an alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, or heteroarylcarbonyl substituent, any of which may be further substituted (e.g., by one or more substituents).

The term “alkenyl” refers to a straight or branched hydrocarbon chain containing 2-12 carbon atoms (unless otherwise noted) and having one or more double bonds. Examples of alkenyl groups include, but are not limited to, allyl, propenyl, 2-butenyl, 3-hexenyl and 3-octenyl groups. One of the double bond carbons may optionally be the point of attachment of the alkenyl substituent.

The term “alkenylene” refers to a divalent alkenyl, e.g. —CH═CH—, —CH₂—CH═CH—, and —CH═CH—CH₂—.

The term “alkynyl” refers to a straight or branched hydrocarbon chain containing 2-12 carbon atoms (unless otherwise noted) and characterized in having one or more triple bonds. Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl, and 3-hexynyl. One of the triple bond carbons may optionally be the point of attachment of the alkynyl substituent.

The term “alkynylene” refers to a divalent alkynyl, e.g. —CH≡CH—, —CH₂—CH≡CH—, and —CH≡CH—CH₂—.

The terms “alkoxyl” or “alkoxy” as used herein refers to an alkyl group, as defined below, having an oxygen radical attached thereto. Representative alkoxy groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. The term “alkoxyalkyl” refers to an alkyl in which one or more hydrogen atoms are replaced by an alkoxy group.

An “ether” is two hydrocarbons covalently linked by an oxygen.

The term “alkyl” refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, and branched-chain alkyl groups. In preferred embodiments, a straight chain or branched chain alkyl has 12 or fewer carbon atoms in its backbone (unless otherwise noted) e.g., from 1-12, 1-8, 1-6, or 1-4. Exemplary alkyl moieties include methyl, ethyl, propyl (e.g., n-propyl or isopropyl), butyl (e.g., n-butyl, isobutyl or t-butyl), pentyl (e.g., n-pentyl, isopentyl or pentan-3-yl), hexyl and hepty.

The term “alkylene” refers to a divalent alkyl, e.g., —CH—, —CH₂ CH₂—, and —CH₂CH₂C₂—.

The term “alkoxylene” refers to an alkylene wherein a CH₂ is substituted with an oxygen. For example, an aryl alkoxylene refers to a group with an alkylene attached to an aryl group through an oxygen, an optionally substituted heteroaryl alkoxylene refers to a group with an alkylene attached to an heteroaryl group through an oxygen.

The term “amino” refers to —NH₂.

The term “aminoalkyl” refers to an alkyl in which one or more hydrogen atoms are replaced by an amino group.

The terms “alkylamino” and “dialkylamino” refer to —NH(alkyl) and —N(alkyl)₂ radicals respectively.

The term “aralkylamino” or “arylalkylamino” refers to a—NH(aralkyl) radical. The term “alkylaminoalkyl” refers to a (alkyl)NH-alkyl-radical; the term “dialkylaminoalkyl” refers to an (alkyl)₂N-alkyl-radical.

The term “amido” refers to a—NHC(O)— or C(O)NH₂ substituent.

The term “aryl” refers to a 6-carbon monocyclic, 10-carbon bicyclic, or 14-carbon tricyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent. Examples of aryl moieties include, but are not limited to, phenyl, naphthyl and the like. The term “arylalkyl” or “aralkyl” refers to alkyl substituted with an aryl. Exemplary aralkyls include but are not limited to benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 9-fluorenyl, benzhydryl, phenethyl, and trityl groups. The term “arylalkenyl” refers to an alkenyl substituted with an aryl. The term “arylalkynyl” refers to an alkynyl substituted with an aryl. Terms such as “arylC₂-C₆ alkyl” are to be read as a further limitation on the size of the alkyl group. The term “arylalkoxy” refers to an alkoxy substituted with aryl. The term “arylenyl” refers to a divalent aryl (i.e., —Ar—).

The terms “cycloalkyl” or “cyclyl” as employed herein include saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, preferably 3 to 8 carbons, and more preferably 3 to 6 carbons, wherein the cycloalkyl group may be optionally substituted. Exemplary cyclyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Cyclyl moieties also include both bridged and fused ring systems. Cyclyl groups also include those that are fused to additional ring systems, which may be saturated or unsaturated. A cyclyl group may thus be a bicyclic group in which one ring is saturated or partially unsaturated and the other is fully unsaturated (e.g., indanyl).

The term “cyclylalkyl” as used herein, refers to an alkyl group substituted with a cyclyl group. Cyclylalkyl includes groups in which more than one hydrogen atom of an alkyl group has been replaced by a cyclyl group.

The term “cycloalkylalkyl” as used herein, refers to an alkyl group substituted with a cycloalkyl group.

The term “halo” or “halogen” refers to any radical of fluorine, chlorine, bromine or iodine.

The term “haloalkyl” refers to an alkyl group that may have any number of hydrogens available on the group replaced with a halogen atom. Representative haloalkyl groups include but are not limited to: —CH₂Cl, —CH₂ClCF₃, —CHBr₂, —CF₃, —CH₂F, —CHF₂, and —CH₂CF₃. The term “fluoroalkyl” refers to an alkyl group that may have any number of hydrogens available on the group replaced with a fluorine atom. Representative fluoroalkyl groups include but are not limited to: —(CH₂F, —CH₂FCF₃, —CHF₂ and —CF₃. The term “haloalkoxy” refers to an alkoxy group that may have any number of hydrogen atoms available on the alkyl group replaced with a halogen atom. Representative haloalkoxy groups include but are not limited to: —OCH₂Cl, —OCH₂ClCF₃, —OCHBr₂, —OCHF₂ or —OCF₃. The term “fluoroalkoxy” refers to an alkoxy group that may have any number of hydrogens available on the group replaced with a fluorine atom, Representative fluoroalkoxy groups include but are not limited to: —OCH₂ F, —OCH₂FCF₃, —OCHF₂ or —OCF₃.

The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur, phosphorus and silicon. A heteroatom may be present in any oxidation state (e.g., any oxidized form of nitrogen, sulfur, phosphorus or silicon) and any charged state (e.g., the quaternized form of any basic nitrogen), and includes a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺ (as in N-substituted pyrrolidinyl).

The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent. Examples of heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, oxazolyl and the like. The term “heteroarylalkyl” or the term “heteroaralkyl” refers to an alkyl substituted with a heteroaryl. The term “heteroarylalkenyl” refers to an alkenyl substituted with a heteroaryl. The term “heteroarylalkynyl” refers to an alkynyl substituted with a heteroaryl. The term “heteroarylalkoxy” refers to an alkoxy substituted with heteroaryl.

The term “heteroaryl” refers to a group having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. A heteroaryl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic. When a heteroaryl is substituted by a hydroxy group, it also includes its corresponding tautomer. The term “heteroaryl,” as used herein, also includes groups in which a heteroaromatic ring is fused to one or more aryl rings. Nonlimiting examples of heteroaryl groups include thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. A ring nitrogen atom of a heteroaryl may be oxidized to form the corresponding N-oxide compound, A nonlimiting example of such a heteroaryl having an oxidized ring nitrogen atom is N-oxopyridyl.

The term “heteroarylalkyl” or “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl. Heteroaralkyl includes groups in which more than one hydrogen atom has been replaced by a heteroaryl group.

As used herein, the terms “heterocycle,” “heterocyclyl” and “heterocyclic ring” are used interchangeably and refer to a stable 3- to 8-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term “nitrogen” includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2/y-pyrrolyl), NH (as in pyrrolidinyl), or NR⁺ (as in N-substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, piperidinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and thiomorpholinyl. A heterocyclyl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic. Additionally, a heterocyclic ring also includes groups in which the heterocyclyl ring is fused to one or more aryl, heteroaryl or cyclyl rings. A ring nitrogen atom of a heterocyclic ring also may be oxidized to form the corresponding N-hydroxy compound.

The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl. Heterocyclylalkyl includes groups in which more than one hydrogen atom has been replaced by a heterocyclyl group.

The terms “hetaralkyl” and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a heteroaryl group. Exemplary heteroaralkyl groups include but are not limited to methylpyridyl or methylpyrimidyl.

The term “heterocyclyl” or “heterocyclylalkyl” refers to a nonaromatic 5-8 membered monocyclic, 5-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent. Examples of heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and include both bridged and fused ring systems. The term “heterocyclylalkyl” refers to an alkyl substituted with a heterocyclyl.

The term “heterocyclylalkyl”, as used herein, refers to an alkyl group substituted with a heterocycle group.

The term “heteroalkyl,” as used herein, refers to a saturate or unsaturated, straight or branched chain aliphatic group, wherein one or more of the carbon atoms in the chain are independently replaced by a heteroatom. Exemplary hetero atoms include O, S, and N.

In the case of aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl etc., groups described as optionally substituted, it is intended that either or both aryl, heteroaryl, cyclyl, heterocyclyl and alkyl moieties may be independently optionally substituted or unsubstituted.

The term “hydroxyalkyl” refers to an alkyl in which one or more hydrogen atoms are replaced by a hydroxy group.

The term “oxo” refers to an oxygen atom (═O), which forms a carbonyl when attached to carbon, an N-oxide when attached to nitrogen, and a sulfoxide or sulfone when attached to sulfur. The term “thioalkyl” as used herein refers to an —S(alkyl) group, where the point of attachment is through the sulfur atom and the alkyl group is as defined above. The term “thiono” or “thioxo” refers to a sulfur atom (═S), which forms a thioketone when attached to carbon.

The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.

The term “substituent” refers to a group “substituted” on a moiety described herein. Any atom on any substituent can be substituted. Substituents can include any substituents described herein. Exemplary substituents include, without limitation, alkyl (e.g., C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12 straight or branched chain alkyl), cycloalkyl, haloalkyl (e.g., perfluoroalkyl such as CF₃), aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, alkenyl, alkynyl, cycloalkenyl, heterocycloalkenyl, alkoxy, haloalkoxy (e.g., perfluoroalkoxy such as OCF₃), halo, hydroxy, carboxy, carboxylate, cyano, nitro, amino, alkylamino, SO₃H, sulfate, phosphate, methylenedioxy (—O—CH₂—O— wherein oxygens are attached to vicinal atoms), ethylenedioxy, oxo, thioxo (e.g., C═S), imino (alkyl, aryl, aralkyl), S(O)_(n) alkyl (where n is 0-2), S(O)_(n) aryl (where n is 0-2), S(O)_(n) heteroaryl (where n is 0-2), S(O)_(n) heterocyclyl (where n is 0-2), amine (mono-, di-, alkyl, cycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, and combinations thereof), ester (alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl), amide (mono-, di-, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, and combinations thereof), sulfonamide (mono-, di-, alkyl, aralkyl, heteroaralkyl, and combinations thereof). In one aspect, the substituents on a group are independently any one single, or any subset of the aforementioned substituents. In another aspect, a substituent may itself be substituted with any one of the above substituents.

As used herein, the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” In general, the term “substituted”, whether preceded by the term “optionally” or not, means that a hydrogen radical of the designated moiety is replaced with the radical of a specified substituent, provided that the substitution results in a stable or chemically feasible compound. The term “substitutable”, when used in reference to a designated atom, means that attached to the atom is a hydrogen radical, which hydrogen atom can be replaced with the radical of a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.

As used herein, the term “optionally substituted” means substituted or unsubstituted.

As used herein, the term “partially unsaturated” refers to a moiety that includes at least one double or triple bond between atoms. The term “partially unsaturated” encompasses rings, e.g., having one or more sites of unsaturation, but that are not completely unsaturated so as to be aryl or heteroaryl.

The term “chiral” refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. With respect to the nomenclature of a chiral center, terms “R” and “S” configuration are as defined by the IUPAC Recommendations. The term “enantiomers” refers to two stereoisomers of a compound which are non-superimposable mirror images of one another. An equimolar mixture of two enantiomers is called a “racemic mixture” or a “racemate.” The term “isomers” or “stereoisomers” refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space. For example, isomers include cis- and trans-isomers, E- and Z-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof. The term “diastereomers” refers to stereoisomers with two or more centers of dissymmetry and whose molecules are not mirror images of one another.

The term “administration” or “administering” includes routes of introducing the compounds, or a composition thereof, of the invention to a subject to perform their intended function. Examples of routes of administration that may be used include injection (subcutaneous, intravenous, parenterally, intraperitoneally, intrathecal), oral, inhalation, rectal and transdermal. The pharmaceutical compositions may be given by forms suitable for each administration route. For example, these compositions are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred. The injection can be bolus or can be continuous infusion. Depending on the route of administration, a compound described herein can be coated with or disposed in a selected material to protect it from natural conditions which may detrimentally affect its ability to perform its intended function. A compound or composition described herein can be administered alone, or in conjunction with either another agent as described above or with a pharmaceutically-acceptable carrier, or both. A compound or composition described herein can be administered prior to the administration of the other agent, simultaneously with the agent, or after the administration of the agent. Furthermore, a compound described herein can also be administered in a pro-drug form which is converted into its active metabolite, or more active metabolite in vivo.

The language “biological activities” of a compound described herein includes all activities elicited by a compound described herein in a responsive subject or cell. It includes genomic and non-genomic activities elicited by these compounds.

The terms “inhibit” and “inhibitor” as used herein means an agent that measurably slows or stops the production of STriatal-Enriched tyrosine Phosphatase (STEP), or decreases or inactivates STEP, or interferes with STEP-mediated biological pathways. Inhibitors of STEP include compounds of the invention, e.g., compounds of Formulas (I), (II), or (III). A compound can be evaluated to determine if it is an inhibitor by measuring either directly or indirectly the activity of STEP in the presence of the compound suspected to inhibit STEP. Exemplary methods of measure STEP inhibition are described in the EXAMPLES herein.

An “effective amount” or “an amount effective” refers to an amount of the compound or composition which is effective, upon single or multiple dose administrations to a subject and for periods of time necessary, in treating a cell, or curing, alleviating, relieving or improving a symptom of a disorder, e.g., a disorder described herein. An effective amount of a compound described herein may vary according to factors such as the disease state, age, and weight of the subject, and the ability of a compound described herein to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of a compound described herein are outweighed by the therapeutically beneficial effects. The term “effective amount” includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result, e.g., modulate or regulate protein tyrosine phosphatases, e.g., STEP, in a subject and/or treat a disorder described herein such as a protein tyrosine phosphatase related disorder. Exemplary disorders include those related to cognition, learning and n memory, neurogenesis. An effective amount may also affect neuronal plasticity, pain perception, mood and anxiety, and neuroendocrine regulation.

An effective amount of a compound described herein may vary according to factors such as the disease state, age, and weight of the subject, and the ability of a compound described herein to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of a compound described herein are outweighed by the therapeutically beneficial effects.

A therapeutically effective amount of a compound described herein (i.e., an effective dosage) may range from about 0.001 to 50 mg/kg body weight, preferably about 0.01 to 40 mg/kg body weight, more preferably about 0.1 to 35 mg/kg body weight, still more preferably about 1 to 30 mg/kg, and even more preferably about 10 to 30 mg/kg. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a compound described herein can include a single treatment or, preferably, can include a series of treatments. In one example, a subject is treated with a compound described herein in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of a compound described herein used for treatment may increase or decrease over the course of a particular treatment.

As used herein, an amount of a compound effective to prevent a disorder, or “a prophylactically effective amount” of the compound refers to an amount effective, upon single- or multiple-dose administration to the subject, in preventing or delaying the occurrence of the onset or recurrence of a disorder or a symptom of the disorder.

The language “improved biological properties” refers to any activity inherent in a compound described herein that enhances its effectiveness in vivo. In a preferred embodiment, this term refers to any qualitative or quantitative improved therapeutic property of a compound described herein, such as reduced off-target effects.

The term “modulate” refers to an increase or decrease, e.g., in the activity of an enzyme in response to exposure to a compound or composition described herein, e.g., the activation or inhibition of STEP, in at least a sub-population of cells in a subject such that a desired end result is achieved (e.g., a therapeutic result). In some embodiments, a compound as described herein inhibits a target described herein, e.g., STEP. In some embodiments, a compound as described herein is activates a target described herein, e.g., STEP.

As used herein, the term “subject” is intended to include human and non-human animals. Exemplary human subjects include a human patient having a disorder, e.g., a disorder described herein, or a normal subject. The term “non-human animals” includes all vertebrates, e.g., non-mammals (such as chickens, amphibians, reptiles) and mammals, such as non-human primates, domesticated and/or agriculturally useful animals, e.g., sheep, dog, cat, cow, pig, etc.

As used herein, the term “treat” or “treating” is defined as applying or administering a compound or composition, alone or in combination with a second compound or composition, to a subject, e.g., a patient, or applying or administering the compound or composition to an isolated tissue or cell, e.g., cell line, from a subject, e.g., a patient, who has a disorder (e.g., a disorder as described herein), a symptom of a disorder, or a predisposition toward a disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disorder, one or more symptoms of the disorder or the predisposition toward the disorder (e.g., to prevent at least one symptom of the disorder or to delay onset of at least one symptom of the disorder).

The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

The term “prodrug” or “pro-drug” includes compounds with moieties that can be metabolized in vivo. Generally, the prodrugs are metabolized in vivo by esterases or by other mechanisms to active drugs. Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19). The prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Hydroxyl groups can be converted into esters via treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides. Preferred prodrug moieties are propionic acid esters and acyl esters. Prodrugs which are converted to active forms through other mechanisms in vivo are also included.

The language “a prophylactically effective amount” of a compound refers to an amount of a compound described herein any formula herein or otherwise described herein which is effective, upon single or multiple dose administration to the patient, in preventing or treating a disease or condition.

The language “reduced off-target effects” is intended to include a reduction in any undesired side effect elicited by a compound described herein when administered in vivo. In some embodiments, a compound described herein has little to no cardio and/or pulmonary toxicity (e.g., when administered to a subject). In some embodiments, a compound described herein has little to no hallucinogenic activity (e.g., when administered to a subject).

The term “selective” means a greater activity against a first target. In some embodiments a compound has a selectivity of at least 1.25-fold, at least 1.5 fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 10-fold or at least 100-fold greater towards a first target relative to a second target. In some embodiments, a compound described herein, e.g., a compound of Formulas (I), (II), or (III) is selective toward STEP relative to one or more other protein tyrosine phosphatases.

The term “subject” includes organisms which are capable of suffering from a serotonin-receptor-related disorder or who could otherwise benefit from the administration of a compound described herein of the invention, such as human and non-human animals. Preferred humans include human patients suffering from or prone to suffering from a serotonin-related disorder or associated state, as described herein. The term “non-human animals” of the invention includes all vertebrates, e.g., mammals, e.g., rodents, e.g., mice, and non-mammals, such as non-human primates, e.g., sheep, dog, cow, chickens, amphibians, reptiles, etc.

The phrases “systemic administration,” “administered systemically”, “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound described herein(s), drug or other material, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

Compounds

The compounds described herein can be used for a variety of purposes, e.g., therapeutic purposes. Many of the compounds modulate STEP activity and can be used, for example to inhibit STEP, e.g., in a subject.

Exemplary compounds include a compound of formula (I):

wherein A, B, E, L, X, Z, R¹, R², R³, m, n and p are as defined above in the section relating to compound of Formula (I). In preferred embodiments, L is NH, B is aryl (e.g., phenyl) that may be optionally substituted, E is aryl (e.g., phenyl), A is N, X is CH and Z is N.

Exemplary compounds include a compound of formula (II):

wherein A, L, X¹. X², X³, X⁴, X⁵, R¹, R², R³, n and p are as defined above in the section relating to compound of Formula (II).

Exemplary compounds include a compound of formula (III):

wherein A, L, X¹, X², X³, X⁴, X⁵, R¹, R², R³, R⁴, m and n are as defined above in the section relating to compound of Formula (III).

Exemplary compounds include a compound of formula (IV):

wherein A, B, E, L, X, Z, R¹, R², R³, m, n and p are as defined above in the section relating to compound of Formula (IV). In preferred embodiments, L is NH, B is aryl (e.g., phenyl) that may be optionally substituted, E is aryl (e.g., phenyl), A is N, X is CH and Z is N.

Exemplary compounds include a compound of formula (V):

wherein A, L, X¹, X², X³, X⁴, X⁵, R¹, R², R³, n and p are as defined above in the section relating to compound of Formula (V).

Exemplary compounds include a compound of formula (VI):

wherein A, L, X¹, X², X³, X⁴, R¹, R², R³, R⁴, m, and n are as defined above in the section relating to compound of Formula (VI).

The present invention includes compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, the replacement of a carbon by a ¹³C- or ¹⁴ C-enriched carbon, or the replacement of a fluorine by a ¹⁹F-enriched fluorine are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays, or as bioactive agents.

In the compounds of the present invention, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom unless otherwise stated (e.g., hydrogen, ²H or deuterium and ³H or tritium). The formulas described herein may or may not indicate whether atoms at certain positions are isotopically enriched. When a structural formula is silent with respect to whether a particular position is isotopically enriched, it is to be understood that the isotopes at that particular position are present in natural abundance or, that the particular position is isotopically enriched with one or more naturally occurring stable isotopes. For example, the formula —CH₂— represents the following possible structures: —CH₂—, —CHD- or —CD₂-.

The variable “D” is defined as deuterium.

The terms “compound” or “compounds,” when referring to a compound of this invention or a compound described herein, refers to a collection of molecules having an identical chemical structure, except that there may be isotopic variation among the constituent atoms of the molecules. Thus, it will be clear to those of skill in the art that a compound represented by a particular chemical structure containing indicated hydrogen atoms will contain lesser amounts of isotopologues having deuterium atoms at one or more of the designated hydrogen positions in that structure. Alternatively, a compound represented by a particular chemical structure containing indicated deuterium atoms will contain lesser amounts of isotopologues having hydrogen atoms at one or more of the designated deuterium positions in that structure. The relative amount of such isotopologues in a compound of this invention will depend on a number of factors including isotopic purity of deuterated reagents used to make the compound and the efficiency of incorporation of deuterium in the various synthetic steps used to prepare the compound. The relative amount of such isotopologues in total will be less than 55% of the compound. In other embodiments, the relative amount of such isotopologues in total will be less than 50%, less than 45%, less than 40%, less than 35%, less than 35%, less than 15%, less than 10%, less than 5%, less than 1% or less than 0.5% of the compound.

The term “isotopologue” refers to a species that differs from a specific compound of this invention only in the isotopic composition thereof. Isotopologues can differ in the level of isotopic enrichment at one or more positions and/or in the position(s) of isotopic enrichment.

The compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomneric mixtures, Described herein are enantiomerically enriched compounds (e.g., a compound resolved to an enantiomeric excess of 60%, 70%, 80%, 85%, 90%, 95%, 99% or greater). All such isomeric forms of these compounds are expressly included in the present invention. The compounds of this invention may also contain linkages (e.g., carbon-carbon bonds) or substituents that can restrict bond rotation, e.g. restriction resulting from the presence of a ring or double bond. Accordingly, all cis/trans and E/Z isomers are expressly included in the present invention. The compounds of this invention may also be represented in multiple tautomeric forms, in such instances, the invention expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented (e.g., alkylation of a ring system may result in alkylation at multiple sites, the invention expressly includes all such reaction products). All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.

Naturally occurring or synthetic isomers can be separated in several ways known in the art. Methods for separating a racemic mixture of two enantiomers include chromatography using a chiral stationary phase (see, e.g., “Chiral Liquid Chromatography,” W. J. Lough, Ed. Chapman and Hall, New York (1989)). Enantiomers can also be separated by classical resolution techniques. For example, formation of diastereomeric salts and fractional crystallization can be used to separate enantiomers. For the separation of enantiomers of carboxylic acids, the diastereomeric salts can be formed by addition of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, and the like. Alternatively, diastereomeric esters can be formed with enantiomerically pure chiral alcohols such as menthol, followed by separation of the diastereomneric esters and hydrolysis to yield the free, enantiomerically enriched carboxylic acid. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts. For example a compound can be resolved to an enantiomeric excess (e.g., 60%, 70%, 80%, 85%, 90%, 95%, 99% or greater) via formation of diasteromeric salts, e.g. with a chiral base, e.g., (+) or (−) α-methylbenzylamine, or via high performance liquid chromatography using a chiral column. In some embodiments a product is purified directly on a chiral column to provide enantiomerically enriched compound.

Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term “stable”, as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic administration to a subject).

Compounds of formulas (I), (II), (Iii), (IV), (V), and (VI) are described herein, for example as provided in the summary above. Exemplary compounds are shown in Tables 1-30 in the Examples section.

Synthetic Methods

A compound described herein may be prepared via a variety of synthetic methods. Representative syntheses are shown in the Examples section.

As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2d Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

Additionally, the compounds disclosed herein can be prepared on a solid support. The term “solid support” refers a material to which a compound is attached to facilitate identification, isolation, purification, or chemical reaction selectivity of the compound. Such materials are known in the art and include, for example, beads, pellets, disks, fibers, gels, or particles such as cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene and optionally grafted with polyethylene glycol, poly-acrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with N,N′-bis-acryloyl ethylene diamine, glass particles coated with hydrophobic polymer, and material having a rigid or semi-rigid surface. The solid supports optionally have functional groups such as amino, hydroxy, carboxy, or halo groups, (see, Obrecht, D. and Villalgrodo, J. M., Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries, Pergamon-Elsevier Science Limited (1998)), and include those useful in techniques such as the “split and pool” or “parallel” synthesis techniques, solid-phase and solution-phase techniques, and encoding techniques (see, for example, Czarnik, A. W., Curr. Opin. Chem. Bio., (1997) 1, 60).

A compound described herein may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., brain, blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

Included herein are pharmaceutically acceptable derivatives or prodrugs of the compounds described herein. A “pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention (for example an imidate ester of an amide), which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound described herein. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. In an exemplary embodiment, the prodrug is a derivative including a group that enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae described herein. In another exemplary embodiment, the prodrug is suitable for treatment or prevention of those diseases and conditions that require the drug molecule to cross the blood brain barrier. In a preferred embodiment, the prodrug enters the brain, where it is converted into the active form of the drug molecule.

Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate and undecanoate. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl)₄ ⁺ salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.

Evaluating Compounds

A variety of methods can be used to evaluate a compound for ability to modulate STEP activity. Evaluation methods include in vitro assays (e.g., enzyme-based assays), in vitro cell-based signaling assays, and in vivo methods (e.g., testing in animal models). The evaluation methods can evaluate binding activity, phosphatase activity, or an activity downstream of STEP, such as the activity of ERK.

For example, a compound described herein may be evaluated using a fluorescence-based phosphatase assay. A phosphate-containing reagent may be used in the assay which, upon dephosphorylation by a phosphatase, generates a fluorescent product that may be detected using a fluorometer or fluorescence plate reader. Data may be expressed as percentage (%) inhibition of enzyme activity. For compounds showing enzymatic activation, data may be represented as percentage of inhibition but with negative values.

Compositions and Routes of Administration

The invention also provides a pharmaceutical composition, comprising an effective amount of a compound described herein (e.g., a compound capable of treating or preventing a condition as described herein, e.g., a compound of any formula herein or otherwise described herein) and a pharmaceutically acceptable carrier.

The compositions delineated herein include the compounds delineated herein (e.g., a compound described herein), as well as additional therapeutic agents if present, in amounts effective for achieving a modulation of disease or disease symptoms, including those described herein.

The term “pharmaceutically acceptable carrier or adjuvant” refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.

Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α-, β-, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.

The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch, Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.

The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.

Topical administration of the pharmaceutical compositions of this invention is useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.

The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

When the compositions of this invention comprise a combination of a compound of the formulae described herein and one or more additional therapeutic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.

The compounds described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.5 to about 100 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active compound.

Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.

Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

Methods of Treatment

The compounds and compositions described herein can be administered to cells in culture, e.g. in vitro or ex vivo, or to a subject, e.g., in vivo, to treat, prevent, and/or diagnose a variety of disorders, including those described herein below.

The compounds and compositions described herein can be administered to a subject, for example using a method described herein, who is suffering from a disorder described herein, e.g., a disorder that would benefit from the modulation of STEP (e.g., activating or inhibiting STEP). The compounds and compositions described herein can be administered to a subject, for example using a method described herein, who is at risk for a disorder described herein, e.g., a disorder that would benefit from the modulation of STEP (e.g., activating or inhibiting STEP).

Inhibitors of STEP may increase phosphorylation of an NMDA-R. Thus, in some embodiments, a compound described herein, e.g., a compound that inhibits STEP, may be useful for treating a disorder in which increasing phosphorylation of an NMDA-R would be beneficial.

Inhibitors of STEP may activate an ERK1 or ERK2 kinase, for example, in the CNS. Thus, in some embodiments, a compound described herein, e.g., a compound that inhibits STEP, may be useful for treating a disorder in which activate an ERK1 or ERK2 kinase would be beneficial.

Compounds described herein may be useful in treating a variety of disorders, including disorders of the CNS. Exemplary disorders include schizophrenia, schizo-affective disorders, major depression, bipolar disorder, cognitive deficit, mild cognitive impairment (MCI), Alzheimer's disease (AD), attention-deficit/hyperactivity disorder (ADHD), dementia, generalized anxiety disorders, panic disorders, obsessive-compulsive disorders, phobias, post-traumatic stress syndrome, anorexia nervosa, drug addiction, ischemic stroke, head trauma or brain injury, Huntington's disease, Parkinson's disease, spinocerebellar degeneration, motor neuron diseases, epilepsy, neuropathic pain, chronic pain, neuropathies, autism and autistic disorders.

Compounds described herein may be useful for treating or preventing central nervous system disorders selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar II type disorder; depression; endogenous depression; major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; agoraphobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; generalized anxiety disorder; acute stress disorder; hysteria; somatization disorder; conversion disorder; pain disorder; hypochondriasis; factitious disorder; dissociative disorder; sexual dysfunction; sexual desire disorder; sexual arousal disorder; erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep disorder; adjustment disorder; alcohol abuse; alcohol intoxication; drug addiction; stimulant intoxication; narcotism; anhedonia; iatrogenic anhedonia; anhedonia of a psychic or mental cause; anhedonia associated with depression; anhedonia associated with schizophrenia; delirium; cognitive impairment; cognitive impairment associated with Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases; cognitive impairment caused by Alzheimer's disease; Parkinson's disease and associated neurodegenerative diseases; cognitive impairment of schizophrenia; cognitive impairment caused by refractory, intractable or chronic schizophrenia; vomiting; motion sickness; obesity; migraine; pain (ache); mental retardation; autism disorder (autism); Tourette's disorder; tic disorder; attention-deficit/hyperactivity disorder; conduct disorder; and Down's syndrome.

Compounds described herein may be useful for treating or preventing disorders selected from schizophrenia, schizoaffective disorder, bipolar disorder, manic-depressive disorder, psychosis, mood and anxiety disorders, mania, drug or substance addiction, cognition disorders, learning disabilities, learning and memory disorders, aging and neurologic disorders associated with or linked with cognitive impairments; mild cognitive impairments (MCI), Alzheimer's disease, Alzheimer-related cognition disorders, Huntington's disease, Parkinson's disease, CADASIL syndrome (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), amnesia, Wernicke-Korsakoff syndrome, Korsakoff syndrome, mild traumatic head injury (MBTI), traumatic head injury (TBI), fragile X syndrome, stroke, attention-deficit and hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), loss of concentration, autism, cerebral palsy, encephalopathy, and narcolepsy. The disorder may affect learning and memory, neurogenesis, neuronal plasticity, pain perception, mood and anxiety, or neuroendocrine regulation. The disorder may be a cognitive deficit disorder. The disorder may involve pain perception or neuroendocrine regulation.

Schizophrenia

In some embodiments, a compound or composition described herein can be used in the treatment of schizophrenia. Schizophrenia is a psychiatric diagnosis that describes a mental disorder characterized by abnormalities in the perception or expression of reality. Distortions in perception may affect all five senses, including sight, hearing, taste, smell and touch, but most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking with significant social or occupational dysfunction. Onset of symptoms typically occurs in young adulthood, with approximately 0.4-0.6% of the population affected. Diagnosis is based on the patient's self-reported experiences and observed behavior.

The disorder is thought to mainly affect cognition, but it also usually contributes to chronic problems with behavior and emotion. People with schizophrenia are likely to have additional (comorbid) conditions, including major depression and anxiety disorders. Social problems, such as long-term unemployment, poverty and homelessness, are common. Furthermore, the average life expectancy of people with the disorder is 10 to 12 years less than those without, due to increased physical health problems and a higher suicide rate.

The Diagnostic and Statistical Manual of Mental Disorders (DSM) contains five sub-classifications of schizophrenia. These include Paranoid type (where delusions and hallucinations are present but thought disorder, disorganized behavior, and affective flattening are absent); Disorganized type (also known as hebephrenic schizophrenia, where thought disorder and flat affect are present together); Catatonic type (the subject may be almost immobile or exhibit agitated, purposeless movement; symptoms can include catatonic stupor and waxy flexibility); Undifferentiated type (psychotic symptoms are present but the criteria for paranoid, disorganized, or catatonic types have not been met); and Residual type (where positive symptoms are present at a low intensity only).

The International Statistical Classification of Diseases and Related Health Problems (10th Revision) defines two additional subtypes. These include Post-schizophrenic depression (a depressive episode arising in the aftermath of a schizophrenic illness where some low-level schizophrenic symptoms may still be present); and Simple schizophrenia (insidious and progressive development of prominent negative symptoms with no history of psychotic episodes.)

An agent for the treatment of schizophrenia may improve so-called positive symptoms in the acute period of schizophrenia such as hallucinations, delusions, excitations and the like. An agent for treating schizophrenia may also improve so-called negative symptoms that are observed in the chronic period of schizophrenia such as apathy, emotional depression, hyposychosis and the like.

Schizoaffective Disorder

Schizoaffective disorder is a psychiatric diagnosis that describes a mental disorder characterized by recurring episodes of elevated or depressed mood, or simultaneously elevated and depressed mood that alternate or occur together with distortions in perception. The perceptual distortion component of the disorder, called psychosis, may affect all five senses, including sight, hearing, taste, smell and touch, but most commonly manifest as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking with significant social and occupational dysfunction. The elevated, depressed or simultaneously elevated and depressed mood episode components of the disorder, called mood disorder, are broadly recognized as depressive and bipolar types of the illness; the division is based on whether the individual has ever had a manic, hypomanic or mixed episode. Onset of symptoms usually begins in early adulthood and is rarely diagnosed in childhood (prior to age 13). The lifetime prevalence of the disorder is uncertain (due to studies using varying diagnostic criteria), although it is generally agreed to be less than 1 percent, and possibly in the range of 0.5 to 0.8 percent. Diagnosis is based on the patient's self-reported experiences and observed behavior. No laboratory test for schizoaffective disorder currently exists. As a group, people with schizoaffective disorder have a more favorable prognosis than people with schizophrenia, but a worse prognosis than those with mood disorders.

The disorder is thought to mainly affect cognition and emotion, but it also usually contributes to ongoing problems with behavior and motivation. People with schizoaffective disorder are likely to have additional (comorbid) conditions, including anxiety disorders and substance abuse. Social problems, such as long-term unemployment, poverty and homelessness, are common. Furthermore, the average life expectancy of people with the disorder is shorter than those without the disorder, due to increased physical health problems and a higher suicide rate.

Cognitive Deficit

Treatment using a compound or composition described herein may improve a cognitive deficit associated with a cognition-related disorder. Cognitive deficit is an inclusive term to describe any characteristic that acts as a barrier to cognitive performance. The term may describe deficits in global intellectual performance, such as mental retardation, it may describe specific deficits in cognitive abilities (learning disorders, dyslexia), or it may describe drug-induced cognitive/memory impairment, such as that seen with alcohol and the benzodiazepines. Cognitive deficits may be congenital or caused by environmental factors such as brain injuries, neurological disorders, or mental illness.

Exemplary cognition-related disorders (e.g., cognitive dysfunction) include, without limitation, mild cognitive impairment (MCI), dementia, delirium, amnestic disorder, Alzheimer's disease, Parkinson's disease and Huntington's disease; memory disorders including memory deficits associated with depression, senile dementia, dementia of Alzheimer's disease; cognitive deficits or cognitive dysfunction associated with neurological conditions including, for example, Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, depression, schizophrenia and other psychotic disorders such as paranoia and manic-depressive illness; cognitive dysfunction in schizophrenia: disorders of attention and learning such as attention deficit disorders (e.g., attention deficit hyperactivity disorder (ADHD)) and dyslexia; cognitive dysfunction associated with developmental disorders such as Down's syndrome and Fragile X syndrome; loss of executive function: loss of learned information; vascular dementia; schizophrenia; cognitive decline; a neurodegenerative disorder; and other dementias, for example, dementia due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple etiologies. Cognition-related disorders also include, without limitation, cognitive dysfunction associated with MCI and dementias such as Lewy Body, vascular, and post stroke dementias. Cognitive dysfunction associated with surgical procedures, traumatic brain injury or stroke may also be treated in accordance with the embodiments described herein.

Major Depression

Major depression (also known as clinical depression, major depressive disorder, unipolar depression, or unipolar disorder) is a mental disorder characterized by a pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Types of Major depressive disorder include, e.g., Atypical depression, Melancholic depression, Psychotic depression, Catatonic depression, Postpartum depression, and Seasonal affective disorder.

Bipolar Disorder

Bipolar disorder, also known as manic depressive disorder, manic depressive psychosis, manic depression or bipolar affective disorder, is a psychiatric diagnosis that describes a category of mood disorders defined by the presence of one or more episodes of abnormally elevated mood clinically referred to as mania or, if milder, hypomania. Individuals who experience manic episodes also commonly experience depressive episodes or symptoms, or mixed episodes in which features of both mania and depression are present at the same time. These episodes are usually separated by periods of “normal” mood, but in some individuals, depression and mania may rapidly alternate, known as rapid cycling. Extreme manic episodes can sometimes lead to psychotic symptoms such as delusions and hallucinations. The disorder has been subdivided into bipolar I, bipolar II, cyclothymia, and other types, based on the nature and severity of mood episodes experienced; the range is often described as the bipolar spectrum.

Anxiety Disorders

Anxiety disorder is a blanket term covering several different forms of abnormal and pathological fear and anxiety. Current psychiatric diagnostic criteria recognize a wide variety of anxiety disorders. Recent surveys have found that as many as 18% of Americans may be affected by one or more of them.

Generalized anxiety disorder is a common chronic disorder characterized by long-lasting anxiety that is not focused on any one object or situation. Those suffering from generalized anxiety experience non-specific persistent fear and worry and become overly concerned with everyday matters. Generalized anxiety disorder is the most common anxiety disorder to affect older adults.

In panic disorder, a person suffers from brief attacks of intense terror and apprehension, often marked by trembling, shaking, confusion, dizziness, nausea, difficulty breathing. These panic attacks, defined by the APA as fear or discomfort that abruptly arises and peaks in less than ten minutes, can last for several hours and can be triggered by stress, fear, or even exercise; although the specific cause is not always apparent. In addition to recurrent unexpected panic attacks, a diagnosis of panic disorder also requires that said attacks have chronic consequences: either worry over the attacks' potential implications, persistent fear of future attacks, or significant changes in behavior related to the attacks. Accordingly, those suffering from panic disorder experience symptoms even outside of specific panic episodes. Often, normal changes in heartbeat are noticed by a panic sufferer, leading them to think something is wrong with their heart or they are about to have another panic attack. In some cases, a heightened awareness (hypervigilance) of body functioning occurs during panic attacks, wherein any perceived physiological change is interpreted as a possible life threatening illness (i.e. extreme hypochondriasis).

Obsessive compulsive disorder is a type of anxiety disorder primarily characterized by repetitive obsessions (distressing, persistent, and intrusive thoughts or images) and compulsions (urges to perform specific acts or rituals). The OCD thought pattern may be likened to superstitions insofar as it involves a belief in a causative relationship where, in reality, one does not exist. Often the process is entirely illogical; for example, the compulsion of walking in a certain pattern may be employed to alleviate the obsession of impending harm. And in many cases, the compulsion is entirely inexplicable, simply an urge to complete a ritual triggered by nervousness. In a minority of cases, sufferers of OCD may only experience obsessions, with no overt compulsions; a much smaller number of sufferers experience only compulsions.

The single largest category of anxiety disorders is that of Phobia, which includes all cases in which fear and anxiety is triggered by a specific stimulus or situation. Sufferers typically anticipate terrifying consequences from encountering the object of their fear, which can be anything from an animal to a location to a bodily fluid.

Post-traumatic stress disorder or PTSD is an anxiety disorder which results from a traumatic experience. Post-traumatic stress can result from an extreme situation, such as combat, rape, hostage situations, or even serious accident. It can also result from long term (chronic) exposure to a severe stressor, for example soldiers who endure individual battles but cannot cope with continuous combat. Common symptoms include flashbacks, avoidant behaviors, and depression.

Combination Therapies

In some embodiments, the subject is being treated with an additional therapeutic agent. Such additional agents include atypical antipsychotics such as aripiprazole, clozapine, ziprasidone, risperidone, quetiapine, olanzapine, amisulpride, asenapine, iloperidone, melperone, paliperidone, perospirone, sertindole and sulpiride; and typical antipsychotics such as haloperidol, molindone, loxapine, thioridazine, molindone, thiothixene, pimozide, fluphenazine, trifluoperazine, mesoridazine, chlorprothixene, chlorpromazine, perphenazine, triflupromazine and zuclopenthixol.

Clinical Outcomes

In some embodiments, treatment with a compound or composition described herein, for example, using a method described herein, improves one or more clinical outcomes. For example, in some embodiments, treatment with a compound or composition described herein may improve cognitive function. Elements of cognitive function include memory, orientation, attention, reasoning, language and praxis.

In some embodiments, clinical outcomes may be assessed using known methods. One such method is the Brief Psychiatric Rating Scale (BPRS), a multi-item inventory of general psychopathology traditionally used to evaluate the effects of drug treatment in schizophrenia. The BPRS psychosis cluster (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) is considered a particularly useful subset for assessing actively psychotic schizophrenic patients.

In some embodiments, clinical outcomes may be assessed using the 7-point Clinical Global Impression (CGI) rating scale, a commonly used measure of symptom severity, treatment response and the efficacy of treatments. The CGI reflects the impression of a skilled observer, fully familiar with the manifestations of schizophrenia, about the overall clinical state of the patient.

In some embodiments, clinical outcomes may be assessed using the 30-item Positive and Negative Symptoms Scale (PANSS). The name refers to the two types of symptoms in schizophrenia, as defined by the American Psychiatric Association: positive symptoms, which refer to an excess or distortion of normal functions (e.g. hallucinations and delusions), and negative symptoms, which represent a dimunition or loss of normal functions.

In some embodiments, clinical outcomes may be assessed using the Scale for Assessing Negative Symptoms (SANS). SANS assesses five symptom complexes to obtain clinical ratings of negative symptoms in patients with schizophrenia. They are: affective blunting; alogia (impoverished thinking); avolition/apathy; anhedonia/asociality; and disturbance of attention. Assessments are conducted on a six-point scale.

The invention is further illustrated by the following examples which are intended to illustrate but not limit the scope of the invention.

EXAMPLES Abbreviations DCM: Dichloromethane

EA, EtOAc or AcOEt: Ethyl acetate PE: Petroleum ether

DIPEA: Diisopropylethylamine

TEA: Triethyl amine rt: Room temperature SOCl₂: Thionyl chloride POCl₃: Phosphorous oxychloride

TH: Tetrahydrofuran

NaOAc: Sodium acetate

MeOH: Methanol

i-AmOH: Isoamyl alcohol NaH: Sodium hydride NaBH₃CN: Sodium cyanoborohydride n-BuLi: n-Butyl lithium LHMDS: Lithium bis(trimethylsilyl)amide LDA: Lithium diisopropylamide i-PrOH: Isopropyl alcohol Na₂SO₄: Sodium sulfate Mg₂SO₄: Magnesium sulfate

MeCN: Acetonitrile

NaOH: Sodium hydroxide

EtOH: Ethanol

CuI: Copper(I) iodide Pd(PPh₃)₂Cl₂: trans-Dichlorobis(triphenylphosphine)palladium(II) MsCl: Methanesulfonyl chloride BINAM: [1,1′-Binaphthalene]-2,2′-diamine Xphos: 2-Dicyclohexylphosphino-2′,4′, 6′-triisopropylbiphenyl Sphos: 2-Dicyclohexylphosphino-2′,6′-dimethoxybiphenyl

DavePhos: 2-(Dicyclohexylphosphino)-2′-(N,N-dimethylamino)biphenyl

Cs₂CO₃: Cesium carbonate K₂CO₃: Potassium carbonate

Mwave or μW or mW: Microwave

t-BuOH: tert-Butanol K₃PO₄: Potassium phosphate Pd(APhos)₂Cl₂:Bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloro palladium(II)

Pd(PPh₃)₄: Tetrakis(triphenylphosphine)palladium (0)

Pd(dppf)₂Cl₂: Dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) PdOAc: Palladium(II) acetate Pd₂dba₃: Tris(dibenzylideneacetone)dipalladium (0) Pd-118: Dichloro[1,1-bis(di-1-butylphosphino)ferrocene]palladium(II) Xantphos: 9,9-Dimethyl-4,5-bis(diphenylphosphino)xanthene BINAP: (±)-2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene EDCI: 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide

HOBt: Hydroxybenzotriazole

NH₄OH: Ammonium hydroxide

H₂O: Water

Pd/C: Palladium on carbon

DMF: N,N-Dimethylformamide

KOCN: Potassium cyanate WSC—HCl or WSCDI: Water Soluble Carbodiimide hydrochloride HATU: O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate HBTU: O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate Py-Brop: Bromotripyrrolidinophosphonium hexafluorophosphate BOP: Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluoro phosphate DBU: diaza(1,3)bicyclo[5.4.0]undecene DMSO: Dimethyl sulfoxide LCMS: Liquid chromatography mass spectrometry HPLC: High performance liquid chromatography

DMA: N,N-dimethylacetamide

h: hour TLC: Thin layer chromatography TFA: Trifluoroacetic acid

Et₃N: Triethylamine DIPEA: N,N-Diisopropylethylamine O.N: Overnight

TBSO: tert-Butyldimethylsilyloxy DME: Dimethyl ether NMP: 1-methyl-2-pyrrolidinone PS-BEMP: 2-tert-Butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine supported on Polystyrene PBr₃: Phosphorus tribromide NaOtBu: Sodium tert-butoxide KI: Potassium iodide

PPh₃: Triphenylphosphine NMM: N-Methylmorpholine HCHO: Formaldehyde

PG: Protecting group ISCO: Teledyne ISCO purification systems BINAM: 1,1′-binaphthyl-2,2′-diamine.

General Experimental

All exemplified target compounds are fully analyzed and characterized (TLC, LCMS, ¹H-NMR) prior to submission for biological evaluation. Thin-layer chromatography was carried out on native silica 254F plates. Visualization was accomplished with ultraviolet or phosphomolybdic acid. ¹H-NMR spectra were recorded on multiple NMR spectrometers, either on 400 MHz on a Avance III 1400 Ultra shield-plus TM digital Spectrometer or on 300 MHz using a Varian Mercury 300Plus Spectrometer, designated by 400 MHz or 300 MHz, respectively. ¹ H-NMR spectra were also recorded on a Bruker Spectrospin 300 MHz Spectrometer at 300.13 MHz in DMSO-d6 with TMS as an internal standard and will be designated as Bruker 300 Hz. NMR assignments are based on a combination of the ¹H, ¹³C, ¹HCOSY, HMBC and HMQC spectra. Coupling constants are given in hertz (Hz). Anhydrous methylene chloride, tetrahydrofuran, and dimethylformamide were obtained by distillation, and other materials are reagent grade.

LC-MS Methods are listed here: Method A: Mobile phase: A=0.1% TFA/H₂O, B=0.01% TFA/MeCN; Gradient: B=5%-95% in 1.5 min; Flow rate: 2.0 mL/min; Column: sunfire-C₁₈, 50×4.6 mm, 3.5 um; Method B: Mobile phase: A=10 mM NH₄HCO₃/H₂O, B=MeCN; Gradient: B=5%-95% in 1.5 min; Flow rate: 2.0 mL/min; Column: Xbridge-C₁₈, 50×4.6 mm, 3.5 um Method C: Mobile phase: A=10 mM ammonium formate/H₂O/4.9% MeCN, B=MeCN; Gradient: B=5%-100% in 2.0 min; Flow rate: 2.5 mL/min; Column: Atlantis T3 3 uM 4.6×30 mm Method D: Mobile phase: A=0.1% formic acid/H₂O/4.9% MeCN, B=MeCN; Gradient: B=5%-100% in 2.0 min; Flow rate: 2.5 mL/min; Column: Atlantis T3 3 uM 4.6×30 mm Method E: Mobile phase: A=0.05% TFA/H₂O, B=0.05% TFA/MeCN; Gradient: B=5%-100% in 3.0 min; Flow rate: 0.8 mL/min; Column: CAPCELL PAK C18 (Shiseido, UG120, 3 mM, 2.0 mm I.D.×50 mm). Representative Conditions of PREP-HPLC are listed here:

PREP-HPLC Condition A (Basic Mobile Phase): Instrument: Gilson 281 Mobile Phase: A=0.01% NH₄HCO₃/H₂O, B=MeCN

Flow Rate: 40.0 mL/min Column: AGT Venusil XBP C₁₈, 10.0 um, 30 mm×100 mm

PREP-HPLC Condition B (Basic Mobile Phase): Instrument: Gilson 281

Mobile Phase: A=NH₃—H₂O, 10 mmol/L, B=MeCN Flow Rate: 40.0 mL/min Column: Waters X-Bridge, 5.0 um, 30 mm×150 mm

PREP-HPLC Condition C (Basic Mobile Phase): Instrument: Gilson 281 Mobile Phase: A=0.01% NH₄HCO₃/H₂O, B=MeCN

Flow Rate: 30.0 mL/min Column: Shimadzu PRC-ODS, 10.0 um, 20 mm×250 mm

Gradient: B=xx %-yy % 0.0 to 8.0 min

-   -   yy %-95% 8.0 to 8.2 min     -   95%-95% 8.2 to 11.0 min         The following table shows the relationship of representative         value (xx %-yy %) of gradient and retention time on LC-MS of         corresponding compound.         25%-30% 0.5-1.0 min         30%-50% 1.0-1.5 min         50%-70% 15-1.75 min         70%-90% 1.7-2.0 min

PREP-HPLC Condition D:

Instrument: Waters 600 pump, Waters 2996, Photodiode Array Detector, Waters Micromass ZQ, Gilson 215 Liquid Handler.

Mobile Phase: A=0.05% TFA/H₂O, B=MeCN

Flow Rate: 36.0 mL/min

Column: Shiseido CAPCELL PAK C18, UG120, 5 uM, 20 mm I.D.×50 mm Gradient: B=5%-100% 0.0 to 4.0 min

Method A: 2-Nitro-5-propoxy-benzamide (i-a)

A mixture of 2-nitro-5-propoxy-benzoic acid (1.97 g, 8.75 mmol) and DMF (0.1 mL) in SOCl₂ (20 mL) was stirred at 65° C. for 2 h. After the reaction was completed, the mixture was cooled to room temperature. SOCl₂ was removed in vacuo and the residue was dissolved in anhydrous CH₂Cl₂ (10 mL), which was added to NH₃—H₂O (28%) dropwise. After 1 h, the precipitate was collected and dried in vacuo to give 1.68 g of i-a as a yellow solid (85.2%). LCMS m/z=208.1 (M−16), 225.1 (M+1) (Method B) (retention time=1.88 min).

Method B: 2-Amino-5-propoxy-benzamide (ii-a)

To a mixture of 2-nitro-5-propoxy-benzamide (1.20 g, 5.36 mmol) in MeOH—H₂O (v/v, 3:1, 60 mL) was added NH₄ Cl (2.84 g, 53.6 mmol) and Fe (2.99 g. 53.6 mmol). The resulting mixture was stirred at 60° C. for 3 h. After the reaction was completed, the mixture was cooled to room temperature and the iron was filtered off. The filtrate was concentrated to 15 mL and the formed precipitate was collected and dried in vacuo to give 1.02 g of ii-a as a pale yellow solid (98%). LCMS m/z=1781 (M−16), 195.1 (M+1) (Method B) (retention time=1.46 min).

Method I: 2-Amino-4-chlorobenzamide (ii-b)

To a mixture of 2-amino-4-chlorobenzoic acid (3.42 g, 20 mmol) in DMF (45 mL) was added HOBt (2.70 g, 20 mmol). After stirring for 10 min, EDC hydrogen chloride (3.82 g, 20 mmol) was added to the mixture. The resulted mixture was stirred at room temperature for 2 h. NH₄OH (28%, 5 mL) was added at 0° C. with vigorous stirring. After addition, the mixture was stirred at room temperature for another 2 h. The reaction mixture was added to water (200 mL) dropwise with stirring, then a precipitate formed. The precipitate was collected and dried in vacuo to give 2.98 g of ii-b as a grey solid (87.6% yield). LCMS m/z=171.0 (M+1), 173.0 (M+3) (Method B) (retention time=1.39 min). ¹H NMR (400 MHz, DMSO-d₆): δ 7.27 (d, J=9.6 Hz, 1H), 6.68 (d, J=2.4 Hz, 1H), 6.60 (dd, J=8.4, 2.0 Hz, 1H), 5.50-5.82 (m, 4H).

Method F for Chlorinating Conditions F1: POCl₃/N,N-dimethylbenzeneamine F2: SOCl₂/DMF/80° C.

F3: SOCl₂ (4-8 equiv.)/DMF/DCM/rt-40)C F4: Phenylphosphinic dichloride/80-120° C.

F5: POCl₃/Δ F6: POCl₃/Toluene/100° C. F7: PBr₃/CH₂Cl₂/DMF/60° C. Method G for Coupling Conditions

G1: i-PrOH/85-100° C.

G2: THF/reflux

G3: i-AmOH/100-130° C.

G4: MeOH/microwave/150° C.

G5: i-AmOH/microwave/150° C.

G6: THF/Et₃N/reflux G7: THF—H₂O/NaOAc/rt-60° C. G8: NaH/THF

G9: n-BuLi/THF

G10: LHMDS/THF G11: LDA/THF G12: KCO₃/DMF/60° C. G13: Cs₂CO₃/DMA/80° C. G14: NaOtBu/DMF/Microwave/100° C. Method J for Coupling Conditions

J1: Pd(PPh₃)₄/t-BuOK/Dioxane J2: Pd₂(dba)₃/Xantphos/Cs₂CO₃/Dioxane

Method C: N-(2-Carbamoyl-4-propoxy-phenyl)-nicotinamide (iii-a)

To a solution of 2-amino-5-propoxy-benzamide (760 mg, 3.91 mmol) in THF (15 mL) and Et₃ N (1 mL) was added nicotinoyl chloride (607 mg, 4.30 mmol) in anhydrous THF (15 min) dropwise. The resulting mixture was stirred at room temperature for 3 h. After the reaction was completed, the volatiles were removed. The residue was washed with H₂O (10 mL). The pH was adjusted to approximately 5 by adding dilute HCl (2N in water). The resulting solid was collected and dried in vacuo to give 1.00 g of iii-a as a pale yellow solid (89.0%). LCMS m/z=300.1 (M+1) (Method B) (retention time=1.60 min).

Method D: 2-benzamido-5-methoxy-3-methylbenzamide (iii-b)

A 50 mL round-bottom flask was charged with nicotinic acid (41 mg, 0.33 mmol, 1.0 eq.), 2-amino-5-methoxy-3-methylbenzamide (60 mg, 0.33 mmol, 1.0 eq.) and HBTU (190 mg, 0.50 mmol, 1.5 eq), which were suspended in 4 mL, of DMF. DIPEA (86 mg, 0.66 mmol, 2.0 eq.) was added dropwise at room temperature and the reaction mixture was stirred overnight. The reaction mixture was added to water (10 mL) dropwise with stirring. The mixture was extracted with ethyl acetate. The ethyl acetate was evaporated and 55 mg of the orange solid (58.5% yield) was obtained. LCMS m/z=286.1 (M+1) (Method B) (retention time=1.24 min).

Method E: 6-Propoxy-2-pyridin-3-yl-1H-quinazolin-4-one (iv-a)

A mixture of N-(2-carbamoyl-4-propoxy-phenyl)-nicotinamide (980 mg, 3.27 mmol) in EtOH (20 mL) was treated with NaOH (654 mg, 16.37 mmol). The resulting mixture was stirred at room temperature for 18 h. After the reaction was completed, the volatiles were removed in vacuo. The residue was partitioned between H₂O (50 mL) and ethyl acetate (50 mL). The aqueous layer was neutralized to pH 7 by slowly adding aq. citric acid and then a precipitate formed. The precipitate was collected and dried to give 1.00 g of iv-a as a grey solid (quantitative yield). LCMS m/z=282.1 (M+1) (Method B) (retention time=1.60 min).

Method F1: 4-Chloro-6-propoxy-2-pyridin-3-yl-quinazoline (v-a)

(This method is representative of method F1, F2, F3 and F4. These three methods can be implemented in a similar way except for substitution of the appropriate chlorinating reagent, solvent and temperature) To a mixture of 6-propoxy-2-pyridin-3-yl-1H-quinazolin-4-one (1.00 g, 3.56 mmol) in POCl₃ (10 mL) was added N,N-dimethylaniline (0.1 mL). The resulting mixture was stirred at 120° C. for 2 h. After the reaction was completed, POCl₃ was removed in vacuo, and the residue was added to ice-water slowly. The pH was adjusted to around 7 by slowly adding NaHCO₃ (sat.) at 0 (C. The resultant solid was collected and purified by chromatography on silica gel eluted with petroleum ether/ethyl acetate (v/v=4:1 to 1:1) to give 580 mg of v-a as a pale yellow solid (54.7%).

Method F5: 4-chloro-6-methoxy-2-(pyridin-3-yl)quinazoline (v-c)

In a sealed tube, phosphorus oxychloride (11 mL, 120 mmol) was added to 6-methoxy-2-(pyridin-3-yl)quinazolin-4(3H)-one (2.70 g, 10.66 mmol). The mixture was refluxed at 120° C. for 12 h. After cooling, the remaining phosphorus oxychloride was removed in vacuo to leave a tan solid. This residue was added to an ice-water mixture (100 mL) with cooling and allowed to stir. The pH of the suspension was adjusted to about pH 9 via dropwise addition of 28% ammonium hydroxide, and stirring was continued for 30 mins. The resulting solid was filtered to give the desired product as a tan solid (2.55 g, 9.39 mmol, 88%). LC-MS m/z=272.0 (M+1) (retention time=2.05) ¹H NMR (300 MHz, DMSO) δ 9.55 (s, 1H), 8.81-8.64 (m, 2H), 8.09 (d, J=9.2 Hz, 1H), 7.78 (dd, J=9.2, 2.8 Hz, 1H), 7.61 (dd, J=7.9, 4.8 Hz, 1H), 7.49 (d, J=2.5 Hz, 1H), 4.00 (s, 3H).

Method F6: 6-Bromo-4-chloro-8-fluoro-2-(pyridin-3-yl)quinazoline (v-d)

To a suspension of 6-bromo-8-fluoro-2-(pyridin-3-yl)quinazolin-4-ol (6.16 g, 0.0192 mol) in toluene (60 mL) was added phosphorus oxychloride (5.30 ml, 0.0579 mol) at room temperature. The mixture was refluxed for 3 h. The solvent was evaporated and water was added to the residue under cooling conditions. The suspension was stirred at room temperature for 30 min, the resulting precipitate was filtered and dried to give the title compound (6.5 g, quantitative). ¹H NMR (400 MHz, DMSO) δ 9.58 (d, J=1.6 Hz, 1H), 8.82 (dd, J=4.7, 1.5 Hz, 1H), 8.80-8.75 (m, 1H), 8.37 (dd, J=9.7, 1.9 Hz, 1H), 8.34-8.29 (m, 1H), 767 (dd, J=7.8, 4.6 Hz, 1H).

Method F7: 4-Bromo-6-methoxy-2-(pyridin-3-yl)quinazoline (v-e)

To a sealed tube containing 6-methoxy-2-(pyridin-3-yl)quinazolin-4(3)-one (1.30 g, 5.13 mmol) in dichloromethane (20 mL) was added 1 M phosphorus tribromide in dichloromethane (10.3 mL, 10.3 mmol) and DMF (2 mL). The reaction mixture was heated at 60° C. for 4 h. After cooling, excess dichloromethane was evaporated leaving a tan residue. This solid was added to an ice-water mixture (100 mL) with cooling and allowed to stir. The pH of the suspension was adjusted to about pH 9 via dropwise addition of 28% ammonium hydroxide, and stirring was continued for 30 mins. The resulting solid was filtered to give the desired product as a tan solid (1.49 g, 4.71 mmol, 92%). LC-MS m/z=318.3 (M+2) (retention time=2.19).

Method G1: 2-(6-Propoxy-2-pyridin-3-yl-quinazolin-4-ylamino)-benzamide (vi-a)

(This method is representative of method G1, G2, and G3. These three methods can be implemented in a similar way except for substitution of the appropriate solvent and temperature) A mixture of 4-chloro-6-propoxy-2-(pyridin-3-yl)quinazoline (90 mg, 0.3 mmol) and 2-aminobenzamide (52 mg, 0.4 mmol) in i-PrOH (5 mL) was stirred at 85° C. for 18 h. The yellow precipitate was collected and washed with i-PrOH (10 mL). The solid was suspended in water (10 mL) and NH₃—H₂O (1 mL) was added. After filtration the solid was dried in vacuo to afford 31.0 mg of vi-a as a white solid (30.8%). LCMS m/z=400.1 (M+1) (Method B) (retention time=1.96 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 9.59 (d, J=2.0 Hz, 1H), 9.58 (d, J=7.6 Hz, 1H), 8.69-8.74 (m, 2H), 8.48 (s, 1H), 7.97 (d, J=6.8 Hz, 2H), 7.90 (d, J=8.8 Hz 1H), 7.74 (t, J=7.6 Hz, 1H), 7.56-7.61 (m, 3H), 7.20 (t, J=7.2 Hz, 1H), 4.16 (t, J=6.4 Hz, 2H), 1.86 (dd, J=14.0, 6.8 Hz, 2H), 1.07 (t, J=7.2 Hz, 3H).

Method G8: 2-(6-ethoxy-2-(pyridin-3-yl)quinazolin-4-yloxy)benzamide (vii-a)

(The method G8 is representative of method G6, G7, G9, G10 and G11. These six methods can be implemented in a similar way except for substitution of the appropriate base, solvent and temperature) To a 2.5 dram reaction vial was first added sodium hydride 60% (0.028 g, 0.700 mmol) and salicylamide (0.072 g, 0.525 mmol) in DMF (2 mL). The mixture was allowed to stir at room temperature for 1 h. Then, 4-chloro-6-ethoxy-2-(pyridin-3-yl)quinazoline (0.100 g, 0.350 mmol) was added to the mixture, and the reaction was allowed to proceed at room temperature overnight. LC-MS analysis of the crude mixture showed about 85% of product formed and 10% remaining starting material. Water (30 mL) was added to the mixture, and the product was extracted with chloroform (3×15 mL). The combined organic layers were dried (Na₂SO₄), filtered, and concentrated. The crude product was purified via ISCO (silica gel, 97.5:2.5 CH₂Cl₂/MeOH; 12 g column) to afford 13.9 mg of the desired product as a white solid (10.3%) LCMS m/z=387 (M+1) (Method C) (retention time=2.05 min). ¹H NMR (300 MHz, DMSO) δ 11.47 (s, 2H), 9.39 (s, 1H), 8.66 (d, J=2.8 Hz, 1H), 8.56-8.47 (m, 1H), 8.01-7.90 (m, 2H), 7.69-7.55 (m, 2H), 7.55-7.40 (m, 2H), 7.05 (t, J=7.5 Hz, 1H), 6.97 (d, J=8.2 Hz, 1H), 4.23 (q, J=6.9 Hz, 2H), 1.44 (t, J=6.9 Hz, 3H).

Method G13: 4-(4-chlorophenyl)-N-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-yl)thiazol-2-amine (vi-c)

(The method G13 is representative of method G12 also. This method can be implemented in a similar way except for substitution of the appropriate base, solvent and temperature) To a suspension of 4-chloro-6-methoxy-2-(pyridine-3-yl)quinazoline (645.2 mg, 2.375 mmol) and 2-amino-4-(4-chlorophenyl)thiazole (1050 mg, 4.98 mmol) in DMA (40 mL) was added Cs₂CO₃ (2430 mg, 7.46 mmol) at room temperature. The mixture was stirred at 80° C. for 9.5 h. Water was added and a precipitate formed which was collected by filtration and washed with H₂O. Recrystallization from acetone/DMF/methanol gave 383.6 mg of the product in a 36% yield as yellow solid, >98% purity by ¹H NMR). ¹H NMR (400 MHz DMSO-d₆) δ 12.52 (s, 1H), 9.78 (d, J=1.56 Hz, 1H), 8.91-8.88 (m, 1H), 8.74 (dd, J=4.74, 1.60 Hz, 1H), 8.33 (brs, 1H), 8.06 (d, J=8.56 Hz, 2H), 7.93 (d, J=9.08 hz, 1H), 7.89 (s, 1H), 7.66-7.59 (m, 2H), 7.55 (d, J=8.56 Hz, 2H), 4.01 (s, 3H).

Method G14: 4-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-1H-pyrazole-5-carboxamide, 2HCl (vi-d)

(The method G14 is representative of method G4 and G5 also. This method can be implemented in a similar way except for substitution of the appropriate solvent and adjustment of the temperature) To a microwave vial containing 4-bromo-6-methoxy-2-(pyridin-3-yl)quinazoline (150.0 mg, 0.47 mmol) in DMF (2 mL) was added 4-amino-1H-pyrazole-5-carboxamide (66.0 mg, 0.52 mmol) and sodium tert-butoxide (50 mg, 0.52 mmol). The reaction mixture was heated at 100° C. for 15 mins by microwave irradiation. Water (50 mL) was added to the reaction mixture, and extracted with ethyl acetate (5×50 mL). The crude material was purified via ISCO (silica, 12 g column, 93% CH₂Cl₂—7% MeOH—0.1% NH₄OH) giving the product as a yellow solid. The free base was then converted to the HCl salt to yield the final product as an orange solid (59.8 mg, 0.14 mmol, 22%). LC-MS m/z=362.4 (M+1) (retention time=1.57) ¹H NMR (300 MHz, DMSO) δ 11.28 (s, 1H), 9.62 (d, J=1.7 Hz, 1H), 9.17 (d, J=7.8 Hz, 1H), 8.93 (dd, J=5.2, 1.3 Hz, 1H), 8.60 (s, 1H), 8.05 (s, 1H), 8.03-7.94 (m, 2H), 7.77 (s, 1H), 7.64 (dd, J=9.2, 2.5 Hz 1H), 7.40 (d, J=2.6 Hz, 1H), 3.97 (s, 3H).

Method J1: 1-(6-Methoxy-2-(pyridin-3-yl)quinazolin-4-yl)-1H-benzo[d]imidazol-2(3H)-one (vi-b)

To a 50-mL two-neck round bottom flask equipped with a reflux condenser was added a mixture of 4-chloro-6-methoxy-2-(pyridin-3-yl)quinazoline (50 mg, 0.18 mmol, 1 eq.) and 1H-benzo[d]imidazol-2(3H)-one (27 mg, 0.21 mmol, 1.1 eq.) in 5 mL of dry 1,4-dioxane. Pd(PPh₃)₄ (10.6 mg, 0.009 mmol, 0.05 eq) and t-BuOK (41 mg, 0.36 mmol, 2 eq.) were added. The resulting mixture was stirred at 100° C. under N₂ atmosphere overnight. After cooling, 20 mL of methanol was added. The mixture was filtered, the filtrate was concentrated in vacuo and then was purified with chromatography on silica gel (ethyl acetate/petroleum ether from 1:4 to 1:2) to give the crude product, which was further purified with reverse phase HPLC to afford 4.8 mg of vi-e as a pale yellow solid (7%). MS m/z=370.1 (M+1) (Method B) (retention time=1.680 min). ¹H NMR (400 MHz, DMSO-d₆): δ 11.51 (s, 1H), 8.78 (d, J=8.0 Hz, 2H), 8.17 (d, J=9.2 Hz, 1H), 7.80 (dd, J=9.2, 2.8 Hz, 1H), 7.70-7.64 (m, 1H), 7.46 (d, J=2.8 Hz, 1H), 7.41 (d, J=8.0 Hz, 1H), 7.20 (d, J=4.0 Hz, 2H), 7.16-7.08 (m, 1H), 3.89 (s, 3H).

Method J2: 6-methoxy-N-(pyridin-2-yl)-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (vi-e)

To a suspension of 4-chloro-6-methoxy-2-(pyridine-3-yl)quinazoline (600 mg, 2.208 mmol) in dioxane (40 mL) under N₂, was added tris(dibenzylideneacetone)dipalladium(0) (103.1 mg, 0.113 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (132.2 mg, 0.228 mmol) and cesium carbonate (1.1289 g, 3.46 mmol) at room temperature. 2-Aminopyridine (229 mg, 2.43 mmol) was added and the mixture was stirred at 100° C. for 2 h 30 min. Water was added and then a precipitate formed. The solid was collected and washed with water. The solid was dissolved in CH₂Cl₂. Purification was carried out using NH-silica gel to give the free base (649.3 mg). The free base was converted to the HC salt by dissolving the compound in CH₂Cl₂/MeOH and 1.5 ml of 4N HCl in ethyl acetate was added and then a precipitate formed. The solid was collected and dried in vacuo (at 40 degrees on and 60 degrees for ca. 3 h) and then washed with methanol. The resulting solid was dried in vacuo at 60 degrees to give 682 mg of the desired product as the HCl salt in a 77% yield as a pale yellow solid. ¹H NMR (DMSO-d₆) δ 11.14 (brs, 1H), 9.58 (s, 1H), 9.13 (dd, J=7.96 Hz, 1H), 8.93 (d, J=5.24 Hz, 1H), 8.54 (d, J=4.72 Hz, 1H), 8.48 (d, J=8.32 Hz, 1H), 8.28 (brs, 1H), 8.09 (brt, J=7.16 Hz, 1H), 8.02-7.96 (m, 2H), 7.65 (dd, J=8.80, 2.48 Hz, 1H), 7.34 (brt, J=6.52 Hz, 1H), 4.01 (s, 3H). The 1H of 2HCl was not observed.

Method J3: N-(Biphenyl-4-yl)-6-methoxy-2-(pyridin-3-yl)quinazolin-4-amine hydrochloride (vi-f)

To a suspension of N-(4-bromophenyl)-6-methoxy-2-(pyridin-3-yl)quinazolin-4-amine (548.7 mg, 1.347 mmol) and phenylboronic acid (270 mg, 2.21 mmol) in dioxane/H₂O (2/1) (30 mL) under N₂ was added Na₂CO₃ (485 mg, 4.58 mmol) and tetrakis(triphenylphosphine) palladium(0) (78 mg, 0.067 mmol) at room temperature. The mixture was stirred at 100° C. for 1 h. Water was added and then a precipitate formed. The solid was dissolved in methanol/acetone at 60° C. The solution was filtrated through Celite to remove any extra palladium. The filtrate was concentrated down to give 493.4 mg of a solid residue in. The solid was added to CH₂Cl₂ followed by addition of 4N HCl in ethyl acetate (0.4 mL) at room temperature to form the HCl salt. The mixture was stirred at room temperature and the resulting solid was filtered and dried in vacuo to give 435.2 mg and a yield of 73% as the HCl salt. ¹H NMR (DMSO-d6) δ 10.24 (br, 1H), 9.54 (s, 1H), 8.92 (d, J=7.52 Hz, 1H), 8.82 (d, J=3.96 Hz, 1H), 8.10 (d, J=2.44 Hz, 1H), 8.03 (d, J=8.68 Hz, 2H), 7.92 (d, J=9.08 Hz, 1H), 7.84 (d, J=8.68 Hz, 2H), 7.81 (m, 1, 7.77-7.75 (m, 2H), 7.62 (dd, J=9.08, 2.44 Hz, 1H), 7.50 (m, 2H), 7.38 (m, 1H), 4.01 (s, 3H). The 1H of HCl was not observed.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 1 and 5 (prepared according to method procedure A-J as designated).

TABLE 1 Puri- Meth- ty od for Salt Molecular LCMS per- Coup- Number Product type Mass ¹H-NMR Solvent LCMS Protocol cent ling 1

399.45 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.59 (d, J = 2.0 Hz, 1H), 9.58 (d, J = 7.6 Hz, 1H), 8.69-8.74 (m, 2H), 8.48 (s, 1H), 7.97 (d, J = 6.8 Hz, 2H), 7.90 (d, J = 8.8 Hz 1H), 7.74 (t, J = 7.6 Hz, 1H), 7.56- 7.61 (m, 3H), 7.20 (t, J = 7.2 Hz, 1H), 4.16 (t, J = 6.4 Hz, 2H), 1.86 (dd, J = 7.2, 6.8 Hz, 2H), 1.07 (t, J = 7.2 Hz, 3H). DMSO 400.1 (M + 1) Method B (NH4HCO3) 95 Meth- od C, G1 2

HCl 398.46 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.20 (s, 1H), 9.79 (s, 1H), 9.02-9.08 (m, 2H), 8.87 (d, J = 3.2 Hz, 1H), 8.53 (s, 1H), 3.34 (d, J = 8.0 Hz, 1H), 8.19 (d, J = 6.8 Hz, 1H), 7.74-7.99 (m, 5H), 7.28 (t, J = 7.6 Hz, 1H), 4.92 (d, J = 4.0 Hz, 2H), 2.87 (d, J = 3.2 Hz, 6H). DMSO 399.1 (M + 1) Method B (NH4HCO3) 95 Meth- od C, G1 3

HCl 424.50 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.07 (s, 1H), 9.64 (d, J = 1.6 Hz, 1H), 9.15 (d, J = 8.0 Hz, 1H), 8.78 (ddd, J = 8.0, 4.0, 2.4 Hz, 1H), 8.73 (dd, J = 4.4, 1.2 Hz, 1H), 8.49 (s, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.92-7.69 (m, 3H), 7.67- 7.74 (m, 2H), 7.62 (dd, J = 8.0, 4.8 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 4.29 (s, 2H), 2.61 (brs, 4H), 1.70 (brs, 4H). DMSO 425.2 (M + 1) Method B (NH4HCO3) 95 Meth- od C, G1 4

422.43 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.87 (s, 1H), 9.52 (s, 1H), 8.67 (d, J = 5.6 Hz, 1H). 7.99 (d, J = 2.4 Hz, 1H), 7.94 (s, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.50-7.58 (m, 3H), 7.30 (t, J = 34.0 Hz, 1H), 7.00 (dd, J = 8.4, 2.0 Hz, 1H), 4.16 (t, J = 6.4 Hz, 2H), 1.86 (dd, J = 7.2, 6.4 Hz, 2H), 1.07 (t, J = 7.2 Hz, 3H). DMSO 423.1 (M + 1) Method B (NH4HCO3) 95 Meth- od C, G1 5

HCl 408.86 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.28 (s, 1H), 9.48 (s, 1H), 8.93 (d, J = 8.4 Hz, 1H), 8.85 (d, J = 4.4 Hz, 1H), 8.18 (dd, J = 7.6, 2.4 Hz, 1H), 8.06 (d, J = 2.0 Hz, 1H), 7.85-7.93 (m, 3H), 7.62 (dd, J = 8.8, 6.4 Hz, 1H), 7.55 (t, J = 8.8 Hz, 1H), 4.17 (t, J = 6.4 Hz, 3H), 1.86 (dd, J = 7.6, 6.4 Hz, 2H), 1.06 (t, J = 7.6 Hz, 3H). DMSO  409.1, 411.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 6

425.31 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.93 (s, 1H), 9.51 (s, 1H), 8.68-8.71 (m, 2H), 8.16 (d, J = 2.4 Hz, 1H), 7.94 (d, J = 2.0 Hz, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.56- 7.60 (m, 2H), 7.37 (s, 1H), 4.14 (t, J = 6.4 Hz, 2H), 1.84 (dd, J = 10.4 Hz, 7.2 Hz, 2H), 1.07 (t, J = 7.6 Hz, 3H). DMSO  425.0, 427.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 7

392.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.06 (s, 1H), 9.49 (s, 1H), 8.77-8.81 (m, 2H), 8.09 (ddd, J = 10.0, 7.6. 2.4 Hz, 1H), 7.88 (d, J = 9.2 Hz, 1H), 7.69-7.74 (m, 2H), 7.54-7.61 (m, 2H), 4.15 (t, J = 6.4 Hz, 2H), 1.86 (dd, J = 14,0, 7.6 Hz, 2H), 1.06 (t, J = 7.2 Hz, 3H). DMSO 393.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 8

425.31 ¹H-NMR (400 MHz,. DMSO-d₆): δ 10.05 (s, 1H), 9.51 (s, 1H), 8.75-8.80 (m, 2H), 8.34 (d, J = 2.4 Hz, 1H), 7.96-8.00 (m, 2H), 7.88 (d, J = 9.2 Hz, 1H), 7.68-7.75 (m, 2H), 7.59 (dd, J = 9.2, 2.8 Hz, 1H), 4.15 (t, J = 6.4 Hz, 2H), 1.86 (dd, J = 7.2, 6.8 Hz, 2H), 1.06 (t, J = 7.6 Hz, 3H). DMSO  425.0, 427.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 9

415.44 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.03 (s, 1H), 9.59 (d, J = 1.2 Hz, 1H), 9.15 (d, J = 8.4 Hz, 1H), 8.69-8.74 (m, 2H), 8.49 (s, 1H), 7.96-8.06 (m, 2H), 7.90 (d, J = 9.2 Hz, 1H), 7.56-7.63 (m, 3H), 7.20 (t, J = 8.0 Hz, 1H), 4.31 (t, J = 4.0 Hz, 2H), 3.79 (t, J = 4.8 Hz, 2H), 3.31 (s, 3H). DMSO 416.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 10

438.43 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.86 (s, 1H), 9.53 (s, 1H), 8.66-8.68 (m, 2H), 8.02 (d, J = 2.8 Hz, 1H), 7.95 (t, J = 2.0 Hz, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.79 (d, J = 1.2 Hz, 1H), 7.48-7.60 (m, 3H), 7.30 (t, J = 74.4 Hz, 1H), 7.00 (dd, J = 8.0, 2.0 Hz, 1H), 4.33 (t, J = 4.8 Hz, 2H), 3.79 (t, J = 4.4 Hz, 2H), 3.37 (s, 3H). DMSO 439.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 11

HCl 424.86 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.27 (s, 1H), 9.48 (s, 1H), 8.93 (d, J = 8.4 Hz, 1H), 8.85 (d, J = 4.8 Hz, 1H), 8.19 (dd, J = 6.8, 2.4 Hz, 1H), 8.10 (d, J = 2.4 Hz, 1H), 7.85-7.93 (m, 3H), 7.64 (dd, J = 9.2, 6.8 Hz, 1H), 7.55 (t, J = 8.8 Hz, 1H), 4.34 (t, J = 4.4 Hz, 2H), 3.78 (t, J = 4.4 Hz, 2H), 3.31 (s, 3H). DMSO  425.1, 427.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 12

397.43 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.07 (s, 1H), 9.50 (s, 1H), 8.78 (dd, J = 17.6, 7.6 Hz, 1H), 8.39 (s, 1H), 8.26 (dd, J = 8.0, 2.0 Hz, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.90 (d, J = 9.2 Hz, 1H), 7.61-7.73 (m, 4H), 4.34 (t, J = 4.8 Hz, 2H), 3.79 (t, J = 4.4 Hz, 2H), 3.35 (s, 3H). DMSO 398.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 13

408.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.86 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.67 (dd, J = 4.8, 1.6 Hz, 1H), 8.64 (dt, J = 8.0, 1.6 Hz, 1H), 8.12 (ddd, J = 13.2, 7.2, 2.4 Hz, 1H), 7.98 (d, J = 2.8 Hz, 1H), 7.86 (d, J = 9.2, 1H), 7.69-7.72 (m, 1H), 7.52-7.60 (m, 3H), 4.31 (t, J = 4.0 Hz, 2H), 3.76-3.80 (m, 2H), 3.37 (s, 3H). DMSO 409.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 14

441.31 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.90 (s, 1H), 9.52 (d, J = 1.2 Hz, 1H), 8.64-8.68 (m, 1H), 8.37 (d, J = 2.8 Hz, 1H), 7.98 (d, J = 2.4 Hz, 1H), 7.96 (dd, J = 10.6, 2.4 Hz, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7.74 (d, J = 9.2 Hz, 1H), 7.59 (dd, J = 8.8, 2.4 Hz, 1H), 7.55 (dd, J = 8.0, 4.8 Hz, 1H), 4.31 (t, J = 4.08 Hz, 2H), 3.78 (t, J = 4.4 Hz, 2H), 3.37 (s, 3H). DMSO  441.0, 443.0 (M + 1) 221.9 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 15

441.31 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.93 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.66-8.70 (m, 2H), 8.18 (s, 1H), 8.17 (s, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.61 (dd, J = 8.8, 2.4 Hz, 1H), 7.56 (dd, J = 7.6, 4.8 Hz, 1H), 7.39 (t, J = 2.0 Hz, 1H), 4.33 (t, J = 4.8 Hz, 2H), 3.79 (t, J = 4.4 Hz, 2H), 3.37 (s, 3H). DMSO  441.1, 443.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 16

HCl 375.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.34 (s, 1H), 9.53 (d, J = 1.2 Hz, 1H), 9.16 (d, J = 1.2 Hz, 1H), 8.74 (dd, J = 4.0, 1.6 Hz, 1H), 8.68-8.69 (m, 2H), 8.20-8.28 (m, 2H), 8.00 (d, J = 8.4 Hz, 1H), 7.89-7.93 (m, 1H), 7.55-7.61 (m, 2H). DMSO  376.0, 378.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 17

393.8 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.37 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.09 (s, 1H), 8.69 (d, J = 10.0 Hz, 1H), 8.68 (d, J = 8.0 Hz, 1H), 8.23-8.27 (m, 2H), 8.11 (s, 1H), 8.78 (s, 2H), 7.50-7.58 (m, 3H). DMSO  394.1, 396.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 18

HCl 394.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.81 (s, 1H), 9.48 (d, J = 0.3 Hz, 1H), 9.23 (d, 0.8 Hz, 1H), 8.69 (d, J = 10.0 Hz, 1H), 8.68 (d, J = 8.0 Hz, 1H), 8.23-8.27 (m, 2H), 8.11 (s, 1H), 8.78 (s, 2H), 7.50- 7.58 (m, 3H). DMSO  395.0, 397.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 19

422.38 1H-NMR (400 MHz, DMSO-d₆): δ 10.11 (brs, 1H), 9.48 (s, 1H), 8.79 (d, J = 4.8 Hz, 1H), 8.83 (d, J = 8.0 Hz, 1H), 8.07 (d, J = 2.0 Hz, 1H), 8.02 (d, J = 2.4 Hz, 1H), 7.88-7.90 (m, 1H), 1.77 (d, J = 8.0 Hz, 1H), 7.52-7.62 (m, 3H), 4.27 (q, J = 7.2 Hz, 2H), 1.46 (t, J = 7.2 Hz, 3H). DMSO 423.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 20

HCl 408.81 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.73 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 9.32 (d, J = 1.6 Hz, 1H), 9.01 (d, J = 4.8 Hz, 1H), 8.91 (d, J = 5.2 Hz, 1H), 8.39 (dd, J = 8.4, 1.6 Hz, 1H), 8.17 (dd, J = 8.3, 2.0 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.90- 7.95 (m, 2H), 7.55 (t, J = 9.2 Hz, 1H), 3.98 (s, 3H). DMSO  409.1, 411.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 21

399.45 ¹H-NMR (400 MHz, DMSO-d₆) δ 12.94 (s, 1H), 9.56 (s, 1H), 9.14 (d, J = 8.0 Hz, 1H), 8.83-8.66 (m, 2H), 8.48 (s, 1H), 8.06-7.91 (m, 2H), 7.76-7.58 (m, 2H), 7.35 (s, 1H), 7.27 (d, J = 2.0 Hz, 1H), 7.18 (t, J = 7.2 Hz, 1H), 4.15 (q, J = 6.8 Hz, 2H), 2.64 (s, 3H), 1.43 (t, J = 6.8 Hz, 1H). DMSO 400.1 (M + 1) Method B (NH4HCO3) 95 Meth-od D, G1 22

440.42 ¹H-NMR (400 MHz, DMSO-d₆) δ 9.84 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H), 8.73-8.60 (m, 2H), 8.14 (s, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.60 (t, J = 8.0 Hz, 1H), 7.53 (dd, J = 7.6, 4.8 Hz, 1H), 7.45 (d, J = 1.6 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 4.23 (q, J = 6.8 Hz, 2H), 2.70 (s, 3H), 1.44 (t, J = 6.8 Hz, 3H) DMSO 440.9 (M + 1) Method A (TFA) 95 Meth-od D, G1 23

405.81 ¹H-NMR (400 MHz, DMSO-d₆) δ 10.08 (s, 1H), 9.42 (s, 1H), 8.68 (d, J = 3.6 Hz, 1H), 8.55 (d, J = 8.4 Hz, 1H), 8.32 (s, 1H), 8.15 (dd, J = 6.8, 2.4 Hz, 1H), 8.04 (s, 1H), 7.93-7.78 (m, 1H), 7.54 (td, J = 8.3, 6.9 Hz, 2H), 4.08 (s, 3H) DMSO  406.1, 408.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 24

493.92 ¹H-NMR (400 MHz, DMSO-d₆) δ 10.00 (s, 1H), 9.49-9.51 (m, 1H), 8.62-8.70 (m, 2H), 8.21 (dd, J = 6.8, 2.8 Hz, 1H), 8.03 (s, 1H), 7.87-7.91 (m, 1H), 7.75 (s, 1H), 7.53-7.59 (m, 2H), 4.02 (s, 3H), 3.64-3.73 (m, 4H), 3.49-3.58 (m, 2H), 3.14-3.22 (m, 2H). DMSO  494.1, 496.1 (M + 1) Method B (NH4HCO4) 95 Meth-od C, G1 25

TFA 369.38 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.51 (s, 1H), 8.78 (d, J = 8.0 Hz, 2H), 8.17 (d, J = 9.2 Hz, 1H), 7.80 (dd, J = 9.2, 2.8 Hz, 1H), 7.70-7.64 (m, 1H), 7.46 (d, J = 2.8 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 4.0 Hz, 2H), 7.16-7.08 (m, 1H), 3.89 (s, 3H). DMSO 370.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, J1 26

408.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.87 (s, 1H), 8.53 (dd, J = 4.7, 1.5 Hz, 1H), 8.23 (d, J = 6.8 Hz, 1H), 8.00 (d, J = 2.6 Hz, 1H), 7.8 (t, J = 2.1 Hz, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.73 (dd, J = 8.2, 1.2 Hz, 1H), 7.58 (dd, J = 9.1, 2.6 Hz, 1H), 7.41- 7.25 (m, 3H), 7.24 (t, J = 74.0 Hz, 1H), 6.96 (dd, J = 8.0, 2.2 Hz, 1H), 3.99 (s, 3H), 2.75 (s, 3H). DMSO 409.1 (M + 1) Method B (NH4HCO3) 95 Meth-od D, G1 27

385.42 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.09 (s, 1H), 9.08 (d, J = 7.8 Hz, 1H), 8.55 (dd, J = 4.8, 1.6 Hz, 1H), 8.49 (s, 1H), 8.22 (dd, J = 7.8,. 1.7 Hz, 1H), 8.01 (s, 1H), 7.95 (dd, J = 7.9, 1.2 Hz, 1H), 7.87 (d, J = 9.6 Hz, 1H), 7.66-7.58 (m, 3H), 7.40 (dd, J = 7.7, 4.8 Hz, 1H), 7.15 (dd, J = 11.5, 4.4 Hz, 1H), 3.99 (s, 3H), 2.77 (s, 3H). DMSO 386.1 (M + 1) Method B (NH4HCO3) 95 Meth-od D, G1 28

394.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.10 (s, 1H), 8.63 (d, J = 4.1 Hz, 1H), 8.43 (d, J = 7.6 Hz, 1H), 8.15 (dd, J = 6.8, 2.5 Hz, 1H), 8.03 (d, J = 2.3 Hz, 1H), 7.88-7.78 (m, 2H), 7.58 (ddd, J = 12.5, 8.3, 4.1 Hz, 2H), 7.49 (t, J = 9.1 Hz, 1H), 3.99 (s, 3H), 2.80 (s, 3H). DMSO  395.1, 397.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 29

HCl 440.5 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.19 (s, 1H), 11.12-10.93 (m, 1H), 9.83 (d, J = 1.5 Hz, 1H), 9.21 (d, J = 7.8 Hz, 1H), 9.01 (d, J = 7.8 Hz, 1H), 8.93-8.89 (m, 1H), 8.53 (s, 1H), 8.36 (dd, J = 11.8, 7.9 Hz, 2H), 8.02-7.73 (m, 6H), 7.29 (d, J = 8.02 Hz, 1H), 5.01 (s, 2H), 3.95-3.81 (m, 4H), 3.37 (s, 4H). DMSO 441.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 30

HCl 449.91 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.05 (s, 1H), 9.56 (s, 1H), 8.73-8.66 (m, 2H), 8.47 (d, J = 8.1 Hz, 1H), 8.28 (dd, J = 6.8, 2.5 Hz, 7.99-7.90 (m, 2H), 7.67-7.50 (m, 3H), 4.16 (s, 2H), 3.62 (s, 4H), 2.53 (s, 4H). DMSO  450.1, 452.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 31

400.33 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.47 (d, J = 2.0 Hz, 2H), 8.70 (dd, J = 4.3, 1.6 Hz, 1H), 8.65-8.59 (m, 1H), 8.06 (s, 1H), 7.91 (dt, J = 8.1, 6.0 Hz, 1H), 7.82 (dd, J = 8.2, 1.2 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.59 (t, J = 8.2 Hz, 1H), 7.51 (ddd, J = 20.0, 10.0, 6.4 Hz, 2H), 7.21 (d, J = 8.4 Hz, 1H). DMSO 401.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 32

HCl 368.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.53 (d, J = 11.3 Hz, 1H), 9.44 (d, J = 1.2 Hz, 1H), 8.84-8.79 (m, 2H), 8.09 (dd, J = 6.8, 2.6 Hz, 1H), 7.97-7.89 (m, 1H),. 7.85-7.75 (m, 3H), 7.57-7.47 (m, 2H). DMSO  369.1, 371.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 33

HCl 359.36 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.21 (d, J = 12.1 Hz, 1H), 9.53 (d, J = 1.2 Hz, 1H), 8.99 (d, J = 8.1 Hz, 1H), 8.39 (d, J = 4.2 Hz, 1H), 8.71 (d, J = 7.9 Hz, 1H), 8.35 (s, 1H), 7.97-7.76 (m, 5H), 7.72- 7.65 (m, 1H), 7.50 (dd, J = 12.1, 7.5 Hz, 1H), 7.29 (t, J = 7.1 Hz, 1H). DMSO 360.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 34

382.34 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.49 (d, J = 1.8 Hz, 1H), 9.42 (s, 1H), 8.71 (dd, J = 4.6, 1.3 Hz, 1H), 8.65 (d, J = 7.8 Hz, 1H), 7.90 (dd, J = 15.8, 9.7 Hz, 2H), 7.73 (dd, J = 19.0, 8.26 Hz, 2H), 7.56- 7.12 (m, 4H), 7.04 (dd, J = 8.2, 1.8 Hz, 1H). DMSO 383.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 35

HCl 400.33 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.43 (s, 1H), 9.52 (s, 1H), 8.89 (d, J = 8.2 Hz, 1H), 8.85 (d, 4.2 Hz, 1H), 8.78 (dd, J = 9.2, 5.9 Hz, 1H), 8.09 (s, 1H), 7.95 (dd, J = 8.2, 1.2 Hz, 1H), 7.80 (dd, J = 7.9, 5.2 Hz, 1H), 7.72-7.58 (m, 3H), 7.21 (d, J = 8.4 Hz, 1H). DMSO 401.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 36

HCl 405.84 ¹H-NMR (400 MHz,. DMSO-d₆): δ 10.74- 10.48 (m, 1H), 9.36 (d, J = 1.6 Hz, 1H), 8.95 (d, J = 8.2 Hz, 1H), 8.89-8.85 (m, 1H), 8.05 (d, J = 1.7 Hz, 1H), 8.02 (d, J = 9.15 Hz, 1H), 7.93-7.86 (m, 2H), 7.73- 7.63 (m, 3H), 7.60-7.52 (m, 2H), 3.98 (s, 3H). DMSO  406.1, 408.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 37

HCl 359.36 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 9.00 (dd, J = 15.4, 8.2 Hz, 2H), 8.36 (d, J = 4.13 Hz, 1H), 8.52 (s, 1H), 8.04-7.94 (m, 3H), 7.86-7.70 (m, 4H), 7.26 (dd, J = 11.2, 4.2 Hz, 1H). DMSO 360.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 38

HCl 368.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.22 (s, 1H), 9.52 (s, 1H), 8.73 (d, J = 3.6 Hz, 1H), 8.69 (td, J = 8.0, 1.8 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.25 (dd, J = 6.8, 2.6 Hz, 1H), 7.91 (ddd, J = 9.0, 4.2, 2.6 Hz, 1H), 7.79 (dd, J = 9.8, 7.9 Hz, 1H), 7.67 (dd, J = 8.2, 5.2 Hz, 1H), 7.61-7.53 (m, 2H). DMSO  369.0, 371.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 39

HCl 400.33 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.52 (d, J = 1.4 Hz, 1H), 9.04 (d, J = 8.0 Hz, 1H), 8.92 (dd, J = 5.2, 1.2 Hz, 1H), 8.52 (d, J = 8.4 Hz, 1H), 8.07 (s, 1H), 7.97 (d, J = 1.2 Hz, 2H), 7.86-7.80 (m, 1H), 7.74-7.68 (m, 1H), 7.62 (t, J = 8.2 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H). DMSO 401.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 40

360.34 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.68 (d,. J = 1.6 Hz, 1H), 8.82 (t, J = 7.9, 1.8 Hz, 1H), 8.71 (dd, J = 4.6, 1.6 Hz, 1H), 8.22 (d, J = 8.2 Hz, 1H), 7.87 (dd, J = 7.8, 1.9 Hz, 1H), 7.73 (dd, J = 9 2, 7.8 Hz, 1H), 7.59 (dt, J = 8.1, 5.0 Hz, 2H), 7.21-7.15 (m, 1H), 6.66 (d, J = 8.2 Hz, 1H), 6.54 (t, J = 7.4 Hz, 1H). DMSO 360.9 (M + 1), 382.9 (M + 23) Method B (NH4HCO3) 95 Meth-od C, G9 41

380.08 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.56 (brs, 1H), 9.62 (d, J = 1.2 Hz, 1H), 9.05 (d, J = 8.4 Hz, 1H), 9.00 (dd, J = 1.6, 4.8 Hz, 1H), 8,71 (d, J = 9.2 Hz, 1H), 8.31 (dd, J = 2.0, 7.2 Hz, 1H), 8.02-7.99 (m, 2H), 7.66 (t, J = 9.2 Hz, 1H), 7.54 (s, 1H), 7.50 (dd, J = 2.4, 9.2 Hz, 1H), 4.11 (s, 3H). DMSO  381.1, 383.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 42

476.67 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.40 (s, 1H), 9.51 (s, 1H), 8.93 (d, J = 8.0 Hz, 1H), 8.88 (d, J = 4.8 Hz, 1H), 8.40 (d, J = 8.8 Hz, 1H), 8.35 (d, J = 1.6 Hz, 1H), 8.20 (dd, J = 4.4, 6.8 Hz, 1H), 8.04 (dd, J = 7.2, 8.8 Hz, 1H), 7.93-7.86 (m, 2H), 7.35 (t, J = 9.2 Hz, 1H). DMSO  477.0, 499.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 43

429.67 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.46 (s, 1H), 9.49 (s, 1H), 8.95 (d, J = 8.1 Hz, 1H), 8.89 (d, J = 4.97 Hz, 1H), 8.60 (d, J = 8.9 Hz, 1H), 8.19 (dd, J = 6.8, 2.6 Hz, 1H), 8.14 (d, J = 1.9 Hz, 1H), 7.96-7.83 (m, 3H), 7.53 (t, J = 9.0 Hz, 1H). DMSO  429.0, 430.9, 433.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 44

HCl 385.42 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.05 (s, 1H), 9.44 (d, J = 1.7 Hz, 1H), 9.16-8.91 (m, 2H), 8.03-7.89 (m, 3H), 7.88-7.82 (m, 1H), 7.75-7.68 (m, 1H), 7.67-7.60 (m, 2H), 7.25 (t, J = 7.6 Hz, 1H), 4.00 (s, 3H), 2.74 (s, 3H). DMSO 386.0 (M + 1) 193.4 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 45

HCl 408.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.37-10.12 (m, 1H), 9.35 (d, J = 1.8 Hz, 1H), 8.95 (dd, J = 4.6, 3.4 Hz, 1H), 8.09 (d, J = 2.3 Hz, 1H), 7.92 (d, J = 9.1 Hz, 1H), 7.87 (s, 1H), 7.84-7.74 (m, 2H), 7.62 (dd, J = 9.1, 2.6 Hz, 1H), 7.54 (t, J = 8.2 Hz, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.05 (dd, J = 8.3, 1.9 Hz, 1H), 4.00 (s, 3H), 2.72 (s, 3H). DMSO 409.0 (M + 1) 205.0 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 46

HCl 394.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.27 (brs, 1H), 9.32 (d, J = 1.7 Hz, 1H), 8.93 (d, J = 7.5 Hz, 1H), 8.19 (dd, J = 6.8, 2.5 Hz, 1H), 8.07 (d, J = 2.3 Hz, 1H), 7.88-7.92 (m, 2H), 7.84 (d, J = 8.1 Hz, 1H), 7.62 (dd, J = 9.2, 2.5 Hz, 1H), 7.54 (t, J = 9.1 Hz, 1H), 4.00 (s, 3H), 2.72 (s, 3H). DMSO  395.0, 397.0 (M + 1)  197.8, 198.8 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 47

HCl 378.37 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.58-10.30 (m, 1H), 9.32 (d, J = 1.9 Hz, 1H), 9.04 (d, J = 7.9 Hz, 1H), 8.17-8.04 (m, 2H), 7.95 (d, J = 9.0 Hz, 2H), 7.73-7.66 (m, 1H), 7.63 (dd, J = 9.2, 2.6 Hz, 1H), 7.60-7.50 (m, 1H), 4.01 (s, 3H), 2.76 (s, 3H). DMSO 379.0 (M + 1) 190.0 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 48

HCl 411.28 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.29 (s, 1H), 9.33 (d, J = 1.7 Hz, 1H), 9.04-8.89 (m, 1H), 8.31 (d, J = 2.4 Hz, 1H), 8.07 (d, J = 2.4 Hz, 1H), 7.97 (dd, J = 8.8, 2.5 Hz, 1H), 7.91 (d, J = 9.1 Hz, 1H), 7.85 (d, J = 8.6 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.62 (dd, J = 9.1, 2.5 Hz, 1H), 4.00 (s, 3H), 2.73 (s, 3H). DMSO  411.0, 413.0 (M + 1)  205.0, 206.9 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 49

411.28 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.30 (s, 1H), 9.31 (d, J = 1.5 Hz, 1H), 8.94 (d, J = 7.3 Hz, 1H), 8.13 (d, J = 1.7 Hz, 2H), 8.07 (d, J = 2.3 Hz, 1H), 7.90 (d, J = 9.2 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.61 (dd, J = 9.1, 2.6 Hz, 1H), 7.41 (d, J = 1.7 Hz, 1H), 4.00 (s, 3H), 2.72 (s, 3H). DMSO  411.0, 413.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 50

HCl 389.84 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.09 (s, 1H), 9.38 (s, 1H), 9.16 (d, J = 8.4 Hz, 1H), 8.83 (d, J = 8.3 Hz, 1H), 8.50 (s, 1H), 8.20 (d, J = 8.8 Hz, 1H), 8.05-7.99 (m, 2H), 7.97 (d, J = 7.9 Hz, 1H), 7.92 (s, 1H), 7.81 (dd, J = 8.8, 2.0 Hz, 1H), 7.68 (t, J = 7.8 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H), 2.82 (s, 3H). DMSO  390.1, 392.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 51

HCl 412.82 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.49 (s, 1H), 9.35 (d, J = 1.7 Hz, 1H), 9.08 (dd, J = 8.3, 1.5 Hz, 1H), 8.75 (d, J = 9.0 Hz, 1H), 8.02 (d, J = 2.1 Hz, 1H), 7.97 (d, J = 8.3 Hz, 1H), 7.87 (s, 1H), 7.80 (dd, J = 9.0, 2.0 Hz, 2H), 7.53 (t, J = 8.2 Hz, 1H), 7.31 (t, J = 74.0 Hz, 1H), 7.06 (dd, J = 8.1, 2.0 Hz, 1H), 2.79 (s, 3H). DMSO  413.0, 415.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 52

399.25 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.49 (s, 1H), 9.32 (d, J = 1.7 Hz, 1H), 9.00 (d, J = 8.4 Hz, 1H), 8.69 (d, J = 8.9 Hz, 1H), 8.20 (dd, J = 6.8, 2.6 Hz, 1H), 8.00 (d, J = 2.1 Hz, 1H), 7.96-7.86 (m, 2H), 7.80 (dd, J = 8.9, 2.1 Hz, 1H), 7.53 (t, J = 9.1 Hz, 1H), 2.76 (s, 3H). DMSO  399.0, 401.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 53

HCl 382.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.55 (s, 1H), 9.32 (d, J = 1.7 Hz, 1H), 9.07 (dd, J = 8.2, 1.2 Hz, 1H), 8.73 (d, J = 8.9 Hz, 1H), 8.08 (ddd, J = 13.0, 7.5, 2.6 Hz, 1H), 8.00 (dd, J = 8.9, 5.2 Hz, 2H), 7.80 (dd, J = 8.9, 2.1 Hz, 1H), 7.71 (dd, J = 6.1, 2.9 Hz, 1H), 7.54 (dd, J = 19.7, 9.2 Hz, 1H), 2.78 (s, 3H) DMSO  383.0, 385.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 54

HCl 415.7 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.63 (s, 1H), 9.30 (d, J = 1.7 Hz, 1H), 9.07 (dd, J = 8.3, 1.8 Hz, 1H), 8.75 (d, J = 9.0 Hz, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 2.1 Hz, 1H), 7.96 (dd, J = 8.3, 2.5 Hz, 1H), 7.77 (dd, J = 8.9, 2.1 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 2.81 (s, 3H). DMSO  415.0,  417.0, 419.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 55

HCl 415.7 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.54 (s, 1H), 9.32 (s, 1H), 9.01 (dd, J = 8.0, 1.8 Hz, 1H), 8.72 (d, J = 9.0 Hz, 1H), 8.11 (d, J = 1.8 Hz, 2H), 8.01 (d, J = 2.0 Hz, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.80 (dd, J = 8.9, 2.0 Hz, 1H), 2.78 (s, 3H). DMSO  415.0,  417.0, 419.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G11 56

379.36 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.16 (s, 1H), 9.47 (s, 1H), 8.79 (dd, J = 8.9, 7.1 Hz, 2H), 7.91 (s, 1H), 7.84-7.77 (m, 2H), 7.76-7.68 (m, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.51 (t, J = 8.2 Hz, 1H), 7.39 (dd, J = 8.9, 2.2 Hz, 1H), 7.29 (t, J = 74.0 Hz, 1H), 7.00 (dd, J = 8.1, 2.1 Hz, 1H), 4.23 (brs, 2H). DMSO 380.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 57

HCl 463.48 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.43-10.20 (m, 2H), 9.72 (s, 1H), 8.89-8.67 (m, 3H), 8.29-8.21 (m, 1H), 7.97 (s, 1H), 7.87-7.80 (m, 1H), 7.81-7.73 (m, 1H), 7.63-7.46 (m, 2H), 7.30 (t, J = 74.0 Hz, 1H), 7.08-6.98 (m, 1H), 5.00 (s, 2H), 4.05-3.65 (m, 4H), 3.39-3.36 (m, 4H). DMSO 464.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 58

HCl 399.45 ¹H-NMR (400 MHz, DMSO-d₆) δ 12.53 (s, 1H), 9.30 (d, J = 1.6 Hz, 1H), 3.03-8.96 (m, 1H), 8.94-8.88 (m, 1H), 8.71 (d, J = 8.4 Hz, 1H), 7.91-7.83 (m, 3H), 7.67-7.55 (m, 3H), 7.25 (t, J = 7.2 Hz, 1H), 3.98 (s, 3H), 2.80-2.74 (m, 6H). DMSO 400.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 59

HCl 389.38 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.27 (s, 1H), 9.23 (s, 1H), 8.98 (d, J = 5.2 Hz, 1H), 8.91 (d, J = 8.0 Hz, 1H), 8.54 (dd, J = 12.0, 2.6 Hz, 1H), 8.48 (s, 1H), 8.07 (dd, J = 3.0, 5.6 Hz, 1H), 7.97-7.93 (m, 2H), 7.66 (d, J = 9.0 Hz, 1H), 7.37 (dd, J = 9.0, 2.4 Hz, 1H), 7.13 (d, J = 2.0 Hz, 1H), 6.91 (dt, J = 8.4, 2.6 Hz, 1H), 3.80 (s, 3H). DMSO 390.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 60

415.70 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.13 (s, 1H), 9.48 (s, 1H), 8.87 (dd, J = 14.0, 6.2 Hz, 2H), 8.54 (d, J = 1.7 Hz, 1H), 8.10 (d, J = 1.8 Hz, 2H), 7.89-7.78 (m, 2H), 7.37 (t, J = 1.8 Hz, 1H), 2.70 (s, 3H). DMSO  414.9,  416.9, 419.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 61

415.70 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.10 (s, 1H), 9.44 (s, 1H), 8.86 (d, J = 7.8 Hz, 1H), 8.79 (d, J = 4.5 Hz, 1H), 8.50 (d, J = 1.7 Hz, 1H), 8.23 (d, J = 2.4 Hz, 1H), 7.89 (dd, J = 8.8, 2.4 Hz, 1H), 7.83-7.71 (m, 2H), 7.62 (d, J = 8.8 Hz, 1H), 2.62 (s, 3H) DMSO  414.9,  416.9, 418.9 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 62

412.82 ¹H-NMR (400 MHz, DMSO-d₆): δ: 10.02 (s, 1H), 9.58 (d, J = 1.8 Hz, 1H), 8.76-8.67 (m, 2H), 8.59 (d, J = 1.8 Hz, 1H), 7.96 (s, 1H), 7.82 (d, J = 6.6 Hz, 2H), 7.54 (ddd, J = 16.4, 10.0, 6.4 Hz, 2H), 7.30 (t, J = 74.0 Hz, 1H), 7.01 (dd, J = 8.0, 2.0 Hz, 1H), 2.74 (s. 3H). DMSO  413.0, 415.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 63

389.84 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.15 (s, 1H), 9.58 (s, 1H), 9.03 (d, J = 0.8 Hz, 1H), 8.78-8.84 (m, 2H), 8.50 (s, 1H), 7.95-8.03 (m, 3H), 7.80 (s, 1H), 7.70-7.74 (m, 2H), 7.23 (d, J = 7.2 Hz, 1H), 2.70 (s, 3H). DMSO  391.0, 392.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 64

371.82 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.31 (s, 1H), 9.48 (d, J = 1.2 Hz, 1H), 9.01 (d, J = 8.4 Hz, 1H), 8.90 (d, J = 4.6 Hz, 1H), 8.61 (d, J = 1.6 Hz, 1H), 8.33 (s, 1H), 8.27 (dd, J = 6.0, 2.0 Hz, 1H), 7.95-7.63 (m, 3H), 2.70 (s, 3H). DMSO 372.0 373.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 65

476.67 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.28 (s, 1H), 9.46 (d, J = 1.2 Hz, 1H), 9.01 (d, J = 1.2 Hz, 1H), 8.83 (dd, J = 8.4, 1.6 Hz, 2H), 8.19-8.14 (m, 2H), 7.89-7.49 (m, 2H). DMSO  476.9, 478.9 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 66

399.25 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.03 (s, 1H), 8.54 (s, 1H), 8.71-8.67 (m, 2H), 8.53 (s, 1H), 8.26 (dd, J = 6.8 Hz, 2.4 Hz, 1H), 7.83 (s, 1H), 7.58-7.52 (m, 2H), 2.72 (s, 3H). DMSO  399.0, 401.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 67

382.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.04 (s, 1H), 9.51 (d, J = 1.2 Hz, 1H), 8.72-8.69 (m, 2H), 8.53 (d, J = 2.0 Hz, 1H), 8.08 (ddd, J = 9.2, 7.6, 2.4 Hz, 1H), 7.79-7.48 (m, 4H), 2.69 (s, 3H). DMSO  383.0, 385.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 68

HCl 399.45 ¹H-NMR (400 MHz, DMSO-d6): δ 13.02 (s, 1H), 9.59 (s, 1H) , 9.09 (d, J = 8.0 Hz, 1H), 8.96 (d, J = 8.4 Hz, 1H) , 8.91 (d, J = 4.61 Hz, 1H), 8.48 (s, 1H), 7.97 (dd, J = 8.0, 2.8 Hz, 4H), 7.72 (t, J = 7.6 Hz, 1H), 7.64-7.61 (m, 2H), 7.26 (t, J = 7.6 Hz, 1H), 4.88-4.82 (m, 1H), 1.43 (d, J = 6.0 Hz, 6H). DMSO 400.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 69

HCl 422.43 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.63 (s, 1H), 9.51 (s, 1H), 9.09 (d, J = 7.6 Hz, 1H), 8.91 (d, J = 7.6 Hz, 1H), 8.23 (s, 1H), 8.03-7.97 (m, 1H), 7.83-7.80 (m, 2H), 7.64 (dd, J = 9.2, 2.4 Hz, 1H), 7.55 (t, J = 8.1 Hz, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.08 (d, J = 7.4 Hz, 1H), 5.02-4.97 (m, 1H), 1.39 (d, J = 6.0 Hz, 6H). DMSO 423.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 70

HCl 408.86 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.61 (s, 1H), 9.48 (s, 1H), 9.05 (d, J = 7.2 Hz, 1H), 8.93 (d, J = 5.2 Hz, 1H), 8.19-8.15 (m, 2H), 8.01-7.92 (m, 3H), 7.63-7.53 (m, 2H), 5.01-4.94 (m, 1H), 1.39 (d, J = 6.0 Hz, 6H). DMSO  409.1, 411.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 71

HCl 425.31 ¹H NMR (400 MHz, DMSO-d₆): δ 9.92 (s, 1H), 9.52 (d, J = 1.2 Hz, 1H), 8.70-8.66 (m, 2H), 8.17 (d, J = 1.6 Hz, 2H), 7.98 (d, J = 2.4 Hz, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.60-7.56 (m, 2H), 7.39 (t, J = 1.8 Hz, 1H), 4.94-4.88 (m, 1H), 1.39 (d, J = 6.0 Hz, 6H). DMSO  424.9, 426.9 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 72

HCl 392.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.28 (s, 1H), 9.49 (d, J = 1.2 Hz, 1H), 8.93 (d, J = 8.0 Hz, 1H), 8.86-8.84 (m, 1H), 8.10-8.05 (m, 2H), 7.93-7.85 (m, 2H), 7.71-7.69 (m, 2H), 7.61-7.52 (m, 1H), 4.97-4.91 (m, 1H), 1.39 (d, J = 6.0 Hz, 6H). DMSO 393.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 73

HCl 385.42 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.03 (s, 1H), 9.53 (d, J = 1.2 Hz, 1H), 9.10 (d, J = 3.4 Hz, 1H), 8.93-8.90 (m, 2H), 8.49 (s, 1H), 8.01-7.91 (m, 4H), 7.69 (t, J = 7.6 Hz, 1H), 7.59-7.54 (m, 2H), 7.24 (t, J = 7.6 Hz, 1H), 4.21 (q, J = 6.8 Hz, 2H), 1.46 (t, J = 6.9 Hz, 3H). DMSO 386.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 74

HCl 367.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.35 (s, 1H), 9.49 (s, 1H), 8.95 (d, J = 7.6 Hz, 1H), 8.85 (d, J = 4.8 Hz, 1H), 8.37 (s, 1H), 8.28 (d, J = 7.6 Hz, 1H), 8.08 (s, 1H), 7.94-7.85 (m, 2H), 7.73-7.60 (m, 3H), 4.28 (q, J = 6.8 Hz, 2H), 1.46 (t, J = 6.8 Hz, 3H). DMSO 368.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 75

HCl 394.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.64 (s, 1H), 9.44 (s, 1H), 8.99 (d, J = 8.4 Hz, 1H), 8.91 (d, J = 4.4 Hz, 1H), 8.17 (d, J = 3.2 Hz, 2H), 7.59-7.50 (m, 2H), 4.26 (q, J = 8.8 Hz, 2H), 1.44 (t, J =- 6.8 Hz, 3H). DMSO 395.1 397.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 76

HCl 411.28 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.48 (s, 1H), 9.47 (s, 1H), 9.02 (d, J = 7.6 Hz, 1H), 8.91 (d, J = 4.4 Hz, 1H), 8.28 (d, J = 1.6 Hz, 1H), 8.13 (s, 1H), 8.01-7.91 (m, 3H), 7.72 (d, J = 8.8 Hz, 1H), 7.59-7.57 (m, 1H), 4.26 (q, J = 6.8 Hz, 2H), 1.44 (t, J = 6.8 Hz, 3H). DMSO 411.0 413.0 415.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 77

HCl 411.28 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 9.48 (s, 1H), 8.93 (d, J = 8.0 Hz, 1H), 8.85 (d, J = 4.8 Hz, 1H), 8.14 (s, 2H), 8.05 (d, J = 1.6 Hz, 1H), 7.92-7.85 (m, 2H), 7.61 (dd, J = 9.1, 1.8 Hz, 1H), 7.41 (s, 1H), 4.26 (q, J = 6.8 Hz, 2H), 1.45 (t, J = 6.8 Hz, 3H). DMSO 411.0 413.1 415.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 78

HCl 378.37 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.39 (s, 1H), 9.49 (s, 1H), 8.98 (d, J = 8.0 Hz, 1H), 8.88 (d, J = 4.8 Hz, 1H), 8.11-8.05 (m, 2H), 7.95-7.91 (m, 2H), 7.72-7.52 (m, 3H), 4.28 (q, J = 6.8 Hz, 2H), 1.45 (t, J = 6.8 Hz, 3H). DMSO 379.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 79

HCl 429.47 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.99 (s, 1H), 9.59 (d, J = 1.6 Hz, 1H), 9.14 (d, J = 7.6 Hz, 1H), 8.75-8.69 (m, 2H), 8.48 (s, 1H), 7.99-7.96 (m, 2H), 7.90 (d, J = 8.8 Hz, 1H), 7.76-7.72 (m, 1H), 7.61-7.56 (m, 3H), 7.22-7.19 (m, 1H), 4.24 (t, J = 6.0 Hz, 2H), 3.56 (t, J = 6.0 Hz, 2H), 3.28 (s, 3H), 2.11-2.04 (m, 2H). DMSO 430.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 80

HCl 380.80 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.67 (s, 1H), 9.18 (d, J = 2.0 Hz, 1H), 8.90 (d, J = 8.4 Hz, 1H), 8.66 (dd, J = 8.8, 2.4 Hz, 1H), 8.35 (d, J = 8.4 Hz, 1H), 8.14-8.08 (m, 2H), 7.90-7.81 (m, 2H), 7.62 (t, J = 9.2 Hz, 1H), 7.09 (d, J = 8.8 Hz, 1H), 3.98 (s, 3H). DMSO  380.9, 382.9 (M + 1) Method A (TFA) 95 Meth-od C, G1 81

HCl 394.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.81 (s, 1H), 9.49 (d, J = 1.2 Hz, 1H), 9.28 (d, J = 0.8 Hz, 1H), 9.15 (d, J = 8.0 Hz, 1H), 9.02 (d, J = 5.2 Hz, 1H), 8.37- 8.34 (m, 1H), 8.12-8.09 (m, 2H), 8.01 (d, J = 8.4 Hz, 1H), 7.95-7.91 (m, 1H), 7.53 (t, J = 9.0 Hz, 1H). DMSO  395.0, 397.0 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 82

385.39 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.63 (d, J = 1.6 Hz, 1H), 9.13 (s, 1H), 8.80-8.75 (m, 2H), 8.21 (d, J = 9.2 Hz, 1H), 7.97-7.94 (m, 1H), 7.82 (dd, J = 9.2, 2.8 Hz, 1H), 7.73 (dd, J = 9.2, 2.4 Hz, 1H), 7.64-7.61 (m, 1H), 7.38-7.32 (m, 2H), 4.18 (q, J = 6.8 Hz, 2H), 3.19 (t, J = 7.0 Hz, 3H). DMSO 386.1 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G10 83

HCl 426.39 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.43 (s, 1H), 9.49 (d, J = 1.6 Hz, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.89 (dd, J = 9.2, 1.6 Hz, 1H), 8.13 (d, J = 2.4 Hz, 1H), 8.05 (s, 1H), 7.97-7.89 (m, 3H), 7.65-7.61 (m, 2H), 7.23 (d, J = 8.4 Hz, 1H), 4.29 (q, J = 6.8 Hz, 2H), 1.46 (t, J = 7.2 Hz, 3H). DMSO 427.1 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 84

426.47 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.00 (s, 1H), 9.55 (s, 1H), 9.12 (d, J = 8.0 Hz, 1H), 8.94 (d, J = 4.8 Hz, 1H), 8.84 (d, J = 8.4 Hz, 1H), 8.11-8.09 (m, 1H), 8.02-7.99 (m, 1H), 7.96 (d, J = 9.2 Hz, 1H), 7.82-7.11 (m, 1H), 7.65 (s, 1H); 7.62-7.59 (m, 1H), 7.30 (t, J = 7.2, Hz, 1H), 5.06-5.03 (m, 1H), 2.15-2.09 (m, 2H), 1.86-1.74 (m, 4H), 1.68-1.65 (m, 2H) DMSO 427.0 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 85

375.81 1H-NMR (400 MHz, DMSO-d6): δ 13.09 (s, 1H), 9.58 (s, 1H), 9.12 (d, J = 8.4 Hz, 1H), 8.94 (d, J = 4.4 Hz, 1H), 8.88 (d, J = 8.4 Hz, 1H), 8.50 (s, 1H), 8.25 (s, 1H), 8.01-7.96 (m, 5H), 7.71 (t, J = 8.0 Hz, 1H), 7.27 (t, J = 8.0 Hz, 1H). DMSO  376.0, 378.0 (M + 1) 397.9 (M + 23) 188.4 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 86

398.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.10 (s, 1H), 9.54 (s, 1H), 8.78 (s, 1H), 8.71-8.67 (m, 2H), 7.96 (s, 1H), 7.91 (d, J = 8.0 Hz, 2H), 7.82 (d, J = 8.0 Hz, 1H), 7.56-7.51 (m, 2H), 7.30 (t, J = 74.0 Hz, 1H), 7.01 (dd, J = 2.0, 8.0 Hz, 1H). DMSO  399.0, 401.0 (M + 1)  199.9, 200.8 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 87

443.7 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.09 (s, 1H), 9.39 (s, 1H), 8.93 (d, J = 8.4 Hz, 1H), 8.90 (d, J = 5.6 Hz, 1H), 8.62 (d, J = 1.6 Hz, 1H), 8.11 (dd, J = 6.8, 2.4 Hz, 1H), 7.95-7.91 (m, 1H), 7.89-7.85 (m, 1H), 7.80 (s, 1H), 7.45 (t, J = 8.8 Hz, 1H), 2.66 (s, 3H). DMSO  443.0,  445.0, 447.0 (M + 1) Method B (NH₄HCO₃) 98 Meth-od C, G1 88

401.42 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.19 (s, 1H), 9.43 (d, J = 8.0 Hz, 1H), 8.53 (s, 1H), 8.31 (dd, J = 4.8, 1.6 Hz, 1H), 8.26 (dd, J = 1.6, 7.2 Hz, 1H), 8.03 (s, 1H), 7.96-7.89 (m, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7,65-7.54 (m, 3H), 7.18-7.12 (m, 2H), 4.02 (s, 3H), 3.98 (s, 3H). DMSO 402.1 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 89

410.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.79 (s, 1H), 8.52 (dd, J = 2.4, 7.2 Hz, 1H), 8.28 (dd, J = 5.6, 2.4 Hz, 1H), 8.12 (dd, J = 2.4, 5.2 Hz, 1H), 7.98-7.94 (m, 2H), 7.82 (d, J = 9.2 Hz, 1H), 7.56 (dd, J = 9.2, 2.8 Hz, 1H), 7.47 (t, J = 9.2 Hz, 1H), 7.14-7.11 (m, 1H), 4.00 (s, 3H), 3.9 (s, 3H). DMSO  411.1, 413.1 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 90

415.44 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.03 (s, 1H), 9.21 (d, J = 2.2 Hz, 1H), 9.16 (d, J = 7.9 Hz, 1H), 8.67 (dd, J = 8.7, 2.4 Hz, 1H), 8.50 (s, 1H), 8.02 (s, 1H), 7.99-7.93 (m, 1H), 7.84 (d, J = 8.9 Hz, 1H), 7.78-7.72 (m, 1H), 7.56 (dd, J = 11.2, 2.1 Hz, 2H), 7.19 (t, J = 7.2 Hz, 1H), 6.99 (d, J = 8.8 Hz, 1H), 4.24 (q, J = 6.9 Hz, 2H), 3.96 (s, 3H), 1.46 (t, J = 6.9 Hz, 3H). DMSO 416.1 (M + 1) Method B (NH₄HCO₃) 95 Meth-od D, G1 91

HCl 405.84 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.28 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 9.31 (d, J = 2.1 Hz, 1H), 8.90 (d, J = 8.3 Hz, 1H), 8.83 (dd, J = 5.0, 1.4 Hz, 1H), 8.58 (s, 1H), 8.12 (s, 1H), 8.01 (d, J = 8.6 Hz, 1H), 7.93 (d, J = 9.1 Hz, 1H), 7.82 (dd, J = 7.9, 5.0 Hz, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.54 (d, J = 2.5 Hz, 1H), 7.30 (dd, J = 8.5, 2.2 Hz, 1H), 3.98 (s, 3H). DMSO  406.0, 408.0 (M + 1) Method A (TFA) 95 Meth-od C, G1 92

429.47 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.99 (s, 1H), 9.21 (d, J = 2.0 Hz, 1H), 9.14 (d, J = 8.4 Hz, 1H), 8.67 (dd, J = 8.7, 2.3 Hz, 1H), 8.49 (s, 1H), 8.05-7.90 (m, 2H), 7.85 (d, J = 9.0 Hz, 1H), 7.75 (t, J = 7.2 Hz, 1H), 7.67-7.47 (m, 2H), 7.20 (t, J = 7.5 Hz, 1H), 6.99 (d, J = 8.8 Hz, 1H), 4.15 (t, J = 6.3 Hz, 2H), 3.96 (s, 3H), 1.07 (t, J = 7.4 Hz, 3H), 1.86 (dd, J = 14.0, 6.7 Hz, 2H). DMSO 430.1 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 93

HCl 389.38 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.34 (s, 1H), 9.52 (d, J = 1.7 Hz, 1H), 8.99 (d, J = 7.8 Hz, 1H), 8.85 (dd, J = 5.2, 1.3 Hz, 1H), 8.22 (d, J = 8.1 Hz, 1H), 8.11-8.00 (m, 2H), 7.95 (d, J = 9.1 Hz, 1H), 7.87 (dd, J = 7.9, 5.3 Hz, 1H), 7.77-7.59 (m, 3H), 7.27-7.16 (m, 1H), 3.99 (s, 3H). DMSO 390.1 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 94

436.29 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.62 (s, 1H), 9.17 (s, 1H), 8.77 (d, J = 8.0 Hz, 1H), 8.76 (d, J = 4.0 Hz, 1H), 8.26-8.07 (m, 3H), 7.83 (dd, J = 9.1, 2.5 Hz, 1H), 7.63 (dd, J = 7.5, 5.0 Hz, 1H), 7.36 (d, J = 2.4 Hz, 1H), 4.18 (q, J = 6.8 Hz, 2H), 1.39 (t, J = 6.9 Hz, 3H). DMSO  436.1, 438.0 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 95

405.84 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.93 (s, 1H), 9.58 (s, 1H), 9.16 (d, J = 9.0 Hz, 1H), 8.70-8.74 (m, 2H), 8.59 (s, 1H), 8.13 (s, 1H), 8.05 (d, J = 2.3 Hz, 1H), 7.92 (d, J = 9.1 Hz, 1H), 7.82 (dd, J = 8.9, 2.1 Hz, 1H), 7.65-7.49 (m, 3H), 3.98 (s, 3H). DMSO  406.1, 408.0 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 96

429.67 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.45 (s, 1H), 9.47 (s, 1H), 9.02-8.92 (m, 3H), 8.18-8.16 (m, 1H), 8.06-8.04 (m, 1H), 7.96-7.84 (m, 3H), 7.54-7.50 (m, 1H). DMSO  429.9,  431.0, 433.0 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 97

398.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.25 (s, 1H), 9.58 (s, 1H), 8.85-8.76 (m, 2H), 8.60 (d, J = 7.2 Hz, 1H), 8.12-8.10 (m, 1H), 7.92 (s, 1H), 7.83-7.80 (m, 1H), 7.71-7.64 (m, 2H), 7.56-7.52 (m, 1H), 7.30 (t, J = 74.0 Hz, 1H), 7.05-7.03 (m, 1H). DMSO  399.0, 401.0 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 98

385.22 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.50 (s, 1H), 9.04 (d, J = 8.0 Hz, 1H), 8.93 (d, J = 5.2 Hz, 2H), 8.64 (d, J = 8.8 Hz, 1H), 8.20-8.18 (m, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.97-7.92 (m, 2H), 7.68-7.64 (m, 1H), 7.53 (t, J = 9.2 Hz, 1H). DMSO  385.0, 386.9 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 99

401.66 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.42 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 8.96 (d, J = 4.0 Hz, 1H), 8.88-8.87 (m, 1H), 8.61 (d, J = 7.6 Hz, 1H), 8.32 (d, J = 2.4 Hz, 1H), 8.14-8.12 (m, 1H), 7.99-7.95 (m, 1H), 7.88 (dd, J = 8.0, 5.2 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.70-7.67 (m, 1H). DMSO  400.9,  402.9, 404.9 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 100

368.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.51 (d, J = 1.2 Hz, 1H), 9.04 (d, J = 3.0 Hz, 1H), 8.92 (d, J = 5.6 Hz, 1H), 8.65 (d, J = 8.0 Hz, 1H), 8.11-8.05 (m, 2H), 7.97 (dd, J = 8.0, 4.0 Hz, 1H), 7.75-7.73 (m, 1H), 7.66 (t, J = 8.0 Hz, 1H), 7.58-7.51 (m, 1H). DMSO 369.0, 371.0 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 101

375.09 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.18 (s, 1H), 9.61 (s, 1H), 9.02 (d, J = 8.4 Hz, 1H), 8.93 (d, J = 8.4 Hz, 1H), 8.83 (d, J = 4.0 Hz, 1H), 8.52 (s, 1H), 8.16-8.08 (m, 2H), 7.98-7.94 (m, 2H), 7.80-7.67 (m, 3H), 7.26 (t, J = 7.6 Hz, 1H). DMSO  376.0, 378.0 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 102

401.68 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.49 (d, J = 2.0 Hz, 1H), 9.00-8.98 (m, 1H), 8.91 (dd, J = 5.2, 1.6 Hz, 1H), 8.64-8.62 (m, 1H), 8.12-8.09 (m, 3H), 7.94 (dd, J = 8.0, 5.2 Hz, 1H), 7.67 (t, J = 8.0 Hz, 1H), 7.41 (t, J = 2.0 Hz, 1H). DMSO  400.9,  402.9, 404.9 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 103

434.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.17 (d, J = 1.2 Hz, 1H), 9.51 (s, 1H), 8.71-8.62 (m, 3H), 8.25-8.22 (m, 1H), 8.04-8.00 (m, 1H), 7.92-7.87 (m, 2H), 7.58-7.53 (m, 2H). DMSO  435.1, 437.1 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 104

448.35 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.16 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H), 8.72-8.68 (m, 3H), 8.05 (d, J = 9.2 Hz, 1H), 7.92-7.95 (m, 2H), 7.80 (dd, J = 8.0, 1.2 Hz, 1H), 7.57-7.53 (m, 2H), 7.31 (t, J = 74.4 Hz, 1H), 7.03 (dd, J = 8.0, 1.2 Hz, 1H). DMSO 449.1 (M + 1) Method B (NH₄HCO₃) 95 Meth-od C, G1 105

425.36 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.24 (s, 1H), 9.59 (s, 1H), 9.05 (d, J = 8.0 Hz, 1H), 8.74-8.73 (m, 2H), 8.54 (s, 1H), 8.10-7.91 (m, 5H), 7.77-7.73 (m, 1H), 7.61-7.58 (m, 1H), 7.26 (t, J = 7.6 Hz, 1H DMSO 426.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 106

448.35 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 8.76 (d, J = 9.1 Hz, 1H), 8.74-8.67 (m, 2H), 7.94 (t, J = 2.0 Hz, 1H), 7.82-7.78 (m, J = 10.3 Hz, 2H), 7.68 (dd, J = 9.0, 1.8 Hz, 1H), 7.59-7.50 (m, 2H), 7.30 (t, J = 74.0 Hz, 1H), 7.03 (dd, J = 8.2, 2.2 Hz, 1H). DMSO 449.0 (M + 1) 225.0 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 107

425.36 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.17 (s, 1H), 9.59 (s, 1H), 9.04 (d, J = 8.0 Hz, 1H), 8.74-8.70 (m, 2H), 8.51 (s, 1H), 8.30 (d, J = 9.0 Hz, 1H), 8.02-7.90 (m, 2H), 7.86-7.69 (m, 3H), 7.65-7.56 (m, 1H), 7.25 (t, J = 9.8 Hz, 1H). DMSO 426.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 108

434.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.26 (s, 1H), 9.52 (s, 1H), 8.81-8.59 (m, 3H), 8.24 (dd, J = 6.9, 2.5 Hz, 1H), 7.89-7.52 (m, 1H), 7.79 (s, 1H), 7.70 (d, J = 9.1 Hz, 1H), 7.65-7.50 (m, 2H). DMSO  435.0, 437.0 (M + 1) 218.1 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 109

455.39 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.35 (s, 1H), 9.58 (s, 1H), 9.27 (s, 1H), 8.83-8.70 (m, 2H), 8.62 (s, 1H), 8.18 (s, 1H), 8.11 (d, J = 8.8 Hz, 1H), 7.92 (d, J = 9.1 Hz, 1H), 7.68-7.58 (m, 2H), 7.54 (d, J = 2.5 Hz, 1H), 7.19 (dd, J = 8.4, 2.17 Hz, 1H), 3.98 (s, 3H). DMSO 456.0 (M + 1) 228.5 (M/2 + 1) Method A (TFA) 95 Meth-od C, J1 110

425.48 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.08 (s, 1H), 9.59 (s, 1H), 9.07 (d, J = 7.6 Hz, 1H), 9.02 (d, J = 8.0 Hz, 1H), 8.89 (d, J = 4.0 Hz, 1H), 8.50 (s, 1H), 7.92-7.99 (m, 4H), 7.73 (t, J = 7.6 Hz, 1H), 7.59-7.60 (m, 2H), 7.25 (t, J = 7.6 Hz, 1H), 2.12-2.15 (m, 2H), 5.02-5.03 (m, 1H), 1.67-1.86 (m, 6H). DMSO 426.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 111

448.46 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.26 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.95 (d, J = 7.2 Hz, 1H), 8.55 (d, J = 4.4 Hz, 1H), 8.08 (s, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 9.6 Hz, 2H), 7.79 (d, J = 8.8 Hz, 1H), 7.60-7.63 (m, 1H), 7.55 (t, J = 8.0 Hz, 1H), 7.31 (t, J = 74.0 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 5.14 (s, 1H), 2.03-2.09 (m, 2H), 1.61-1.81 (m, 6H). DMSO 449.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 112

434.89 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.47 (s, 1H), 8.97 (d, J = 7.6 Hz, 1H), 8.89 (d, J = 4.4 Hz, 1H), 8.16-8.19 (m, 1H), 7.53-7.61 (m, 2H), 8.10 (s, 1H), 7.90-7.96 (m, 3H), 5.15 (s, 1H), 2.09-2.10 (m, 2H), 1.67-1.78 (m, 6H). DMSO  435.0, 437.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 113

451.35 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 9.49 (s, 1H), 8.85 (d, J = 7.6 Hz, 1H), 8.80 (d, J = 4.0 Hz, 1H), 8.32 (s, 1H), 8.03 (s, 1H), 7.97-7.99 (m, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.77-7.79 (m, 1H), 7.75 (d, J = 8.3 Hz, 1H), 7.55-7.58 (m, 1H), 5.13 (s, 1H), 2.08 (d, J = 8.4 Hz, 2H), 1.79 (d, J = 9.6 Hz, 4H). DMSO  451.0, 453.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 114

418.44 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.24 (s, 1H), 9.49 (s, 1H), 8.92 (d, J = 8.0 Hz, 1H), 8.40 (d, J = 6.4 Hz, 1H), 8.04-8.11 (m, 2H), 7.92 (d, J = 9.2 Hz, 1H), 7.84-7.91 (m, 1H), 7.69-7.71 (m, 1H), 7.52-7.61 (m, 2H), 5.13 (s, 1H), 2.06-2.11 (m, 2H), 1.65-1.81 (m, 6H). DMSO 419.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 115

407.47 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.70 (s, 1H), 9.45 (s, 1H), 8.98 (d, J = 6.8 Hz, 1H), 8.89 (d, J = 6.0 Hz, 1H), 8.37 (s, 1H), 8.32 (d, J = 6.8 Hz, 1H), 8.18 (s, 1H), 7.93 (t, J = 9.2 Hz, 2H), 7.70 (t, J = 7.2 Hz, 2H), 7.56 (d, J = 8.8 Hz, 1H), 5.18 (s, 1H), 2.09 (s, 2H), 1.77 (m, 4H), 1.66 (m, 2H). DMSO 408.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 116

401.68 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.81 (s, 1H), 9.47 (s, 1H), 8.71 (d, J = 6.4 Hz, 1H), 8.62 (d, J = 7.6 Hz, 1H), 8.26 (s, 1H), 7.88 (t, J = 7.2 Hz, 3H), 7.75-7.73 (m, 2H), 7.57-7.56 (m, 1H). DMSO  401.0, 403.0 405.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 117

368.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.74 (s, 1H), 9.45 (d, J = 1.2 Hz, 1H), 8.70 (dd, J = 4.4, 1.6 Hz, 1H), 8.60 (d, J = 8.0 Hz, 1H), 8.04-8.00 (m, 1H), 7.88-7.85 (m, 2H), 7.74 (dd, J = 8.4, 1.6 Hz, 1H), 7.85-7.63 (m, 1H), 7.57-7.56 (m, 2H). DMSO  369.1, 371.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 118

436.34 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.33 (s, 1H), 8.87-8.20 (m, 2H), 8.27 (d, J = 1.6 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.90-7.72 (m, 3H), 7.39-7.36 (m, 2H), 3.44 (brs, 4H), 2.05 (brs, 4H). DMSO  435.9,  437.9, 439.8 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 119

403.43 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.38 (s, 1H), 9.43 (d, J = 1.2 Hz, 1H), 8.85-8.80 (m, 2H), 8.07-8.05 (m, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.81 (t, J = 6.8 Hz, 1H), 7.69-7.67 (m, 1H), 7.58-7.83 (m, 1H), 7.43-7.41 (m, 2H), 3.45 (brs, 4H), 2.06 (brs, 4H). DMSO 403.9 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 120

368.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.28 (s, 1H), 9.49 (s, 1H), 8.77-8.87 (m, 3H), 8.06-8.12 (m, 1H), 7.90-7.95 (m, 2H), 7.78-7.81 (m, 1H), 7.57-7.73 (m, 1H), 7.53 (dd, J = 19.6 Hz, 9.2 Hz, 1H). DMSO  369.0, 371.1 (M + 1) Method A (TFA) 95 Meth-od C, G1 121

401.68 1H-NMR (400 MHz, DMSO-d6): δ 10.37 (s, 1H), 9.52 (s, 1H), 8.95 (d, J = 3.2 Hz, 1H), 8.87 (m, 1H), 8.81 (s, 1H), 8.32 (d, J = 2.0 Hz, 1H), 7.95-7.99 (m, 3H), 7.87-7.89 (m, 1H), 7.72 (d, J = 8.8 Hz, 1H). DMSO  401.0,  403.0, 405.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 122

385.22 1H-NMR (400 MHz, DMSO-d6): δ 10.09 (s, 1H), 9.50 (s, 1H), 8.69 (s, 2H), 8.64 (d, J = 8.0 Hz, 1H), 8.26 (dd, J = 10.6 Hz, 1.8 Hz, 1H), 7.89-7.90 (m, 3H), 7.51-7.57 (m, 2H). DMSO  385.0, 387.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 123

357.8 1H-NMR (400 MHz, DMSO-d6): δ 10.25 (s, 1H), 9.52 (s, 1H), 8.67-8.76 (m, 3H), 8.44 (s, 1H), 8.27 (m, 1H), 7.96 (s, 2H), 7.66-7.69 (m, 2H), 7.57-7.59 (m, 1H). DMSO 358.0 (M + 1) Method A (TFA) 95 Meth-od C, G1 124

411.86 1H-NMR (400 MHz, DMSO-d6): δ 10.53 (s, 1H), 9.54 (s, 1H), 9.08 (d, J = 8.4 Hz, 1H), 8.94-8.90 (m, 2H), 8.15 (d, J = 8.4 Hz, 2H), 8.00-7.93 (m, 5H), 7.39 (s, 2H). DMSO  412.0, 414.0 (M + 1) Method A (TFA) 95 Meth-od C, G1 125

411.86 1H-NMR (400 MHz, DMSO-d6): δ 10.64 (s, 1H), 9.54 (s, 1H), 9.22 (s, 1H), 8.92-8.98 (m, 2H), 8.70 (s, 1H), 8.10 (s, 1H), 8.03-8.05 (m, 1H), 7.95 (s, 2H), 7.69 (s, 2H), 7.53 (s, 2H). DMSO  412.0, 414.0 (M + 1) Method A (TFA) 95 Meth-od C, G1 126

364.35 1H-NMR (400 MHz, DMSO-d6): δ 10.65 (s, 1H), 9.47 (s, 1H), 9.02 (d, J = 7.6 Hz, 1H), 8.92 (s, 1H), 8.21 (s, 1H), 8.08-8.10 (m, 1H), 7.95-7.97 (m, 2H), 7.74-7.75 (m, 1H), 7.54-7.62 (m, 2H), 4.00 (s, 3H). DMSO 365.1 (M + 1), 183.1 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 127

397.26 1H-NMR (400 MHz, DMSO-d6): δ 10.56 (s, 1H), 9.48 (s, 1H), 9.02 (d, J = 8.0 Hz, 1H), 8.91-8.92 (m, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.16-8.17 (m, 1H), 7.92-8.03 (m, 3H), 7.72 (d, J = 8.8 Hz, 1H), 7.58-7.61 (m, 1H), 4.00 (s, 3H). DMSO  397.0, 399.0 (M + 1), 200.1 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 128

407.45 1H-NMR (400 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.55 (s, 1H), 8.92-8.84 (m, 2H), 8.16-8.09 (m, 3H), 7.95-7.89 (m, 3H), 7.83-7.79 (m, 1H), 7.62-7.58 (m, 1H), 7.36 (s, 2H), 3.40 (s, 3H). DMSO 408.1 (M + 1) Method A (TFA) 95 Meth-od C, G1 129

362.81 1H-NMR (400 MHz, DMSO-d6): δ 10.06 (s, 1H), 9.51 (s, 1H), 8.82-8.85 (m, 2H), 8.10- 8.11 (m, 1H), 8.05 (d, J = 2.0 Hz, 1H), 7.98-7.93 (m, 2H), 7.75-7.77 (m, 1H), 7.59-7.61 (m, 1H), 7.52 (t, J = 8.0 Hz, 1H), 7.27-7.28 (m, 1H), 3.99 (s, 3H). DMSO  363.0, 365.0 (M + 1), 182.1 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 130

380.8 1H-NMR (300 MHz, DMSO-d6): δ 10.02 (s, 1H), 9.50 (s, 1H), 7.7 -8.79 (m, 2H), 8.19-8.24 (m, 1H), 7.86-8.00 (m, 3H), 7.52-7.70 (m, 3H), 3.98 (s, 3H). DMSO  381.1, 383.1 (M + 1), 191.1 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 131

371.39 1H-NMR (300 MHz, DMSO-d6): δ 13.08 (s, 1H), 9.59 (s, 1H), 9.07 (d, J = 8.1 Hz, 1H), 8.96 (d, J = 8.1 Hz, 1H), 8.83 (d, J = 3.9 Hz, 1H), 8.49 (s, 1H), 7.89-7.99 (m, 3H), 7.80-7.84 (m, 1H), 7.72 (t, J = 7.8 Hz, 1H), 7.60-7.63 (m, 2H), 7.23 (t, J = 7.5 Hz, 1H), 3.98 (s, 3H). DMSO 371.9 (M + 1) Method A (TFA3) 95 Meth-od C, G1 132

362.81 1H-NMR (400 MHz, DMSO-d6): δ 10.12 (s, 1H), 9.28 (s, 1H), 8.69 (d, J = 4.0 Hz, 1H), 8.59 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 2.8 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.68-7.70 (m, 2H), 7.57-7.63 (m, 2H), 7.48-7.53 (m, 1H), 7.40-7.44 (m, 1H), 3.86 (s, 3H). DMSO  363.0, 365.1 (M + 1), 182.1 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 133

348.35 1H-NMR (400 MHz, DMSO-d6): δ 9.46 (s, 1H), 9.11 (s, 1H), 8.79-8.76 (m, 2H), 8.00-7.94 (m, 1H), 7.83-7.73 (m, 3H), 7.62-7.48 (m, 3H), 3.00 (s, 3H). DMSO 349.1 (M + 1), 175.1 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 134

381.26 1H-NMR (400 MHz, DMSO-d6): δ 9.48 (s, 1H), 9.13 (s, 1H), 8.75-8.77 (m, 2H), 8.18 (s, 1H), 7.72-7.85 (m, 5H), 7.49-7.50 (m, 1H), 3.00 (s, 3H). DMSO  381.0,  383.0, 385.0 (M + 1) Method A (TFA) 95 Meth-od C, G1 135

364.8 1H-NMR (400 MHz, DMSO-d6): δ 9.43 (m, 2H), 8.94-8.89 (m, 2H), 8.08- 8.06 (m, 1H), 7.92-7.81 (m, 4H), 7.57-7.53 (m, 2H), 3.03 (s, 3H). DMSO  365.0, 367.0 (M + 1), 183.1 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 136

337.38 1H-NMR (400 MHz, DMSO-d6): δ 9.52-9.44 (m, 2H), 8.98 (d, J = 8.0 Hz, 1H), 8.92 (d, J = 4.4 Hz, 1H), 8.36-8.19 (m, 2H), 8.02-7.84 (m, 3H), 7.73-7.69 (m, 2H), 7.55 (d, J = 6.8 Hz, 1H), 3.04 (s, 3H). DMSO 338.1 (M + 1), 169.6 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 137

364.35 1H-NMR (400 MHz, DMSO-d6): δ 9.97 (s, 1H), 9.51 (s, 1H), 8.69-8.66 (m, 2H), 8.16-8.08 (m, 2H), 7.75-7.73 (m, 1H), 7.61-7.53 (m, 3H), 7.40 (d. J = 7.6 Hz, 1H), 4.01 (s, 3H). DMSO 183.1 (M/2 + 1) 365.1 (M + 1) Method A (TFA) 95 Meth-od C, G1 138

397.26 1H-NMR (400 MHz, DMSO-d6): δ 10.01 (s, 1H), 9.53 (s, 1H), 8.67-8.70 (m, 2H), 8.41 (d, J = 2.4 Hz, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.95-7.99 (m, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.56-7.63 (m, 2H), 7.42 (d, J = 8.4 Hz, 1H), 4.02 (s, 3H). DMSO  397.0, 399.0 (M + 1) Method A (TFA) 95 Meth-od C, G1 139

380.8 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.48 (s, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.89 (d, J =4.8 Hz, 1H), 8.15-8.22 (m, 2H), 7.92-7.95 (m, 2H), 7.62 (t, J = 8.0 Hz, 1H), 7.52 (t, J = 8.8 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 4.02 (s, 3H). DMSO 191.1 (M/2 + 1)  381.1, 383.1 (M + 1) Method A (TFA) 95 Meth-od C, G1 140

401.68 1H-NMR (400 MHz, DMSO-d6): δ 10.11 (s, 1H), 8.50 (m, 1H), 8.63-8.70 (m, 3H), 8.14 (d, J = 2.0 Hz, 2H), 7.92 (m, 2H), 7.57 (m, 1H), 7.38 (t, J = 1.6 Hz, 1H). DMSO  401.0, 403.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 141

348.35 1H-NMR (400 MHz, DMSO-d6): δ 9.46 (s, 1H), 9.11 (s, 1H), 8.76-8.70 (m, 2H), 7.95-7.99 (m, 1H), 7.78-7.60 (m, 3H), 7.54-7.44 (m, 3H), 3.00 (s, 3H). DMSO 175.1 (M/2 + 1) 349.1 (M + 1) Method A (TFA) 95 Meth-od C, G1 142

397.26 1H-NMR (400 MHz, DMSO-d6): δ 10.30 (s, 1H), 8.39 (s, 1H), 8.83 (s, 2H), 8.03-8.12 (m, 3H), 7.79-7.81 (m, 2H), 7.50-7.51 (m, 1H), 7.32 (s, 1H), 3.96 (s, 3H). DMSO  397.0,  399.0, 401.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 143

452.34 1H-NMR (400 MHz, DMSO-d6): δ 9.86 (s, 1H), 9.51 (s, 1H), 8.65-8.66 (m, 2H), 8.34 -8.35 (m, 1H), 7.95-7.96 (m, 1H), 7.72- 7.80 (m, 4H), 7.54 (m, 1H), 3.84 (m, 4H), 3.56 (m, 4H). DMSO  452.1, 454.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 144

435.88 1H-NMR (400 MHz, DMSO-d6): δ 9.83 (s, 1H), 9.49 (s, 1H), 8.62-8.65 (m, 2H), 8.21-8.23 (m, 1H), 7.89-7.91 (m, 1H), 7.78-7.81 (m, 1H), 7.72-7.73 (m, 2H), 7.51-7.54 (m, 2H), 3.84 (t, J = 4.0 Hz, 4H), 3.36 (m, 4H). DMSO  436.1, 438.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 145

419.43 1H-NMR (400 MHz, DMSO-d6): δ 10.50 (s, 1H), 9.45 (s, 1H), 8.83-8.90 (m, 2H), 8.06-8.08 (m, 1H), 7.70-7.93 (m, 5H), 7.56 (dd, J = 19.6, 9.6 Hz, 1H), 3.82-3.83 (m, 4H), 3.39-3.41 (m, 4H). DMSO 420.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 146

408.46 1H-NMR (400 MHz, DMSO-d6): δ 10.54 (s, 1H), 9.44 (s, 1H), 8.90 (d, J = 8.0 Hz, 1H), 8.84 (d, J = 4.4 Hz, 1H), 8.34 (s, 1H), 8.27 (d, J = 7.2 Hz, 1H), 7.67- 7.92 (m, 6H), 3.82-3.83 (m, 4H), 3.39-3.40 (m, 4H). DMSO 409.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 147

452.34 1H-NMR (400 MHz, DMSO-d6): δ 10.42 (s, 1H), 9.42 (s, 1H), 8.85-8.87 (m, 2H), 8.11 (s, 2H), 7.73-7.88 (m, 4H), 7.38 (s, 1H), 3.82-3.83 (m, 4H), 3.39-3.40 (m, 4H). DMSO  452.1,  454.1, 456.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 148

426.47 1H-NMR (400 MHz, DMSO-d6): δ 12.93 (s, 1H), 9.57 (m, 1H), 9.12 (d, J = 8.4 Hz, 1H), 8.68-8.72 (m, 2H), 8.56 (s, 1H), 8.02 (d, J = 6.8 Hz, 1H), 7.96 (s, 1H), 7.72-7.84 (m, 3H), 7.56-7.57 (m, 1H), 7.40 (m, 1H), 7.19 (t, J = 8.0 Hz, 1H), 3.84 (t, J = 4.4 Hz, 4H), 3.35 (t, J = 4.4 Hz, 4H). DMSO 427.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 149

393.84 1H-NMR (400 MHz, DMSO-d6): δ 9.71 (s, 1H), 9.48 (s, 1H), 8.62-8.63 (m, 2H), 8.23 (m, 1H), 7.92 (m, 1H), 7.77 (d, J = 9.6 Hz, 1H), 7.51-7.56 (m, 3H), 7.42 (m, 1H), 3.12 (s, 6H). DMSO  394.1, 396.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 150

377.39 1H-NMR (400 MHz, DMSO-d6): δ 9.72 (s, 1H), 9.48 (m, 1H), 8.60-8.63 (m, 2H), 8.08- 8.14 (m, 1H), 7.77 (d, J = 9.2 Hz, 1H), 7.69-7.71 (m, 1H), 7.50-7.57 (m, 3H), 7.42-7.43 (m, 1H), 3.12 (s, 6H). DMSO 378.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 151

410.3 1H-NMR (400 MHz, DMSO-d6): δ 9.72 (s, 1H), 9.49 (s, 1H), 8.60-8.64 (m, 2H), 8.17 (s, 2H), 7.76 (d, J = 8.8 Hz, 1H), 7.51-7.53 (m, 2H), 7.37 (s, 1H), 7.32 (s, 1H), 3.11 (s, 6H). DMSO  410.1,  412.0, 414.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 152

410.3 1H-NMR (400 MHz, DMSO-d6): δ 10.44 (s, 1H), 9.45 (s, 1H), 8.83-8.91 (m, 2H), 8.26-8.27 (m, 1H), 7.72-7.99 (m, 4H), 7.57-7.61 (m, 2H), 3.14 (s, 6H). DMSO  410.1,  412.1, 414.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 153

366.42 1H-NMR (400 MHz, DMSO-d6): δ 9.82 (s, 1H), 9.48 (s, 1H), 8.55-8.64 (m, 2H), 8.41 (s, 1H), 8.28 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 9.6 Hz, 1H), 7.69 (t, J = 8.0 Hz, 1H), 7.50-7.61 (m, 3H), 7.43 (m, 1H), 3.12 (s, 6H). DMSO 367.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 154

435.23 1H-NMR (400 MHz, DMSO-d6): δ 10.57 (s, 1H), 9.53 (s, 1H), 8.86-8.94 (m, 3H), 8.32-8.33 (m, 1H), 8.21 (s, 1H), 7.97-8.01 (m, 2H), 7.84-7.88 (m, 1H), 7.73 (d, J = 8.8 Hz, 1H). DMSO  435.1,  437.1, 439.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 155

402.32 1H-NMR (400 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.51-9.52 (m, 1H), 8.65-8.78 (m, 3H), 8.19 (s, 1H), 8.11 (m, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.71 (m, 1H), 7.55-7.59 (m, 2H). DMSO 403.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 156

435.23 1H-NMR (400 MHz, DMSO-d6): δ 10.65 (s, 1H), 9.46 (s, 1H), 8.88- 8.97 (m, 3H), 8.17 (s, 1H), 8.10-8.11 (m, 2H), 7.97 (s, 1H), 7.95 (s, 1H), 7.39 (s, 1H). DMSO  435.1,  437.0, 439.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 157

418.77 1H-NMR (400 MHz, DMSO-d6): δ 10.62 (s, 1H), 9.52 (s, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.88-8.90 (m, 2H), 8.20-8.23 (m, 2H), 8.01 (d, J = 8.0 Hz, 1H), 7.92-7.95 (m, 2H), 7.54 (t, J = 9.2 Hz, 1H). DMSO  419.1, 421.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 158

409.36 1H-NMR (400 MHz, DMSO-d6): δ 13.24 (s, 1H), 9.56 (s, 1H), 9.10 (d, J = 8.4 Hz, 1H), 8.96 (s, 1H), 8.87 (d, J = 8.0 Hz, 1H), 8.54 (s, 1H), 8.33 (d, J = 8.8 Hz, 1H), 8.18 (s, 1H), 7.95-8.01 (m, 4H), 7.70 (t, J = 7.6 Hz, 1H), 7.27 (t, J = 7.2 Hz, 1H). DMSO 410.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 159

391.35 1H-NMR (400 MHz, DMSO-d6): δ 10.82 (s, 1H), 8.50 (s, 1H), 9.04 (d, J = 8.0 Hz, 1H), 8.96 (d, J = 8.8 Hz, 2H), 8.37 (s, 1H), 8.30-8.28 (m, 1H), 8.21 (s, 1H), 7.98 (d, J = 7.6 Hz, 2H), 7.68-7.69 (m, 2H). DMSO 392.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 160

450.34 1H-NMR (400 MHz, DMSO-d6): δ 10.40 (s, 1H), 9.54-9.55 (m, 1H), 8.82-8.84 (m, 1H), 8.67-8.73 (m, 2H), 8.16-8.21 (m, 2H), 7.93-8.00 (m, 2H), 7.54-7.64 (m, 2H), 7.21 (d, J = 8.0 Hz, 1H). DMSO 451.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 161

416.78 1H-NMR (400 MHz. DMSO-d6): δ 10.10 (s, 1H), 9.49 (s, 1H), 8.62-8.72 (m, 3H), 8.13 (s, 1H), 7.88-7.92 (m, 3H), 7.51-7.60 (m, 2H), 7.14-7.16 (m, 1H). DMSO  417.1, 419.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 162

375.81 1H-NMR (400 MHz, DMSO-d6): δ 13.13 (s, 1H), 9.53 (s, 1H), 9.01 (d, J = 8.0 Hz, 1H), 8.68-8.72 (m, 2H), 8.50 (s, 1H), 8.10 (d, J = 8.8, 1H), 7.88-7.97 (m, 3H), 7.70-7.72 (m, 2H), 7.57-7.59 (m, 1H), 7.22 (t, J = 7.6, 1H). DMSO  376.0, 378.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 163

376.8 1H-NMR (400 MHz, DMSO-d6): δ 12.07 (s, 1H), 9.56 (s, 1H), 8.84 (d, J = 8.4 Hz, 1H), 8.71-8.73 (m, 2H), 8.34 (s, 1H), 7.96-8.09 (m, 3H), 7.59-7.80 (m, 2H), 7.29 (t, J = 7.2 Hz, 1H). DMSO  377.0, 379.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 164

394.37 1H-NMR (400 MHz, DMSO-d6): δ 9.90 (s, 1H), 9.53 (s, 1H), 8.67 (d, J = 5.2 Hz, 2H), 7.99 (d, J = 2.4 Hz, 1H), 7.94 (m, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.80 (d, J = 8.4 Hz, 7.49-7.59 (m, 3H), 7.31 (t, J = 74.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 1H), 3.99 (s, 3H). DMSO 395.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 165

HCl 458.51 1H-NMR (400 MHz, DMSO-d6): δ 9.42 (s, 1H), 8.98 (d, J = 8.4 Hz, 1H), 8.68-8.71 (m, 2H), 7.94 (d, J = 7.6 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.57 (t, J = 5.6 Hz, 1H), 7.53 (s, 1H), 7.38 (s, 1H), 7.19 (t, J = 7.2 Hz, 1H), 4.52 (s, 2H), 4.00 (s, 3H), 3.63 (s, 2H), 2.89 (s, 6H). DMSO 459.1 (M + 1) 230.2 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 166

467.92 1H-NMR (400 MHz, DMSO-d6): δ 9.71 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.62-8.67 (m, 2H), 8.20 (dd, J = 6.8, 2.4 Hz, 1H), 7.86-7.89 (m, 2H), 7.51-7.55 (m, 2H), 7.31 (s, 1H), 4.24 (t, J = 6.0 Hz, 2H), 3.98 (s, 3H), 2.77 (t, J = 5.6 Hz, 2H), 2.29 (s, 6H). DMSO 468.1 (M + 1) 234.6 (M/2 + 1) Method B (NH4HCO3) 95 Meth-od C, G1 167

HCl 428.82 1H-NMR (400 MHz, DMSO-d6): δ 10.41 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.98 (d, J = 8.4 Hz, 1H), 8.88 (dd, J = 5.2, 1.6 Hz, 1H), 8.13 (d, J = 2.8 Hz, 1H), 8.00 (t, J = 2.0 Hz, 1H), 7.89-7.95 (m, 3H), 7.62 (dd, J = 9.2, 3.2 Hz, 1H), 7.36 (t, J = 73.6 Hz, 1H), 7.16 (d, J = 2.0 Hz, 1H), 4.01 (s, 3H). DMSO  429.1, 431.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 168

385.42 1H-NMR (400 MHz, DMSO-d6): δ 13.03 (s, 1H), 9.62 (d, J = 1.6 Hz, 1H), 9.20 (d, J = 8.4 Hz, 1H), 8.74-8.77 (m, 1H), 8.70 (dd, J = 4.4, 1.6 Hz, 1H), 8.48 (s, 1H), 7.96-7.99 (m, 2H), 7.72-7.76 (m, 1H), 7.57- 7.60 (m, 1H), 7.47 (m, 1H), 7.41 (m, 1H), 7.17-7.21 (m, 1H), 3.95 (s, 3H), 2.72 (s, 3H). DMSO 386.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 169

HCl 368.77 1H-NMR (400 MHz, DMSO-d6): δ 10.31 (s, 1H), 9.47 (s, 1H), 8.86-8.93 (m, 2H), 8.54 (dd, J = 10.0, 2.8 Hz, 1H), 8.21 (dd, J = 6.8, 2.4 Hz, 1H), 7.82-8.00 (m, 4H), 7.52 (t, J = 9.2 Hz, 1H). DMSO  369.0, 371.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 170

HCl 400.33 1H-NMR (400 MHz, DMSO-d6): δ 10.35 (s, 1H), 9.53 (s, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.89 (d, J = 4.0 Hz, 1H), 8.60 (dd, J = 10.4, 3.2 Hz, 1H), 7.97-8.09 (m, 3H), 7.88-7.92 (m, 2H), 7.62 (t, J = 8.0 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H). DMSO 401.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 171

359.36 1H-NMR (400 MHz, DMSO-d6): δ 13.06 (s, 1H), 9.58 (s, 1H), 9.07 (d, J = 8.4 Hz, 1H), 8.72 (d, J = 5.6 Hz, 2H), 8.52 (s, 1H), 7.96-8.02 (m, 3H), 7.83-7.87 (m, 2H), 7.74 (t, J = 8.0 Hz, 1H), 7.59 (t, J = 6.0 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H). DMSO 360.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 172

HCl 382.34 1H-NMR (400 MHz, DMSO-d6): δ 10.30 (s, 1H), 9.53 (d, J = 1.2 Hz, 1H), 8.98 (d, J = 8.0 Hz, 1H), 8.88 (d, J = 4.4 Hz, 1H), 8.62 (dd, J = 10.0, 2.8 Hz, 1H), 8.01-8.05 (m, 1H), 7.84-7.92 (m, 4H), 7.50-7.56 (m, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.03 (dd, J = 8.0, 2.0 Hz, 1H). DMSO 383.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 173

348.35 1H-NMR (400 MHz, DMSO-d6): δ 10.09 (s, 1H), 9.51 (s, 1H), 8.79- 8.76 (m, 2H), 8.38 (s, 1H), 8.16-8.11 (m, 1H), 7.36-7.66 (m, 4H), 7.59-7.50 (m, 1H), 2.57 (s, 3H). DMSO 349.1 (M + 1), 175.1 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 174

364.8 1H-NMR (300 Hz, CD3OD): δ 9.50 (d, J = 1.2 Hz, 1H), 9.14 (d, J = 8.4 Hz, 1H), 8.94 (d, J = 4.8 Hz, 1H), 8.35 (s, 1H), 8.09-7.99 (m, 2H), 7.93 (s, 2H), 7.78-7.73 (m, 1H), 7.39 (t, J = 9.0 Hz, 1H), 2.64 (s, 3H). CD3OD  365.1, 367.1 (M + 1) Method A (TFA) 95 Meth-od C, G1 175

381.26 1H-NMR (400 MHz, DMSO-d6): δ 10.13 (s, 1H), 9.51 (s, 1H), 8.84-8.79 (m, 2H), 8.36-8.34 (m, 2H), 7.96 (dd, J = 8.8, 2.5 Hz, 1H), 7.85-7.70 (m, 4H), 2.55 (s, 3H). DMSO  381.0, 383.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 176

346.81 1H-NMR (300 Hz, CD3OD): δ 9.48 (d, J = 1.2 Hz, 1H), 8.99-8.95 (m, 1H), 8.82-8.80 (m, 1H), 8.30-8.29 (m, 1H), 7.90-7.81 (m, 5H), 7.52-7.46 (m, 2H), 2.62 (s, 3H). DMSO  347.0, 349.1 (M + 1) Method A (TFA) 95 Meth-od C, G1 177

346.81 1H-NMR (400 MHz, DMSO-d6): δ 10.12 (s, 1H), 9.52 (s, 1H), 8.84-8.78 (m, 2H), 8.42 (s, 1H), 8.16-8.15 (m, 1H), 7.94-7.91 (m, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.75-7.71 (m, 1H), 7.50 (t, J = 8.1 Hz, 1H), 7.27-7.23 (m, 1H), 2.56 (s, 3H). DMSO  347.1, 349.1 (M + 1) Method A (TFA) 95 Meth-od C, G1 178

380.37 1H-NMR (400 MHz, DMSO-d6): δ 10.60 (s, 1H), 9.50 (d, J = 2.1 Hz, 1H), 9.00 (d, J = 8.1 Hz, 1H), 8.90 (dd, J = 5.1, 1.2 Hz, 1H), 8.55 (s, 1H), 8.43 (s, 1H), 8.25 (d, J = 7.8 Hz, 1H), 7.96-7.90 (m, 2H), 7.84 (d, J = 8.1 Hz, 1H), 7.27 (t, J = 8.2 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 2.62 (s, 3H). DMSO 381.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 179

414.81 1H-NMR (400 MHz, DMSO-d6): δ 10.59 (s, 1H), 9.50 (s, 1H), 9.02 (d, J = 8.4 Hz, 1H), 8.92 (d, J = 5.2 Hz, 1H), 8.59 (d, J = 2.8 Hz, 1H), 8.54 (s, 1H), 8.34 (dd, J = 8.6, 2.6 Hz, 1H), 7.96-7.90 (m, 2H), 7.81 (d, J = 8.8 Hz, 2H), 2.56 (s, 3H). DMSO  415.1, 417.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 180

401.37 1H-NMR (400 MHz, DMSO-d6): δ 13.91 (s, 1H), 10.38 (s, 1H), 9.59 (s, 1H), 8.79-8.76 (m, 1H), 8.73 (d, J = 4.8 Hz, 1H), 8.61 (d, J = 2.4 Hz, 1H), 8.44 (s, 1H), 8.33 (dd, J = 9.0, 2.6 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.81 (dd, J = 8.4, 1.2 Hz, 1H), 7.60-7.57 (m, 1H), 2.58 (s, 3H). DMSO 402.0 (M + 1) Method A (TFA) 95 Meth-od C, G1 181

381.26 1H-NMR (400 MHz, DMSO-d6): δ 10.40 (s, 1H), 9.47 (s, 1H), 8.98 (d, J = 7.5 Hz, 1H), 8.91 (d, J = 4.5 Hz, 1H), 8.48 (s, 1H), 8.12 (d, J = 2.1 Hz, 2H), 7.97-7.93 (m, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.40 (s, 1H), 2.55 (s, 3H). DMSO  381.0, 383.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 182

390.82 1H-NMR (400 MHz, DMSO-d6): δ 12.25 (s, 1H), 9.54 (s, 1H), 9.25 (s, 1H), 8.84-8.80 (m, 2H), 8.09 (d, J = 8.0 Hz, 1H), 7.96 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 9.2 Hz, 1H), 7.77-7.75 (m, 1H), 7.29 (d, J = 8.4 Hz, 1H), 2.56 (s, 3H). DMSO  391.1, 393.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 183

366.34 1H-NMR (400 MHz, DMSO-d6): δ 9.98 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.69 (dd, J = 4.8, 1.6 Hz, 1H), 8.66-8.63 (m, 1H), 8.30 (s, 1H), 7.99-7.95 (m, 2H), 7.82 (d, J = 8.4 Hz, 1H), 7.76 (dd, J = 8.6, 1.4 Hz, 1H), 7.58-7.55 (m, 1H), 2.55 (s, 3H). DMSO 367.1 (M + 1), 184.1 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 184

415.7 1H-NMR (400 MHz, DMSO-d6): δ 10.09 (s, 1H), 9.51 (s, 1H), 8.75-8.72 (m, 2H), 8.38 (s, 2H), 8.32 (s, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.66-7.64 (m, 1H), 2.55 (s, 3H). DMSO  414.8, 416.8 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 185

354.4 1H-NMR (400 MHz, DMSO-d6): δ 10.26 (s, 1H), 9.56 (s, 1H), 8.93 (d, J = 8.0 Hz, 1H), 8.81 (d, J = 4.0 Hz, 1H), 8.65 (s, 1H), 8.48 (s, 1H), 8.21 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.88-7.88 (m, 3H), 7.65 (t, J = 7.6 Hz, 1H), 2.65 (s, 3H), 2.58 (s, 3H). DMSO 355.1 (M + 1), 178.1 (M/2 + 1) Method A (TFA) 95 Meth-od C, G1 186

356.38 1H-NMR (400 MHz, DMSO-d6): δ 12.18 (s, 1H), 9.57 (s, 1H), 9.07 (d, J = 8.4 Hz, 1H), 8.71 (d, J = 5.6 Hz, 2H), 8.10 (d, J = 8.0 Hz, 1H), 7.99 (s, 1H), 7.86-7.76 (m, 3H), 7.58 (t, J = 6.2 Hz, 1H), 7.23 (t, J = 7.4 Hz, 1H), 2.55 (s, 3H). DMSO 357.1 (M + 1) Method A (TFA) 95 Meth-od C, G1 187

337.38 1H-NMR (400 MHz, DMSO-d6): δ 10.10 (s, 1H), 9.51 (s, 1H), 8.65-8.70 (m, 2H), 3.45 (s, 1H), 8.38 (s, 1H), 8.28 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.69 (t, J = 7.8 Hz, 1H), 7.62 (d, J = 7.2 Hz, 1H), 7.54-7.57 (m, 1H), 2.56 (s, 3H). DMSO 338.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 188

355.39 1H-NMR (400 MHz, DMSO-d6): δ 13.11 (s, 1H), 9.61 (s, 1H), 9.09 (d, J = 8.8 Hz, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.81 (s, 1H), 8.50 (s, 1H), 8.01-7.98 (m, 2H), 7.96 (dd, J = 7.8, 1.0 Hz, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.78-7.72 (m, 3H), 7.23 (t, J = 7.4 Hz, 1H), 2.56 (s, 3H). DMSO 356.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 189

385.42 1H-NMR (400 MHz, DMSO-d6): δ 12.62 (s, 1H), 9.58 (s, 1H), 9.03 (d, J = 8.4 Hz, 1H), 8.92 (d, J = 4.0 Hz, 1H), 8.74-8.69 (m, 2H), 7.92-7.87 (m, 2H), 7.72 (t, J = 7.6 Hz, 1H), 7.66-7.56 (m, 3H), 7.23 (t, J = 7.6 Hz, 1H), 4.00 (s, 3H), 2.84 (d, J = 4.4 Hz, 3H). DMSO 386.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 190

461.51 1H-NMR (400 MHz, DMSO-d6): δ 12.40 (s, 1H), 9.57 (d, J = 1.2 Hz, 1H), 9.48 (t, J = 6.0 Hz, 1H), 8.89 (d, J = 8.8 Hz, 1H), 8.73-8.68 (m, 2H), 7.96 (dd, J = 8.0, 1.2 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.76-7.72 (m, 1H), 7.61-7.55 (m, 3H), 7.34-7.20 (m, 6H), 4.52 (d, J = 5.6 Hz, 2H), 3.93 (s, 3H). DMSO 462.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 191

368.77 1H NMR (300 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.55-9.45 (m, 1H), 8.93-8.76 (m, 2H), 8.63 (d, J = 8.9 Hz, 1H), 8.10 (ddd, J = 13.2, 7.5, 2.6 Hz, 1H), 7.97 (d, J = 2.1 Hz, 1H), 7.80-7.67 (m, 3H), 7.62-7.49 (m, 1H). DMSO  369.0, 371.0 (M + 1) Method B (NH4HCO3) 97 Meth-od C, G1 192

401.68 1H NMR (300 MHz, DMSO-d6): δ 10.38 (s, 1H), 9.58-9.43 (m, 1H), 8.90-8.79 (m, 2H), 8.65 (d, J = 9.0 Hz, 1H), 8.33 (d, J = 2.4 Hz, 1H), 8.01-7.90 (m, 2H), 7.82-7.68 (m, 3H). DMSO  401.0,  403.0, 405.0 (M + 1) Method B (NH4HCO3) 97 Meth-od C, G1 193

367.23 1H NMR (300 MHz, DMSO-d6): δ 10.19 (s, 1H), 9.53 (d, J = 2.1 Hz, 1H), 8.78-8.56 (m, 3H), 8.17 (t, J = 2.0 Hz, 1H), 7.96 (d, J = 2.1 Hz, 1H), 7.93-7.85 (m, 1H), 7.75 (dd, J = 8.9, 2.2 Hz, 1H), 7.58 (ddd, J = 8.0, 4.8, 0.7 Hz, 1H), 7.51 (t, J = 8.1 Hz, 1H), 7.26 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H). DMSO  367.0, 369.0 (M + 1) Method B (NH4HCO3) 98 Meth-od C, G1 194

376.80 1H NMR (300 MHz, DMSO-d6): δ 13.11 (s, 1H), 10.27 (s, 1H), 9.58 (d, J = 2.1 Hz, 1H), 8.87-8.62 (m, 4H), 8.21-8.10 (m, 1H), 7.96 (d, J = 2.1 Hz, 1H), 7.82-7.68 (m, 2H), 7.64-7.53 (m, 2H). DMSO  377.0, 379.0 (M + 1) Method A (TFA) 95 Meth-od C, G1 195

401.68 1H NMR (300 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.52-9.49 (m, 1H), 8.85-8.73 (m, 2H), 8.61 (d, J = 9.0 Hz, 1H), 8.18-8.08 (m, 2H), 7.99-7.95 (m, 1H), 7.77 (dd, J = 8.9, 2.2 Hz, 1H), 7.71 (dd, J = 7.8, 5.0 Hz, 1H), 7.42-7.39 (m, 1H). DMSO  401.0,  403.0, 405.0 (M + 1) Method B (NH4HCO3) 97 Meth-od C, G1 196

386.76 1H-NMR (300 MHz, DMSO-d6): δ 10.43 (s, 1H), 9.49 (d, J = 1.9 Hz, 1H), 8.95-8.82 (m, 2H), 8.64 (d, J = 9.0 Hz, 1H), 8.01-7.82 (m, 4H), 7.78 (dd, J = 8.9, 2.2 Hz, 1H). DMSO  387.0, 389.1 (M + 1) Method B (NH4HCO3) 97 Meth-od C, G1 197

411.86 1H NMR (400 MHz, DMSO-d6): δ 10.50 (brs, 1H), 9.56 (s, 1H), 9.08-8.93 (m, 1H), 8.92-8.82 (m, 1H), 8.73 (d, J = 8.9 Hz, 1H), 8.21-8.11 (m, 2H), 8.02 (d, J = 1.9 Hz, 1H), 7.98-7.77 (m, 4H), 7.38 (s, 2H). DMSO  412.1, 414.1 (M + 1) Method B (NH4HCO3) 97 Meth-od C, G1 198

385.22 1H NMR (400 MHz, DMSO-d6): δ 10.25 (s, 1H), 9.51 (d, J = 1.4 Hz, 1H), 8.77-8.69 (m, 2H), 8.60 (d, J = 9.0 Hz, 1H), 8.27-8.20 (m, 1H), 7.97 (d, J = 2.1 Hz, 1H), 7.90 (ddd, J = 9.0, 4.3, 2.6 Hz, 1H), 7.76 (dd, J = 8.9, 2.1 Hz, 1H), 7.64 (dd, J = 8.0, 4.9 Hz, 1H), 7.55 (t, J = 9.1 Hz, 1H). DMSO  385.0, 387.0 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 199

357.80 1H NMR (400 MHz, DMSO-d6): δ 10.36 (s, 1H), 9.53-9.49 (m, 1H), 8.81-8.70 (m, 2H), 8.64 (d, J = 8.9 Hz, 1H), 8.45-8.36 (m, 1H), 8.29-8.21 (m, 1H), 7.98 (d, J = 2.1 Hz, 1H), 7.77 (dd, J = 8.9, 2.1 Hz, 1H), 7.74-7.61 (m, 3H). DMSO  357.9, 359.9 (M + 1) Method B (NH4HCO3) 99 Meth-od C, G1 200

435.23 1H-NMR (400 MHz, DMSO-d6): δ 10.44 (s, 1H), 9.53 (s, 1H), 8.84-8.74 (m, 2H), 8.69-8.61 (m, 2H), 8.26 (dd, J = 8.8, 2.6 Hz, 1H), 7.99 (d, J = 2.1 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.78 (dd, J = 8.9, 2.1 Hz, 1H), 7.70 (dd, J = 7.7, 5.3 Hz, 1H). DMSO  435.0, 437.0 (M + 1) Method B (NH4HCO3) 99 Meth-od C, G1 201

400.78 1H-NMR (400 MHz, DMSO-d6): δ 10.45 (s, 1H), 9.53 (d, J = 1.5 Hz, 1H), 3.85 (d, J = 8.1 Hz, 1H), 8.82 (dd, J = 5.0, 1.4 Hz, 1H), 8.69 (d, J = 9.0 Hz, 1H), 8.49 (s, 1H), 8.21 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 2.1 Hz, 1H), 7.83-7.67 (m, 3H), 7.56 (d, J = 7.8 Hz, 1H). DMSO  401.1, 403.0 (M + 1) Method B (NH4HCO3) 99 Meth-od C, G1 202

375.79 1H-NMR (400 MHz, DMSO-d6): δ 10.47 (s, 1H), 9.49 (s, 1H), 8.87-8.77 (m, 2H), 8.63 (d, J = 8.9 Hz, 1H), 8.42 (dd, J = 5.8, 2.7 Hz, 1H), 8.26 (ddd, J = 9.1, 4.9, 2.8 Hz, 1H), 7.98 (d, J = 2.1 Hz, 1H), 7.83-7.72 (m, 2H), 7.66 (t, J = 9.1 Hz, 1H). DMSO  375.9, 377.9 (M + 1) Method B (NH4HCO3) 99 Meth-od C, G1 203

348.35 1H-NMR (400 MHz, DMSO-d6): δ 10.42 (s, 1H), 9.51 (s, 1H), 8.91 (d, J = 6.8 Hz, 1H), 8.86 (d, J = 4.4 Hz, 1H), 8.57 (d, J = 8.3 Hz, 1H), 8.11 (ddd, J = 13.0, 7.5, 2.5 Hz, 1H), 7.90-7.68 (m, 3H), 7.65-7.46 (m, 2H), 2.56 (s, 3H). DMSO 349.1 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 204

381.26 1H-NMR (400 MHz, DMSO-d6): δ 10.05 (s, 1H), 9.54 (s, 1H), 8.75-8.65 (m, 2H), 8.46 (d, J = 8.5 Hz, 1H), 8.42 (d, J = 2.4 Hz, 1H), 7.98 (dd, J = 8.8, 2.4 Hz, 1H), 7.72 (d, J = 9.1 Hz, 2H), 7.57 (dd, J = 7.9, 4.9 Hz, 1H), 7.53 (d, J = 8.5 Hz, 1H), 2.55 (s, 3H). DMSO  381.0, 383.0 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 205

364.35 1H-NMR (400 MHz, DMSO-d6): δ 9.98 (s, 1H), 9.53 (s, 1H), 8.79-8.58 (m, 2H), 8.49 (d, J = 9.0 Hz, 1H), 8.13 (ddd, J = 9.2, 7.1, 1.7 Hz, 1H), 7.84-7.65 (m, 1H), 7.67-7.46 (m, 2H), 7.41-7.23 (m, 2H), 3.97 (s, 3H). DMSO 365.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 206

364.80 1H-NMR (400 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.50 (d, J = 1.4 Hz, 1H), 8.92-8.77 (m, 2H), 8.53 (d, J = 8.5 Hz, 1H), 8.24 (dd, J = 6.8, 2.5 Hz, 1H), 7.98-7.87 (m, 1H), 7.83-7.70 (m, 2H), 7.60-7.50 (m, 2H), 2.56 (s, 3H). DMSO  365.1, 367.1 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 207

381.26 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.53 (s, 1H), 8.87-8.73 (m, 2H), 8.50 (d, J = 8.5 Hz, 1H), 8.17 (d, J = 1.7 Hz, 2H), 7.77 (s, 1H), 7.72 (dd, J = 7.8, 5.1 Hz, 1H), 7.57 (dd, J = 8.4, 0.9 Hz, 1H), 7.39 (t, J = 1.6 Hz, 1H), 2.56 (s, 3H). DMSO  381.1, 383.0 (M + 1) Method B (NH4HCO3) 99 Meth-od C, G1 208

337.38 1H-NMR (400 MHz, DMSO-d6): δ 10.12 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.77-8.63 (m, 2H), 8.53-8.42 (m, 2H), 8.28 (d, J = 8.3 Hz, 1H), 7.75 (s, 1H), 7.69 (t, J = 7.9 Hz, 1H), 7.62 (d, J = 7.7 Hz, 1H), 7.60-7.51 (m, 2H), 2.55 (s, 3H). DMSO 338.2 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 209

355.39 1H-NMR (400 MHz, DMSO-d6): δ 13.09 (s, 1H), 9.60 (s, 1H), 9.02 (d, J = 8.4 Hz, 1H), 8.96 (d, J = 8.4 Hz, 1H), 8.85 (d, J = 4.0 Hz, 1H), 8.49 (s, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.92 (s, 1H), 7.83 (dd, J = 8.0, 5.2 Hz, 1H), 7.80 (s, 1H), 7.73 (t, J = 7.4 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.25 (t, J = 7.6 Hz, 1H), 2.56 (s, 3H). DMSO 356.1 (M + 1) Method B (NH4HCO3) 99 Meth-od C, G1 210

375.81 1H-NMR (400 MHz, DMSO-d6): 13.13 (s, 1H), 9.59 (s, 1H), 9.03-8.89 (m, 3H), 3.50 (s, 1H), 8.21-8.19 (d, J = 8.6 Hz, 1H), 7.99-7.87 (m, 4H), 7.82-7.79 (dd, J = 8.8, 2.3 Hz, 1H), 7.74-7.70 (m, 1H), 7.28-7.24 (m, 1H). DMSO  376.1, 378.1 (M + 1) Method B (NH4HCO3) 98 Meth-od C, G1 211

444.79 1H-NMR (400 MHz, DMSO-d6): δ 13.68 (brs, 1H), 11.98 (s, 1H), 9.49 (s, 1H), 8.83-8.64 (m, 2H), 8.11-7.90 (m, 3H), 7.81 (d, J = 2.0 Hz, 1H), 7.75-7.62 (m, 2H), 7.22 (t, J = 7.6 Hz, 1H). DMSO  444.9, 446.9 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 212

HCl 466.79 1H-NMR (400 MHz, DMSO-d6): δ 10.36 (s, 1H), 9.62 (s, 1H), 8.90 (dd, J = 8.2, 1.3 Hz, 1H), 8.69 (d, J = 9.0 Hz, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.99 (d, J = 2.1 Hz, 1H), 7.92-7.86 (m, 1H), 7.86-7.79 (m, 1H), 7.77 (dd, J = 8.9, 2.1 Hz, 1H), 7.53 (t, J = 8.2 Hz, 1H), 7.30 (t, J = 73.3 Hz, 1H), 7.04 (dd, J = 8.1, 2.1 Hz, 1H). DMSO  466.9, 468.9 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 213

469.67 1H-NMR (400 MHz, DMSO-d6): δ 10.31 (s, 1H), 9.57 (s, 1H), 8.85 (dd, J = 8.1, 1.3 Hz, 1H), 8.60 (d,. J = 9.0 Hz, 1H), 8.35-8.23 (m, 1H), 8.06 (d, J = 8.2 Hz, 1H), 8.00-7.90 (m, 2H), 7.80-7.65 (m, 2H). DMSO  468.9, 470.8 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 214

436.77 1H-NMR (400 MHz, DMSO-d6): δ 10.35 (s, 1H), 9.56 (s, 1H), 8.84 (d, J = 8.3 Hz, 1H), 8.64 (d, J = 9.0 Hz, 1H), 8.14-7.99 (m, 2H), 7.95 (d, J = 2.1 Hz, 1H), 7.81-7.65 (m, 2H), 7.59-7.48 (m, 1H). DMSO  436.9, 438.9 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 215

440.37 1H-NMR (400 MHz, DMSO-d6): δ 13.81 (brs, 1H), 11.97 (s, 1H), 9.57 (s, 1H), 9.01-8.91 (m, 1H), 8.84 (d, J = 8.3 Hz, 1H), 8.06 (dd, J = 7.9, 1.4 Hz, 1H), 8.01 (d, J = 8.2 Hz, 1H), 7.82 (d, J = 9.1 Hz, 1H), 7.79-7.70 (m, 1H), 7.52 (dd, J = 9.1, 2.6 Hz, 1H), 7.49-7.44 (m, 1H), 7.20 (t, J = 7.6 Hz, 1H), 3.94 (s, 3H). DMSO 441.1 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 216

396.80 1H-NMR (400 MHz, DMSO-d6): δ 11.89 (s, 1H), 9.80 (s, 1H), 8.34 (dd, J = 9.6, 2.6 Hz, 1H), 8.22 (s, 1H), 8.11 (dd, J = 6.9, 2.6 Hz, 1H), 7.88 (d, J = 2.7 Hz, 1H), 7.84-7.77 (m, 1H), 7.74 (d, J = 9.1 Hz, 1H), 7.56-7.43 (m, 2H), 6.44 (d, J = 9.6 Hz, 1H), 3.95 (s, 3H). DMSO  397.1, 399.1 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 217

410.37 1H-NMR (400 MHz, DMSO-d6): δ 11.89 (s, 1H), 9.80 (s, 1H), 8.36 (dd, J = 9.6, 2.6 Hz, 1H), 8.25 (d, J = 2.2 Hz, 1H), 7.92 (d, J = 2.6 Hz, 1H), 7.80-7.67 (m, 3H), 7.53-7.46 (m, 2H), 7.27 (t, J = 74.0 Hz, 1H), 6.98 (dd, J = 8.2, 2.0 Hz, 1H), 6.43 (d, J = 9.5 Hz, 1H), 3.96 (s, 3H). DMSO 411.1 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 218

387.39 1H-NMR (400 MHz, DMSO-d6): δ 12.98 (s, 1H), 12.58-12.05 (m, 1H), 8.55 (s, 2H), 8.41 (s, 1H), 8.33 (dd, J = 9.7, 2.5 Hz, 1H), 8.11-7.98 (m, 1H), 7.97- 7.86 (m, 2H), 7.79-7.64 (m, 3H), 7.44-7.29 (m, 1H), 6.52 (d, J = 9.7 Hz, 1H), 3.98 (s, 3H). DMSO 388.2 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 219

389.38 1H-NMR (400 MHz, DMSO-d6): δ 12.73 (s, 1H), 9.56 (s, 1H), 9.10 (dd, J = 8.9, 5.4 Hz, 1H), 8.79-8.63 (m, 2H), 8.50 (s, 1H), 8.08 (s, 1H), 7.95-7.76 (m, 2H), 7.68-7.45 (m, 4H), 3.97 (s, 3H). DMSO 390.1 (M + 1) Method B (NH4HCO3) 98 Meth-od C, G1 220

369.80 1H-NMR (400 MHz, DMSO-d6): δ 14.87 (brs, 1H), 10.08 (brs, 1H), 8.85-7.66 (m, 6H), 7.69-6.63 (m, 3H), 3.96 (s, 3H). DMSO  397.1, 399.1 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 221

387.39 1H-NMR (400 MHz, DMSO-d6): δ 14.80 (brs, 1H), 13.19 (s, 1H), 8.68 (d, J = 7.3 Hz, 1H), 8.44 (s, 1H), 8.38 (d, J = 8.0 Hz, 1H), 8.13 (d, J = 9.1 Hz, 1H), 8.10-8.03 (m, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.90 (s, 1H), 7.86 (s, 1H), 7.78-7.65 (m, 2H), 7.43 (t, J = 7.5 Hz, 1H), 6.78 (t, J = 6.8 Hz, 1H), 3.99 (s, 3H). DMSO 388.1 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 222

410.37 1H-NMR (400 MHz, DMSO-d6): δ 15.33 (brs, 1H), 13.47 (brs, 1H), 11.69 (s, 1H), 8.62 (dd, J = 7.5, 2.1 Hz, 1H), 8.45 (d, J = 2.3 Hz, 1H), 8.17 (d, J = 9.2 Hz, 1H), 8.07 (dd, J = 6.2, 2.1 Hz, 1H), 7.81-7.68 (m, 3H), 7.61 (t, J = 8.1 Hz, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.26-7.18 (m, 1H), 6.80-6.69 (m, 1H), 4.03 (s, 3H). DMSO 411.1 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 223

401.22 1H-NMR (400 MHz, DMSO-d6): δ 11.22 (brs, 1H), 8.47 (d, J = 8.8 Hz, 1H), 8.30 (dd, J = 9.6, 2.3 Hz, 1H), 8.27- 8.18 (m, 1H). 8.11 (dd, J =- 6.8, 2.4 Hz, 1H), 7.90-7.73 (m, 2H), 7.60 (dd, J = 8.8, 1.8 Hz, 1H), 7.47 (t, J = 9.1 Hz, 1H), 6.44 (d, J = 9.6 Hz, 1H). DMSO  401.0, 403.0 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 224

414.79 1H-NMR (400 MHz, DMSO-d6): δ 12.00 (s, 1H), 10.07 (s, 1H), 8.54 (d, J = 8.9 Hz, 1H), 8.34 (dd, J = 9.6, 2.6 Hz, 1H), 8.30 (d, J = 2.3 Hz, 1H), 7.87-7.69 (m, 3H), 7.62 (dd, J = 8.9, 2.1 Hz, 1H), 7.48 (t, J = 8.2 Hz, 1H), 7.26 (t, J = 74.0 Hz, 1H), 7.00 (dd, J = 8.1, 2.0 Hz, 1H), 6.44 (d, J = 9.6 Hz, 1H). DMSO  415.1, 417.1 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 225

432.78 1H-NMR (400 MHz, DMSO-d6): δ 12.06 (s, 1H), 10.15 (s, 1H), 8.55 (d, J = 9.0 Hz, 1H), 8.34 (dd, J = 9.6, 2.5 Hz, 1H), 8.29 (s, 1H), 7.97 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 2.1 Hz, 1H), 7.65 (dd, J = 8.8, 2.1 Hz, 1H), 7.57 (t, J = 8.2 Hz, 1H), 7.17 (d, J = 7.8 Hz, 1H), 6.44 (d, J = 9.6 Hz, 1H). DMSO  433.0, 435.0 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 226

428.36 1H-NMR (400 MHz, DMSO-d6): δ 12.28 (brs, 1H), 8.47-8.06 (m, 3H), 8.06-7.76 (m, 3H), 7.67-7.59 (m, 2H), 7.28 (s, 1H), 6.47 (d, J = 9.7 Hz, 1H), 3.98 (s, 3H). DMSO 429.1 (M + 1) Method B (NH4HCO3) 94 Meth-od C, G1 227

401.42 1H-NMR (400 MHz, DMSO-d6): δ 12.97 (s, 1H), 12.27 (s, 1H), 8.73-8.56 (m, 1H), 8.53 (s, 1H), 8.42 (s, 1H), 8.33 (dd, J = 9.7, 2.6 Hz, 1H), 8.04-7.86 (m, 3H), 7.74-7.59 (m, 3H), 7.34 (t, J = 8.7 Hz, 1H), 6.52 (d, J = 9.7 Hz, 1H), 4.23 (q, J = 6.9 Hz, 2H), 1.45 (t, J = 6.9 Hz, 3H). DMSO 402.2 (M + 1) Method B (NH4HCO3) 100  Meth-od C, G1 228

465.91 1H-NMR (400 MHz, DMSO-d6): δ 8.43-8.31 (m, 2H), 8.27 (s, 1H), 8.14 (dd, J = 6.7, 2.3 Hz, 1H), 7.89-7.70 (m, 3H), 7.47 (t, J = 9.1 Hz, 1H), 6.44 (d, J = 9.6 Hz, 1H), 3.62 (d, J = 9.3 Hz, 6H), 2.42 (s, 4H). DMSO  466.1, 468.1 (M + 1) Method B (NH4HCO3) 97 Meth-od C, G1 229

436.41 1H-NMR (400 MHz, DMSO-d6): δ 10.28 (brs, 1H), 9.47 (s, 1H), 8.91 (d, J = 7.2 Hz, 1H), 8.84 (d, J = 5.2 Hz, 1H), 8.08-8.06 (m, 2H), 7.91 (d, J = 7.6 Hz, 1H), 7.85 (t, J = 8 Hz, 1H), 7.65-7.60 (m, 2H), 7.54-7.52 (m, 1H), 4.17 (t, J = 7.6 Hz, 2H), 1.86 (q, J = 6.8 Hz, 2H), 1.08-1.03 (m, 3H). DMSO 423.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 230

403.41 1H-NMR (400 MHz, DMSO-d6): δ 13.42 (s, 1H), 9.53 (s, 1H), 9.10 (d, J = 12.8 Hz, 1H), 8.70-8.65 (m, 2H), 8.50 (s, 1H), 8.07-8.04 (m, 2H), 7.86 (d, J = 8.8 Hz, 1H), 7.60-7.55 (m, 2H), 7.48 (s, 1H), 7.06-7.01 (m, 1H), 4.21 (q, J = 6.8 Hz, 2H), 1.45 (t, J = 7.2 Hz, 3H). DMSO 403.9 (M + 1) Method A (TFA) 95 Meth-od C, G1 231

440.42 1H-NMR (400 MHz, DMSO-d6): δ 10.57 (s, 1H), 9.48 (s, 1H), 9.01 (d, J = 7.6 Hz, 1H), 8.90 (d, J = 5.2 Hz, 1H), 8.19 (s, 1H), 8.04 (s, 1H), 7.98 (d, J = 8.8 Hz, 2H), 7.93 (t, J = 5.8 Hz, 1H), 7.64-7.60 (m, 2H), 7.22 (d, J = 8.4 Hz, 1H), 4.19 (t, J = 6.4 Hz, 1H), 1.87-1.81 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H). DMSO 440.9 (M + 1) Method A (TFA) 95 Meth-od C, G1 232

359.12 1H-NMR (400 MHz, DMSO-d6): δ 13.10 (s, 1H), 9.54 (s, 1H), 8.96 (d, J = 8.4 Hz, 8.22-8.17 (m, 1H), 7.97-7.93 (m, 2H), 7.70-7.59 (m, 4H), 7.21 (t, J = 8.0 Hz, 1H). DMSO 360.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 233

381.26 1H-NMR (400 MHz, DMSO-d6): δ 9.48 (s, 1H), 9.08 (s, 1H), 8.67-8.70 (m, 1H), 3.64 (d, J = 8.0 Hz, 1H), 7.98 (s, 2H), 7.76-7.73 (m, 2H), 7.55-7.57 (m, 1H), 7.43-7.46 (m, 1H), 7.36 (s, 1H), 2.99 (s, 3H). DMSO  381.0,  383.0, 385.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 234

HCl 408.4 1H-NMR (400 MHz, DMSO-d6): δ 10.38 (s, 1H), 9.51 (s, 1H), 9.00 (d, J = 7.2 Hz, 1H), 8.88 (d, J = 4.8 Hz, 1H), 8.13 (s, 1H), 7.96 (d, J = 7.2 Hz, 1H), 7.88-7.91 (m, 2H), 7.86 (s, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 2.4 Hz, 1H), 7.62 (dd, J = 9.2, 2.0 Hz,. 1H), 7.55 (t, J = 8.4 Hz, 1H), 7.31 (t, J = 74.0 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 4.28 (q, J = 6.8 Hz, 2H), 1.46 (t, J = 6.8 Hz, 3H). DMSO 409.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 235

412.36 1H-NMR (400 MHz, DMSO-d6): δ 10.81 (s, 1H), 9.49 (s, 1H), 9.02 (d, J = 8.4 Hz, 1H), 8.91 (dd, J = 5.2, 1.2 Hz, 1H), 8.31 (d, J = 2.0 Hz, 1H), 8.06 (s, 1H), 8.01 (d, J = 8.8 Hz, 2H), 7.94-7.91 (m, 1H), 7.64-7.60 (m, 2H), 7.22 (d, J = 8.4 Hz, 1H), 4.02 (s, 3H). DMSO 412.9 (M + 1) Method A (TFA) 95 Meth-od C, G1 236

395.46 1H-NMR (400 MHz, DMSO-d6): δ 9.64 (s, 1H), 8.90 (s, 1H), 8.77 (dd, J = 13.5, 6.2 Hz, 2H), 8.19 (d, J = 9.2 Hz, 1H), 7.81 (dd, J = 9.2, 2.4 Hz, 1H), 7.72=7.56 (m, 3H), 7.33 (d, J = 2.0 Hz, 1H), 4.15 (q, J = 6.8 Hz, 2H), 2.39 (s, 3H), 2.35 (s, 3H), 1.38 (t, J = 6.8 Hz, 3H). DMSO 396.2 (M + 1) Method B (NH4HCO3) 98 Meth-od C, G1 237

376.8 1H-NMR (400 MHz, DMSO-d6): δ 11.64 (brs, 1H), 11.31 (brs, 1H), 9.45 (s, 1H), 8.82-8.69 (m, 1H), 8.61 (s, 1H), 8.15 (d, J = 2.0 Hz, 1H), 8.04-7.91 (m, 1H), 7.81 (dd, J = 8.9, 2.1 Hz, 1H), 7.70-7.55 (m, 1H), 7.47 (s, 1H), 7.06 (s, 1H), 5.98 (d, J = 8.2 Hz, 1H). DMSO  376.9, 378.9 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 238

412.23 1H-NMR (400 MHz, DMSO-d6): δ 10.70 (s, 1H), 9.62 (d, J = 2.4 Hz, 1H), 9.51 (d, J = 1.6 Hz, 1H), 8.76-8.79 (m, 2H), 8.57 (dd, J = 6.8, 2.0 Hz, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.94 (dd, J = 6.8, 2.0 Hz, 1H), 7.71 (m, 2H). DMSO  412.0,  414.0, 416.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 239

381.26 1H-NMR (400 MHz, DMSO-d6): 10.04 (s, 1H), 9.59 (d, J = 1.2 Hz, 1H), 8.74-8.70 (m, 2H), 8.42-8.39 (m, 2H), 7.98 (dd, J = 2.4 Hz, 1H), 7.79 (d, J = 7.2 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.59-7.55 (m, 2H), 2.75 (s, 3H). DMSO  381,    383    (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 240

348.35 1H-NMR (400 MHz, DMSO-d6): 10.00 (s, 1H), 9.57 (d, J = 1.2 Hz, 1H), 8.72-8.70 (m, 2H), 8.38 (d, J = 8.4 Hz, 1H), 8.17-8.12 (m, 1H), 7.79-7.74 (m, 2H), 7.59-7.50 (m, 3H), 2.74 (s, 3H). DMSO 349.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 241

355.39 1H-NMR (400 MHz, DMSO-d6): 11.10 (s, 1H), 9.60 (d, J = 1.6 Hz, 1H), 9.16 (d, J = 8.4 Hz, 1H), 8.82-8.72 (m, 2H), 8.50 (s, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.97-7.92 (m, 2H), 7.77-7.72 (m, 2H), 7.63-7.60 (m, 2H), 7.24-7.19 (m, 1H), 2.76 (s, 3H). DMSO 356.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 242

337.4 1H-NMR (400 MHz, DMSO-d6): 10.12 (s, 1H), 9.57 (s, 1H), 8.73-8.70 (m, 2H), 8.46 (s, 1H), 8.41 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 7.6 Hz, 1H), 7.72-7.56 (m, 4H), 2.76 (s, 3H). DMSO 338.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 243

396.37 1H-NMR (400 MHz, DMSO-d6): 10.07 (s, 1H), 9.59 (s, 1H), 8.75-8.69 (m, 2H), 8.44 (d, J = 8.0 Hz, 1H), 8.20 (s, 1H), 7.97-7.94 (m, 1H), 7.89 (d, J = 7.2 Hz, 1H), 7.62-7.54 (m, 3H), 7.16 (d, J = 8.4 Hz, 1H), 2.76 (s, 3H). DMSO 397.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 244

378.37 1H-NMR (400 MHz, DMSO-d6): 9.98 (s, 1H), 9.60 (s, 1H), 8.75-8.69 (m, 2H), 8.44 (d, J = 8.0 Hz, 1H), 7.98 (s, 1H), 7.84 (d, J = 7.6 Hz, 1H), 7.79 (d, J = 6.8 Hz, 1H), 7.58-7.00 (m, 4H), 6.98 (d, J = 2.0 Hz, 1H), 2.76 (s, 3H). DMSO 379.2 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 245

360.34 1H-NMR (400 MHz, DMSO-d6): δ 11.95-11.11 (m, 2H), 9.43 (d, J = 1.6 Hz, 1H), 8.71 (dd, J = 4.7, 1.5 Hz, 1H), 8.56 (td, J = 8.0, 1.9 Hz, 1H), 8.15 (dd, J = 9.2, 5.3 Hz, 1H), 8.08 (dd, J = 9.4, 2.7 Hz, 1H), 8.02-7.88 (m, 2H), 7.54 (dd, J = 7.90, 4.81 Hz, 1H), 7.50-7.40 (m, 1H), 7.04 (t, J = 7.1 Hz, 1H), 6.96 (d, J = 8.1 Hz, 1H). DMSO 360.8 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 246

393.8 1H-NMR (400 MHz, DMSO-d6): δ 13.29 (s, 1H), 9.54 (s, 1H), 9.29 (s, 1H), 8.06 (d, J = 0.9 Hz, 1H), 7.99 (d, J = 8.5 Hz, 2H), 7.82 (dd, J = 26.4, 8.4 Hz, 2H), 7.58 (dd, J = 7.9, 4.8 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 8.72 (d, J = 3.6 Hz, 1H), 8.67 (d, J = 7.8 Hz, 1H), 8.64-8.53 (m, 1H). DMSO  394.0, 396.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 247

1H-NMR (400 MHz, DMSO-d6): δ 13.36 (brs, 1H), 9.54 (s, 1H), 9.36-9.08 (m, 1H), 8.12 (d, J = 8.8 Hz, 2H), 8.08-7.96 (m, 1H), 7.94-7.78 (m, 2H), 7.57 (dd, J = 7.8, 4.8 Hz, 1H), 7.29- 7.16 (m, 1H), 8.94-8.49 (m, 3H). DMSO 444.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 248

376.8 1H-NMR (400 MHz, DMSO-d6): δ 9.57 (s, 1H), 8.71 (d, J = 5.6 Hz, 2H), 8.40 (d, J = 1.8 Hz, 1H), 8.01-7.97 (m, 2H), 7.89 (dd, J = 7.8, 1.5 Hz, 1H), 7.63-7.51 (m, 1H), 7.29 (t, J = 7.4 Hz, 1H), 6.79 (d, J = 8.4 Hz, 1H), 6.76-6.74 (m, 1H). DMSO  377.0, 379.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 249

426.35 1H-NMR (400 MHz, DMSO-d6): δ 9.70 (d, J = 1.5 Hz, 1H), 8,74 (td, J = 8.0, 1.9 Hz, 1H), 8.71 (dd, J = 4.7, 1.7 Hz, 1H), 8.50 (d, J = 9.0 Hz, 1H), 7.88 (dd, J = 7.8, 1.9 Hz, 1H), 7.76 (d, J = 1.1 Hz, 1H), 7.20-7.11 (m, 1H), 7.64-7.56 (m, 2H)., 6.70-6.60 (m, 1H), 6.52 (dd, J = 10.8, 3.9 Hz, 1H). DMSO 427.1 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 250

360.34 1H-NMR (400 MHz, DMSO-d6): δ 9.69 (s, 1H), 8.83 (d, J = 7.4 Hz, 1H), 8.71 (d, J = 3.9 Hz, 1H), 8.49 (t, J = 7.2 Hz, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.63-7.51 (m, 3H), 7.14 (t, J = 7.0 Hz, 1H), 6.61 (d, J = 8.0 Hz, 1H), 6.46 (t, J = 7.2 Hz, 1H). DMSO 360.8 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 251

400.43 1H-NMR (400 MHz, DMSO-d6): δ 12.92 (s, 1H), 9.04 (d, J = 8.3 Hz, 1H), 8.66 (dd, J = 7.7, 1.7 Hz, 1H), 8.48 (s, 1H), 8.10 (dd, J = 4.6, 1.7 Hz, 1H), 8.01-7.94 (m, 2H), 7.89 (d, J = 8.9 Hz, 1H), 7.72 (t, J = 7.7 Hz, 1H), 7.55 (m, 2H), 7.20 (t, J = 7.5 Hz, 1H), 6.74 (dd, J = 7.7, 4.7 Hz, 1H), 4.24 (q, J = 6.9 Hz, 2H), 1.46 (t, J = 6.9 Hz, 3H). DMSO 401.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 252

483.44 1H-NMR (400 MHz, DMSO-d6): δ 13.28 (s, 1H), 9.54 (s, 1H), 9.28 (s, 1H), 8.70-8.66 (m, 2H), 8.59 (s, 1H), 8.11 (d, J = 8.8 Hz, 2H), 7.90 (d, J = 8.9 Hz, 1H), 7.64-7.49 (m, 3H), 7.18 (d, J = 8.2 Hz, 1H), 4.14 (t, J = 6.2 Hz, 2H), 1.86 (q, J = 6.8 Hz, 2H), 1.07 (t, J = 7.2 Hz, 3H). DMSO 484.0 (M + 1) Method B (NH4HCO3) 95 Meth-od C, G1 253

1H-NMR (400 MHz, DMSO-d6): δ 13.24 (s, 1H), 9.56 (s, 1H), 9.39 (d, J = 2.1 Hz, 1H), 8.77-8.73 (m, 2H), 8.55 (s, 1H), 8.09 (s, 1H), 8.00 (d, J = 8.6 Hz, 1H), 7.90 (d, J = 9.1 Hz, 1H), 7.65 (dd, J = 7.9, 4.9 Hz, 1H), 7.59 (dd, J = 9.1, 2.5 Hz, 1H), 4.24 (q, J = 6.9 Hz, 2H), 1.46 (t, J = 6.9 Hz, 3H). DMSO  420.0, 422.0 (M + 1) Method B (NH4HCO3) 95 Meth- od C, G1 254

469.42 1H-NMR (400 MHz, DMSO-d6): δ 13.34 (s, 1H), 9.60 (s, 1H), 9.35 (s, 1H), 8.77 (d, J = 3.5 Hz, 1H), 8.72 (d, J = 7.9 Hz, 1H), 8.67 (s, 1H), 8.22 (s, 1H), 8.17 (d, J = 8.8 Hz, 1H), 7.94 (d, J = 9.1 Hz, 1H), 7.69-7.58 (m, 2H), 7.55 (s, 1H), 7.24 (d, J = 8.5 Hz, 1H), 4.29 (q, J = 7.0 Hz, 2H), 1.53 (t, J = 6.9 Hz, 3H). DMSO 470.2 (M + 1) Method B (NH4HCO3) 95 Meth- od C, G1 255

403.41 1H-NMR (400 MHz, DMSO-d6): δ 11.43 (s, 1H), 9.53 (s, 1H), 8.68-8.66 (m, 2H), 8.56 (d, J = 8.3 Hz, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.88 (d, J = 9.1 Hz, 1H), 7.72-7.64 (m, 1H), 7.61-7.47 (m, 3H), 7.17-7.08 (m, 1H), 4.23 (q, J = 6.9 Hz, 2H), 1.46 (t, J = 6.9 Hz, 3H). DMSO 404.2 (M + 1) Method B (NH4HCO3) 95 Meth- od C, G1 Reten- Puri- Meth- Molecu- tion LCMS ty od of Salt lar ¹H NMR Time Pro- per- Coup- Number Product Type Mass ¹H NMR Solvent LCMS (min) tocol cent ling 256

HCl 456.723 1H NMR (300 MHz, DMSO) δ 9.55 (s, 1H), 9.09 (d, J = 8.0 Hz, 1H), 9.01-8.76 (m, 2H), 8.50 (s, 1H), 8.37 (s, 1H), 8.13-7.91 (m, 4H), 7.85 (d, J = 8.9 Hz, 1H), 7.69 (t, J = 7.7 Hz, 1H), 7.25 (t, J = 7.6 Hz, 1H). DMSO 420   (M + 1) 1.89 Method D 100 Meth- od G1 257

HCl 524.39 1H NMR (300 MHz, DMSO) δ 10.68 (s, 1H), 9.50 (s, 1H), 9.08 (d, J = 8.1 Hz, 1H), 8.92 (d, J = 5.2 Hz, 1H), 8.28 (s, 1H), 8.11 (s, 1H), 8.06-7.93 (m, 2H), 7.87 (d, J = 7.6 Hz, 1H), 7.70-7.51 (m, 2H), 7.19 (d, J =7.6 Hz, 1H), 4.28 (t, J = 9.1 Hz, 2H), 4 DMSO 452   (M + 1) 1.34 Method D 100 Meth-od G1 258

HCl 474.89 1H NMR (300 MHz, DMSO) δ 10.36 (s, 1H), 9.52 (s, 1H), 9.00 (d, J = 8.2 Hz, 1 H), 8.89 (d, J = 4.4 Hz, 1H), 8.12 (s, 1H), 8.02-7.78 (m, 4H), 7.64 (d, J = 9.2 Hz, 1H), 7.54 (t, J = 8.2 Hz, 1H), 7.07 (d, J = 7.7 Hz, 1H), 4.08-3.87 (m, 5H), 3.46 (s, 3H). DMSO 439   (M + 1) 2.21 Method C  98 Meth- od G1 259

HCl 460.86 1H NMR (300 MHz, DMSO) δ 10.61 (s, 1H), 9.51 (s, 1H), 9.10 (d, J = 8.2 Hz, 1H), 8.94 (d, J = 4.9 Hz, 1H), 8.22 (s, 1H), 8.08-7.94 (m, 2H), 7.93-7.78 (m, 2H), 7.65 (d, J = 9.1 Hz, 1H), 7.53 (t, J = 8.2 Hz, 1H), 7.08 (d, J = 7.3 Hz, 1H), 4.01 (s, 3H), 3 DMSO 425   (M + 1) 1.64 Method C  98 Meth- od G11 260

HCl 429.67 No Data 428.9 (M + 1) 2.35 Method C 100 Meth- od G1 261

HCl 443.24 1H NMR (300 MHz, DMSO) δ 10.35 (s, 1H), 9.52 (d, J = 1.5 Hz, 1H), 8.97 (dd, J = 6.6, 1.8 Hz, 2H), 8.91-8.83 (m, 1H), 8.07 (dd, J = 8.9, 2.0 Hz, 1H), 7.85 (dd, J = 14 6, 8.2 Hz, 4H), 7.54 (dd, J = 11.7, 4.6 Hz, 1H), 7.31 (s, 1H), 7.10-6.99 (m, 1H). DMSO  442.96 (M + 1) 2.36 Method C 100 Meth- od G1 262

HCl 426.39 1H NMR (300 MHz, DMSO) δ 10.71 (s, 1H), 9.47 (s, 1H), 9.01 (d, J = 8.2 Hz, 1H), 8.90 (d, J = 4.0 Hz, 1H), 8.23 (s, 1H), 8.08-7.86 (m, 4H), 7.61 (t, J = 8.2 Hz, 2H), 7.22 (d, J = 7.6 Hz, 1H), 4.28 (d, J = 7.0 Hz, 2H), 1.44 (t, J = 6.9 Hz, 3H). DMSO 427.1 (M + 1) 2.47 Method C  93 Meth- od G1 263

HCl 446.13 1H NMR (300 MHz, DMSO) δ 10.35 (s, 1H), 9.47 (s, 1H), 8.90 (s, 3H), 8.27 (s, 1H), 8.02 (d, J = 8.9 Hz, 1H), 7.94 (d, J = 8.8 Hz, 1 H), 7.81 (d, J = 9.0 Hz, 2H), 7.68 (d, J = 8.8 Hz, 1H). DMSO 494.0 (M + 1) 2.29 Method C  91 Meth- od G1 264

395.46 1H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 8.88 (s, 1H), 8.83-8.71 (m, 2H), 8.18 (d, J = 9.2 Hz, 1H), 7.30 (dd, J = 9.2, 2.3 Hz, 1H), 7.69-7.57 (m, 3H), 7.32 (d, J = 2.1 Hz, 1H), 4.14 (q, J = 6.6 Hz, 2H), 2.39 (s, 3H), 2.35 (s, 3H), 1.37 (t, J = 6.9 Hz, 3 DMSO  396.10 (M + 1) 2.3 Method C 100 Meth- od G1 265

HCl 469.53 1H NMR (300 MHz, DMSO) δ 12.13 (s, 1H), 9.54 (s, 1H), 8.99 (d, J = 7.4 Hz, 1H), 8.85 (s, 2H), 8.61 (d, J = 8.2 Hz, 1H), 7.95 (d, J = 9.1 Hz, 1H), 7.86 (d, J = 7.3 Hz, 2H), 7.68 (dd, J = 15.1, 7.8 Hz, 3H), 7.32 (d, J = 6.8 Hz, 1H), 4.00 (s, 3H), 3.71 (d, J DMSO 470.1 (M + 1) 2.15 Method C 100 Meth- od G1 266

HCl 455.51 1H NMR (300 MHz, DMSO) δ 12.07 (s, 1H), 9.52 (s, 1H), 8.82-8.65 (m, 4H), 7.88 (dd, J = 8.1, 5.0 Hz, 2H), 7.73-7.55 (m, 4H), 7.27 (t, J = 7.2 Hz, 1H), 3.98 (m, 1H), 3.82 (d, J = 10.4 Hz, 2H), 3.35 (t, J = 11.7 Hz, 2H), 1.68 (d, J = 10.3 Hz, 2H), 1.55- DMSO 456.1 (M + 1) 2.09 Method C 100 Meth- od G1 267

HCl 408.36 1H NMR (300 MHz, DMSO) δ 10.57 (s, 1H), 9.45 (d, J = 1.5 Hz, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.89 (d, J = 3.9 Hz, 1H), 8.16 (d, J = 2.3 Hz, 1H), 8.05 (d, J = 2.0 Hz, 1H), 7.94 (t, J = 7.4 Hz, 2H), 7.63 (ddd, J = 9.3, 6.9, 2.3 Hz, 2H), 7.52 (d, J = 8.7 Hz, DMSO 409.1 (M + 1) 2.3 Method C 100 Meth- od G1 268

HCl 367.4 1H NMR (300 MHz, DMSO) δ 11.12 (s, 1H), 9.81 (s, 1H), 9.43-9.37 (m, 1H), 8.58 (ddd, J = 8.0, 4.8, 1.4 Hz, 2H), 8.09 (d, J = 2.5 Hz, 1H), 7.89 (d, J = 2.2 Hz, 1H), 7.80 (s, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.53-7.41 (m, 3H), 7.17 (t, J = 7.5 Hz, 1H), 7.0 DMSO 368.1 (M + 1) 1.98 Method C 100 Meth- od G1 269

386.4 1H NMR (300 MHz, DMSO) δ 11.47 (s, 2H), 9.39 (s, 1H), 8.66 (d, J = 2.8 Hz, 1H), 8.56-8.47 (m, 1H), 8.01-7.90 (m, 2H), 7.69-7.55 (m, 2H), 7.55-7.40 (m, 2H), 7.05 (t, J = 7.5 Hz, 1H), 6.97 (d, J = 8.2 Hz, 1H), 4.23 (q, J = 6.9 Hz, 2H), 1.44 (t, J = DMSO 387.0 (M + 1) 2.05 Method C 100 Meth- od G8 270

407.45 1H NMR (300 MHz, DMSO) δ 10.52 (s, 1H), 9.44 (s, 1H), 8.92 (d, J = 7.4 Hz, 1H), 8.86 (d, J = 5.1 Hz, 1H), 8.46 (d, J = 6.4 Hz, 1H), 8.01 (d, J = 8.7 Hz, 2H), 7.92-7.74 (m, 6H), 7.68 (dd, J = 9.2, 2.4 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 3.98 (s, 4H). DMSO 408.0 (M + 1) 1.92 Method C 100 Meth-od G1, with two drops of conc. HCl 271

HCl 385.42 1H NMR (300 MHz, DMSO) δ 9.75 (s, 1H), 9.66 (s, 1H), 9.39 (s, 1H), 8.61 (d, J = 3.1 Hz, 1H), 8.54 (d, J = 8.2 Hz, 1H), 7.85 (s, 1H), 7.82 (s, 2H), 7.71 (d, J = 7.4 Hz, 1H), 7.54 (d, J = 9.1 Hz, 1H), 7.46 (dd, J = 7.5, 5.2 Hz, 1H), 7.35-7.23 (m, 2H), 3.9 DMSO 386.1 (M + 1) 1.79 Method C  96 Meth- od G2 272

HCl 413.47 1H NMR (300 MHz, DMSO) δ 12.30 (s, 1H), 9.57 (d, J = 2.1 Hz, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.77-8.67 (m, 2H), 8.63 (d, J = 7.7 Hz, 1H), 7.94-7.83 (m, 2H), 7.71 (t, J = 7.1 Hz, 1H), 7.66-7.52 (m, 3H), 7.25 (t, J = 7.4 Hz, 1H), 4.24-4.06 (m, 1H), 3 DMSO 414.2 (M + 1) 2.36 Method C 100 Meth- od G1 273

HCl 387.46 1H NMR (300 MHz, DMSO) δ 10.96 (s, 1H), 10.29 (s, 1H), 9.85 (s, 1H), 9.51 (d, J = 2.0 Hz, 1H), 8.71-8.62 (m, 2H), 8.47 (dd, J = 8.2, 0.9 Hz, 1H), 7.89 (d, J = 9.1 Hz, 1H), 7.67-7.62 (m, 2H), 7.60 (d, J = 2.5 Hz, 1H), 7.57 (d, J = 2.6 Hz, 1H), 7.55-7 DMSO 388.1 (M + 1) 2.01 Method C  95 Meth- od G1 274

HCl 399.45 1H NMR (300 MHz, DMSO) δ 12.45 (s, 1H), 9.57 (d, J = 1.3 Hz, 1H), 8.96 (dd, J = 8.4, 0.9 Hz, 1H), 8.89 (t, J = 5.2 Hz, 1H) 8.75-8.66 (m, 2H), 7.94-7.84 (m, 2H), 7.72 (t, J = 7.9 Hz, 1H), 7.65-7.52 (m, 3H), 7.24 (t, J = 7.8 Hz, 1H), 4.00 (s, 3H), 3. DMSO 400.3 (M + 1) 2.21 Method C 100 Meth- od G1 275

HCl 453.42 1H NMR (300 MHz, DMSO) δ 11.70 (s, 1H), 9.54 (d, J = 2.0 Hz, 1H), 9.40 (t, J = 6.1 Hz, 1H), 8.79 (d, J = 7.7 Hz, 1H), 8.73-8.63 (m, 2H), 7.89 (d, J = 9.8 Hz, 2H), 7.76 (t, J = 7.1 Hz, 1H), 7.64-7.50 (m, 3H), 7.30 (t, J = 7.1 Hz, 1H), 4.16-4.01 (m, 2 DMSO 454.0 (M + 1) 2.28 Method C 100 Meth- od G1 276

421.25 1H NMR (300 MHz, DMSO) δ 9.26 (d, J = 2.2 Hz, 1H), 8.71-8.62 (m, 2H), 8.46 (dt, J = 8.0, 1.9 Hz, 1H), 8.21 (dd, J = 8.9, 2.3 Hz, 1H), 8.03 (d, J = 8.9 Hz, 1H), 7.89 (s, 1H), 7.78 (dd, J = 7.6, 1.6 Hz, 1H), 7.72-7.62 (m, 1H), 7.56-7.45 (m, 3H), 7.32 DMSO 423.0 (M + 1) 1.85 Method C  94 Meth- od G1 277

HCl 447.49 1H NMR (300 MHz, DMSO) δ 11.25 (s, 1H), 10.46 (s, 1H), 9.45 (s, 1H), 8.93 (d, J = 7.9 Hz, 1H), 8.82 (d, J = 3.9 Hz, 1H), 8.22 (d, J = 8.1 Hz, 1H), 7.97-7.79 (m, 4H), 7.73 (t, J = 7.1 Hz, 1H), 7.62 (dd, J = 9.1, 2.5 Hz, 1H), 7.53-7.39 (m, 3H), 7.19 (t, DMSO 448.1 (M + 1) 2.67 Method C 100 Meth- od G1 278

HCl 399.45 1H NMR (300 MHz, DMSO) δ 12.59 (s, 1H), 9.57 (d, J = 1.4 Hz, 1H), 9.03 (dd, J = 8.4, 0.9 Hz, 1H), 8.91 (d, J = 4.6 Hz, 1H), 8.76-8.64 (m, 2H), 7.88 (t, J = 7.8 Hz, 2H), 7.72 (t, J = 7.9 Hz, 1H), 7.63-7.53 (m, 3H), 7.22 (td, J = 7.9, 1.1 Hz, 1H), 4.28 DMSO 400.1 (M + 1) 2.5  Method C 100 Meth- od G1 279

HCl 399.45 1H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.37 (d, J = 1.4 Hz, 1H), 8.61 (dd, J = 4.7, 1.7 Hz, 1H), 8.58-8.51 (m, 1H), 7.84 (dd, J = 9.0, 5.3 Hz, 3H), 7.65-7.42 (m, 4H), 7.38 (t, J = 7.5 Hz, 1H), 3.95 (s, 3H), 2.74 (s, 6H). DMSO 400.1 (M + 1) 2.2  Method C 100 Meth- od G1 280

HCl 439.51 1H NMR (300 MHz, DMSO) δ 12.05 (s, 1H), 9.51 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 8.1 Hz, 1H), 8.88 (dd, J = 5.2, 1.3 Hz, 1H), 8.60 (d, J = 7.0 Hz, 1H), 8.44 (d, J = 8.0 Hz, 1H), 8.00-7.87 (m, 2H), 7.83 (dd, J = 7.8, 1.4 Hz, 1H), 7.77 (d, J = 1.9 Hz, 1H), DMSO 440.1 (M + 1) 2.52 Method C 100 Meth- od G1 281

HCl 403.41 1H NMR (300 MHz, DMSO) δ 10.98 (s, 1H), 9.50 (s, 1H), 8.72-8.55 (m, 3H), 8.38 (d, J = 8.2 Hz, 1H), 7.87 (d, J = 8.9 Hz, 1H), 7.72-7.45 (m, 4H), 7.19-7.07 (m, 1H), 3.96 (s, J = 5.2 Hz, 3H), 2.73 (d, J = 4.5 Hz, 3H). DMSO 404.1 (M + 1) 2.18 Method C 100 Meth- od G1 282

HCl 417.44 1H NMR (300 MHz, DMSO) δ 10.96 (s, 1H), 9.50 (d, J = 1.9 Hz, 1H), 8.71-8.55 (m, 3H), 8.33 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H), 7.66 (dd, J = 14.8, 8.3 Hz, 1H), 7.60-7.47 (m, 3H), 7.21-7.05 (m, 1H), 4.24 (q, J = 6.9 Hz, 2H), 2.73 (d, J = 4. DMSO 419.1 (M + 1) 2.38 Method C 100 Meth- od G1 283

HCl 439.39 1H NMR (300 MHz, DMSO) δ 13.10 (s, 1H), 9.68 (d, J = 1.1 Hz, 1H), 9.52 (d, J = 1.4 Hz, 1H), 8.75-8.58 (m, 3H), 8.26 (s, 1H), 8.15 (d, J = 8.2 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.59-7.47 (m, 3H), 7.45 (d, J = 2.5 Hz, 1H), 3.95 (s, 3H). DMSO 440.1 (M + 1) 2.25 Method C 100 Meth- od G1 284

HCl 453.42 1H NMR (300 MHz, DMSO) δ 13.08 (s, 1H), 9.70 (s, 1H), 9.55 (d, J = 1.3 Hz, 1H), 8.77-8.60 (m, 3H), 8.26 (s, 1H), 8.15 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 9.1 Hz, 1H), 7.62-7.39 (m, 4H), 4.21 (q, J = 7.1 Hz, 2H), 1.45 (t, J = 6.9 Hz, 3H). DMSO 454.1 (M + 1) 2.43 Metho C  95 Meth- od G1 285

HCl 410.43 1H NMR (300 MHz, DMSO) δ 12.87 (s, 1H), 9.50 (d, J = 1.5 Hz, 2H), 8.73- 8.59 (m, 3H), 8.26 (s, 1H), 8.07 (d, J = 8.2 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.64 (dd, J = 8.1, 1.5 Hz, 1H), 7.59-7.49 (m, 2H), 7.42 (d, J = 2.4 Hz, 1H), 4.19 (q, J = 6.9 Hz, 2H DMSO 411.1 (M + 1) 2.16 Method C  95 Meth- od G1 286

HCl 397.43 1H NMR (300 MHz, DMSO) δ 13.63 (s, 1H), 9.55 (s, 1H), 9.13 (d, J = 8.3 Hz, 1H), 8.75-8.58 (m, 3H), 7.84 (d, J = 9.8 Hz, 1H), 7.69-7.48 (m, 4H), 7.01 (d, J = 7.4 Hz, 1H), 3.94 (s, 3H), 3.46-3.36 (m, 2H), 2.96 (t, J =- 5.7 Hz, 2H). DMSO 398.3 (M + 1) 2.12 Method C 100 Meth- od G1 287

HCl 411.46 1H NMR (300 MHz, DMSO) δ 13.61 (s, 1H), 9.56 (s, 1H), 9.14 (d, J = 8.1 Hz, 1H), 8.75- 8.60 (m, 3H), 7.84 (d, J = 9.8 Hz, 1H), 7.70-7.46 (m, 4H), 7.02 (d, J = 7.2 Hz, 1H), 4.19 (q, J = 6.9 Hz, 3H), 3.48-3.3 (m, 2H),7 2.96 (t, J = 6.1 Hz, 2H), 1.44 (t, DMSO 412.4 (M + 1) 2.4  Method C 100 Meth- od G1 288

HCl 383.4 1H NMR (300 MHz, DMSO) δ 11.62 (s, 1H), 9.60 (d, J = 1.5 Hz, 1H), 9.02 (s, 1H), 8.88 (d, J = 8.0 Hz, 1H), 8.80-8.65 (m, 2H), 7.90 (d, J = 9.0 Hz, 1H), 7.75 (t, J = 7.9 Hz, 1H), 7.66-7.51 (m, 3H), 7.27 (d, J = 7.6 Hz, 1H), 4.47 (s, 2H), 3.97 (s, 3H). DMSO 384.1 (M + 1) 2.01 Method C  95 Meth- od G1 289

HCl 421.4 1H NMR (300 MHz, DMSO) δ 12.07 (s, 1H), 9.48 (d, J = 1.6 Hz, 1H), 8.76-8.55 (m, 3H), 8.34 (s, 1H), 8.14 (s, 1H), 7.87 (d, J = 9.1 Hz, 1H), 7.62-7.49 (m, 2H), 7.38 (d, J = 2.5 Hz, 1H), 7.14 (ddd, J = 11.5, 9.0, 2.6 Hz, 1H), 4.19 (q, J = 6.9 Hz, 2H), 1. DMSO 422.2 (M + 1) 2.35 Method C 100 Meth- od G1 290

HCl 412.44 1H NMR (300 MHz, DMSO) δ 9.82 (s, 1H), 9.50 (d, J = 2.0 Hz, 1H), 8.68-8.58 (m, 2H), 7.98 (d, J = 2.5 Hz, 1H), 7.85 (d, J = 1.8 Hz, 1H), 7.80 (d, J = 9.1 Hz, 1H), 7.55-7.43 (m, 3H), 7.23 (d, J = 8.4 Hz, 1H), 3.96 (s, 3H), 3.37 (d, J = 4.2 Hz, 6H). DMSO 413.0 (M + 1) 1.79 Method C Meth- od G1 291

HCl 426.47 1H NMR (300 MHz, DMSO) δ 9.78 (s, 1H), 9.50 (d, J = 2.0 Hz, 1H), 8.68-8.57 (m, 2H), 7.97 (d, J = 2.5 Hz, 1H), 7.85 (d, J = 1.3 Hz, 1H), 7.79 (d, J = 9.1 Hz, 1H), 7.55-7.43 (m, 3H), 7.22 (d, J = 8.4 Hz, 1H), 4.22 (q, J = 6.9 Hz, 2H), 3.37 (d, J = 4.3 H DMSO 427.1 (M + 1) 1.92 Method C Meth- od G1 292

404.39 1H NMR (300 MHz, DMSO) δ 9.36 (d, J = 1.4 Hz, 1H), 8.66 (d, J = 2.7 Hz, 1H), 8.52 (d, J = 7.8 Hz, 1H), 7.97 (d, J = 8.9 Hz, 2H), 7.64 (d, J = 13.5 Hz, 2H), 7.50 (dd, J = 7.7, 4.2 Hz, 1H), 6.86 (t, J = 6.8 Hz, 1H), 6.70 (dd, J = 11.8, 1.7 Hz, 1H), 4.22 (q, DMSO 405.1 (M + 1) 1.98 Method C  95 Meth- od G8 293

406.82 1H NMR (300 MHz, DMSO) δ 9.23 (d, J = 1.4 Hz, 1H), 8.63 (d, J = 3.6 Hz, 1H), 8.43 (d, J = 8.0 Hz, 1H), 8.00 (d, J = 9.1 Hz, 1H), 7.92 (s, 1H), 7.81-7.65 (m, 4H), 7.55 (dd, J = 8.4, 2.1 Hz, 1H), 7.48 (dd, J = 6.7, 3.8 Hz, 1H), 7.37 (s, 1H), 3.97 (s, 3H). DMSO 407.1 (M + 1) 1.88 Method C 100 Meth- od G8 294

HCl 406.46 1H NMR (300 MHz, DMSO) δ 10.11 (s, 1H), 9.39 (d, J = 1.4 Hz, 1H), 8.63 (dd, J = 4.7, 1.7 Hz, 1H), 8.59-8.53 (m, 1H), 8.50 (dd, J = 8.2, 0.8 Hz, 1H), 8.03 (dd, J = 8.0, 1.4 Hz, 1H), 7.96-7.84 (m, 2H), 7.65-7.46 (m, 4H), 3.94 (s, 3H), 3.25 (s, 3H). DMSO 407.1 (M + 1) 2.13 Method C  95 Meth- od G1 Salt Number Starting Material 1 Starting Material 2 Product Type 295

296

297

298

299

300

301

302

303

304

305

306

307

308

HCl 309

HCl 310

HCl 311

HCl 312

3 HCl 313

2 HCl 314

HCl 315

HCl 316

317

318

319

320

321

322

323

324

HCl 325

HCl 326

HCl 327

HCl 328

HCl 329

2 HCl 330

HCl 331

2 HCl 332

HCl 333

HCl 334

HCl 335

HCl 336

HCl 337

HCl 338

339

340

341

342

343

344

HCl 345

HCl 346

HCl 347

HCl 348

HCl 349

HCl 350

HCl 351

2 HCl 352

2 HCl 353

HCl 354

HCl 355

HCl 356

HCl 357

HCl 358

HCl 359

HCl 360

HCl 361

HCl 362

HCl 363

HCl 364

2 HCl 365

2 HCl 366

2 HCl 367

2 HCl 368

2 HCl 369

HCl 370

HCl 371

2 HCl 372

2 HCl 373

2 HCl 374

2 HCl 375

2 HCl 376

2 HCl 377

2 HCl 378

2 HCl 379

2 HCl 380

2 HCl 381

HCl 382

HCl 383

2 HCl 384

2 HCl 385

2 HCl 386

2 HCl 387

2 HCl 388

2 HCl 389

2 HCl 390

HCl 391

HCl 392

HCl 393

HCl 394

HCl 395

HCl 396

HCl 397

HCl 398

399

400

2 HCl 401

2 HCl 402

2 HCl 403

2 HCl 404

HCl 405

HCl 406

HCl 407

2 HCl 408

HCl 409

HCl 410

HCl 411

412

HCl 413

Method ¹H NMR Purity of Number ¹H NMR Solvent percent Coupling 295 ¹H NMR (400 MHz, DMSO) δ 13.12 (s, 1H), 9.90 (s, 1H), 9.47 (d, J = 1.4 Hz, 1H), 8.70-8.54 (m, 2H), 8.20-8.15 (m, 1H), 8.14 (s, 1H), 8.01 (d, J = 2.6 Hz, 1H), 7.88-7.75 (m, 2H), 7.65 (d, J = 8.9 Hz, 1H), 7.59-7.44 (m, 2H), 3.98 (s, 3H). DMSO >98 G1 296 ¹H NMR (400 MHz, DMSO) δ 10.04 (s, 1H), 9.54-9.47 (m, 1H), 9.36 (s, 1H), 8.72 (d, J = 2.0 Hz, 1H), 8.69-8.59 (m, 2H), 8.19 (d, J = 8.8 Hz, 1H), 8.08-7.97 (m, 2H), 7.86 (d, J = 9.1 Hz, 1H), 7.61-7.47 (m, 2H), 3.99 (s, 3H). DMSO >98 G1 297 ¹H NMR (400 MHz, DMSO) δ 9.64 (s, 1H), 9.55-9.45 (m, 1H), 8.72 - 8.60 (rn, 2H), 7.95 (d, J = 2.7 Hz, 1H), 7.82 (d, J= 9.1 Hz, 1H), 7.58-7.48 (m, 3H), 7.34 (dd, J = 8.7, 2.5 Hz, 1H), 6.96 (d, J = 8.7 Hz, 1H), 4.39-4.23 (m, 4H), 3.97 (s, 3H). DMSO >98 G1 298 ¹H NMR (400 MHz, DMSO) δ 11.21 (s, 1H), 9.79 (s, 1H), 9.53 (d, J = 1.4 Hz, 1H), 8.75-8.58 (m, 2H), 8.07 (s, 1H), 8.03 (d, J = 2.7 Hz, 1H), 7.82 (d, J = 9.1 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.56-7.47 (m, 2H), 7.43 (dd, J = 8.5, 1.8 Hz, 1H), 7.39-7.34 (m, 1H), 6.50-6.41 (m, 1H), 3.99 (s, 3H). DMSO >98 G1 299 ¹H NMR (400 MHz, DMSO) δ 9.54 (s, 1H), 9.42-9.34 (m, 1H), 8.61 (dd, J = 4.7, 1.7 Hz, 1H), 8.57-8.47 (m, 1H), 7.93 (d, J = 2.7 Hz, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.56-7.44 (m, 2H), 7.19 (dd, J = 7.9, 1.5 Hz, 1H), 7.00-6.91 (m, 1H), 6.88 (dd, J = 8.2, 1.6 Hz, 1H), 4.34-4.17 (m, 4H), 3.95 (s, 3H). DMSO >98 G1 300 ¹H NMR (400 MHz, DMSO) δ 10.76 (s, 1H), 10.01 (s, 1H), 9.17-9.06 (m, 1H), 8.53 (dd, J = 4.7, 1.7 Hz, 1H), 8.36-8.27 (m, 1H), 8.05 (d, J = 2.7 Hz, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.60-7.48 (m, 2H), 7.36 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.32-7.28 (m, 1H), 7.25 (d, J = 6.8 Hz, 1H), 7.16-7.04 (m, 1H), 6.54 (dd, J = 3.0, 1.9 Hz, 1H), 3.98 (s, 3H). DMSO >98 G1 301 ¹H NMR (400 MHz, DMSO) δ 10.02 (s, 1H), 9.48 (d, J = 1.5 Hz, 1H), 9.33 (d, J = 1.0 Hz, 1H), 8.69-8.59 (m, 2H), 8.37 (d, J = 1.7 Hz, 1H), 8.10 (dd, J = 9.0, 2.1 Hz, 1H), 8.00 (d, J = 2.7 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.86 (d, J = 9.1 Hz, 1H), 7.57 (dd, J = 9.1, 2.7 Hz, 1H), 7.54-7.47 (m, 1H), 3.99 (s, 3H). DMSO >98 G1 302 ¹H NMR (400 MHz, DMSO) δ 10.52 (s, 1H), 9.18 (dd, J = 2.2. 0.8 Hz, 1H), 8.60 (dd, J = 4.7, 1.7 Hz, 1H), 8.45-8.36 (m, 1H), 8.03 (d, J = 2.7 Hz, 1H), 7.97-7.90 (m, 2H), 7.88 (d, J = 7.0 Hz, 1H), 7.77 (dd, J = 9.0, 7.1 Hz, 1H), 7.61 (dd, J = 9.1, 2.7 Hz, 1H), 7.44 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 4.01 (s, 3H). DMSO >98 G1 303 ¹H NMR (400 MHz, DMSO) δ 9.86 (s, 1H), 9.60-9.56 (rn, 1H), 8.72-8.67 (m, 1H), 8.65 (dd, J = 4.8, 1.7 Hz, 1H), 8.26-8.21 (m, 1H), 8.05 (d, J = 2.7 Hz, 1H), 7.83 (d, J = 9.1 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.56-7.50 (m, 2H), 7.46 (dd, J = 8.5, 1.8 Hz, 1H), 7.35 (d, J = 3.1 Hz, 1H), 6.46 (dd, J = 3.1, 0.8 Hz, 1H), 3.99 (s, 3H), 3.86 (s, 3H). DMSO >98 G1 304 ¹H NMR (400 MHz, DMSO) δ.96 (s, 1H), 9.51-9.45 (m, 1H), 8.68-8.59 (m, 2H), 8.57-8.52 (m, 1H), 8.02-7.88 (m, 3H), 7.87-7.80 (m, 1H), 7.58-7.46 (m, 2H), 3.98 (s, 3H), 2.83 (s, 3H). DMSO >98 G1 305 ¹H NMR (400 MHz, DMSO) δ 9.94 (s, 1H), 9.51-9.43 (rn, 1H), 8.68-8.58 (m, 2H), 8.39 (d, J = 2.0 Hz, 1H), 7.99 (d, J = 2.7 Hz, 1H), 7.87-7.80 (m, 2H), 7.78 (d, J = 8.6 Hz, 1H), 7.54 (dd, J = 9.1, 2.7 Hz, 1H), 7.51 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 4.19 (s, 3H), 3.98 (s, 3H). DMSO >98 G1 306 ¹H NMR (400 MHz, DMSO) δ 9.72 (s, 1H), 9.52-9.47 (m, 1H), 8.67-8.60 (m, 2H), 7.98 (d, J = 2.7 Hz, 1H), 7.82 (d, J = 9.1 Hz, 1H), 7.78-7.74 (rn, 1H), 7.68-7.62 (m, 1H), 7.55-7.48 (m, 2H), 7.32 (d, J = 8.1 Hz, 1H), 3.97 (s, 3H), 2.99-2.88 (m, 4H), 2.15-2.04 (m, 2H). DMSO >98 G1 307 ¹H NMR (400 MHz, CDCl₃) δ 9.74 (s, 1H), 9.37-9.31 (m, 1H), 8.60 (dd, J = 4.7, 1.7 Hz, 1H), 8.53-8.46 (m, 1H), 7.95 (d, J = 2.7 Hz, 1H), 7.82 (d, J = 9.1 Hz, 1H), 7.52 (dd, J = 9.1, 2.7 Hz, 1H), 7.47 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.34 (d, J = 7.0 Hz, 1H), 7.31-7.24 (m, 1H), 7.22 (d, J = 7.1 Hz, 1H), 3.96 (s, 3H), 2.99 (t, J = 7.3 Hz, 2H), 2.82 (t, J = 7.4 Hz, 2H), 2.06-1.96 (m, 2H). DMSO >98 G1 308 ¹H NMR (400 MHz, DMSO) δ 10.45 (s, 1H), 9.50-9.44 (m, 1H), 8.94-8.87 (m, 1H), 8.83 (dd, J = 5.1, 1.5 Hz, 1H), 8.54 (d, J = 2.0 Hz, 1H), 8.13 (d, J = 2.4 Hz, 1H), 8.02 (d, J = 8.7 Hz, 1H), 7.97-7.89 (m, 2H), 7.83 (dd, J = 8.0, 5.2 Hz, 1H), 7.63 (dd, J = 9.1, 2.7 Hz, 1H), 4.01 (s, 3H), 2.83 (s, 3H). DMSO >98 G1 309 ¹H NMR (400 MHz, DMSO) δ 10.64 (s, 1H), 9.47 (d, J = 1.5 Hz, 1H), 8.94 (d, J = 8.1 Hz, 1H), 8.86 (dd, J = 5.2, 1.5 Hz, 1H), 8.54-8.48 (m, 1H), 8.23-8.16 (m, 1H), 8.04-7.94 (m, 2H), 7.92-7.83 (m, 2H), 7.78 (d, J = 5.4 Hz, 1H), 7.65 (dd, J = 9.1, 2.6 Hz, 1H), 7.51 (dd, J = 5.4, 0.7 Hz, 1H), 4.02 (s, 3H). DMSO >98 G1 310 ¹H NMR (400 MHz, DMSO) δ 10.86 (s, 1H), 9.43 (d, J = 1.6 Hz, 1H), 8.94 (d, J = 7.5 Hz, 1H), 8.89 (dd, J = 5.2, 1.5 Hz, 1H), 8.30-8.20 (m, 1H), 8.13-7.99 (m, 3H), 7.94-7.84 (m, 1H), 7.74 (d, J = 1.3 Hz, 2H), 7.67 (dd, J = 9.1, 2.5 Hz, 1H), 7.08 (d, J = 2.2 Hz, 1H), 4.02 (s, 3H). DMSO >98 G1 311 ¹H NMR (400 MHz, DMSO) δ 10.53 (s, 1H), 9.48 (d, J = 1.5 Hz, 1H), 8.93 (d, J = 7.7 Hz, 1H), 8.85 (dd, J = 5.2, 1.5 Hz, 1H), 8.44 (d, J = 1.9 Hz, 1H), 8.20-8.15 (m, 1H), 8.13 (d, J = 8.7 Hz, 1H), 7.97 (d, J = 8.1 Hz, 1H), 7.92 (dd, J = 8.7, 2.0 Hz, 1H), 7.86 (dd, J = 7.8, 5.1 Hz, 1H), 7.64 (dd, J = 9.1, 2.6 Hz, 1H), 4.02 (s, 3H), 2.85 (s, 3H). DMSO >98 G1 312 ¹H NMR (400 MHz, DMSO) δ 10.85 (s, 1H), 9.54 (d, J = 1.5 Hz, 1H), 9.47 (s, 1H), 9.32 (s, 1H), 9.03 (d, J = 8.0 Hz, 1H), 8.93-8.87 (m, 1H), 8.86-8.78 (m, 2H), 8.44 (dd, J = 8.8, 1.9 Hz, 1H), 8.14 (d, J = 2.1 Hz, 1H), 8.10 (d, J = 8.7 Hz, 1H), 7.99-7.89 (rn, 2H), 7.78-7.71 (m, 1H), 7.55 (d, J = 8.7 Hz, 1H). DMSO >98 G1 313 ¹H NMR (400 MHz, DMSO) δ 11.07 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.51 (d, J = 2.0 Hz, 1H), 9.46-9.39 (rn, 1H), 9.10-9.01 (m, 1H), 8.97-8.88 (m, 2H), 8.86 (dd, J = 5.3, 1.3 Hz, 1H), 8.63-8.55 (m, 1H), 8.48 (dd, J = 8.8, 1.9 Hz, 1H), 8.15 (d, J = 8.7 Hz, 1H), 8.04-7.90 (m, 4H), 7.79 (d, J = 5.4 Hz, 1H), 7.52 (dd, J = 5.4, 0.7 Hz, 1H). DMSO >98 G1 314 ¹H NMR (400 MHz, DMSO) δ 10.49 (s, 1H), 9.48 (d, J = 1.5 Hz, 1H), 8.93 (d, J = 7.9 Hz, 1H), 8.85 (dd, J = 5.2, 1.5 Hz, 1H), 8.24 (s, 1H), 8.16 (d, J = 2.5 Hz, 1H), 8.05 (d, J = 2.2 Hz, 1H), 7.96 (d, J = 9.1 Hz, 1H), 7.87 (dd, J = 8.1, 5.3 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.72 (dd, J = 8.4, 1.8 Hz, 1H), 7.64 (dd, J = 9.1, 2.6 Hz, 1H), 7.03 (dd, J = 2.2, 1.0 Hz, 1H), 4.02 (s, 3H). DMSO >98 G1 315 ¹H NMR (400 MHz, DMSO) δ 10.72 (s, 1H), 9.46 (d, J = 1.5 Hz, 1H), 8.96 (d, J = 8.2 Hz, 1H), 8.87 (dd, J = 5.2, 1.5 Hz, 1H), 8.50 (d, J = 1.8 Hz, 1H), 8.21 (d, J = 2.4 Hz, 1H), 8.06-7.96 (rn, 2H), 7.93-7.84 (m, 2H), 7.78 (d, J = 5.4 Hz, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.51 (dd, J = 5.4, 0.7 Hz, 1H), 4.29 (q, J = 7.0 Hz, 2H), 1.46 (t, J = 7.0 Hz, 3H). DMSO >98 G1 316 ¹H NMR (400 MHz, DMSO) δ 10.04 (s, 1H), 9.60-9.52 (rn, 1H), 8.75-8.63 (m, 2H), 8.16 (d, J = 2.0 Hz, 1H), 8.04-7.95 (m, 2H), 7.93-7.83 (m, 2H), 7.63-7.53 (m, 2H), 6.32 (d, J = 1.2 Hz, 1H), 4.01 (s, 3H), 2.47 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 317 ¹H NMR (400 MHz, DMSO) δ 11.82 (s, 1H), 10.06 (s, 1H), 9.53-9.46 (m, 1H), 8.81-8.70 (m, 2H), 8.04 (d, J = 2.6 Hz, 1H), 7.88 (d, J = 9.1 Hz, 1H), 7.81 (d, J = 2.1 Hz, 1H), 7.67 (dd, J = 7.9, 5.0 Hz, 1H), 7.57 (dd, J = 9.1, 2.7 Hz, 1H), 7.53 (dd, J = 8.7, 2.1 Hz, 1H), 7,39 (d, J = 8.6 Hz, 1H), 4.00 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 318 ¹H NMR (400 MHz, DMSO) δ 9.89 (s, 1H), 9.57-9.48 (m, 1H), 8.72-8.58 (m, 2H), 8.01 (d, J = 2.1 Hz, 1H), 7.99 (d, J = 2.7 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.59-7.49 (m, 3H), 7.43 (d, J = 8.6 Hz, 1H), 3.98 (s, 3H), 3.41 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 319 ¹H NMR (400 MHz, DMSO) δ 9.88 (s 1H), 9.52-9.44 (m, 1H), 8.71-8.59 (m, 2H), 8.02-7.91 (m, 2H), 7.83 (d, J = 9.1 Hz, 1H), 7.66 (dd, J = 8.4, 2.0 Hz, 1H), 7.58-7.48 (m, 2H), 7.36 (d, J = 8.4 Hz, 1H), 3.98 (s, 3H), 3.40 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 320 ¹H NMR (400 MHz, DMSO) δ 10.01 (s, 1H), 9.58-9.51 (m, 1H), 9.45 (s, 1H), 8.75 (d, J = 1.9 Hz, 1H), 8.71-8.63 (m, 2H), 8.25 (d, J = 8.7 Hz, 1H), 8.08-8.00 (m, 2H), 7.86 (d, J = 9.1 Hz, 1H), 7.61-7.50 (m, 2H), 4.00 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 321 ¹H NMR (400 MHz, DMSO) δ 10.43 (s, 1H), 9.72 (s, 1H), 9.51-9.45 (m, 1H), 8.67-8.57 (m, 2H), 7.96 (d, J = 2.7 Hz, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.73-7.68 (m, 1H), 7.64 (dd, J = 8.3, 2.1 Hz, 1H), 7.56-7.48 (m, 2H), 6.93 (d, J = 8.3 Hz, 1H), 3.97 (s, 3H), 3.58 (s, 2H). DMSO >98 G1 (0.1 N HCl added) 322 ¹H NMR (400 MHz, DMSO) δ 9.95 (s, 1H), 9.54-9.45 (m, 1H), 8.67 (dd, J = 4.7, 1.7 Hz, 1H), 8.66-8.60 (m, 1H), 8.15 (d, J = 2.4 Hz, 1H), 7.94 (d, J = 2.6 Hz, 1H), 7.89-7.83 (m, 2H), 7.63-7.52 (rn, 3H), 3.98 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 323 ¹H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.75 (s, 1H), 9.55-9.49 (m, 1H), 8.69- 8.62 (m, 2H), 7.96 (d, J = 2.7 Hz, 1H), 7.83 (d, J = 9.1 Hz, 1H), 7.58-7.49 (m, 3H), 7.35 (dd, J = 8.7, 2.5 Hz, 1H), 7.06 (d, J = 8.6 Hz, 1H), 4.62 (s, 2H), 3.97 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 324 ¹H NMR (400 MHz, DMSO) δ 10.24 (s, 1H), 9.58-9.51 (m, 1H), 8.92-8.84 (m, 1H), 8.80 (dd, J = 5.0, 1.5 Hz, 1H), 8.16 (d, J = 2.0 Hz, 1H), 8.07 (d, J = 2.6 Hz, 1H), 7.98 (dd, J = 8.8, 2.1 Hz, 1H), 7.91 (d, J = 9.1 Hz, 1H), 7.83-7.72 (m, 2H), 7.61 (dd, J = 9.1, 2.6 Hz, 1H), 6.37 (s, 1H), 4.75 (d, J = 1.2 Hz, 2H), 4.01 (s, 3H), 3.47 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 325 ¹H NMR (400 MHz, DMSO) δ 12.01 (s, 1H), 10.15 (s, 1H), 9.58 (d, J = 1.5 Hz, 1H), 8.94-8.86 (m, 1H), 8.78 (dd, J = 5.0, 1.5 Hz, 1H), 8.07 (d, J = 2.6 Hz, 1H), 8.04-7.98 (m, 1H), 7.91 (dd, J = 9.3, 2.2 Hz, 2H), 7.78-7.69 (m, 2H), 7.66 (dd, J = 8.5, 2.0 Hz, 1H), 7.61 (dd, J = 9.1, 2.7 Hz, 1H), 6.44 (d, J = 9.5 Hz, 1H), 4.01 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 326 ¹H NMR (400 MHz, DMSO) δ 12.19 (s, 1H), 10.21 (s, 1H), 9.58-9.51 (rn, 1H), 8.94-8.86 (m, 1H), 8.81 (dd, J = 5.1, 1.6 Hz, 1H), 8.10 (d, J = 2.6 Hz, 1H), 7.96-7.88 (m, 2H), 7.79 (dd, J = 7.9, 5.1 Hz, 1H), 7.68-7.56 (rn, 3H). 4.00 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 327 ¹H NMR (400 MHz, DMSO) δ 10.43 (s, 1H), 9.57-9.50 (m, 1H), 9.07-8.98 (m, 1H), 8.88 (dd, J = 5.2, 1.4 Hz, 1H), 8.16 (d, J = 2.5 Hz, 1H), 8.06 (d, J = 1.9 Hz, 1H), 8.00-7.89 (m, 2H), 7.75 (d, J = 8.5 Hz, 1H), 7.67 (dd, J = 8.5, 2.0 Hz, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 4.02 (s, 3H), 3.47 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 328 ¹H NMR (400 MHz, DMSO) δ 10.68 (s, 1H), 10.24 (s, 1H), 9.45 (d, J = 1.6 Hz, 1H), 9.05-8.95 (m, 1H), 8.92 (dd, J = 5.2, 1.5 Hz, 1H), 8.25-8.16 (rn, 1H), 8.09-7.99 (m, 1H), 7.98-7.89 (m, 1H), 7.71-7.60 (m, 3H), 6.98 (d, J = 8.3 Hz, 1H), 4.00 (s, 3H), 2.99 (t, J = 7.5 Hz, 2H), 2.57-2.52 (m, 2H). DMSO >98 G1 (0.1 N HCl added) 329 ¹H NMR (400 MHz, DMSO) δ 12.05 (s, 1H), 10.98 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 9.32 (s, 1H), 9.03 (d, J = 8.2 Hz, 1H), 8.98 (d, J = 1.7 Hz, 1H), 8.92 (dd, J = 5.3, 1.4 Hz, 1H), 8.53 (d, J = 2.6 Hz, 1H), 8.46 (dd, J = 8.8, 1.8 Hz, 1H), 8.30 (s, 1H), 8.13 (d, J = 2.1 Hz, 1H), 8.09 (d, J = 8.7 Hz, 1H), 7.95 (dd, J = 7.7, 5.3 Hz, 1H), 7.82 (dd, J = 8.6, 2.1 Hz, 1H), 7.26 (d, J = 8.6 Hz, 1H), 4.06 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 330 ¹H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.54 (d, J = 1.5 Hz, 1H), 9.05-8.97 (m, 1H), 8.87 (dd, J = 5.2, 1.5 Hz, 1H), 8.15-8.06 (m, 3H), 8.00-7.87 (m, 3H), 7.81 (d, J = 8.5 Hz, 1H), 7.64 (dd, J = 9.1, 2.7 Hz, 1H), 6.43 (d, J = 9.4 Hz, 1H), 4.02 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 331 ¹H NMR (400 MHz, DMSO) δ 12.05 (s, 1H), 10.77 (s, 1H), 9.51 (d, J = 1.5 Hz, 1H), 9.43- 9.35 (m, 1H), 9.31-9.21 (m, 1H), 9.04- 8.93 (m, 1H), 8.88 (dd, J = 5.2, 1.5 Hz, 1H), 8.81 (dd, J = 5.1, 1.4 Hz, 1H), 8.73 (d, J = 8.4 Hz, 1H), 8.42 (dd, J = 8.8, 1.8 Hz, 1H), 8.13 (d, J = 2.1 Hz, 1H), 8.09 (d, J = 8.7 Hz, 1H), 7.94-7.83 (m, 2H), 7.80 (dd, J = 8.6, 2.2 Hz, 1H), 7.27 (d, J = 8.6 Hz, 1H). DMSO >98 G1 (0.1 N HCl added) 332 ¹H NMR (400 MHz, DMSO) δ 10.57 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 9.09-9.01 (rn, 1H), 8.90 (dd, J = 5.3, 1.5 Hz, 1H), 8.65-8.59 (m, 1H), 8.24-8.16 (m, 2H), 8.14 (dd, J = 9.6, 0.8 Hz, 1H), 8.03-7.92 (m, 2H), 7.65 (dd, J = 9.1, 2.7 Hz, 1H), 4.03 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 333 ¹H NMR (400 MHz, DMSO) δ 11.81 (s, 1H), 10.31 (s, 1H), 9.58 (d, J = 1.5 Hz, 1H), 9.08 (d, J = 7.9 Hz, 1H), 8.87 (dd, J = 5.2, 1.5 Hz, 1H), 8.13 (d, J = 2.6 Hz, 1H), 8.04 (d, J = 2.0 Hz, 1H), 7.98-7.88 (m, 2H), 7.81 (d, J = 8.8 Hz, 1H), 7.69 (dd, J = 8.8, 2.1 Hz, 1H), 7.63 (dd, J = 9.1, 2.7 Hz, 1H), 6.36 (s, 1H), 4.02 (s, 3H), 2.46 (d, J = 1.1 Hz, 3H). DMSO >98 G1 (0.1 N HCl added) 334 ¹H NMR (400 MHz, DMSO) δ 10.51 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 9.08-9.02 (m, 1H), 8.90 (dd, J = 5.3, 1.5 Hz, 1H), 8.63-8.59 (m, 1H), 8.22-8.10 (m, 3H), 8.00-7.92 (m, 2H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 4.30 (q, J = 7.0 Hz, 2H), 1.46 (t, J = 7.0 Hz, 3H). DMSO >98 G1 (0.1 N HCl added) 335 ¹H NMR (400 MHz, DMSO) δ 11.99 (s, 1H), 10.34 (s, 1H), 9.62-9.52 (m, 1H), 9.11 (d, J = 8.2 Hz, 1H), 8.90 (d, J = 4.4 Hz, 1H), 8.13 (d, J = 2.6 Hz, 1H), 8.06 (d, J = 1.8 Hz, 1H), 8.00-7.88 (m, 3H), 7.75 (d, J = 8.6 Hz, 1H), 7.68-7.60 (m, 2H), 6.46 (d, J = 9.5 Hz, 1H), 4.29 (q, J = 7.0 Hz, 2H), 1.46 (t, J = 7.0 Hz, 3H). DMSO >98 G1 (0.1 N HCl added) 336 ¹H NMR (400 MHz, DMSO) δ 11.02 (s, 1H), 10.49 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 9.02 (d, J = 8.1 Hz, 1H), 8.90 (dd, J = 5.2, 1.5 Hz, 1H), 8.15 (d, J = 2.3 Hz, 1H), 8.00 (d, J = 9.1 Hz, 1H), 7.93 (dd, J = 7.8, 5.4 Hz, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.54 (d, J = 2.4 Hz, 1H), 7.35 (dd, J = 8.7, 2.5 Hz, 1H), 7.08 (d, J = 8.6 Hz, 1H), 4.64 (s, 2H), 4.28 (q, J = 6.9 Hz, 2H), 1.45 (t, J = 7.0 Hz, 3H). DMSO >98 G1 (0.1 N HCl added) 337 ¹H NMR (400 MHz, DMSO) δ 10.36 (s, 1H), 10.25 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.98 (d, J = 8.1 Hz, 1H), 8.86 (dd, J = 5.2, 1.5 Hz, 1H), 8.10 (d, J = 2.4 Hz, 1H), 7.94 (d, J = 9.1 Hz, 1H), 7.87 (dd, J = 7.7, 5.2 Hz, 1H), 7.61 (dd, J = 9.1, 2.6 Hz, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.36 (dd, J = 8.1, 2.1 Hz, 1H), 7.28 (d, J = 8.1 Hz, 1H), 4.27 (q, J = 7.0 Hz, 2H), 2.93 (t, J = 7.5 Hz, 2H), 2.56-2.52 (m, 2H), 1.45 (t, J = 7.0 Hz, 3H). DMSO >98 G1 (0.1 N HCl added) 338 ¹H NMR (400 MHz, DMSO) δ 10.25 (s, 1H), 9.50-9.39 (m, 1H), 9.03 (dd, J = 2.1, 0.7 Hz, 1H), 8.52 (dd, J = 4.7, 1.7 Hz, 1H), 8.48 (d, J = 6.0 Hz, 1H), 8.31-8.24 (m, 1H), 8.16 (d, J = 8.2 Hz, 1H), 8.12 (d, J = 2.7 Hz, 1H), 8.04 (d, J = 7.3 Hz, 1H), 7.91-7.78 (rn, 3H), 7.58 (dd, J = 9.1, 2.7 Hz, 1H), 7.35 (ddd, J = 8.0, 4.8, 0.7 Hz, 1H), 4.01 (s, 3H). DMSO >98 J2 339 ¹H NMR (400 MHz, DMSO) δ 10.23 (s, 1H), 9.37 (dd, J = 2.1, 0.7 Hz, 1H), 8.62 (dd, J = 4.7, 1.7 Hz, 1H), 8.57-8.49 (m, 1H), 7.93 (d, J = 2.7 Hz, 1H), 7.89 (d, J = 9.1 Hz, 1H), 7.58 (dd, J = 9.1, 2.7 Hz, 1H), 7.47 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.40-7.30 (m, 3H), 3.98 (s, 3H). DMSO >98 J2 340 ¹H NMR (400 MHz, DMSO) δ 11.31 (s, 1H), 9,56 (s, 1H), 9.54 (dd, J = 2.1, 0.7 Hz, 1H), 8.80-8.66 (rn, 2H), 8.14 (d, J = 9.2 Hz, 1H), 7.77 (dd, J = 9.2, 2.8 Hz, 1H), 7.58 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.36 (d, J = 2.8 Hz, 1H), 7.03-6.94 (m, 1H), 6.68 (dd, J = 7.3, 0.8 Hz, 1H), 6.56 (dd, J = 8.2, 0.8 Hz, 1H), 3.86 (s, 3H). DMSO >98 J2 341 ¹H NMR (400 MHz, DMSO) δ 10.00 (s, 1H), 9.54-9.49 (m, 1H), 8.75 (s, 1H), 8.69-8.62 (m, 2H), 8.50 (d, J = 1.7 Hz, 1H), 8.02 (d, J = 2.7 Hz, 1H), 7.91-7.85 (m, 2H), 7.83 (dd, J = 8.6, 1.9 Hz, 1H), 7.60-7.51 (m, 2H), 4.00 (s, 3H). DMSO >98 J2 342 ¹H NMR (400 MHz, DMSO) δ 10.08 (s, 1H), 9.34-9.27 (m, 1H), 8.60 (dd, J = 4.7, 1.7 Hz, 1H), 8.51-8.44 (rn, 1H), 7.94 (d, J = 2.7 Hz, 1H), 7.88 (d, J = 9.1 Hz, 1H), 7.58 (dd, J = 9.1, 2.7 Hz, 1H), 7.56=7.51 (m, 1H), 7.51-7.47 (m, 2H), 7.45 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 3.98 (s, 3H). DMSO >98 J2 343 ¹H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.93 (s, 1H), 9.26 (d, J = 1.4 Hz, 1H), 8.59 (dd, J = 4.8, 1.7 Hz, 1H), 8.50-8.43 (m, 1H), 8.01 (d, J = 2.7 Hz, 1H), 7.98 (d, J = 9.5 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.55 (dd, J = 9.1, 2.7 Hz, 1H), 7.49-7.42 (m, 1H), 7.36 (d, J = 8.3 Hz, 1H), 6.55 (dd, J = 9.5, 1.7 Hz, 1H), 3.98 (s, 3H), 2.33 (s, 3H). DMSO >98 J2 344 ¹H NMR (400 MHz, DMSO) δ 9.34-9.28 (m, 1H), 8.81-8.75 (m, 1H), 8.74-8.65 (m, 1H), 8.06 (d, J = 9.2 Hz, 1H), 7.93 (d, J = 2.7 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.80-7.72 (m, 2H), 7.69 (d, J = 2.8 Hz, 1H), 7.59 (dd, J = 8.8, 2.7 Hz, 1H), 4.00 (s, 3H). DMSO >98 G8 using DMF instead of THF 345 ¹H NMR (400 MHz, DMSO) δ 9.35-9.29 (m, 1H), 8.87-8.78 (m, 2H), 8.19 (d, J = 9.4 Hz, 1H), 8.09 (d, J = 9.2 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.86 (dd, J = 8.0, 5.3 Hz, 1H), 7.77 (dd, J = 9.1, 2.9 Hz, 1H), 7.72 (d, J = 2.8 Hz, 1H), 7.67 (d, J = 2.3 Hz, 1H), 7.54 (dd, J = 8.5, 2.3 Hz, 1H), 6.56 (d, J = 9.6 Hz, 1H), 4.02 (s, 3H). DMSO >98 G12 at room tempera-ture 346 ¹H NMR (400 MHz, DMSO) δ 11.98 (s, 1H), 9.29 (d, J = 1.7 Hz, 1H), 8.88-8.87 (m, 2H), 8.08 (d, J = 9.2 Hz, 1H), 7.97 (d, J = 9.6 Hz, 1H), 7.88 (dd, J = 8.1, 5.4 Hz, 1H), 7.81 (d, J = 2.6 Hz, 1H), 7.78-7.72 (m, 2H), 7.67 (dd, J = 8.9, 2.6 Hz, 1H), 7.48 (d, J = 8.9 Hz, 1H), 6.60 (d, J = 9.5 Hz, 1H), 4.02 (s, 3H). DMSO >98 G12 at room tempera-ture 347 ¹H NMR (400 MHz, DMSO) δ 9.33-9.28 (m, 1H), 8.87-8.67 (m, 2H), 8.06 (d, J = 9.1 Hz, 1H), 7.91-7.79 (m, 1H), 7.75 (dd, J = 9.1, 2.9 Hz, 1H), 7.71 (d, J = 2.8 Hz, 1H), 7.67-7.61 (m, 2H), 7.58-7.51 (m, 2H), 4.01 (s, 3H). DMSO >98 G12 at room tempera-ture 348 ¹H NMR (400 MHz, DMSO) δ 9.28 (d, J = 2.0 Hz, 1H), 8.85-8.67 (m, 2H), 8.06 (d, J = 9.0 Hz, 1H), 7.88-7.77 (m, 1H), 7.77-7.69 (m, 2H), 7.62-7.54 (m, 2H), 7.51-7.45 (m, 2H), 7.44-7.37 (m, 1H), 4.02 (d, J = 3.9 Hz, 3H). DMSO >98 G12 at room tempera-ture 349 ¹H NMR (400 MHz, DMSO) δ 9.23 (dd, J = 2.1, 0.7 Hz, 1H), 8.80 (dd, J = 5.2, 1.6 Hz, 1H), 8.72-8.64 (m, 1H), 8.09 (d, J = 9.1 Hz, 1H), 7.84-7.71 (m, 4H), 7.66 (dd, J = 8.1, 1.6 Hz, 1H), 7.61-7.54 (m, 1H), 7.52-7.45 (m, 1H), 4.02 (s, 3H). DMSO >98 G12 at room tempera-ture 350 ¹H NMR (400 MHz, DMSO) δ 9.22 (d, J = 1.7 Hz, 1H), 8.87-8.79 (m, 1H), 8.77-8.67 (m, 1H), 8.06 (d, J = 9.2 Hz, 1H), 7.92-7.79 (m, 1H), 7.74 (dd, J = 9.1, 2.9 Hz, 1H), 7.70 (d, J = 2.8 Hz, 1H), 7.45-7.37 (m, 2H), 7.33-7.27 (m, 1H), 7.17-7.09 (m, 1H), 4.01 (s, 3H), 3.71 (s, 3H). DMSO >98 G12 at room tempera-ture 351 ¹H NMR (400 MHz, DMSO) δ 12.03 (s, 1H), 10.69 (s, 1H), 9.65 (d, J = 1.8 Hz, 1H), 9.26-9.21 (m, 1H), 9.20-9.12 (m, 1H), 8.99-8.88 (m, 2H), 8.52 (d, J = 2.6 Hz, 1H), 8.49-8.42 (m, 1H), 8.25-8.17 (m, 1H), 8.15-8.08 (m, 2H), 8.02-7.96 (m, 1H), 7.93 (d, J = 9.4 Hz, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.72 (dd, J = 8.5, 1.9 Hz, 1H), 6.47 (d, J = 9.6 Hz, 1H), 4.04 (s, 3H). DMSO >98 G1 352 ¹H NMR (400 MHz, DMSO) δ 12.04 (s, 1H), 10.92 (s, 1H), 9.65 (d, J = 1.7 Hz, 1H), 9.58-9.50 (m, 1H), 9.46-9.39 (m, 1H), 9.27-9.18 (m, 1H), 9.01-8.92 (m, 2H), 8.88 (dd, J = 5.3, 1.2 Hz, 1H), 8.48 (dd, J = 8.8, 1.9 Hz, 1H), 8.20-8.10 (m, 2H), 8.09-8.01 (m, 2H), 7.93 (d, J = 9.5 Hz, 1H), 7.81-7.72 (m, 2H), 6.47 (d, J = 9.5 Hz, 1H). DMSO >98 G1 353 1H NMR (300 MHz, DMSO) δ 10.90 (s, 1H), 9.63 (s, 1H),. 8.89 (d, J = 8.0 Hz, 1H), 8.76 (d, J = 4.0 Hz, 1H), 8.19 (d, J = 2.1 Hz, 1H), 7.89 (d, J = 9.1 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1H) 7.78-7.65 (m, 2H), 7.63-7.49 (m, 2H), 7.47-7.33 (m, 2H), 3.98 (s, 3H). DMSO >98 G1 354 1H NMR (300 MHz, DMSO) δ 11.44 (s, 1H), 9.58 (d, J = 1.8 Hz, 1H), 9.16 (d, J = 8.2 Hz, 1H), 8.96 (dd, J = 5.3, 1.3 Hz, 1H), 8.29 (d, J = 2.5 Hz, 1H), 8.13 (d, J = 9.2 Hz, 1H), 7.99 (dd, J = 8.0, 5.4 Hz, 1H), 7.72-7.49 (m, 2H), 7.44-7.27 (m, 3H), 7.12 (s, 1H), 3.99 (s, 3H), 2.52 (s, 3H). DMSO >98 G1 355 1H NMR (300 MHz, DMSO) δ 11.38 (s, 1H), 9.53 (s, 1H), 9.18 (d, J = 8.1 Hz, 1H), 8.97 (d, J = 5.3 Hz, 1H), 8.21 (s, 1H), 8.14-8.02 (m, 1H), 7.92 (d, J = 9.1 Hz, 1H), 7.60 (d, J = 9.1 Hz, 1H), 6.90 (s, 1H), 3.99 (s, 3H). DMSO >98 G1 356 1H NMR (300 MHz, DMSO) δ 11.30 (s, 1H), 9.59 (d, J = 1.8 Hz, 1H), 9.19 (d, J = 8.2 Hz, 1H), 8.97 (dd, J = 5.3, 1.2 Hz, 1H), 8.24 (d, J = 2.5 Hz, 1H), 8.11-7.93 (m, 2H), 7.76-7.54 (m, 4H), 7.40 (t, J = 7.6 Hz, 1H), 7.26 (s, 1H), 7.21 (d, J = 7.4 Hz, 1H), 3.98 (s, 3H), 2.41 (s, 3H). DMSO >98 G1 357 1H NMR (300 MHz, DMSO) δ 11.21 (s, 1H), 9.59 (d, J = 1.7 Hz, 1H), 9.22 (d, J = 8.1 Hz, 1H), 9.02-8.95 (m, 1H), 8.23 (d, J = 2.5 Hz, 1H), 8 13-7.96 (m, 3H), 7.85 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 8.7 Hz, 2H), 7.60 (dd, J = 9.1, 2.6 Hz, 1H), 7.31 (s, 1H), 3.98 (s, 3H). DMSO >98 G1 358 1H NMR (300 MHz, DMSO) δ 10.87 (s, 1H), 9.65-9.55 (m, 1H), 8.93 (dt, J = 8.0, 1.8 Hz, 1H), 8.81 (dd, J = 5.0, 1.6 Hz, 1H), 8.18 (d, J = 2.6 Hz, 1H), 7.94-7.,82 (m, 4H), 7.78 (dd, J = 8.0, 5.0 Hz, 1H), 7.60-7.46 (m, 4H), .44-7.35 (m, 1H), 7.32 (s, 1H), 3.98 (s, 3H). DMSO >98 G1 359 H NMR (300 MHz, DMSO) δ 11.29 (s, 1H), 9.59 (s, 1H), 9.20 (d, J = 8.1 Hz, 1H), 9.01-8.94 (m, 1H), 8.25 (s, 1H), 8.12- 7.98 (m, 2H), 7.90-7.75 (m, 2H), 7.62 (d, J = 9.1 Hz, 1H), 7.21 (s, 1H), 7.08 (d, J = 8.6 Hz, 2H), 3.99 (s, 3H), 3.84 (s, 3H). DMSO >98 G1 360 1H NMR (300 MHz, DMSO) δ 11.29 (s, 1H), 9.60 (s, 1H), 9.21 (d, J = 8.0 Hz, 1H), 8.99 (d, J = 5.3 Hz, 1H), 8.26 (d, J = 2.2 Hz, 1H), 8.11-7.99 (m, 2H), 7.77 (d, J = 8.0 Hz, 2H), 7.62 (dd, J = 9.1, 2.4 Hz, 1H), 7.32 (d, J = 8.1 Hz, 2H), 7.26 (s, 1H), 3.99 (s, 3H), 2.37 (s, 3H). DMSO >98 G1 361 1H NMR (300 MHz, DMSO) δ 11.00 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 8.96 (dt, J = 8.1, 1.7 Hz, 1H), 8.86 (dd, J = 5.1, 1.5 Hz, 1H), 8.19 (d, J = 2.6 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H), 7.83 (dt, J = 9.5, 4.8 Hz, 1H), 7.55 (dd, J = 9.1, 2.6 Hz, 1H), 6.72 (s, 1H), 3.95 (d, J = 7.0 Hz, 3H), 2.35 (d, J = 3.5 Hz, 3H). DMSO >98 G1 362 H NMR (300 MHz, DMSO) δ 11.21 (s, 1H), 9.58 (d, J = 1.5 Hz, 1H), 9.21-9.06 (m, 1H), 8.95 (d, J = 4.3 Hz, 1H), 8.22 (d, J = 2.3 Hz, 1H), 8.09-7.92 (m, 2H), 7.70-7.51 (m, 3H), 7.24-7.17 (m, 1H), 7.13 (s, 1H), 3.99 (s, 3H). DMSO >98 G1 363 1H NMR (300 MHz, DMSO) δ 11.07 (s, 1H), 9.60 (s, 1H), 9.13 (d, J = 6.5 Hz, 1H), 8.93 (d, J = 5.1 Hz, 1H), 8.23 (s, 1H), 8.05-7.85 (m, 4H), 7.67-7.54 (m, 1H), 7.43-7.23 (m, 3H), 3.99 (s, 3H). DMSO >98 G1 364 1H NMR (300 MHz, DMSO) δ 11.16 (s, 1H), 9.57 (d, J = 1.5 Hz, 1H), 9.14 (d, J = 8.1 Hz, 1H), 8.93 (d, J = 5.2 Hz, 1H), 8.18 (d, J = 2.4 Hz, 1H), 8.03-7.89 (rn, 4H), 7.61-7.54 (m, 2H), 7.32 (s, 1H), 3.97 (s, 3H). DMSO >98 G1 365 1H NMR (300 MHz, DMSO) δ 11.29 (s, 1H), 9.58 (d, J = 1.6 Hz,. 1H), 9.27 (d, J = 8.2 Hz, 1H), 9.06- 8.99 (m, 1H), 8.18 (d, J = 2.5 Hz, 1H), 8.10 (dd, J = 8.1, 5.5 Hz, 1H), 8.02 (d, J = 9.1 Hz, 1H), 7.91 (dd, J = 10.7, 1.8 Hz, 1H), 7.80-7.65 (m, 2H), 7.57 (dd, J = 9.1, 2.6 Hz, 1H), 7.29 (s, 1H), 3.96 (s, 3H). DMSO >98 G1 366 1H NMR (300 MHz, DMSO) δ 11.17 (s, 1H), 9.60 (s, 1H), 9.24 (d, J = 8.2 Hz, 1H), 8.98 (d, J = 5.1 Hz, 1H), 8.22 (d, J = 2.5 Hz, 1H), 8.11-8.04 (m, 1H), 8.02-7.91 (m, 2H), 7.82-7.68 (m, 2H), 7.62 (dd, J = 9.1, 2.5 Hz, 1H), 7.36 (s, 1H), 4.01 (d, J = 11.0 Hz, 3H). DMSO >98 G1 367 1H NMR (300 MHz, DMSO) δ 11.53 (s, 1H), 9.58 (d, J = 1.8 Hz, 1H), 9.20 (d, J = 8.2 Hz, 1H), 8.98 (dd, J = 5.3, 1.3 Hz, 1H), 8.25 (d, J = 2.5 Hz, 1H), 8.12 (d, J = 9.1 Hz, 1H), 8.04-7.95 (rn, 1H), 7.80-7.68 (rn, 2H), 7.63-7.57 (rn, 1H), 7.56-7.48 (rn, 1H), 7.31 (s, 1H), 3.99 (d, J = 6.7 Hz, 3H). DMSO >98 G1 368 1H NMR (300 MHz, DMSO) δ 11.24 (s, 1H), 9.59 (d, J = 1.7 Hz, 1H), 9.26 (d, J = 8.3 Hz, 1H), 9.00 (d, J = 4.2 Hz, 1H), 8.23 (d, J = 2.6 Hz, 1H), 8.16 (d, J = 2.0 Hz, 1H), 8.09 (dd, J = 8.1, 5.4 Hz, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.91 (dd, J = 8.4, 2.1 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.62 (dd, J = 9.1, 2.5 Hz, 1H), 7.37 (s, 1H), 3.98 (s, 3H). DMSO >98 G1 369 1H NMR (300 MHz, DMSO) δ 11.33 (s, 1H), 9.62 (s, 1H), 9.27 (d, J = 8.4 Hz, 1H), 9.01 (d, J = 5.2 Hz, 1H), 8.29-8.19 (m, 3H), 8.13-8.01 (m, 2H), 7.79-7.73 (m, 2H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.42 (s, 1H), 3.99 (s, 3H). DMSO >98 G1 370 1H NMR (300 MHz, DMSO) δ 11.31 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 9.07 (d, J = 7.9 Hz, 1H), 8.92 (d, J = 4.0 Hz, 1H), 8.26 (d, J = 2.5 Hz, 1H), 8.04 (d, J = 9.1 Hz, 1H), 7.98-7.68 (m, 5H), 7.63 (dd, J = 9.2, 2.5 Hz, 1H), 7.13 (s, 1H), 4.00 (s, 3H). DMSO >98 G1 371 1H NMR (300 MHz, CDCl3) δ 11.29 (s, 1H), 9.57 (d, J = 1.8 Hz, 1H), 9.07 (d, J = 8.1 Hz, 1H), 8.93 (dd, J = 5.2, 1.3 Hz, 1H), 8.25 (d, J = 2.5 Hz, 1H), 8.07-7.97 (m, 2H), 7.92 (dd, J = 8.0, 5.3 Hz, 1H), 7.67-7.51 (m, 4H), 7.28 (s, 1H), 3.99 (s, 3H). DMSO >98 G1 372 1H NMR (300 MHz, DMSO) δ 11.32 (s, 1H), 9.60 (d, J = 1.7 Hz, 1H), 9.27 (d, J = 8.1 Hz, 1H), 9.03 (d, J = 5.4 Hz, 1H), 8.22 (d, J = 2.5 Hz, 1H), 8.12 (dd, J = 8.1, 5.7 Hz, 1H), 8.03 (d, J = 8.8 Hz, 3H), 7.59 (dd, J = 9.1, 2.5 Hz, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.32 (s, 1H), 3.98 (d, J = 6.7 Hz, 3H). DMSO >98 G1 373 1H NMR (300 MHz, DMSO) δ 11.38 (s, 1H), 9.61 (d, J = 1.6 Hz, 1H), 9.26 (d, J = 8.2 Hz, 1H), 9.02 (d, J = 5.3 Hz, 1H), 8.23 (d, J = 2.4 Hz, 1H), 8.12-8.01 (m, 2H), 7.95 (d, J = 8.0 Hz, 1H), 7.89 (s, 1H), 7.71-7.56 (m, 2H), 7.45-7.33 (m, 2H), 4.10-3.90 (m, 3H). DMSO >98 G1 374 1H NMR (300 MHz, DMSO) δ 11.29 (s, 1H), 9.56 (s, 1H), 9.12 (d, J = 7.7 Hz, 1H), 8.94 (d, J = 4.9 Hz, 1H), 8.26 (d, J = 2.3 Hz, 1H), 8.07-7.90 (m, 2H), 7.71-7.57 (m, 2H), 7.51 (s, 1H), 7.47-7.37 (m, 1H), 7.17 (s, 1H), 3.99 (s, 3H), 2.53 (s, 3H). DMSO >98 G1 375 1H NMR (300 MHz, DMSO) δ 13.13-11.88 (m, 1H), 9.66 (d, J = 1.4 Hz, 1H), 9.36 (d, J = 8.2 Hz, 1H), 9.00 (d, J = 5.4 Hz, 1H), 8.38 (d, J = 2.2 Hz, 1H), 8.14 (dd, J = 8.1, 5.6 Hz, 1H), 8.01 (d, J = 7.5 Hz, 2H), 7.89 (d, J = 9.1 Hz, 1H), 7.78 (s, 1H), 7.64-7.35 (m, 9H), 5.23 (s, 2H). DMSO >98 J NaOtBu, Pd(OAc)2, Tri-t-butyl- phos- phonium tetrafluoro- borate, Toluene 376 1H NMR (300 MHz, DMSO) δ 12.49 (s, 1H), 9.63 (s, 1H), 9.27 (d, J = 8.1 Hz, 1H), 8.96 (d, J = 5.4 Hz, 1H), 8.34 (s, 1H), 8.07 (dd, J = 8.1, 5.6 Hz, 1H), 7.99 (d, J = 3.3 Hz, 2H), 7.85 (d, J = 9.1 Hz, 1H), 7.80 (s, 1H), 7.64-7.35 (m, 9H), 5.21 (s, 2H). DMSO >98 J NaOtBu, Pd(OAc)2, Tri-t-butyl- phos- phonium tetrafluoro- borate, Toluene 377 1H NMR (300 MHz, DMSO) δ 9.56 (d, J = 1.8 Hz, 1H), 9.30-9.21 (m, 1H), 9.01 (dd, J = 5.5, 1.2 Hz, 1H), 8.18-8.03 (m, 2H), 7.76-7.64 (m, 2H), 7.55-7.45 (m, 2H), 7.33 (dd, J = 8.6, 2.3 Hz, 1H), 4.69 (t, J = 7.9 Hz, 2H), 3.92 (s, 3H), 3.26 (t, J = 7.8 Hz, 2H). DMSO >98 G8 378 1H NMR (300 MHz, DMSO) δ 9.54 (d, J = 1.9 Hz, 1H), 8.70-8.65 (m, 2H), 7.95 (d, J = 9.2 Hz, 1H), 7.66-7.50 (m, 2H), 7.45-7.36 (m, 2H), 7.27 (t, J = 8.0 Hz, 1H), 7.07 (d, J = 7.9 Hz, 1H), 4.61 (t, J = 8.1 Hz, 2H), 3.87 (s, 3H), 3.38-3.17 (m, 5H). DMSO >98 G8 at 50° C. 379 1H NMR (400 MHz, DMSO) δ 9.54 (d, J = 1.9 Hz, 1H), 9.28-9.18 (m, 1H), 8.99 (dd, J = 5.5, 1.3 Hz, 1H), 8.18-8.02 (m, 2H), 7.69 (dd, J = 9.2, 2.7 Hz, 1H), 7.58-7.46 (m, 2H), 7.39 (dd, J = 8.2, 5.9 Hz, 1H), 6.96-6.85 (m, 1H), 4.71 (t, J = 8.0 Hz, 2H), 3.92 (s, 3H), 3.22 (t, J = 7.8 Hz, 2H). DMSO >98 G8 at 50° C. 380 1H NMR (300 MHz, DMSO) δ 9.55 (d, J = 1.8 Hz, 1H), 9.11 (d, J = 8.1 Hz, 1H), 8.93 (dd, J = 5.3, 1.4 Hz, 1H), 8.10-7.93 (m, 2H), 7.76 (dd, J = 8.7, 4.7 Hz, 1H), 7.67 (dd, J = 9.2, 2.6 Hz, 1H), 7.52 (d, J = 2.6 Hz, 1H), 7.28 (dd, J = 8.4, 2.6 Hz, 1H), 7.12 (td, J = 9.0, 2.7 Hz, 1H), 4.70 (t, J = 7.9 Hz, 2H), 3.92 (s, 3H), 3.26 (t, J = 7.5 Hz, 2H). DMSO >98 G8 at 50° C. 381 1H NMR (300 MHz, DMSO) δ 9.66 (d, J = 2.0 Hz, 1H), 9.15-9.06 (m, 1H), 8.91 (dd, J = 5.2. 1.5 Hz, 1H), 8.27-8.17 (m, 2H), 8.01 (d, J = 8.9 Hz, 1H), 7.94 (dd, J = 8.2, 5.2 Hz, 1H), 7.88-7.78 (m, 2H), 7.42 (d, J = 2.7 Hz, 1H), 7.35 (dd, J = 8.8, 2.2 Hz, 1H), 6.96 (d, J = 3.5 Hz, 1H), 3.91 (s, 3H). DMSO >98 G8 at 50° C. 382 1H NMR (300 MHz, DMSO) δ 9.56 (d, J = 1.6 Hz, 1H), 9.26 (d, J = 8.2 Hz, 1H), 9.05-8.98 (m, 1H), 8.20-8.02 (m, 2H), 7.69 (dd, J = 9.2, 2.7 Hz, 1H), 7.53-7.40 (m, 2H), 7.32 (dd, J = 14.0, 8.0 Hz, 1H), 6.92 (t, J = 8.5 Hz, 1H), 4.71 (t, J = 7.9 Hz, 2H), 3.91 (s, 3H), 3.28 (t, J = 7.8 Hz, 2H). DMSO >98 G8 at 50° C. 383 1H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.5 Hz, 1H), 9.23-9.09 (m, 1H), 8.93 (dd, J = 5.3, 1.5 Hz, 1H), 8.31-8.16 (m, 2H), 8.08-7.93 (m, 2H), 7.82 (dd, J = 9.2, 2.8 Hz, 1H), 7.56 (dd, J = 9.4, 2.5 Hz, 1H), 7.43 (d, J = 2.7 Hz, 1H), 7.19 (td, J = 9.2, 2.7 Hz, 1H), 7.02-6.89 (m, 1H), 3.91 (s, 3H). DMSO >98 G8 at 50° C. 384 1H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.6 Hz, 1H), 9.23- 9.09 (m, 1H), 8.94 (dd, J = 5.3, 1.5 Hz, 1H), 8.26-8.14 (m, 2H), 8.00 (dd, J = 8.1, 5.3 Hz, 1H), 7.90-7.73 (m, 3H), 7.45 (d, J = 2.7 Hz, 1H), 7.25-7.10 (m, 1H), 6.98 (d, J = 3.5 Hz, 1H), 3.92 (s, 3H). DMSO >98 G8 at 50° C. 385 1H NMR (300 MHz, DMSO) δ 9.54 (d, J = 1.8 Hz, 1H), 9.21 (dt, J = 8.2, 1.6 Hz, 1H), 8.98 (dd, J = 5.5, 1.3 Hz, 1H), 8.20-8.00 (m, 2H), 7.68 (dd, J = 9.2, 2.7 Hz, 1H), 7.55-7.31 (m, 3H), 7.00-6.78 (m, 1H), 4.69 (t, J = 7.9 Hz, 2H), 4.19 (q, J = 7.0 Hz, 2H), 3.22 (t, J = 7.9 Hz, 2H), 1.41 (t, J = 6.9 Hz, 3H). DMSO >98 G8 at 50° C. 386 1H NMR (300 MHz, DMSO) δ 9.42 (d, J = 1.5 Hz, 1H), 9.06 (d, J = 8.1 Hz, 1H), 8.93 (d, J = 5.4 Hz, 1H), 8.09-7.99 (m, 2H), 7.68 (dd, J = 9.1, 2.7 Hz, 1H), 7.53 (d, J = 2.6 Hz, 1H), 7.30-7.16 (m, 3H), 4.66 (t, J = 7.9 Hz, 2H), 3.98 (s, 3H), 3.29 (t, J = 7.7 Hz, 2H). DMSO >98 G8 at 50° C. 387 1H NMR (300 MHz, DMSO) δ 9.37 (d, J = 1.4 Hz, 1H), 9.11 (d, J = 8.2 Hz, 1H), 8.99 (d, J = 4.9 Hz, 1H), 8.14 (dd, J = 8.2, 5.6 Hz, 1H), 8.06 (d, J = 9.2 Hz, 1H), 7.70 (dd, J = 9.2, 2.6 Hz, 1H), 7.51 (d, J = 2.7 Hz, 1H), 7.45-7.36 (m, 2H), 7.26-7.15 (m, 1H), 4.83 (d, J = 9.5 Hz, 1H), 4.49- 4.38 (m, 2H), 4.00 (s, 3H), 3.48-3.28 (m, 1H), 3.27-3.05 (m, 1H). DMSO >98 G8 at 50° C. 388 1H NMR (400 MHz, DMSO) δ 9.56 (d, J = 1.9 Hz, 1H), 9.31-9.19 (m, 1H), 9.00 (dd, J = 5.5, 1.3 Hz, 1H), 8.21-8.02 (rn, 2H), 7.73-7.64 (m, 2H), 7.47 (dd, J = 5.4, 2.4 Hz, 2H), 7.32 (dd, J = 8.6, 2.3 Hz, 1H), 4.67 (t, J = 8.0 Hz, 2H), 4.18 (q, J = 7.0 Hz, 2H), 3.26 (t, J = 7.8 Hz, 2H), 1.41 (t, J = 6.9 Hz, 3H). DMSO >98 G8 at 50° C. 389 1H NMR (400 MHz, DMSO) δ 9.54 (d, J = 1.8 Hz, 1H), 9.25 (dt, J = 8.2, 1.6 Hz, 1H), 9.04 (dd, J = 5.5, 1.1 Hz, 1H), 8.26 (d, J = 2.1 Hz, 1H), 8.16 (dd, J = 8.0, 5.6 Hz, 1H), 8.11-7.96 (m, 2H), 7.91 (d, J = 8.6 Hz, 1H), 7.47 (d, J = 2.1 Hz, 1H), 7.34 (dd, J = 8.6, 2.3 Hz, 1H), 4.68 (t, J = 7.9 Hz, 2H), 3.25 (t, J = 7.8 Hz, 2H). DMSO >98 G8 at 50° C. 390 ¹H NMR (400 MHz, DMSO) δ 9.37 (d, J = 1.4 Hz, 1H), 8.82 (dd, J = 5.1, 1.5 Hz, 1H), 8.76 {dd, J = 8.1 Hz, 1H), 8.62 (d, J = 1.9 Hz, 1H), 8.46 (dd, J = 8.8, 2.1 Hz, 1H), 8.20 (d, J = 8.7 Hz, 1H), 7.91 (dd, J = 6.3, 2.6 Hz, 1H), 7.80 (dd, J = 8.0, 5.1 Hz, 1H), 7.71-7.59 (m, 2H), 7.52-7.38 (m, 3H), 7.10-7.01 (m, 1H), 3.89 (s, 3H). DMSO >98 G8 with DMF instead of THF 391 1H NMR (400 MHz, DMSO) δ 9.383 (d, J = 1.4 Hz, 1H), 8.82 (d, J = 5.1 Hz, 1H), 8.76 (d, J = 7.9 Hz, 1H), 8.63 (d, J = 1.8 Hz, 1H), 8.46 (dd, J = 8.8, 2.2 Hz, 1H), 8.20 (d, J = 8.7 Hz, 1H), 7.97 (d, J = 2.7 Hz, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.84-7.76 (m, 1H), 7.64 (dd, J = 8.8, 2.7 Hz, 1H), 7.52-7.39 (m, 3H), 7.10- 7.02 (m, 1H), 3.88 (s, 3H). DMSO >98 G8 with DMF instead of THF 392 ¹H NMR (400 MHz, DMSO) δ 9.39 (t, J = 3.2 Hz, 1H), 8.93-8.82 (m, 2H), 8.62 (d, J = 1.8 Hz, 1H), 8.47 (dd, J = 8.8, 2.2 Hz, 1H), 8.21 (d, J = 9.0 Hz, 1H), 7.91 (dd, J = 8.1, 5.3 Hz, 1H), 7.84- 7.77 (m, 1H), 7.73-7.63 (m, 1H), 7.53-7.40 (m, 4H), 7.09-7.03 (m, 1H), 3.87 (d, J = 6.5 Hz, 3H). DMSO >98 G8 with DMF instead of THF 393 ¹H NMR (400 MHz, DMSO) δ 11.71 (s, 1H), 11.10 (s, 1H), 9.42 (d, J = 1.9 Hz, 1H), 8.90-8.69 (m, 2H), 8.62 (d, J = 1.7 Hz, 1H), 8.40 (dd, J = 8.8, 1.9 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.84-7.69 (m, 1H), 7.57-7.40 (m, 3H), 7.11- 7.02 (m, 2H), 6.96 (d, J = 8.3 Hz, 1H), 3.89 (s, 3H). DMSO >98 G8 with DMF instead of THF 394 ¹H NMR (400 MHz, DMSO) δ 9.43-9.29 (m, 1H), 8.75-8.64 (m, 2H), 8.60-8.48 (m, 1H), 8.47-8.32 (m, 1H), 8.21-8.01 (m, 2H), 7.86-7.74 (m, 2H), 7.64 (d, J = 8.6 Hz, 1H), 7.59-7.34 (m, 4H), 7.13-7.01 (m, 1H), 6.87 (d, J = 8.7 Hz, 1H), 3.90 (t, J = 5.3 Hz, 3H). DMSO >98 G8 with DMF instead of THF 395 ¹H NMR (400 MHz, DMSO) δ 9.24 (dd, J = 2.2, 0.8 Hz, 1H), 8.76 (dd, J = 5.0, 1.7 Hz, 1H), 8.61-8.54 (m, 1H), 8.49 (dd, J = 1.8, 1.1 Hz, 1H), 8.21-8.12 (m, 2H), 7.75 (dd, J = 8.0, 1.5 Hz, 1H), 7.70-7.62 (m, 2H), 7.62-7.53 (m, 1H), 7.53-7.44 (m, 1H). DMSO >98 G8 with DMF instead of THF 396 ¹H NMR (400 MHz, DMSO) δ 11.71 (s, 1H), 11.10 (s, 1H), 9.42 (d, J = 1.9 Hz, 1H), 8.90-8.69 (m, 2H), 8.62 (d, J = 1.7 Hz, 1H), 8.40 (dd, J = 8.8, 1.9 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.84-7.69 (m, 1H), 7.57-7.40 (m, 3H), 7.11-7.02 (m, 2H), 6.96 (d, J = 8.3 Hz, 1H), 3.89 (s, 3H). DMSO >98 G12 397 ¹H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.99 (d, J = 8.2 Hz, 1H), 8.88 (dd, J = 5.3, 1.5 Hz, 1H), 8.30 (d, J = 2.5 Hz, 1H), 8.14-8.06 (m, 1H), 7.99-7.88 (m, 2H), 7.78 -7.66 (m, 2H), 7.61-7.51 (m, 3H), 7.50-7.34 (m, 3H), 5.34 (s, 2H). DMSO >98 Method G1 398 ¹H NMR (400 MHz, DMSO) δ 9.96 (s, 1H), 9.52 (d, J = 1.4 Hz, 1H), 8.68 (dd, J = 9.9 Hz, 1H), 8.65 (d, J = 9.9 Hz, 1H), 8.16 (dd, J = 2.5, 5.4 Hz, 2H), 7.68-7.41 (m, 2H), 7.78-7.66 (m, 8H), 7.39-7.19 (m, 1H), 5.30 (s, 2H). DMSO >98 Method G1 399 1H NMR (DMSO-d6) pprn 12.52 (s, 1H), 9.78 (d, J = 1.56 Hz, 1H), 8.91-8.88 (m, 1H), 8.74 (dd, J = 4.74, 1.60 Hz, 1H), 8.33 (brs, 1H), 8.06 (d, J = 8.56 Hz, 2H), 7.93 (d, J = 9.08 hz, 1H), 7.89 (s, 1H), 7.66-7.59 (rn, 2H), 7.55 (d, J = 8.56 Hz, 2H), 4.01 (s, 3H). DMSO >98 G13 400 1H NMR (DMSO-d6) ppm 12.80-12.40 (br, 1H), 9.77 (d, J = 1.84 Hz, 1H), 9.32 (d, J = 8.04 Hz, 1H), 8.97 (dd, J = 5.36, 1.40 Hz, 1H), 8.34 (d, J = 2.68 Hz, 1H), 8.09-8.06 (m, 3H), 7.97 (d, J = 9.12 Hz, 1H), 7.91 (s, 1H), 7.64 (dd, J = 9.12, 2.68 Hz, 1H), 7.55 (d, J = 8.60 Hz, 2H), 4.01 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 401 1H NMR (DMSO-d6) ppm 11.14 (brs, 1H), 9.58 (s, 1H), 9.13 (dd, J = 7.96 Hz, 1H), 8.93 (d, J = 5.24 Hz, 1H), 8.54 (d, J = 4.72 Hz, 1H), 8.48 (d, J = 8.32 Hz, 1H), 8.28 (brs, 1H), 8.09 (brt, J = 7.16 Hz, 1H), 8.02-7.96 (m, 2H), 7.65 (dd, J = 8.80, 2.48 Hz, 1H), 7.34 (brt, J = 6.52 Hz, 1H), 4.01 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 J2 402 1H NMR (DMSO-d6) ppm 10.89 (s, 1H), 9.57 (d, J = 1.60 Hz, 1H), 9.04 (d, J = 8.04 Hz, 1H), 8.88 (dd, J = 5.16, 1.40 Hz, 1H), 8.55 (dd, J = 2.64, 0.52 Hz, 1H), 8.50 (d, J = 8.92 Hz, 1H), 8.22 (d, J = 2.68 Hz, 1H), 8.08 (d, J = 8.92, 2.68 Hz, 1H), 7.94-7.90 (m, 2H), 7.61 (dd, J = 9.08, 2.68 Hz, 1H), 3.99 (s, 3H). The 1H of 2HCl was not observed. DMSO DMSO J2 403 1H NMR (DMSO-d6) ppm 10.53 (s, 1H), 9.38 (s, 1H), 8.99 (d, J = 8.08 Hz, 1H), 8.88 (d, J = 4.60 Hz, 1H), 8.11 (brs, 1H), 8.01-7.95 (m, 2H), 7.90 (d, J = 8.60 Hz, 2H), 7.66 (dd, J = 9.12, 2.68 Hz, 1H), 7.50 (d, J = 8.60 Hz, 2H), 6.93 (s, 1H), 4.00 (s, 3H), 3.80 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 J2 404 1H NMR (DMSO-d6) ppm 11.81 (brs, 1H), 9.64 (s, 1H), 9.00 (d, J = 7.48 Hz, 1H), 8.85 (brs, 1H), 8.14 (d, J = 2.56 Hz, 1H), 8.00 (d, J = 8.60 Hz, 2H), 7.96 (d, J = 9.08 Hz, 1H), 7.86 (br, 1H), 7.66-7.63 (m, 3H), 7.25 (s, 1H), 4.00 (s, 3H). The 1H of HCl was not observed. DMSO >98 J2 405 1H NMR (DMSO-d6) ppm 11.80 (brs, 1H), 9.55 (brs, 1H), 9.04 (d, J = 7.92 Hz, 1H), 8.88 (brs, 1H), 8.14 (d, J = 2.60 Hz, 1H), 8.05-8.02 (m, 2H), 7.96 (d, J = 9.12 Hz, 1H), 7.89 (m, 1H), 7.64 (dd, J = 9.12, 2.60 Hz, 1H), 7.42 (t, J = 8.84 Hz, 2H), 7.23 (s, 1H), 3.99 (s, 3H). The 1H of HCl was not observed. DMSO >98 J2 406 1H NMR (DMSO-d6) ppm 10.31 (s, 1H), 9.37 (s, 1H), 8.88 (m, 2H), 8.04 (d, J = 2.60 Hz, 1H), 7.94 (d, J = 9.12 Hz, 1H), 7.91 (m, 1H), 7.64 (dd, J = 9.12, 2.68 Hz, 1H), 7.56 (d, J = 1.83 Hz, 1H), 6.40 (d, J = 1.88 Hz, 1H), 3.98 (s, 3H), 3.74 (s, 3H) . The 1H of HCl was not observed. DMSO >98 J2 407 1H NMR (DMSO-d6) ppm 12.89 (brs, 1H), 9.56 (s, 1H), 8.92 (d, J = 4.92 Hz, 2H), 8.04 (d, J = 8.84 Hz, 1H), 7.98 (d, J = 2.88 Hz, 1H), 7.84 (br, 1H), 7.71-7.66 (m, 3H), 7.45-7.39 (m, 2H), 4.00 (s, 3H), 3.94 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 J2 408 1H NMR (DMSO-d6) ppm 10.39 (s, 1H), 9.38 (s, 1H), 8.90 (d, J = 8.00 Hz, 1H), 8.84 (d, J = 4.76 hz, 1H), 8.06 (d, J = 2.68 Hz, 1H), 7.95 (d, J = 9.16 Hz, 1H), 7.90-7.88 (m, 3H), 7.65 (dd, J = 9.16, 2.68 Hz, 1H), 7.44 (brt, J = 7.40 Hz, 2H), 7.35-7.31 (m, 1H), 6.88 (s, 1H), 3.99 (s, 3H), 3.80 (s, 3H). The 1H of HCl was not observed. DMSO >98 J2 Tempera-ture at 100° C. 409 1H NMR (DMSO-d6) ppm 10.44 (brs, 1H), 9.01 (s, 1H), 8.68 (brs, 1H), 8.39 (brs, 1H), 8.23 (s, 1H), 8.07 (brs, 1H), 7.84 (d, J = 9.04 Hz, 1H), 7.70-7.54 (m, 2H), 7.44 (brd, J = 7.32 Hz, 2H), 7.15 (brt, J = 7.56 Hz, 2H), 7.00 (brt, 7.40 Hz, 1H), 3.97 (s, 3H), 3.93 (s, 3H). The 1H of HCl was not observed. DMSO >98 J2 Tempera-ture at 100° C. 410 1H NMR (DMSO-d6) ppm 11.13 (s, 1H), 9.59 (d, J = 1.64 Hz, 1H), 9.03 (brs, 1H), 8.88 (brs, 1H), 8.63 (d, J = 2.52 Hz, 1H), 8.23 (d, J = 2.32 Hz, 1H), 7.93-7.82 (brm, 4H), 7.61-7.53 (m, 3H), 7.35-7.31 (brm, 2H), 4.00 (s, 3H). The 1H of HCl was not observed. DMSO >98 J2 Tempera-ture at 100° C. 411 1H NMR (DMSO-d6) ppm 9.54 (s, 1H), 8.79 (s, 1H), 8.69 (d, J = 7.60 Hz, 1H), 7.89 (brd, J = 8.96 Hz, 2H), 7.68-7.58 (m, 4H), 7.38-7.30 (m, 2H), 3.98 (s, 3H). The 1H of NH— was not observed. DMSO >98 J2 Tempera-ture at 100° C. 412 1H NMR (DMSO-d6) ppm 9.70 (s, 1H), 9.05 (d, J = 7.88 Hz, 1H), 8.85 (brd, J = 4.44 Hz, 1H), 8.24 (brs, 1H), 8.04 (d, J = 8.44 Hz, 2H), 7.94 (d, J = 9.00 Hz, 1H), 7.84 (m, 1H), 7.66 (d, J = 8.44 Hz, 2H), 7.62 (dd, J = 9.00, 2.64 Hz, 1H), 3.99 (s, 3H). The 1H of HCl and NH— were not observed. DMSO >98 G12 Tempera-ture at 100° C. 413 1H NMR (CDCl3) ppm 15.18 (brs, 1H), 9.57 (d, J = 2.32 Hz, 1H), 8.86 (dd, J = 4.80, 1.56 Hz, 1H), 8.59-8.56 (m, 1H), 7.78-7.73 (m, 4H), 7.55-7.52 (m, 1H), 7.43 (d, J = 8.56 Hz, 2H), 7.38 (dd, J = 8.88, 2.96 Hz, 1H), 7.34 (s, 1H), 3.97 (s, 3H), 3.30 (s, 3H), 3.11 (s, 3H). CDCl3 >98 J2 Tempera-ture at 100° C. Salt Number Starting Material 1 Starting Material 2 Product type 414

2 HCl 415

2 HCl 416

HCl 417

HCl 418

HCl 419

HCl 420

HCl 421

422

HCl 423

HCl 424

HCl 425

HCl 426

HCl 427

HCl 428

4 HCl 429

HCl 430

2 HCl 431

HCl 432

HCl 433

HCl 434

2 HCl 435

2 HCl 436

HCl 437

438

HCl 439

HCl 440

HCl 441

HCl 442

2 HCl 443

2 HCl 444

2 HCl 445

2 HCl 446

HCl 447

2 HCl 448

HCl 449

2 HCl 450

2 HCl 451

HCl 452

HCl 453

2 HCl 454

2 HCl 455

HCl 456

2 HCl 457

HCl 458

HCl 459

HCl 460

2 HCl 461

2 HCl 462

2 HCl 463

2 HCl 464

2 HCl 465

2 HCl 466

2 HCl 467

HCl 468

2 HCl 469

2 HCl 470

HCl 471

2 HCl 472

3 HCl 473

2 HCl 474

475

HCl 476

HCl 477

HCl 478

HCl 479

HCl 480

HCl 481

HCl 482

HCl 483

HCl 484

HCl 485

HCl 486

2 HCl 487

2 HCl 488

2 HCl 489

2 HCl 490

491

492

493

2 HCl 494

495

496

497

2 HCl 498

499

2 HCl 501

HCl 502

503

504

HCl 505

506

507

508

509

510

511

512

513

514

2 HCl 515

HCl 516

517

HCl 518

2 HCl 519

2 HCl 520

HCl 521

HCl 1758

3 HCl 1759

3 HCl ¹H NMR Purity Method Retention LCMS Number ¹H NMR Solvent percent of Coupling LCMS Time Method 414 1H NMR (DMSO-d6) ppm 9.72 (s, 1H), 9.16 (brs, 1H), 8.93 (d, J = 4.36 Hz, 1H), 8.14 (br, 1H), 7.96 (brm, 2H), 7.63 (dd, J = 9.08, 2.56 Hz, 1H), 7.00 (s, 1H), 3.98 (s, 3H), 2.37 (s, 3H). The 1H of 2HCl and NH— were not observed. DMSO >98 G12 Temperature at 100° C. 415 1H NMR (DMSO-d6) ppm 12.60 (brs, 1H), 9.78 (s, 1H), 9.12 (d, J = 8.00 Hz, 1H), 8.86 (brs, 1H), 8.35 (brd, J = 2.60 Hz, 1H), 8.01 (d, J = 8.56 Hz, 2H), 7.96 (d, J = 9.08 Hz, 1H), 7.92 (s, 1H), 7.86 (m, 1H), 7.69 (d, J = 8.56 Hz, 2H), 7.63 (dd, J = 9.08, 2.60 Hz, 1H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G12 Temperature at 100° C. 416 1H NMR (DMSO-d6) ppm 12.80-12.40 (br, 1H), 9.79 (d, J = 1.64 Hz, 1H), 9.16 (d, J = 7.88 Hz, 1H), 8.88 (d, J = 3.88 Hz, 1H), 8.36 (brd, J = 2.64 Hz, 1H), 8.06-8.04 (m, 2H), 7.96 (d, J = 9.08 Hz, 1H), 7.90 (m, 1H), 7.85 (s, 1H), 7.63 (dd, J = 9.08, 2.64 Hz, 1H), 7.49 (m, 2H), 7.38 (m, 1H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G12 Temperature at 100° C. 417 1H NMR (DMSO-d6) ppm 12.80 (s, 1H), 9.74 (d, J = 1.60 Hz, 1H), 9.01 (brs, 1H), 8.83 (brs, 1H), 8.31 (d, J = 2.64 Hz, 1H), 8.15 (d, J = 1.00 Hz, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.78 (br, 1H), 7.64 (dd, J = 9.12, 2.64 Hz, 1H), 3.99 (s, 3H). The 1H of HCl was not observed. DMSO >98 G12 Temperature at 100° C. 418 1H NMR (DMSO-d6) ppm 12.60 (br, 1H), 9.79 (d, J = 1.72 Hz, 1H), 9.19 (d, J = 8.00 Hz, 1H), 8.93 (dd, J = 5.16, 1.44 Hz, 1H), 8.23 (brs, 1H), 8.10 (s, 1H), 7.99 (m, 1H), 7.95 (d, J = 9.08 Hz, 1H), 7.77-7.75 (br, 2H), 7.62 (dd, J = 9.08, 2.72 Hz, 1H), 7.50 (m, 2H), 7.37 (m, 1H), 3.99 (s, 3H). The 1H of HCl was not observed. DMSO >98 G12 Temperature at 100° C. 419 1H NMR (DMSO-d6) ppm 12.56 (s, 1H), 9.78 (s, 1H), 9.09 (d, J = 8.20 Hz, 1H), 8.84 (d, J = 3.96 Hz, 1H), 8.35 (d, J = 2.60 Hz, 1H), 8.10-8.07 (m, 2H), 7.95 (d, J = 9.12 Hz, 1H), 7.83 (brt, J = 6.60 Hz, 2H), 7.63 (dd, J = 9.12, 2.60 Hz, 1H), 7.32 (m, 2H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G12 Temperature at 100° C. 420 1H NMR (DMSO-d6) ppm 9.74 (s, 1H), 9.04 (d, J = 6.68 Hz, 1H), 8.86 (brs, 1H), 8.29 (brs, 1H), 8.05 (brs, J = 7.44 Hz, 2H), 7.97 (d, J = 9.08 Hz, 1H), 7.89 (br, 1H), 7.67-7.58 (m, 4H), 4.00 (s, 3H). The 1H of HCl and NH— were not observed. DMSO >98 G12 Temperature at 100° C. 421 1H NMR (DMSO-d6) ppm 9.88 (s, 1H), 9.51 (dd, J = 2.16, 0.8 Hz, 1H), 8.68-8.64 (m, 2H), 7.98 (d, J = 2.40 Hz, 1H), 7.91 (d, J = 8.84 Hz, 2H), 7.86 (d, J = 9.12 Hz, 1H), 7.68 (d, J = 8.34 Hz, 2H), 7.58-7.53 (m, 2H), 3.98 (s, 3H). DMSO >98 G1 422 1H NMR (DMSO-d6) ppm 10.24 (br, 1H), 9.54 (s, 1H), 8.92 (d, J = 7.52 Hz, 1H), 8.82 (d, J = 3.96 Hz, 1H), 8.10 (d, J = 2.44 Hz, 1H), 8.03 (d, J = 8.68 Hz, 2H), 7.92 (d, J = 9.08 Hz, 1H), 7.84 (d, J = 8.68 Hz, 2H), 7.81 (m, 1H), 7.77-7.75 (m, 2H), 7.62 (dd, J = 9.08, 2.44 Hz, 1H), 7.50 (m, 2H), 7.38 (m, 1H), 4.01 (s, 3H). The 1H of HCl was not observed. DMSO >98 J3 using Na₂CO₃ instead of K₂CO₃ 423 1H NMR (DMSO-d6) ppm 9.72 (s, 1H), 9.09 (d, J = 8.00 Hz, 1H), 8.89 (d, J = 4.24 Hz, 1H), 8.26 (brs, 1H), 8.12-8.09 (m, 2H), 7.96 (d, J = 9.12 Hz, 1H), 7.91 (m, 1H), 7.64 (dd, J = 9.12, 2.64 Hz, 1H), 7.45 (t, J = 8.80 Hz, 2H), 3.99 (s, 3H). The 1H of HCl and NH— were not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 424 1H NMR (DMSO-d6) ppm 10.30-10.15 (br, 1H), 9.54 (s, 1H), 8.91 (brs, 1H), 8.82 (brs, 1H), 8.10 (brs, 1H), 8.04 (d, J = 8.56 Hz, 2H), 7.92 (d, J = 9.6 Hz, 1H), 7.85 (d, J = 8.56 Hz, 2H), 7.80 (m, 1H), 7.79 (d, J = 8.56 Hz, 2H), 7.65-7.59 (brm, 1H), 7.55 (d, J = 8.56 Hz, 2H), 4.01 (s, 3H). The 1H of HCl was not observed. DMSO >98 J3 425 1H NMR (DMSO-d6) ppm 9.91 (s, 1H), 9.53 (d, J = 1.84 Hz, 1H), 8.69 (d, J = 5.56 Hz, 2H), 8.31 (t, J = 1.88 Hz, 1H), 7.99 (d, J = 2.68 Hz, 1H), 7.98-7.94 (m, 1H), 7.87 (d, J = 9.08 Hz, 1H), 7.60-7.54 (m, 2H), 7.46 (t, J = 8.04 Hz, 1H), 7.39-7.35 (m, 1H), 3.99 (s, 3H). The 1H of HCl was not observed. DMSO >98 G1 426 1H NMR (DMSO-d6) ppm 10.25 (br, 1H), 9.52 (s, 1H), 8.89 (brs, 1H), 8.88 (brs, 1H), 8.22 (brs, 1H), 8.11 (brs, 1H), 7.98-7.92 (brm, 2H), 7.80-7.70 (brm, 3H), 7.63-7.69 (brm, 2H), 7.55-7.50 (brm, 3H), 7.41 (m, 1H), 4.00 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ at 120° C. 427 1H NMR (DMSO-d6) ppm 10.31 (br, 1H), 9.51 (brs, 1H), 8.92 (brd, J = 7.44 Hz, 1H), 8.84 (brs, 1H), 8.22 (brs, 1H), 8.12 (brd, J = 2.28 Hz, 1H), 8.00-7.93 (brm, 2H), 7.83-7.77 (brm, 3H), 7.64-7.54 (brm, 5H), 4.01 (s, 3H). The 1H of HCl was not observed. DMSO >98 J3 using Na₂CO₃ instead of K₂CO₃ 428 1H NMR (DMSO-d6) ppm 9.73 (d, J = 1.72 Hz, 1H), 9.06 (d, J = 8.08 Hz, 1H), 8.88 (d, J = 3.72 Hz, 1H), 8.28 (brs, 1H), 8.01-7.96 (m, 3H), 7.88 (m, 1H), 7.81 (d, J = 8.60 Hz, 2H), 7.65 (dd, J = 9.08, 2.64 Hz, 1H), 4.00 (s, 3H). The 1H of 4HCl and NH— were not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 429 1H NMR (DMSO-d6) ppm 12.60 (br, 1H), 9.78 (d, J = 1.76 Hz, 1H), 9.28 (d, J = 8.04 Hz, 1H), 8.95 (dd, J = 5.20, 1.20 Hz, 1H), 8.36 (d, J = 2.28 Hz, 1H), 8.04-7.93 (m, 4H), 7.77 (s, 1H), 7.64 (dd, J = 9.12, 2.68 Hz, 1H), 7.30 (d, J = 8.04 Hz, 2H), 4.02 (s, 3H), 2.36 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 430 1H NMR (DMSO-d6) ppm 12.70-12.40 (br, 1H), 9.71 (s, 1H), 9.27 (d, J = 8.20 Hz, 1H), 8.94 (d, J = 4.24 Hz, 1H), 8.34 (d, J = 2.64 Hz, 1H), 8.13 (t, J = 1.80 Hz, 1H), 8.04-7.95 (m, 4H), 7.63 (dd, J = 9.08, 2.68 Hz, 1H), 7.52 (t, J = 7.88 Hz, 1H), 7.44-7.42 (m, 1H), 4.02 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 431 1H NMR (DMSO-d6) ppm 12.57 (br, 1H), 9.80 (brs, 1H), 9.04 (d, J = 7.36 Hz, 1H), 8.82 (brs, 1H), 8.34 (brs, 1H), 7.99 (brd, J = 7.28 Hz, 1H), 7.95 (d, J = 9.08 Hz, 1H), 7.82 (brs, 1H), 7.76 (brm, 1H), 7.62 (m, 2H), 7.50-7.41 (m, 2H), 4.00 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 432 1H NMR (DMSO-d6) ppm 10.40 (br, 1H), 9.23 (s, 1H), 8.80 (d, J = 4.68 Hz, 1H), 8.66 (brd, J = 8.20 Hz, 1H), 7.92 (brs, 1H), 7.87 (brd, J = 9.28 Hz, 1H), 7.78 (brm, 1H), 7.63-7.52 (m, 5H), 7.47-7.44 (m, 2H), 7.21-7.12 (m, 3H), 3.91 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 433 1H NMR (DMSO-d6) ppm 12.34 (br, 1H), 9.75 (s, 1H), 9.01 (d, J = 7.52 Hz, 1H), 8.81 (brs, 1H), 8.40-8.20 (br, 1H), 7.92 (d, J = 9.08 Hz, 1H), 7.77 (m, 1H), 7.60 (dd, J = 9.08, 2.72 Hz, 1H), 6.95 (br, 1H), 3.98 (s, 3H), 2.67 (m, 1H), 2.05 (m, 2H), 1.83-1.70 (m, 3H), 1.54-1.23 (m, 5H). The 1H of HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 434 1H NMR (DMSO-d6) ppm 12.58 (br, 1H), 9.79 (s, 1H), 9.19 (d, J = 7.32 Hz, 1H), 8.90 (d, J = 5.6 Hz, 1H), 8.36 (s, 1H), 7.96 (d, J = 9.08 Hz, 1H), 7.94 (m, 1H), 7.88 (s, 1H), 7.65-7.62 (m, 3H), 7.40 (t, J = 8.16 Hz, 1H), 6.96-6.93 (m, 1H), 4.02 (s, 3H), 3,84 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 435 1H NMR (DMSO-d6) ppm 12.80-12.40 (br, 1H), 9.79 (d, J = 1.44 Hz, 1H), 9.26 (d, J = 8.24 Hz, 1H), 8.93 (d, J = 4.08 Hz, 1H), 8.36 (d, J = 2.28 Hz, 1H), 8.02-7.96 (m, 4H), 7.68 (s, 1H), 7.64 (dd, J = 9.12, 2.68 Hz, 1H), 7.05 (d, J = 8.92 Hz, 2H), 4.02 (s, 3H), 3.82 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 436 1H NMR (DMSO-d6) ppm 12.52 (br, 1H), 9.79 (s, 1H), 9.23 (d, J = 8.00 Hz, 1H), 8.91 (d, J = 4.12 Hz, 1H), 8.35 (brs, 1H), 8.25 (d, J = 7.6 Hz, 1H), 7.96 (d, J = 9.08 Hz, 1H), 7.93 (m, 1H), 7.85 (s, 1H), 7.64 (dd, J = 9.08, 2.68 Hz, 1H), 7.39-7.35 (m, 1H), 7.18 (d, J = 7.72 Hz, 1H), 7.11-7.07 (m, 1H), 4.02 (s, 3H), 3.96 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 437 1H NMR (DMSO-d6) ppm 9.94 (s, 1H), 9.27 (d, J = 1.92 Hz, 1H), 8.59 (dd, J = 4.72, 1.68 Hz, 1H), 8.45 (dt, J = 8.04, 1.8 Hz, 1H), 7.96 (d, J = 2.72 Hz, 1H), 7.84 (d, J = 8.28 Hz, 2H), 7.67 (d, J = 8.00 Hz, 1H), 7.55 (m, 2H), 7.46-7.43 (m, 1H), 7.33 (m, 1H), 3.96 (s, 3H). DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ at 120° C. 438 1H NMR (DMSO-d6) ppm 10.48 (br, 1H), 9.23 (s, 1H), 8.83 (brd, J = 3.68 Hz, 1H), 8.70 (brd, J = 7.36 Hz, 1H), 7.95 (brs, 1H), 7.91 (d, J = 9.12 Hz, 1H), 7.82 (m, 1H), 7.63-7.51 (m, 5H), 7.48 (d, J = 8.52 Hz, 2H), 7.26 (d, J = 8.52 Hz, 2H), 3.93 (s, 3H). The 1H of HCl was not observed. DMSO >98 J3 using Na₂CO₃ instead of K₂CO₃ 439 1H NMR (DMSO-d6) ppm 12.60 (br, 1H), 9.78 (s, 1H), 9.17 (d, J = 7.96 Hz, 1H), 8.88 (d, J = 4.20 Hz, 1H), 8.35 (d, J = 2.60 Hz, 1H), 8.24-8.21 (m, 1H), 7.96 (d, J = 9.08 Hz, 1H), 7.91-7.88 (brm, 1H), 7.74 (d, J = 2.48 Hz, 1H), 7.63 (dd, J = 9.08, 2.60 Hz, 1H), 7.47-7.41 (m, 1H), 7.36 8m, 2H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 at 100° C. 440 1H NMR (DMSO-d6) ppm 12.60-12.45 (br, 1H), 9.79 (d, J = 1.52 Hz, 1H), 9.15 (d, J = 8.36 Hz, 1H), 8.88 (d, J = 5.04 Hz, 1H), 8.35 (d, J = 2.44 Hz, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.89 (brt, J = 7.08 Hz, 2H), 7.82 (brm, 1H), 7.81 (s, 1H), 7.63 (dd, J = 9.12, 2.44 Hz, 1H), 7.37 (t, J = 7.64 Hz, 1H), 7.19 (d, J = 7.48 Hz, 1H), 4.02 (s, 3H), 2.40 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 at 100° C. 441 1H NMR (DMSO-d6) ppm 12.60 (br, 1H), 9.77 (s, 1H), 9.25 (d, J = 8.08 Hz, 1H), 8.93 (d, J = 4.28 Hz, 1H), 8.34 (d, J = 2.60 Hz, 1H), 8.01-7.84 (m, 5H), 7.63 (dd, J = 9.12, 2.60 Hz, 1H), 7.56-7.51 (m, 1H), 7.21 (m, 1H). The 1H of HCl was not observed. DMSO >98 G13 at 100° C. 442 1H NMR (DMSO-d6) ppm 12.66 (brs, 1H), 9.78 (d, J = 1.68 Hz, 1H), 9.27 (d, J = 8.08 Hz, 1H), 8.94 (dd, J = 5.20, 1.40 Hz, 1H), 8.36 (d, J = 2.56 Hz, 1H), 8.17 (d, J = 8.84 Hz, 2H), 8.01 (m, 1H), 7.97 (d, J = 9.08 Hz, 1H), 7.93 (s, 1H), 7.64 (dd, J = 9.08, 2.56 Hz, 1H), 7.49 (brd, J = 8.84 Hz, 2H), 4.02 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 at 100° C. 443 1H NMR (DMSO-d6) ppm 12.64 (br, 1H), 9.79 (s, 1H), 9.13 (d, J = 7.56 Hz, 1H), 8.87 (d, J = 5.08 Hz, 1H), 8.36 (d, J = 2.60 Hz, 1H), 8.27 (d, J = 8.00 Hz, 2H), 8.08 (s, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.87 (m, 1H), 7.86 (d, J = 8.00 Hz, 2H), 7.64 (dd, J = 9.12, 2.60 Hz, 1H), 4.02 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 at 100° C. 444 1H NMR (MeOD-d4) ppm 9.79 (s, 1H), 9.37 (br, 1H), 8.49 (dd, J = 5.28, 1.32 Hz, 1H), 8.12 (m, 1H), 8.09 (d, J = 2.72 Hz, 1H), 7,98 (d, J = 9.16 Hz, 1H), 7.68 (dd, J = 9.16, 2.72 Hz, 1H), 7.58 (d, J = 7.12 Hz, 1H), 7.42-7.30 (m, 3H), 7.30 (s, 1H), 4.05 (s, 3H), 2.50 (s, 3H). The 1H of 2HCl was not observed. MeOD >98 G13 445 1H NMR (DMSO-d6) ppm 12.59 (br, 1H), 9.78 (d, J = 1.48 Hz, 1H), 9,19 (d, J = 8.00 Hz, 1H), 8.90 (dd, J = 5.16, 1.48 Hz, 1H), 8.34 (d, J = 2.60 Hz, 1H), 8.10-8.04 (m, 1H), 7.97-7.88 (m, 4H), 7.64 (dd, J = 2.60 Hz, 1H), 7.59-7.52 (m, 1H), 4.02 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 446 1H NMR (DMSO-d6) ppm 12.61 (br, 1H), 9.78 (d, J = 1.72 Hz, 1H), 9.20 (d, J = 7.92 Hz, 1H), 8.90 (d, J = 4.00 Hz, 1H), 8.35 (d, J = 2.60 Hz, 1H), 8.27-8.21 (m, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.93 (m, 1H), 7.71 (d, J = 2.56 Hz, 1H), 7.64 (dd, J = 9.12, 2.60 Hz, 1H), 7.43 (m, 1H), 7.27 (m, 1H), 4.02 (s, 1H). The 1H of HCl was not observed. DMSO >98 G13 447 1H NMR (DMSO-d6) ppm 12.57 (br, 1H), 9.77 (d, J = 1.76 Hz, 1H), 9.25 (d, J = 8.08 Hz, 1H), 8.93 (dd, J = 5.16, 1.2 Hz, 1H), 8.34 (d, J = 2.60 Hz, 1H), 8.29 (t, J = 1.76 Hz, 1H), 8.05 (dd, J = 7.84, 1.12 Hz, 1H), 8.02-7.98 (m, 1H), 7.99 (s, 1H), 7.96 (d, J = 9.08 Hz, 1H), 7.64 (dd, J = 9.08, 2.60 Hz, 1H), 7.58-7.56 (m, 1H), 7.45 (t, J = 7.84 Hz, 1H), 4.02 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 448 1H NMR (DMSO-d6) ppm 12.62 (br, 1H), 9.77 (d, J = 1.52 Hz, 1H), 9.10 (d, J = 8.16 Hz, 1H), 8.85 (dd, J = 5.00, 1.56 Hz, 1H), 8.34 (d, J = 2.60 Hz, 1H), 8.24 (d, J = 8.60 Hz, 2H), 8.13 (s, 1H), 7.96 (d, J = 8.60 Hz, 2H), 7.96 (d, J = 9.08 Hz, 1H), 7.86-7.83 (brm, 1H), 7.63 (dd, J = 9.08, 2.60 Hz, 1H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 449 1H NMR (DMSO-d6) ppm 12.56 (brs, 1H), 9.79 (brs, 1H), 9.11 (d, J = 8.04 Hz, 1H), 8.87 (brs, 1H), 8.43 (brs, 1H), 8.34 (brs, 2H), 8.09 (s, 1H), 7.96 (d, J = 9.08 Hz, 1H), 7.87 (brs, 1H), 7.74 (brd, J = 5.00 Hz, 2H), 7.64 (dd, J = 9.08, 2.48 Hz, 1H), 4.03 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 at 100° C. 450 1H NMR (DMSO-d6) ppm 12.63 (br, 1H), 9.80 (d, J = 1.72 Hz, 1H), 9.27 (d, J = 8.16 Hz, 1H), 8.93 (dd, J = 5.20, 1.36 Hz, 1H), 8.33 (d, J = 2.24 Hz, 1H), 7.99 (m, 1H), 7.98 (d, J = 9.08 Hz, 1H), 7.88 (brd, J = 7.72 Hz, 1H), 7.71-7.75 (m, 2H), 7.70-7.63 (m, 2H), 7.45 (s, 1H), 3.98 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 at 100° C. 451 1H NMR (DMSO-d6) ppm 12.70 (br, 1H), 9.79 (d, J = 1.60 Hz, 1H), 9.30 (d, J = 7.56 Hz, 1H), 8.95 (d, J = 4.96 Hz, 1H), 8.34 (d, J = 2.20 Hz, 1H), 8.02 (m, 1H), 7.98 (d, J = 9.12 Hz, 1H), 7.85-7.77 (m, 2H), 7.73 (s, 1H), 7.64 (dd, J = 9.12, 2.68 Hz, 1H), 7.52 (m, 1H), 7.36 (m, 1H), 4.00 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 452 1H NMR (DMSO-d6) ppm 12.64 (br, 1H), 9.78 (d, J = 1.72 Hz, 1H), 9.19 (d, J = 7.92 Hz, 1H), 8.90 (d, J = 3.88 Hz, 1H), 8.36 (d, J = 2.64 Hz, 1H), 8.02-7.91 (m, 3H), 7.83 (d, J = 2.40 hz, 1H), 7.64 (dd, J = 9.08, 2.64 Hz, 1H), 7.46 (m, 1H), 7.36 (m, 1H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 453 1H NMR (DMSO-d6) ppm 12.62 (br, 1H), 9.77 (d, J = 1.84 Hz, 1H), 9.30 (d, J = 8.00 Hz, 1H), 8.46 (dd, J = 5.36, 1.48 Hz, 1H), 8.48 (br, 1H), 8.39-8.33 (m, 2H), 8.08 (s, 1H), 8.05 (m, 1H), 7.97 (d, J = 9.12 Hz, 1H), 7.85-7.83 (m, 1H), 7.71 (t, J = 7.84 Hz, 1H), 7.64 (dd, J = 9.12, 2.60 Hz, 1H), 4.02 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 454 1H NMR (DMSO-d6) ppm 12.65 (br, 1H), 9.79 (d, J = 1.72 Hz, 1H), 9.25 (d, J = 8.04 Hz, 1H), 8.92 (d, J = 5.36 Hz, 1H), 8.36 (d, J = 2.60 Hz, 1H), 8.24-8.22 (,m, 1H), 7.97 (d, J = 9.08 Hz, 1H), 7.96 (m, 1H), 7.69 (s, 1H), 7.65 (dd, J = 9.08, 2.60 Hz, 1H), 7.55 (m, 3H), 4.02 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 455 1H NMR (DMSO-d6) ppm 12.52 (br, 1H), 9.78 (d, J = 1.48 Hz, 1H), 9.03 (d, J = 6.6 Hz, 1H), 8.81 (d, J = 4.72 Hz, 1H), 8.34 (d, J = 2.56 Hz, 1H), 8.09 (d, J = 7.88 Hz, 1H), 8.03 (brs, 2H), 7.96 (d, J = 9.12 Hz, 1H), 7.78 (br, 1H), 7.65 (m, 2H), 7.38 (m, 1H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 456 1H NMR (DMSO-d6) ppm 12.45 (br, 1H), 9.78 (d, J = 1.64 Hz, 1H), 9.15 (br, 1H), 8.89 (d, J = 4.52 Hz, 1H), 8.30 (brs, 1H), 7.94 (d, J = 9.08 Hz, 1H), 7.90 (brm, 1H), 7.76 (m, 2H), 7.62 (dd, J = 9.08, 2.64 Hz, 1H), 7.51 (m, 2H), 7.40 (m, 1H), 3.99 (s, 3H), 2.61 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 457 1H NMR (DMSO-d6) ppm 12.55 (br, 1H), 9.78 (d, J = 1.48 Hz, 1H), 9.08 (d, J = 8.48 Hz, 1H), 8.84 (dd, J = 5.04, 1.56 Hz, 1H), 8.34 (d, J = 2.72 Hz, 1H), 8.09 (s, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.84 (m, 1H), 7.77 (m, 2H), 7.64 (dd, J = 9.12, 2.72 Hz, 1H), 7.25 (m, 1H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 458 1H NMR (DMSO-d6) ppm 12.55 (br, 1H), 9.77 (d, J = 1.56 Hz, 1H), 9.14 (d, J = 8.00 Hz, 1H), 8.87 (dd, J = 5.08, 1.48 Hz, 1H), 8.34 (d, J = 2.60 Hz, 1H), 7.98 (m, 1H), 7.96 (d, J = 9.08 Hz, 1H), 7.89-7.86 (brm, 1H), 7.83 (d, J = 2.44 Hz, 1H), 7.64 (dd, J = 9.08, 2.60 Hz, 1H), 7.47-7.41 (m, 1H), 7.29 (m, 1H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 459 1H NMR (DMSO-d6) ppm 12.66 (br, 1H), 9.79 (d, J = 1.60 Hz, 1H), 9.25 (d, J = 7.16 Hz, 1H), 8.92 (d, J = 5.20 Hz, 1H), 8.35 (d, J = 2.56 Hz, 1H), 7.98 (d, J = 9.12 Hz, 1H), 7.97 (m, 1H), 7.68 (s, 1H), 7.64 (dd, J = 9.12, 2.56 Hz, 1H), 7.55 (m, 1H), 7.27 (m, 2H), 3.99 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 460 1H NMR (DMSO-d6) ppm 9.73 (s, 1H), 9.17 (brs, 1H), 8.92 (dd, J = 5.16, 1.4 Hz, 1H), 8.30-8.10 (br, 1H), 7.97 (d, J = 9.04 Hz, 1H), 7.96 (m, 1H), 7.63 (dd, J = 9.04, 2.72 Hz, 1H), 7.02 (s, 1H), 3.98 (s, 3H), 2.57 (d, J = 7.16 Hz, 2H), 2.08 (m, 1H), 0.94 (d, J = 6.60 Hz, 6H). The 1H of HCl and NH— were not observed. DMSO >98 G13 461 1H NMR (DMSO-d6) ppm 12.80-12.20 (br, 1H), 9.78 (d, J = 1.76 Hz, 1H), 9.28 (d, J = 8.04 Hz, 1H), 8.96 (dd, J = 5.28, 1.32 Hz, 1H), 8.29 (brs, 1H), 8.07-8.03 (brm, 1H), 7.95 (d, J = 9.12 Hz, 1H), 7.79 (d, J = 8.60 Hz, 2H), 7.62 (dd, J = 9.12, 2.64 Hz, 1H), 7.57 (d, J = 8.60 Hz, 2H), 3.99 (s, 3H), 2.61 (brs, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 462 1H NMR (DMSO-d6) ppm 12.80-12.20 (br, 1H), 9.74 (s, 1H), 9.19 (d, J = 4.96 Hz, 1H), 8.91 (dd, J = 5.2, 1.4 Hz, 1H), 8.22 (brs, 1H), 7.96 (br, 1H), 7.95 (d, J = 9.08 Hz, 1H), 7.61 (dd, J = 9.08, 2.68 Hz, 1H), 7.35-7.31 (m, 4H), 7.23 (m, 1H), 7.09 (brs, 1H), 4.07 (brs, 2H), 3.96 (brs, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 463 1H NMR (DMSO-d6) ppm 12.50 (br, 1H), 9.78 (d, J = 1.76 Hz, 1H), 9.25 (brs, 1H), 8.96 (brd, J = 4.68 Hz, 1H), 8.29 (brs, 1H), 8.04 (brs, 1H), 7.96 (d, J = 9.20 Hz, 1H), 7.70 (brm, 2H), 7.63 (dd, J = 9.20, 2.68 Hz, 1H), 7.51 (brm, 2H), 7.41 (brm, 1H), 3.99 (s, 3H), 3.02 (q, J = 7.40 Hz, 2H), 1.49 (t, J = 7.40 Hz, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 464 1H NMR (DMSO-d6) ppm 12.53 (br, 1H), 9.78 (d, J = 1.76 Hz, 1H), 9.20 (d, J = 8.36 Hz, 1H), 8.94 (dd, J = 5.2, 1.4 Hz., 1H), 8.29 (brs, 1H), 8.00 (brm, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.66-7.61 (m, 3H), 7.52 (brm, 2H), 7.43 (t, J = 7.40 Hz, 1H), 3.98 (s, 3H), 1.43 (d, J = 6.8 Hz, 6H). The 1H of 2HCl was not observed. The CH proton of iPr group was not observed because of overlapping the H2O peak. DMSO >98 G13 465 1H NMR (DMSO-d6) ppm 12.59 (brs, 1H), 9.77 (d, J = 1.72 Hz, 1H), 9.25 (d, J = 7.76 Hz, 1H), 8.96 (d, J = 4.04 Hz, 1H), 8.29 (br, 1H), 8.04 (m, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.69 (brd, J = 7.12 Hz, 2H), 7.63 (dd, J = 9.12, 2.68 Hz, 1H), 7.51 (t, J = 7.36 Hz, 2H), 7.42 (t, J = 7.36 Hz, 1H), 3.99 (s, 3H), 2.96 (t, J = 7.52 Hz, 2H), 1.78 (m, 2H), 1.01 (t, J = 7.24 Hz, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 466 1H NMR (DMSO-d6) ppm 12.96 (brs, 1H), 9.74 (d, J = 2.04 Hz, 1H), 9.11 (d, J = 7.96 Hz, 1H), 8.90 (d, J = 4.96 Hz, 1H), 8.31 (brd, J = 2.64 Hz, 1H), 7.97 (d, J = 9.12 Hz, 1H), 7.87 (brm, 1H), 7.83-7.80 (m, 2H), 7.64 (dd, J = 9.12, 2.62 Hz, 1H), 7.48 (m, 3H), 4.25 (q, J = 7.04 Ha, 2H), 3.98 (s, 3H), 1.29 (t, J = 7.04 Hz, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 467 1H NMR (DMSO-d6) ppm 12.63 (br, 1H), 9.76 (d, J = 1.76 Hz, 1H), 9.29 (d, J = 8.16 Hz, 1H), 8.95 (dd, J = 5.28, 1.36 Hz, 1H), 8.32 (brd, J = 2.60 Hz, 1H), 8.07 (d, J = 8.52 Hz, 2H), 8.08-8.00 (m, 1H), 7.95 (d, J = 9.12 Hz, 1H), 7.90 (s, 1H), 7.61 (dd, J = 9.12, 2.60 Hz, 1H), 7.55 (d, J = 8.52 Hz, 2H), 4.24 (q, J = 6.88 Hz, 2H), 1.47 (t, J = 6.88 Hz, 3H). The 1H of HCl was not observed. DMSO >98 G13 468 1H NMR (DMSO-d6) ppm 12.58 (brs, 1H), 9.76 (d, J = 1.80 Hz, 1H), 9.27 (d, J = 8.16 Hz, 1H), 8.94 (dd, J = 5.20, 1.32 Hz, 1H), 8.32 (d, J = 2.48 Hz, 1H), 8.09-8.01 (m, 2H), 7.96-7.89 (m, 3H), 7.62-7.52 (m, 2H), 4.29 (q, J = 6.88 Hz, 2H), 1.47 (t, J = 6.88 Hz, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 469 1H NMR (DMSO-d6) ppm 9.72 (s, 1H), 9.13 (brd, J = 5.52 Hz, 1H), 8.92 (d, J = 3.52 Hz, 1H), 8.16 (brs, 1H), 7.95 (brd, J = 9.08 Hz, 2H), 7.62 (dd, J = 2.4 Hz, 1H), 7.39 (brs, 1H), 3.97 (s, 3H), 2.47 (s, 3H). The 1H of 2HCl and NH— were not observed. DMSO >98 G13 470 1H NMR (DMSO-d6) ppm 12.58 (brs, 1H), 9.76 (d, J = 1.68 Hz, 1H), 9.17 (d, J = 8.12 Hz, 1H), 8.89 (dd, J = 5.12, 1.48 Hz, 1H), 8.32 (d, J = 2.56 Hz, 1H), 8.01-8.00 (m, 1H), 7.94 (d, J = 9.08 Hz, 1H), 7.930-7.90 (m, 1H), 7.81 (d, J = 2.4 Hz, 1H), 7.60 (dd, J = 9.08, 2.40 Hz, 1H), 7.50-7.43 (m, 1H), 7.38-7.33 (m, 1H), 4.28 (q, J = 7.00 Hz, 2H), 1.47 (t, J = 7.00 Hz, 3H). The 1H of HCl was not observed. DMSO >98 G13 471 1H NMR (DMSO-d6) ppm 12.53 (brs, 1H), 9.73 (d, J = 1.76 Hz, 1H), 9.29 (d, J = 8.16 Hz, 1H), 8.95 (dd, J = 5.32, 1.36 Hz, 1H), 8.29 (d, J = 2.56 Hz, 1H), 8.05-8.02 (brm, 1H), 7.97-7.92 (m, 1H), 7.93 (d, J = 9.08 Hz, 1H), 7.78 (d, J = 2.36 Hz, 1H), 7.60 (dd, J = 9.08, 2.6 Hz, 1H), 7.46-7.40 (m, 1H), 7.31-7.25 (m, 1H), 4.27 (q, J = 6.92 Hz, 2H), 1.47 (t, J = 6.92 Hz, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 472 1H NMR (DMSO-d6) ppm 12.61 (brs, 1H), 9.76 (d, J = 1.8 Hz, 1H), 9.29 (d, J = 8.16 Hz, 1H), 8.95 (dd, J = 5.24, 1.2 Hz, 1H), 8.32 (d, J = 2.52 Hz, 1H), 8.24-8.20 (m, 1H), 8.05-8.01 (brm, 1H), 7.95 (d, J = 9.08 Hz, 1H), 7.68 (d, J = 2.52 HZ, 1H), 7.61 (dd, J = 9.08, 2.52 Hz, 1H), 7.46-7.40 (m, 1H), 7.28-7.24 (m, 1H), 4.28 (q, J = 6.92 Hz, 2H), 1.47 (t, J = 6.92 Hz, 3H). The 1H of 3HCl was not observed. DMSO >98 G13 473 1H NMR (DMSO-d6) ppm 12.63 (brs, 1H), 9.78 (d, J = 1.68 Hz, 1H), 9.32 (d, J = 8.12 Hz, 1H), 8.97 (d, J = 5.24 Hz, 1H), 8.35 (d, J = 2.16 Hz, 1H), 8.08-8.04 (m, 3H), 7.96 (d, J = 9.08 Hz, 1H), 7.85 (s, 1H), 7.62 (dd, J = 9.08, 2.52 Hz, 1H), 7.49 (t, J = 7.44 Hz, 2H), 7.38 (t, J = 7.28 Hz, 1H), 4.30 (q, J = 6.96 Hz, 2H), 1.47 (t, J = J = 6.96 Hz, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 474 1H NMR (DMSO-d6) ppm 12.68 (s, 1H), 9.73 (d, J = 1.64 Hz, 1H), 8.87-8.84 (m, 1H), 8.75-8.73 (m, 1H), 8.33 (brs, 1H), 8.24 (brs, 1H). 7.93 (d, J = 9.16 Hz, 1H), 7.64-7.59 (m, 2H), 4.34 (q, J = 7.08 Hz, 2H), 3.98 (s, 3H), 1.34 (t, J = 7.08 Hz, 3H). DMSO >98 G13 475 1H NMR (300 MHz, DMSO) δ 10.35 (s, 1H), 9.42 (s, 1H), 8.99-8.76 (m, 2H), 8.11 (d, J = 6.7 Hz, 1H), 7.99-7.75 (m, 3H), 7.67-7.43 (m, 2H), 7.23 (d, J = 8.2 Hz, 1H), 4.14 (s, 3H). DMSO 98 G1 381   (M + 1) 2.07 Method A (Formic acid) 476 1H NMR (300 MHz, DMSO) δ 13.78 (s, 1H), 9.62 (d, J = 1.7 Hz, 1H), 9.21 (d, J = 8.1 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.07 (dd, J = 7.9, 5.3 Hz, 1H), 7.83 (d, J = 9.1 Hz, 2H), 7.63-7.50 (m, 4H), 7.41 (d, J = 6.5 Hz, 2H), 7.14 (d, J = 2.5 Hz, 1H), 5.30 (s, 1H), 3.91 (s, 3H), 2.15 (s, 3H). DMSO 95 Method G1 468.1 (M + 1) Method C 477 1H NMR (300 MHz, DMSO) δ 13.78 (s, 1H), 9.64 (d, J = 1.5 Hz, 1H), 9.11 (d, J = 8.2 Hz, 1H), 8.90 (d, J = 3.8 Hz, 1H), 7.95 (dd, J = 10.6, 2.6 Hz, 1H), 7.84 (d, J = 9.1 Hz, 2H), 7.60-7.48 (m, 4H), 7.38 (d, J = 6.5 Hz, 2H), 7.17 (d, J = 2.4 Hz, 1H), 5.28 (s, 1H), 4.14 (q, J = 6.9 Hz, 2H), 2.15 (s, 3H), 1.42 (t, J = 6.9 Hz, 3H). DMSO 95 Method G1 482.1 (M + 1) Method C 478 1H NMR (300 MHz, DMSO) δ 12.59 (s, 1H), 9.56 (s, 1H), 8.70 (d, J = 5.8 Hz, 2H), 8.58 (d, J = 5.2 Hz, 1H), 7.95 (d, J = 5.2 Hz, 2H), 7.87 (d, J = 9.1 Hz, 2H), 7.64-7.49 (m, 2H), 7.40 (d, J = 2.4 Hz, 1H), 4.21 (q, J = 6.8 Hz, 2H), 1.44 (t, J = 6.9 Hz, 3H). DMSO 99 Method G1 392.1 (M + 1) Method C 479 1H NMR (300 MHz, DMSO) δ 13.75 (s, 1H), 9.60 (s, 1H), 8.98 (s, 1H), 8.82 (d, J = 3.6 Hz, 1H), 7.82 (d, J = 9.0 Hz, 3H), 7.52 (d, J = 9.3 Hz, 1H), 7.15 (s, 1H), 6.94-6.62 (s, 1H), 4.13 (d, J = 6.9 Hz, 2H), 2.90 (d, J = 21.9 Hz, 4H), 2.41 (s, 2H), 1.43 (t, J = 6.9 Hz, 3H). DMSO 95 Method G1 432.1 (M + 1) Method C 480 1H NMR (300 MHz, DMSO) δ 12.50 (s, 1H), 9.56 (s, 1H), 8.89 (s, 1H), 8.68 (d, J = 5.3 Hz, 2H), 8.00-7.79 (m, 3H), 7.73 (d, J = 7.2 Hz, 4H), 7.62-7.38 (m, 9H), 7.34 (d, J = 2.2 Hz, 2H), 4.18 (dd, J = 13.5, 6.5 Hz, 2H), 1.43 (t, J = 6.9 Hz, 3H). DMSO 99 Method G1 468.1 (M + 1) Method C 481 1H NMR (300 MHz, DMSO) δ 12.51 (s, 1H), 9.54 (s, 1H), 8.86 (s, 1H), 8.74-8.61 (m, 2H), 7.90 (s, J = 15.7 Hz, 2H), 7.83 (d, J = 9.1 Hz, 1H), 7.72 (d, J = 7.1 Hz, 2H), 7.63-7.40 (m, 6H), 7.33 (d, J = 2.3 Hz, 1H), 3.92 (s, 3H). DMSO 99 Method G1 454.1 (M + 1) Method C 482 1H NMR (300 MHz, DMSO) δ 13.70 (s, 1H), 9.70 (d, J = 2.1 Hz, 1H), 8.81 (d, J = 8.0 Hz, 1H), 8.70 (dd, J = 4.8, 1.7 Hz, 1H), 7.90 (d, J = 9.1 Hz, 1H), 7.66-7.53 (m, 2H), 7.29 (d, J = 2.2 Hz, 1H), 3.95 (s, 3H), 2.78 (d, J = 12.9 Hz, 4H), 1.78 (s, 4H). DMSO 99 Method G1 432.1 (M + 1) Method C 483 1H NMR (300 MHz, DMSO) δ 13.64 (s, 1H), 9.68 (s, 1H), 8.79 (d, J = 7.9 Hz, 1H), 8.69 (d, J = 4.7 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H), 7.63-7.50 (m, 2H), 7.24 (s, 1H), 4.18 (q, J = 6.7 Hz, 2H), 2.76 (d, J = 10.4 Hz, 4H), 1.78 (s, 4H), 1.43 (t, J = 6.9 Hz, 3H). DMSO 99 Method G1 446.1 (M + 1) Method C 484 1H NMR (300 MHz, DMSO) δ 12.82 (s, 1H), 9.67 (d, J = 2.1 Hz, 1H), 8.77 (dt, J = 8.1, 2.0 Hz, 1H), 8.71 (dd, J = 4.8, 1.7 Hz, 1H), 7.87 (d, J = 9.1 Hz, 1H), 7.83 (s, 1H), 7.60-7.53 (m, 3H), 7.48 (s, 1H), 7.20 (d, J = 2.6 Hz, 1H), 4.20 (q, J = 6.9 Hz, 2H), 2.90 (d, J = 4.7 Hz, 3H), 1.44 (t, J = 6.9 Hz, 3H). DMSO 95 Method G1 422.1 (M + 1) Method C 485 1H NMR (300 MHz, DMSO) δ 9.66 (s, 1H), 9.44 (d, J = 1.4 Hz, 1H), 8.64-8.55 (m, 2H), 7.90 (s, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.76 (d, J = 2.5 Hz, 1H), 7.69 (s, 2H), 7.54-7.45 (m, 2H), 4.19 (q, J = 7.0 Hz, 2H), 4.04 (s, 3H), 1.42 (t, J = 6.9 Hz, 3H). DMSO 99 Method G1 390.1 (M + 1) Method C 486 1H NMR (300 MHz, DMSO) δ 9.57 (d, J = 1.5 Hz, 1H), 9.07 (d, J = 4.6 Hz, 1H), 8.94 (dd, J = 5.2, 1.4 Hz, 1H), 8.04 (d, J = 9.1 Hz, 1H), 7.97 (dd, J = 6.7, 5.0 Hz, 1H), 7.67 (dd, J = 9.1, 2.8 Hz, 1H), 7.55 (d, J = 2.7 Hz, 1H), 7.36 (dd, J = 6.4, 2.3 Hz, 2H), 7.14-7.03 (m, 2H), 3.74 (s, 3H), 3.69 (s, 3H). DMSO 99 Method G1 382.5 (M + 1) Method C 487 1H NMR (300 MHz, DMSO) δ 12.59 (s, 1H), 9.58 (d, J = 2.0 Hz, 1H), 8.94 (d, J = 8.2 Hz, 1H), 8.84 (d, J = 5.2 Hz, 1H), 8.73 (s, 1H), 8.09 (s, 1H), 7.95 (s, 3H), 7.82 (dd, J = 8.4, 5.4 Hz, 2H), 7.75 (d, J = 7.4 Hz, 2H), 7.59-7.42 (m, 3H). DMSO 99 Method G1 458.4 (M + 1) Method C 488 1H NMR (300 MHz, DMSO) δ 13.79 (s, 1H), 9.49 (d, J = 1.5 Hz, 1H), 8.96 (d, J = 8.0 Hz, 1H), 8.86 (d, J = 3.7 Hz, 1H), 7.95-7.71 (m, 4H), 7.65 (d, J = 1.6 Hz, 1H), 6.76 (s, 1H), 2.85 (d, J = 22.5 Hz, 4H), 2.44-2.29 (m, 2H). DMSO 93 Method G1 422.4 (M + 1) Method C 489 1H NMR (300 MHz, DMSO) δ 9.53 (d, J = 1.8 Hz, 1H), 9.04 (d, J = 7.9 Hz, 1H), 8.93 (d, J = 3.9 Hz, 1H), 7.95 (dd, J = 8.0, 5.2 Hz, 1H), 7.90-7.78 (m, 2H), 7.70 (d, J = 1.7 Hz, 1H), 2.29 (s, 3H), 2.24 (s, 3H). DMSO 94 Method G1 410.3 (M + 1) Method C 490 1H NMR (300 MHz, DMSO) δ 13.07 (s, 1H), 9.93 (d, J = 1.8 Hz, 1H), 9.64 (d, J = 1.6 Hz, 1H), 8.90-8.78 (m, 1H), 8.76-8.62 (m, 2H), 8.29 (s, 1H), 8.18 (d, J = 8.3 Hz, 1H), 7.89 (d, J = 9.1 Hz, 1H), 7.71 (dd, J = 8.3, 1.9 Hz, 1H), 7.65 (s, 1H), 7.57 (dd, J = 9.1, 2.5 Hz, 1H), 7.53-7.44 (m, 2H), 7.01 (s, 1H), 4.21 (q, J = 6.9 Hz, 2H), 3.34 (s, 3H), 1.44 (t, J = 6.9 Hz, 3H), DMSO 99 Method G1 464.2 (M + 1) Method C 491 1H NMR (300 MHz, DMSO) δ 9.78 (s, 1H), 9.50 (d, J = 2.0 Hz, 1H), 8.68-8.57 (m, 2H), 7.97 (d, J = 2.5 Hz, 1H), 7.85 (d, J = 1.8 Hz, 1H), 7.79 (d, J = 9.1 Hz, 1H), 7.55-7.43 (m, 3H), 7.22 (d, J = 8.4 Hz, 1H), 4.22 (q, J = 6.9 Hz, 2H), 3.37 (d, J = 4.3 Hz, 6H), 1.43 (t, J = 6.9 Hz, 3H). DMSO 99 Method G1 427.5 (M + 1) Method C 492 1H NMR (300 MHz, DMSO) δ 11.48 (s, 1H), 10.97 (s, 1H), 9.28 (d, J = 1.5 Hz, 1H), 8.64 (dd, J = 4.6, 1.7 Hz, 1H), 8.40 (d, J = 8.1 Hz, 1H), 7.94-7.80 (m, 3H), 7.53-7.35 (m, 2H), 7.02 (t, J = 7.5 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 4.04 (s, H). DMSO 99 Method F5, G13 391.1 (M + 1) Method C 493 1H NMR (300 MHz, DMSO) δ 11.28 (s, 1H), 9.62 (d, J = 1.7 Hz, 1 H), 9.17 (d, J = 7.8 Hz, 1H), 8.93 (dd, J = 5.2, 1.3 Hz, 1H), 8.60 (s, 1H), 8.05 (s, 1H), 8.03-7.94 (m, 2H), 7.77 (s, 1H), 7.64 (dd, J = 9.2, 2.5 Hz 1H), 7.40 (d, J = 2.6 Hz, 1H), 3.97 (s, 3H). DMSO 99 Method G14 362.4 (M + 1) Method C 494 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.14 (s, 1H), 9.54 (s, 1H), 8.70-8.67 (m, 2H), 8.48 (s, 1H), 8.16 (s, 1H), 7.96-7.89 (m, 3H), 7.60 (t, J = 8.0 Hz, 1H), 7.55-7.52 (m, 1H), 7.17 (d, J = 8.8 Hz, 1H), 3.71 (s, 2H), 2.72-2.65 (m, 8H). DMSO 95 Method G1 498.1 (M + 1) t = 2.128 min Method B (NH4HCO3) 495 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.71 (s, 1H), 9.37 (s, 1H), 8.93 (s, 1H), 8.67 (d, J = 3.2 Hz, 1H), 8.48 (d, J = 8.0 Hz, IH), 7.93 (s, 1H), 7.39 (d, J = 8.0 Hz, 1H), 7.65 (m, 2H), 7.04 (d, J = 8.0 Hz, 1H), 2.95 (t, J = 8.0 Hz, 2H), 2.64 (t, J = 8.0 Hz, 2H). DMSO 95 Method G1 402.0 (M + 1) t = 1.746 min Method B (NH4HCO3) 496 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.38 (s, 1H), 9.51 (s, 1H), 8.67-8.60 (m, 3H), 8.24-8.10 (m, 2H), 7.88-7.83 (m, 2H), 7.58-7.55 (m, 3H), 7.33 (dd, J = 7.2, 4.8 Hz, 1H), 3.97 (s, 3H). DMSO 95 Method J1 373.0 (M + 1) t = 1.523 min Method B (NH4HCO3) 497 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.92 (s, 1H), 9.30 (s, 1H), 8.60 (d, J = 3.4 Hz, 1H), 8.48 (d, J = 8.0 Hz, 1H), 8.40 (d, J = 4.4 Hz, 1H), 7.87 (d, J = 2.2 Hz, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.59-7.40 (m, 5H), 4.24 (q, J = 6.9 Hz, 2H), 2.55 (d, J = 4.5 Hz, 3H), 1.45 (t, J = 6.9 Hz, 3H). DMSO 95 Method G1 418.2 (M + 1) t = 1.782 min Method B (NH₄HCO₃) 498 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.14 (s, 1H), 9.54 (d, J = 2.0 Hz, 1H), 8.70-8.67 (m, 2H), 8.50 (s, 1H), 8.15 (s, 1H), 7.94- 7.92 (m, 3H), 7.61 (t, J = 8.0 Hz, 1H), 7.55 (dd, J = 8.0, 4.8 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 3.90 (s, 2H), 3.17 (s, 4H), 2.98 (s, 4H). DMSO 95 Method G1 530.0 (M + 1) t = 1.856 min Method B (NH₄HCO₃) 499 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.19 (s, 1H), 9.65 (s, 1H), 9.17 (d, J = 8.2 Hz, 1H), 8.97 (d, J = 4.5 Hz, 1H), 8.93 (s, 1H), 8.81 (d, J = 8.2 Hz, 1H), 8.45 (s, 1H), 8.40 (dd, J = 8.7, 1.7 Hz, 1H), 8.16 (d, J = 8.7 Hz, 1H), 7.99 (dd, J = 16.0, 10.4 Hz, 3H), 7.74 (t, J = 7.4 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 3.38 (s, 3H). DMSO 95 Method G1 420.1 (M + 1) t = 1.478 min Method B (NH₄HCO₃) 501 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.46 (s, 1H), 9.46 (s, 1H), 8.97 (d, J = 7.9 Hz, 1H), 8.93 (d, J = 4.4 Hz, 1H), 8.77 (d, J = 12.1 Hz, 1H), 8.55 (s, 1H), 8.16-7.91 (m, 4H), 7.83 (t, J = 7.5 Hz, 1H), 7.73 (d, J = 9.3 Hz, 1H), 7.05 (t, J = 6.9 Hz, 1H). DMSO 95 Method G1 378.1 (M + 1) t = 1.873 min Method B (NH₄HCO₃) 502 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.00 (s, 1H), 9.83 (s, 1H), 9.17 (d, J = 8.0 Hz, 1H), 9.00 (d, J = 8.0 Hz, 1H), 8.73-8.72 (m, 1H), 8.49 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.92 (s, 1H), 7.76 (t, J = 7.2 Hz, 1H), 7.63-7.53 (m, 3H), 7.28 (d, J = 7.6 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H). DMSO 95 Method G1 358.0 (M + 1) t = 1.644 min Method B (NH₄HCO₃) 503 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.34 (s, 1H), 9.50 (s, 1H), 8.69 (d, J = 3.6 Hz, 1H), 8.65 (d, J = 7.6 Hz, 1H), 8.40 (d, J = 8.4 Hz, 1H), 8.15 (s, 1H), 8.10 (s, 1H), 8.00-7.97 (m, 1H), 7.91-7.84 (m, 2H), 7.69-7.66 (m, 1H), 7.55-7.52 (m, 1H), 7.16 (t, J = 9.2 Hz, 1H). DMSO 95 Method G1 378.0 (M + 1) t = 1.780 min Method B (NH₄HCO₃) 504 1H-NMR (300 MHz, DMSO): δ 10.48 (s, 1H), 9.57 (s, 1H), 9.13 (d, J = 7.6 Hz, 1H), 8.97-8.80 (m, 2H), 8.31 (s, 1H), 8.19 (s, 1H), 8.10 (d, J = 6.5 Hz, 1H), 7.97 (d, J = 9.1 Hz, 2H), 7.83 (d, J = 7.7 Hz, 1H), 7.66 (t, J = 7.9 Hz, 2H), 7.47 (d, J = 5.4 Hz, 1H), 4.02 (s, 3H). DMSO 95 Method G1 396.1 (M + 1) Method C 505 ¹H NMR (400 MHz, DMSO) δ 15.71 (s, 1H), 10.01 (s, 1H), 9.59-9.51 (m, 1H), 8.73-8.62 (m, 2H), 8.60-8.54 (m, 1H), 8.13-7.96 (m, 2H), 7.93-7.82 (m, 2H), 7.62-7.49 (m, 2H), 4.01 (s, 3H). DMSO >98 G1 506 ¹H NMR (400 MHz, DMSO) δ 10.77 (s, 1H), 9.75 (s, 1H), 9.55-9.46 (m, 1H), 8.73-8.60 (m, 2H), 7.96 (d, J = 2.7 Hz, 1H), 7.83 (d, J = 9.1 Hz, 1H), 7.63 (m, J = 2.1 Hz, 1H), 7.58-7.47 (m, 3H), 6.99 (d, J = 8.5 Hz, 1H), 4.64 (s, 2H), 3.97 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 507 ¹H NMR (400 MHz, DMSO) δ 12.54 (s, 1H), 9.85 (s, 1H), 9.51 (s, 1H), 8.70-8.60 (m, 2H), 8.27- 8.16 (m, 2H), 8.03 (d, J = 2.5 Hz, 1H), 7.83 (d, J = 9.1 Hz, 1H), 7.72-7.59 (m, 2H), 7.56-7.47 (m, 2H), 3.99 (s, 3H). DMSO >98 G1 508 ¹H NMR (400 MHz, DMSO) δ 9.87 (s, 1H), 9.50-9.47 (m, 1H), 8.66-8.61 (m, 2H), 8.21 (s, 1H), 8.16 (d, J = 1.6 Hz, 1H), 8.02 (d, J = 2.7 Hz, 1H), 7.83 (d, J = 9.1 Hz, 1H), 7.74 (dd, J = 8.7, 1.9 Hz, 1H), 7.67 (d, J = 8.6 Hz, 1H), 7.56-7.47 (m, 2H), 3,99 (s, 3H), 3.90 (s, 3H). DMSO >98 G1 509 ¹H NMR (400 MHz, DMSO) δ 9.90 (s, 1H), 9.47 (dd, J = 2.1, 0.8 Hz, 1H), 8.67-8.60 (m, 2H), 8.15 (d, J = 2.1 Hz, 1H), 7.97 (d, J = 2.7 Hz, 1H), 7.88-7.81 (m, 2H), 7.57-7.49 (m, 2H), 7.44 (d, J = 8.7 Hz, 1H), 3.98 (s, 3H), 3.47 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 510 ¹H NMR (400 MHz, DMSO) δ 10.76 (s, 1H), 10.62 (s, 1H), 9.71 (s, 1H), 9.53-9.48 (m, 1H), 8.68-8.62 (m, 2H), 7.98 (d, J = 2.6 Hz, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.63 (d, J = 1.8 Hz, 1H), 7.55-7.49 (m, 2H), 7.37 (dd, J = 8.4, 2.0 Hz, 1H), 7.01 (d, J = 8.3 Hz, 1H), 3.97 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 511 ¹H NMR (400 MHz, DMSO) δ 9.96 (s, 1H), 9.49 (dd, J = 2.1, 0.8 Hz, 1H), 8.79 (s, 1H), 8.67-8.61 (m, 2H), 8.39-8.36 (m, 1H), 8.02 (d, J = 2.7 Hz, 1H), 7.90- 7.84 (m, 3H), 7.56 (dd, J = 9.1, 2.7 Hz, 1H), 7.54-7.50 (m, 1H), 3.99 (s, 3H). DMSO >98 J2 512 ¹H NMR (400 MHz, DMSO) δ 9.87 (s, 1H), 9.48 (dd, J = 2.1, 0.8 Hz, 1H), 8.67-8.61 (m, 2H), 8.10-8.08 (m, 1H), 8.00 (d, J = 2.7 Hz, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.65-7.63 (m, 2H), 7.57- 7.49 (m, 2H), 4.22 (s, 3H), 3.99 (s, 3H). DMSO >98 G1 513 ¹H NMR (400 MHz, DMSO) δ 9.92 (s, 1H), 9.49 (dd, J = 2.1, 0.8 Hz, 1H), 8.67-8.60 (m, 2H), 8.22 (d, J = 1.8 Hz, 1H), 8.00 (d, J = 2.7 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.70-7.64 (m, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.57-7.49 (m, 2H), 4.21 (s, 3H), 3.98 (s, 3H). DMSO >98 J2 514 ¹H NMR (400 MHz, DMSO) δ 10.97 (s, 1H), 9.43 (d, J = 1.6 Hz, 1H), 8.98-8.91 (m, 1H), 8.89 (dd, J = 5.2, 1.3 Hz, 1H), 8.43 (s, 1H), 8.27 (s, 1H), 8.13-8.04 (m, 2H), 7.92-7.85 (m, 1H), 7.73 (d, J = 9.2 Hz, 1H), 7.70-7.63 (m, 2H), 4.21 (s, 3H), 4.02 (s, 3H). DMSO >98 G1 515 ¹H NMR (400 MHz, DMSO) δ 11.90 (s, 1H), 10.45 (s, 1H), 9.46 (d, J = 1.7 Hz, 1H), 8.97-8.89 (m, 1H), 8.85 (dd, J = 5.2, 1.5 Hz, 1H), 8.16-8.10 (m, 2H), 8.03-7.97 (m, 2H), 7.94 (d, J = 9.1 Hz, 1H), 7.90-7.82 (m, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.44 (d, J = 8.8 Hz, 1H), 6.58 (d, J = 9.4 Hz, 1H), 4.00 (s, 3H). DMSO >98 G1 (0.1 N HCl added) 516 ¹H NMR (400 MHz, DMSO) δ 9.90 (s, 1H), 9.53-9.50 (m, 1H), 8.68-8.63 (m, 2H), 8.27 (d, J = 2.0 Hz, 1H), 8.01 (d, J = 2.7 Hz, 1H), 7.96 (d, J = 8.6 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.81 (dd, J = 8.7, 2.1 Hz, 1H), 7.58-7.50 (m, 2H), 4.20 (s, 3H), 3.99 (s, 3H). DMSO >98 G1 517 ¹H NMR (300 MHz, DMSO) δ 11.35 (s, 1H), 9.58 (d, J = 1.6 Hz, 1H), 9.24 (d, J = 8.2 Hz, 1H), 9.05-8.97 (m, 1H), 9.05-8.95 (m, 1H), 8.21 (d, J = 2.4 Hz, 1H), 8.11-8.02 (m, 3H), 7.90 (d, J = 7.8 Hz, 1H), 7.58 (dd, J = 8.8, 2.0 Hz, 2H), 7.52-7.46 (m, 1H), 7.28 (s, 1H), 3.98 (d, J = 9.2 Hz, 3H). DMSO >98 G1 518 ¹H NMR (300 MHz, DMSO) δ 11.32 (s, 1H), 9.60 (s, 1H), 9.23 (d, J = 8.0 Hz, 1H), 8.98 (d, J = 5.4 Hz, 1H), 8.26 (s, 1H), 8.06 (dd, J = 13.2, 7.3 Hz, 2H), 7.63 (d, J = 9.1 Hz, 1H), 7.50-7.36 (m, 4H), 7.32 (s, 1H), 7.06-6.90 (m, 1H), 3.99 (s, 3H), 3.86 (s, 3H). DMSO >98 G1 519 1H NMR (300 MHz, DMSO) δ 13.17 (s, 1H), 11.46 (s, 1H), 9.19 (d, J = 1.7 Hz, 1H), 8.95-8.78 (m, 2H), 8.31 (d, J = 2.6 Hz, 1H), 8.18 (d, J = 9.2 Hz, 1H), 7.86 (dd, J = 7.9, 5.4 Hz, 1H), 7.77-7.54 (m, 3H), 7.44 (dd, J = 11.4, 3.9 Hz, 1H), 7.20-7.02 (m, 1H), 4.01 (s, 3H). DMSO >98 G1 520 ¹H NMR (300 MHz, DMSO) δ 11.10 (s, 1H), 9.59 (d, J = 1.8 Hz, 1H), 9.15 (d, J = 8.0 Hz, 1H), 8.93 (d, J = 3.9 Hz, 1H), 8.22 (d, J = 2.6 Hz, 1H), 7.99 (t, J = 7.4 Hz, 2H), 7.72 (dd, J = 8.4, 4.7 Hz, 2H), 7.63-7.50 (m, 2H), 7.35 (s, 1H), 7.27-7.18 (m, 1H), 3.99 (s, 3H). DMSO >98 G1 521 ¹H NMR (300 MHz, DMSO) δ 11.51 (s, 1H), 9.63 (d, J = 1.9 Hz, 1H), 9.18 (d, J = 8.1 Hz, 1H), 8.98 (dd, J = 5.2, 1.2 Hz, 1H), 8.31 (d, J = 2.5 Hz, 1H), 8.17 (d, J = 9.1 Hz, 1H), 8.01 (dd, J = 8.0, 5.3 Hz, 1H), 7.84 (dd, J = 7.7, 1.5 Hz, 1H), 7.66 (dd, J = 9.1, 2.5 Hz, 1H), 7.48-7.35 (m, 2H), 7.21 (d, J = 8.2 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 3.99 (d, J = 6.3 Hz, 6H). DMSO >98 G1 1758 1H NMR (DMSO-d6) ppm 13.00-12.40 (br, 1H), 9.79 (d, J = 1.68 Hz, 1H), 9.30 (d, J = 8.20 Hz, 1H), 8.95 (dd, J = 5.32, 1.44 Hz, 1H), 8.71 (d, J = 4.24 Hz, 1H), 8.37 (brd, J = 2.56 Hz, 1H), 8.25-8.21 (m, 2H), 8.11-8.02 (m, 2H), 7.98 (d, J = 9.12 Hz, 1H), 7.66 (dd, J = 9.12, 2.68 Hz, 1H), 7.53-7.50 (m, 1H), 4.03 (s, 3H). The 1H of 3HCl was not observed. DMSO >98 G13 1759 IH NMR (DMSO-d6) pprn 10.35 (br, 1H), 9.37 (d, J = 1.6 Hz, 1H), 8.96 (d, J = 7.28 Hz, 1H), 8.90 (d, J = 4.2 Hz, 1H), 8.04 (s, 1H), 7.98 (m, 1H), 7.95 (d, J = 9.16 Hz, 1H), 7.64 (dd, J = 9.16, 2.56 Hz, 1H), 6.18 (s, 1H), 3.98 (s, 3H), 3.66 (s, 3H), 2.24 (s, 3H). The 1H of 3HCl was not observed. DMSO >98 J2

Method K: 2-Amino-5-methoxybenzoic acid (viii-a)

5-Methoxy-2-nitrobenzoic acid (30.0 g, 152.2 mmol) was hydrogenated over Pd/C (10% c, 300 mg) in THF (250 mL) at room temperature under H₂ balloon. The mixture was stirred for 18 h. After the reaction was completed, the catalyst was removed by filtration over Celite and the filtrate was concentrated to afford 25.0 g of 2-amino-5-methoxybenzoic acid as a brown solid (98%). LCMS m/z=168.1 (M+1), 150.1 (M−17) (Method B) (retention time=0.53 min) ¹H NMR (400 MHz, DMSO-d₆): δ 7.31 (d, J=2.8 Hz, 1H), 6.61 (dd, J=8.8, 3.2 Hz, 1H), 6.44 (d, J=8.8 Hz, 1H), 3.60 (s, 3H).

Method H: 6-Methoxyquinazoline-2,4(1H, 3H)-dione (ix-a)

2-Amino-5-methoxybenzoic acid (13.0 g, 77.8 mmol, 1.0 eq.) was suspended in water (200 mL) and glacial acetic acid (5.2 mL) at 35° C. A freshly prepared solution of potassium cyanate (8.21 g, 101.4 mmol, 1.3 eq.) in water (86 mL) was added dropwise to the stirred mixture. After 4 h, NaOH (104.0 g, 2600 mL, 33.4 eq.) was added in portions, keeping the reaction temperature below 40° C. A clear solution was obtained momentarily before a precipitate formed. After cooling, the precipitate was filtered off and dissolved in hot water which was acidified to pH 5. The precipitate was collected and washed with water, dried by lyophilization to afford 9.63 g of 6-methoxyquinazoline-2, 4(1K, 3H)-dione as a white solid (65%). LCMS m/z=193.1 (M+1) (Method B) (retention time=1.22 min). ¹H NMR (400 MHz, DMSO-d₆): δ 11.26 (s, 1H), 11.01 (s, 1H), 7.31-7.25 (m, 2H), 7.10 (d, 1H, J=8.8 Hz), 3.77 (s, 3H).

Method F1: 2,4-Dichloro-6-methoxyquinazoline (x-a)

To a mixture of 6-methoxyquinazoline-2,4(1H, 3H)-dione (9.63 g, 50.2 mmol) in POCl₃ (150 mL) was added N,N-dimethylaniline (0.5 mL). The resulting mixture was stirred at 120° C. for 2 h. After the reaction was completed, POCl₃ was removed in vacuo, and the residue was added to ice-water slowly. The pH was adjusted to ˜7 by slowly adding NaHCO₃ (sat.) at 0° C., then a precipitate formed. The solid was collected and dried in vacuo to give 11.2 g of 2,4-dichloro-6-methoxyquinazoline in a 98% yield as a brown solid. LCMS m/z=229.1, 231.0 (M+1) (Method B) (retention time=1.87 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 7.89 (d, J=9.2 Hz, 1H), 7.71 (dd, J=8.8, 2.4 Hz, 1H), 7.38 (d, J=1.6 Hz, 1H), 3.91 (s, 3H).

Method M: 2-Chloro-6-methoxyquinazolin-4-ol (xi-a)

A mixture of 2,4-dichloro-6-methoxyquinazoline (4.20 g, 18.5 mmol, 1.0 eq.) in THF (60 mL) and 1120 (60 mL) was treated with NaOH (4.00 g, 100 mmol, 5.4 eq.). The resulting mixture was stirred at 40° C. for 2 h. The reaction color turned to dark green and then a precipitate formed. After the reaction was completed, the mixture was cooled to room temperature. The precipitate was filtered off and the filtrate was concentrated down to 60 mL. The pH was then adjusted to 6 by adding 2N HCl in water. The precipitate which formed was collected and dried in vacuo to give 4.00 g of 2-chloro-6-methoxyquinazolin-4-ol as a grey solid (98%). LCMS m/z=211.1, 213.0 (M+1) (Method B) (retention time=1.11 min).

Method N: 6-Methoxy-2-(pyridin-3-yl) quinazolin-4-ol (xii-a)

To a mixture of 2-chloro-6-methoxyquinazolin-4-ol (1.20 g, 5.7 mmol, 1.0 eq.), pyridin-3-ylboronic acid (1.27 g, 8.6 mmol, 1.5 eq.), K₂ CO₃ (2.37 g, 17.1 mmol, 3.0 eq.) in dioxane (100 mL) and 1H₂O (10 ml) was added Pd(PPh₃)₂Cl₂ (230 mg, 0.29 mmol, 0.05 eq.) under N₂ atmosphere. The resulting mixture was stirred at 105° C. under N₂ atmosphere overnight. After reaction was completed, the mixture was cooled to room temperature, and the resultant precipitate was removed by filtration. The filtrate was concentrated in vacuo and the residue was partitioned between H₂O (30 mL) and ethyl acetate (100 mL×3). The combined organic layers were washed with brine, dried over MgSO₄. After filtration and evaporation, the crude product was obtained, which was combined with the filter cake and dried in vacuo to give 1.35 g of 6-methoxy-2-(pyridin-3-yl) quinazolin-4-ol as a gray solid. LCMS m/z=254.1 (M+1) (Method B) (retention time=1.39 min). The crude product was used for the next step without further purification.

Method F1: 4-Chloro-6-methoxy-2-(pyridin-3-yl)quinazoline (xiii-a)

To a mixture of 6-methoxy-2-(pyridin-3-yl) quinazolin-4-ol (600 mg, 2.37 mmol) in POCl₃ (5 mL) was added N,N-dimethyl aniline (1 drop). The resulting mixture was stirred at 120° C. for 30 min. After the reaction was completed, POCl₃ was removed in vacuo, and the residue was added to ice-water slowly. The pH was adjusted to ˜7 by slowly adding NaHCO₃ (sat.) at 0° C. and then a precipitate formed. The solid was collected and was purified by chromatography on silica gel eluted with petroleum ether/ethyl acetate (v/v=4:1 to 1:1) to give 260 mg of 4-chloro-6-methoxy-2-(pyridin-3-yl)quinazoline as a pale yellow solid (40.4%). LCMS m/z=272.1, 274.0 (M+1) (Method B) (retention time=1.90 min).

Method G1: N-(2-Fluorophenyl)-6-methoxy-2-(pyridin-3-yl)quinazolin-4-amine (xiv-a)

A mixture of 4-chloro-6-methoxy-2-(pyridin-3-yl)quinazoline (80 mg, 0.293 mmol, 1.0 eq.) and 2-fluoroaniline (65 mg, 0.58 mmol, 2 eq.) in i-PrOH (5 mL) was stirred at 85° C. for 18 h. After the reaction was completed, the mixture was filtered, and the filter cake was washed with H₂O (10 ml) and diethyl ether (10 mL). After drying, the crude product was purified by PREP-HPLC (Condition C: Gradient: B=5%-50%, Target Peak: at 7.2 min) to give 16.5 mg of N-(2-fluorophenyl)-6-methoxy-2-(pyridin-3-yl)quinazolin-4-amine as a yellow solid, yield 16.4%. LCMS m/z=347.0 (M+1) (Method A) (retention time=1.31 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 10.08 (s, 1H), 9.33 (s, 1H), 8.72 (d, J=4.4 Hz, 1H), 8.66 (d, J=8.0 Hz, 1H), 8.80 (d, J=1.2 Hz, 1H), 7.88 (d, J=9.2 Hz, 1H), 7.70-7.65 (m, 2H), 7.58 (dd, J=8.8, 1.2 Hz, 1H), 7.44-7.35 (m, 3H), 3.97 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 6 substituting with appropriate nitro benzoic acid, boronic acid and aniline

TABLE 2 Salt Molecular Number Product type Mass ¹H-NMR 522

455.34 1H-NMR (400 MHz, DMSO-d6): δ 9.76 (s, 1H), 9.52-9.51 (m, 1H), 8.63-8.66 (m, 2H), 8.32 (d, J = 2.4 Hz, 1H), 7.94- 7.91 (m, 2H), 7.72 (d, J = 8.3 Hz, 1H), 7.54 (q, J = 3.2 Hz, 1H), 7.32 (s, 1H), 4.87-4.90 (m, 1H), 3.96 (s, 3H), 1.38 (d, J = 6.0 Hz, 6H). 523

438.88 1H-NMR (400 MHz, DMSO-d6): δ 9.58 (s, 1H), 9.49 (d, J = 2.0 Hz, 1H), 8.60- 8.66 (m, 2H), 8.18 (dd, J = 6.4, 2.4 Hz, 1H), 7.84-7.88 (m, 2H), 7.50-7.54 (m, 2H), 7.31 (s, 1H), 4.85-4.88 (m, 1H), 3.96 (s, 3H), 1.38 (d, J = 6.4 Hz, 6H). 524

422.43 1H-NMR (400 MHz, DMSO-d6): δ 9.76 (s, 1H), 9.48 (s, 1H), 8.60-8.65 (m, 2H), 8.04-8.10 (m, 1H), 7.92 (s, 1H), 7.49- 7.66 (m, 3H), 7.30 (s, 1H), 4.86-4.92 (m, 1H), 3.96 (s, 3H), 1.37 (d, J = 6.0 Hz, 6H) 525

HCl 429.47 1H-NMR (400 MHz, DMSO-d6): δ 12.96 (s, 1H), 9.60 (d, J = 8.0 Hz, 1H), 9.14 (d, J = 8.0 Hz, 1H), 8.68-8.74 (m, 2H), 8.46 (s, 1H), 7.95-7.96 (m, 2H), 7.74- 7.70 (m, 1H), 7.59-7.54 (m, 2H), 7.36 (s, 1H), 7.19-7.15 (m, 1H), 4.76-4.82 (m, 1H), 3.99 (s, 3H), 1.44 (d, J = 6.0 Hz, 6H). 526

452.45 1H-NMR (400 MHz, DMSO-d6): δ 9.70 (s, 1H), 9.52-9.53 (m, 1H), 8.64-8.67 (m, 2H), 7.89-7.94 (m, 2H), 7.73-7.74 (m, 1H), 7.48-7.53 (m, 3H), 7.32 (t, J = 83.6 Hz, 1H), 6.96-6.99 (m, 1H), 4.89- 4.92 (m, 1H), 3.98 (s, 3H), 1.38 (d, J = 6.0 Hz, 6H). 527

455.34 1H-NMR (400 MHz, DMSO-d6): δ 9.53 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 8.64- 8.68 (m, 2H), 8.12-8.13 (m, 2H), 7.90 (s, 1H), 7.54-7.58 (m, 1H), 7.34-7.36 (m, 2H), 4.86-4.92 (m, 1H), 3.98 (s, 3H), 1.40 (d, J = 6.0 Hz, 6H). 528

455.34 1H-NMR (400 MHz, DMSO-d6): δ 9.76 (s, 1H), 9.52 (d, J = 1.2 Hz, 1H), 8.64- 8.67 (m, 2H), 8.32 (d, J = 2.8 Hz, 1H), 7.94 (dd, J = 6.8, 2.4 Hz, 1H), 7.86 (s, 1H), 7.72 (d, J = 8.3 Hz, 1H), 7.53-7.56 (m, 1H), 7.32 (s, 1H), 4.14 (t, J = 6.4 Hz, 2H), 3.99 (s, 3H), 1.85-1.92 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H). 529

438.88 1H-NMR (400 MHz, DMSO-d6): δ 9.72 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.62- 8.66 (m, 2H), 8.20 (dd, J = 6.4, 2.4 Hz, 1H), 7.85-7.89 (m, 2H), 7.50-7.55 (m, 2H), 7.31 (s, 1H), 4.13 (t, J = 6.4 Hz, 2H), 3.98 (s, 3H), 1.82-1.90 (m, 2H), 1.06 (t, J = 7.6 Hz, 3H). 530

422.43 1H-NMR (400 MHz, DMSO-d6): δ 9.74- 9.76 (m, 1H), 9.52 (d, J = 1.6 Hz, 1H), 8.64-8.69 (m, 2H), 8.08-8.14 (m, 1H), 7.90 (s, 1H), 7.68-7.70 (m, 1H), 7.52- 7.60 (m, 2H), 7.34 (s, 1H), 4.16 (t, J = 6.4 Hz, 2H), 4.01 (s, 3H), 1.85-1.94 (m, 2H), 1.09 (t, J = 7.2 Hz, 3H). 531

HCl 429.47 1H-NMR (400 MHz, DMSO-d6): δ 12.86 (s, 1H), 9.59 (d, J = 1.6 Hz, 1H), 9.05 (d, J = 8.4 Hz, 1H), 8.85 (d, J = 8.0 Hz, 1H), 8.76-8.78 (m, 1H), 8.44 (s, 1H), 7.96 (dd, J = 8.0, 1.6 Hz, 2H), 7.70-7.73 (m, 2H), 7.53 (s, 1H), 7.37 (s, 1H), 6.96- 7.22 (m, 1H), 4.16 (t, J = 6.4 Hz, 2H), 4.01 (s, 3H), 1.86-1.90 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H). 532

452.45 1H-NMR (400 MHz, DMSO-d6): δ 9.67 (s, 1H), 9.50 (d, J = 4.0 Hz, 1H), 8.62- 8.65 (m, 2H), 7.89-7.92 (m, 3H), 7.44- 7.54 (m, 1H), 7.29-7.31 (m, 3H), 7.26 (t, J = 74.0 Hz, 1H), 4.14 (t, J = 6.8 Hz, 2H), 3.98 (s, 3H), 1.84-1.90 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H). 533

HCl 454.88 1H-NMR (400 MHz, DMSO-d6): δ 9.73 (s, 1H), 9.50 (d, J = 2.4 Hz, 1H), 8.62- 8.67 (m, 2H), 8.20 (dd, J = 7.2 Hz, 2.8 Hz, 1H), 7.85-7.89 (m, 2H), 7.51-7.57 (m, 2H), 7.33 (s, 1H), 4.31 (t, J = 4.0 Hz, 2H), 3.99 (s, 3H) 3.80 (t, J = 4.8 Hz, 2H), 3.37 (s, 3H). 534

445.47 1H-NMR (400 MHz, CD3OD): δ 9.34 (s, 1H), 8.92 (d, J = 6.0 Hz, 1H), 8.73 (m, 2H), 7.84 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.54 (t, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.15 (s, 2H), 4.21 (s, 2H), 3.92 (s, 3H), 3.78 (t, J = 4.4 Hz, 2H), 3.40 (s, 3H). 535

HCl 468.45 1H-NMR (400 MHz, DMSO-d6): δ 9.72 (s, 1H), 9.53 (s, 1H), 8.66 (d, J = 5.6 Hz, 2H), 7.91 (d, J = 6.4 Hz, 2H), 7.75 (d, J = 7.2 Hz, 1H), 7.51 (dd, J = 7.6 Hz, 2H), 7.34 (s, 1H), 7.30 (t, J = 74.0 Hz, 1H), 6.97 (dd, J = 8.0, 2.0 Hz, 1H), 4.32 (t, J = 4.4 Hz, 2H), 3.99 (s, 3H), 3.80 (t, J = 4.4 Hz, 2H), 3.37 (s, 3H). 536

468.91 1H-NMR (400 MHz, DMSO-d6): δ 10.42 (s, 1H), 9.47 (s, 1H), 8.96 (d, J = 6.4 Hz, 1H), 8.90 (d, J = 5.2 Hz, 1H), 8.11 (dd, J = 6.8 Hz, 2.4 Hz, 1H), 8.05 (s, 2H), 7.85- 7.94 (m, 2H), 7.55 (t, J = 9.2 Hz, 1H), 7.47 (s, 1H) 4.26 (t, J = 6.4 Hz, 2H), 4.01 (s, 3H), 3.55 (t, J = 6.0 Hz, 2H), 3.29 (s, 3H), 2.06-2.13 (m, 2H). 537

397.26 1H-NMR (400 MHz, DMSO-d6): δ 10.08 (s, 1H), 9.54 (s, 1H), 8.76 (s, 2H), 8.49 (d, J = 7.0 Hz, 1H), 8.36 (s, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.66-7.23 (m, 2H), 7.33 (s, 2H), 3.98 (s, 3H). 538

397.26 1H-NMR (400 MHz, DMSO-d6): 10.00 (s, 1H), 8.54 (d, J = 1.3 Hz, 1H), 8.71- 8.56 (m, 2H), 8.47 (d, J = 9.2 Hz, 1H), 8.17 (s, 1H), 8.16 (s, 1H), 7.59-7.56 (m, 1H), 7.35-7.30 (m, 3H), 3.98 (s, 3H). 539

364.35 1H-NMR (400 MHz, DMSO-d6): δ 9.94 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.70- 8.65 (m, 2H), 8.47 (d, J = 8.4 Hz, 1H), 8.12 (ddd, J = 13.2, 7.6, 2.8 Hz, 1H), 7.72-7.70 (m, 1H), 7.58-7.49 (m, 2H), 7.32-7.27 (m, 2H), 3.97 (s, 3H). 540

353.38 1H-NMR (400 MHz, DMSO-d6): δ 10.06 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.71- 8.66 (m, 2H), 8.50-8.43 (m, 2H), 8.26- 8.24 (m, 1M), 7.70-7.54 (m, 3H), 7.34- 7.30 (m, 2H), 3.98 (s, 3H), 541

394.37 1H-NMR (400 MHz, DMSO-d6): δ 9.93 (s, 1H), 9.54 (s, 1H), 8.68 (d, J = 5.2 Hz, 2H), 8.51 (d, J = 9.2 Hz, 1H), 7.96 (s, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.55-7.10 (m, 5H), 6.96 (dd, J = 8.0, 2.0 Hz, 1H), 3.96 (s, 3H). 542

371.39 1H-NMR (400 MHz, DMSO-d6): δ 12.97 (s, 1H), 9.60 (s, 1H), 9.10 (d, J = 8.4 Hz, 1H), 8.75-8.71 (m, 2H), 8.48 (s, 1H), 8.07 (d, J = 9.6 Hz, 1H), 7.95-7.90 (m, 2H), 7.74-7.70 (m, 1H), 7.58 (dd, J = 8.0, 4.8 Hz, 1H), 7.35-7.33 (m, 2H), 7.19 (t, J = 7.2 Hz, 1H), 3.97 (s, 3H). 543

431.7 1H-NMR (400 MHz, DMSO-d6): δ 10.03 (s, 1H), 9.49-9.48 (m, 1H), 8.69-8.67 (m, 1H), 8.63-8.59 9m, 1H), 8.31 (d, J = 2.4 Hz, 1H), 8.04 (s, 1H), 8.00 (s, 1H), 7.93-7.90 (m, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.56-7.53 (m, 1H), 4.07 (s, 3H). 544

431.7 1H-NMR (400 MHz, DMSO-d6): δ 9.94 (s, 1H), 9.46 (d, J = 3.2 Hz, 1H), 8.68 (dd, J = 4.8, 2.0 Hz, 1H), 8.60-8.57 (m, 1H), 8.09 (s, 1H), 8.08 (s, 1H), 7.97 (s, 2H), 7.54 (dd, J = 8.8, 4.8 Hz, 1H), 7.38 (t, J = 2.0 Hz, 1H), 4.05 (s, 3H). 545

415.25 1H-NMR (400 MHz, DMSO-d6): δ 10.02 (s, 1H), 9.47 (s, 1H), 8.70-8.62 (m, 2H), 8.19-8.17 (m, 1H), 8.04 (s, 1H), 8 00 (s, 1H), 7.84-7.88 (m, 1H), 7.59-7.53 (m, 2H), 4.07 (s, 3H). 546

398.79 1H-NMR (400 MHz, DMSO-d6): δ 10.01 (s, 1H), 9.47 (d, J = 1.6 Hz, 1H), 8.69- 8.67 (m, 1H), 8.62-8.59 (m, 1H), 8.08- 8.04 (m, 2H), 8.00 (s, 1H), 7.65-7.53 (m, 3H), 4.07 (s, 3H). 547

428.82 1H-NMR (400 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.45 (d, J = 1.2 Hz, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.83 (d, J = 4.0 Hz, 1H), 8.21 (s, 1H), 8.00 (s, 1H), 7.85-7.78 (m, 3H), 7.55-7.51 (m, 1H), 7.31 (t, J = 72.8 Hz, 1H), 7.05-7.03 (m, 1H), 4.07 (s, 3H). 548

387.82 1H-NMR (400 MHz, DMSO-d6): δ 10.62 (s, 1H), 9.38 (s, 1H), 8.97-8.90 (m, 2H), 8.32-8.26 (m, 3H), 7.97-7.94 (m, 2H), 7.69-7.65 (m, 2H), 4.08 (s, 3H). 549

405.84 1H-NMR (400 MHz, DMSO-d6): δ 12.98 (s, 1H), 9.36 (s, 1H), 8.94-8.77 (m, 3H), 8.48 (s, 1H), 7.98-7.83 (m, 4H), 7.59- 7.14 (m, 2H), 7.17 (s, 1H), 3.96 (s, 3H). 550

436.12 1H-NMR (400 MHz, DMSO-d6): δ 10.24 (s, 1H), 9.39 (s, 1H), 8.87 (s, 1H), 8.81 (d, J = 4.4 Hz, 1H), 8.73 (d, J = 8.0 Hz, 1H), 8.24 (s, 1H), 8.01 (s, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.76-7.73 (m, 1H), 7.66 (d, J = 8.8 Hz, 1H). 551

410.26 1H-NMR (400 MHz, DMSO-d6): δ 13.15 (s, 1H), 9.46 (s, 1H), 8.87 (d, J = 8.4 Hz, 1H), 8.74 (d, J = 3.6 Hz, 1H), 8.68 (d, J = 7.2 Hz, 1H), 8.49 (s, 1H), 8.23 (s, 1H), 8.02 (s, 2H), 7.94 (d, J = 8.0 Hz, 1H), 7.69-7.61 (m, 2H), 7.23-7.20 (m, 1H). 552

433.24 1H-NMR (400 MHz, DMSO-d6): δ 10.30 (s, 1H), 9.53 (s, 1H), 9.02 (s, 1H), 8.83- 8.80 (m, 2H), 8.20 (s, 1H), 7.91 (s, 1H), 7.81-7.79 (m, 1H), 7.74-7.71 (m, 1H), 7.56-7.52 (m, 1H), 7.30 (t, J = 73.6 Hz, 1H), 7.05 (d, J = 8.8 Hz, 1H). 553

419.67 1H-NMR (400 MHz, DMSO-d6): δ 10.43 (s, 1H), 9.40 (s, 1H), 8.97 (s, 1H), 8.89- 8.85 (m, 2H), 8.15-8.14 (m, 1H), 8.05 (s, 1H), 7.89-7.87 (m, 2H), 7.51-7.47 (m, 1H). 554

403.21 1H-NMR (400 MHz, DMSO-d6): δ 10.39 (s, 1H), 9.40 (s, 1H), 8.96 (s, 1H), 8.84- 8.89 (m, 2H), 8.04-8.00 (m, 2H), 7.88 (s, 1H), 7.69-7.67 (m, 1H), 7.54-7.47 (m, 1H). 555

436.12 1H-NMR (400 MHz, DMSO-d6): δ 10.26 (s, 1H), 8.28 (s, 1H), 8.88 (d, J = 4.8 Hz, 1H), 8.85 (s, 1H), 8.76 (d, J = 8.0 Hz, 1H), 7.97 (s, 1H), 7.96 (s, 1H), 7.90- 7.86 (m, 2H), 7.29 (s, 1H). 556

441.31 1H-NMR (400 MHz, DMSO-d6): δ 9.74 (s, 1H), 9.50 (s, 1H), 8.66-8.64 (m, 2H), 8.31 (s, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.84 (s, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.52 (dd, J = 7.4, 5.0 Hz, 1H), 7.29 (s, 1H), 4.22 (q, J = 6.8 Hz, 2H), 3.97 (s, 3H), 1.45 (t, J = 6.8 Hz, 3H). 557

424.86 1H-NMR (400 MHz, DMSO-d6) δ 9.93 (s, 1H), 9.48 (s, 1H), 8.74-8.73 (m, 2H), 8.18-8.16 (m, 1H), 7.90-7.85 (m, 2H), 7.67-7.65 (m, 1H), 7.53 (t, J = 9 Hz, 1H), 7.33 (s, 1H), 4.24 (q, J = 7.2 Hz, 2H), 3.98 (s, 3H), 1.46 (t, J = 7.2 Hz, 3H). 558

408.4 1H-NMR (400 MHz, DMSO-d6): δ 9.68 (s, 1H), 9.49 (s, 1H), 8.66-8.61 (m, 2H), 8.10-8.04 (m, 1H), 7.84 (s, 1H), 7.66- 7.64 (m, 1H), 7.56-7.49 (m, 2H), 7.30 (s, 1H), 4.23 (q, J = 6.8 Hz, 2H), 3.98 (s, 3H), 1.46 (t, J = 6.8 Hz, 3H). 559

397.43 1H-NMR (400 MHz, DMSO-d6): δ 10.27 (s, 1H), 9.43 (s, 1H), 8.82-8.78 (m, 2H), 8.32 (s, 1H), 8.23 (d, J = 7.6 Hz, 1H), 7.98 (s, 1H), 7.77-7.73 (m, 1H), 7.68- 7.60 (m, 2H), 7.35 (s, 1H), 4.23 (q, J = 6.8 Hz, 2H), 3.96 (s, 3H), 1.44 (t, J = 6.8 Hz, 3H). 560

410.83 1H-NMR (400 MHz, DMSO-d6): δ 9.89 (s, 1H), 9.48 (s, 1H), 8.74 (d, J = 6.0 Hz, 2H), 8.16 (dd, J = 6.8, 2.4 Hz, 1H), 7.85- 7.88 (m, 2H), 7.67 (t, J = 6.4 Hz, 1H), 7.53 (t, J = 8.7 Hz, 1H), 7.32 (s, 1H), 3.93 (s, 6H). 561

394.37 1H-NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H), 9.49 (s, 1H), 8.77 (d, J = 6.4 Hz, 2H), 8.02-8.08 (m, 1H), 7.90 (s, 1H), 7.70-7.74 (m, 1H), 7.64-7.66 (m, 1H), 7.52-7.59 (m, 1H), 7.33 (s, 1H), 3.99 (s, 3H), 3.98 (s, 3H). 562

383.4 1H-NMR (400 MHz, DMSO-d6): δ 9.87 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.63- 8.68 (m, 2H), 8.38 (s, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.89 (s, 1H), 7.69 (t, J = 7.8 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.52- 7.56 (m, 1H), 7.33 (s, 1H), 4.00 (s, 3H), 3.98 (s, 3H). 563

427.28 1H-NMR (400 MHz, DMSO-d6): δ 9.70 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.66 (d, J = 4.8 Hz, 1H), 8.62 (d, J = 8.0 Hz, 1H), 8.11 (d, J = 1.2 Hz, 2H), 7.73 (s, 1H), 7.53 (dd, J = 7.6, 4.8 Hz, 1H), 7.31 (s, 1H), 7.28 (s, 1H), 3.97 (s, 6H). 564

2 HCl 389.3824 1H-NMR (400 MHz, DMSO-d6): δ 13.08 (s, 1H), 9.40 (s, 1H), 8.86 (d, J = 8.1 Hz, 1H), 8.78 (s, 1H), 8.53 (d, J = 10.0 Hz, 1H), 8.46 (s, 1H), 8.03 (d, J = 8.7 Hz, 1H), 8.00-7.88 (m, 2H), 7.73 (t, J = 7.8 Hz, 1H), 7.66 (d, J = 10.3 Hz, 2H), 7.28 (t, J = 7.6 Hz, 1H), 3.99 (s, 3H). 565

2 HCl 401.4180 1H-NMR (400 MHz, CD3OD): δ 9.20 (s, 1H), 8.85 (s, 1H), 8.78 (s, 1H), 8.72 (d, J = 8.2 Hz, 1H), 8.02 (d, J = 9.1 Hz, 1H), 7.95 (d, J = 7.7 Hz, 1H), 7.77-7.67 (m, 3H), 7.39 (t, J = 7.6 Hz, 1H), 4.18 (s, 3H), 4.08 (s, 3H). ¹H-NMR LCMS Purity Method for Number Solvent LCMS Protocol Percent Coupling 522 DMSO 454.9, 457.0 (M + 1), 228.8 (M/2 + 1) Method A (TFA) 95 Method N, G1 523 DMSO 439.1, 441.1 (M + 1), 220.1, 220.8 (M/2 + 1) Method A (TFA) 95 Method N, G1 524 DMSO 423.2 (M + 1), 212.2 (M/2 + 1) Method A (TFA) 95 Method N, G1 525 DMSO 430.2 (M + 1) 215.7 (M/2 + 1) Method A (TFA) 95 Method N, G1 526 DMSO 453.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 527 DMSO 455.0, 457.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 528 DMSO 455.1, 457.1 (M + 1) 229.1 (M/2 + 1) Method A (TFA) 95 Method N, G1 529 DMSO 439.1, 441.1 (M + 1) 220.1, 220.8 (M/2 + 1) Method A (TFA) 95 Method N, G1 530 DMSO 423.0 (M + 1) 445.0 (M + 23) 212.1 (M/2 + 1) Method A (TFA) 95 Method N, G1 531 DMSO 430.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 532 DMSO 453.1 (M + 1) 227.2 (M/2 + 1) Method A (TFA) 95 Method N, G1 533 DMSO 455.1, 457.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 534 CD3OD 446.2, 447.2 (M + 1) Method B (NH4HCO3) 95 Method N, G1 535 DMSO 469.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 536 DMSO 469.0, 471.0 (M + 1) 234.9, 235.6 (M/2 + 1) Method A (TFA) 95 Method N, G1 537 DMSO 397.1, 399.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 538 DMSO 397.0, 399.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 539 DMSO 365.2 (M + 1) Method B (NH4HCO3) 95 Method N, G1 540 DMSO 354.2 (M + 1) Method B (NH4HCO3) 95 Method N, G1 541 DMSO 395.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 542 DMSO 372.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 543 DMSO 430.9, 432.9, 434.9 (M + 1) Method B (NH4HCO3) 95 Method N, G1 544 DMSO 430.9, 432.9, 434.9 (M + 1) Method B (NH4HCO3) 95 Method N, G1 545 DMSO 415.1, 417.0, 419.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 546 DMSO 399.1, 401.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 547 DMSO 429.1, 431.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 548 DMSO 387.9, 390.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 549 DMSO 405.9, 408.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 550 DMSO 434.9, 436.9, 438.8 (M + 1) Method B (NH4HCO3) 95 Method N, G1 551 DMSO 410.0, 412.0, 413.9 (M + 1) 432.0 (M + 22) Method A (TFA) 95 Method N, G1 552 DMSO 432.9, 434.9 (M + 1) Method B (NH4HCO3) 95 Method N, G1 553 DMSO 419.0, 421.0, 423.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 554 DMSO 402.9, 404.9 (M + 1) Method B (NH4HCO3) 95 Method N, G1 555 DMSO 434.9, 436.9, 438.9 (M + 1) Method A (TFA) 95 Method N, G1 556 DMSO 441.0, 443.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 557 DMSO 425.0, 427.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 558 DMSO 409.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 559 DMSO 398.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 560 DMSO 411.1, 413.1 (M + 1) Method A (TFA) 95 Method N, G1 561 DMSO 395.0 (M + 1) 198.1 (M/2 + 1) Method A (TFA) 95 Method N, G1 562 DMSO 384.2 (M + 1) Method B (NH4HCO3) 95 Method N, G1 563 DMSO 427.1, 429.1, 431.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 564 DMSO 390.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 565 MeOD 402.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1

Method O1: CuI/Pd(PPh₃)₂Cl₂/Et₃N/DMF/rt

-   -   O2: Propargyl bromide/CuI/Pd(PPh₃)₂C₂/Nucleophile/DMF/rt     -   O3: Pd(OAc)₂/PPh₃/TBAB/piperidine/THF—H₂O/rt

Method O1: 6-(3-(tert-butyldimethylsilyloxy)prop-1-ynyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (xv-a)

A suspension of N-(3-chloro-4-fluorophenyl)-6-iodo-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 5-iodo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (1.00 g, 2.10 mmol), tert-butyldimethyl(2-propynyloxy)silane (0.85 ml, 4.20 mmol), copper(I) iodide (4.0 mg, 0.021 mmol), dichlorobis(triphenylphosphine) palladium (II) (Pd(PPh₃)₂Cl₂) (29 mg, 0.042 mmol), and triethylamine (1.17 ml, 8.39 mmol) in DMF (15 mL) was stirred overnight at room temperature under argon atmosphere, Water (30 mL) and ethyl acetate (30 mL) were added to the mixture. The resultant precipitate was removed by filtration. The filtrate was extracted with EtOAc (2×50 mL). The combined organic layer was washed with water (1×100 mL) and brine (1×100 mL) and was dried over Na₂SO₄. After filtration and evaporation, the crude product was obtained, which was purified by column chromatography on silica gel (eluted with hexane/ethyl acetate 6:1 to 1:3) to give 0.73 g of 6-(3-(tert-butyldimethylsilyloxy)prop-1-ynyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine as light brown solid (67%). LCMS m/z=519 (M+1) (Method D) (retention time=3.22 min). ¹H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.35 (s, 1H), 8.62-8.44 (m, 3H), 8.11 (dd, J=6.8, 2.6 Hz, 1H), 7.76-7.66 (m, 3H), 7.45-7.30 (m, 2H), 4.48 (s, 2H), 0.75 (s, 9H), 0.16 (s, 6H).

Method P: 6-(3-(tert-butyldimethylsilyloxy)propyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (xvi-a)

A suspension of 6-(3-(tert-butyldimethyl silyloxy)prop-1-ynyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (0.20 g, 0.39 mmol) and 5% Pd—S—C (40 mg) in EtOAc (5 mL) and MeOH (5 mL) was stirred overnight at room temperature under hydrogen atmosphere. The reaction mixture was filtered through Celite. The filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel (eluted with hexane/ethyl acetate 6:1 to 2:3) to give 0.15 g of 6-(3-(tert-butyldimethylsilyloxy)propyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine as yellow solid (74%). LCMS m/z=523 (M+1) (Method D) (retention time=3.35 min). ¹H NMR (300 MHz, CDCl₃) δ 9.69 (dd, J=2.2, 0.8 Hz, 1H), 8.79-8.65 (m, 2H), 8.07 (dd, J=6.5, 2.7 Hz, 1H), 7.94 (d, J=8.5 Hz, 1H), 7.76-7.61 (m, 3H), 7.47-7.37 (m, 2H), 7.31-7.18 (min, 1H), 3.68 (t, J=6.1 Hz, 2H), 3.01-2.83 (m, 2H), 2.03-1.86 (m, 2H), 0.94 (s, 9H), 0.08 (s, 6H).

Method Q: 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propan-1-ol (xvii-a)

To a suspension of 6-(3-(tert-butyldimethylsilyloxy)propyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (0.35 g, 0.67 mmol) in MeOH (10 mL) was added 1-chloroethyl chloroformate (7.2 μl, 0.067 mmol). The mixture was stirred overnight at room temperature. Methanol was removed in vacuo. Sat. NaHCO₃ aqueous (10 mL) and CH₂Cl₂ (10 mL) were added to the residue and stirred for a while. The resultant solid was collected by filtration and dried to give 0.25 g of 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propan-1-ol as light yellow solid (91%). MS i/z=409 (M+1) (Method D) (retention time=1.71 min), ¹H NMR (300 MHz, DMSO) δ 10.01 (s, 1H), 9.51 (s, 1H), 8.66 (m, 2H), 8.37 (s, 1H), 8.29-8.20 (m, 1H), 7.94-7.67 (m, 3H), 7.63-7.43 (m, 2H), 4.60 (t, J=5.0 Hz, 1H), 3.56-3.35 (m, 2H), 2.94-2.69 (m, 2H), 2.15-1.56 (m, 2H).

Method R: 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propyl methanesulfonate (xviii-a)

To a suspension of 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propan-1-ol (0.25 g, 0.61 mmol) and triethylamine (0.17 ml, 1.22 mmol) in CH₂Cl₂ (10 mL) was added methanesulfonyl chloride (0.057 ml, 0.73 mmol). The mixture was stirred at room temperature for 1 h. Water (10 mL.) was added to the mixture and stirred for a while. The resultant precipitate was collected by filtration and washed with CH₂Cl₂ and dried to give 0.27 g of 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propyl methanesulfonate as pale yellow solid (91%), which was used without further purification.

Method G4: N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)propyl)-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (xviv-a)

(This method is representative of method G4 and G5. These two methods can be implemented in a similar way except for substitution of the appropriate solvent and temperature) A solution of 3.-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propyl methanesulfonate (40 mg, 82 mmol) and 40% Me₂NH aqueous (1 mL) in methanol (2 mL) was placed in a microwave reaction vial. The mixture was heated under microwave irradiation conditions at 150° C. for 30 minutes after which the solvent was removed in vacuo. The crude product was obtained, which was purified by column chromatography on basic silica gel (eluted with ethyl acetate/methanol 1:0→5:1). The HCl salt generated by 4 M HCl in dioxane was crystallized from 2-propanol to give 10 mg of N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)propyl)-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride as pale brown powder (24%). LCMS m/z=436 (M+1) (Method C) (retention time=1.68 min). ¹H NMR (300 MHz, DMSO) δ 10.59 (s, 1H), 10.18 (s, 1H), 9.51 (s, 1H), 8.98-8.76 (m, 2H), 8.65 (s, 1H), 8.26 (dd, J=6.8, 2.6 Hz, 1H), 8.05-7.74 (m, 4H), 7.54 (t, J=9.1 Hz, 1H), 3.19-3.03 (m, 2H), 2.97-2.83 (m, 2H), 2.78 (s, 3H), 2.77 (s, 3H), 2.16 (s, 2H).

N-(3-chloro-4-florophenyl)-6-(3-morpholinoprop-1-ynyl)-2-(pyridin-3-yl) quinazolin-4-amine (xx-a)

To a solution of N-(3-chloro-4-fluorophenyl)-6-iodo-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 5-iodo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (2.19 g, 4.6 mmol, 1 eq.), Pd(PPh₃)₂Cl₂ (161 mg, 0.23 mmol, 0.05 eq.), CuI (87 mg, 0.46 mmol, 0.1 eq.) in morpholine (15 mL) was added 3-bromoprop-1-yne (814 mg, 6.9 mmol, 1.5 eq.) at 0° C. under Ar atmosphere, following a procedure from Tetrahedron, 2007, 63, 10671-10683. The mixture was stirred at 40° C. overnight. After cooling, the mixture was filtered and methanol (60 mL) was added to the filtrate to form a precipitate. The precipitate was collected and re-crystallized from ethyl acetate twice to afford 1.60 g of xx-a as yellow solid (yield 74%). LCMS m/z=474.1 (M+1), 476.1 (M+3) (Method C) (retention time=1.97 min).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 8 substituting with appropriate nucleophile.

TABLE 3 Num- Salt Molecular ber Product type Mass ¹H-NMR 566

519.085 1H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.35 (s, 1H), 8.62-8.44 (m, 3H), 8.11 (dd, J = 6.8, 2.6 Hz, 1H), 7.76-7.66 (m, 3H), 7.45-7.30 (m, 2H), 4.48 (s, 2H), 0.75 (s, 9H), 0.00 (s, 6H). 567

523.117 1H NMR (300 MHz, CDCl3) δ 9.69 (dd, J = 2.2, 0.8 Hz, 1H), 8.79-8.65 (m, 2H), 8.07 (dd, J = 6.5, 2.7 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.76- 7.61 (m, 3H), 7.47-7.37 (m, 2H), 7.31-7.18 (m, 1H), 3.68 (t, J = 6.1 Hz, 2H), 3.01-2.83 (m, 2H), 2.03-1. 568

408.856 1H NMR (300 MHz, DMSO) δ 10.01 (s, 1H), 9.51 (s, 1H), 8.66 (m, 2H), 8.37 (s, 1H), 8.29-8.20 (m, 1H), 7.94- 7.67 (m, 3H), 7.63-7.43 (m, 2H), 4.60 (t, J = 5.0 Hz, 1H), 3.56-3.35 (m, 2H), 2.94-2.69 (m, 2H), 2.15-1.56 (m, 2H). 569

2 HCl 508.846 1H NMR (300 MHz, DMSO) δ 10.59 (s, 1H), 10.18 (s, 1H), 9.51 (s, 1H), 8.98-8.76 (m, 2H), 8.65 (s, 1H), 8.26 (dd, J = 6.8, 2.6 Hz, 1H), 8.05-7.74 (m, 4H), 7.54 (t, J = 9.1 Hz, 1H), 3.19-3.03 (m, 2H), 2.97-2.83 (m, 2H), 2.78 (s, 3H), 2.77 (s, 3H), 2. 570

409.841 1H NMR (300 MHz, CDCl3) δ 9.49 (d, J = 1.4 Hz, 1H), 8.73-8.51 (m, 2H), 8.14 (s, 1H), 8.01 (d, J = 8.6 Hz, 1H), 7.81 (dd, J = 8.6, 1.9 Hz, 1H), 7.51-7.13 (m, 4H), 3.77 (dd, J = 11.5, 6.2 Hz, 2H), 3.11-2.85 (m, 2H), 2.16-1.93 (m, 2H), 1.44 (t, J = 5 571

2 HCl 550.882 1H NMR (300 MHz, DMSO) δ 10.83- 10.37 (m, 2H), 9.51 (s, 1H), 8.97-8.74 (m, 2H), 8.62 (s, 1H), 8.27 (d, J = 4.2 Hz, 1H), 8.05-7.72 (m, 4H), 7.54 (t, J = 9.0 Hz, 1H), 3.96 (d, J = 12.7 Hz, 2H), 3.76 (t, J = 12.1 Hz, 2H), 3.47 (d, J = 12.0 Hz, 2H), 3.24 572

422.882 1H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.51 (s, 1H), 8.75-8.60 (m, 2H), 8.37 (s, 1H), 8.26 (dd, J = 6.9, 2.6 Hz, 1H), 7.99-7.88 (m, 1H), 7.88- 7.73 (m, 2H), 7.60-7.46 (m, 2H), 3.39 (dd, J = 8.4, 4.1 Hz, 2H), 3.27 (s, 3H), 2.92-2.78 (m, 2H), 2.05 573

HCl 548.909 1H NMR (300 MHz, DMSO) δ 10.69 (s, 1H), 10.12 (s, 1H), 9.51 (s, 1H), 9.02-8.30 (m, 2H), 8.69 (s, 1H), 8.27 (dd, J = 6.9, 2.7 Hz, 1H), 8.08-7.78 (m, 4H), 7.54 (t, J = 9.1 Hz, 1H), 3.46 (d, J = 10.2 Hz, 2H), 3.17-3.00 (m, 2H), 2.99-2.75 (m, 4H), 2.3 574

HCl 500.395 1H NMR (300 MHz, DMSO) δ 10.68 (s, 1H), 9.49 (s, 1H), 9.12-8.99 (m, 1H), 8.94 (d, J = 3.9 Hz, 1H), 8.58 (d, J = 11.5 Hz, 1H), 8.17 (dd, J = 6.7, 2.6 Hz, 1H), 8.07-7.82 (m, 5H), 7.55 (t, J = 9.1 Hz, 1H), 3.43-3.29 (m, 2H), 3.08-2.65 (m, 5H), 2.09- 575

HCl 600.39 1H NMR (300 MHz, DMSO) δ 11.79 (s, 1H), 10.81 (s, 1H), 9.50 (s, 1H), 8.98 (d, J = 8.2 Hz, 1H) 8.89 (d, J = 5.0 Hz, 1H), 8.75 (s, 1H), 8.27 (d, J = 4.8 Hz, 1H), 8.10-7.79 (m, 4H), 7.53 (t, J = 9.1 Hz, 1H), 5.18-3.09 (m, 10H), 3.01-2.69 (m, 5H), 2.37 576

473.93 1H NMR (300 MHz, DMSO) δ 10.17 (s, 1H), 9.52 (s, 1H), 8.70 (s, 1H), 8.66 (d, J = 8.1 Hz, 1H), 8.55 (d, J = 8.4 Hz, 1H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 7.93 (s, 2H), 7.70 (d, J = 8.4 Hz, 1H), 7.61- 7.51 (m, 2H), 3.67-3.61 (m, 6H), 2.61- 2.55 (m, 4H). 577

435.92 1H NMR (300 MHz, DMSO) δ 10.08 (s, 1H), 9.54 (s, 1H), 8.77-8.63 (m, 2H), 8.52 (d, J = 8.4 Hz, 1H), 8.29 (d, J = 6.8 Hz, 1H), 7.93 (s, 1H), 7.79 (s, 1H), 7.64- 7.51 (m, 3H), 3.00 (t, J = 8.2 Hz, 2H), 2.87 (t, J = 7.6 Hz, 2H), 2.72 (s, 6H), 2.14-1.99 ( 578

519.09 1H NMR (300 MHz, DMSO) δ 10.17 (s, 1H), 9.67-9.43 (m, 1H), 8.68 (s, 2H), 8.55 (d, J = 8.4 Hz, 1H), 8.28 (s, 1H), 7.89 (s, 2H), 7.68 (s, 1H), 7.56 (d, J = 9.1 Hz, 2H), 4.64 (s, 2H), 0.92 (s, 9H), 0.18 (s, 6H). 579

404.82 1H NMR (300 MHz, DMSO) δ 10.19 (s, 1H), 9.51 (s, 1H), 8.65 (d, J = 8.1 Hz, 2H), 8.64 (d, J = 8.4 Hz, 1H), 8.26 (s, 1H), 7.85 (s, 2H), 7.67-7.60 (m, 1H), 7.52 (d, J = 7.0 Hz, 2H), 5.48 (s, 1H), 4.39 (d, J = 5.8 Hz, 2H). 580

477.96 1H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.51 (s, 1H), 8.73-8.61 (m, 2H), 8.45 (d, J = 8.6 Hz, 1H), 8.28 (dd, J = 6.8, 2.5 Hz, 1H), 7.97-7.86 (m, 1H), 7.71 (s, 1H), 7.60-7.47 (m, 3H), 3.63-3.51 (m, 4H), 2.82 (t, J = 7.5 Hz, 2H), 2.42-2.25 (m, 6H), 581

523.12 1H NMR (300 MHz, CDCl3) δ 9.67 (d, J = 1.3 Hz, 1H), 8.76-8.66 (m, 2H), 8.03 (dd, J = 6.5, 5.7 Hz, 1H), 7.82- 7.74 (m, 2H), 7.64 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 7.46 (s, 1H), 7.44-7.37 (m, 2H), 7.20 (t, J = 3.7 Hz, 1H), 3.67 (t, J = 6.1 Hz, 2H), 2.95 582

408.86 1H NMR (300 MHz, CD3OD) δ 9.50 (d, J = 1.3 Hz, 1H), 8.77 (d, J = 8.0 Hz. 1H), 8.62 (dd, J = 4.9, 1.6 Hz, 1H), 8.26 (d, J = 8.5 Hz, 1H), 8.18 (dd, J = 6.7, 2.6 Hz, 1H), 7.83-7.71 (m, 2H), 7.61-7.47 (m, 2H), 7.30 (t, J = 9.0 Hz, 1H), 3.65 (t, J = 6.4 Hz 583

494.03 1H NMR (300 MHz, CD3OD) δ 9.50- 9.46 (m, 1H), 8.77-8.70 (m, 1H), 8.61 (dd, J = 4.9, 1.6 Hz, 1H), 8.22 (d, J = 8.5 Hz, 1H), 8.17 (dd, J = 6.8, 2.6 Hz, 1H), 7.75 (ddd, J = 9.0, 4.2, 2.7 Hz, 1H), 7.70 (s, 1H), 7.54 (ddd, J = 8.0, 4.9, 0.8 Hz, 1H), 7.46 (d 584

522 1H NMR (300 MHz, DMSO) δ 10.15 (s, 1H), 8.74-8.61 (m, 2H), 8.25 (d, J = 3.5 Hz, 1H), 7.96-7.80 (m, 4H), 7.59- 7.46 (m, 2H), 3.79 (s, 2H), 3.18 (s, 4H), 3.06 (s, 4H). 585

526.06 1H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.52 (d, J = 2.0 Hz, 1H), 8.72- 8.62 (m, 2H), 8.37 (s, 1H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 7.96-7.88 (m, 1H), 7.83 (d, J = 2.6 Hz, 2H), 7.61-7.50 (m, 2H), 3.10 (s, J = 17.4 Hz, 6H), 2.95-2.80 (m, 8H), 2.58- 586

HCl 494.82 1H NMR (300 MHz, DMSO) δ 10.49 (s, 1H), 9.50 (s, 1H), 8.96-8.53 (m, 5H), 8.25 (dd, J = 6.9, 2.5 Hz, 1H), 8.05-7.73 (m, 4H), 7.54 (t, J = 9.1 Hz, 1H), 3.02-2.78 (m, 4H), 2.64-2.37 (m, 3H), 2.15-1.99 (m, 2H). 587

HCl 480.79 1H NMR (300 MHz, DMSO) δ 10.61 (s, 1H), 9.50 (s, 1H), 9.00-8.78 (m, 2H), 8.66 (s, 1H), 8.25 (dd, J = 6.8, 2.6 Hz, 1H), 8.13-7.75 (m, 7H), 7.54 (t, J = 9.1 Hz, 1H), 3.02-2.73 (m, 4H), 2.14-1.94 (m, 2H). 588

431.89 1H NMR (300 MHz, DMSO) δ 10.18 (s, 1H), 8.65 (d, J = 6.6 Hz, 1H), 8.56 (d, J = 8.7 Hz, 1H), 8.28 (dd, J = 6.9, 2.5 Hz, 1H), 8.01 (s, 1H), 7.91 (dd, J = 7.0, 3.5 Hz, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.68-7.39 (m, 3H), 4.07 (s, 2H), 2.67 (s, 6H). 589

435.92 1H NMR (300 MHz, DMSO) δ 10.06 (s, 1H), 9.53 (s, 1H), 8.76-8.62 (m, 2H), 8.51 (d, J = 8.4 Hz, 1H), 8.28 (dd, J = 6.9, 2.5 Hz, 1H), 7.92 (dd, J = 4.5, 1.8 Hz, 1H), 7.79 (s, 1H), 7.65-7.49 (m, 3H), 3.08-2.95 (m, 2H), 2.86 (t, J = 7.6 Hz, 2H), 2.71 (s, J = 7.2 Hz, 6H), 2.05 (dt, J = 13.8, 7.1 Hz, 2H). 590

409.44 1H NMR (300 MHz, DMSO): δ 13.19 (s, 1H), 9.11 (s, 1H), 8.88 (s, 1H), 8.53 (s, 1H), 8.29 (s, 1H), 8.06 (s, 1H), 7.94 (d, J = 10.6 Hz, 4H), 7.78 (s, 1H), 7.25 (s, 1H), 4.44 (s, 2H), 3.37 (s, 3H). 591

413.47 ¹H-NMR Retention LCMS Purity Method for Number Solvent LCMS Time (Min) Protocol Percent Coupling 566 DMSO 519 (M + 1) 3.22 Method D 96 Method O1 567 DMSO 523 (M + 1) 3.35 Method D 100 Methods O1, P 568 DMSO 409 (M + 1) 1.71 Method D 100 Methods O1, P, Q 569 DMSO 436 (M + 1) 1.68 Method C 100 Method G4 570 CDCl3 410 (M + 1) 1.95 Method D 100 Methods O1, P, Q 571 DMSO 478 (M + 1) 2.01 Method C 100 Method G4 572 DMSO 423 (M + 1) 2.09 Method D 100 Method G4 573 DMSO 476 (M + 1) 1.79 Method C 100 Method G4 574 DMSO 464 (M + 1) 1.78 Method D 95 Method G4 followed by acylation with acetyl chloride/TE A/DCM, rt 575 DMSO 491 (M + 1) 1.76 Method C 100 Method G4 576 DMSO 473.9 (M + 1) 2.2 Method C 100 Method O1 577 DMSO 436.0 (M + 1) 1.68 Method C 100 Methods O1, P 578 DMSO 518.8 (M + 1) 3.18 Method C 100 Method O1 579 DMSO 404.9 (M + 1) 2.05 Method C 100 Methods O1, Q 580 DMSO 477.9 (M + 1) 1.99 Method C 100 Methods O1, P 581 CDCl3 523.1 (M + 1) 3.35 Method C 100 Methods O1, P 582 CD3OD 409.0 (M + 1) 1.99 Method C 100 Methods O1, P, Q 583 CD3OD 494.0 (M + 1) 2.29 Method C 91 Method G4 584 DMSO 522.0 (M + 1) 2.18 Method C 100 Method O2 585 DMSO 526.1 (M + 1) 2.11 Method C 91 Methods O2, P 586 DMSO 422 (M + 1) 1.64 Method B (Ammonium formate) 100 Method O2 587 DMSO 408 (M + 1) 1.60 Method B (Ammonium formate) 100 Method O2 588 DMSO 431.9 (M + 1) Method C 99 Method O1 589 DMSO 436.0 (M + 1) Method C 99 Method O1, P 590 DMSO 410.5 (M + 1) Method C 95 Method O1 591 DMSO 414.5 (M + 1) Method C 95 Method O1, P

Method N1: Pd(APhos)₂Cl₂/K₃PO₄ or Cs₂CO₃/Boronic acid or ester/Dioxane-H₂O, heat Method N2: Pd(PPh₃)₂Cl₂/K₂CO₃ Boronic acid or ester/DME-EtOH—H₂O/microwave, 120° C.

Method N3: Pd(OAc)₂/Xphos/Cs₂CO₃/THF—H₂O, 80° C.

Method N4: Pd(OAc)₂/Sphos/K₂CO₃/MeCN—H₂O, microwave, 120° C. Method N5: Pd(PPh₃)₄/K₃PO₄/Dioxane-H₂O, heat Method N6: Pd(dppf)Cl₂—CH₂Cl₂/K₃PO₄/Dioxane-H₂O, heat

N-(3-chloro-4-fluorophenyl)-6-(6-methoxypyridin-3-yl)-2-(pyridin-3-yl)quinazolin-4-amine (xxi-a)

A 2.0 dram reaction vial was charged with 6-bromo-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 5-bromo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (100 mg, 0.233 mmol, 1.0 equiv), 6-methoxypyridin-3-ylboronic acid (44.5 mg, 0.291 mmol, 1.25 equiv), Pd(APhos)₂Cl₂ (6.6 mg, 0.0093 mmol, 4 mol %) and potassium phosphate monohydrate (69 mg, 0.70 mmol, 3.0 equiv). The mixture was suspended in dioxane/water (9:1, 4 mL), and the reaction was heated at 90° C. for 14 h. The reaction mixture was cooled to room temperature, diluted with water (15 mL) and the resultant precipitate was collected by filtration. The crude product was purified by stirring in methanol for 30 min at 60° C. to give the desired product as a pale yellow solid (58 mg, 54%) LCMS m/z=458.1 (M+1) (Method C) (retention time=2.56 min). ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.53 (s, 1H), 8.82 (s, 1H), 8.70 (dd, J=16.9, 5.4 Hz, 3H), 8.25 (d, J=8.6 Hz, 3H), 8.01-7.87 (m, 2H), 7.57 (dd, J=11.2, 6.0 Hz, 2H), 7.03 (d, J=8.6 Hz, 1H), 3.94 (s, 3H).

N-(3-chloro-4-fluorophenyl)-7-(6-methoxypyridin-3-yl)-2-(pyridin-3-yl)quinazolin-4-amine (xxi-b)

A microwave vial was charged with 7-bromo-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 4-bromo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (100 mg, 0.233 mmol), 6-methoxypyridin-3-ylboronic acid (44.5 mg, 0.291 mmol, 1.25 equiv), Pd(PPh₃)₂Cl₂ (8.1 mg, 5 mol %) and potassium carbonate (160.1 mg, 1.16 mmol, 5.0 equiv). The mixture was suspended in DME/water/ethanol (7:3:2, 4 mL), and the reaction was heated under microwave irradiation conditions at 120° C. for 10 minutes. The crude reaction mixture was diluted with water (10 mL) and then filtered. The solid residue was dissolved in methanol/THF (1:1, 5 mL) with heating and then filtered through Celite to remove the catalyst. The resulting filtrate was concentrated to afford the desired product as a tan solid (7.0 mg, 6.5%). LCMS m/z=458.1 (M+1) (Method C) (retention time=2.51 min). ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.55 (s, 1H), 8.76 (d, J=2.5 Hz, 1H), 8.72-8.65 (m, 2H), 8.62 (d, J=8.6 Hz, 1H), 8.34-8.26 (m, 2H), 8.15 (d, J=1.6 Hz, 1H), 8.02 (d, J=8.7 Hz, 1H), 7.97-7.88 (m, 1H), 7.61-7.49 (m, 2H), 6.99 (d, J=8.7 Hz, 1H), 3.94 (s, 3H).

N-(3-chloro-4-fluorophenyl)-7-(piperidin-1-ylmethyl)-2-(pyridin-3-yl)quinazolin-4-amine (xxi-c)

A dry 15 mL sealed tube was charged with 7-bromo-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 4-bromo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (100 mg, 0.233 mmol), potassium 1-trifluoroboratomethylpiperidine (52.5 mg, 0.256 mmol), cesium carbonate (227.5 mg, 0.698 mmol), Pd(OAc)₂ (1.6 mg, 3 mol %) and XPhos (6.7 mmol, 6 mol %) in THF/water (10:1, 3.3 mL). The reaction mixture was stirred at 80° C. for 16 hours. The reaction mixture was filtered through a pad of Celite and solvent was removed in vacuo. The crude product was purified by ISCO (silica, 12 g column, 97% dichloromethane—3% methanol—0.1% NH₄OH) to yield the desired compound as a yellow solid (23.3 mg, 22%). LCMS m/z=448.0 (M+1) (Method C) (retention time=1.95 min). ¹H NMR (300 MHz, CD₃OD) δ 9.40 (d, J=1.4 Hz, 1H), 8.70-8.62 (m, 1H), 8.56 (dd, J=4.9, 1.6 Hz, 1H), 8.18-8.09 (m, 2H), 7.69 (ddd, J=6.8, 4.1, 2.1 Hz, 2H), 7.54-7.45 (m, 2H), 7.23 (t, J=9.0 Hz, 1H), 3.61 (s, 2H), 2.47 (s, 4H), 1.64 (dd, J=13.9, 8.9 Hz, 5H), 1.49 (d, J=4.1 Hz, 2H).

N-(3-chloro-4-fluorophenyl)-6-(3-chlorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (xxi-d)

A mixture of N-(3-chloro-4-fluorophenyl)-6-iodo-2-(pyridin-3-yl)quinazolin-4-amine (1.0 g, 2.10 mmol), 3-chlorophenylboronic acid (0.49 g, 3.13 mmol), Pd(PPh₃)₄ (0.24 g, 0.210 mmol), K₃PO₄ (1.34 g, 6.31 mmol) in dioxane (20 mL) and water (2.0 mL) was stirred under reflux for 2 h. Ethyl acetate (20 mL) was added to the cooled mixture and filtered. The filtered solid was recrystallized from DMF and water to give the title compound (0.50 g, 51.6%). ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.54 (s, 1H), 8.87 (s, 1H), 8.74-8.65 (m, 2H), 8.31-8.23 (m, 2H), 8.04-7.85 (m, 4H), 7.64-7.49 (m, 4H).

2-(7-(3-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide dihydrochloride (xxi-e)

A mixture of 2-(7-bromo-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (0.40 g, 0.952 mmol), 3-fluorophenylboronic acid (0.20 g 1.43 mmol), Pd(dppf)₂Cl₂ (77 mg, 0.094 mmol), K₃ PO₄ (606 mg, 2.85 mmol) in dioxane (8 mL) and water (2 mL) was refluxed under argon atmosphere for 4 h and cooled. Ethyl acetate (10 ml) was added to the mixture and a precipitate formed and was filtered. The filtered solid was recrystallized from DMF and water to give the title compound as free form. The solid as free form was suspended in ethyl acetate (10 mL) and 4N HCl in ethyl acetate (0.71 mL) was added to the suspension. A precipitate formed and was subjected to sonication for 20 min, filtered and dried to give the title compound (0.24 g, 49.6%). ¹H NMR (400 MHz, DMSO) δ 13.19 (s, 1H), 9.64 (s, 1H), 9.21-9.08 (m, 1H), 9.07-8.89 (m, 2H), 8.51 (s, 1H), 8.38-8.26 (m, 2H), 8.16 (d, J=8.5 Hz, 1H), 8.07-787 (m, 3H), 7.83-7.70 (m, 3H), 7.62 (dd, J=14.2, 7.7 Hz, 1H), 7.40-7.22 (m, 2H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 11 substituting with appropriate boronic acid/ester or boronate salt, catalyst and solvent

TABLE 4 Salt Molecular

PRODUCT type Mass ¹H-NMR

2 HCl 536.401 ¹H NMR (300 MHz, DMSO) δ 11.34 (s, 1H), 10.53 (s, 1H), 9.56 (s, 1H), 9.17- 8.95 (m, 2H), 8.89 (d, J = 4.5 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 8.08-7.81 (m, 4H), 7.62-6.98 (m, 3H), 4.53 (s, 2H), 4.05-3.74 (m, 4H), 3.48-3.07 (m, 4H).

HCl 515.406 ¹H NMR (300 MHz, DMSO) δ 10.40 (s, 1H), 9.51 (s, 1H), 9.00-8.78 (m, 2H), 8.55 (s, 1H), 8.20 (d, J = 4.4 Hz, 1H), 8.03-7.75 (m, 4H), 7.54 (t, J = 9.1 Hz, 1H), 4.68 (s, 2H), 3.83 (d, J = 11.2 Hz, 2H), 3.44-3.18 (m, 4H), 1.98-1.78 (m, 1H), 1.62 (d, J

448.920 1H NMR (300 MHz, DMSO) δ 10.10 (s, 1H), 9.51 (s, 1H), 8.75-8.60 (m, 2H), 8.47 (s, 1H), 8.32- 8.19 (m, 1H), 7.97- 7.77 (m, 3H), 7.63- 7.44 (m, 2H), 4.62 (s, 2H), 4.16-3.97 (m, 1H), 1.88-1.42 (m, 8H).

457.89 ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.53 (s, 1H), 8.82 (s, 1H), 8.70 (dd, J = 16.9, 5.4 Hz, 3H), 8.25 (d, J = 8.6 Hz, 3H), 8.01-7.87 (m, 2H), 7.57 (dd, J = 11.2, 6.0 Hz, 2H), 7.03 (d, J = 8.6 Hz, 1H), 3.94 (s, 3H).

449.91 ¹H NMR (300 MHz, DMSO) δ 10.13 (s, 1H), 9.52 (s, 1H), 8.67 (d, J = 9.8 Hz, 2H), 8.47 (s, 1H), 8.34-8.20 (m, 1H), 8.02-7.84 (m, 3H), 7.54 (t, J = 9.2 Hz, 2H), 3.64 (d, J = 17.6 Hz, 6H), 2.43 (s, 4H).

456.9

445.88 ¹H NMR (300 MHz, DMSO) δ 10.04 (s, 1H), 9.52 (s, 1H), 8.68 (t, J = 6.5 Hz, 2H), 8.51 (s, 1H), 8.22 (dd, J = 6.7, 2.4 Hz, 1H), 8.03- 7.83 (m, 3H), 7.54 (dd, J = 11.9, 6.6 Hz, 2H), 2.50 (s, 3H), 2.33 (s, 3H).

427.86 ¹H NMR (300 MHz, DMSO) δ 10.10 (s, 1H), 9.51 (s, 1H), 9.13 (s, 1H), 8.86 (s, 1H), 8.66 (s, 3H), 8.24 (s, 3H), 7.94 (d, J = 8.7 Hz, 2H), 7.55 (dd, J = 16.7, 9.9 Hz, 3H).

430.86 ¹H NMR (300 MHz, DMSO) δ 9.98 (s, 1H), 9.51 (d, J = 1.6 Hz, 1H), 8.66 (dd, J = 11.7, 2.2 Hz, 3H), 8.38- 8.20 (m, 2H), 8.20-8.02 (m, 2H), 8.02-7.80 (m, 2H), 7.71- 7.42 (m, 2H), 3.93 (s, 3H).

449.91 ¹H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.52 (d, J = 1.3 Hz, 1H), 8.77- 8.55 (m, 2H), 8.41 (s, 1H), 8.28 (dd, J = 6.9, 2.6 Hz, 1H), 8.08-7.77 (m, 3H), 7.65-7.44 (m, 2H), 3.34 (s, 8H), 3.15- 2.90 (m, 5H), 2.90- 2.64 (m, 5H).

445.85 ¹H NMR (300 MHz, DMSO) δ 10.09 (s, 1H), 9.50 (s, 1H), 8.88-8.74 (m, 2H), 8.66 (dd, J = 14.1, 5.5 Hz, 2H), 8.56- 8.42 (m, 1H), 8.23 (dd, J = 10.0, 5.7 Hz, 2H), 7.98-7.85 (m, 2H), 7.62-7.46 (m, 2H), 7.45-7.36 (m, 1H).

512.97 ¹H NMR (300 MHz, DMSO) δ 10.05 (s, 1H), 9.51 (s, 1H), 8.70 (dd, J = 24.1, 7.0 Hz, 4H), 8.22 (dd, J = 14.3, 7.3 Hz, 2H), 8.10 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 7.4 Hz, 2H), 7.00 (d, J = 8.8 Hz, 1H), 3.74 (s, 4H), 3.55 (d, J = 4.7

456.9 ¹H NMR (300 MHz, DMSO) δ 10.16 (s, 1H), 9.53 (s, 1H), 8.81 (s, 1H), 8.73- 8.60 (m, 2H), 8.30- 8.20 (m, 2H), 7.99- 7.89 (m, 2H), 7.55 (dd, J = 8.2, 4.7 Hz, 2H), 7.46 (t, J = 7.6 Hz, 3H), 7.10-6.96 (m, 1H), 3.88 (s, 3H).

486.92 ¹H NMR (300 MHz, DMSO) δ 10.16 (s, 1H), 9.54 (s, 1H), 8.79 (d, J = 9.7 Hz, 1H), 8.71 (s, 2H), 8.26 (d, J = 8.7 Hz, 1H), 7.95 (dd, J = 8.7, 3.7 Hz, 2H), 7.56 (dd, J = 11.7, 6.4 Hz, 1H), 7.43 (d, J = 15.2 Hz, 2H), 7.22-7.06 (m, 2H), 3.92 (s, 3H), 3.84 (s,

486.92

390.84

539.99 ¹H NMR (300 MHz, DMSO) δ 10.15 (s, 1H), 9.51 (s, 1H), 8.84 (s, 1H), 8.66 (dd, J = 9.7, 6.5 Hz, 2H), 8.29-8.19 (m, 2H), 7.92 (ddd, J = 8.9, 7.5, 4.6 Hz, 4H), 7.65-7.48 (m, 4H), 3.64 (s, 6H), 3.35 (s, 2H).

526

471.91 ¹H NMR (300 MHz, DMSO) δ 10.03 (s, 1H), 9.56 (d, J = 2.1 Hz, 1H), 8.77-8.66 (m, 3H), 8.64 (s, 1H), 8.24 (ddd, J = 8.7, 6.6, 2.6 Hz, 2H), 8.13 (s, 1H), 7.96- 7.90 (m, 1H), 7.62- 7.52 (m, 2H), 7.01 (d, J = 8.7 Hz, 1H), 3.94 (s, 3H), 2.78 (s, 3H).

474.34 ¹H NMR (300 MHz, DMSO) δ 10.09 (s, 1H), 9.53 (s, 1H), 8.77 (s, 1H), 8.67 (dd, J = 12.3, 4.1 Hz, 3H), 8.35 (d, J = 2.3 Hz, 1H), 8.27-8.13 (m, 2H), 8.02-7.88 (m, 2H), 7.72 (d, J = 8.8 Hz, 1H), 7.55 (dd, J = 7.7, 4.6 Hz, 1H), 7.00 (d, J = 8.6 Hz, 1H), 3.

442.88

465.91 ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.54 (s, 1H), 8.75-8.63 (m, 3H), 8.20 (dd, J = 8.2, 5.6 Hz, 2H), 8.09 (d, J = 8.5 Hz, 2H), 8.01 (d, J = 8.5 Hz, 2H), 7.88 (s, 1H), 7.55 (d, J = 9.1 Hz, 2H), 2.76 (s, 3H).

457.89 ¹H NMR (300 MHz, DMSO) δ 10.18 (s, 1H), 9.51 (s, 1H), 8.92 (s, 1H), 8.67 (dd, J = 12.7, 5.8 Hz, 2H), 8.39-8.16 (m, 3H), 7.91(dd, J = 14.8, 5.7 Hz, 2H), 7.65-7.45 (m, 3H), 7.35 (s, 1H), 3.94 (s, 3H).

514.93 ¹H NMR (300 MHz, DMSO) δ 10.19 (s, 1H), 9.52 (s, 1H), 8.86 (s, 1H), 8.67 (dd, J = 10.1, 3.4 Hz, 2H), 8.28 (ddd, J = 9.4, 7.7, 2.1 Hz, 2H), 8.06- 7.75 (m, 2H), 7.54 (dd, J = 9.0, 4.1 Hz, 4H), 3.99 (s, 3H), 3.82 (s, 3H)

451.88 ¹H NMR (300 MHz, DMSO) δ 10.16 (s, 1H), 9.50 (s, 1H), 8.86 (s, 1H), 8.66 (dd, J = 15.2, 6.9 Hz, 2H), 8.35- 8.16 (m, 2H), 8.15-7.82 (m, 6H), 7.55 (dd, J = 11.1, 6.0 Hz, 2H).

436.47

421.45

449.91 ¹H NMR (300 MHz, DMSO) δ 10.06 (s, 1H), 9.52 (d, J = 1.3 Hz, 1H), 8.73- 8.64 (m, 2H), 8.51 (d, J = 8.5 Hz, 1H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 7.96- 7.86 (m, 1H), 7.82 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.57 (t, J = 3.9 Hz, 1H), 7.52 (t, J = 9.1 Hz, 1H), 3.69 (s, 2H), 3.62 (s, 4H), 2.44 (s, 4H).

457.89 ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.55 (s, 1H), 8.76 (d, J = 2.5 Hz, 1H), 8.72-8.65 (m, 2H), 8.62 (d, J = 8.6 Hz, 1H), 8.34-8.26 (m, 2H), 8.15 (d, J = 1.6 Hz, 1H), 8.02 (d, J = 8.7 Hz, 1H), 7.97-7.88 (m, 1H), 7.61-7.49 (m, 2H), 6.99 (d, J = 8.7 Hz, 1H), 3.94 (s, 3H).

462.95 ¹H NMR (300 MHz, CD₃OD) δ 9.40 (s, 1H), 8.66 (d, J = 8.0 Hz, 1H), 8.56 (s, 1H), 8.19-8.09 (m, 2H), 7.74 (s, 1H), 7.72-7.65 (m, 1H), 7.54-7.45 (m, 2H), 7.24 (t, J = 9.0 Hz, 1H), 3.68 (d, J = 8.0 Hz, 2H), 2.75- 2.41 (m, 8H), 2.30 (s, 3H).

433.91

435.92

430.865 ¹H NMR (300 MHz, DMSO) δ 10.01 (s, 1H), 9.52 (d, J = 1.3 Hz, 1H), 8.72-8.60 (m, 2H), 8.49 (d, J = 8.6 Hz, 1H), 8.44 (s, 1H), 8.28 (dd, J = 6.9, 2.6 Hz, 1H), 8.15 (s, 1H), 8.03 (d, J = 1.5 Hz, 1H), 7.95-7.83 (m, 2H), 7.60-7.45 (m, 2H), 3.91 (s, 3H).

465.97 ¹H NMR (300 MHz, CD₃OD) δ 9.56-9.50 (m, 1H), 8.79 (dt, J = 8.1, 1.6 Hz, 1H), 8.63 (dd, J = 4.9, 1.7 Hz, 1H), 8.30 (s, 1H), 8.19 (dd, J = 6.7, 2.6 Hz, 1H), 7.91 (d, J = 1.1 Hz, 2H), 7.80 (ddd, J = 9.0, 4.2, 2.7 Hz, 1H), 7.58 (dd, J = 8.0, 4.9 Hz, 1H), 7.33 (t, J = 9.0 Hz, 1H), 3.75 (s, 2H), 2.84-2.66 (m, 8H).

491.94 ¹H NMR (300 MHz, DMSO) δ 10.00 (s, 1H), 9.52 (s, 1H), 8.73-8.63 (m, 2H), 8.42 (s, 1H), 8.28 (dd, J = 6.8, 2.6 Hz, 1H), 7.92 (ddd, J = 6.8, 4.2, 2.0 Hz, 1H), 7.85 (s, 2H), 7.60-7.50 (m, 2H), 3.56-3.43 (m, 9H), 3.07 (t, J = 7.6 Hz, 2H), 2.79 (t, J = 7.7 Hz, 2H).

463.93 ¹H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.54 (s, 1H), 8.67 (d, J = 5.3 Hz, 2H), 8.30-8.22 (m, 2H), 7.96-7.87 (m, 1H), 7.73 (s, 1H), 7.60-7.46 (m, 2H), 3.60 (s, 6H), 2.71 (s, 3H), 2.41 (s, 4H).

419.43 ¹H NMR (300 MHz, DMSO) δ 9.41 (d, J = 1.4 Hz, 1H), 9.15 (d, J = 1.7 Hz, 1H), 8.74- 8.64 (m, 3H), 8.55 (dt, J = 7.9, 1.8 Hz, 1H), 8.42 (dd, J = 8.7, 2.0 Hz, 1H), 8.36-8.29 (m, 1H), 8.15 (d, J = 8.7 Hz, 1H), 7.90 (dd, J = 7.8, 1.7 Hz, 1H), 7.61 (dd, J = 8.0, 4.8 Hz, 1H), 7.53 (dd, J = 7.9, 4.8 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 6.93 (d, J = 7.7 Hz, 1H). ¹H-NMR Retention LCMS Purity Method for

Solvent LCMS Time (min) Protocol Percent Coupling

DMSO 464 (M + 1) 2.01 Method C 100 Method N3

DMSO 479 (M + 1) 2.08 Method D 97 Method N3

DMSO 449 (M + 1) 2.62 Method D 92 Method N3

DMSO 458.2 (M + 1) 2.56 Method C 100 Method N1

DMSO 449.9 (M + 1) 2.13 Method C 100 Method N3

DMSO 456.0 (M + 1) 2.64 Method C 100 Method N1

DMSO 446 (M + 1) 2.35 Method C 100 Method N1

DMSO 427.95 (M + 1) 2.25 Method C 100 Method N1

DMSO 430.9 (M + 1) 2.17 Method C 100 Method N1

DMSO 449.9 (M + 1) 2.04 Method C 100 Method N1

DMSO 445.9 (M + 1) 2.43 Method C 99 Method N1

DMSO 512.9 (M + 1) 2.5 Method C 100 Method N1

DMSO 458.9 (M + 1) 2.65 Method C 100 Method N1

DMSO 486.9 (M + 1) 2.48 Method C 100 Method N1

DMSO 487.1 (M + 1) 2.58 Method C 100 Method N1

DMSO 390.9 (M + 1) 2.48 Method C 100 Method N1

DMSO 539.9 (M + 1) 2.23 Method C 100 Method N1

526.16 (M + 1) 2.55 Method C 94 Method N1

CDCl₃ 471.9 (M + 1) 2.93 Method C 100 Method N1

DMSO 474.02 (M + 1) 2.72 Method C 100 Method N1

DMSO 443.1 (M + 1) 2.37 Method C 100 Method N1

DMSO 466.1 (M + 1) 2.78 Method C 100 Method N1

DMSO 458.1 (M + 1) 2.62 Method C 100 Method N1

DMSO 515.1 (M + 1) 2.54 Method C 100 Method N1

DMSO 452.0 (M + 1) 2.61 Method C 96 Method N1

437.2 (M + 1) 2.08 Method C 95 Method N1

422.2 (M + 1) 1.8 Method C 100 Method N1

DMSO 449.9 (M + 1) 2.13 Method C 100 Method N3

DMSO 458.1 (M + 1) 2.51 Method C 100 Method N2

CD₃OD 463.0 (M + 1) 1.71 Method C 100 Method N3

434.0 (M + 1) 1.73 Method C 100 Method N3

436.0 (M + 1) 1.84 Method C 100 Method N3

DMSO 431.0 (M + 1) 2.12 Method C 100 Method N2

CD₃OD 466.0 (M + 1) 2.46 Method C 94 Method N3

DMSO 491.9 (M + 1) 2 Method C 93 Method N1

DMSO 464.0 (M + 1) 2.52 Method C 100 Method N3

DMSO 420.1 (M + 1) 2.12 Method C 99 Method N4 Starting Starting Number Material 1 Material 2 629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

Salt Number Product type 629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

2 HCl 667

HCl 668

2 HCl 669

HCl 670

HCl 671

HCl 672

HCl 673

HCl 674

HCl 675

HCl 676

HCl 677

2 HCl 678

HCl 679

2 HCl 680

681

682

683

684

685

686

687

688

689

690

691

HCl 692

HCl 693

3 HCl 694

3 HCl 695

HCl 696

HCl 697

HCl 698

HCl 699

2 HCl 700

2 HCl 701

2 HCl 702

2 HCl 703

2 HCl 704

2 HCl 705

2 HCl 706

2 HCl 707

2 HCl 708

HCl 709

HCl 710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

HCl 738

739

740

741

742

743

744

745

746

2 HCl 747

¹H NMR Purity Method of Number ¹H NMR Solvent Percent Coupling 629 ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.54 (s, 1H), 8.87 (s, 1H), 8.74-8.65 (m, 2H), 8.31- 8.23 (m, 2H), 8.04-7.85 (m, 4H), 7.64-7.49 (m, 4H). DMSO >98 N5 630 ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.54 (d, J = 1.4 Hz, 1H), 8.86 (s, 1H), 8.76- 8.64 (m, 2H), 8.26 (dd, J = 6.8, 2.3 Hz, 2H), 8.03-7.89 (m, 4H), 7.70-7.52 (m, 4H). DMSO >98 N5 631 ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.54 (d, J = 1.4 Hz, 1H), 8.86 (s, 1H), 8.76- 8.64 (m, 2H), 8.26 (dd, J = 6.8, 2.3 Hz, 2H), 8.03-7.89 (m, 4H), 7.70-7.52 (m, 4H). DMSO >98 N5 632 ¹H NMR (400 MHz, DMSO) δ 10.22-10.11 (m, 1H), 9.54 (s, 1H), 8.86-8.77 (m, 1H), 8.74- 8.65 (m, 2H), 8.30-8.17 (m, 2H), 8.01-7.90 (m, 2H), 7.74- 7.66 (m, 2H), 7.60-7.51 (m, 2H), 7.51-7.42 (m, 1H), 7.28 (d, J = 7.5 Hz, 1H), 2.45 (s, 3H). DMSO >98 N5 633 ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.61-9.53 (m, 1H), 8.92 (s, 1H), 8.73-8.67 (m, 2H), 8.43-8.24 (m, 3H), 8.14-7.89 (m, 3H), 7.84-7.76 (m, 1H), 7.66-7.53 (m, 2H). DMSO >98 N5 634 ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H), 8.89 (s, 1H), 8.75- 8.67 (m, 2H), 8.35-8.22 (m, 2H), 8.00 (d, J = 8.7 Hz, 1H), 7.96- 7.90 (m, 1H), 7.84-7.75 (m, 2H), 7.66-7.52 (m, 3H), 7.34-7.27 (m, 1H). DMSO >98 N5 635 ¹H NMR (400 MHz, DMSO) δ 10.27 (s, 1H), 9.54 (d, J = 1.2 Hz, 1H), 8.94 (s, 1H), 8.77- 8.66 (m, 3H), 8.40-8.21 (m, 4H), 7.99 (d, J = 8.9 Hz, 1H), 7.88 (t, J = 8.0 Hz, 2H), 7.61-7.50 (m, 2H). DMSO >98 N5 636 ¹H NMR (400 MHz, DMSO) δ 10.13 (s, 1H), 9.56 (s, 1H), 8.77-8.68 (m, 2H), 8.65 (s, 1H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 8.04-7.97 (m, 2H), 7.96-7.88 (m, 1H), 7.70-7.43 (m, 6H). DMSO >98 N5 637 ¹H NMR (400 MHz, DMSO) δ 10.10 (s, 1H), 9.56 (s, 1H), 8.76-8.68 (m, 2H), 8.63 (s, 1H), 8.28 (dd, J = 6.7, 2.7 Hz, 1H), 8.05 (dd, J = 8.7, 1.8 Hz, 1H), 8.00-7.90 (m, 2H), 7.70- 7.43 (m, 4H), 7.21 (d, J = 8.1 Hz, 1H), 7.14 (t, J = 7.4 Hz, 1H), 3.82 (s, 3H). DMSO >98 N5 638 ¹H NMR (400 MHz, DMSO) δ 10.16 (s, 1H), 9.54 (s, 1H), 8.81 (s, 1H), 8.74-8.64 (m, 2H), 8.30- 8.17 (m, 2H), 8.01-7.87 (m, 4H), 7.61-7.51 (m, 2H), 7.42 (t, J = 8.8 Hz, 2H). DMSO >98 N5 639 1H NMR (400 MHz, DMSO) δ 10.21 (s, 1H), 9.57 (s, 1H), 8.80 (d, J = 1.8 Hz, 1H), 8.76-8.69 (m, 2H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 8.14 (dd, J = 8.6, 1.8 Hz, 1H), 8.10-8.02 (m, 2H), 7.97- 7.88 (m, 2H), 7.83 (d, J = 6.8 Hz, 1H), 7.70 (td, J = 7.6, 1.2 Hz, 1H), 7.63-7.52 (m, 2H). DMSO >98 N5 640 ¹H NMR (400 MHz, DMSO) δ 10.12 (s, 1H), 9.55 (s, 1H), 8.77- 8.66 (m, 2H), 8.62 (s, 1H), 8.25 (dd, J = 6.8, 2.3 Hz, 1H), 8.16 (d, J = 8.3 Hz, 1H), 7.99-7.80 (m, 4H), 7.80-7.71 (m, 2H), 7.61- 7.49 (m, 2H). DMSO >98 N5 641 1H NMR (400 MHz, DMSO) δ 9.57 (s, 1H), 8.85-8.55 (m, 3H), 8.20-7.95 (m, 3H), 7.85-7.20 (m, 7H) DMSO >98 N5 642 ¹H NMR (400 MHz, DMSO) δ 10.19 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H), 8.83 (s, 1H), 8.74- 8.66 (m, 2H), 8.32-8.23 (m, 2H), 8.02-7.89 (m, 2H), 7.61- 7.53 (m, 2H), 7.05 (d, J = 2.2 Hz, 2H), 6.62 (t, J = 2.1 Hz, 1H), 3.88 (s, 6H). DMSO >98 N5 643 ¹H NMR (400 MHz, DMSO) δ 10.18 (s, 1H), 9.55 (d, J = 2.0 Hz, 1H), 8.81 (d, J = 1.7 Hz, 1H), 8.74-8.65 (m, 2H), 8.31- 8.20 (m, 2H), 8.04-7.88 (m, 2H), 7.65-7.53 (m, 2H), 7.42- 7.34 (m, 1H), 7.23-7.09 (m, 2H), 6.83 (dd, J = 8.3, 1.9 Hz, 1H), 3.02 (s, 6H). DMSO >98 N5 644 1H NMR (400 MHz, DMSO) δ 10.14 (s, 1H), 9.55 (s, 1H), 8.77- 8.68 (m, 2H), 8.65 (d, J = 1.5 Hz, 1H), 8.28 (dd, J = 6.9, 2.6 Hz, 1H), 8.05 (dd, J = 8.6, 1.7 Hz, 1H), 8.01-7.90 (m, 2H), 7.60- 7.51 (m, 2H), 7.29-7.21 (m, 1H), 7.18 (dd, J = 8.3, 1.6 Hz, 1H), 7.12 (dd, J = 7.6, 1.6 Hz, 1H), 3.89 (s, 3H), 3.58 (s, 3H). DMSO >98 N5 645 1H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.56 (s, 1H), 8.74- 8.67 (m, 2H), 8.64 (s, 1H), 8.28 (dd, J = 6.9, 2.6 Hz, 1H), 8.06 (dd, J = 8.6, 1.7 Hz, 1H), 7.98- 7.89 (m, 2H), 7.62-7.51 (m, 2H), 7.14 (d, J = 9.0 Hz, 1H), 7.09 (d, J = 3.1 Hz, 1H), 7.02 (dd, J = 8.9, 3.1 Hz, 1H), 3.81 (s, 3H), 3.76 (s, 3H). DMSO >98 N5 646 1H NMR (400 MHz, DMSO) δ 9.99 (s, 1H), 9.56 (d, J = 0.9 Hz, 1H), 8.71 (dd, J = 7.1, 1.6 Hz, 2H), 8.46 (d, J = 1.5 Hz, 1H), 8.29 (dd, J = 6.9, 2.6 Hz, 1H), 8.00-7.87 (m, 2H), 7.73 (dd, J = 8.5, 1.7 Hz, 1H), 7.63-7.47 (m, 2H), 7.41 (t, J = 8.4 Hz, 1H), 6.84 (d, J = 8.5 Hz, 2H), 3.77-3.66 (m, 6H). DMSO >98 N5 647 ¹H NMR (400 MHz, DMSO) δ 10.06-9.96 (m, 1H), 9.52 (s, 1H), 8.75-8.62 (m, 3H), 8.40- 8.33 (m, 1H), 8.28-8.22 (m, 1H), 8.22-8.14 (m, 1H), 7.97- 7.85 (m, 3H), 7.64-7.49 (m, 2H), 7.16 (s, 1H). DMSO >98 N5 648 ¹H NMR (400 MHz, DMSO) δ 10.10 (s, 1H), 9.54 (s, 1H), 8.85 (s, 1H), 8.77-8.65 (m, 2H), 8.32 (d, J = 3.7 Hz, 1H), 8.26 (dd, J = 6.8, 2.6 Hz, 1H), 8.12 (s, 1H), 7.94 (d, J = 8.7 Hz, 2H), 7.86-7.76 (m, 2H), 7.64- 7.54 (m, 2H). DMSO >98 N5 649 1H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.53 (s, 1H), 8.78 (s, 1H), 8.71-8.64 (m, 2H), 8.26-8.19 (m, 2H), 7.95-7.90 (m, 2H), 7.77-7.69 (m, 2H), 7.60-7.53 (m, 2H), 7.26 (t, J = 3.7 Hz, 1H). DMSO >98 N5 650 ¹H NMR (400 MHz, DMSO) δ 10.12 (s, 1H), 9.55 (d, J = 2.2 Hz, 1H), 8.75-8.67 (m, 3H), 8.33-8.23 (m, 2H), 8.13 (dd, J = 8.7, 1.8 Hz, 1H), 8.00- 7.90 (m, 3H), 7.63-7.51 (m, 2H), 7.22 (dd, J = 7.3, 5.0 Hz, 1H), 3.95 (s, 3H). DMSO >98 N5 651 ¹H NMR (400 MHz, DMSO) δ 10.22 (s, 1H), 9.53 (s, 1H), 8.97 (s, 1H), 8.75 (d, J = 5.5 Hz, 2H), 8.73-8.64 (m, 2H), 8.38-8.30 (m, 1H), 8.24 (d, J = 6.8 Hz, 1H), 8.05-7.97 (m, 1H), 7.97-7.88 (m, 3H), 7.63-7.51 (m, 2H). DMSO >98 N5 652 1H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.50 (s, 1H), 9.33 (s, 2H), 9.26 (s, 1H), 8.90 (s, 1H), 8.69 (d, J = 3.6 Hz, 1H), 8.64 (d, J = 8.0 Hz, 1H), 8.33 (d, J = 8.6 Hz, 1H), 8.22 (dd, J = 6.7, 2.0 Hz, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.93-7.86 (m, 1H), 7.61-7.48 (m, 2H). DMSO >98 N5 653 ¹H NMR (400 MHz, DMSO) δ 10.10 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H), 8.77-8.67 (m, 2H), 8.61 (s, 1H), 8.26 (dd, J = 6.9, 2.6 Hz, 1H), 8.12 (dd, J = 8.7, 1.8 Hz, 1H), 8.01-7.89 (m, 3H), 7.62-7.51 (m, 2H), 4.02 (s, 3H), 4.00 (s, 3H). DMSO >98 N5 654 ¹H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.56 (s, 1H), 8.77-8.68 (m, 2H), 8.65 (d, J = 1.6 Hz, 1H), 8.30 (dd, J = 6.9, 2.6 Hz, 1H), 8.17 (dd, J = 8.7, 1.7 Hz, 1H), 7.99-7.88 (m, 2H), 7.61-7.50 (m, 2H), 7.42-7.33 (m, 2H), 7.21-7.08 (m, 2H), 2.53 (s, 6H). DMSO >98 N5 655 ¹H NMR (400 MHz, DMSO) δ 10.08 (s, 1H), 9.55 (s, 1H), 8.74-8.66 (m, 2H), 8.63 (s, 1H), 8.26 (dd, J = 6.8, 2.5 Hz, 1H), 8.12 (d, J = 8.7 Hz, 1H), 7.97- 7.88 (m, 3H), 7.62-7.51 (m, 2H), 6.61 (d, J = 3.1 Hz, 1H), 3.97 (s, 3H), 3.96 (s, 3H). DMSO >98 N5 656 ¹H NMR (400 MHz, DMSO) δ 10.21 (s, 1H), 9.54 (d, J = 2.0 Hz, 1H), 8.91 (s, 1H), 8.76- 8.65 (m, 2H), 8.31 (d, J = 8.8 Hz, 1H), 8.26 (dd, J = 6.8, 2.6 Hz, 1H), 8.15-7.89 (m, 7H), 7.61-7.52 (m, 2H), 7.46 (s, 1H). DMSO >98 N5 657 ¹H NMR (400 MHz, DMSO) δ 10.21 (s, 1H), 9.54 (d, J = 2.0 Hz, 1H), 8.91 (s, 1H), 8.76- 8.65 (m, 2H), 8.31. (d, J = 8.8 Hz, 1H), 8.26 (dd, J = 6.8, 2.6 Hz, 1H), 8.15-7.89 (m, 7H), 7.61-7.52 (m, 2H), 7.46 (s, 1H). DMSO >98 N5 658 ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.54 (s, 1H), 8.88 (s, 1H), 8.79-8.61 (m, 2H), 8.34- 8.22 (m, 2H), 8.05-7.84 (m, 4H), 7.72 (t, J = 8.0 Hz, 1H), 7.65-7.53 (m, 2H), 7.47 (d, J = 8.4 Hz, 1H). DMSO >98 N5 659 1H NMR (400 MHz, DMSO) δ 10.06 (s, 1H), 9.53 (s, 1H), 8.75 (s, 1H), 8.75-8.66 (m, 3H), 8.28- 8.21 (m, 1H), 8.20 (dd, J = 7.7, 1.8 Hz, 1H), 8.06 (dd, J = 8.9, 2.5 Hz, 1H), 7.96-7.90 (m, 2H), 7.58-7.54 (m, 2H), 6.81 (d, J = 8.9 Hz, 1H), 3.11 (s, 6H). DMSO >98 N5 660 ¹H NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 9.54 (s, 1H), 8.51 (s, 1H), 8.76 (s, 1H), 8.74-8.66 (m, 2H), 8.39 (d, J = 2.7 Hz, 1H), 8.37-8.30 (m, 1H), 8.26 (dd, J = 6.8, 2.6 Hz, 1H), 8.03-7.97 (m, 1H), 7.97-7.90 (m, 1H), 7.85 (d, J = 1.9 Hz, 1H), 7.62-7.52 (m, 2H), 3.98 (s, 3H). DMSO >98 N5 661 ¹H NMR (400 MHz, DMSO) δ 10.06 (s, 1H), 9.52 (d, J = 1.3 Hz, 1H), 8.76 (d, J = 19.6 Hz, 1H), 8.73-8.61 (m, 3H), 8.29-8.16 (m, 3H), 7.99-7.87 (m, 2H), 7.61- 7.51 (m, 2H), 6.98 (d, J = 8.6 Hz, 1H), 4.39 (q, J = 7.0 Hz, 2H), 1.37 (t, J = 7.0 Hz, 3H). DMSO >98 N5 662 ¹H NMR (400 MHz, DMSO) δ 10.11 (s, 1H), 9.53 (dd, J = 2.1, 0.7 Hz, 1H), 8.75 (d, J = 1.9 Hz, 1H), 8.73-8.64 (m, 2H), 8.25 (dd, J = 6.9, 2.6 Hz, 1H), 8.19 (dd, J = 8.7, 1.9 Hz, 1H), 7.97-7.89 (m, 2H), 7.61-7.50 (m, 3H), 7.41 (dd, J = 8.1, 1.9 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H), 6.13 (s, 2H). DMSO >98 N5 663 ¹H NMR (400 MHz, DMSO) δ 10.19 (s, 1H), 9.54 (s, 1H), 8.85 (s, 1H), 8.76-8.66 (m, 2H), 8.33- 8.22 (m, 2H), 8.00-7.89 (m, 2H), 7.62-7.52 (m, 3H), 7.43 (s, 1H), 7.14 (s, 1H), 3.91 (s, 3H). DMSO >98 N5 664 ¹H NMR (400 MHz, DMSO) δ 10.16 (s, 1H), 9.52 (d, J = 1.3 Hz, 1H), 8.89-8.81 (m, 1H), 8.73-8.64 (m, 2H), 8.37-8.28 (m, 1H), 8.28-8.21 (m, 1H), 8.01-7.86 (m, 2H), 7.81-7.69 (m, 2H), 7.60-7.51 (m, 2H), 7.33 (s, 1H), 3.97 (s, 3H). DMSO >98 N5 665 1H NMR (400 MHz, DMSO) δ 10.1.9 (s, 1H), 9.53 (d, J = 1.9 Hz, 1H), 8.89 (s, 1H), 8.73- 8.61 (m, 2H), 8.57 (d, J = 4.5 Hz, 1H), 8.34-8.18 (m, 2H), 8.09-7.86 (m, 5H), 7.62-7.49 (m, 2H), 2.88-2.80 (m, 4H). DMSO >98 N5 666 ¹H NMR (400 MHz, DMSO) δ 10.57 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 9.21 (s, 2H), 9.08- 9.02 (m, 1H), 9.02-8.96 (m, 1H), 8.89 (dd, J = 5.2, 1.5 Hz, 1H), 8.39-8.30 (m, 1H), 8.25- 8.18 (m, 1H), 8.07-7.87 (m, 3H), 7.56 (t, J = 9.1 Hz, 1H). DMSO >98 N5 667 ¹H NMR (400 MHz, DMSO) δ 10.78 (s, 1H), 9.53 (s, 1H), 9.16- 9.02 (m, 2H), 8.99-8.88 (m, 1H), 8.66-8.55 (m, 1H), 8.38 (d, J = 8.2 Hz, 1H), 8.20 (d, J = 5.0 Hz, 1H), 8.04 (dt, J = 27.3, 13.6 Hz, 7H), 7.57 (t, J = 8.8 Hz, 1H), 2.84 (d, J = 3.8 Hz, 3H). DMSO >98 N5 668 ¹H NMR (400 MHz, DMSO) δ 10.49 (s, 1H), 9.53 (d, J = 1.5 Hz, 1H), 8.99-8.83 (m, 3H), 8.34-8.25 (m, 1H), 8.21 (dd, J = 6.8, 2.6 Hz, 1H), 8.03 (d, J = 8.7 Hz, 1H), 7.98-7.91 (m, 1H), 7.86 (dd, J = 7.8, 5.2 Hz, 1H), 7.78-7.70 (m, 2H), 7.57 (t, J = 9.1 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.29 (d, J = 7.5 Hz, 1H), 2.45 (s, 6H). DMSO >98 N5 669 ¹H NMR (400 MHz, DMSO) δ 10.22 (s, 1H), 9.55 (d, J = 1.4 Hz, 1H), 8.81-8.70 (m, 3H), 8.25 (dd, J = 6.8, 2.6 Hz, 1H), 8.13-8.05 (m, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.97-7.89 (m, 1H), 7.64 (dd, J = 7.9, 4.9 Hz, 1H), 7.61-7.49 (m, 2H), 7.37-7.26 (m, 2H), 2.41 (s, 3H). DMSO >98 N5 670 ¹H NMR (400 MHz, DMSO) δ 10.77 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 9.09-8.95 (m, 2H), 8.90 (dd, J = 5.2, 1.5 Hz, 1H), 8.41-8.29 (m, 1H), 8.23 (dd, J = 6.8, 2.6 Hz, 1H), 8.05 (d, J = 8.7 Hz, 1H), 8.01-7.88 (m, 2H), 7.56 (t, J = 9.1 Hz, 1H), 7.50-7.38 (m, 2H), 7.32 (d, J = 8.2 Hz, 1H), 3.97 (s, 3H), 2.23 (s, 3H). DMSO >98 N5 671 ¹H NMR (400 MHz, DMSO) δ 10.77 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 9.09-8.95 (m, 2H), 8.90 (dd, J = 5.2, 1.5 Hz, 1H), 8.41-8.29 (m, 1H), 8.23 (dd, J = 6.8, 2.6 Hz, 1H), 8.05 (d, J = 8.7 Hz, 1H), 8.01-7.88 (m, 2H), 7.56 (t, J = 9.1 Hz, 1H), 7.50-7.38 (m, 2H), 7.32 (d, J = 8.2 Hz, 1H), 3.97 (s, 3H), 2.23 (s, 3H). DMSO >98 N5 672 ¹H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.47 (d, J = 1.6 Hz, 1H), 9.04-8.94 (m, 2H), 8.89 (dd, J = 5.3, 1.5 Hz, 1H), 8.26 (dd, J = 8.8, 1.9 Hz, 1H), 8.18 (dd, J = 6.8, 2.6 Hz, 1H), 8.09-8.00 (m, 1H), 8.00-7.87 (m, 3H), 7.86-7.77 (m, 1H), 7.68-7.57 (m, 1H), 7.53 (t, J = 9.1 Hz, 1H). DMSO >98 N5 673 ¹H NMR (400 MHz, DMSO) δ 10.82 (s, 1H), 9.53 (s, 1H), 9.17- 9.04 (m, 1H), 9.04-8.93 (m, 2H), 8.34 (dd, J = 8.7, 1.7 Hz, 1H), 8.18 (dd, J = 6.8, 2.6 Hz, 1H), 8.08 (d, J = 8.6 Hz, 1H), 8.05- 7.89 (m, 2H), 7.57 (t, J = 9.0 Hz, 1H), 7.53-7.44 (m, 3H), 7.09-6.98 (m, 1H), 4.82 (dt, J = 11.7, 5.9 Hz, 1H), 1.33 (d, J = 6.0 Hz, 6H). DMSO >98 N5 674 ¹H NMR (400 MHz, DMSO) δ 10.60 (s, 1H), 9.50 (d, J = 1.7 Hz, 1H), 9.11-9.02 (m, 1H), 8.99-8.91 (m, 1H), 8.76 (d, J = 8.8 Hz, 1H), 8.25 (d, J = 1.4 Hz, 1H), 8.19 (dd, J = 6.8, 2.6 Hz, 1H), 8.10-7.92 (m, 4H), 7.82-7.72 (m, 1H), 7.65-7.56 (m, 1H), 7.52 (t, J = 9.1 Hz, 1H). DMSO >98 N5 675 ¹H NMR (400 MHz, DMSO) δ 10.51 (s, 1H), 9.51 (d, J = 1.7 Hz, 1H), 9.07-9.00 (m, 1H), 8.93 (dd, J = 5.3, 1.4 Hz, 1H), 8.75 (d, J = 8.8 Hz, 1H), 8.28 (d, J = 1.7 Hz, 1H), 8.21 (dd, J = 6.8, 2.6 Hz, 1H), 8.10 (dd, J = 8.7, 1.9 Hz, 1H), 8.02-7.93 (m, 2H), 7.74-7.65 (m, 2H), 7.52 (t, J = 9.1 Hz, 1H), 7.40- 7.31 (m, 1H). DMSO >98 N5 676 ¹H NMR (400 MHz, DMSO) δ 10.63 (s, 1H), 9.54 (d, J = 1.7 Hz, 1H), 9.10 (d, J = 8.1 Hz, 1H), 8.95 (dd, J = 5.3, 1.4 Hz, 1H), 8.81 (d, J = 8.7 Hz, 1H), 8.26-8.14 (m, 2H), 8.08-7.91 (m, 3H), 7.75-7.64 (m, 1H), 7.51 (ddd, J = 14.7, 14.2, 6.9 Hz, 2H), 7.44-7.34 (m, 1H). DMSO >98 N5 677 ¹H NMR (400 MHz, DMSO) δ 10.52 (s, 1H), 9.60-9.49 (m, 1H), 9.37-9.31 (m, 1H), 8.99 (d, J = 8.3 Hz, 1H), 8.95-8.81 (m, 3H), 8.75 (d, J = 8.3 Hz, 1H), 8.40 (d, J = 1.7 Hz, 1H), 8.30-8.18 (m, 2H), 8.04-7.87 (m, 3H), 7.56 (t, J = 9.1 Hz, 1H). DMSO >98 N5 678 ¹H NMR (400 MHz, DMSO) δ 10.42 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 9.38 (s, 2H), 9.30 (s, 1H), 9.00-8.92 (m, 1H), 8.92- 8.86 (m, 1H), 8.76 (d, J = 8.7 Hz, 1H), 8.34 (d, J = 1.7 Hz, 1H), 8.23 (dd, J = 6.8, 2.6 Hz, 1H), 8.15 (dd, J = 8.6, 1.8 Hz, 1H), 7.99-7.85 (m, 2H), 7.52 (t, J = 9.1 Hz, 1H). DMSO >98 N5 679 ¹H NMR (400 MHz, DMSO) δ 10.47 (s, 1H), 9.58-9.49 (m, 1H), 9.21 (s, 2H), 9.09-8.98 (m, 1H), 8.92 (d, J = 3.8 Hz, 1H), 8.77 (d, J = 8.8 Hz, 1H), 8.32 (d, J = 1.8 Hz, 1H), 8.27-8.20 (m, 1H), 8.15 (dd, J = 8.7, 1.8 Hz, 1H), 8.03-7.89 (m, 2H), 7.55 (t, J = 9.1 Hz, 1H), 4.02 (s, 3H). DMSO >98 N5 680 ¹H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.56 (d, J = 1.3 Hz, 1H), 8.75-8.67 (m, 2H), 8.60 (d, J = 8.7 Hz, 1H), 8.32 (dd, J = 6.9, 2.6 Hz, 1H), 8.10 (d, J = 1.6 Hz, 1H), 8.03-7.87 (m, 4H), 7.60-7.50 (m, 2H), 7.12 (d, J = 8.8 Hz, 2H), 3.85 (s, 3H). DMSO >98 N5 681 ¹H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.55-9.46 (m, 1H), 8.69-8.60 (m, 2H), 8.56 (d, J = 8.7 Hz, 1H), 8.25 (dd, J = 6.9, 2.6 Hz, 1H), 8.10 (d, J = 1.8 Hz, 1H), 7.96 (dd, J = 8.7, 1.9 Hz, 1H), 7.91-7.85 (m, 1H), 7.55-7.35 (m, 5H), 7.03- 6.95 (m, 1H), 3.83 (s, 3H). DMSO >98 N5 682 ¹H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.55 (d, J = 1.9 Hz, 1H), 8.74-8.67 (m, 2H), 8.57 (d, J = 8.7 Hz, 1H), 8.32 (dd, J = 6.9, 2.6 Hz, 1H), 8.00- 7.91 (m, 2H), 7.80 (dd, J = 8.6, 1.7 Hz, 1H), 7.60-7.41 (m, 4H), 7.21 (d, J = 7.8 Hz, 1H), 7.12 (td, J = 7.4, 0.9 Hz, 1H), 3.84 (s, 3H). DMSO >98 N5 683 ¹H NMR (400 MHz, DMSO) δ 10.10 (s, 1H), 9.55 (s, 1H), 8.74- 8.65 (m, 2H), 8.56 (d, J = 8.6 Hz, 1H), 8.35-8.26 (m, 1H), 7.99- 7.89 (m, 2H), 7.81 (s, 1H), 7.70 (dd, J = 8.6, 1.6 Hz, 1H), 7.63- 7.47 (m, 6H), 7.40 (s, 1H). DMSO >98 N5 684 ¹H NMR (400 MHz, DMSO) δ 10.16 (s, 1H), 9.61-9.53 (m, 1H), 8.76-8.62 (m, 3H), 8.35- 8.28 (m, 1H), 8.24 (d, J = 1.8 Hz, 1H), 8.16-7.99 (m, 6H), 7.99-7.92 (m, 1H), 7.63-7.51 (m, 2H), 7.45 (s, 1H). DMSO >98 N5 685 ¹H NMR (400 MHz, DMSO) δ 10.21 (s, 1H), 9.55 (d, J = 1.5 Hz, 1H), 8.78-8.62 (m, 3H), 8.31 (dd, J = 6.9, 2.6 Hz, 1H), 8.15-8.00 (m, 2H), 8.00-7.80 (m, 5H), 7.74-7.65 (m, 1H), 7.64-7.51 (m, 2H). DMSO >98 N5 686 ¹H NMR (400 MHz, DMSO) δ 10.18 (s, 1H), 9.60-9.55 (m, 1H), 8.77-8.65 (m, 2H), 8.46 (s, 1H), 8.37-8.28 (m, 2H), 8.17-8.10 (m, 1H), 7.99-7.93 (m, 2H), 7.81-7.72 (m, 2H), 7.62-7.50 (m, 3H). DMSO >98 N5 687 ¹H NMR (400 MHz, DMSO) δ 10.18 (s, 1H), 9.56 (d, J = 2.2 Hz, 1H), 8.75-8.61 (m, 3H), 8.32 (dd, J = 6.8, 2.6 Hz, 1H), 8.07 (s, 1H), 7.99-7.91 (m, 1H), 7.91-7.85 (m, 1H), 7.82-7.75 (m, 1H), 7.61-7.50 (m, 3H), 7.47-7.36 (m, 2H). DMSO >98 N5 688 ¹H NMR (400 MHz, DMSO) δ 10.14 (s, 1H), 9.60-9.53 (m, 1H), 8.74-8.61 (m, 3H), 8.31 (dd, J = 6.9, 2.6 Hz, 1H), 8.20 (d, J = 1.8 Hz, 1H), 8.06 (dd, J = 8.7, 1.9 Hz, 1H), 7.99-7.90 (m, 1H), 7.86-7.77 (m, 2H), 7.65-7.48 (m, 3H), 7.37-7.26 (m, 1H). DMSO >98 N5 689 ¹H NMR (400 MHz, DMSO) δ 10.13 (s, 1H), 9.56 (d, J = 1.5 Hz, 1H), 8.75-8.60 (m, 3H), 8.31 (dd, J = 6.9, 2.6 Hz, 1H), 8.15 (d, J = 1.7 Hz, 1H), 8.07- 7.88 (m, 4H), 7.65-7.49 (m, 2H), 7.39 (t, J = 8.8 Hz, 2H). DMSO >98 N5 690 ¹H NMR (400 MHz, DMSO) δ 10.14 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 8.76-8.60 (m, 3H), 8.34-8.25 (m, 1H), 8.21 (d, J = 1.7 Hz, 1H), 8.13 (d, J = 8.4 Hz, 2H), 8.10-7.97 (m, 3H), 7.97-7.87 (m, 1H), 7.62-7.45 (m, 2H). DMSO >98 N5 691 ¹H NMR (400 MHz, DMSO) δ 10.45 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 8.99-8.91 (m, 1H), 8.91-8.83 (m, 1H), 8.75 (d, J = 8.8 Hz, 1H), 8.42 (s, 1H), 8.31 (t, J = 3.2 Hz, 1H), 8.29-8.22 (m, 2H), 8.13 (dd, J = 8.7, 1.8 Hz, 1H), 8.08 (d, J = 7.8 Hz, 1H), 8.03-7.92 (m, 2H), 7.86 (dd, J = 8.0, 5.2 Hz, 1H), 7.65 (t, J = 7.7 Hz, 1H), 7.59-7.46 (m, 2H). DMSO >98 N5 692 ¹H NMR (400 MHz, DMSO) δ 10.38 (s, 1H), 9.56 (d, J = 1.5 Hz, 1H), 8.93 (d, J = 8.2 Hz, 1H), 8.85 (dd, J = 5.1, 1.5 Hz, 1H), 8.71 (d, J = 8.8 Hz, 1H), 8.27 (dd, J = 6.8, 2.6 Hz, 1H), 8.21 (d, J = 1.7 Hz, 1H), 8.10 (dd, J = 8.7, 1.8 Hz, 1H), 8.01- 7.90 (m, 3H), 7.83 (dd, J = 7.8, 5.0 Hz, 1H), 7.64-7.46 (m, 4H). DMSO >98 N5 693 ¹H NMR (400 MHz, DMSO) δ 10.91 (s, 1H), 9.52 (d, J = 1.5 Hz, 1H), 9.14 (d, J = 8.1 Hz, 1H), 9.00 (dd, J = 5.4, 1.2 Hz, 1H), 8.91 (d, J = 8.8 Hz, 1H), 8.34 (d, J = 5.1 Hz, 1H), 8.20 (dd, J = 6.8, 2.6 Hz, 1H), 8.14- 8.04 (m, 2H), 8.04-7.89 (m, 2H), 7.75-7.48 (m, 4H), 3.18 (s, 6H). DMSO >98 N5 694 ¹H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.52 (d, J = 1.7 Hz, 1H), 9.08 (d, J = 8.0 Hz, 1H), 8.97 (dd, J = 5.3, 1.4 Hz, 1H), 8.30 (d, J = 8.3 Hz, 1H), 8.33 (d, J = 2.3 Hz, 1H), 8.18 (dd, J = 6.8, 2.6 Hz, 1H), 8.10 (dd, J = 8.8, 1.8 Hz, 1H), 8.04-7.91 (m, 2H), 7.85 (d, J = 8.7 Hz, 2H), 7.56 (t, J = 9.1 Hz, 1H), 7.09 (s, 2H), 3.05 (s, 6H). DMSO >98 N5 695 ¹H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.53 (d, J = 1.7 Hz, 1H), 9.07 (d, J = 8.2 Hz, 1H), 8.95 (dd, J = 5.3, 1.4 Hz, 1H), 8.78 (d, J = 8.7 Hz, 1H), 8.26 (s, 1H), 8.21 (dd, J = 6.8, 2.6 Hz, 1H), 8.09 (dd, J = 8.7, 1.8 Hz, 1H), 8.04-7.92 (m, 2H), 7.79-7.67 (m, 2H), 7.55 (t, J = 9.1 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.32 (d, J = 7.5 Hz, 1H), 2.45 (s, 3H). DMSO >98 N5 696 ¹H NMR (400 MHz, DMSO) δ 10.48 (s, 1H), 9.54 (d, J = 1.5 Hz, 1H), 8.97 (d, J = 8.1 Hz, 1H), 8.93-8.84 (m, 1H), 8.71 (d, J = 8.8 Hz, 1H), 8.30-8.16 (m, 2H), 8.08 (dd, J = 8.7, 1.8 Hz, 1H), 8.01-7.78 (m, 4H), 7.55 (t, J = 9.1 Hz, 1H), 7.39 (d, J = 7.9 Hz, 2H), 2.40 (s, 3H). DMSO >98 N5 697 ¹H NMR (400 MHz, DMSO) δ 10.68 (s, 1H), 9.52 (s, 1H), 9.08 (d, J = 8.1 Hz, 1H), 8.95 (d, J = 4.7 Hz, 1H), 8.82 (d, J = 8.7 Hz, 1H), 8.25-8.12 (m, 2H), 8.06- 7.88 (m, 3H), 7.63-7.48 (m, 3H), 7.47-7.35 (m, 1H). DMSO >98 N5 698 ¹H NMR (400 MHz, DMSO) δ 10.47 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 9.01-8.92 (m, 1H), 8.87 (dd, J = 5.1, 1.4 Hz, 1H), 8.73 (d, J = 8.7 Hz, 1H), 8.24 (dd, J = 6.8, 2.6 Hz, 1H), 8.09 (s, 1H), 7.99-7.78 (m, 4H), 7.59-7.42 (m, 2H), 7.37-7.25 (m, 1H). DMSO >98 N5 699 ¹H NMR (400 MHz, DMSO) δ 13.12 (s, 1H), 9.59 (s, 1H), 9.10 (d, J = 8.1 Hz, 1H), 9.00-8.86 (m, 2H), 8.50 (s, 1H), 8.22- 8.07 (m, 2H), 8.03-7.86 (m, 4H), 7.72 (t, J = 7.9 Hz, 1H), 7.28 (t, J = 7.1 Hz, 1H). DMSO >98 Scheme 4 synthesis using method N6 coupling 700 ¹H NMR (400 MHz, DMSO) δ 13.19 (s, 1H), 9.64 (s, 1H), 9.21-9.08 (m, 1H), 9.07-8.89 (m, 2H), 3.51 (s, 1H), 8.38- 8.26 (m, 2H), 8.16 (d, J = 8.5 Hz, 1H), 8.07-7.87 (m, 3H), 7.83-7.70 (m, 3H), 7.62 (dd, J = 14.2, 7.7 Hz, 1H), 7.40- 7.22 (m, 2H). DMSO >98 N6 701 ¹H NMR (400 MHz, DMSO) δ 13.17 (s, 1H), 9.65 (s, 1H), 9.13- 8.99 (m, 2H), 8.89 (d, J = 5.1 Hz, 1H), 8.50 (s, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.21 (d, J = 1.8 Hz 1H), 8.11 (dd, J = 3.6, 1.9 Hz, 1H), 8.05-7.84 (m, 5H), 7.81-7.67 (m, 1H), 7.46-7.34 (m, 2H), 7.27 (dd, J = 11.8, 4.5 Hz, 1H). DMSO >98 N6 702 ¹H NMR (400 MHz, DMSO) δ 13.19 (s, 1H), 9.66 (d, J = 1.8 Hz, 1H), 9.20 (d, J = 7.5 Hz, 1H), 9.04-8.89 (m, 2H), 8.50 (s, 1H), 8.35 (d, J = 8.7 Hz, 1H), 8.17 (s, 1H), 8.11-7.86 (m, 4H), 7.86-7.68 (m, 2H), 7.65-7.52 (m, 1H), 7.52-7.39 (m, 2H), 7.39-7.23 (m, 1H). DMSO >98 N6 703 ¹H NMR (400 MHz, DMSO) δ 13.17 (s, 1H), 9.62 (d, J = 1.6 Hz, 1H), 9.18 (d, J = 8.2 Hz, 1H), 9.03-8.91 (m, 2H), 8.51 (s, 1H), 8.34-8.20 (m, 2H), 8.16-7.86 (m, 5H), 7.84-7.68 (m, 2H), 7.68-7.54 (m, 1H), 7.35-7.19 (m, 1H). DMSO >98 N6 704 ¹H NMR (400 MHz, DMSO) δ 13.19 (s, 1H), 9.61 (d, J = 1.8 Hz, 1H), 9.32-9.22 (m, 1H), 9.02 (dd, J = 5.5, 1.2 Hz, 1H), 8.88 (d, J = 7.8 Hz, 1H), 8.75 (s, 1H), 8.53 (s, 1H), 8.28 (d, J = 8.7 Hz, 1H), 8.16-8.07 (m, 2H), 8.01-7.88 (m, 3H), 7.85- 7.76 (m, 1H), 7.76-7.65 (m, 1H), 7.54-7.42 (m, 1H), 7.37- 7.19 (m, 2H). DMSO >98 N6 705 ¹H NMR (400 MHz, DMSO) δ 13.20 (s, 1H), 9.63 (s, 1H), 9.26 (d, J = 8.1 Hz, 1H), 9.01 (d, J = 5.0 Hz, 1H), 8.91 (d, J = 3.3 Hz, 1H), 8.52 (s, 1H), 8.33 (d, J = 8.7 Hz, 1H), 8.21-8.06 (m, 2H), 8.06-7.87 (m, 3H), 7.72 (t, J = 7.7 Hz, 1H), 7.66-7.52 (m, 2H), 7.49-7.35 (m, 1H), 7.29 (t, J = 7.5 Hz, 1H). DMSO >98 N6 706 ¹H NMR (400 MHz, DMSO) δ 9.64 (d, J = 1.7 Hz, 1H), 9.25 (d, J = 3.2 Hz, 1H), 9.05-8.89 (m, 2H), 8.67-8.45 (m, 1H), 8.34 (d, J = 8.7 Hz, 1H), 8.19 (s, 1H), 8.09 (dd, J = 8.0, 5.5 Hz, 1H), 8.04-7.88 (m, 3H), 7.79-7.62 (m, 2H), 7.56-7.35 (m, 2H), 7.35-7.23 (m, 1H). DMSO >98 N6 707 ¹H NMR (400 MHz, DMSO) δ 13.18 (s, 1H), 9.62 (d, J = 1.6 Hz, 1H), 9.16 (d, J = 8.1 Hz, 1H), 9.08-8.88 (m, 2H), 8.51 (s, 1H), 8.37-8.23 (m, 2H), 8.19-8.09 (m, 1H), 8.09-7.88 (m, 3H), 7.83-7.63 (m, 3H), 7.43-7.32 (m, 1H), 7.32-7.21 (m, 1H). DMSO >98 N6 708 ¹H NMR (400 MHz, DMSO) δ 10.52 (s, 1H), 9.56 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 7.8 Hz, 1H), 8.92 (d, J = 4.8 Hz, 1H), 8.78 (d, J = 8.8 Hz, 1H), 8.24 (d, J = 1.7 Hz, 1H), 8.13-8.08 (m, 2H), 8.08-7.98 (m, 3H), 7.98-7.88 (m, 1H), 7.63 (t, J = 8.2 Hz, 1H), 7.42 (t, J = 8.8 Hz, 2H), 7.28-7.15 (m, 1H). DMSO >98 N6/F5 followed by G1 709 ¹H NMR (400 MHz, DMSO) δ 10.60 (s, 1H), 9.56 (s, 1H), 9.07 (d, J = 7.9 Hz, 1H), 8.93 (d, J = 4.3 Hz, 1H), 8.77 (d, J = 8.7 Hz, 1H), 8.41 (s, 1H), 8.37-8.27 (m, 1H), 8.24 (d, J = 1.7 Hz, 1H), 8.11 (dd, J = 8.7, 1.8 Hz, 1H), 8.08-7.94 (m, 3H), 7.79-7.65 (m, 2H), 7.41 (t, J = 8.8 Hz, 2H). DMSO >98 N6/F5 followed by G1 710 1H NMR (DMSO-d6) ppm 3.81 (s, 3H), 3.88 (s, 3H), 7.11-7.71 (m, 9H), 7.91 (d, 1H, J = 8.7 Hz), 8.23 (d, 1H, J = 8.7 Hz), 8.53-8.64 (m, 2H), 8.87 (d, 1H, J = 1.5 Hz), 9.37 (d, 1H, J = 1.5 Hz), 9.83 (s, 1H) DMSO >98 N6/F5 followed by G1 711 1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.04 (d, 1H, J = 4.1 Hz), 7.48-7.57 (m, 5H), 7.98 (dd, 1H, J = 7.1, 1.7 Hz), 8.26-8.29 (m, 3H), 8.27 (dd, 1H, J = 7.1, 8.7 Hz), 8.78-9.53 (m, 3H), 9.54 (s, 1H), 10.37 (s, 1H) DMSO >98 N6/F5 followed by G1 712 1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.05 (d, 1H, J = 4.1 Hz), 7.48-7.57 (m, 4H), 7.88 (dd, 1H, J = 7.1, 1.7 Hz), 8.25-8.29 (m, 3H), 8.37 (dd, 1H, J = 7.1, 8.7 Hz), 8.78-9.53 (m, 3H), 9.54 (s, 1H), 10.37 (s, 1H) DMSO >98 N6/F5 followed by G1 713 1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.05-7.51 (m, 9H), 7.95 (d, 1H, J = 8.7 Hz), 8.26 (d, 1H, J = 8.7 Hz), 8.54-8.88 (m, 3H), 9.38 (s, 1H), 10.19 (s, 1H) DMSO >98 N6/F5 followed by G1 714 1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.04-7.06 (m, 2H), 7.46- 7.76 (m, 8H), 7.95 (d, 2H, J = 8.6 Hz), 8.24 (d, 1H, J = 1.7 Hz), 8.69-8.87 (m, 3H), 9.56 (s, 1H), 10.18 (s, 1H) DMSO >98 N6/F5 followed by G1 715 1H NMR (DMSO-d6) ppm 3.84 (s, 3H), 3.89 (s, 3H), 6.81-7.56 (m, 2H), 7.40-7.70 (m, 7H), 7.95 (d, 1H, J = 8.5 Hz), 8.23 (d, 1H, J = 1.5 Hz), 8.69-8.89 (m, 3H), 9.58 (s, 1H), 10.06 (s, 1H) DMSO >98 N6/F5 followed by G1 716 1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.03-7.06 (m, 1H), 7.50- 8.39 (m, 10H), 8.86-8.98 (m, 3H), 9.58 (s, 1H), 10.06 (s, 1H) DMSO >98 N6/F5 followed by G1 717 1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.02-7.07 (m, 2H), 7.31 (s, 1H), 7.47-7.56 (m, 5H), 7.81- 8.26 (m, 4H), 8.26-8.90 (m, 3H), 9.57 (s, 1H), 10.27 (s, 1H) DMSO >98 N6/F5 followed by G1 718 1H NMR (DMSO-d6) ppm 3.87 (s, 3H), 7.03-7.50 (m, 8H), 7.98 (d, 1H, J = 8.7 Hz), 8.30 (d, 1H, J = 8.7 Hz), 8.48-8.91 (m, 3H), 9.30 (s, 1H), 10.19 (s, 1H) DMSO >98 N6/F5 followed by G1 719 1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.03-7.54 (m, 8H), 7.97 (d, 1H, J = 8.7 Hz), 8.28 (d, 1H, J = 8.7 Hz), 8.56-8.86 (m, 3H), 9.40 (s, 1H), 10.23 (s, 1H) DMSO >98 N6/F5 followed by G1 720 1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.03-7.52 (m, 8H), 7.95 (d, 1H, J = 8.7 Hz), 8.26 (d, 1H, J = 8.7 Hz), 8.52-8.85 (m, 3H), 9.38 (s, 1H), 10.17 (s, 1H) DMSO >98 N6/F5 followed by G1 721 1H NMR (DMSO-d6) ppm 3.87 (s, 3H), 7.05-7.54 (m, 8H), 8.00 (d, 1H, J = 8.7 Hz), 8.27 (d, 1H, J = 8.7 Hz), 8.55-8.87 (m, 3H), 9.38 (s, 1H), 10.34 (s, 1H) DMSO >98 N6/F5 followed by G1 722 1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.05-7.53 (m, 7H), 7.93 (s, 1H), 7.96 (d, 1H, J = 8.7 Hz), 8.16 (s, 1H), 8.26 (d, 1H, J = 8.7 Hz), 8.74-8.89 (m, 3H), 9.55 (s, 1H), 10.27 (s, 1H) DMSO >98 N6/F5 followed by G1 723 1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.03-7.54 (m, 7H), 7.92 (s, 1H), 7.97 (d, 1H, J = 8.7 Hz), 8.28 (d, 1H, J = 8.7 Hz), 8.56- 8.85 (m, 3H), 9.40 (s, 1H), 10.25 (s, 1H) DMSO >98 N6/F5 followed by G1 724 1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.03-7.74 (m, 8H), 7.98 (d, 1H, J = 8.7 Hz), 8.27 (d, 1H, J = 8.7 Hz), 8.52-8.87 (m, 3H), 9.32 (s, 1H), 10.22 (s, 1H) DMSO >98 N6/F5 followed by G1 725 1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.05-7.71 (m, 8H), 7.99 (d, 1H, J = 8.6 Hz), 8.30 (d, 1H, J = 8.7 Hz), 8.67-8.92 (m, 3H), 9.37 (s, 1H), 10.52 (s, 1H) DMSO >98 N6/F5 followed by G1 726 1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.03-7.71 (m, 9H), 7.99 (d, 1H, J = 8.7 Hz), 8.29 (d, 1H, J = 8.7 Hz), 8.67-8.92 (m, 3H), 9.37 (s, 1H), 10.52 (s, 1H) DMSO >98 N6/F5 followed by G1 727 1H NMR (DMSO-d6 at 70° C.) ppm 3.89 (s, 3H), 7.02-7.52 (m, 8H), 7.90 (d, 1H, J = 8.5 Hz), 7.93 (s, 1H), 7.99 (d, 1H, J = 8.6 Hz), 8.22 (s, 1H), 8.74- 8.91 (m, 3H), 9.52 (s, 1H), 10.23 (s, 1H) DMSO >98 N6/F5 followed by G1 728 ¹H NMR (DMSO-d₆) ppm 2.50 (s, 3H), 3.89 (s, 3H), 7.06 (s, 1H), 7.49-7.85 (m, 9H), 8.01-8.96 (m, 4H), 9.58 (s, 1H), 10.50 (s, 1H) DMSO >98 N6/F5 followed by G1 729 ¹H NMR (DMSO-d₆) ppm 3.89 (s, 3H), 7.04 (br s, 1H), 7.22 (s, 1H), 7.49-8.30 (m, 9H), 8.77- 8.91 (m, 3H), 9.55 (s, 1H), 10.37 (s, 1H) DMSO >98 N6/F5 followed by G1 730 ¹H NMR (DMSO-d₆) ppm 3.89 (s, 3H), 7.04 (s, 1H), 7.49-8.32 (m, 9H), 8.91-9.04 (m, 3H), 9.54 (s, 1H), 10.63 (s, 1H) DMSO >98 N6/F5 followed by G1 731 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 7.03 (s, 1H), 7.44-8.25 (m, 9H), 8.71-8.84 (m, 3H), 9.52 (s, 1H), 10.23 (s, 1H) DMSO >98 N6/F5 followed by G1 732 ¹H NMR (400 MHz, DMSO) δ 12.02 (s, 1H), 10.53 (s, 1H), 9.49 (s, 1H), 9.02-8.72 (m, 3H), 8.30 (dd, J = 8.7, 1.6 Hz, 1H), 8.05 (dd, J = 32.2, 5.3 Hz, 2H), 7.81-7.72 (m, 2H), 7.49 (dd, J = 8.0, 5.4 Hz, 3H), 7.25 (t, J = 9.2 Hz, 1H), 7.11-6.98 (m, 1H), 3.89 (s, 3H). DMSO >98 N6/F5 followed by G1 733 ¹H NMR (400 MHz, DMSO) δ 10.54 (s, 1H), 9.43 (s, 1H), 8.86 (d, J = 1.8 Hz, 1H), 8.64 (dd, J = 21.1, 5.9 Hz, 2H), 8.31 (dd, J = 8.7, 1.9 Hz, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.59-7.45 (m, 4H), 7.42-7.30 (m, 3H), 7.09-6.98 (m, 1H), 3.89 (s, 3H). DMSO >98 N6/F5 followed by G1 734 ¹H NMR (400 MHz, DMSO) δ 13.18 (s, 1H), 10.57 (s, 1H), 9.48 (s, 1H), 8.98 (d, J = 1.3 Hz, 1H), 8.78 (t, J = 7.1 Hz, 2H), 8.30 (dd, J = 8.7, 1.7 Hz, 1H), 8.18 (d, J = 8.4 Hz, 2H), 8.01 (d, J = 8.7 Hz, 1H), 7.83 (dd, J = 8.9, 1.8 Hz, 1H), 7.74- 7.62 (m, 2H), 7.56-7.43 (m, 2H), 7.09-7.01 (m, 1H), 3.90 (s, 3H). DMSO >98 N6/F5 followed by G1 735 ¹H NMR (400 MHz, DMSO) δ 11.16 (s, 1H), 10.11 (s, 1H), 9.51 (d, J = 1.2 Hz, 1H), 8.91 (d, J = 1.7 Hz, 1H), 8.71-8.58 (m, 2H), 8.23 (dd, J = 8.7, 1.9 Hz, 1H), 7.95 (dd, J = 23.9, 5.2 Hz, 2H), 7.60-7.34 (m, 5H), 7.06-6.98 (m, 1H), 6.06 (s, 2H), 3.89 (s, 3H). DMSO >98 N6/F5 followed by G1 736 ¹H NMR (400 MHz, DMSO) δ 10.78 (s, 1H), 10.65 (s, 1H), 10.08 (s, 1H), 9.55 (d, J = 2.0 Hz, 1H), 8.88 (d, J = 1.8 Hz, 1H), 8.76-8.66 (m, 2H), 8.24 (dd, J = 8.7, 1.9 Hz, 1H), 7.94 (d, J78.7 Hz, 1H), 7.65 (d, J = 1.9 Hz, 1H), 7.58 (dd, J = 7.7, 5.1 Hz, 1H), 7.49 (dt, J = 4.7, 3.1 Hz, 3H), 7.41 (dd, J = 8.4, 2.0 Hz, 1H), 7.08-6.99 (m, 3H), 3.88 (s, 3H). DMSO >98 N6/F5 followed by G1 737 ¹H NMR (400 MHz, DMSO) δ 9.93 (s, 1H), 9.40 (s, 1H), 8.86 (d, J = 1.7 Hz, 1H), 8.64 (dd, J = 28.9, 5.8 Hz, 2H), 8.27 (dd, J = 8.7, 1.9 Hz, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.87 (d, J = 2.6 Hz, 1H), 7.61-7.45 (m, 5H), 7.38 (dd, J = 8.8, 2.6 Hz, 1H), 7.24 (d, J = 8.9 Hz, 1H), 7.09- 6.98 (m, 1H), 3.89 (d, J = 2.9 Hz, 1H), 3.83 (s, 3H). DMSO >98 N6/F5 followed by G1 738 ¹H NMR (400 MHz, DMSO) δ 10.19 (s, 1H), 9.56 (s, 1H), 8.88 (d, J = 1.7 Hz, 1H), 8.75 (t, J = 7.2 Hz, 2H), 8.27 (dd, J = 8.6, 1.4 Hz, 1H), 8.14 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.84 (dd, J = 8.2, 2.0 Hz, 1H), 7.63 (dd, J = 7.7, 4.9 Hz, 1H), 7.48 (dd, J = 11.4, 4.0 Hz, 4H), 7.10-6.98 (m, 1H), 3.89 (s, 3H), 3.83 (s, 3H). DMSO >98 N6/F5 followed by G1 739 ¹H NMR (400 MHz, DMSO) δ 10.07 (s, 1H), 9.55 (s, 1H), 8.85 (s, 1H), 8.70 (d, J = 5.5 Hz, 2H), 8.24 (dd, J = 8.7, 1.5 Hz, 1H), 8.10 (d, J = 2.4 Hz, 1H), 7.99-7.83 (m, 2H), 7.60- 7.40 (m, 4H), 7.30 (d, J = 9.0 Hz, 1H), 7.04 (dd, J = 7.1, 4.4 Hz, 1H), 3.90 (s, 3H), 2.29 (s, 3H). DMSO >98 N6/F5 followed by G1 740 ¹H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.60 (s, 1H), 8.89 (d, J = 1.8 Hz, 1H), 8.71 (dd, J = 12.8, 6.3 Hz, 2H), 8.24 (dd, J = 8.7, 1.9 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.68 (d, J = 1.7 Hz, 1H), 7.61-7.45 (m, 5H), 7.44- 7.37 (m, 1H), 7.24 (d, J = 8.0 Hz, 1H), 3.89 (s, 3H), 3.65 (s, 3H). DMSO >98 N6/F5 followed by G1 741 ¹H NMR (400 MHz, DMSO) δ 10.04 (s, 1H), 9.60 (s, 1H), 8.89 (d, J = 1.7 Hz, 1H), 8.71 (dd, J = 12.7, 6.3 Hz, 2H), 8.24 (dd, J = 8.7, 1.9 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.68 (d, J = 1.7 Hz, 1H), 7.59-7.45 (m, 4H), 7.44-7.37 (m, 1H), 7.25 (t, J = 6.7 Hz, 1H), 7.07-6.98 (m, 1H), 3.89 (s, 6H), 2.19 (s, 3H). DMSO >98 N6/F5 followed by G1 742 ¹H NMR (400 MHz, DMSO) δ 9.73 (s, 1H), 9.37 (s, 1H), 8.86 (d, J = 1.6 Hz, 1H), 8.63 (d, J = 3.4 Hz, 1H), 8.54 (d, J = 8.0 Hz, 1H), 8.23 (dd, J = 8.7, 1.8 Hz, 1H), 7.91 (d, J = 8.7 Hz, 1H), 7.55-7.42 (m, 5H), 7.05- 6.98 (m, 1H), 6.77 (d, J = 2.6 Hz, 1H), 6.68 (dd, J = 8.6, 2.6 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.79 (s, 3H). DMSO >98 N6/F5 followed by G1 743 ¹H NMR (400 MHz, DMSO) δ 10.25 (s, 1H), 9.56 (s, 1H), 8.84 (d, J = 1.7 Hz, 1H), 8.71 (d, J = 9.1 Hz, 1H), 8.27 (dd, J = 8.7, 1.8 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.86-7.77 (m, 2H), 7.65-7.56 (m, 1H), 7.52-7.44 (m, 4H), 7.09-6.99 (m, 2H), 3.89 (s, 3H). DMSO >98 N6/F5 followed by G1 744 ¹H NMR (400 MHz, DMSO) δ 10.42 (s, 1H), 9.55 (s, 1H), 8.87 (d, J = 26.7 Hz, 3H), 8.31 (dd, J = 8.7, 1.7 Hz, 2H), 8.17 (d, J = 1.7 Hz, 2H), 8.02 (d, J = 8.7 Hz, 1H), 7.81 (s, 1H), 7.54-7.39 (m, 3H), 7.11-6.98 (m, 1H), 3.89 (s, 3H). DMSO >98 N6/F5 followed by G1 745 ¹H NMR (400 MHz, DMSO) δ 14.27 (s, 1H), 9.79 (s, 1H), 9.32 (d, J = 8.4 Hz, 1H), 8.98 (d, J = 5.2 Hz, 1H), 8.34 (dd, J = 8.7, 1.8 Hz, 1H), 8.29-8.19 (m, 2H), 8.07 (dd, J = 14.6, 8.3 Hz, 2H), 7.93 (s, 1H), 7.64 (d, J = 5.9 Hz, 1H), 7.52 (t, J = 7.9 Hz, 1H), 7.39 (dd, J = 8.9, 4.9 Hz, 2H), 7.23 (d, J = 5.8 Hz, 1H), 7.08 (dd, J = 8.2, 1.8 Hz, 1H), 3.86 (s, 3H). DMSO >98 N6/F5 followed by G1 746 ¹H NMR (400 MHz, DMSO) δ 11.10 (s, 1H), 9.36 (s, 1H), 9.11 (s, 1H), 9.00 (dd, J = 23.2, 6.7 Hz, 2H), 8.41 (d, J = 9.1 Hz, 1H), 8.16 (d, J = 8.7 Hz, 1H), 8.05 (dd, J = 7.9, 5.5 Hz, 1H), 7.80-7.65 (m, 2H), 7.59-7.44 (m, 3H), 7.41-7.32 (m, 1H), 7.06 (d, J = 8.0 Hz, 1H), 3.90 (s, 3H). DMSO N6/F5 followed by G1 747 ¹H NMR (400 MHz, DMSO) δ 12.92 (d, J = 17.9 Hz, 1H), 9.64 (s, 1H), 9.09 (d, J = 7.9 Hz, 1H), 8.92 (d, J = 4.9 Hz, 1H), 8.52 (d, J = 5.4 Hz, 1H), 8.38 (s, 1H), 8.30 (dd, J = 8.7, 1.7 Hz, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.98- 7.84 (m, 3H), 7.50 (t, J = 7.9 Hz, 1H), 7.39 (dd, J = 8.1, 5.0 Hz, 2H), 7.06 (dd, J = 8.2, 1.8 Hz, 2H), 3.89 (s, 3H). DMSO >98 N6/F5 followed by G1 Starting Starting Number Material 1 Material 2 748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788 789 790 791 792 793 794 795 796 797 798 799 800 801 Salt Number Product type ¹H NMR 748

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.71 (s, 1H), 9.56 (s, 1H), 9.45 (s, 2H), 9.29 (s, 1H), 9.22 (s, 1H), 9.13 (d, J = 7.8 Hz, 1H), 8.96 (d, J = 4.3 Hz, 1H), 8.47 (d, J = 8.4 Hz, 1H), 8.16-8.08 (m, 2H), 8.07-7.99 (m, 1H), 7.75 (s, 1H), 7.59 (dd, J = 19.3, 9.0 Hz, 1H). 749

¹H NMR (400 MHz, DMSO) δ 10.12 (s, 1H), 9.55 (d, J = 1.4 Hz, 1H), 8.74-8.66 (m, 3H), 8.28 (d, J = 4.9 Hz, 1H), 8.17-8.08 (m, 2H), 7.98- 7.91 (m, 2H), 7.73 (d, J = 9.1 Hz, 1H), 7.61-7.51 (m, 2H), 7.22 (dd, J = 7.3, 5.0 Hz, 1H), 3.95 (s, 3H). 750

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.92 (s, 1H), 9.55 (d, J = 1.5 Hz, 1H), 9.33 (s, 1H), 9.10-8.99 (m, 2H), 8.93 (d, J = 5.2 Hz, 1H), 8.54 (d, J = 2.5 Hz, 1H), 8.46 (dd, J = 8.8, 1.8 Hz, 1H), 8.33 (s, 1H), 8.18 (ddd, J = 13.0, 7.4, 2.4 Hz, 1H), 8.08 (d, J = 8.7 Hz, 1H), 8.01-7.93 (m, 1H), 7.84 (d, J = 9.0 Hz, 1H), 7.57 (dd, J = 19.7, 9.1 Hz, 1H), 4.03 (s, 3H). 751

HCl ¹H NMR (400 MHz, DMSO) δ 10.57 (s, 1H), 9.53 (d, J = 1.7 Hz, 1H), 9.00 (dd, J = 14.9, 4.8 Hz, 2H), 8.90 (dd, J = 5.1, 1.4 Hz, 1H), 8.78 (d, J = 2.1 Hz, 1H), 8.31 (dt, J = 8.7, 2.2 Hz, 2H), 8.11 (ddd, J = 12.9, 7.5, 2.5 Hz, 1H), 8.03 (d, J = 8.7 Hz, 1H), 7.93 (dd, J = 8.0, 5.1 Hz, 1H), 7.75 (dd, J = 6.0, 2.9 Hz, 1H), 7.63-7.51 (m, 1H), 7.03 (d, J = 8.6 Hz, 1H), 3.94 (d, J = 8.4 Hz, 3H). 752

¹H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.52 (s, 1H), 9.14 (d, J = 5.6 Hz, 2H), 8.84 (s, 1H), 8.68 (dd, J = 14.0, 6.4 Hz, 2H), 8.28 (dd, J = 8.7, 1.7 Hz, 1H), 8.17-8.06 (m, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.70 (d, J = 9.0 Hz, 1H), 7.62-7.50 (m, 2H), 4.02 (s, 3H). 753

¹H NMR (400 MHz, DMSO) δ 10.17 (s, 1H), 9.54 (d, J = 1.5 Hz, 1H), 9.16 (d, J = 1.9 Hz, 1H), 8.93 (d, J = 1.7 Hz, 1H), 8.74-8.60 (m, 3H), 8.35- 8.26 (m, 2H), 8.19-8.07 (m, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.77-7.69 (m, 1H), 7.64-7.51 (m, 3H). 754

¹H NMR (400 MHz, DMSO) δ 10.12 (s, 1H), 9.53 (d, J = 1.4 Hz, 1H), 8.79-8.62 (m, 3H), 8.24-8.06 (m, 2H), 7.94 (t, J = 7.7 Hz, 1H), 7.73 (dd, J = 6.2, 2.9 Hz, 1H), 7.56 (ddd, J = 15.3, 10.1, 4.8 Hz, 3H), 7.41 (dd, J = 8.1, 1.8 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H), 6.13 (s, 2H). 755

2 HCl ¹H NMR (400 MHz, DMSO) δ 11.36 (s, 1H), 9.73 (d, J = 1.7 Hz, 1H), 9.52 (d, J = 1.8 Hz, 1H), 9.13-9.02 (m, 3H), 8.96 (dd, J = 5.4, 1.4 Hz, 1H), 8.79 (d, J = 6.9 Hz, 2H), 8,56 (dd, J = 8.9, 1.9 Hz, 1H), 8.19 (ddd, J = 13.0, 7.5, 2.5 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 8.02 (dd, J = 8.0, 5.4 Hz, 1H), 7.90 (dt, J = 9.0, 2.8 Hz, 1H), 7.62-7.50 (m, 1H). 756

¹H NMR (400 MHz, DMSO) δ 10.19 (s, 1H), 9.55 (d, J = 1.4 Hz, 1H), 8.86 (d, J = 1.7 Hz, 1H), 8.69 (dd, J = 8.8, 2.9 Hz, 2H), 8.25 (dd, J = 8.7, 1.8 Hz, 1H), 8.18-8.07 (m, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 7.2 Hz, 2H), 7.78-7.68 (m, 1H), 7.62-7.53 (m, 4H), 7.47 (t, J = 7.4 Hz, 1H). 757

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.84 (s, 1H), 9.55 (s, 1H), 9.19-9.05 (m, 2H), 8.95 (d, J = 4.1 Hz, 1H), 8.53 (s, 1H), 8.41 (dd, J = 8.7, 1.7 Hz, 1H), 8.28 (s, 1H), 8.16-8.07 (m, 3H), 8.05-7.92 (m, 2H), 7.79 (d, J = 9.1 Hz, 1H), 7.70-7.46 (m, 3H). 758

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.78 (s, 1H), 9.55 (d, J = 1.8 Hz, 1H), 9.12 (d, J = 8.6 Hz, 2H), 8.96 (dd, J = 5.4, 1.4 Hz, 1H), 8.40 (dd, J = 8.8, 1.8 Hz, 1H), 8.16-7.96 (m, 8H), 7.79-7.71 (m, 1H), 7.64-7.53 (m, 1H), 7.47 (s, 1H). 759

HCl ¹H NMR (400 MHz, DMSO) δ 10.41 (s, 1H), 9.56 (s, 1H), 8.98-8.77 (m, 3H), 8.23-8.02 (m, 4H), 7.99-7.65 (m, 5H), 7.56 (dd, J = 19.1, 9.4 Hz, 1H). 760

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.51 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 8.1 Hz, 1H), 8.95-8.84 (m, 2H), 8.21-8.02 (m, 3H), 7.93 (dt, J = 10.6, 5.3 Hz, 1H), 7.77- 7.68 (m, 1H), 7.63-7.51 (m, 3H), 7.49-7.38 (m, 1H). 761

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.51 (s, 1H), 9.55 (d, J = 1.5 Hz, 1H), 9.03 (d, J = 8.2 Hz, 1H), 8.91 (dd, J = 5.3, 1.5 Hz, 1H), 8.82 (s, 1H), 8.16-8.00 (m, 3H), 7.94 (dd, J = 8.0, 5.2 Hz, 1H), 7.87- 7.78 (m, 1H), 7.75-7.66 (m, 1H), 7.61-7.44 (m, 2H), 7.39-7.28 (m, 1H). 762

HCl ¹H NMR (400 MHz, DMSO) δ 10.75 (s, 1H), 9.53 (d, J = 1.7 Hz, 1H), 9.07 (dd, J = 23.2, 4.9 Hz, 2H), 8.95 (dd, J = 5.3, 1.4 Hz, 1H), 8.36 (dd, J = 8.8, 1.9 Hz, 1H), 8.15-7.96 (m, 3H), 7.76 (dd, J = 9.0, 4.1 Hz, 1H), 7.64-7.50 (m, 1H), 7.41 (dt, J = 12.9, 1.6 Hz, 2H), 6.99-6.90 (m, 1H), 3.90 (s, 3H). 763

HCl ¹H NMR (400 MHz, DMSO) δ 10.54 (s, 1H), 9.55 (s, 1H), 9.05 (d, J = 8.2 Hz, 1H), 8.92 (d, J = 4.6 Hz, 1H), 8.84 (s, 1H), 8.17-8.02 (m, 3H), 7.96 (dd, J = 7.9, 5.4 Hz, 1H), 7.72 (d, J = 9.0 Hz, 1H), 7.56 (dd, J = 19.6, 9.1 Hz, 1H), 7.39-7.21 (m, 3H), 3.89 (s, 3H). 764

HCl ¹H NMR (400 MHz, DMSO) δ 10.68 (s, 1H), 9.51 (d, J = 1.3 Hz, 1H), 9.04 (d, J = 3.1 Hz, 1H), 8.97-8.87 (m, 2H), 8.51 (s, 1H), 8.32-8.22 (m, 2H), 8.16-8.05 (m, 2H), 8.00- 7.90 (m, 2H), 7.80-7.73 (m, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.60-7.47 (m, 2H). 765

HCl ¹H NMR (400 MHz, DMSO) δ 10.43 (s, 1H), 9.46 (d, J = 1.3 Hz, 1H), 9.01 (d, J = 8.1 Hz, 1H), 8.91 (d, 1H), 8.63 (s, 1H), 8.13-7.91 (m, 3H), 7.73- 7.66 (m, 1H), 7.59-7.49 (m, 2H), 7.44 (dd, J = 8.2, 1.8 Hz, 1H), 7.07 (d, J = 8.1 Hz, 1H), 6.12 (s, 2H). 766

¹H NMR (400 MHz, DMSO) δ 10.33 (s, 1H), 9.52 (s, 1H), 8.83 (s, 1H), 8.70 (d, J = 6.3 Hz, 2H), 8.32 (d, J = 8.6 Hz, 2H), 8.13-8.03 (m, 1H), 7.70 (d, J = 7.3 Hz, 1H), 7.58 (dd, J = 7.3, 5.7 Hz, 3H), 7.42 (s, 1H), 3.95 (s, 3H). 767

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.71 (s, 1H), 9.52-9.41 (m, 3H), 9.26 (s, 1H), 9.11- 9.02 (m, 2H), 8.96 (d, J = 5.4 Hz, 1H), 8.37 (d, J = 11.6 Hz, 1H), 8.14-7.99 (m, 2H), 7.80-7.71 (m, 1H), 7.55 (d, J = 9.1 Hz, 1H). 768

HCl ¹H NMR (400 MHz, DMSO) δ 10.53 (s, 1H), 9.51 (d, J = 1.6 Hz, 1H), 9.07-9.00 (m, 1H), 8.91 (dd, J = 5.3, 1.5 Hz, 1H), 8.79 (s, 1H), 8.20 (dd, J = 11.9, 1.6 Hz, 1H), 8.13- 8.03 (m, 1H), 8.00-7.91 (m, 3H), 7.76-7.68 (m, 1H), 7.62-7.44 (m, 4H). 769

3 HCl ¹H NMR (400 MHz, DMSO) δ 11.13 (s, 1H), 9.64 (d, J = 1.7 Hz, 1H), 9.47 (d, J = 1.5 Hz, 1H), 9.38 (s, 1H), 9.09 (t, J = 7.3 Hz, 2H), 9.01- 8.94 (m, 1H), 8.91-8.83 (m, 1H), 8.39 (dd, J = 11.6, 1.3 Hz, 1H), 8.22-8.13 (m, 1H), 8.11-7.98 (m, 2H), 7.93- 7.84 (m, 1H), 7.53 (dd, J = 19.7, 9.2 Hz, 1H). 770

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.69 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 9.12 (d, J = 8.2 Hz, 1H), 8.97 (dd, J = 5.4, 1.4 Hz, 1H), 8.81 (d, J = 8.7 Hz, 1H), 8.30 (d, J = 1.3 Hz, 1H), 8.15-7.99 (m, 3H), 7.96-7.88 (m, 2H), 7.81-7.72 (m, 1H), 7.63-7.47 (m, 4H). 771

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.89 (s, 1H), 9.54-9.45 (m, 2H), 9.17 (t, J = 8.6 Hz, 1H), 9.10-8.93 (m, 4H), 8.48 (d, J = 1.6 Hz, 1H), 8.25- 8.06 (m, 4H), 7.89-7.79 (m, 1H), 7.53 (dd, J = 19.6, 9.2 Hz, 1H). 772

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.54 (d, J = 1.7 Hz, 1H), 9.40 (s, 2H), 9.31 (s, 1H), 9.20 (d, J = 8.2 Hz, 1H), 9.02 (d, J = 4.3 Hz, 1H), 8.89 (d, J = 8.7 Hz, 1H), 8.43 (s, 1H), 8.22 (dd, J = 8.7, 1.9 Hz, 1H), 8.17- 8.06 (m, 2H), 7.82-7.74 (m, 1H), 7.56 (dd, J = 19.7, 9.2 Hz, 1H). 773

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.81 (s, 1H), 9.56 (s, 1H), 9.11 (d, J = 8.2 Hz, 1H), 8.94 (dd, J = 17.5, 6.7 Hz, 2H), 8.42 (d, J = 11.9 Hz, 2H), 8.28 (s, 1H), 8.22-7.94 (m, 5H), 7.81 (d, J = 8.8 Hz, 1H), 7.71-7.45 (m, 3H). 774

HCl ¹H NMR (400 MHz, DMSO) δ 10.32 (s, 1H), 9.54 (s, 1H), 8.95-8.78 (m, 2H), 8.65 (d, J = 8.8 Hz, 1H), 8.19-8.09 (m, 2H), 8.02 (d, J = 8.7, 1H), 7.85-7.69 (m, 2H), 7.62-7.37 (m, 3H), 7.09 (d, J = 7.0 Hz, 1H), 6.13 (s, 2H). 775

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.59 (s, 1H), 9.56 (d, J = 1.7 Hz, 1H), 9.11 (d, J = 8.1 Hz, 1H), 9.01-8.88 (m, 1H), 8.79 (d, J = 8.7 Hz, 1H), 8.18-8.06 (m, 2H), 8.05- 7.91 (m, 2H), 7.82-7.72 (m, 2H), 7.61-7.52 (m, 2H), 7.48-7.37 (m, 2H). 776

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.46 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 9.04 (dt, J = 8.1, 1.6 Hz, 1H), 8.91 (dd, J = 5.2, 1.4 Hz, 1H), 8.73 (d, J = 8.7 Hz, 1H), 8.24 (d, J = 1.8 Hz, 1H), 8.15-8.04 (m, 2H), 7.96 (dd, J = 8.0, 5.3 Hz, 1H), 7.84-7.70 (m, 2H), 7.65-7.48 (m, 2H), 7.39-7.25 (m, 1H). 777

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.62 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 9.12 (d, J = 8.1 Hz, 1H), 8.96 (dd, J = 5.3, 1.3 Hz, 1H), 8.78 (d, J = 8.7 Hz, 1H), 8.25 (d, J = 1.7 Hz, 1H), 8.16-7.91 (m, 6H), 7.81-7.69 (m, 1H), 7.56 (dd, J = 19.7, 9.1 Hz, 1H), 7.41 (t, J = 8.8 Hz, 1H). 778

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.65 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 9.14 (d, J = 8.1 Hz, 1H), 8.97 (dd, J = 5.4, 1.3 Hz, 1H), 8.81 (d, J = 8.7 Hz, 1H), 8.20-8.00 (m, 3H), 7.96-7.71 (m, 3H), 7.63-7.42 (m, 2H), 7.38-7.25 (m, 1H). 779

HCl ¹H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.00 (d, J = 8.1 Hz, 1H), 8.90 (dd, J = 5.2, 1.4 Hz, 1H), 8.71 (d, J = 8.7 Hz, 1H), 8.23 (d, J = 1.8 Hz, 1H), 8.17-8.01 (m, 3H), 7.93 (dd, J = 8.0, 5.2 Hz, 1H), 7.84-7.71 (m, 2H), 7.69- 7.49 (m, 2H). 780

2 HCl 1H NMR (400 MHz, DMSO) δ 10.78 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.19 (d, J = 8.1 Hz, 1H), 9.06-8.96 (m, 1H), 8.87 (d, J = 8.7 Hz, 1H), 8.22-8.04 (m, 3H), 7.93 (t, J = 10.1 Hz, 1H), 7.78 (dd, J = 6.1, 2.9 Hz, 1H), 7.64- 7.49 (m, 3H), 7.47-7.35 (m, 1H). 781

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.47 (s, 1H), 9.53 (d, J = 1.7 Hz, 1H), 9.08 (d, J = 8.1 Hz, 1H), 8.94 (dd, J = 5.3, 1.3 Hz, 1H), 8.74 (d, J = 8.8 Hz, 1H), 8.29 (d, J = 1.8 Hz, 1H), 8.17-7.95 (m, 3H), 7.80- 7.55 (m, 3H), 7.61-7.48 (m, 1H), 7.42-7.30 (m, 1H). 782

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.20 (s, 1H), 9.63 (s, 1H), 9.20 (d, J = 8.1 Hz, 1H), 8.97 (dd, J = 5.3, 1.3 Hz, 1H), 8.89 (d, J = 8.3 Hz, 1H), 8.56 (d, J = 1.6 Hz, 1H), 8.46 (s, 1H), 8.31 (dd, J = 8.7, 1.8 Hz, 1H), 8.13-7.92 (m, 4H), 7.90-7.83 (m, 2H), 7.77-7.70 (m, 1H), 7.59 (dd, J = 10.4, 4.8 Hz, 2H), 7.53-7.46 (m, 2H), 7.34-7.25 (m, 1H). 783

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.22 (s, 1H), 9.65 (s, 1H), 9.19 (d, J = 8.1 Hz, 1H), 9.00-8.91 (m, 2H), 8.44 (d, J = 12.8 Hz, 2H), 8.18-7.89 (m, 5H), 7.84-7.70 (m, 2H), 7.56-7.45 (m, 1H), 7.38-7.23 (m, 2H). 784

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.15 (s, 1H), 9.65 (s, 1H), 9.38-9.27 (m, 3H), 9.17 (d, J = 9.2 Hz, 1H), 8.92 (dd, J = 25.3, 6.7 Hz, 2H), 8.68 (s, 1H), 8.45 (d, J = 8.9 Hz, 2H), 8.12 (d, J = 9.8 Hz, 1H), 8.04-7.92 (m, 3H), 7.74 (t, J = 7.6 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H). 785

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.10 (s, 1H), 9.63 (s, 1H), 9.18 (d, J = 8.0 Hz, 1H), 8.96 (dd, J = 5.3, 1.3 Hz, 1H), 8.87 (d, J = 8.1 Hz, 1H), 8.46 (d, J = 21.1 Hz, 2H), 8.27 (dd, J = 8.7, 1.3 Hz, 1H), 8.09-7.89 (m, 4H), 7.74 (t, J = 7.1 Hz, 1H), 7.46 (d, J = 1.8 Hz, 1H), 7.38 (dd, J = 8.1, 1.9 Hz, 1H), 7.30 (t, J = 7.2 Hz, 1H), 7.12 (d, J = 8.1 Hz, 1H), 6.12 (s, 2H). 786

2 HCl 1H NMR (DMSO-d6) ppm 9.79 (d, J = 1.56 Hz, 1H), 9.26 (brd, J = 7.2 Hz, 1H), 9.00-8.90 (brm, 2H), 8.18 (d, J = 8.64 Hz, 1H), 8.11 (d, J = 8.64 Hz, 1H), 8.01 (brt, J = 6.28 Hz, 1H), 7.86- 7.80 (brm, 1H), 7.72 (d, J = 3.96 Hz, 1H), 7.53-7.46 (m, 2H), 7.37-7.32 (brm, 1H). The 1H of 2HCl and NH— were not observed. 787

1H NMR (DMSO-d6) ppm 12.63 (brs, 1H), 9.80 (d, J = 1.64 Hz, 1H), 9.05-8.91 (brm, 2H), 8.76 (brd, J = 4.6 Hz, 1H), 8.10 (brd, J = 8.64 Hz, 1H), 8.02 (d, J = 8.64 Hz, 1H), 7.86-7.80 (brm, 1H), 7.66-7.62 (brm, 1H), 7.51-7.45 (brm, 1H), 7.34-7.30 (brm, 1H), 6.94 (brs, 1H), 2.35 (brs, 3H). 788

1H NMR (300 MHz, CD3OD) δ 9.40 (s, 1H), 8.65 (s, J = 8.0 Hz, 1H), 8.56 (d, J = 3.2 Hz, 1H), 8.18-8.08 (m, 2H), 7.76- 7.65 (m, 2H), 7.54-7.44 (m, 2H), 7.23 (t, J = 9.0 Hz, 1H), 3.66 (s, J = 8.0 Hz, 2H), 2.55 (s, J = 20.6 Hz, 8H), 2.30 (s, 3H). 789

790

791

¹H-NMR (400 MHz, DMSO- d₆): δ 12.20 (s, 1H), 9.64 (s, 1H), 9.58 (s, 1H), 8.73 (d, J = 5.5 Hz, 2H), 8.60 (s, 1H), 8.53 (dd, J = 7.2, 1.5 Hz, 1H), 8.28-8.25 (m, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.61- 7.58 (m, 1H), 7.50 (t, J = 4.5 Hz, 3H), 7.30 (d, J = 5.8 Hz, 1H), 7.06 (dd, J = 7.4, 4.1 Hz, 1H), 6.49 (t, J = 6.9 Hz, 1H), 3.91 (s, 3H). 792

HCl ¹H-NMR (400 MHz, DMSO- d₆): δ 13.42 (s, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.64 (td, J = 7.6, 2.0 Hz, 1H), 8.51 (s, 1H), 8.44 (d, J = 4.4 Hz, 1H), 8.01- 7.95 (m, 3H), 7.68-7.58 (m, 4H), 7.24 (t, J = 7.8 Hz, 1H), 4.26 (q, J = 2.8 Hz, 2H), 1.47 (t, J = 2.8 Hz, 3H). 793

HCl ¹H-NMR (400 MHz, DMSO- d₆): δ 10.31 (s, 1H), 9.13 (d, J = 2.0 Hz, 1H), 8.83 (td, J = 8.4, 2.4 Hz, 1H), 8.09 (d, J = 1.2 Hz, 2H), 7.93 (d, J = 8.4 Hz, 2H), 7.66-7.60 (m, 2H), 7.36 (dd, J = 8.8, 2.4 Hz, 1H), 7.22 (d, J = 8.0 Hz, 1H), 4.28 (q, J = 6.8 Hz, 2H), 1.47 (t, J = 6.8 Hz, 3H). 794

2HCl 795

3HCl 1H-NMR (300 MHz, DMSO): δ 13.10 (s, 1H), 9.61 (s, 1H), 9.12 (d, J = 9.8 Hz, 1H), 8.93 (s, 1H), 8.83 (d, J = 15.2 Hz, 2H), 8.66 (s, 1H), 8.58-8.36 (m, 3H), 8.08 (d, J = 11.6 Hz, 2H),7.96 (d, J = 9.2 Hz, 3H), 7.73 (s, 1H), 7.29 (t, J = 8.7 Hz, 1H), 4.02 (s, 3H). 796

3HCl 1H-NMR (300 MHz, DMSO): δ 12.79 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.18 (d, J = 8.2 Hz, 1H), 9.08 (d, J = 6.7 Hz, 2H), 9.05-8.96 (m, 2H), 8.63- 8.46 (m, 4H), 8.39 (s, 1H), 8.08 (dd, J = 11.6, 8.5 Hz, 2H), 7.92 (d, J = 6.7 Hz, 1H), 7.77 (s, 1H), 7.68 (t, J = 7.1 Hz, 1H), 7.32 (t, J = 7.2 Hz, 1H). 797

3HCl 1H-NMR (300 MHz, DMSO): δ 12.81 (s, 1H), 9.54 (s, 1H), 9.45 (s, 1H), 9.23 (d, J = 8.2 Hz, 1H), 9.08-8.93 (m, 3H), 8.83 (s, 1H), 8.52 (d, J = 8.2 Hz, 1H), 8.47-8.34 (m, 2H), 8.14 (ddd, J = 12.9, 8.1, 4.9 Hz, 3H), 7.92 (d, J = 6.6 Hz, 1H), 7.79 (s, 1H), 7.68 (t, J = 7.2 Hz, 1H), 7.32 (t, J = 7.2 Hz, 1H). 798

2HCl 1H-NMR (300 MHz, DMSO): δ 13.20 (s, 1H), 9.62 (s, 1H), 9.13 (d, J = 8.1 Hz, 1H), 8.94 (d, J = 3.5 Hz, 2H), 8.55 (s, 1H), 8.48 (s, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.06 (d, J = 8.7 Hz, 1H), 7.96 (s, 3H), 7.74 (s, 1H), 7.55-7.40 (m, 3H), 7.29 (s, 1H), 7.06 (d, J = 7.4 Hz, 1H), 3.90 (s, 3H). 799

1H-NMR (300 MHz, DMSO): δ 13.13 (s, 1H), 9.60 (d, J = 1.4 Hz, 1H), 9.12 (d, J = 7.8 Hz, 1H), 8.73 (dd, J = 9.7, 6.4 Hz, 2H), 8.52 (s, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 8.14 (d, J = 8.7 Hz, 1H), 8.08-7.88 (m, 4H), 7.76 (d, J = 7.2 Hz, 1H), 7.59 (dd, J = 7.4, 4.8 Hz, 1H), 7.23 (t, J = 7.1 Hz, 1H), 3.94 (s, 3H). 800

¹H NMR (400 MHz, DMSO) δ 10.08 (s, 1H), 9.59-9.49 (m, 1H), 8.79-8.63 (m, 3H), 8.55 (d, J = 2.1 Hz, 1H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 8.18 (dd, J = 8.7, 1.9 Hz, 1H), 8.02- 7.90 (m, 3H), 7.63-7.51 (m, 2H), 6.62 (d, J = 8.6 Hz, 1H), 6.24 (s, 2H). 801

1H NMR (DMSO-d6) ppm 9.78 (brs, 1H), 9.20-8.80 (br, 3H), 8.14 (brd, J = 8.64 Hz, 1H), 8.04 (d, J = 8.64 Hz, 1H), 7.83 brm, 2H), 7.52- 7.47 (m, 1H), 7.35-7.31 (m, 1H), 7.00 (brs, 1H), 2.36 (brs, 3H), 2.30 (brs, 3H). The 1H of MsOH and NH were not observed. ¹H NMR Purity Method LCMS Number Solvent percent of Coupling LCMS Method 748 DMSO >98 Method N6 749 DMSO >98 Method N6 750 DMSO >98 Method N6 751 DMSO >98 Method N6 752 DMSO >98 Method N6 753 DMSO >98 Method N6 754 DMSO >98 Method N6 755 DMSO >98 Method N6 756 DMSO >98 Method N6 757 DMSO >98 Method N6 758 DMSO >98 Method N6 759 DMSO >98 Method N6 760 DMSO >98 Method N6 761 DMSO >98 Method N6 762 DMSO >98 Method N6 763 DMSO >98 Method N6 764 DMSO >98 Method N6 765 DMSO >98 Method N6 766 DMSO >98 Method N6 767 DMSO >98 Method N6 768 DMSO >98 Method N6 769 DMSO >98 Method N6 770 DMSO >98 Method N6 771 DMSO >98 Method N6 772 DMSO >98 Method N6 773 DMSO >98 Method N6 774 DMSO >98 Method N6 775 DMSO >98 Method N6 776 DMSO >98 Method N6 777 DMSO >98 Method N6 778 DMSO >98 Method N6 779 DMSO >98 Method N6 780 DMSO >98 Method N6 781 DMSO >98 Method N6 782 DMSO >98 Method N6 783 DMSO >98 Method N6 784 DMSO >98 Method N6 785 DMSO >98 Method N6 786 DMSO >98 N6 using Na₂CO₃ instead of K₃PO₄ 787 DMSO >98 N6 using Na₂CO₃ instead of K₃PO₄ 788 CD3OD   99 Method N3 463.0 (M + 1) Method C 789   99 Method N3 434.0 (M + 1) Method C 790   99 Method N3 436.0 (M + 1) Method C 791 DMSO   95 Method N1 422.2 (M + 1) Method B (NH4HCO3) 792 DMSO   95 Method N1 404.0 (M + 1) Method B (NH4HCO3) 793 DMSO   95 Method N1 445.0 (M + 1) Method B (NH4HCO3) 794 DMSO   95 Method N1 382.5 (M + 1) Method C 795 DMSO   95 Method N1 449.4 (M + 1) Method C 796 DMSO   95 Method N1 419.1 (M + 1) Method C 797 DMSO   95 Method N1 419.1 (M + 1) Method C 798 DMSO   95 Method N1 448.1 (M + 1) Method C 799 DMSO   95 Method N1 422.2 (M + 1) Method C 800 DMSO >98 N5 801 DMSO >98 N6 using Na₂CO₃ instead of K₃PO₄ Salt Molecular Number PRODUCT type Mass 802

494.87 803

458.89 804

427.86 805

426.87 806

456.9 807

456.9 Method ¹H-NMR LCMS Purity for Number ¹H-NMR Solvent LCMS Protocol percent Coupling 802 ¹H-NMR (400 MHz, DMSO-d₆): δ10.18 (s, 1H), 9.21 (d, J = 1.8 Hz, 1H), 8.65-8.60 (m, 2H), 8.34- 8.24 (m, 2H), 7.96-7.90 (m, 2H), 7.85-7.68 (m, 4H), 7.56 (t, J = 9.0 Hz, 1H), 7.51-7.44 (m, 2H). DMSO 495.0, 497.0 (M + 1) Method B (NH4HCO3) 95 Method N1 803 ¹H-NMR (400 MHz, DMSO-d₆): δ10.14 (s, 1H), 9.44 (s, 1H), 8.73- 8.63 (m, 1H), 8.55 (t, J = 6.5 Hz, 2H), 8.27 (d, J = 4.6 Hz, 1H), 7.96 (d, J = 6.8 Hz, 2H), 7.76-7.64 (m, 3H), 7.58-7.52 (m, 2H), 7.31 (t, J = 9.2 Hz, 1H), 2.37 (s, 3H). DMSO 459.0, 461.0 (M + 1) Method B (NH4HCO3) 95 Method N1 804 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.19 (s, 1H), 9.42 (d, J = 1.5 Hz, 1H), 8.74 (d, J = 5.6 Hz, 2H), 8.69- 8.63 (m, 2H), 8.52 (d, J = 8.0 Hz, 1H), 8.28 (dd, J = 6.8, 2.6 Hz, 1H), 8.05 (d, J = 7.2 Hz, 1H), 7.96- 7.91 (m, 1H), 7.80 (dd, J = 14.6, 6.8 Hz, 3H), 7.59-7.52 (m, 2H). DMSO 428.0, 430.0 (M + 1) 214.6 (M/2 + 1) Method A (TFA) 95 Method N1 805 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.13 (s, 1H), 9.43 (d, J = 1.6 Hz, 1H), 8.66 (dd, J = 4.7, 1.6 Hz, 1H), 8.59-8.56 (m, 1H), 8.52 (td, J = 7.9, 1.8 Hz, 1H), 8.30 (dd, J = 6.84, 2.60 Hz, 1H), 7.99-7.92 (m, 2H), 7.82-7.73 (m, 3H), 7.58- 7.51 (m, 4H), 7.46 (t, J = 7.4 Hz, 1H). DMSO 427.1, 429.1 (M + 1) Method A (TFA) 95 Method N1 806 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.13 (s, 1H), 9.45 (s, 1H), 8.67 (dd, J = 4.7, 1.7 Hz, 1H), 8.62- 8.49 (m, 2H), 8.29 (dd, J = 6.8, 2.6 Hz, 1H), 8.03-7.88 (m, 2H), 7.81- 7.68 (m, 1H), 7.62-7.49 (m, 2H), 7.48-7.30 (m, 3H), 7.04 (dd, J = 7.8, 2.1 Hz, 1H), 3.87-3.81 (m, 3H). DMSO 457.1, 459.1 (M + 1) Method A (TFA) 95 Method N1 807 ¹H-NMR (400 MHz, DMSO-d6): δ10.10 (s, 1H), 9.31 (d, J = 1.6 Hz, 1H), 8.63 (dd, J = 4.8, 1.7 Hz, 1H), 8.61-8.52 (m, 1H), 8.41 (td, J = 8.0, 1.9 Hz, 1H), 8.30 (dd, J = 6.9, 2.6 Hz, 1H), 7.97-7.92 (m, 1H), 7.83 (dd, J = 7.2, 1.2 Hz, 1H), 7.73- 7.66 (m, 1H), 7.62- 7.40 (m, 3H), 7.36 (dd, J = 7.4, 1.7 Hz, 1H), 7.19 (d, J = 8.1 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 3.66 (s, 3H). DMSO 457.1, 459.1 (M + 2) Method B (NH4HCO3) 95 Method N1

indicates data missing or illegible when filed

Method S: N⁴-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)-N⁶-(3(pyrrolidin-1-yl)propyl)quinazoline-4,6-diamine (xxii-a)

A 2.0 dram reaction vial was charged with 6-bromo-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 5-bromo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (100 mg, 0.233 mmol, 1.0 equiv), 3-(pyrrolidin-1-yl)propan-1-amine (40 mg, 0.345 mmol, 1.5 equiv), copper(I) iodide (4.4 mg, 0.023 mmol, 0.1 equiv), L-proline (5.3 mg, 0.046 nm tool, 0.2 equiv), and potassium carbonate (96 mg, 0.69 mmol, 3.0 equiv) in 1DMF (3 mL). The reaction mixture was heated at 100° C. overnight. After cooling, water was added to the reaction mixture, and the resultant precipitate was collected by filtration. The crude product was purified via prep-TLC (silica, 2000 micron plate, 95% dichloromethane—5% methanol—0.1% NH₄OH) to yield the desired compound as a brown solid (17.2 mg, 15%). LCMS m/z=477.4 (M+1) (Method C) (retention time=1.68 min). ¹H NMR (300 MHz, DMSO) δ 9.68 (s, 1H), 9.46 (s, 1H), 8.59 (d, J=9.4 Hz, 2H), 8.25 (dd, J=6.8, 2.6 Hz, 1H), 7.93 (dd, J=8.3, 3.5 Hz, 1H), 7.69-7.59 (m, 1H), 7.52 (dd, J=11.0, 7.1 Hz, 2H), 7.36-7.19 (m, 2H), 6.41 (s, 1H), 3.34 (m, 2H) 2.69 (m, 6H), 2.02-1.82 (m, 2H), 1.75 (bs, 4H).

Method T: N-(3-chloro-4-fluorophenyl)-6-(2-morpholinoethoxy)-2-(pyridin-3-yl)quinazolin-4-amine (xxii-b)

A 2.5 dram reaction vial was charged with N-(3-chloro-4-fluorophenyl)-6-iodo-2-(pyridin-3-yl)quinazolin-4-amine (0.250 g, 0.524 mmol), 2-morpholinoethanol (1 ml, 8.17 mmol) as solvent, copper(I) iodide (0.020 g, 0.105 mmol), racemic-2,2′-diamino-1,1′-binaphthyl (0.030 g, 0.105 mmol), and cesium carbonate (0.513 g, 1.573 mmol). The reaction mixture was heated at 110° C. overnight. After cooling, water was added to the reaction mixture, and the resultant precipitate was collected by filtration. The solid residue was purified via ISCO (silica, 12 g column, 95% dichloromethane—5% methanol—0.1% NH₄OH) to yield the desired compound as a brown solid. The solid was further washed with a mixture of water and saturated NaHCO₃ solution and dried. The product off the column was further purified by prep TLC (silica gel, 1000 micron, 95% dichloromethane—5% methanol—0.1% NH₄OH) to afford the desired product as a light brown solid (21.2 mg, 8%), LCMS m/z=480.0 (M+1) (Method C) (retention time=2.09 min). ¹H NMR (300 MHz, DMSO) δ 9.81 (s, 1H), 9.47 (d, J=1.8 Hz, 1H), 8.66-8.57 (m, 2H), 8.21 (dd, J=6.8, 2.6 Hz, 1H), 7.92 (d, J=2.5 Hz, 1H), 7.87 (ddd, J=8.9, 4.3, 2.7 Hz, 1H), 7.81 (d, J=9.1 Hz, 1H), 7.57-7.47 (m, 3H), 4.25 (t, J=5.8 Hz, 2H), 3.64-3.55 (m, 4H), 2.78 (t, J=5.7 Hz, 2H), 2.55-2.49 (m, 4H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 20 substituting with appropriate amine or alcohol

TABLE 5 Salt Molecular ¹H-NMR Retention LCMS Purity Method for Number Product type Mass ¹H-NMR Solvent LCMS Time (min.) Protocol Percent Coupling 808

476.98 1H NMR (300 MHz, DMSO) δ 9.68 (s, 1H), 9.46 (s, 1H), 8.59 (d, J = 9.4 Hz, 2H), 8.25 (dd, J = 6.8, 2.6 Hz, 1H), 7.93 (dd, J = 8.3, 3.5 Hz, 1H), 7.69-7.59 (m, 1H), 7.52 (dd, J =11.0, 7.1 Hz, 2H), 7.36-7.19 (m, 2H), 6.41 (s, 1H), 3.34 (m, 2H), 2.69 (m, DMSO 477.4 (M + 1) 1.68 Method C 95 Method S 809

492.98 1H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 9.46 (s, 1H), 8.60 (td, J = 4.2, 2.4 Hz, 2H), 8.23 (dd, J = 6.8, 2.6 Hz, 1H), 7.90 (ddd, J = 8.9, 4.2, 2.6 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.57-7.45 (m, 2H), 7.32 (dd, J = 9.1, 2.2 Hz, 1H), 7.20 (s, 1H), 6.38 (s DMSO 493 (M + 1) 1.97 Method C 100 Method S 810

423.87 1H NMR (300 MHz, DMSO) δ 9.60 (s, 1H), 9.46 (s, 1H), 8.60 (dd, J = 9.1, 3.1 Hz, 2H), 8.22 (dd, J = 6.9, 25 Hz, 1H), 7.89 (ddd, J = 9.0, 4.3, 2.7 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7 58-7.46 (m, 2H), 7.37 (dd, J = 9.1, 2.2 Hz, 1H), 7.25 (s, 1H), 6.40 (t DMSO 423.9 (M + 1) 2.16 Method C 100 Method S 811

463.93 1H NMR (300 MHz, DMSO) δ 9.62 (s, 1H), 9.49 (d, J = 1.7 Hz, 1H), 8.70- 8.59 (m, 2H), 8.27 (dd, J = 6.9, 2.5 Hz, 1H), 8.19 (dd, J = 9.0, 5.0 Hz, 1H), 7.91- 7.82 (m, 1H), 7.57-7.43 (m, 2H), 7.01 (dd, J = 9.0, 2.1 Hz, 1H), 6.77 (t, J = 5.3 Hz, 1H), 6.72 DMSO 464.0 (M + 1) 2.19 Method C 100 Method S 812

449.91 1H NMR (300 MHz, DMSO) δ 9.65 (s, 1H), 9.49 (d, J = 2.1 Hz, 1H), 8.69- 8.59 (m, 2H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 8.20 (d, J = 9.0 Hz, 1H), 7.87 (ddd, J = 9.0, 4.3, 2.7 Hz, 1H), 7.56- 7.43 (m, 2H), 7.00 (dd, J = 9.1, 2.2 Hz, 1H), 6.79 (d, J = 2.1 Hz, DMSO 449.9 (M + 1) 2.12 Method C 100 Method S 813

409.84 1H NMR (300 MHz, DMSO) δ 9.71 (s, 1H), 9.46 (s, 1H), 8.66-8.55 (m, 2H), 8.24 (d, J = 4.3 Hz, 1H), 796-7.87 (m, 1H), 7.64 (d, J = 9.1 Hz, 1H), 7.58- 7.46 (m, 3H), 7.36 (d, J = 9.0 Hz, 1H), 7.28 (s, 1 H), 6.38 (s, 1H), 4.96 (s, 1H), 3.69 (s, 2H), 3.42 DMSO 409.9 (M + 1) 1.86 Method C 100 Method S 814

463.93 1H NMR (300 MHz, DMSO) δ 9.59 (s, 1H), 9 45 (d, J = 1.2 Hz, 1H), 8.60 (dd, J = 7.4, 5.7 Hz, 2H), 6.23 (dd, J = 6.8, 2.5 Hz, 1H), 7.90 (dd, J = 9.0, 2.7 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.57- 7.46 (m, 2H, 7.36 (d, J = 9.1 Hz, 1H), 7.19 (s, 1H), 6.38 (s DMSO 464.0 (M + 1) 2.19 Method C 95 Method S 815

479.93 1H NMR (300 MHz, DMSO) δ 9.81 (s, 1H), 9.47 (d, J = 1.8 Hz, 1H), 8.66- 8.57 (m, 2H), 8.21 (dd, J = 6.8, 2.6 Hz, 1H), 7.92 (d, J = 2.5 Hz, 1H), 7.87 (ddd, J = 8.9, 4.3, 2.7 Hz, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.57-7.47 (m, 3H), 4.25 (t, J = 5.8 Hz, 2H), DMSO 480.0 (M + 1) 2.09 Method C 91 Method T 816

423.87 1H NMR (300 MHz, DMS0) δ 9.60 (s, 1H), 9.47 (s, 1 H), 8.67-8.55 (m, 2H), 8.23 (dd, J = 6.9, 2.5 Hz, 1H), 7.90 (ddd, J = 9.0, 4.3, 2.7 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.58-7.47 (m, 2H), 7.37 (dd, J = 9.1, 2.2 Hz, 1H), 7.25 (d, J = 1.3 Hz, 1H), 6.41 (t, J = 5.6 Hz, 1H), 3.63 (t, J = 5.7 Hz, 2H), 3.48- 3.35 (m, 5H). DMSO 423.9 (M + 1) Method C 99 Method S 817

437.9 1H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 9.47 (s, 1H), 8.66-8.55 (m, 2H), 8.23 (dd, J = 6.9, 2.5 Hz, 1H), 7.90 (ddd, J = 8.8, 4.3, 2.5 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.58-7.45 (m, 2H), 7.32 (dd, J = 9.0, 1.8 Hz, 1H), 7.21 (s, 1H), 6.34 (t, J = 5.0 Hz, 1H), 3.50 (t, J = 6.1 Hz, 2H), 3.31-3.20 (m, 5H), 1.92 (p, J = 6.5 Hz, 2H). DMSO 438.1 (M + 1) Method C 99 Method S 818

449.91 1H NMR (300 MHz, DMSO) δ 9.61 (s, 1H), 9.46 (d, J = 2.1 Hz, 1H), 8.65- 8.56 (m, 2H), 8.23 (dd, J = 6.9, 2.6 Hz, 1H), 7.90 (ddd, J = 8.9, 4.2, 2.6 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.58- 7.47 (m, 2H), 7.40 (dd, J = 8.9, 2.2 Hz, 1H), 7.26 (d, J = 1.7 Hz, 1H), 6.39 (t, J = 5.7 Hz, 1H), 4.12 (t, J = 6.2 Hz, 1H), 3.85 (dd, J = 14.2, 7.2 Hz, 1H), 3.70 (dd, J = 14.2, 7.7 Hz, 1H), 3.34-3.25 (m, 5H), 2.15-1.99 (m, 1H), 1.97- 1.80 (m, 3H), 1.74-158 (m, 2H). DMSO 449.9 (M + 1) Method C 94 Method S 819

1H-NMR (300 MHz, DMSO): δ 10.04 (s, 1H), 9.48 (s, 1H), 8.67 (s, 2H), 8.43- 8.31 (m, 1H), 8.14-8.01 (m, 1H), 7.72 (d, J = 9.0 Hz, 1H), 7.65 (s, 1H), 7.54 (dd, J = 9.7 Hz, 2H), 7.35 (d, J = 9.0 Hz, 1H), 6.77 (s, 1H), 3.67 (broad doublet, 4H), 3.41 (bs, 2H). 3.08 (d, J = 4.7 Hz, 2H), 2.03 (bs, 2H). 1.91 (bs, 2H). DMSO 463.9 (M + 1) Method C 95 Method S

Method U: 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (xxiii-a)

To a suspension of 2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (synthesized as described in Scheme 1 and 4, substituting 5-methoxy-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid) (371 mg, 1.0 mmol) in CH₂Cl₂ (4.5 mL) was slowly added boron tribromide, 1M solution in dichloromethane (4.5 ml, 4.5 mmol) at 0° C. The reaction mixture was stirred overnight at room temperature after which it was carefully poured into a vigorously stirring mixture of ice and saturated solution of aqueous NaHCO₃. The resultant solid was collected by filtration, dried and then stirred in a saturated solution of aqueous NH₄Cl for 1 h after which the suspension was filtered to give the desired product as a yellowish tan solid (262 mg, 73%). LCMS m/z=357.9 (M+1) (Method C) (retention time=1.68 min), ¹H NMR (300 MHz, DMSO) δ 12.80 (s, 1H), 10.50 (s, 1H), 9.57 (s, 1H), 9.15 (d, J=8.5 Hz, 1H), 8.70 (t, J=7.3 Hz, 2H), 8.50 (s, 1H), 8.08-7.79 (m, 3H), 7.73 (t, J=7.5 Hz, 1H), 7.57 (dd, J=7.6, 4.8 Hz, 1H), 7.46 (d, J=8.5 Hz, 2H), 7.19 (t, J=7.6 Hz, 1H).

Method V: 2-(6-(2-chloroethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (xxiv-a)

The suspension of 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (50 mg, 0.14 mmol), 1-bromo-2-chloroethane (0.015 ml, 0.15 mmol), and potassium carbonate (23 mg, 0.17 mmol) in DMF (5 mL) was stirred for 3 days at room temperature. Water (10 mL) was added to the mixture and extracted with ethyl acetate (2×10 mL). The combined organic layer was washed with water (1×20 mL) and brine (1×20 mL) and was dried over MgSO₄. After filtration and evaporation, the crude product was obtained, which was washed with hexane and dried to give 48 mg of 2-(6-(2-chloroethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide as light brown solid (79%).

Method G4: 2-(6-(2-morpholinoethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (xxv-a)

2-(6-(2-morpholinoethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide was prepared from 2-(6-(3-chloroethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide and morpholine in a manner analogous to that described for N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)propyl)-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride in Scheme 9 using Method G4 to give 50 mg of 2-(6-(2-morpholinoethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide as light yellow solid. LCMS m/z=485 (M+1) (Method C) (retention time=1.71 min). ¹H NMR (300 MHz, DMSO) δ 9.57 (s, 1H), 9.12 (d, J=8.5 Hz, 1H), 8.78-8.63 (m, 2H), 8.48 (s, 1H), 8.02-7.93 (m, 2H), 7.88 (d, J=9.0 Hz, 1H), 7.73 (t, J=8.0 Hz, 1H), 7.63-7.49 (m, 3H), 7.20 (t, J=7.6 Hz, 1H), 4.29-4.16 (m, 2H), 3.65-3.51 (m, 4H), 3.44-3.21 (m, 2H), 2.45-2.31 (m, 4H), 2.06-1.91 (m, 2H).

Method W: 2-(6-(2-(2-methylamino)-2-oxoethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide

The suspension of 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (synthesized as described in Scheme 24) (0.20 g, 0.56 mmol), 2-chloro-N-methylacetamide (90 mg, 0.80 mmol), cesium carbonate (0.37 g, 112 mmol) and potassium iodide (0.19 g, 1.12 mmol) in DMF (10 mL) was stirred for 4 days at room temperature. Water (20 mL) was added to the mixture. The resultant solid was collected by filtration. The obtained solid was washed with CH₂Cl₂-THF (1:1) solution and dried to give 0.11 g of 2-(6-(2-(methylamino)-2-oxoethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide as pale brown solid (46%), LCMS m/z=429 (M+1) (Method C) (retention time=1.65 min). ¹H NMR (300 MHz, DMSO) δ 9.58 (s, 1H), 9.12 (d, J=8.4 Hz, 1H), 8.82-8.64 (m, 2H), 8.48 (s, 1H), 8.32-8.17 (m, 1H), 8.10-7.87 (m, 3H), 7.81-7.49 (m, 4H), 7.21 (t, J=7.5 Hz, 1H), 4.66 (s, 2H), 2.71 (d, J=4.5 Hz, 3H).

Method X: 2-(6-(2-(dimethylamino)ethoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide

A suspension of 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (synthesized as described in Scheme 24) (25 mg, 0.07 mmol), 2-chloro-N,N-dimethylethylamine hydrochloride (20 mg, 0.14 mmol) and cesium carbonate (68.4 mg, 0.21 mmol) in DMF (1 mL) was stirred at 60° C. overnight. The reaction mixture was cooled to room temperature, diluted with water (5 mL) and extracted with dichloromethane (3×5 mL). The combined organic extracts were dried over Na₂SO₄ and concentrated in vacuo. The crude product was purified by prep-TLC (silica, 2000 micron plate, 95% dichloromethane—5% methanol—0.1% NH₄OH) to yield the desired compound as a brown solid (12.6 mg, 40%). LCMS m/z=428.9 (M+1) (Method C) (retention time=1.41 min). ¹H NMR (300 MHz, DMSO) δ 12.99 (s, 1H), 9.59 (d, J=1.3 Hz, 1H), 9.12 (d, J=8.4 Hz, 1H), 8.81-8.66 (m, 2H), 8.52 (s, 1H), 8.06-7.88 (m, 3H), 7.80-7.53 (m, 4H), 7.22 (t, J=7.6 Hz, 1H), 4.46 (s, 2H), 3.35 (s, 2H), 2.69 (s, 6H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 23 substituting with appropriate nucleophile.

TABLE 6 Salt Molecular Number Product type Mass 820

484.550 821

470.523 822

442.470 823

HCl 561.94 824

HCl 598.44 825

469.42 826

483.44 827

HCl 564.91 828

437.85 829

493.92 830

479.93 831

HCl 580.91 832

451.88 833

HCl 566.88 834

366.78 835

428.44 836

484.51 837

442.47 838

357.37 839

2HCl 443.86 840

2HCl 457.89 841

448.48 842

448.48 843

425.48 844

457.89 845

487.91 Starting Starting Salt Number Material R¹ Material R³ Product Type 846

HCl 847

848

849

2HCl 850

2HCl 851

2HCl 852

3HCl 853

3HCl 854

2HCl 855

2HCl 856

2HCl 857

HCl 858

859

HCl 860

2HCl 861

3HCl 862

2HCl 863

2HCl 864

2HCl 865

3HCl 866

4HCl 867

HCl 868

2HCl 869

3HCl 870

2HCl 871

4HCl 872

2HCl 873

3HCl 874

2HCl 875

3HCl 876

CF3COOH 1757

¹H-NMR Retention LCMS Purity Method for Number ¹H-NMR Solvent LCMS Time (min.) Protocol Percent Coupling 820 1H NMR (300 MHz, DMSO) δ DMSO 485 1.71 Method C 100 Methods V, 9.57 (s, 1H), 9.12 (d, J = 8.5 Hz, (M + 1) G4 1H), 8.78-8.63 (m, 2H), 8.48 (s, 1H), 8.02-7.93 (m, 2H), 7.88 (d, J = 9.0 Hz, 1H), 7.73 (t, J = 8.0 Hz, 1H), 7.63-7.49 (m, 3H), 7.20 (t, J = 7.6 Hz, 1H), 4.29- 4.16 (m, 2H), 3.65-3.51 (m 821 1H NMR (300 MHz, DMSO) δ DMSO 471 1.75 Method C 100 Methods V, 9.58 (s, 1H), 9.24-9.08 (m, 1H), (M + 1) G4 followed 8.82-8.61 (m, 2H), 8.49 (s, 1H), by acylation 8.09-7.84 (m, 3H), 7.73 (t, J = with acetyl 7.8 Hz, 1H), 7.67-7.47 (m, 3H), chloride/TE 7.19 (t, J = 7.5 Hz, 1H), 4.29- A in DCM 4.09 (m, 2H), 3.63-3.42 (m, at rt. 2H), 3.07-2.77 (m, 3H), 2.2 822 1H NMR (300 MHz, DMSO) δ DMSO 443 1.63 Method C 100 Method W 9.58 (s, 1H), 9.16 (d, J = 8.4 Hz, (M + 1) 1H), 8.82-8.60 (m, 2H), 8.49 (s, 1H), 8.05-7.80 (m, 3H), 7.79- 7.68 (m, 1H), 7.67-7.51 (m, 2H), 7.43 (s, 1H), 7.29-7.12 (m, 1H), 5.03 (s, 2H), 3.10 (s, 3H), 2.89 (s, 3H). 823 1H NMR (300 MHz, DMSO) δ DMSO 526 2.02 Method C 100 Method W 10.51 (s, 1H), 9.49 (s, 1H), 8.95 (M + 1) (d, J = 6.6 Hz, 1H), 8.85 (d, J = 5.0 Hz, 1H), 8.26 (s, 1H), 8.10 (s, 1H), 8.03-7.80 (m, 3H), 7.73- 7.51 (m, 2H), 7.19 (d, J = 7.4 Hz, 1H), 5.12 (s, 2H), 3.75-3.36 (m, 8H). 824 1H NMR (300 MHz, DMSO) δ DMSO 526 2.25 Method C 100 Methods V, 10.98 (s, 1H), 10.59 (s, 1H), 9.50 (M + 1) G4 (s, 1H), 8.96 (d, J = 8.1 Hz, 1H), 8.86 (d, J = 5.1 Hz, 1H), 8.31 (s, 1H), 8.10 (s, 1H), 8.07-7.93 (m, 2H), 7.92-7.80 (m, 1H), 7.71- 7.54 (m, 2H), 7.21 (d, J = 8.0 Hz, 1H), 4.47-4.23 (m, 2 825 1H NMR (300 MHz, DMSO) δ DMSO 470 2.04 Method C 100 Method W 9.95 (s, 1H), 9.51 (s, 1H), 8.76- (M + 1) 8.56 (m, 2H), 8.26-8.08 (m, 2H), 8.01 (s, 1H), 7.95-7.81 (m, 2H), 7.70-7.56 (m, 2H), 7.52 (dd, J = 7.9, 4.9 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 4.69 (s, 2H), 2.71 (d, J = 4.5 Hz, 3H). 826 1H NMR (300 MHz, DMSO) δ DMSO 484 1.71 Method D 100 Method W 9.92 (s, 1H), 9.51 (s, 1H), 8.74- (M + 1) 8.57 (m, 2H), 8.17 (s, 1H), 8.01 (d, J = 2.5 Hz, 1H), 7.96-7.83 (m, 2H), 7.70-7.46 (m, 3H), 7.16 (d, J = 7.0 Hz, 1H), 5.03 (s, 2H), 3.06 (s, 3H), 2.88 (s, 3H). 827 1H NMR (300 MHz, DMSO) δ DMSO 492 1.81 Method C 100 Methods V, 10.59 (s, 1H), 9.99 (s, 1H), 9.49 (M + 1) G4 (s, 1H), 8.97 (d, J = 7.7 Hz, 1H), 8.87 (d, J = 5.3 Hz, 1H), 8.33- 8.18 (m, 2H), 8.04-7.83 (m, 3H), 7.68-7.47 (m, 2H), 4.41- 4.27 (m, 2H), 3.55-3.43 (m, 2H), 3.34-3.20 (m, 2H), 3.03-2. 828 1H NMR (300 MHz, DMSO) δ DMSO 438 1.65 Method D 100 Method W 9.87 (s, 1H), 9.49 (s, 1H), 8.76- (M + 1) 8.53 (m, 2H), 8.32-8.08 (m, 2H), 8.01-7.77 (m, 3H), 7.69- 7.43 (m, 3H), 4.67 (s, 2H), 2.71 (d, J = 4.6 Hz, 3H). 829 1H NMR (300 MHz, DMSO) δ DMSO 494 1.98 Method C  98 Method W 9.86 (s, 1H), 9.50 (s, 1H), 8.76- (M + 1) 8.57 (m, 2H), 8.27 (d, J = 7.0 Hz, 1H), 8.05-7.80 (m, 3H), 7.69- 7.45 (m, 3H), 5.04 (s, 2H), 3.78- 3.41 (m, 8H). 830 1H NMR (300 MHz, DMSO) δ DMSO 480 2.20 Method C 100 Method W 9.85 (s, 1H), 9.50 (s, 1H), 8.76- (M + 1) 8.53 (m, 2H), 8.26 (dd, J = 6.9, 2.5 Hz, 1H), 8.08-7.76 (m, 3H), 7.71-7.41 (m, 3H), 4.98 (s, 2H), 3.52-3.09 (m, 4H), 1.37-0.88 (m, 6H). 831 1H NMR (300 MHz, DMSO) δ DMSO 508 2.14 Method C 100 Methods V, 10.71 (s, 2H), 9.48 (s, 1H), 9.10- (M + 1) G4 8.95 (m, 1H), 8.94-8.79 (m, 1H), 8.36-8.27 (m, 1H), 8.26- 8.16 (m, 1H), 8.07-7.83 (m, 3H), 7.68-7.46 (m, 2H), 4.39- 4.18 (m, 2H), 4.05-3.89 (m, 2H), 3.79 (t, J = 11.9 Hz, 2H), 3.53- 832 1H NMR (300 MHz, DMSO) δ DMSO 452 1.99 Method C 100 Method W 9.85 (s, 1H), 9.50 (s, 1H), 8.71- (M + 1) 8.58 (m, 2H), 8.25 (dd, J = 6.8, 2.5 Hz, 1H), 8.01-7.80 (m, 3H), 7.66-7.45 (m, 3H), 5.02 (s, 2H), 3.06 (s, 3H), 2.88 (s, 3H). 833 1H NMR (300 MHz, DMSO) δ DMSO 494 2.10 Method C 100 Methods V, 11.18 (s, 1H), 10.93 (s, 1H), 9.48 (M + 1) G4 (s, 1H), 9.08 (d, J = 8.4 Hz, 1H), 8.94 (d, J = 5.0 Hz, 1H), 8.42 (s, 1H), 8.23 (dd, J = 6.8, 2.5 Hz, 1H), 8.12-7.89 (m, 3H), 7.63 (d, J = 9.1 Hz, 1H), 7.54 (t, J = 9.1 Hz, 1H), 4.45-4.26 (m, 834 1H NMR (300 MHz, DMSO) δ DMSO 367 1.69 Method D 100 Method U 9.98-9.59 (m, 1H), 9.53-9.41 (M + 1) (m, 1H), 8.71-8.48 (m, 2H), 8.31 (dd, J = 6.9, 2.5 Hz, 1H), 8.01-7.85 (m, 1H), 7.83-7.66 (m, 2H), 7.59-7.35 (m, 3H). 835 1H NMR (300 MHz, DMSO) δ DMSO 429 1.65 Method C 100 Method W 9.58 (s, 1H), 9.12 (d, J = 8.4 Hz, (M + 1) 1H), 8.82-8.64 (m, 2H), 8.48 (s, 1H), 8.32-8.17 (m, 1H), 8.10- 7.87 (m, 3H), 7.81-7.49 (m, 4H), 7.21 (1, J = 7.5 Hz, 1H), 4.66 (s, 2H), 2.71 (d, J = 4.5 Hz, 3H). 836 1H NMR (300 MHz, DMSO) δ DMSO 485 1.72 Method C  91 Method W 9.58 (s, 1H), 9.13 (d, J = 8.3 Hz, (M + 1) 1H), 8.78-8.64 (m, 2H), 8.50 (s, 1H), 8.02-7.80 (m, 3H), 7.73 (t, J = 7.9 Hz, 1H), 7.68-7.53 (m, 2H), 7.49 (s, 1H), 7.20 (t, J = 7.5 Hz, 1H), 5.07 (s, 2H), 3.79-3.40 (m, 8H). 837 1H NMR (300 MHz, DMSO) δ DMSO 443 1 .69 Method C 100 Method W 9.59 (s, 1H), 9.12 (d, J = 8.4 Hz, (M + 1) 1H), 8.78-8.63 (m, 1H), 8.49 (s, 1H), 8.29 (s, 1H), 8.11-7.88 (m, 2H), 7.79-7.47 (m, 4H), 7.26- 7.14 (m, 1H), 4.58 (s, 2H), 3.27- 3.08 (m, 2H), 1.18-0.93 (m, 3H). 838 1H NMR (300 MHz, DMSO) δ DMSO 357.9 1.68 Method C 100 Method U 12.80 (s, 1H), 10.50 (s, 1H), 9.57 (M + 1) (s, 1H), 9.15 (d, J = 8.5 Hz, 1H), 8.70 (t, J = 7.3 Hz, 2H), 8.50 (s, 1H), 8.08-7.79 (m, 3H), 7.73 (t, J = 7.5 Hz, 1H), 7.57 (dd, J = 7.6, 4.8 Hz, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.19 (t, J = 7.6 Hz, 1H). 839 1H NMR (300 MHz, DMSO) δ DMSO 443.9 1.87 Method C 100 Method U 10.57 (s, 1H), 9.49 (s, 1H), 8.97 (M + 1) (d, J = 8.2 Hz, 1H), 8.89 (s, 1H), 8.81 (s, 1H), 8.16 (ddd, J = 12.2, 10.9, 5.2 Hz, 3H), 8.05 (d, J = 2.3 Hz, 1H), 8.00-7.86 (m, 3H), 7.55 (1, J = 9.1 Hz, 1H), 6.55 (d, J = 9.5 Hz, 1H). 840 1H NMR (300 MHz, DMSO) δ DMSO 458.0 2.12 Method D 100 Method U 10.27 (s, 1H), 9.47 (s, 1H), 9.09 (M + 1) (d, J = 8.1 Hz, 1H), 8.91 (d, J = 4.4 Hz, 1H), 8.56 (s, 1H), 8.18- 8.08 (m, 2H), 8.01 (d, J = 6.3 Hz, 3H), 7.96-7.89 (m, 1H), 7.49 (t, J = 9.1 Hz, 1H), 6.52 (d, J = 9.6 Hz, 1H), 2.71 (s, 3H). 841 1H NMR (300 MHz, DMSO) δ DMSO 449.2 1.93 Method C  96 Method X 13.08 (s, 1H), 9.59 (s, 1H), 9.16 (M + 1) (d, J = 8.4 Hz, 1H), 8.88-8.44 (m, 5H), 8.12-7.85 (m, 4H), 7.73 (q, J = 8.7 Hz, 3H), 7.58 (dd, J = 7.9, 4.8 Hz, 1H), 7.49 (dd, J = 7.8, 4.8 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 5.36 (s, 2H). 842 1H NMR (300 MHz, DMSO) δ DMSO 449.1 1.89 Method C 100 Method X 13.00 (s, 1H), 9.57 (s, 1H), 9.12 (M + 1) (d, J = 8.4 Hz, 1H), 8.76-8.60 (m, 4H), 8.50 (s, 1H), 8.03-7.89 (m, 3H), 7.68 (dd, J = 15.6, 5.2 Hz, 3H), 7.57 (t, J = 4.6 Hz, 3H), 7.19 (t, J = 7.6 Hz, 1H), 5.37 (s, 2H). 843 1H NMR (300 MHz, DMSO) δ DMSO 426.2 2.46 Method C 100 Method X 12.95 (s, 1H), 9.56 (s, 1H), 9.10 (M + 1) (d, J = 8.4 Hz, 1H), 8.75-8.64 (m, 2H), 8.46 (s, 1H), 7.98-7.91 (m, 2H), 7.85 (dd, J = 9.0, 0.8 Hz, 1H), 7.71 (t, J = 7.9 Hz, 1H), 7.61-7.48 (m, 3H), 7.18 (t, J = 7.6 Hz, 1H), 4.12 (d, J = 6.6 Hz, 2H), 2.84 (dd, J = 14.3, 7.4 Hz, 1H), 2.18-2.05 (m, 2H), 1.97- 1.84 (m, 5H). 844 1H-NMR (400 MHz, DMSO-d6): DMSO 458.1, 460.1 Method A  95 Method X δ 9.95 (s, 1H), 9.54 (d, J = 1.6 (M + 1) Hz, 1H), 8.82 (d, J = 1.7 Hz, 1H), 229.6, 230.3 8.78-8.59 (m, 3H), 8.29 (dd, J = (M/2 + 1) 6.8, 2.6 Hz, 1H), 8.16 (d, J = 2.5 Hz, 1H), 8.06-7.86 (m, 3H), 7.69 (dd, J = 9.1, 2.5 Hz, 1H), 7.64-7.47 (m, 3H), 5.37 (s, 2H). 845 1H-NMR (400 MHz, DMSO-d6): DMSO 488.1, 490.1 Method A  95 Method X δ 9.74 (s, 1H), 9.34 (s, 1H), 8.57- (M + 1) 8.41 (m, 2H), 8.22 (d, J = 2.2 244.6, 245.4 Hz, 1H), 8.10 (dd, J = 6.8, 2.6 (M/2 + 1) Hz, 1H), 7.95 (d, J = 2.5 Hz, 1H), 7.80-7.63 (m, 3H), 7.53-7.30 (m, 3H), 6.82-6.68 (m, 1H), 5.07 (s, 2H), 3.71 (s, 3H). ¹H NMR Purity Method Number ¹H NMR Solvent percent of Coupling 846 1H NMR (400 MHz, DMSO) δ 9.31 (d, J = 1.7 Hz, DMSO >98 Method X 1H), 8.83-8.76 (m, 1H), 8.76-8.67 (m, 1H), using K₂CO₃ 8.07 (d, J = 9.2 Hz, 1H), 7.86 (dd, J = 6.3, 2.8 Hz instead of 1H), 7.83-7.73 (m, 2H), 7.70 (d, J = 2.8 Hz, 1H), Cs₂CO₃ 7.68-7.61 (m, 1H), 7.60-7.52 (m, 1H), 5.12 (s, 2H), 3.05 (s, 3H), 2.88 (s, 3H). 847 1H NMR (400 MHz, DMSO) δ 9.28 (dd, J = 2.2, 0.8 DMSO >98 Method X Hz, 1H), 8.65 (dd, J = 4.8, 1.7 Hz, 1H), 8.50- using K₂CO₃ 8.44 (m, 1H), 8.04 (d, J = 9.2 Hz, 1H), 7.92 (d, J = instead of 2.7 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.75 (dd, J = Cs₂CO₃ 9.2, 2.9 Hz, 1H), 7.67 (d, J = 2.8 Hz, 1H), 7.56 (dd, J = 8.8, 2.7 Hz, 1H), 7.52 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 5.10 (s, 2H), 3.05 (s, 3H), 2.88 (s, 3H). 848 ¹H NMR (400 MHz, CDCl₃) δ 9.45 (dd, J = 2,1, 0.8 CDCl3 >98 Method X Hz, 1H), 8.61 (dd, J = 4.8, 1.7 Hz, 1H), 8.59- using K₂CO₃ 8.53 (m, 1H), 8.01 (dd, J = 8.7, 0.8 1H), 7.72- instead of 7.62 (m, 2H), 7.56-7.47 (m, 2H), 7.39-7.29 Cs₂CO₃ (m, 4H), 4.90 (s, 2H), 3.15 (s, 3H), 3.04 (s, 3H). 849 1H NMR (300 MHz, DMSO) δ 13.01-11.72 (m, DMSO >98 W 1H), 9.70 (s, 1H), 9.40-9.30 (m, 1H), 8.99 (d, J = 4.5 Hz, 1H), 8.23 (d, J = 2.6 Hz, 1H), 8.12 (dd, J = 8.1, 5.5 Hz, 1H), 8.06-7.98 (m, 2H), 7.92 (d, J = 9.1 Hz, 1H), 7.84 (d, J = 4.9 Hz, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.56-7.49 (m, 2H), 5.05 (s, 3H), 3.11 (s, 3H), 2.92 (s, 3H). 850 1H NMR (300 MHz, DMSO) δ 9.74 (d, J = 1.8 Hz, DMSO >98 W 1H), 9.47-9.36 (m, 1H), 9.01 (dd, J = 5.5, 1.2 Hz, 1H), 8.28 (d, J = 2.6 Hz, 1H), 8.16 (dd, J = 8.2, 5.5 Hz, 1H), 8.06-7.93 (m, 3H), 7.81 (s, 1H), 7.66 (dd, J = 9.1, 2.6 Hz, 1H), 7.54-7.44 (m, 2H), 7.42-7.33 (m, 1H), 5.07 (s, 2H), 3.11 (s, 3H), 2.91 (s, 3H). 851 1H NMR (300 MHz, DMSO) δ 12.67 (s, 1H), 9.31- DMSO >98 W 9.25 (m, 1H), 8.73 (dd, J = 4.8, 1.6 Hz, 1H), 8.52- 8.42 (m, 1H), 7.74 (d, J = 3.9 Hz, 1H), 7.66 (d, J = 2.9 Hz, 1H), 7.61-7.47 (m, 4H), 7.45-7.31 (m, 3H), 5.27 (s, 2H), 3.30 (s, 3H). 852 1H NMR (300 MHz, DMSO) δ 9.56 (d, J = 1.8 Hz, DMSO >98 W 1H), 9.25 (d, J = 8.2 Hz, 1H), 9.08-8.98 (m, 1H), 8.81 (d, J = 4.5 Hz, 1H), 8.31 (td, J = 7.8, 1.6 Hz, 1H), 8.20-8.08 (m, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.88-7.63 (m, 4H), 7.47 (d, J = 2.1 Hz, 1H), 7.30 (dd, J = 8.6, 2.2 Hz, 1H), 5.60 (s, 2H), 4.63 (t, J = 7.8 Hz, 2H), 3.25 (t, J = 7.7 Hz, 2H). 853 1H NMR (300 MHz, DMSO) δ 9.56 (d, J = 1.8 Hz, DMSO >98 W 1H), 9.22 (d, J = 8.3 Hz, 1H), 9.00 (dd, J = 5.5, 1.3 Hz, 1H), 8.80 (d, J = 4.4 Hz, 1H), 8.29 (td, J = 7.8, 1.6 Hz, 1H), 8.21-8.05 (m, 2H), 8.00-7.66 (m, 5H), 7.29 (dd, J = 8.4, 2.6 Hz, 1H), 7.12 (td, J = 9.0, 2.8 Hz, 1H), 5.59 (s, 2H), 4.66 (t, J = 7.8 Hz, 2H), 3.25 (t, J = 7.6 Hz, 2H). 854 1H NMR (300 MHz, DMSO) δ 9.55 (d, J = 1.8 Hz, DMSO >98 W 1H), 9.30-9.18 (m, 1H), 9.00 (dd, J = 5.5, 1.3 Hz, 1H), 8.18-3.02 (m, 2H), 7.87 (dd, J = 8.8, 4.8 Hz, 1H), 7.71 (dd, J = 9.2, 2.7 Hz, 1H), 7.49 (d, J = 2.7 Hz, 1H), 7.29 (dd, J = 8.4, 2.6 Hz, 1H), 7.13 (td, J = 9.1, 2.8 Hz, 1H), 5.05 (s, 2H), 4.63 (d, J = 7.7 Hz, 2H), 3.25 (t, J = 7.5 Hz, 2H), 3.02 (s, 3H), 2.86 (s, 3H). 855 1H NMR (300 MHz, DMSO) δ 9.55 (d, J = 1.7 Hz, DMSO >98 W 1H), 9.15 (d, J = 8.2 Hz, 1H), 8.99-8.90 (m, 1H), 8.10-7.98 (m, 2H), 7.77 (dd, J = 8.9, 4.7 Hz, 1H), 7.67 (dd, J = 9.1, 2.7 Hz, 1H), 7.51 (d, J = 2.6 Hz, 1H), 7.28 (dd, J = 8.4, 2.7 Hz, 1H), 7.12 (dd, J = 10.3, 7.7 Hz, 1H), 4.70 (t, J = 7.8 Hz, 2H), 4.23-4.14 (m, 2H), 3.26 (t, J = 7.9 Hz, 2H), 1.41 (t, J = 6.9 Hz, 3H). 856 1H NMR (300 MHz, DMSO) δ 9.54 (d, J = 1.7 Hz, DMSO >98 W 1H), 9.19 (d, J = 8.1 Hz, 1H), 8.98 (d, J = 4.3 Hz, 1H), 8.15-8.02 (m, 2H), 7.90-7.72 (m, 2H), 7.60 (d, J = 2.6 Hz, 1H), 7.53-7.41 (m, 1H), 7.40- 7.05 (m, SH), 5.34 (s, 2H), 4.59 (t, J = 7.8 Hz, 2H), 3.22 (t, J = 7.5 Hz, 2H). 857 ¹H NMR (400 MHz, DMSO) δ 10.56 (s, 1H), 9.49 DMSO >98 Method W (d, J = 1.8 Hz, 1H), 9.11 (d, J = 8.0 Hz, 1H), 8.95 (dd, J = 5.4, 1.3 Hz, 1H), 8.26 (dd, J = 24.6, 3.5 Hz, 2H), 8.12-7.95 (m, 3H), 7.71 (dt, J = 9.1, 4.5 Hz, 2H), 7.56 (dd, J = 19.7, 9.1 Hz, 1H), 4.75 (s, 2H), 2.72 (d, J = 5.0 Hz, 3H). 858 ¹H NMR (400 MHz, DMSO) δ 9.77 (br s, J = 81.7 DMSO >98 Method W Hz, 1H), 9.50 (d, J = 1.5 Hz, 1H), 8.71-8.57 (m, 2H), 8.22-8.07 (m, 1H), 7.97 (t, J = 5.1 Hz, 1H), 7.87 (d, J = 9.1 Hz, 1H), 7.81-7.39 (m, 4H), 5.01 (s, 2H), 3.07 (s, 3H), 2.90 (s, 3H). 859 ¹H NMR (400 MHz, DMSO) δ 10.62 (s, 1H), 9.50 DMSO >98 Method W (d, J = 1.7 Hz, 1H), 9.01 (d, J = 3.1 Hz, 1H), 8.90 (dd, J = 5.3, 1,5 Hz, 1H), 8.32 (d, J = 2.3 Hz, 1H), 8.20-8.09 (m, 1H), 7.95 (dd, J = 8.5, 4.7 Hz, 2H), 7.83-7.74 (m, 1H), 7.67 (dd, J = 9.1, 2.6 Hz, 1H), 7.55 (dd, J = 19.7, 9.1 Hz, 1H), 5.15 (s, 2H), 4.29-3.00 (m, 8H). 860 ¹H NMR (400 MHz, DMSO) δ 10.39 (s, 1H), 9.51 DMSO >98 Method W (d, J = 1.6 Hz, 1H), 8,81 (dd, J = 19.3, 6.0 Hz, 2H), 8.29 (s, 1H), 8.16 (dd, J = 10.6, 7.5 Hz, 1H), 7.94 (d, J = 9.0 Hz, 1H), 7.77 (s, 2H), 7.69-7.51 (m, 2H), 4.67 (s, 2H), 3.99 (s, 2H), 3.81 (br s, 4H), 3.70 (br s, 4H). 861 ¹H NMR (400 MHz, DMSO) δ 10.82 (s, 1H), 9.50 DMSO >98 Method W (d, J = 1.3 Hz, 1H), 9.02 (d, J = 8.0 Hz, 1H), 8.90 (d, J = 4.4 Hz, 1H), 8.46 (s, 1H), 8.21-8.10 (m, 1H), 8.03-7.90 (m, 2H), 7.84 (d, J = 8.7 Hz, 1H), 7.68 (dd, J = 9.1, 2.3 Hz, 1H), 7.55 (dd, J = 19.6, 9.3 Hz, 1H), 4,67 (s, 2H), 3,23-3.05 (m, 6H), 2.10-1.78 (m, 4H). 862 ¹H NMR (400 MHz, DMSO) δ 10.77 (s, 1H), 9.49 DMSO >98 Method W (d, J = 1.6 Hz, 1H), 9.12 (d, J = 8.1 Hz, 1H), 8.99- 8.91 (m, 1H), 8.23 (d, J = 2.1 Hz, 1H), 8.12- 7.99 (m, 3H), 7.78-7.71 (m, 1H), 7.66-7.54 (m, 2H), 4.02 (d, J = 6.5 Hz, 2H), 2.24-2.00 (m, 1H), 1.07 (d, J = 6.7 Hz, 6H). 863 ¹H NMR (400 MHz, CDCl₃) δ 10.71 (s, 1H), 9.80 (s, DMSO >98 Method W 1H), 9.40 (d, J = 8.2 Hz, 1H), 3.95 (d, J = 5.2 Hz, 1H), 8.54 (d, J = 2.4 Hz, 1H), 8.24 (d, J = 9.2 Hz, 1H), 8.08 (dd, J = 8.0, 5.6 Hz, 1H), 7.86-7.76 (m, 1H), 7.69 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 8.8, 2.2 Hz, 1H), 7.31 (s, 1H), 5.08 (s, 2H), 3.69 (t, J = 6.8 Hz, 2H), 3.55 (t, J = 6.9 Hz, 2H), 2.13-2.01 (m, 2H), 1.98-1.35 (m, 2H). 864 1H NMR (400 MHz, DMSO) δ 10.62 (s, 1H), 9.50 DMSO >98 Method W (d, J = 1.9 Hz, 1H), 9.12 (d, J = 8.2 Hz, 1H), 8.96 (dd, J = 5.5, 1.4 Hz, 1H), 8.27 (d, J = 2.6 Hz, 1H), 8.20 (d, J = 8.0 Hz, 1H), 8.15-7.97 (m, 3H), 7.75 (ddd, J = 11.9, 7.4, 3.3 Hz, 2H), 7.56 (dt, J = 10.6, 9.1 Hz, 1H), 4.74 (s, 2H), 4.07-3.93 (m, 1H), 1.13 (d, J = 6.6 Hz, 6H).. 865 ¹H NMR (400 MHz, DMSO) δ 10.8 (s, 1H), 9.51 DMSO >98 Method W (d, J = 1.8 Hz, 1H), 9.15 (d, J = 8.2 Hz, 1H), 8.97 (dd, J = 5.4, 1.3 Hz, 1H), 8.82-8.74 (m, 1H), 8.55 (d, J = 2.6 Hz, 1H), 8.23-8.19 (m, 1H), 8.16- 8.01 (m, 3H), 7.94 (d, J = 7.9 Hz, 1H), 7.85- 7.75 (m, 2H), 7.70 (dd, J = 7.0, 5.8 Hz, 1H), 7.61- 7.49 (m, 1H), 5,63 (s, 2H). 866 ¹H NMR (400 MHz, DMSO) δ 10.62 (s, 1H), 9.50 DMSO >98 Method W (d, J = 1.8 Hz, 1H), 9.11 (d, J = 8.1 Hz, 1H), 8.95 (d, J = 5.4 Hz, 1H), 8.76 (d, J = 5.0 Hz, 1H), 8.42 (s, 1H), 8.18 (t, J = 7.8 Hz, 1H), 8.08-7.96 (m, 4H), 7.89 (d, J = 7.8 Hz, 1H), 7.80 (dd, J = 9.1, 2.6 Hz, 1H), 7.64 (t, J = 8.2 Hz, 2H), 7.24 (d, J = 8.3 Hz, 1H), 5.57 (s, 2H). 867 1H NMR (300 MHz, DMSO) d 9.58 (s, 1H), 9.05 (d, DMSO  94 Method X J = 8.2 Hz, 1H), 8.98 (d, J = 8.1 Hz, 1H), 8.88 (d, (K2CO3, DMF- J = 5.1 Hz, 1H), 8.47 (s, 1H), 8.05-7.85 (m, 4H), THF (1:1), rt) 7.71 (m, 1H), 7.61 (d, J = 8.1 Hz, 2H), 7.24 (dd, J = 7.6 Hz, 1H). 868 1H NMR (300 MHz, DMSO) δ 13.07 (s, 1H), 9.59 DMSO  99 Method X (d, J = 1.4 Hz, 1H), 9.13 (d, J = 8.1 Hz, 1H), 8.97 (d, J = 7.8 Hz, 1H), 8.92 (d, J = 4.1 Hz, 1H), 8.49 (s, 1H), 8.08-7.92 (m, 4H), 7.80-7.64 (m, 3H), 7.26 (td, J = 7.8, 1.1 Hz, 1H), 7.14 (d, J = 1.5 Hz, 1H), 7.09 (dd, J = 7.9, 1.6 Hz, 1H), 6.95 (d, J = 7.9 Hz, 1H), 6.03 (s, 2H), 5.19 (s, 2H). 869 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.67 (s, 1H), 9.40 DMSO  98 Method X (d, J = 7.6 Hz, 1H), 9.01 (d, J = 8.4 Hz, 2H), 8.93 (d, J = 8.4 Hz, 1H), 8.31 (d, J = 7.6 Hz, 1H), 8.22 (t, J = 7.2 Hz, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.97- 7.92 (m, 2H), 7.79-7.71 (m, 3H), 7.33 (t, J = 8.0 Hz, 1H), 5.54 (s, 2H). 870 ¹H-NMR (400 MHz, CD3OD): δ 9.62 (d, J = 6.9 Hz, MeOD  95 Method W 1H), 9.40 (d, J = 8.2 Hz, 1H), 8.99 (d, J = 5.3 Hz, 1H), 8.82 (t, J = 8.2 Hz, 1H), 8.22 (dd, J = 8.1, 5.7 Hz, 1H), 8.02-7.88 (m, 2H), 7.76-7.60 (m, 3H), 7.31 (t, J = 7.6 Hz, 1H), 4.81 (q, J = 8.1 Hz, 2H). 871 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.96 (s, 1H), DMSO-d₆  95 Method X 9.59 (s, 1H), 9.24 (d, J = 8.1 Hz, 1H), 9.00 (s, 1H), 8.80 (d, J = 5.7 Hz, 2H), 8.50 (s, 1H), 8.22 (t, J = 7.2 Hz, 1H), 8.09 (d, J = 9.2 Hz, 2H), 7.99- 7.79 (m, 5H), 7.74-7.54 (m, 6H), 7.30 (t, J = 7.5 Hz, 1H), 5.55 (s, 2H). 872 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.82 (s, 1H), DMSO  95 Method X 9.58 (s, 1H), 9.13 (d, J = 6.9 Hz, 1H), 8.93 (s, 1H), 8.82 (d, J = 8.0 Hz, 1H), 8.43 (s, 1H), 8.04- 7.88 (m, 4H), 7.74-7.69 (m, 3H), 7.28 (t, J = 7.6 Hz, 1H), 7.01-6.91 (m, 2H), 6.87-6.85 (m, 2H), 4.74-4.70 (m, 1H), 4.55-4.53 (m, 1H), 4.50- 4.47 (m, 1H), 4.29-4.24 (m, 1H). 873 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.07 (s, 1H), DMSO  95 Method X 9.61 (s, 1H), 9.05-9.00 (m, 2H), 8.88 (d, J = 4 Hz, 1H), 8.51 (s, 1H), 8.25 (s, 1H), 8.11-8.08 (m, 2H), 7.99-7.97 (m, 3H), 7.91-7.88 (m, 2H), 7.76-7.72 (m, 2H), 7.47 (dd, J = 2.0, 8.8 Hz, 1H), 7.27 (t, J = 8.8 Hz, 1H), 5.61 (s, 2H). 874 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.89 (s, 1H), DMSO  95 Method X 10.72 (s, 1H), 9.83 (s, 1H), 9.38 (d, J = 8.2 Hz, 1H), 9.22 (d, J = 5.6 Hz, 1H), 9.03 (d, J = 8.3 Hz, 1H), 8.51 (s, 1H), 8.37-8.27 (m, 1H), 8.02-7.86 (m, 3H), 7.71 (t, J = 7.6 Hz, 1H), 7.55 (d, J = 9.0 Hz, 1H), 7.51 (s, 1H), 7.25 (t, J = 7.5 Hz, 1H), 4.71 (d, J = 7.3 Hz, 2H), 1.56 (s, 1H), 0.81-0.64 (m, 4H). 875 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.88 (s, 1H), DMSO  95 Method X 9.57 (s, 1H), 9.24 (d, J = 8.1 Hz, 1H), 9.01 (d, J = 5.3 Hz, 1H), 8.73 (d, J = 8.2 Hz, 1H), 8.49 (s, 1H), 8.37 (t, J = 7.8 Hz, 1H), 8.10 (dd, J = 11.3, 7.0 Hz, 2H), 7.97 (d, J = 7.8 Hz, 2H), 7.86 (s, 2H), 7.80 (d, J = 7.1 Hz, 2H), 7.71 (t, J = 7.8 Hz, 1H), 7.30 (t, J = 7.5 Hz, 1H), 5.65 (s, 2H); 2.78 (s, 3H). 876 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.93 (s, 1H), DMSO  95 Method W 10.74 (s, 1H), 9.75 (s, 1H), 9.40 (s, 1H), 9.05 (d, J = 8.0 Hz, 2H), 8.99 (d, J = 6.0 Hz, 1H), 7.99 (s, 1H), 7.98-7.96 (m, 1H), 7.89-7.86 (m, 2H), 7.72-7.51 (m, 2H), 7.24 (t, J = 6.0 Hz, 1H), 5.84 (s, 2H), 3.60-3.56 (m, 2H), 3.43-3.39 (m, 2H), 2.06-2.01 (m, 2H), 1.99-1.84 (m, 2H). 1757  ¹H NMR (400 MHz, DMSO) δ 9.32-9.27 (m, 1H), DMSO >98 Method W 8.66 (dd, J = 4.8, 1.7 Hz, 1H), 8.64-8.60 (m, using K₂CO₃ 1H), 8.50-8.43 (m, 1H), 8.10-8.03 (m, 1H), instead of 7.93-7.80 (m, 4H), 7.68-7.60 (m, 2H), 7.59- Cs₂CO₃ 7.49 (m, 2H), 7.39 (ddd, J = 7.5, 4.8, 1.1 Hz, 1H), 5.43 (s, 2H).

Method Y: 2-Amino-N-cyclohexyl-benzamide (ii-b)

To a dry reaction vial was added cyclohexylamine (40 uμmol, 1.0 eq) and PS-carbodiimide resin (72 μmol, 1.8 eq). The solution of 2-amino-benzoic acid (44 μmol, 1.1 eq), diisopropyl ethyl amine (10 μLl) and HOBt (44 μmol, 1.1 eq) in THF (500 μL) was added to the above vial. The reaction mixture was heated at 40° C. for 6 h on a shaker. The resin was removed by filtration and washed with 10% MeOH/CH₂Cl₂. The solvent was removed in vacuo and the residue was applied to solid phase extraction cartridge (basic silica, 200 mg) and eluted with 50% EtOAc/CH₂Cl₂. After removal of the solvents, the crude 2-amino-N-cyclohexyl-benzamide was obtained and used for the following reaction.

Method Z: N-Cyclohexyl-2-(6-methoxy-2-pyridin-3-yl-quinazolin-4-ylamino)-benzamide (xiv-f)

To the crude amide was added the solution of 4-chloro-6-methoxy-2-pyridin-3-yl-quinazoline (20 μmol) in 2-propanol (200 μL). The mixture was refluxed for 8 h. After evaporation, the residue was dissolved in 5% TFA/MeOH-DMF (1:1) and purified by PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 27, replacing cyclohexylamine with the appropriate amine.

TABLE 7 Exact LCMS Method of Number Product Mass (M + 1) Coupling 877

489 490 Methods Y, Z 878

453 454 Methods Y, Z 879

495 496 Methods Y, Z 880

495 496 Methods Y, Z 881

491 492 Methods Y, Z 882

491 492 Methods Y, Z 883

493 494 Methods Y, Z 884

467 468 Methods Y, Z 885

441 442 Methods Y, Z 886

529 530 Methods Y, Z 887

543 544 Methods Y, Z 888

543 544 Methods Y, Z 889

543 544 Methods Y, Z 890

487 488 Methods Y, Z 891

493 494 Methods Y, Z 892

467 468 Methods Y, Z 893

441 442 Methods Y, Z 894

529 530 Methods Y, Z 895

543 544 Methods Y, Z 896

543 544 Methods Y, Z 897

543 544 Methods Y, Z 898

487 488 Methods Y, Z 899

467 468 Methods Y, Z 900

501 502 Methods Y, Z 901

465 466 Methods Y, Z 902

435 436 Methods Y, Z 903

519 520 Methods Y, Z 904

487 488 Methods Y, Z 905

487 488 Methods Y, Z 906

467 468 Methods Y, Z 907

501 502 Methods Y, Z 908

465 466 Methods Y, Z 909

435 436 Methods Y, Z 910

519 520 Methods Y, Z

Method Z: Synthesis of N-(4-chlorophenyl)-6-methoxy-2-(pyridin-3-yl)quinazolin-4-amine (vi-k)

To 4-chloroaniline (24 μmol) was added the solution of 4-chloro-6-methoxy-2-pyridin-3-yl-quinazoline (20 mmol) in 2-propanol (200 μL). The mixture was refluxed for 8 h. After evaporation, the residue was dissolved in 5% TFA/MeOH-DMF (1:1) and purified by PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound as the TFA salt whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 29, replacing 4-chloroaniline with the appropriate aniline.

TABLE 8 Exact LCMS Method of Number Product Mass (M + 1) Coupling 911

362 363 Method Z 912

358 359 Method Z 913

396 397 Method Z 914

392 393 Method Z 915

388 389 Method Z 916

372 373 Method Z 917

388 389 Method Z 918

342 343 Method Z 919

353 354 Method Z 920

416 417 Method Z 921

396 397 Method Z 922

396 397 Method Z 923

356 357 Method Z 924

364 365 Method Z 925

372 373 Method Z 926

392 393 Method Z 927

376 377 Method Z 928

426 427 Method Z 929

407 408 Method Z 930

430 431 Method Z 931

440 441 Method Z 932

392 393 Method Z 933

380 381 Method Z 934

380 381 Method Z 935

380 381 Method Z 936

434 435 Method Z 937

421 422 Method Z 938

378 379 Method Z 939

376 377 Method Z 940

387 388 Method Z 941

414 415 Method Z 942

392 393 Method Z 943

380 381 Method Z 944

390 391 Method Z 945

428 429 Method Z 946

428 429 Method Z 947

391 392 Method Z 948

356 357 Method Z 949

377 378 Method Z 950

392 393 Method Z 951

368 369 Method Z 952

397 398 Method Z 953

441 442 Method Z 954

379 380 Method Z 955

401 402 Method Z 956

383 384 Method Z 957

382 383 Method Z 958

379 380 Method Z 959

393 394 Method Z 960

411 412 Method Z 961

379 380 Method Z 962

370 371 Method Z 963

385 386 Method Z 964

427 428 Method Z 965

395 396 Method Z 966

379 380 Method Z 967

402 403 Method Z 968

384 385 Method Z

Method Z: Synthesis of 6-chloro-N-(4-chlorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (vi-c)

To 4-chloroaniline (24 μmol) was added the solution of 4,6-dichloro-2-(pyridin-3-yl)quinazoline (20 μmol) in 2-propanol (200 μL). The mixture was refluxed for 8 h. After evaporation, the residue was dissolved in 5% TFA/MeOH-DMF (1:1) and purified by PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound as the TFA salt whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 31, replacing 4-chloroaniline with the appropriate aniline,

TABLE 9 Exact LCMS Method of Number Product Mass (M + 1) Coupling 969

366 367 Method Z 970

362 363 Method Z 971

366 367 Method Z 972

346 347 Method Z 973

392 393 Method Z 974

392 393 Method Z 975

419 420 Method Z 976

392 393 Method Z 977

346 347 Method Z 978

350 351 Method Z 979

350 351 Method Z 980

350 351 Method Z 981

376 377 Method Z 982

420 421 Method Z 983

360 361 Method Z 984

360 361 Method Z 985

360 361 Method Z 986

360 361 Method Z 987

368 369 Method Z 988

368 369 Method Z 989

380 381 Method Z 990

376 377 Method Z 991

396 397 Method Z 992

380 381 Method Z 993

430 431 Method Z 994

392 393 Method Z 995

396 397 Method Z 996

380 381 Method Z 997

382 383 Method Z 998

384 385 Method Z 999

465 466 Method Z 1000

357 358 Method Z 1001

396 397 Method Z 1002

425 426 Method Z 1003

380 381 Method Z 1004

434 435 Method Z 1005

396 397 Method Z 1006

384 385 Method Z 1007

446 447 Method Z 1008

415 416 Method Z 1009

381 382 Method Z 1010

381 382 Method Z 1011

396 397 Method Z

N-(3-Carbamoylthiophen-2-yl)nicotinamide (iii-b)

To a solution of 2-aminothiophene-3-carboxamide (800 mg, 5.63 mmol, 1.0 eq.) in THF (15 mL) and Et₃ N (626 mg, 6.19 mmol, 1.1 eq.) was added nicotinoyl chloride (795 mg, 5.63 mmol, 1.0 eq.) in anhydrous THF (15 mL) dropwise. The resulted mixture was stirred at room temperature overnight. After the reaction was completed, the volatiles were evaporated. The residue was washed with CH₂Cl₂ (20 mL). The resulting solid was collected and dried in vacuo to give 1.50 g of N-(3-carbamoylthiophen-2-yl)nicotinamide as a brown solid (quantitative yield). LCMS m/z=248.1 (M+1) (Method B) (retention time=1.34 min).

2-(Pyridin-3-yl)thieno[2,3-d]pyrimidin-4(3H)-one (iv-b)

A mixture of N-(3-carbamoylthiophen-2-yl)nicotinamide (1.50 g salt, 6.07 mmol, 1.0 eq.) in EtOH (300 mL) was added NaOH (1.50 g, 37.5 mmol, 6.18 eq.). The resulting mixture was stirred at 80° C. for 7 days. After the reaction was completed, the volatiles were removed in vacuo. Water (20 mL) was added to the residue and the pH1 was adjusted to around 2 by adding dilute HCl (2N in water). The solution was concentrated in vacuo to give 11.0 g of the HCl salt as a beige solid. LCMS m/z=230.0 (M+1) (Method B) (retention time=1.21 min). The crude product containing salts were used for the next step without further purification.

4-Chloro-2-(pyridin-3-yl)thieno[2,3-d]pyrimidine (v-c)

The suspension of 2-(pyridin-3-yl)thieno[2,3-d]pyrimidin-4(3H)-one (6.0 g, containing salts) in POCl₃ (30 ml.) was stirred at 120° C. for 10 h. After the reaction was completed, the mixture was added to ice-water slowly. The pH was adjusted to ˜7 by slowly adding NI-1H₃.H₂O at 0° C., then a precipitate formed. The solid was collected and 540 mg of 4-chloro-2-(pyridin-3-yl)thieno[2,3-d]pyrimidine was obtained as a brown solid, LCMS m/z=247.9, 250.0 (M+1) (Method B) (retention time=1.85 min).

N-(3-Chloro-4-fluorophenyl)-2-(pyridin-3-yl)thieno[2,3-d]pyrimidin-4-amine (vi-l)

A mixture of 4-chloro-2-(pyridin-3-yl)thieno[2,3-d]pyrimidine (80 mg, 0.32 mmol, 1.0 eq.) and 3-chloro-4-fluorobenzenamine (93 mg, 0.64 mmol, 2.0 eq.) in i-AmOH (8 mL) was stirred at 130° C. overnight. A yellow precipitate formed and was collected and washed with MeOH (10 mL). The solid was suspended in H₂O (10 mL) and NH₃—H₂O (1 mL) was added. After filtration and drying in vacuo, 23.0 mg of the product was obtained as a yellow solid (20.0%). LCMS m/z=357.0, 359.0 (M+1) (Method B) (retention time=1.96 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 9.99 (s, 1H), 9.48 (d, J=1.6 Hz, 1H), 8.70-8.67 (m, 1H), 8.63 (d. J=8.0 Hz, 1H), 8.27 (dd, J=6.8, 2.6 Hz, 1H), 7.76-7.93 (m, 3H), 7.54-7.57 (m, 2H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 33, replacing 4-fluoro-3-chloroaniline with the appropriate aniline.

TABLE 10 Molec- ¹H- Method Num- Salt ular NMR LCMS Purity for ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1012

347.39 1H-NMR (400 MHz, DMSO-d6): δ 12.69 (s, 1H), 9.55 (d, J = 1.3 Hz, 1H), 9.00 (d, J = 8.0 Hz, 1H), 8.44 (s, 1H), 8.60-8.78 (m, 2H), 7.82-8.00 (m, 3H), 7.42-7.79 (m, 3H), 7.20 (t, J = 7.2 Hz, 1H). DMSO 348.1 (M + 1) Method B (NH4HCO3) 95 Method C, G3 1013

370.38 1H-NMR (400 MHz, DMSO-d6): δ 9.96 (s, 1H), 9.51 (d, J = 1.2 Hz, 1H), 8.60-8.77 (m, 2H), 7.98-7.94 (m, 2H), 7.71-7.86 (m, 2H), 7.56-7.50 (m, 1H), 7.30 (t, J = 74.0 Hz, 1H), 6.96 (dd, J = 8.8, 2.0 Hz, 1H), DMSO 371.0 (M + 1) Method B (NH4HCO3) 95 Method C, G3 1014

388.37 1H-NMR (400 MHz, DMSO-d6): δ 10.04 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.58-8.75 (m, 2H), 8.18 (s, 1H), 7.77-8.00 (m, 3H), 7.50-7.65 (m, 2H), 7.08-7.18 (m, 1H) DMSO 389.0 (M + 1) Method B (NH4HCO3) 95 Method C, G3 1015

356.8  1H-NMR (400 MHz, DMSO-d6): δ 9.99 (s, 1H), 9.48 (d, J = 1.6 Hz, 1H), 8.70-8.67 (m, 1H), 8.63 (d, J = 8.0 Hz, 1H), 8.27 (dd, J = 6.8, 2.6 Hz, 1H), 7.76-7.93 (m, 3H), 7.54-7.57 (m, 2H). DMSO 357.0, 359.0 (M + 1) Method B (NH4HCO3) 95 Method C, G3

Method AA: 2-Amino-N-(cyclopropylmethyl)benzamide (ii-c)

A 100 ml, round bottom flask was charged with anthranilic acid (500 mg, 3.65 mmol), added DMF (15 mL) under nitrogen atmosphere and stirring. Then, added N-methylmorpholine (1 mL, 9.12 mmol), aminomethylcyclopropane (311 mg, 4.38 mmol), N-ethyl-N′-dimethylaminopropylcarbodiimide (EDCI) (840 mg, 4.38 mmol) and HOBt (670 mg, 4.38 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with water and extracted with diethyl ether (50 mL×2). The organic extracts were combined, washed with brine, dried over MgSO₄, filtered and concentrated to afford amorphous colorless 2-amino-N-(cyclopropylmethyl)benzamide (500 mg, 72% yield), which was checked by NMR and used for next step without further purification. ¹H-NMR (Bruker 300 MHz, DMSO-d₆) δ 0.20-1.01 (m, 4H), 1.01-1.04 (m, 1H), 3.06-3.11 (m, 2H), 6.37-8.21 (m, 7H).

Method Z: 2-(6-chloro-2-(pyridin-3-yl)quinazolin-4-ylamino)-N-(cyclopropylmethyl)benzamide (xiv-g)

A 100 mL round bottom flask was charged with 4,6-dichloro-2-(pyridin-3-yl)quinazoline (synthesized as described in Scheme 1 and 4, substituting 5-chloro-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid) (150 mg, 0.54 mmol) and 2-amino-N-(cyclopropylmethyl)benzamide) (310 mg, 1.63 mmol) and anhydrous i-PrOH (20 mL) was added and refluxed for 3 h. The reaction mixture was cooled to room temperature and Et₃ N (3 eq) was added. The solvent was removed in vacuo. To the crude product was added a water-methanol mixture (5:1, 50 mL), and then sonicated for 5 min. The solidified compound was collected by filtration, and the solid was recrystallized from hot methanol and washed with water. The product was dried at 50° C. to give 2-(6-chloro-2-(pyridin-3-yl)quinazolin-4-ylamino)-N-(cyclopropylmethyl)benzamide as a colorless cotton (220 mg, 94%). The structure was confirmed by NMR and elemental analysis. ¹H NMR (Bruker 300 MHz, DMSO-d₆) ppm 0.20-0.98 (m, 5H), 3.07-3.21 (m, 2H), 7.24-8.26 (m, 7H), 8.68-9.55 (m, 5H), 12.22 (s, 1H). CHN Calcd. C, 67.05; H, 4.69; N, 16.29.

Found C, 67.15; H, 4.89; N, 16.25

The compounds in the following table were prepared in a manner analogous to that described in Scheme 34, replacing aminomethylcyclopropane with the appropriate amine.

TABLE 11 ¹H-NMR Purity Method of Number Product ¹H-NMR Solvent percent Coupling 1016

¹H NMR (DMSO-d₆) ppm 1.46 (d, 3H, J = 6.7 Hz), 3.90 (s, 3H), 5.17-5.22 (m, 1H), 7.19-7.98 (m, 12H), 8.67-8.71 (m, 2H), 8.90 (d, 1H, J = 8.2 Hz), 9.22 (d, 1H, J = 8.3 Hz), 9.55 (s, 1H), 12.18 (s, 1H). DMSO >93 Method Z 1017

¹H NMR (DMSO-d₆) ppm 1.49- 1.62 (m, 8H), 3.99 (s, 3H), 4.24- 4.26 (m, 1H), 7.24-7.71 (m, 7H), 8.65-9.55 (m, 5H), 12.19 (s, 1H). DMSO >98 Method Z 1018

¹H NMR (DMSO-d₆) ppm 0.88- 1.99 (m, 7H), 3.14-3.16 (m, 2H), 3.02 (s, 3H), 7.57-7.91 (m, 7H), 8.68-9.55 (m, 5H), 12.19 (s, 1H). DMSO >98 Method Z 1019

¹H NMR (DMSO-d₆) ppm 1.07- 1.12 (m, 3H), 3.44-3.52 (m, 2H), 4.01 (s, 3H), 7.24-786 (m, 8H), 8.68-9.55 (m, 5H), 12.19 (s, 1H). DMSO >98 Method Z 1020

1H NMR (DMSO-d₆) ppm 0.87- 0.92 (m, 3H), 1.53-1.62 (m, 2H, ), 3.30-3.32 (m, 2H), 3.98 (s, 3H), 7.21-7 89 (m 7H), 8.67-9.55 (m, 5H), 12.38 (s, 1H). DMSO >98 Method Z 1021

1H NMR (DMSO-d₆) ppm 0.83- 1.51 (m, 7H), 3.30-3.32 (m, 2H), 3.99 (s, 3H), 7.24-7.90 (m, 7H), 8.67-9.55 (m, 5H), 12.38 (s, 1H). DMSO >98 Method Z 1022

1H NMR (DMSO-d₆) ppm 0.79- 1.52 (m, 9H), 3.25-3.30 (m, 2H), 3.98 (s, 3H), 7.21-7.88 (m, 7H), 8.68-9.55 (m, 5H), 12.30 (s, 1H). DMSO >98 Method Z 1023

1H NMR (DMSO-d₆) ppm 0.80- 1.49 (m, 11H), 3.26-3.30 (m, 2H), 3.99 (s, 3H), 7.24-7.90 (m, 7H), 8.67-9.56 (m, 5H), 12.30 (s, 1H). DMSO >98 Method Z 1024

1H NMR (DMSO-d₆) ppm 3.99- 4.10 (m, 5H), 5.07-5.33 (m, 2H), 5.89-5.91(m, 1H), 7.24-7.90 (m, 7H), 8.68-9.55 (m, 5H), 12.30 (s, 1H). DMSO >98 Method Z 1025

1H NMR (DMSO-d₆) ppm 3.13 (s, 1H), 3.99-4.12 (m, 5H), 7.21-7.89 (m, 7H), 8.67-9.54 (m, 5H), 12.30 1H). DMSO >98 Method Z 1026

1H NMR (DMSO-d₆) ppm 1.68- 2.22 (m, 6H), 3.99 (s, 3H), 4.24- 4.26 (m, 1H), 7.22-7.92 (m, 7H), 8.66-9.55 (m, 5H), 12.30 (s, 1H). DMSO >98 Method Z 1027

1H NMR (DMSO-d₆) ppm 1.41- 1.86 (m, 12H), 3.90 (br s, 4H), 7.23-7.89 (m, 7H), 8.63-9.55 (m, 5H), 12.30 (s, 1H). DMSO >98 Method Z 1028

1H NMR (DMSO-d₆) ppm 0.85- 1.60 (m, 9H), 3.27-3.33 (m, 2H), 3.99 (s, 3H), 7.21-7.91 (m, 7H), 8.68-9.55 (m, 5H), 12.19 (s, 1H). DMSO >98 Method Z 1029

1H NMR (DMSO-d₆) ppm 1.03- 1.34 (m, 6H), 3.17-3.31 (m, 4H), 7.40-7.88 (m 7H), 8.55-10.03 (m, 5H), 12.32 (s, 1H). DMSO >98 Method Z 1030

1H NMR (DMSO-d₆) ppm 0.83- 1.52 (m, 5H), 3.20-3.29 (m, 2H), 7.27-8.21 (m, 7H), 8.67-9.53 (m, 5H), 12.33 (s, 1H). DMSO >98 Method Z 1031

1H NMR (DMSO-d₆) ppm 1.02- 1.07 (m, 3H), 3.24-3.32 (m, 2H), 7.27-8.22 (m, 7H), 8.67-9.53 (m, 5H), 12.34 (s, 1H). DMSO >98 Method Z 1032

1H NMR (DMSO-d₆) ppm 0.75- 1.37 (m, 7H), 3.18-3.20 (m, 2H) , 7.21-8.19 (m, 7H), 8.64-9.48 (m, 5H), 12.15 (s, 1H). DMSO >98 Method Z 1033

1H NMR (DMSO-d₆) ppm 3.90- 3.92 (m, 2H), 5.02-5.17 (m, 2H), 5.81-5.86 (m, 1H), 7.27-8.23 (m, 7H), 8.68-9.55 (m, 5H), 12.25 (s, 1H). DMSO >98 Method Z 1034

1H NMR (DMSO-d₆) ppm 0.78- 1.42 (m, 11H), 3.20-3.29 (m, 2H), 7.25-7.91 (m, 7H), 8.23-9.53 (m, 5H), 12.17 (s, 1H). DMSO >98 Method Z 1035

¹H NMR (DMSO-d₆) ppm 3.06 (s, 1H), 4.05-4.08 (m, 2H), 7.28-8.22 (m, 7H), 8.65-9.51 (m, 5H), 12.12 (s, 1H). DMSO >98 Method Z 1036

1H NMR (DMSO-d₆) ppm 0.88- 1.92 (m, 7H), 3.05-3.16 (m, 2H), 7.23-7.94 (m, 7H), 8.22-9.54 (m, 5H), 12.21 (s, 1H). DMSO >98 Method Z 1037

1H NMR (DMSO-d₆) ppm 1.37- 1.79 (m, 12H), 3.90-3.96 (m, 1H), 7.25-8.24 (m, 7H), 8.55-9.52 (m, 5H), 12.07 (s, 1H). DMSO >98 Method Z 1038

1H NMR (DMSO-d₆) ppm 1.49- 1.85 (m, 8H), 4.24-4.26 (m, 1H), 7.23-7.69 (m, 6H), 7.85-9.53 (m, 6H), 12.06 (s, 1H). DMSO >98 Method Z 1039

1H NMR (DMSO-d₆) ppm 1.12- 1.14 (m, 6H), 4.11-4.18 (m, 1H), 7.23-7.94 (m, 8H), 8.33-9.53 (m, 4H), 12.30 (s, 1H). DMSO >98 Method Z 1040

1H NMR (DMSO-d₆) ppm 0.84- 1.16 (m, 9H), 3.28-3.34 (m, 2H), 7.23-7.91 (m, 6H), 8.25-9.53 (m, 6H), 12.16 (s, 1H). DMSO >98 Method Z 1041

1H NMR (DMSO-d₆) ppm 0.79- 1.52 (m, 9H), 3.25-3.32 (m, 2H), 7.24-7.91 (m, 6H), 8.23-9.53 (m, 6H), 12.18 (s, 1H). DMSO >98 Method Z 1042

1H NMR (DMSO-d₆) ppm 1.04- 1.81 (m, 10H), 3.77-3.82 (m, 1H), 7.21-8.05 (m, 8H), 8.65-9.52 (m, 4H), 11.96 (s, 1H). DMSO >98 Method Z 1043

1H NMR (DMSO-d₆) ppm 0.47- 0.67 (m, 4H), 2.85-2.88 (m, 1H), 7.26-8.26 (m, 7H), 8.66-9.52 (m, 5H), 12.26 (s, 1H). DMSO >98 Method Z 1044

1H NMR (DMSO-d₆) ppm 1.14 (s, 9H), 7.30-7.93 (m, 7H), 8.21- 9.50 (m, 5H), 12.22 (s, 1H). DMSO >98 Method Z 1045

1H NMR (DMSO-d₆) ppm 3.98 (s, 3H), 4.36 (s, 2H), 6.47 (s, 1H), 7.21-7.91 (m, 9H), 8.68-9.56 (m, 5H), 12.22 (s, 1H). DMSO >98 Method Z 1046

1H NMR (DMSO-d₆) ppm 4.30 (s, 2H), 6.42 (s, 1H), 7.28-8.24 (m, 9H), 8.70-9.53 (m, 5H), 12.22 (s, 1H). DMSO >98 Method Z 1047

1H NMR (DMSO-d₆) ppm 1.69- 2.55 (m, 6H), 4.41-4.44 (m, 1H), 7.23-8.24 (m, 7H), 8.65-9.54 (m, 5H), 12.06 (s, 1H). DMSO >98 Method Z 1048

1H NMR (DMSO-d₆) ppm 4.55 (s, 2H), 7.17-8.21 (m, 12H), 8.65- 9.54 (m, 5H), 12.06 (s, 1H). DMSO >98 Method Z 1049

1H NMR (DMSO-d₆) ppm 7.02- 8.67 (m, 15H), 9.47 (s, 1H), 10.04 (s, 1H), 12.06 (s, 1H). DMSO >98 Method Z 1050

1H NMR (DMSO-d₆) ppm 2.75- 2.80 (m, 2H), 3.48-3.54 (m, 2H), 7.08-8.20 (m, 12H) 8.69-9.56 (m, 5H), 12.16 (s, 1H). DMSO >98 Method Z 1051

1H NMR (DMSO-d₆) ppm 4.01- 4.10 (m, 2H), 7.28-8.27 (m, 7H), 8.59-9.51 (m, 5H), 11.45 (s, 1H). DMSO >98 Method Z 1052

1H NMR (DMSO-d₆) ppm 4.38- 4.57 (m, 4H), 7.27-8.24 (m, 7H), 8.69-9.56 (m, 5H), 12.10 (s, 1H). DMSO >98 Method Z 1053

1H NMR (DMSO-d₆) ppm 2.85- 2.92 (br s, 3H), 7.20-8.22 (m, 7H), 8.67-9.56 (m, 5H), 12.61 (s, 1H). DMSO >98 Method Z 1054

1H NMR (DMSO-d₆) ppm 1.04- 1.81 (m, 10H), 3.77-3.82 (m, 1H), 7.24-8.05 (m, 8H), 8.65-9.52 (m, 4H), 12.27 (s, 1H). DMSO >98 Method Z 1055

1H NMR (DMSO-d₆) ppm 2.49- 2.51 (m, 2H), 3.57-3.59 (m, 2H), 7.21-8.16 (m, 12H), 8.69-9.56 (m, 5H), 12.16 (s, 1H). DMSO >98 Method Z 1056

1H NMR (DMSO-d₆) ppm 0.79- 1.44 (m, 11H), 3.26-3.30 (m, 2H), 7.24-7.92 (m, 7H), 8.67-9.52 (m, 5H), 12.45 (s, 1H). DMSO >98 Method Z 1057

1H NMR (DMSO-d₆) ppm 1.04- 1.16 (m, 3H), 3.33-3.38 (m, 2H), 7.20-8.22 (m, 7H), 8.60-9.53 (m, 5H), 12.34 (s, 1H). DMSO >98 Method Z 1058

1H NMR (DMSO-d₆) ppm 7.09- 8.68 (m, 15H), 9.51 (s, 1H), 10.34 (s, 1H), 12.06 (s, 1H). DMSO >98 Method Z 1059

1H NMR (DMSO-d₆) ppm 3.78 (s, 3H), 4.43 (s, 2H), 6.77-8.23 (m, 11H), 8.68-9.54 (m, 5H), 12.06 (s, 1H). DMSO >98 Method Z 1060

1H NMR (DMSO-d₆) ppm 3.69 (s, 3H), 4.48 (s, 2H), 6.89-8.15 (m, 11H), 8.68-9.54 (m, 5H), 12.44 (s, 1H). DMSO >98 Method Z 1061

1H NMR (DMSO-d₆) ppm 2.24 (s, 3H), 4.46 (s, 2H), 7.03-8.13 (m, 11H), 8.67-9.54 (m, 5H), 12.21 (s, 1H). DMSO >98 Method Z 1062

1H NMR (DMSO-d₆) ppm 4.51 (s, 2H), 7.11-8.14 (m, 11H), 8.67- 9.54 (m, 5H), 12.34 (s, 1H). DMSO >98 Method Z 1063

1H NMR (DMSO-d₆) ppm 4.47 (s, 2H), 7.05-8.14 (m, 11H), 8.67- 9.54 (m, 5H), 12.37 (s, 1H). DMSO >98 Method Z 1064

1H NMR (DMSO-d₆) ppm 3.95 (s, 3H), 4.47 (s, 2H), 7.05-8.14 (m, 11H), 8.67-9.54 (m, 5H), 12.32 (s, 1H). DMSO >98 Method Z Meth- Pur- od ¹H ity of Num- Starting Starting Salt NMR per- Coup- ber Material R¹ Material R³ Product Type ¹H NMR Solvent cent ling 1065

¹H NMR (DMSO-d₆) ppm 4.52 (d, 2H, J = 5.8 Hz), 7.21-7.30 (m, 5H), 7.50 (t, J = 7.9 Hz, 1H), 7.68 (t, J = 7.8 Hz, 1H), 7.89- 7.92 (m, 3H), 8.21 (d, J = 1.8 Hz, 1H), 8.65- 8.70 (m, 3H), 8.99 (s, 1H), 9.52 (s, 1H), 11.88 (s, 1H) DMSO >98 Meth- od Y, Z 1066

¹H NMR (DMSO-d₆) ppm 4.49 (d, 2H, J = 5.6 Hz), 7.24-7.35 (m, 5H), 7.50 (t, J = 7.2 Hz, 1H), 7.70 (t, J = 7.6 Hz, 1H), 7.91- 7.95 (m, 3H), 8.22 (d, J = 1.5 Hz, 1H), 8.67- 8.73 (m, 3H), 9.19 (s, 1H), 9.53 (s, 1H), 11.98 (s, 1H) DMSO >98 Meth- od Y, Z 1067

¹H NMR (DMSO-d₆) ppm 4.58 (d, 2H, J = 5.7 Hz), 7.16-7.36 (m, 5H), 7.50 (t, J = 7.5 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.88- 7.96 (m, 3H), 8.22 (d, J = 1.5 Hz, 1H), 8.65- 8.69 (m, 3H), 8.98 (s, 1H), 9.52 (s, 1H), 11.87 (s, 1H) DMSO >98 Meth- od Y, Z 1068

¹H NMR (DMSO-d₆) ppm 4.47 (d, 2H, J = 5.6 Hz), 7.30 (br s, 5H), 7.54 (t, J = 7.7 Hz, 1H), 7.70 (t, J = 7.8 Hz, 1H), 7.88- 7.96 (m, 3H), 8.15 (d, J = 1.5 Hz, 1H), 8.68-8.81 (m, 3H), 8.98 (s, 1H), 9.52 (s, 1H), 12.29 (s, 1H) DMSO >98 Meth- od Y, Z 1069

¹H NMR (DMSO-d₆) ppm 4.57 (d, 2H, J = 5.6 Hz), 7.23-7.29 (m, 5H), 7.39 (t, J = 7.9 Hz, 1H), 7.71 (t, J = 7.9 Hz, 1H), 7.94- 7.99 (m, 3H), 8.15 (d, J = 1.4 Hz, 1H), 8.68- 8.84 (m, 3H), 9.24 (s, 1H), 9.55 (s, 1H), 12.23 (s, 1H) DMSO >98 Meth- od Y, Z 1070

¹H NMR (DMSO-d₆) ppm 4.50 (d, 2H, J = 5.5 Hz), 7.25-7.53 (m, 5H), 7.69 (t, J = 7.1 Hz, 1H), 7.73 (t, J = 7.0 Hz, 1H), 7.94- 8.15 (m, 3H), 8.18 (d, J = 1.4 Hz, 1H), 8.68- 8.82 (m, 3H), 9.24 (s, 1H), 9.54 (s, 1H), 12.21 (s, 1H) DMSO >98 Meth- od Y, Z 1071

¹H NMR (DMSO-d₆) ppm 3.90 (s, 3H), 4.56 (d, 2H, J = 5.6 Hz), 7.22-7.44 (m, 7H), 7.44 (t, J = 7.9 Hz, 1H), 7.74 (t, J = 7.9 Hz, 1H), 7.94- 7.99 (m, 2H), 8.68- 8.81 (m, 3H), 9.24 (s, 1H), 9.55 (s, 1H), 12.19 (s,1H) DMSO >98 Meth- od Y, Z 1072

HCl ¹H NMR (400 MHz, DMSO-d₆): δ 12.17 (s, 1H), 9.52 (s, 1H), 9.08 (s, 1H), 8.95 (d, J = 7.6 Hz, 1H), 8.85 (s, 1H), 8.66 (d, J = 7.8 Hz, 1H), 7.91 (t, J = 9.4 Hz, 2H), 7.84 (s, 1H), 7.75-7.67 (m, 1H), 7.65 (s, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.30 (t, J = 7.3 Hz, 1H), 4.47 (d, J = 47.3 Hz, 2H), 4.26 (d, J = 6.8 Hz, 2H), 3.58-3.50 (m, 2H), 1.47 (t, J = 6.7 Hz, 3H). DMSO   95 Meth- od Y, Z

Method AB: Methyl 3-(4-hydroxy-2-(pyridin-3-yl)quinazolin-6-yl)acrylate (xxvi-a)

To a solution of 6-iodo-2-(pyridin-3-yl) quinazolin-4-ol (synthesized as described in Scheme 1 and 4, substituting 5-iodo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid) (3.00 g, 8.6 mmol, 1.0 eq.), Pd(OAc)₂ (48 mg, 0.21 mmol, 0.025 eq.) and PPh₃ (113 mg, 0.43 mmol, 0.05 eq.) in DMF (8 mL) was added methyl acrylate (3.22 g, 25.8 mmol, 3.0 eq.) and DIPEA (1.22 g, 9.46 mmol, 1.1 eq.) under Ar atmosphere. The mixture was stirred at 110° C. overnight. After cooling, the mixture was filtered and the solid was washed with ethyl acetate three times to afford 1.30 g of xxxvi-a as green solid (yield 49%). LCMS m/z=308.0 (M+1) (Method B) (retention time=1.41 min).

Methyl 3-(4-hydroxy-2-(pyridin-3-yl)quinazolin-6-yl)propanoate (xxvii-a)

Methyl 3-(4-hydroxy-2-(pyridin-3-yl)quinazolin-6-yl)propanoate was prepared in a manner analogous to that described for 2-amino-5-methoxybenzoic acid in Method K, replacing 5-methoxy-2-nitrobenzoic acid with methyl 3-(4-hydroxy-2-(pyridin-3-yl)quinazolin-6-yl)acrylate to afford 1.40 g of xxvii-a in quantitative yield as a yellow solid. LCMS m/z=310.0 (M+1) (Method B) (retention time=1.42 min).

3-(4-Chloro-2-pyridin-3-yl-quinazolin-6-yl)-propionic acid methyl ester (xxviii-a)

3-(4-Chloro-2-pyridin-3-yl-quinazolin-6-yl)-propionic acid methyl ester (prepared in a manner analogous to that described for 4-chloro-6-propoxy-2-pyridin-3-yl-quinazoline using Method F, replacing 6-propoxy-2-pyridin-3-yl-1H-quinazolin-4-one with methyl 3-(4-hydroxy-2-(pyridin-3-yl)quinazolin-6-yl)propanoate) was obtained in quantitative yield to give 1.50 g of xxvii-a as a red solid. LCMS m/z=328.1, 330.0 (M+1) (Method B) (retention time=1.86 min).

3-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-propionic acid methyl ester (xxviv-a)

3-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-propionic acid methyl ester (prepared in a manner analogous to that described for 2-(6-propoxy-2-pyridin-3-yl-quinazolin-4-ylamino)-benzamide in Method G1, replacing 4,7-dichloro-2-(4-chlorophenyl)quinazoline and 2-aminobenzamide with 3-(4-chloro-2-pyridin-3-yl-quinazolin-6-yl)-propionic acid methyl ester and 3-chloro-4-fluoro-phenylamine) was obtained in a 43% yield to give 1.04 g of xxviv-a as a yellow solid. LCMS m/z=437.1, 439.1 (M+1) (Method B) (retention time=1.62 min).

Method AC: 3-(4-(3-Chloro-4-fluorophenylamino)-2-(pyridin-3-yl) quinazolin-6-yl)propanoic acid (xxx-a)

To a solution of 3-[4-(3-chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-propionic acid methyl ester (1.04 g, 2.39 mmol, 1.0 eq.) in DMF (20 mL) was added a solution of NaOH (0.57 g, 14.3 mmol, 6.0 eq.) in H₂O (8 mL). The mixture was stirred at room temperature for 2 h. 50 mL of water was added to the mixture. After filtration, the resulting filter cake was washed with water and dried in vacuo to give 933 mg of xxx-a as a yellow solid (yield 93%). LCMS m/z=423.1, 425.1 (M+1) (Method A) (retention time=1.51 min).

3-(4-(3-Chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)-N,N-dimethyl propanamide (xxxi-a)

3-(4-(3-Chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)-N,N-dimethyl propanamide (prepared in a manner analogous to that described for 2-benzamido-5-methoxy-3-methylbenzamide in Method D, replacing nicotinic acid and 2-amino-5-methoxy-3-methylbenzamide with 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propanoic acid and dimethylamine hydrochloride) was obtained in 90% yield to give 891 mg of xxxi-a as a yellow solid. LCMS m/z=450.0, 452.0 (M+1) (Method B) (retention time=1.834 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 9.95 (s, 1H), 9.51 (d, J=1.6 Hz, 1H), 8.69-8.63 (m, 2H), 8.38 (s, 1H), 8.28 (dd, J=6.8, 2.4 Hz, 1H), 7.94-7.90 (m, 1H), 7.81 (s, 2H), 7.55-7.51 (m, 2H), 3.04 (t, J=7.6 Hz, 2H), 2.99 (s, 3H), 2.85 (s, 3H), 2.77 (t, J=8.0 Hz, 2H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 36, replacing dimethylamine with the appropriate amine and 4-fluoro, 3-chloro aniline with the appropriate aniline.

TABLE 12 Salt Molecular ¹H-NMR LCMS Purity Method for Number PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1073

421.85 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.01 (s, 1H), 9.52 (s, 1H), 8.65-8.69 (m, 2H), 8.39 (s, 1H), 8.28 (d, J = 5.2 Hz, 1H), 7.92-7.93 (m, 1H), 7.82 (q, J = 8.0 Hz, 2H), 7.52-7.57 (m, 2H), 7.35 (s, 1H), 6.84 (s, 1H), 3.05 (t, J = 7.2 Hz, 2H), 2.51-2.54 (m, 2H). DMSO 422.1 (M + 1) Method B (NH4HCO3) 95 Method C 1074

435.43 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.01 (s, 1H), 9.55 (d, J = 2.4 Hz, 1H), 8.68-8.70 (m, 2H), 8.47 (s, 1H), 7.97-7.99 (m, 1H), 7.79-7.36 (m, 3H), 7.50- 7.55 (m, 2H), 7.36 (s, 1H), 7.30 (t, J = 73.6 Hz, 1H), 6.99 (dd, J = 8.4, 2.4 Hz, 1H), 6.82 (s, 1H), 3.05 (t, J = 8.0 Hz, 2H), 2.52 (t, J = 8.4 Hz, 2H). DMSO 436.2 (M + 1) Method B (NH4HCO3) 95 Method C 1075

435.88 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.00 (s, 1H), 9.52 (s, 1H), 8.65-8.69 (m, 2H), 8.39 (s, 1H), 8.27- 8.29 (m, 1H), 7.79 (dd, J = 9.2, 2.4 Hz, 1H), 7.76- 7.85 (m, 3H), 7.52-7.57 (m, 2H), 3.05 (t, J = 7.6 Hz, 2H), 2.57 (d, J = 4.4 Hz, 3H), 2.52-2.54 (m, 2H). DMSO 436.1 (M + 1) Method B (NH4HCO3) 95 Method D 1076

449.91 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.95 (s, 1H), 9.51 (d, J = 1.6 Hz, 1H), 8.63-8.59 (m, 2H), 8.38 (s, 1H), 8.28 (dd, J = 6.8, 2.4 Hz, 1H), 7.90-7.94 (m, 1H), 7.81 (s, 2H), 7.51-7.55 (m, 2H), 3.04 (t, J = 7.6 Hz, 2H), 2.99 (s, 3H), 2.35 (s, 3H), 2.77 (t, J = 8.0 Hz, 2H). DMSO 450.0 (M + 1) Method B (NH4HCO3) 95 Method D 1077

540.01 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.01 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 8.61-8.74 (m, 2H), 8.41 (s, 1H), 8.28 (dd, J = 6.8, 2.6 Hz, 1H), 7.80-7.99 (m, 3H), 7.46-7.63 (m, 2H), 3.89 (s, 4H), 3.20 (s, 2H), 3.08 (t, J = 7.4 Hz, 4H), 2.90 (t, J = 7.6 Hz, 2H). DMSO 540.2, 542.2 (M + 1) Method B (NH4HCO3) 95 Method D

(E)-4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-but-3-enenitrile (xxxii-a)

(E)-4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-but-3-enenitrile (prepared in a manner analogous to that described for (E)-methyl 3-(4-hydroxy-2-(pyridin-3-yl)quinazolin-6-yl)acrylate using Method AB, replacing 6-iodo-2-(pyridin-3-yl)quinazolin-4-ol and methyl acrylate with N-(3-chloro-4-fluorophenyl)-6-iodo-2-(pyridin-3-yl)quinazolin-4-amine and but-3-enenitrile) was obtained in a 48% yield to give 400 mg of xxii-a as grey solid. LCMS m/z=416.0 (M+1) (Method B) (retention time=1.99 min).

4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-butyronitrile (xxxiii-a)

4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-butyronitrile (prepared in a manner analogous to that described for 2-amino-5-methoxybenzoic acid in Method K, replacing 5-methoxy-2-nitrobenzoic acid with (E)-4-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)but-3-enenitrile) was obtained in a 95% yield to give 190 mg of xxxiii-a as a brown solid. LCMS m/z=418.1 (M+1) (Method B) (retention time=1.95 min).

Method AD: 4-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)butanoic acid (xxxiv-a)

4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-butyronitrile (190 mg, 046 mmol, 1.0 eq.) was treated with concentrated HCl (8 mL). The mixture was stirred at 100° C. for 2 days. The volatiles were removed in vacuo, and the residue was washed with water to afford 70 mg of xxxiv-a in a 35% yield as a yellow solid. LCMS m/z=437.1, 439.1 (M+1) (Method B) (retention time=1.46 min).

4-(4-(3-Chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)-1-morpholino butan-1-one (xxxv-a)

4-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl) quinazolin-6-yl)-1-morpholinobutan-1-one was prepared in a manner analogous to that described for 2-benzamido-5-methoxy-3-methylbenzamide in Method D, replacing nicotinic acid and 2-amino-5-methoxy-3-methylbenzamide with 4-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl) butanoic acid and morpholine to give 32 mg of xxxv-a in a 40% yield as a beige solid. LCMS m/z=506.2, 508.1 (M+1) (Method 1) (retention time=1.85 min). ¹H NMR (400 MHz, DMSO-d₆): δ 10.04 (s, 1H), 9.52 (d, J=1.6 Hz, 1H), 8.69-8.65 (m, 2H), 8.39-8.38 (m, 1H), 8.27 (dd, J=6.8, 2.8 Hz, 1H), 7.94-7.90 (m, 1H), 7.86-7.84 (m, 1H), 7.80-7.77 (m, 1H), 7.57-7.52 (m, 2H), 3.56-3.53 (m, 4H), 3.46-3.41 (m, 4H), 2.85 (t, J=8.0 Hz, 2H), 2.40 (t, J=7.6 Hz, 2H), 1.97 (t, J=7.6 Hz, 2H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 38 in the synthesis of 4-(4-(3-Chloro-4-fluorophenyl amino)-2-(pyridin-3-yl) quinazolin-6-yl)-1-morpholino butan-1-one, replacing (E)-4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-but-3-enenitrile with 4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazoline-6-carbonitrile.

TABLE 13 Num- Salt Molecular ¹H-NMR LCMS Purity Method for ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1078

411.46 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.64 (d, J = 1.6 Hz, 1H), 8.78 (td, J = 7.9, 1.8 Hz, 1H), 8.71 (dd, J = 4.7, 1.6 Hz, 1H), 7.94 (d, J = 9.2 Hz, 1H), 7.59 (brs, 1H), 7.58 (dd. J = 7.6, 4.8 Hz, 1H). 7.52 (dd, J = 9.2. 2.8 Hz, 1H), 7.16 (t, J = 7.6 Hz, 1H), 7.08 (d, J = 6.4 Hz, 1H), 6.84 (dd, J = 8.0, 1.1 Hz, 1H), 6.69 (s, 1H), 4.36 (t, J = 6.5 Hz, 2H), 4.09 (t, J = 6.4 Hz, 2H), 3.46 (s, 3H), 2.30 (s, 3H). DMSO 412.2 (M + 1) Method B (NH4HCO3) 95 Method C, G 1079

506.96 ¹H NMR (400 MHz, DMSO-d₆): δ 10.42 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.08 (d, J = 1.2 Hz, 1H), 8.73- 8.65 (m, 3H), 8.28 (dd, J = 6.8, 2.4 Hz, 1H), 7.97- 7.93 (m, 2H), 7.60-7.53 (m, 2H), 3.60-3.58 (m, 4H), 3.51-3.46 (m, 2H), 2.55-2.53 (m, 2H), 2.41- 2.48 (m, 4H), DMSO 508.1 (M + 1) 254.1 254.9 (M/2 + 1) Method B (NH4HCO3) 95 Method C, G, C 1080

461.92 ¹H NMR (400 MHz, DMSO-d₆): δ 10.21 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 8.72-8.67 (m, 2H), 8.64 (d, J = 1.2 Hz, 1H), 8.28 (dd, J = 7.0, 2.6 Hz, 1H), 7.95- 7.86 (m, 3H), 7.60-7.53 (m, 2H), 3.68 (d, J = 2.4 Hz, 2H), 3.37-3.34 (m, 2H), 1.65-1.51 (m, 6H). DMSO 462.0 464.0 (M + 1) 232.3 (M/2 + 1) Method A (TFA) 95 Method C, G, C 1081

479.96 ¹H NMR (400 MHz, DMSO-d₆): δ 10.20 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.72-8.67 (m, 2H), 8.54 (d, J = 1.2 Hz, 1H), 8.28 (dd, J = 6.8, 2.8 Hz, 1H), 7.97- 7.90 (m, 3H), 7.60-7.54 (m, 2H), 3.97-3.94 (m, 2H), 3.66-3.60 (m, 2H), 2.77-2.67 (m, 4H). DMSO 480.0 482.0 (M + 1) 240.6 (M/2 + 1) Method A (TFA) 95 Method C, G, C 1082

421.85 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.20 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 8.79-8.64 (m, 3H), 8.29 (dd, J = 6.8, 2.6 Hz, 1H), 8.01-7.87 (m, 3H), 7.53-7 .60 (m, 2H), 3.15-3.05 (m, 3H), 3.02 (s, 3H). DMSO 422.1, 424.1 (M + 1) Method B (NH₄HCO₃) 95 Method C, G, D 1083

463.89 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.22 (s, 1H), 9.55 (d, J = 1.4 Hz, 1H), 8.77-8.65 (m, 3H), 8.02-7 .87 (m, 3H), 7.60-7.54 (m, 2H), 3.56-3.39 (m, 2H), 3.82-3.55 (m, 6H). DMSO 464.1, 466.1 (M + 1) Method B (NH₄HCO₃) 95 Method C, G, D 1084

407.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.41 (s, 1H), 9.54 (d, J = 1.5 Hz, 1H), 9.08 (d, J = 1.3 Hz, 1H), 8.76- 8.63 (m, 3H), 8.32-8.20 (m, 2H), 7.96-7.93 (m, 2H), 7.63-7.50 (m, 2H), 2.88 (d, J = 4.5 Hz, 3H). DMSO 408.0, 410.0 (M + 1) Method B (NH₄HCO₃) 95 Method C, G, D 1085

447.89 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 9.55 (d, J = 1.5 Hz, 1H), 8.68-8.77 (m, 3H), 8.28 (dd, J = 6.9, 2.6 Hz, 1H), 8.02 (dd, J = 8.6, 1.6 Hz, 1H), 7.99-7.90 (m, 2H), 7.53-7.58 (m, 2H), 3.57 (t, J = 6.8 Hz, 2H), 3.51 (t, J = 6.4 Hz, 2H), 1.85-1.95 (m, 4H). DMSO 448.1, 420.1 (M + 1) Method B (NH₄HCO₃) 95 Method C, G, D 1086

476.93 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.22 (s, 1H), 9.54 (d, J = 1.5 Hz, 1H), 8.75-8.63 (m, 3H), 8.29 (dd, J = 6.8, 2.6 Hz, 1H), 8.01-7.84 (m, 3H), 7.60-7.53 (m, 2H), 3.72 (d, J = 2.2 Hz, 2H), 3.51-3.39 (m, 2H), 2.48-2.40 (m, 2H), 2.33 (d, J = 1.3 Hz, 2H), 2.24 (s, 3H). DMSO 477.1, 479.1 (M + 1) 239.1, 239.9 (M/2 + 1) Method B (NH₄HCO₃) 95 Method C, G, D 1087

511.96 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.19 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.59-8.82 (m, 3H), 8.26 (dd, J = 6.8, 2.6 Hz, 1H), 7.81-8.14 (m, 3H), 7.57 (m, 2H), 3.83-4.10 (m, ,4H), 3.33-3.35 (m, 4H). DMSO 512.1, 514.1 (M + 1) Method B (NH4HCO3) 95 Method C, G, D 1088

481.91 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.23 (d, J = 1.2 Hz, 1H), 8.72- 8.74 (m, 3H), 8.22-8.42 (m, 2H), 7.85-8.12 (m, 2H), 7.55-7.59 (m, 2H), 4.61 (t, J = 5.4 Hz, 1H), 3.47 (t, J = 5.2 Hz, 2H), 3.37 (s, 6H), DMSO 482.1, 484.2 (M + 1) Method B (NH4HCO3) 95 Method C, G, D 1089

421.85 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 9.59 (d, J = 1.2 Hz, 1H), 8.72-8.77 (m, 2H), 8.68 (d, J = 8.4 Hz, 1H), 8.34 (dd, J = 7.2, 2.0 Hz, 1H), 7.96- 8.00 (m, 1H), 7.92 (m, 1H), 7.72-7.74 (m, 1H), 7.58-7.65 (m, 2H), 3.13 (s, 3H), 3.03 (s, 3H). DMSO 422.0 (M + 1) Method A (TFA) 95 Method C, G, D 1090

394.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.25 (s, 1H), 9.54 (s, 1H), 8.68-8.70 (m, 2H), 8.60 (d, J = 8.4 Hz, 1H), 8.37 (s, 1H), 8.32 (dd, J = 7.2, 2.8 Hz, 1H), 8.11 (d, J = 7.2 Hz, 1H), 7.93-7.97 (m, 1H), 7.51- 7.58 (m, 2H). DMSO 395.0 (M + 1) Method A (TFA) 95 Method C, G, D 1091

476.93 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.19 (s, 1H), 9.53 (s, 1H), 8.62-8.72 (m, 3H), 8.29 (dd, J = 6.8, 2.4 Hz, 1H), 7.91-7.94 (m, 1H), 7.83 (s, 1H), 7.66 (d, J = 8.8 Hz, 1H), 7.53-7.59 (m, 2H), 3.69-3.71 (s, 2H), 3.36-3.38 (s, 2H), 2.42-2.44 (s, 2H), 2.30- 2.32 (s, 2H), 2.23 (s, 3H). DMSO 477.2 (M + 1) 239.1 (1/2M +1) Method B (NH4HCO3) 95 Method C, G, D 1092

463.89 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.18 (s, 1H), 9.52 (s, 1H), 8.H)-8.71 (m, 3H), 8.28 (d, J = 4.8 Hz, 1H), 7.87-7.96 (m, 2H), 7.68 (d, J = 8.0 Hz, 1H), 7.52-7.58 (m, 2H), 3.61-3.71 (m, 6H), 3.40 (m, 2H). DMSO 464.1 (M + 1) Method B (NH4HCO3) 95 Method G, D 1093

393.8 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.20 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 8.62-8.72 (m, 3H), 8.42 (d, J = 1.2 Hz, 1H), 8.37 (s, 1H), 8.30 (dd, J = 7.2, 2.8 Hz, 1H), 8.08 (dd, J = 8.4, 1.2 Hz, 1H), 7.91-7.95 (m, 1H), 7.71 (s, 1H), 7.53-7.60 (m, 2H). DMSO 394.1 (M + 1) Method B (NH4HCO3) 95 Method G, D 1094

407.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.19 (s, 1H), 9.53 (s, 1H), 8.84 (d, J = 4.0 Hz, 1H), 8.60-8.72 (m, 3H), 8.35 (s, 1H), 8.29 (dd, J = 6.8, 2.8 Hz, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.90-7.93 (m, 1H), 7.52- 7.59 (m, 2H), 2.87 (d, J = 4.8 Hz, 3H). DMSO 408.1 (M + 1) Method B (NH4HCO3) 95 Method G, D 1095

HCl 506.96 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.20 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.85 (t, J = 5.6 Hz, 1H), 8.61- 8.72 (m, 3H), 8.36 (d, J = 1.2 Hz, 1H), 7.93 (dd, J = 6.4, 2.4 Hz, 1H), 8.03 (dd, J = 8.8, 1.6 Hz, 1H), 7.91- 7.95 (m, 1H), 7.52-7.59 (m, 2H), 3.60 (t, J = 4.4 Hz, 4H), 3.46-3.48 (q, J = 6.4 Hz, 2H), 2.51-2.54 (m, 2H), 2.42-2.48 (m, 4H). DMSO 507.1 (M + 1) 254.1 (M/2 +1) Method B (NH4HCO3) 95 Method G, C 1096

511.96 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.22 (s, 1H), 9.56 (d, J = 1.8 Hz, 1H), 8.61-8.79 (m, 3H), 8.31 (dd, J = 6.8, 2.6 Hz, 1H), 7.88-8.11 (m, 2H), 7.78 (dd, J = 8.4, 1.4 Hz, 1H), 7.51-7.66 (m, 2H), 4.12 (brs, 2H), 3.76 (brs, 2H), 3.30-3.33 (m, 4H). DMSO 512.1, 514.2 (M + 1) Method B (NH4HCO3) 95 Method G, D 1097

474 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.64 (brs, 1H), 9.53 (s, 1H), 9.44 (t, J = 6.4 Hz, 1H), 9.35 (s, 1H), 8.90 (d, J = 8.0 Hz, 1H), 8.85 (d, J = 4.8 Hz, 1H), 8.35 (dd, J = 8.4, 1.2 Hz, 1H), 8.27 (dd, J = 6.8, 2.4 Hz, 1H), 8.00-7.97 (m, 2H), 7.82 (dt, J = 13.2, 5.2 Hz, 1H), 7.55 (t, J = 8.8 Hz, 1H), 4.22-4.18 (m, 2H). DMSO 475.7, 476.6 (M + 1) Method B (NH4HCO3) 95 Method C, G, D

Method AE: 2-(7-(Methylamino)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (xxxvi-a)

A mixture of 2-(7-amino-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (160 mg, 0.449 mmol, 1.0 eq.) and HCHO (40%, 37 mg, 0.494 mmol, 1.1 eq.), acetic acid (2 drops) were stirred at room temperature for 0.5 h. NaBH₃CN (34 mg, 0.449 mmol, 1.0 eq.) was added and the mixture was stirred at room temperature overnight. After filtration, the filtrate was concentrated to give the crude product, which was purified by reverse phase chromatography (MeOH/H₂O=3:7) to afford 28 mg of xxxvi-a as a white solid (17%). LCMS m/z=371.1 (M+1), 372.1 (M+2) (Method B) (retention time=1.60 min). ¹H NMR (400 MHz, DMSO-d₆): δ 12.71 (s, 1H), 9.58 (d, J=1.6 Hz, 1H), 9.14-9.12 (m, 1H), 8.74-8.69 (m, 2H), 8.45 (s, 1H), 7.93-7.91 (m, 1H), 7.85 (d, J=92 Hz, 2H), 7.67-7.71 (m, 1H), 7.59-7.55 (m, 1H), 7.12-7.16 (m, 1H), 7.06-7.03 (m, 1H), 6.82-6.81 (m, 1H), 6.70 (d, J=2.4 Hz, 1H), 2.84 (d, J=4.8 Hz, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 41, replacing formaldehyde with the appropriate aldehyde and 2-aminobenzamide with the appropriate aniline.

TABLE 14 Molec- ¹H- Purity Method Num- Salt ular NMR LCMS per- for ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol cent Coupling 1098

370.41 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.87 (s, 1H), 9.57 (d, J = 1.2 Hz, 1H), 9.25 (d, J = 8.8 Hz, 1H), 8.65- 8.71 (m, 2H), 8.47 (s, 1H), 7.95-7.99 (m, 2H), 7.69-7.74 (m, 2H), 7.56 (dd, J = 7.7, 5.0 Hz, 1H), 7.33 (dd, J = 9.1, 1.9 Hz, 1H), 7.16 (t, J = 7.2 Hz, 1H), 6.90 (d, J = 1.2 Hz, 1H), 6.62 (d, J = 4.8 Hz, 1H), 2.88 (d, J = 4.8 Hz, 3H). DMSO 371.1 (M + 1) Method B (NH₄HCO₃) 95 Method AE 1099

370.41 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.71 (s, 1H), 9.58 (d, J = 1.4 Hz, 1H), 9.13 (d, J = 7.7 Hz, 1H), 8.80- 8.64 (m, 2H), 8.45 (s, 1H), 7.92 (dd, J = 7.9, 1.4 Hz, 1H), 7.85 (d, J = 9.2 Hz, 2H), 7.76-7.62 (m, 1H), 7.57 (dd, J = 7.9, 4.8 Hz, 1H), 7.15 (dd, J = 11.2, 4.0 Hz, 1H), 7.04 (dd, J = 9.0, 2.3 Hz, 1H), 6.81 (q, J = 4.8 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 2.85 (d, J = 4.9 Hz, 3H). DMSO 371.1 (M + 1) Method B (NH₄HCO₃) 95 Method AE

Method AG: 1-(Benzyloxy)-3-chloro-7-methoxyisoquinoline (xxxvii-a)

1,3-dichloro-7-methoxyisoquinoline (2.00 g, 8.8 mmol, 1.0 eq.) was dissolved in 30 mL anhydrous toluene and sodium benzyloxide (2.30 g, 17.6 mmol, 2.0 eq.) was added. The mixture was heated to 80° C. for 18 h. TLC indicated the reaction was complete.

The mixture was concentrated to give the crude product, which was purified by chromatography on silica gel (eluted with petroleum ether) to give 2.20 g of xxxvii-a as a white solid (84.6%). LCMS m/z=300.1, 302.0 (M+1) (Method B) (retention time=2.23 min).

1-(Benzyloxy)-7-methoxy-3-(pyridin-3-yl)isoquinoline (xxxviii-a)

1-(Benzyloxy)-7-methoxy-3-(pyridin-3-yl)isoquinoline was prepared using Method N2. 1-(Benzyloxy)-3-chloro-7-methoxyisoquinoline (93 mg, 0.5 mmol, 1.0 eq.), potassium carbonate (357 mg, 2.5 mmol, 5.0 eq.), and Pd(PPh₃)₂Cl₂ (18 mg, 0.026 mmol, 0.05 eq.) was dissolved in the mixed solvent of 1,4-dioxane (3 mL) and water (1 mL). The resulting mixture was stirred at 120° C. for 30 min under the microwave condition. The solid was filtrated off and the filtrate was concentrated. The residue was partitioned between ethyl acetate and water. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate. After filtration and evaporation, the residue was purified by silica gel chromatography (petroleum ether/ethyl acetate=1:10) to afford 100 mg of xxxviii-a as a yellow solid (84.7%).

7-Methoxy-3-(pyridin-3-yl)isoquinolin-1-ol (xxxviv-a)

7-Methoxy-3-(pyridin-3-yl)isoquinolin-1-ol (prepared in a manner analogous to that described for 2-amino-5-methoxybenzoic acid in Method K, replacing 5-methoxy-2-nitrobenzoic acid with 1-(benzyloxy)-7-methoxy-3-(pyridin-3-yl) isoquinoline) was obtained in a 63.6% yield to give 280 mg of xxxviv-a as a yellow solid. This was carried on without further purification,

1-Chloro-7-methoxy-3-(pyridin-3-yl)isoquinoline (xl-a)

1-Chloro-7-methoxy-3-(pyridin-3-yl)isoquinoline (prepared in a manner analogous to that described for 4-chloro-6-propoxy-2-pyridin-3-yl-quinazoline in Method F1, replacing 6-propoxy-2-pyridin-3-yl-1H-quinazolin-4-one with 3-(pyridin-3-yl)isoquinolin-1-ol) was obtained in a 73.0% yield to give 60 mg of xl-a as a brown solid. MS m/z=241.1 (M+1) (Method A) (retention time=1.34 min).

N-(3-Chloro-4-fluorophenyl)-7-methoxy-3-(pyridin-3-yl)isoquinolin-1-amine (xli-a)

N—(N-(3-chloro-4-fluorophenyl)-7-methoxy-3-(pyridin-3-yl)isoquinolin-1-amine was prepared using Method J. A mixture of 1-chloro-7-methoxy-3-(pyridin-3-yl)isoquinoline (40 mg, 0.17 mmol, 1.0 eq.), 3-chloro-4-fluoro aniline (30 mg, 0.21 mmol, 1.2 eq.), Pd₂(dba)₃ (10 mg, 0.011 mmol, 0.06 eq.), Xantphos (15 mg, 0.026 mmol, 0.15 eq.), cesium carbonate (167 mg, 0.52 mmol, 3.0 eq.) was suspended in the mixed solvent of 1,4-dioxane (4 mL) and water (1 mL). The resulting mixture was stirred at 120° C. for 30 min under the microwave conditions. After cooling, the resulting mixture was partitioned between water and ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate. After filtration and evaporation, the residue was purified by prep-HPLC to afford 3 mg of xli-a as a yellow solid (yield 5.2%). LCMS m/z=380.1 (M+1) (Method B). ¹H NMR (400 MHz, DMSO-d₆): δ 9.35 (s, 1H), 9.30 (d, J=2.0 Hz, 1H), 8.57 (dd, J=4.7, 1.5 Hz, 1H), 8.41 (td, J=8.0, 1.8 Hz, 1H), 8.30 (dd, J=6.9, 2.6 Hz, 1H), 7.94-7.87 (m, 4H), 7.43-7.49 (m, 3H), 3.99 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 43, replacing with the appropriate isoquinoline and aniline.

TABLE 15 Mo- Puri- Method lec- ¹H- ty for Num- Salt ular NMR LCMS per- Cou- ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol cent pling 1100

379.81 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.35 (s, 1H), 9.30 (d, J = 2.0 Hz, 1H), 8.57 (dd, J = 4.7, 1.5 Hz, 1H), 8.41 (td, J = 8.0, 1.8 Hz, 1H), 8.30 (dd, J = 6.9, 2.6 Hz, 1H), 7.94-7.87 (m, 4H), 7.43-7.49 (m, 3H), 3.99 (s, 3H). DMSO 380.1, 382.0 (M + 1) Method B (NH4HCO3) 95 Method J 1101

411.38 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.46 (s, 1H), 9.31 (d, J = 1.75 Hz, 1H), 8.57 (dd, J = 4.6, 1.3 Hz, 1H), 8.45-8.41 (m, 1H), 8.19 (s, 1H), 7.99-7.94 (m, 2H), 7.91-7.86 (m, 2H), 7.54-7.44 (m, 3H), 7.01 (d, J = 8.1 Hz, 1H), 4.00 (s, 3H). DMSO 412.1 (M + 1) Method B (NH4HCO3) 95 Method J 1102

388.39 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.35 (s, 1H), 9.34 (d, J = 1.9 Hz, 1H), 8.80 (d, J = 8.4 Hz, 1H), 8.59 (dd, J = 4.7, 1.48 Hz, 1H), 8.49-8.45 (m, 1H), 8.26 (s, 1H), 8.13 (s, 1H), 8.02 (s, 1H), 7.97-7.92 (m, 1H), 7.61 (td, J = 14.9, 7.5 Hz, 1H), 7.56-7.48 (m, 3H), 6.95 (dd, J = 10.3, 8.3 Hz, 1H), 3.98 (s, 3H). DMSO 389.1 (M + 1) Method B (NH4HCO3) 95 Method J 1103

370.4 ¹H-NMR (400 MHz, CDCl3): δ 11.89 (s, 1H), 9.39 (s, 1H), 9.29 (s, 1H), 8.63- 8.59 (m, 1H), 8.42- 8.37 (m, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.60-7.62 (m, 4H), 7.44-7.33 (m, 3H), 7.05-7.00 (m, 1H), 4.06 (s, 3H). CDCl3 371.1 (M + 1) Method B (NH4HCO3) 95 Method J 1104

407.37 ¹H-NMR (400 MHz, CDCl3): δ 9.28 (s, 1H), 8.60 (d, J = 4.6 Hz, 1H), 8.34 (d, J = 7.8 Hz, 1H), 7.85 (s, 1H), 7.79 (d, J = 8.9 Hz, 1H), 7.63 (s, 1H), 7.43- 7.35 (m, 2H), 7.22 (d, J = 8.6 Hz, 1H), 7.17 (s, 1H), 7.09- 7.03 (m, 2H), 4.00 (s, 3H). CDCl3 408.1 (M + 1) Method B (NH4HCO3) 95 Method J 1105

454.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.00 (s, 1H), 9.43 (d, J = 1.2 Hz, 1H), 9.35 (s, 1H), 8.63 (d, J = 3.7 Hz, 1H), 8.53 (s, 1H), 8.48-8.44 (m, 1H), 8.03-8.09 (m, 3H), 7.97 (d, J = 8.9 Hz, 1H), 7.65 (d, J = 1.8 Hz, 1H), 7.56-7.50 (m, 2H), 7.05 (dd, J = 8.6, 1.93 Hz, 1H), 4.01 (s, 3H). DMSO 455.1 (M + 1) Method B (NH4HCO3) 95 Method J 1106

455.91 1H-NMR (400 MHz, DMSO-d₆): δ 9.65 (s, 1H), 9.37 (d, J = 1.7 Hz, 1H), 8.83 (s, 1H), 8.63 (dd, J = 4.7, 1.3 Hz, 1H), 8.54-8.43 (m, 1H), 8.35 (dd, J = 6.9, 2.6 Hz, 1H), 8.15 (dd, J = 8.5, 1.4 Hz, 1H), 8.03 (t, J = 4.3 Hz, 2H), 7.91- 7.95 (m, 1H), 7.46- 7.55 (m, 5H), 7.11-7.01 (m, 1H), 3.91 (s, 3H). DMSO 456.1, 458.1 (M + 1) Method B (NH₄HCO₃) 95 Method J 1107

¹H-NMR (400 MHz, DMSO-d₆): δ 9.63 (s, 1H), 9.36 (d, J = 1.9 Hz, 1H), 9.19 (d, J = 1.9 Hz, 1H), 8.91 (s, 1H), 8.67 (dd, J = 4.8, 1.5 Hz, 1H), 8.62 (dd, J = 4.7, 1.5 Hz, 1H), 8.53-8.44 (m, 1H), 8.35-8.32 (m, 2H), 8.19 (dd, J = 8.5, 1.5 Hz, 1H), 8.13- 8.01 (m, 2H), 7.92 (ddd, J = 9.1, 4.3, 2.7 Hz, 1H), 7.61 (dd, J = 7.9, 4.8 Hz, 1H), 7.55 (dd, J = 8.0, 4.8 Hz, 1H), 7.50 (t, J = 9.1 Hz, 1H). DMSO 426.7 428.7 (M + 1) Method B (NH4HCO3) 95 Method J

Method AI: Ethyl 2-cyano-4,4-diethoxybutanoate (xlii-a)

2-Bromo-1,1-diethoxyethane (4 g, 20 mmol, 1.0 eq.) was added to a mixture of ethyl 2 cyanoacetate (11.4 g, 101 mmol, 5.0 eq.), K₂CO₃ (2.8 g, 20 mmol, 1.0 eq.) and NaI (200 mg, 1.3 mmol, 0.06 eq.), as described in J. Chem. Soc., 1960, 131-138. The reaction mixture was refluxed for 4 h at 145° C. After cooling, the reaction mixture was purified by chromatography on silica gel (eluted with petroleum ether/ethyl acetate (80:1→40:1→10:1) to give 3.57 g of xlii-a as a colorless oil (78%). ¹H NMR (400 MHz, CDCl₃): δ 4.70 (t, J=5.6 Hz, 1H), 4.26 (q, J=7.2 Hz, 2H), 3.78-3.64 (m, 3H), 3.62-3.45 (m, 2H), 2.35-2.14 (m, 2H), 1.34 (q, J=7.2 Hz, 3H), 1.25-1.16 (m, 6H).

Method AJ: 2-(Pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ol (xliii)

To a solution of nicotinimidamide (5.03 g, 41.6 mmol, 1.2 eq.) in EtOH (100 mL), was added NaOMe (4.8 g, 88.8 mmol, 2.5 eq.). The mixture was stirred at room temperature for 4 h. The reaction mixture was added to ethyl 2-cyano-4,4-diethoxybutanoate (8.00 g, 34.9 mmol, 1 eq.). This mixture was stirred at 105° C. overnight. After cooling, the reaction mixture was acidified with conc. HCl and stirred at room temperature for 2 h. A precipitate formed and was collected and washed with H₂O (20 mL×2). After lyophilization, 3.10 g of product: was obtained as a gray yellow solid (yield 41.8%). LCMS=213.1 (M+1) (Method B) (retention time=1.07 min)¹H NMR (400 MHz, DMSO-d₆): δ 12.26 (s, 1H), 12.04 (s, 1H), 9.23 (d, J=1.6 Hz, 1H), 8.70 (dd, J=4.8, 1.2 Hz, 1H), 8.43-8.40 (m, 1H), 7.55 (dd, J=8.0, 4.8 Hz, 1H), 7.12 (d, J=1.6 Hz, 1H), 6.51 (d, J=2.8 Hz, 1H).

4-Chloro-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (xlv-a)

4-Chloro-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (prepared in a manner analogous to that described for 4-chloro-6-propoxy-2-pyridin-3-yl-quinazoline in Method F1 replacing 6-propoxy-2-pyridin-3-yl-1H-quinazolin-4-one with 2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ol) to give 450 mg of xliv-a in a 69.0% yield as a brown solid. LCMS m/z=231.0, 233.0 (M+1) (Method B) (retention time=1.60 min).

N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (xlv-a)

N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (prepared in a manner analogous to that described for N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)propyl)-2-(pyridin-3-yl)quinazolin-4-amine using Method G6, replacing 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propyl methanesulfonate with 4-chloro-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine) to give a 11.3% yield, 10 Mg of xlv-a as brown solid. LCMS m/z=340.1, 342.0 (M+1) (Method B) (retention time=1.814 min). ¹H NMR (400 MHz, DMSO-d₆): δ 9.48 (d, J=1.6 Hz, 1H), 8.62 (dd, J=4.8, 1.6 Hz, 1H), 8.60-8.56 (m, 1H), 8.27 (dd, J=6.4, 2.4 Hz, 1H), 8.06 (ddd, J=8.8, 4.0, 2.8 Hz, 1H), 7.71 (d, J=3.6 Hz, 1H), 7.66 (t, J=9.2 Hz, 1H), 7.50 (dd, J=8.0, 4.8 Hz, 1H), 7.41 (br s, 2H), 6.85 (d, J=3.6 Hz, 1H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 45, replacing with the appropriate aniline.

TABLE 16 Molec- ¹H- Method Num- Salt ular NMR LCMS Purity for ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1108

330.34 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.29 (s, 1H), 12.09 (s, 1H), 9.54 (d, J = 1.2 Hz, 1H), 9.11 (d, J = 8.4 Hz, 1H), 8.65-8.68 (m, 1H), 8.35 (s, 1H), 7.89 (dd, J = 8.0, 1.2 Hz, 1H), 7.79 (s, 1H), 7.67 (td, J = 8.8, 1.2 Hz, 1H), 7.55 (dd, J = 7.2, 4.8 Hz, 1H), 7.43-7.41 (m, 1H), 7.10 (td, J = 8.0, 1.2 Hz, 1H), 6.49 (d, J = 3.6 Hz, 1H). DMSO 331.1 (M + 1) Method B (NH4HCO3) 95 Method AJ, F, G6 1109

371.32 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.02 (d, J = 1.3 Hz, 1H), 9.75 (s, 1H), 9.50 (d, J = 1.5 Hz, 1H), 8.68-8.53 (m, 2H), 8.29 (s, 1H), 7.94- 7.75 (m, 1H), 7.61- 7.44 (m, 2H), 7.41- 7.29 (m, 1H), 7.04 (s, 1H), 6.88 (dd, J = 3.4, 1.9 Hz, 1H). DMSO 372.0 (M + 1) Method A (TFA) 95 Method AJ, F, G6 1110

366.32 1H-NMR (400 MHz, DMSO-d6): δ 11.98 (s, 1H), 9.69 (s, 1H), 9.48 (d, J = 1.8 Hz, 1H), 8.64-8.59 (m, 2H), 8.19 (d, J = 2.0 Hz, 1H), 7.63 (dd, J = 8.8, 2.0 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 7.34 (d, J = 3.0 Hz, 1H), 6. DMSO 368.1 (M + 1) Method A (TFA) 95 Method AJ, F, G6 1111

339.75 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.51 (s, 1H), 8.78 (d, J = 8.0 Hz, 2H), 8.17 (d, J = 9.2 Hz, 1H), 7.80 (dd, J = 9.2, 2.8 Hz, 1H), 7.70-7.64 (m, 1H), 7.46 (d, J = 2.8 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 4.0 Hz, 2H), 7.16-7.08 (m, 1H). DMSO 340.1, 342.0 (M + 1) Method B (NH4HCO3) 95 Method AJ, F, G6

Method AK: 4-Chloro-7-methyl-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (xliv-a)

To a solution of 4-chloro-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (80 mg, 0.34 mmol, 1.0 eq.) in dry DMF (20 mL) was added Cs₂CO₃ (221 mg, 0.68 mmol, 2.0 eq.) and iodomethane (54.3 mg, 0.38 mmol, 1.1 eq.) at 0° C. The reaction mixture was warmed to room temperature and stirred for 2.5 h. The reaction mixture was poured into ice water and extracted with EtOAc (20 mL×3). The combined organic layers were dried over anhydrous Na₂SO₄. After filtration and concentration, the residue was purified by chromatography on silica gel (petroleum ether/ethyl acetate 8:1) to give 65 mg of xlvi-a as brown solid (56.7%).

N-(3-chloro-4-fluorophenyl)-7-methyl-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (xlvii-a)

N-(3-chloro-4-fluorophenyl)-7-methyl-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (prepared in a manner analogous to that described for N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)propyl)-2-(pyridin-3-yl)quinazolin-4-amine using Method G6, replacing 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propyl methanesulfonate with 4-chloro-7-methyl-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine) to give a 70.0% yield, 30 mg of xlvii-a as a brown solid. LCMS m/z=354.1, 356.1 (M+1) (Method B) (retention time=1.94 min). ¹H NMR (400 MHz, DMSO-d₆): δ 9.97 (s, 1H), 9.53 (s, 1H), 9.15 (d, J=8.0 Hz, 1H), 8.91 (d, J=5.2 Hz, 1H), 8.25 (dd, J=6.8, 2.4 Hz, 1H), 8.04 (dd, J=7.6, 5.6 Hz, 1H), 7.94-7.90 (m, 1H), 7.48-7.43 (m, 2H), 6.95 (d, J=3.2 Hz, 1H), 3.88 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 46, replacing with the appropriate aniline.

TABLE 17 Molec- ¹H- Method Num- Salt ular NMR LCMS Purity for ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1112

HCl 353.78 ¹H NMR (400 MHz, DMSO-d₆): δ 9.97 (s, 1H), 9.53 (s, 1H), 9.15 (d, J = 8.0 Hz, 1H), 8.91 (d, J = 5.2 Hz, 1H), 8.25 (dd, J = 6.8, 2.4 Hz, 1H), 8.04 (dd, J = 7.6, 5.6 Hz, 1H), 7.94-7.90 (m, 1H), 7.48-7.43 (m, 2H), 6.95 (d, J = 3.2 Hz, 1H), 3.88 (s, 3H). DMSO 354.1, 356.1 (M + 1) Method B (NH4HCO3) 95 Method AK, G6 1113

385.34 ¹H NMR (400 MHz, DMSO-d₆): δ 9.81 (s, 1H), 9.56 (d, J = 1.6 Hz, 1H), 8.69- 8.64 (m, 2H), 8.29 (s, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.55- 7.51 (m, 2H), 7.41 (d, J = 3.6 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 3.6 Hz, 1H), 3.87 (s, 3H). DMSO 386.1 (M + 1) Method B (NH4HCO3) 95 Method AK, G6 1114

1H-NMR (400 MHz, DMSO-d6): δ 12.32 (s, 1H), 9.61 (s, 1H), 9.11 (d, J = 7.6 Hz, 1H), 9.11 (d, J = 7.6 Hz, 1H), 8.74 (dt, J = 8.0, 1.9 Hz, 1H), 8.67 (d, J = 3.6 Hz, 1H), 8.38 (s, 1H), 8.38 (s, 1H), 7.90 (dd, J = 7.9, 1.4 Hz, 1H), 7.82 (s, 1H), 7.68 (dd DMSO 344.9 (M + 1) Method B (NH4HCO3) 95 Method AK, G6

Method AL: 4-(5,6-dimethyl-1H-benzo[d]imidazol-1-yl)-2-(pyridin-3-yl)quinazoline-6-carboxamide (xlviii-a)

To a suspension of 4-oxo-2-(pyridin-3-yl)-1,4-dihydroquinazoline-6-carboxamide (prepared as described in scheme 4) (100 mg, 0.376 mmol, 1.0 eq.) in dry DMF (20 mL) was added benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (216 mg, 0.488 mmol, 1.3 eq.) and diaza(1,3)bicyclo[5.4.0]undecene (114.5 mg, 0.752 mmol, 2.0 eq.) following a procedure outlined in J. Org. Chem., 2007, 72, 1019440210. To the clear solution was then added 5,6-dimethyl-1H-benzo[d]imidazole (165.2 mg, 1.13 mmol, 3.0 eq.) and the mixture was stirred overnight at room temperature. The resultant precipitate was then collected by filtration and washed with dichloromethane, water, and ether. The product was dried in vacuo to give 26.3 mg of the desired product: (xlviii-a) as an off-white solid (6.7%). LCMS m/z=395.1 (M+1) (Method C) (retention time=1.68 min). ¹H NMR (300 MHz, DMSO) δ 9.69 (s, 1H), 8.90 (s, 1H), 8.82 (d, J=15.2 Hz, 2H), 8.66 (s, 1H), 8.54 (d, j=8.6 Hz, 1H), 8.42 (s, 1H), 8.30 (d, J=8.5 Hz, 1H), 7.79 (s, 1H), 7.68 (s, 3H), 2.39 (s, 3H), 2.36 (s, 3H).

Method AM: Synthesis of 2-(6-(2-(piperidin-1-yl)ethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (xlviv-a)

To 1-(2-chloroethyl)piperidine (45 μmol) was added the solution of 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (30 μmol) in NMP (200 μL) PS-BEMP (90 μmol) was added to the vials by resin dispenser. After the reaction mixture was heated at 90° C. for 12 h, the residue was diluted with methanol and purified by mass triggered PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 51, replacing 1-(2-chloroethyl)piperidine with the appropriate alkyl halide.

TABLE 18 Mass Found Pur- Num- Starting Starting Salt Exact (M + ity ber Material 1 Material 2 Product Type Mass 1) (%) 1116

468 469 98 1117

454 455 98 1118

456 457 98 1119

468 469 98 1120

482 483 98 1121

TFA 496 497 98 1122

465 466 98 1123

505 506 98

To a suspension of ethyl 2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-4-phenylthiazole-5-carboxylate (1.3956 g, 2.89 mmol) in dioxane (40 mL) was added 1N NaOH (20 ml, 20.00 mmol) at room temperature to give a clear solution. The reaction mixture was stirred at room temperature for 1 h and then warmed to 50° C. overnight, however starting material remained. An additional 20 mL of 1N NaOH was added and heating was continued at 50° C. for 1 h and at 70° C. for 5 h 30 min. The reaction mixture was cooled to room temperature and diluted with water and ethyl acetate. The water phase was removed and adjusted to an acidic pH with 1N HCl (40 mL). A precipitate formed and was collected and washed with water. The product was dried in vacuo to give 1.20 g of a brown solid in a 91% yield, ¹H NMR (DMSO-d₆) ppm 12.88 (hr, 2H), 9.77 (dd, J=2.12, 0.6 Hz, 1H), 8.92-8.89 (m, 1H), 8.78 (dd, J=4.8, 1.68 Hz, 1H), 8.32 (br, 1H), 7.96 (d, J=9.12 Hz, 1H), 7.82-7.80 (m, 2H), 7.70-7.67 (m, 1H), 7.63 (dd, J=9.12, 2.68 Hz, 1H), 7.50-7.44 (m, 3H), 3.98 (s, 3H).

Method AN: 2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-N-methyl-4-phenylthiazole-5-carboxamide

To a suspension of 2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-4-phenylthiazole-5-carboxylic acid (291.8 mg, 0.641 mmol) in DMF (20 mL) under nitrogen atmosphere was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (189 mg, 0.986 mmol) and 1-hydroxybenzotriazole hydrate (147 mg, 0.961 mmol) at room temperature. The reaction mixture was stirred at room temperature for 10 min to give a clear solution and methylamine in a methanol solution (4 mL) was added at room temperature. The reaction mixture was stirred at room temperature for 2 h 15 min. Additional methyl amine in a methanol solution (4 mL) was added at room temperature and then heated to 50° C. for 1 h followed by room temperature for 2 days. The reaction mixture was partitioned between water and ethyl acetate. The water phase was collected and a solid precipitated from the water phase. The solid was filtered and dried in an oven at 60° C. to give 107.9 mg (0.23 mmol) as the parent compound. The parent compound was suspended in methanol and 4N HCl in ethyl acetate (ca. 2 mL) was added to give a clear solution which precipitated over time. The solid was collected by filtration and dried in oven at 60° C. for 2 days to give 82.4 mg of the HCl salt as a yellow solid in 24% yield. ¹H NMR (DMSO-d_(c)) δ 12.77 (brs, 1H), 9.76 (d, J=1.72. Hz, 1H), 9.18 (d, J=7.88 Hz, 1H), 8.92 (d J=5.04 Hz, 1H), 8.35 (brs, 1H), 8.27 (brd, J=4.56 Hz, 1H), 7.99-7.965 (m, 2H), 7.79 (brd, J=7.16 Hz, 2H), 7.65 (dd. J=9.12, 2.56 Hz, 1H), 7.50-7.41 (m, 3H), 4.00 (s, 3H), 2.76 (d, J=4.56 Hz, 3H). The 1H of 2HCl was not observed.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 53, replacing N-methyl amine with the appropriate alkyl amine.

TABLE 19 Starting Starting Salt Number Material 1 Material 2 Product Type 1124

2 HCl 1125 NH₃

2 HCl 1126

Method ¹H NMR Purity of Number ¹H NMR Solvent percent Coupling 1124 1H NMR (DMSO-d6) ppm 12.77 (brs, 1H), 9.76 (d, J = 1.72 Hz, 1H), 9.18 (d, J = 7.88 Hz, 1H), 8.92 (d J = 5.04 Hz, 1H), 8.35 (brs, 1H), 8.27 (brd, J = 4.56 Hz, 1H), 7.99-7.965 (m, 2H), 7.79 (brd, J = 7.16 Hz, 2H), 7.65 (dd, J = 9.12, 2.56 Hz, 1H), 7.50-7.41 (m, 3H), 4.00 (s, 3H), 2.76 (d, J = 4.56 Hz, 3H). The 1H of 2HCl was not observed. DMSO >98 Method AN 1125 1H NMR (DMSO-d6) ppm 12.75 (brs, 1H), 9.77 (d, J = 1.52 Hz, 1H), 9.13 (brs, 1H), 8.88 (brd, J = 5.08 Hz, 1H), 8.34 (d, J = 2.04 Hz, 1H), 7.98 (d, J = 9.12 HZ, 1H), 7.90 (brm, 1H), 7.83-7.80 (m, 2H), 7.66-7.53 (brm, 3H), 7.51-7.42 (m, 3H), 4.00 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 Method AN 1126 1H NMR (DMSO-d6) ppm 12.66 (s, 1H), 9.76 (s, 1H), 8.88 (d, J = 7.76 HZ, 1H), 8.75 (d, J = 3.68 Hz, 1H), 8.40-8.20 (br, 2H), 7.94 (br, 1H), 7.80 (d, J = 7.16 Hz, 2H), 7.63 (m, 2H), 7.49-7.41 (m, 3H), 3.99 (s, 3H), 3.24 (q, J = 7.24 Hz, 2H), 1.07 (t, J = 7.24 Hz, 3H) DMSO >98 Method AN

Method AO: N-tert-butyl-2-(4-(3,4-difluorophenyl-amino)-2-(pyridin-3-yl)quinazolin-6-yloxy)acetamide

To a solution of carboxylic acid derivative (500 mg, 1.2 mmol) in UMP was added 2-aminoisobutane (134 mg, 1.8 mmol), NMM (0.4 mL, 3.6 mmol), WSCDI (282 mg, 1.4 mmol) and HOBT (22.5 mg, 1.4 mmol). The reaction mixture was stirred at room temperature overnight. The resulting solution was poured into ice-water and the precipitate formed and was filtered off. The solid was washed with water and dried to give 350 mg (62% yield) of desired product, ¹H NMR (400 MHz, DMSO) δ 9.86 (s, 1H), 9.49 (d, J=1.5 Hz, 1H), 8.71-8.57 (m, 2H), 8.11 (ddd, J=13.3, 7.5, 2.5 Hz, 1H), 8.00-7.93 (m, 1H), 7.87 (d, J=9.1 Hz, 1H), 7.67 (ddd, J=11.7, 7.1, 2.1 Hz, 2H), 7.59-7.47 (m, 3H), 4.61 (s, 2H), 1.35 (s, 9H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 54, replacing 2-aminoisobutane with the appropriate alkyl amine.

TABLE 20 Starting Starting Number Material R¹ Material R³ Product 1127

1128

1129

Method Salt ¹H NMR Purity of Number Type ¹H NMR Solvent percent Coupling 1127 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.60 (s, 1H), 9.48 (d, J = 1.9 Hz, 1H), 9.14 (dt, J = 8.2, 1.6 Hz, 1H), 8.96 (dd, J = 5.5, 1.3 Hz, 1H), 8.37 (t, J = 6.0 Hz, 1H), 8.24 (d, J = 2.6 Hz, 1H), 8.11-7.97 (m, 3H), 7.74 (ddd, J = 11.8, 7.4, 3.3 Hz, 2H), 7.55 (dt, J = 10.5, 9.1 Hz, 1H), 4.79 (s, 2H), 3.01 (t, J = 6.5 Hz, 2H), 1.86-1.59 (m, 1H), 0.85 (d, J = 6.7 Hz, 6H). DMSO >98 Method AO 1128 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.81 (s, 1H), 9.50 (d, J = 1.9 Hz, 1H), 9.16 (d, J = 8.2 Hz, 1H), 8.98 (dd, J = 5.5, 1.3 Hz, 1H), 8.40 (d, J = 2.5 Hz, 1H), 8.29 (t, J = 6.4 Hz, 1H), 8.18-7.95 (m, 3H), 7.83-7.67 (m, 2H), 7.55 (dt, J = 10.5, 9.1 Hz, 1H), 4.88 (s, 2H), 2.98 (d, J = 6.4 Hz, 1H), 0.84 (s, 9H). DMSO >98 Method AO 1129 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.87 (s, 1H), 9.50 (d, J = 1.9 Hz, 1H), 9.16 (d, J = 8.2 Hz, 1H), 8.98 (dd, J = 5.5, 1.3 Hz, 1H), 8.41 (d, J = 2.5 Hz, 1H), 8.23-7.96 (m, 4H), 7.85-7.66 (m, 2H), 7.55 (dt, J = 10.5, 9.1 Hz, 1H), 4.85 (s, 2H), 3.80-3.43 (m, 1H), 1.65-1.21 (m, 4H), 0.81 (t, J = 7.4 Hz, 6H). DMSO >98 Method AO

2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-1,N-dimethyl-1H-benzo[d]imidazole-1-carboxamide (334.1 mg, 0.760 mmol) was dissolved in concentrated HCl (0.063 ml, 0.760 mmol). The solution was stirred at room temperature overnight and then at 50° C. for 3 h 30 min followed by 100° C. for 3 h. The solid was collected and dried in vacuo to give 116.2 mg of a yellow solid in a yield 35%. ¹H NMR (DMSO-d₆) δ 13.22 (br, 1H), 9.55 (s, 1H), 8.92 (dd, J=4.96, 1.36 Hz, 1H), 8.88 (br, 1H), 8.01 (d, J=9.12 Hz, 1H), 7.92 (br, 1H), 7.83 (br, 1H), 7.67 (dd, J=9.12, 2.80 Hz, 1H), 7.61 (m, 2H), 7.38 (m, 2H), 3.97 (s, 3H), The 1H of 2HCl and NH— were not observed.

4-(4-chlorophenyl)-2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-N,N-dimethyl-1H-imidazole-1-carboxamide and concentrated HCl_((aq)) (10 mL) were added to a round bottom flask, a precipitate appeared upon refluxing the mixture for 3 h. The solid was collected (373.4 mg) and tritiated with CH₂Cl₂/methanol overnight. The product was filtered and dried to give 261.7 mg of a solid. A suspension of the product in methanol was added to a 1N solution of NaOH _((aq.)) (5 nit) followed by CH₂Cl₂ and H₂O. The solid was collected and washed with methanol to give 255.7 mg (0.596 mmol) of the parent product. The free parent was suspended in CH₂Cl₂/methanol and converted to the HCl salt by addition of a 0.3 ml solution of 4N HCl in ethyl acetate. The HCl salt was collected and dried in vacuo to give 248.4 mg as brown solid in a 26% yield. ¹H NMR (DMSO-d₆) δ 13.61 (br, 1H), 12.81 (br, 1H), 9.46 (5, 1H), 8.87 (d, J=5.2.4 Hz, 1H), 8.70 (br, 1H), 7.91-7.87 (m, 5H), 7.75 (m, 1H), 7.62-7.56 (m, 3H), 3.95 (s, 3H). The 1H ref 2HCl was not observed.

To a mixture of N-(6-(benzyloxy)-2-(pyridin-3-yl)quinazolin-4-yl)-4-(4-chlorophenyl)thiazol-2-amine and catechol, dimethyl ether (0.16 g, 1.15 mmol) was added methanesulfonic acid (4.0 mL). The mixture was stirred for 1 hr and was then poured into water. The slurry was added to a stirring sat. NaHCO_(3(aq)), solution slowly and allowed to stir for 30 min. The precipitate was filtered to give a brown solid which was washed with methanol to give 4-(4-(4-chlorophenyl)thiazol-2-ylamino)-2-(pyridin-3-yl)quinazolin-6-ol (0.23 g, 91.0%).

Scheme 59: Synthesis of 4-(4-phenylthiazol-2-ylamino)-2-(pyridin-3-34)quinazolin-6-ol (Compound 1133)

Synthesis of 4-(4-phenylthiazol-2-ylamino)-2-(pyridin-3-yl)quinazolin-6-ol was performed in a similar manner to that described for 4-(4-(4-chlorophenyl)thiazol-2-ylamino)-2-(pyridin-3-yl)quinazolin-6-ol substituting for 4-(4-phenylthiazol-2-ylamino)-2-(pyridin-3-yl)quinazolin-6-ol for the N-(6-(benzyloxy)-2-(pyridin-3-yl)quinazolin-4-yl)-4-(4-chlorophenyl)thiazol-2-amine giving 4-(4-phenylthiazol-2-ylamino)-2-(pyridin-3-yl)quinazolin-6-ol. ¹H NMR (300 MHz, DMSO) δ 10.06-9.22 (m, 2H), 8.95 (dt, J=7.9, 1.6 Hz, 1H), 8.62 (dd, J=4.7, 1.4 Hz, 1H), 7.99 (d, J=7.5 Hz, 2H), 7.87 (d, J=2.8 Hz, 1H), 7.59-7.47 (m, 2H), 7.45-7.32, (m, 3H), 7.30-7.09 (m, 2H).

To a mixture of 4-chloro-6-methoxy-2-(pyridin-3-yl)quinazoline (0.50 g, 1.84 mmol) and 5′-fluorospiro[[1,3]-dioxolane-2,3′-indulin]-2′-one (0.42 g, 2.02 mmol) in dry DMSO (4 mL) was added KOH powder (0.11 g, 2.02 mmol). The reaction mixture was stirred for 15 h at room temperature and then the reaction mixture was poured into water. The aqueous layer was washed with ethyl acetate 20 mL) and the resulting aqueous layer was acidified with 5N HCl to give a precipitate. The solid was filtered to give 2-(5-fluoro-2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)phenyl)-1,3-dioxolane-2-carboxylic acid as a light yellow powder (0.27 g, 0.58 mmol, 32%). LCMS m/z=432 (M+1) (Method C) ¹H NMR (300 MHz, DMSO) δ 9.50-9.38 (m, 2H), 8.69-8.59 (m, 2H), 8.42 (dd, J=9.7, 5.3 Hz, 1H), 7.86 (d, J=9.1 Hz, 1H), 7.64 (d, J=2.6 Hz, 1H), 7.61-7.41 (m, 4H), 4.25-4.11 (m, 4H), 3.98 (s, 3H).

In a 50 mL round-bottomed flask was added 2,4-dichloro-6-iodoquinazoline (0.52 g, 1.6 mmol), 3-chloro-4-fluoroaniline (0.30 g, 2.1 mmol), and sodium acetate (0.20 g, 2.4 mmol) in THF (6 mL) and water (2 mL) to give a brown suspension. After being stirred at room temperature for 6 days, the reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (2×10 mL). The organic layers were combined and washed with brine (1×20 mL), dried over Na₂SO₄, filtered and concentrated. The resulting product, was washed with CH₂Cl₂ and dried to give 0.51 g of 2-chloro-N-(3-chloro-4-fluorophenyl)-6-iodoquinazolin-4-amine as a tight brown solid in a 73% yield, ¹H NMR (300 MHz, DMSO) δ 10.29 (s, 1H), 8.95 (s, 1H), 8.14 (dd, J=1.5, 9.0 Hz, Ft), 8.06 (dd, J=2.7, 6.6 Hz, 1H), 7.81-7.76 (m, 1H), 7.52-7.46 (m, 2H).

In a 50 mL round-bottomed flask was added 2-chloro-N-(3-chloro-4-fluorophenyl)-6-iodoquinazolin-4-amine (200 mg, 0.46 mmol), N,N-dimethylpropargylamine (99 mL, 0.92 mmol), NEt₃ (0.26 mL, 1.84 mmol), CuI (0.88 mg, 4.6 mmol) and PdCl₂(PPh₃)₂ (6.5 mg, 9.2 mmol) in DMF (3 mL) to give a light yellow suspension. The mixture was stirred at room temperature overnight under an argon atmosphere. The reaction mixture was diluted with water (10 mL) and ethyl acetate (10 mL) and then a precipitate formed. The resulting precipitate was removed by filtration through Celite. The filtrate was extracted with ethyl acetate (2×10 mL). The combined organic layer was washed with water (1×15 mL) and brine (1×15 mL) and was dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted with CH₂Cl₂/MeOH 1:0 to 9:1). The desired product was washed with CH₂Cl₂ to give 61 mg of 2-chloro-N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)prop-1-ynyl)quinazolin-4-amine, as pale yellow solid in a 34% yield. LCMS m/z=389 (M+1) (Method C) (retention time=2.2.4 min). ¹H NMR (300 MHz, DMSO) δ 10.30 (s, 1H), 8.68 (s, 1H), 8.07 (dd, J=2.7, 6.9 Hz, 1H), 7.86 (dd, J=1.8, 8.7 Hz, 1H), 7.81-7.70 (m, 1H), 7.68 (d, J=8.4 Hz, 1 H), 7.49 (t, 3=9.2 Hz, 1H), 3.52 (s, 2H), 2.2.8 (s, 6H).

In a 50 mL round-bottomed flask was added 2-chloro-N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)prop-1-ynyl)quinazolin-4-amine, (61 mg, 0.16 mmol), 3-pyridineboronic acid (25 mg, 0.20 mmol), K₂CO₃ (0.11 mg, 0.78 mmol) and PdCl₂(PPh₃)₂, (5.5 mg, 7.8 mM) in dioxane (2 mL) to give a yellow suspension. The mixture was heated at reflux for 3 h under argon. After cooling to room temperature, water (10 mL) and ethyl acetate (10 mL) were added to the mixture to form a precipitate. The resulting precipitate was filtered through Celite. The filtrate was extracted with ethyl acetate (2×10 mL) and the combined organic layers were washed with water (1×15 mL) and brine (1×15 mL) and then dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted with AcOEt/MeOH 1:0 to 9:1). The desired product was washed with CH₂Cl₂ to give 25 mg of N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)prop-1-ynyl)-2-(pyridin-3-yl)quinazolin-4-amine as a light brown solid in 37% yield. LCMS m/z=432 (M+1) (Method C) (retention time=1.86 ruin). ¹H NMR (300 MHz, DMSO) δ 10.13 (s, 1H), 9.51 (s, 1H), 8.77-8.56 (m, 3H), 8.26 (dd, 3=6.9, 2.5 Hz, 1H), 8.02-7.78 (m, 3H), 7.64-7.47 (m, 2H), 3.54 (s, 2H), 2.30 (s, 6H).

A mixture of 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (200 mg, 0.283 mmol), (isocyanatomethyl)benzene (5 mL) and Et₃N (57 mg, 0.283 mmol) in tetrahydrofuran (THF) (10 in T) was stirred at room temperature overnight. Water (10 mL) was added to the above mixture and the mixture was concentrated in vacuo. The precipitate was collected by filtration and washed with water (6 mL×2) to afford 72 mg of the desired product as a white solid in a yield 26.0%. LCMS: rt=1.829 min, [MH]⁺=491.1 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.05 (s, 1H), 9.63 (s, 1H), 9.07 (d, J=8.5 Hz, 1H), 8.87 (d, J=8.0 Hz, 1H), 8.79 (d, J=3.7 Hz, 1H), 8.59 (t, J=6.1 Hz, 1H), 8.49 (s, 1H), 8.02-7.89 (m, 4H), 7.82-7.68 (m, 3H), 7.46-7.22 (m, 6H), 4.35 (d, J=6.1 Hz, 2H).

4-(2-carbamoylphenylamino)-2-(pyridin-3-yl)quinazolin-6-yl ethylcarbamate was synthesized in a similar manner to that described for 4-(2-carbamoylphenylamino)-2-(pyridin-3-yl)quinazolin-6-yl benzylcarbamate substituting isocyanatoethane for (isocyanatomethyl)benzene. The resulting product was analyzed by LCMS: rt=1.11 min, [M+1]⁺=429.0, ¹H-NMR (400 MHz, DMSO-d₆): δ 13.06 (s, 1H), 9.66 (s, 1H), 9.10 (d, 0.1=8.3 Hz, 1H), 8.87-8.80 (m, 2H), 8.51 (s, 1H), 8.06-7.94 (m, 4H), 7.88 (s, 1H), 7.79-7.63 (m, 3H), 7.24 (t, J=7.6 Hz, 1H), 3.22-3.11 (m, 2H), 1.14 (t, J=7.2 Hz, 3H).

A mixture of 4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazoline-carbonitrile (1.5 g, 4.0 mmol) in HCl (cone, 25 mL) was heated to 100° C. and stirred overnight. After cooling and filtration, the solid was washed with water (10 mL) twice to give 1.4 g of the desired product 4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazoline-6-carboxylic acid as a yellow solid in a 89.0% yield. LCMS: r.t=1.271 min, [M+H]⁺=394.9

A mixture of 4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazoline-6-carboxylic acid (900 mg, 2.4 mmol), DIPEA (620 mg, 4.8 mmol) and HATU (1.4 g, 3.6 mmol) in DMF (10 mL) was pre-stirred for 20 min, and 2,2,2-trifluoro-N-methylethanamine (360 mg, 2.4 mmol) was added in one portion. The resulting mixture was stirred at room temperature overnight. Water (80 mL) was added and a precipitate formed which was collected and purified by prep-HPLC to afford 490 mg of the desired product 4-(3-chloro-4-fluorophenylamino)-N-methyl-2-(pyridin-3-yl)-N-(2,2,2-trifluoroethyl)quinazoline-6-carboxamide as a white solid in 42.0% yield. LCMS: r.t=1.970 min, 490.0 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.79 (brs, 1H), 9.59 (s, 1H), 9.19 (d, J=7.6 Hz, 1H), 9.04 (d, J=4.8 Hz, 1H), 8.90 (s, 1H), 8.22-8.00 (m, 5H), 7.62 (t, J=9.2 Hz, 1H), 4.55-4.52 (m, 2H), 3.22 (s, 3H).

To a mixture of 4-(3-chloro-4-fluorophenylamino)-N-methyl-2-(pyridin-3-yl)-N-(2,2,2-trifluoroethyl)quinazoline-6-carboxamide (60 mg, 0.12 mmol) THF (1 mL) was added BH₃-THF (2 mol/L, 1 mL). The mixture was stirred at room temperature overnight. Methanol (0.2 mL) was added to quench the reaction mixture. The mixture was purified by prep-HPLC to give the desired product N-(3-chloro-4-fluorophenyl)-6-((methyl(2,2,2-trifluoroethyl)amino)methyl)-2-(pyridin-3-yl)quinazolin-4-amine (GL0001H-3309) as a white solid 15 mg in a yield of 26.0%. LCMS: r.t=2.154 min, [MH]⁺=476.1. ¹H-NMR (400 MHz, DMSO-d₆): δ 10.09 (s, 1H), 9.53 (s, 1H), 8.70-8.66 (m, 2H), 8.44 (s, 1H), 8.27-8.25 (m, 1H), 7.93-7.91 (m, 3H), 7.57-7.55 (m, 2H), 3.93 (s, 2H), 3.39-3.32 (m, 2H), 2.40 (s, 3H).

Synthesis of 4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)-N-(2,2,2-trifluoroethyl)quinazoline-6-carboxamide (compound 1139)

4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)-N-(2,2,2-trifluoroethyl)quinazoline-6-carboxamide was synthesized in a similar manner to that described for 4-(3-chloro-4-fluorophenylamino)-N-methyl-2-(pyridin-3-yl)-N-(2,2,2-trifluoroethyl)quinazoline-6-carboxamide substituting 2,2,2-trifluoroethylamine for 2,2,2-trifluoro-N-methylethylamine. The resulting product was analyzed. LCMS: r.t=1.934 min, [M+1]⁺=476.0. ¹H-NMR (400 MHz, DMSO-d₆): δ 10.43 (s, 1H), 9.54 (s, 1H), 9.32 (t, J=6.1 Hz, 1H), 9.14 (s, 1H), 8.72 (d, J=4.6 Hz, 1H), 8.68 (d, J=8.0 Hz, 1H), 8.32 (d, J=8.7 Hz, 1H), 8.27 (dd, J=6.7, 2.2 Hz, 1H), 7.98 (d, J=8.7 Hz, 1H), 7.96-7.90 (m, 1H), 7.62-7.51 (m, 2H), 4.27-4.14 (m, 2H).

Method E for Cyclization

E1: Sodium methoxide/Toluene

E2: NaOH/EtOH Method G for Coupling Conditions

G1: i-PrOH/85-100° C.

G2: THF/reflux

G3: i-AmOH/100-130° C.

G4: MeOH/microwave/150° C.

G5: i-AmOH/microwave/150° C.

G6: THF/Et₃N/reflux

Method D: N-(2-carbamoylphenyl)pyridazine-4-carboxamide (iii-c)

A mixture of pyridazine-4-carboxylic acid (500 mg, 4.0 mmol, 1.0 eq.), 2-aminobenzamide (603 mg, 4.4 mmol, 1.1 eq.) and HBTU (3.0 g, 8.0 mmol, 2.0 eq.) was suspended in 15 mL of DMF. DIPEA (2.0 mL, 1.56 g, 12.0 mmol, 3.0 eq.) was added dropwise at room temperature and was stirred over night. After quenching with water, the resulting precipitate was collected and washed with a small amount of DCM. A white solid (388 mg) was obtained, LCMS m/z=243.1 (M+1) (Method B) (retention time=0.99 min) was used in the next step without further purification.

Method E1: 2-(pyridazin-4-yl)quinazolin-4(3H)-one (iv-f)

A 100 mL round-bottom flask equipped with a Dean-Stark trap was charged with a mixture of N-(2-carbamoylphenyl)pyridazine-4-carboxamide (300 mg, 1.0 eq.), sodium methoxide (401 mg, 7.4 mmol, 6.0 eq.) and 10 mL of anhydrous toluene. The reaction mixture was heated to 110° C. and refluxed overnight. After cooling, the volatiles were removed in vacuo and the residue was quenched with a saturated aqueous solution of NH₄Cl (10 mL). The pH of the mixture was adjusted to 3 with 10% HCl in water. The solution was extracted with DCM (50 ml×3). The combined organic layers were washed with brine, dried over Na₂SO₄. After filtration and evaporation, 88 mg of a yellow solid was obtained, LCMS m/z=225.1 (M+1) (Method A) (retention time=1.10 min) which was used in the next step without further purification.

Method F5: 4-chloro-2-(pyridazin-4-yl)quinazoline (v-f)

A 100-mL round-bottom flask was charged with 2-(pyridazin-4-yl) quinazolin-4(3H)-one (30 mg) which was suspended in 3 mL of POCl₃. The reaction mixture was heated to reflux for 1 h. The reaction mixture turned to a clear brown solution. After cooling, 50 mL of ice/water was carefully added. An aqueous ammonia solution (25% by weight in water) was added dropwise to the mixture with stirring until the pH of the mixture was adjusted to 7˜8. An internal temperature of 0° C. was maintained by the addition of ice. The mixture was warmed to room temperature and extracted with DCM (50 ml×3). The combined organic layers were washed with brine, dried over Na₂SO₄. After filtration and evaporation, 32 mg was obtained as a light brown solid. LCMS m/z=242.9 (M+1) (Method B) (retention time=1.65 min). The solid was used directly in the next step without further purification.

Method G1: N-(3,4-difluorophenyl)-2-(pyridazin-4-yl)quinazolin-4-amine (vi-r)

(This method is representative of method G1, G2, and G3. These three methods can be implemented in a similar way except for substitution of the appropriate solvent and temperature) The mixture of 4-chloro-2-(pyridazin-4-yl)quinazoline (10 mg, 0.041 mmol, 1 eq.) and 3,4-difluorobenzenamine (11 mg, 0.082 mmol, 2 eq.) was suspended in i-PrOH. The mixture was heated at 85° C. overnight. After cooling, the resulting precipitate was filtered and purified on HPLC (Condition C). 7.3 mg of N-(3,4-difluorophenyl)-2-(pyridazin-4-yl)quinazolin-4-amine was obtained (yield 53%). LCMS m/z=336.0 (M+1) (Method B) (retention time=1.731 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 10.00 (dd, J=2.2, 1.3 Hz, 1H), 9.44 (dd, J=5.4, 1.2 Hz, 1H), 8.59 (d, J=8.1 Hz, 1H), 8.39 (dd, J=5.4, 2.4 Hz, 1H), 8.05-8.13 (m, 1H), 7.99 (s, 1H), 7.97 (d, J=3.6 Hz, 1H), 7.72-7.79 (m, 2H), 7.51-7.61 (m, 1H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 1 and 64 (prepared according to method procedure A-G as designated).

TABLE 21 Puri- Method Molec- ¹H- ty for Num- Salt ular NMR LCMS per- Coup- ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol cent ling 1140

402.66 1H-NMR (400 MHz, CD3OD): δ 9.40 (s, 1H), 9.84-9.86 (m, 2H), 8.52 (d, J = 8.4 Hz, 1H), 8.15 (s, 1H), 8.02 (s, 1H), 7.84 (dd, J = 9.2, 2.4 Hz, 1H), 7.66- 7.67 (m, 2H). CD3OD 402.0, 404.0, 405.9 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1141

386.21 1H-NMR (400 MHz, DMSO-d6): δ 10.78 (s, 1H), 9.49 (s, 1H), 8.89 (d, J = 10.8 Hz, 2H), 8.75 (d, J = 8.8 Hz, 1H), 8.44 (dd, J = 6.8, 2.4 Hz, 1H), 8.12 (d, J = 2.0 Hz, 1H), 7.94- 7.99 (m, 1H), 7.87 (dd, J = 8.8, 2.0 Hz, 1H), 7.56 (t, J = 9.2 Hz, 1H). DMSO 386.0, 388.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1142

369.76 1H-NMR (400 MHz, CD3OD): δ 9.40 (s, 1H), 8.76 (d, J = 10.8 Hz, 2H), 8.40 (d, J = 8.8 Hz, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.80-7.86 (m, 1H), 7.68 (dd, J = 8.8, 1.6 Hz, 1H), 7.52 (d, J = 9.2 Hz, 1H), 7.33 (q, J = 9.2 Hz, 1H). CD3OD 370.0, 372.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1143

376.8 1H-NMR (400 MHz, CD3OD): δ 9.55 (s, 1H), 8.80 (d, J = 7.2 Hz, 3H), 8.26 (d, J = 8.8 Hz, 1H), 8.04 (s, 1H), 7.85 (d, J = 6.8 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.66 (t, J = 7.2 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H). CD3OD 377.1, 379.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1144

358.78 1H-NMR (400 MHz, CD3OD): δ 9.39 (d, J = 1.6 Hz, 1H), 8.79 (d, J = 6.8 Hz, 2H), 8.47 (d, J = 9.2 Hz, 1H), 8.20 (s, 1H), 8.05-8.10 (m, 2H), 7.77 (dd, J = 8.8, 2.0 Hz, 1H), 7.63- 7.66 (m, 2H). CD3OD 359.0, 361.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1145

399.78 1H-NMR (400 MHz, DMSO-d6): δ 10.63 (s, 1H), 9.52 (d, J = 1.2 Hz, 1H), 8.86 (t, J = 6.0 Hz, 2H), 8.77 (d, J = 8.4 Hz, 1H), 8.12 (d, J = 15.6 Hz, 2H), 7.85 (d, J = 8.8 Hz, 2H), 7.53 (t, J = 8.0 Hz, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.04 (dd, J = 8.0, 1.6 Hz, 1H). DMSO 400.0, 402.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1146

402.66 1H-NMR (400 MHz, CD3OD): δ 9.40 (s, 1H), 8.85-8.88 (m, 2H), 8.53 (d, J = 9.2 Hz, 1H), 8.17 (d, J = 2.0 Hz, 1H), 7.80-7.88 (m, 3H), 7.46 (s, 1H). CD3OD 401.9, 403.9, 405.9 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1147

377.78 1H-NMR (400 MHz, DMSO-d6): δ 12.28 (s, 1H), 9.58 (s, 1H), 9.14 (d, J = 8.4 Hz, 1H), 8.87 (s, 1H), 8.80 (d, J = 2.0 Hz, 1H), 8.28 (d, J = 9.2 Hz, 1H), 8.07- 8.12 (m, 2H), 7.86 (dd, J = 8.8, 2.0 Hz, 1H), 7.77 (t, J = 8.8 Hz, 1H), 7.26 (t, J = 7.6 Hz, 1H). DMSO 378.1, 380.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1148

381.79 1H-NMR (400 MHz, DMSO-d6): δ 11.69- 11.49 (m, 1H), 9.40 (d, J = 1.2 Hz, 1H), 9.00-8.86 (m, 3H), 8.24 (dd, J = 6.6, 2.1 Hz, 1H), 7.91 (ddd, J = 8.9, 4.2, 2.6 Hz, 1H), 7.71 (d, J = 1.4 Hz, 1H), 7.61 (t, J = 9.0 Hz, 1H), 7.49 (dd, J = 9.2, 2.3 Hz, 1H), 4.00 (s, 3H). DMSO 382.1, 384.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1149

395.36 1H-NMR (400 MHz, DMSO-d6): δ 9.96 (s, 1H), 9.57 (d, J = 1.4 Hz, 1H), 8.83- 8.74 (m, 2H), 8.57 (d, J = 9.1 Hz, 1H), 8.28 (t, J = 2.0 Hz, 1H), 7.86 (dd, J = 8.2, 1.2 Hz, 1H), 7.50-7.32 (m, 3H), 7.31 (t, J = 74.0 Hz, 1H), 6.94 (dd, J = 8.0, 2.2 Hz, 1H), 3.98 (s, 3H). DMSO 396.1, (M + 1), 397.2 (M + 2) Method B (NH4HCO3) 95 Method C, G1 1150

383.33 1H-NMR (400 MHz, DMSO-d6): δ 10.27 (s, 1H), 9.57 (s, 1H), 8.80 (dd, J = 19.8, 1.7 Hz, 2H), 8.72- 8.66 (m, 1H), 8.50 (s, 1H), 8.07-7.94 (m, 3H), 7.75 (t, J = 7.2 Hz, 1H), 7.57 (t, J = 8.2 Hz, 1H), 7.14 (d, J = 8.8 Hz, 1H). DMSO 384.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1151

385.42 1H-NMR (400 MHz, DMSO-d6): δ 13.01 (s, 1H), 10.04 (s, 1H), 9.40 (d, J = 5.4 Hz, 1H), 9.20 (d, J = 8.4 Hz, 1H), 8.48 (s, 1H), 8.42 (dd, J = 5.3, 1.9 Hz, 1H), 8.04-7.94 (m, 2H), 7.84 (d, J = 9.2 Hz, 1H), 7.75 (t, J = 7.9 Hz, 1H), 7.58 (d, J = 9.2 Hz, 1H), 7.20 (t, J = 7.5 Hz, 1H), 7.13 (s, 1H), 3.15 (s, 6H). DMSO 386.0 (M + 1) Method A (TFA) 95 Method D, G1 1152

HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.96 (s, 1H), 9.97 (d, J = 1.1 Hz, 1H), 9.55 (d, J = 5.5 Hz, 1H), 8.61 (dd, J = 5.5, 2.2 Hz, 1H), 8.15 (dd, J = 6.8, 2.6 Hz, 1H), 8.08 (d, J = 9.3 Hz, 1H), 7.94 (ddd, J = 8.9, 4.3, 2.6 Hz, 1H), 7.74 (s, 1H), 7.62 (dd, J = 9.4, 2.5 Hz, 1H), 7.56 (t, J = 9.1 Hz, 1H), 3.16 (s, 6H). DMSO 395.1, 397.1 (M + 1) Method A (TFA) 95 Method D, G1 1153

HCl 408.4 1H-NMR (400 MHz, DMSO-d6): δ 10.71 (brs, 1H), 10.01-9.99 (m, 1H), 9.52 (dd, J = 5.5, 1.0 Hz, 1H), 8.60 (dd, J = 5.5, 2.3 Hz, 1H), 8.07 ((d, J = 9.2 Hz 1H), 7.85-7.78 (m, 2H), 7.71 (s, 1H), 7.65 (dd, J = 9.3, 2.5 Hz, 1H), 7.56 (t, J = 8.2 Hz, 1H), 7.33 (t, J = 74.0 Hz, 1H), 7.09 (dd, J = 8.1, 2.1 Hz, 1H), 3.17 (s, 6H). DMSO 409.1 (M + 1) Method A (TFA) 95 Method D, G1 1154

372.38 1H-NMR (400 MHz, DMSO-d6): δ 13.13 (s, 1H), 9.63 (d, J = 1.2 Hz, 1H), 9.34 (d, J = 7.6 Hz, 1H), 8.91- 8.84 (m, 1H), 8.79 (d, J = 2.4 Hz, 1H), 8.49 (s, 1H), 8.12 (d, J = 9.6 Hz, 1H), 8.03- 7.85 (m, 2H), 7.75- 7.61 (m, 1H), 7.48- 7.30 (m, 2H), 7.28- 7.06 (m, 1H), 3.99 (s, 3H). DMSO 373.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1155

381.79 1H-NMR (400 MHz, DMSO-d6): δ 10.16 (s, 1H), 9.99-9.95 (m, 1H), 9.42 (dd, J = 5.2, 1.2 Hz, 1H), 8.58-8.51 (m, 1H), 8.35 (dd, J = 5.2, 2.4 Hz, 1H), 8.21 (dd, J = 6.8, 2.4 Hz, 1H), 7.93 (ddd, J = 8.8, 4.2, 2.7 Hz, 1H), 7.53 (dd, J = 11.7, 6.4 Hz, 1H), 7.32 (dd, J = 6.6, 2.6 Hz, 2H), 3.97 (s, 3H). DMSO 382.0, 384.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1156

395.36 1H-NMR (400 MHz, DMSO-d6) δ 10.07 (s, 1H), 10.01 (d, J = 1.3 Hz, 1H), 9.43 (dd, J = 5.2, 1.2 Hz, 1H), 8.55 (d, J = 10.0 Hz, 1H), 8.40 (dd, J = 5.2, 2.0 Hz, 1H), 7.91 (d, J = 2.0 Hz, 1H), 7.86- 7.77 (m, 1H), 7.55-7.35 (m, 3H), 7.32 (t, J = 74.0 Hz, 1H), 7.01 (dd, J = 8.0, 2.0 Hz, 1H), 3.99 (s, 3H). DMSO 396.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1157

376.80 1H-NMR (400 MHz, DMSO-d6): δ 13.34 (s, 1H), 9.61 (d, 1H), 9.28 (d, J = 8.4 Hz, 1H), 8.87 (s, 1H), 8.80 (s, 1H), 8.53 (s, 1H), 8.25 (s, 1H), 7.94-8.06 (m, 4H), 7.70 (t, J = 8.0 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H). DMSO 377.0, 379.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1158

358.78 1H-NMR (400 MHz, DMSO-d6): δ 10.35 (s, 1H), 9.54 (s, 1H), 8.77-8.84 (m, 4H), 8.32 (d, J = 8.0 Hz, 1H), 8.00-8.03 (m, 2H), 7.62-7.70 (m, 2H). DMSO 359.0, 361.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1159

386.21 1H-NMR (400 MHz, DMSO-d6): δ 10.55 (s, 1H), 9.50 (s, 1H), 8.83 8.87 (m, 3H), 8.47-8.49 (m, 1H), 7.96-8.06 (m, 3H), 7.54 (t, J = 9.2 Hz, 1H). DMSO 386.0, 388.0, 390.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1160

402.66 1H-NMR (400 MHz, DMSO-d6): δ 10.54 (s, 1H), 9.53 (s, 1H), 8.84-8.88 (m, 3H), 8.62 (d, J = 2.0 Hz, 1H), 8.01-8.07 (m, 3H), 7.73 (d, J = 8.8 Hz, 1H). DMSO 401.9, 403.9, 406.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1161

402.66 1H-NMR (400 MHz, DMSO-d6): δ 10.42 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 8.87- 8.88 (m, 1H), 8.82 (d, J = 2.4 Hz, 1H), 8.36 (d, J = 2.0 Hz, 2H), 8.00-8.07 (m, 2H), 7.40 (t, J = 1.6 Hz, 1H). DMSO 401.9, 403.8, 405.8 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1162

468.25 1H-NMR (400 MHz, DMSO-d6): δ 13.36 (s, 1H), 9.59 (d, J = 1.2 Hz, 1H), 9.15- 9.12 (m, 1H), 8.90- 8.85 (m, 2H), 8.68 (d, J = 1.2 Hz, 1H), 8.52 (s, 1H), 8.28- 8.25 (m, 1H), 8.07 (s, 1H), 7.99-7.96 (m, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.74-7.70 (m, 1H), 7.28 (t, J = 7.6 Hz, 1H). DMSO 469.0 (M + 1) Method B (NH4HCO3) 90 Method C, G1 1163

491.23 1H-NMR (400 MHz, DMSO-d6): δ 10.83 (s, 1H), 9.32 (s, 1H), 9.07 (s, 1H), 8.74 (s, 2H), 8.16 (dd, J = 8.0, 1.6 Hz, 1H), 7.87 (s, 1H), 7.74- 7.64 (m, 2H), 7.39 (t, J = 8.0 Hz, 1H), 7.16 (t, J = 74.0 Hz, 1H), 6.96-6.92 (m, 1H). DMSO 492.0 (M + 1) Method B (NH4HCO3) 90 Method C, G1 1164

477.66 1H-NMR (400 MHz, DMSO-d6): δ 11.48 (s, 1H), 9.42 (s, 1H), 9.34 (s, 1H), 8.95- 8.93 (m, 2H), 8.35- 8.30 (m, 2H), 7.97- 7.90 (m, 2H), 7.60 (t, J = 9.0 Hz, 1H). DMSO 478.0, 480.0 (M + 1) Method B (NH4HCO3) 90 Method C, G1 1165

413.81 1H-NMR (400 MHz, DMSO-d6): δ 10.07 (s, 1H), 9.99 (s, 1H), 9.40 (d, J = 5.6 Hz, 1H), 8.56 (d, J = 1.6 Hz, 1H), 8.36 (dd, J = 5.2, 2.0 Hz, 1H), 7.87 (m, 1H), 7.81 (m, 1H), 7.53 (t, J = 7.8 Hz, 1H), 7.30 (t, J = 74.0 Hz, 1H), 8.36 (dd, J = 8.4, 2.0 Hz, 1H), 2.70 (s, 3H). DMSO 414.1, 416.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1166

400.24 1H-NMR (400 MHz, DMSO-d6): δ 10.16 (s, 1H), 10.01 (s, 1H), 9.46 (d, J = 5.2 Hz, 1H), 8.56 (d, J = 1.6 Hz, 1H), 8.39 (dd, J = 5.4, 2.2 Hz, 1H), 8.20 (dd, J = 7.2, 2.6 Hz, 1H), 7.95-7.91 (m, 1H), 7.89 (s, 1H), 7.57 (t, J = 9.0 Hz, 1H), 2.75 (s, 3H). DMSO 400.0, 402.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1167

409.39 1H-NMR (400 MHz, DMSO-d6): δ 10.05- 10.3 (m, 2H), 9.45 (dd, J = 5.2, 1.2 Hz, 1H), 8.42 (dd, J = 5.2, 1.2 Hz, 1H), 8.06 (d, J = 2.8 Hz, 1H), 7.97-7.94 (m, 2H), 7.86 (dd, J= 8.0, 1.2 Hz, 1H), 7.66-7.60 (m, 2H), 7.38 (t, J = 74.0 Hz, 1H), 7.10-7.08 (m, 1H), 4.32 (q, J = 6.8 Hz, 2H), 1.51 (t, J = 7.0 Hz, 3H). DMSO 410.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1168

379.36 1H-NMR (400 MHz, DMSO-d6): δ 10.13 (s, 1H), 10.07 (d, J = 2.0 Hz, 1H), 9.44 (dd, J = 5.2, 2.4 Hz, 1H), 8.48-8.44 (m, 2H), 7.93 (t, J = 2.0 Hz, 1H), 7.86- 7.84 (m, 2H), 7.66- 7.62 (m, 1H), 7.54 (t, J = 8.4 Hz, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.02 (dd, J = 8.0, 2.4 Hz, 1H), 2.77 (s, 3H). DMSO 380.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1169

444.23 1H-NMR (400 MHz, DMSO-d6): δ 10.17 (s, 1H), 9.55 (s, 1H), 8.98 (s, 1H), 8.79 (d, J = 12.8 Hz, 2H), 8.26 (s, 1H), 8.08 (d, J = 9.2 Hz, 1H), 7.92-7.88 (m, 2H), 7.52-7.50 (m, 1H), 7.32 (t, J = 71.6 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H). DMSO 444.0, 446.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1170

430.66 1H-NMR (400 MHz, DMSO-d6): δ 10.11 (s, 1H), 9.52 (s, 1H), 8.89 (d, J = 1.2 Hz, 1H), 8.83 (s, 1H), 8.77 (d, J = 2.4 Hz, 1H), 8.56 (dd, J = 6.8, 2.4 Hz, 1H), 8.05 (dd, J = 9.2, 2.0 Hz, 1H), 8.02- 7.96 (m, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.49 (t, J = 9.2 Hz, 1H). DMSO 430.0, 432.0, 434.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1171

386.41 1H-NMR (400 MHz, DMSO-d6): δ 13.07 (s, 1H), 9.63 (s, 2H), 9.33 (s, 1H), 8.95 (d, J = 8.0 Hz, 1H), 8.50 (s, 1H), 7.99- 7.94 (m, 3H), 7.76- 7.71 (m, 1H), 7.62- 7.59 (m, 2H), 7.24 (t, J = 7.4 Hz, 1H), 4.23 (q, J = 7.0 Hz, 2H), 1.46 (t, J = 7.0 Hz, 3H). DMSO 387.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1172

372.38 1H-NMR (400 MHz, DMSO-d6): δ 13.11 (s, 1H), 9.61 (s, 2H), 9.34 (s, 1H), 8.91 (d, J = 8.0 Hz, 1H), 8.49 (s, 1H), 7.98- 7.95 (m, 3H), 7.72 (t, J = 8.0 Hz, 1H), 7.62-7.60 (m, 2H), 7.24 (t, J = 7.6 Hz, 1H), 3.97 (s, 3H). DMSO 373.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1173

HCl 379.32 1H-NMR (400 MHz, DMSO-d6): δ 10.55 (brs, 1H), 9.59 (s, 2H), 9.35 (s, 1H), 8.68 (d, J = 8.4 Hz, 1H), 8.09-8.07 (m, 1H), 8.00-7.96 (m, 2H), 7.76-7.72 (m, 1H), 7.67 (dd, J = 8.8, 2.0 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H). DMSO 380.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1174

HCl 464.47 1H-NMR (400 MHz, DMSO-d6): δ 10.14 (s, 1H), 9.59 (s, 1H), 8.80 (m, 2H), 8.62 (d, J = 7.6 Hz, 1H), 8.30 (s, 1H), 7.90 (s, 2H), 7.70 (d, J = 7.6 Hz, 1H), 7.53- 7.45 (m, 1H), 7.39- 6.86 (m, 1H), 7.30 (t, J = 74.1 Hz, 1H), 3.73 (s, 2H), 3.63- 3.58 (m, 4H), 2.48- 2.43 (m, 4H). DMSO 465.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1175

357.37 1H-NMR (400 MHz, DMSO-d6): δ 9.70 (s, 1H), 9.43 (d, J = 8.4 Hz, 1H), 8.90 (s, 1H), 8.78 (d, J = 2.0 Hz, 1H), 8.22 (d, J = 8.0 Hz, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 2.8 Hz, 1H), 7.60-7.65 (m, 2H), 7.09-7.13 (m, 3H), 2.76 (s, 3H). DMSO 358.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1176

365.79 1H-NMR (400 MHz, DMSO-d6): δ 10.02 (s, 1H), 9.62 (s, 1H), 8.85 (s, 1H), 8.76 (d, J = 2.4 Hz, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.03-8.07 (m, 1H), 7.81 (d, J = 6.8 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.49 (t, J = 9.2 Hz, 1H), 2.75 (s, 3H). DMSO 366.0, 368.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1177

379.36 1H-NMR (400 MHz, DMSO-d6): δ 10.02 (s, 1H), 9.64 (s, 1H), 8.83 (s, 1H), 8.76 (d, J = 2.0 Hz, 1H), 8.50 (d, J = 8.0 Hz, 1H), 8.38 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 6.8 Hz, 1H), 7.61 (t, J = 7.8 Hz, 1H), 7.49 (t, J = 8.4 Hz, 1H), 7.32 (t, J = 74.0 Hz, 1H), 6.95 (d, J = 7.2 Hz, 1H), 2.75 (s, 3H). DMSO 380.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1178

382.25 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.62 (s, 1H), 8.86 (t, J = 2.4 Hz, 1H), 8.78 (t, J = 3.2 Hz, 2H), 8.52 (d, J = 8.4 Hz, 1H), 8.10-8.13 (m, 1H), 7.83 (d, J = 7.2 Hz, 1H), 7.68 (d, J = 9.2 Hz, 1H), 7.63 (t, J = 7.6 Hz, 1H), 2.75 (s, 3H). DMSO 381.9, 383.9 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1179

349.34 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.60 (s, 1H), 8.87 (s, 1H), 8.78 (d, J = 2.4 Hz, 1H), 8.50-8.60 (m, 2H), 7.80-7.85 (m, 2H), 7.61 (t, J = 7.8 Hz, 1H), 7.46-7.54 (m, 1H), 2.74 (s, 3H). DMSO 350.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1180

382.25 1H-NMR (400 MHz, DMSO-d6), δ 10.20 (s, 1H), 9.62 (s, 1H), 8.85 (s, 1H), 8.77 (d, J = 2.8 Hz, 1H), 8.47-8.52 (m, 3H), 7.81 (d, J = 3.2 Hz, 1H), 7.60 (t, J = 7.8 Hz, 1H), 7.31 (t, J = 1.6 Hz, 1H), 2.51 (s, 3H). DMSO 381.9, 383.9 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1181

338.37 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.64 (s, 1H), 8.86 (d, J = 9.2 Hz, 2H), 8.78 (d, J = 8.0 Hz, 1H), 8.51 (d, J = 8.0 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 7.2 Hz, 1H), 7.61-7.65 (m, 3H), 2.76 (s, 3H). DMSO 339.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1182

383.33 1H-NMR (400 MHz, DMSO-d6): δ 10.24 (s, 1H), 9.99 (s, 1H), 9.41 (d, J = 5.2 Hz, 1H), 8.62 (d, J = 8.4 Hz, 1H), 8.36- 8.38 (m, 1H) 8.10 (s, 1H), 7.95-7.98 (m, 3H), 7.73-7.74 (m, 1H), 7.62 (t, J = 8.0 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H). DMSO 384.2 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1183

365.34 1H-NMR (400 MHz, DMSO-d6): δ 10.19 (s, 1H), 10.01 (s, 1H), 9.41-9.43 (m, 1H), 8.63 (d, J = 8.0 Hz, 1H), 8.39- 8.41 (m, 1H), 7.93- 7.97 (m, 3H), 7.84 (d, J = 8.4 Hz, 1H), 7.74 (m, 1H), 7.54- 7 56 (m, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.02-7.04 (m, 1H). DMSO 366.2 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1184

398.25 1H-NMR (400 MHz, DMSO-d6): δ 10.27 (s, 1H), 9.96 (s, 1H), 9.44 (d, J = 4.8 Hz, 1H), 8.40-8.41 (m, 1H), 8.29 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 2.4 Hz, 1H), 7.99-8.02 (m, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.56- 7.58 (m, 1H), 3.99 (s, 3H). DMSO 398.0, 400.0, 402.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1185

381.79 1H-NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H), 9.36-9.38 (m, 1H), 8.27-8.29 (m, 1H), 8.14-8.16 (m, 1H), 7.51 (s, 1H), 7.83-7.91 (m, 3H), 7.51-7.56 (m, 2H), 3.97 (s, 3H). DMSO 382.1, 384.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1186

365.34 1H-NMR (400 MHz, DMSO-d6): δ 9.95- 10.00 (m, 2H), 9.40 (d, J = 5.6 Hz, 1H), 8.32-8.33 (m, 1H), 8.06 (m, 1H), 7.96 (s, 1H), 7.89 (d, J = 9.2 Hz, 1H), 7.69 (m, 1H), 7.54-7.59 (m, 2H), 3.98 (s, 3H). DMSO 366.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1187

354.36 1H-NMR (400 MHz, DMSO-d6): δ 10.00 (s, 1H), 9.90 (m, 1H), 9.35-9.36 (m, 1H), 8.23-8.30 (m, 3H), 7.84-7.90 (m, 2H), 7.62-7.71 (m, 2H), 7.54-7.57 (m, 1H), 3.96 (s, 3H). DMSO 355.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1188

413.35 1H-NMR (400 MHz, DMSO-d6): δ 9.96- 10.0 (m, 2H), 8.39- 8.40 (m, 1H), 8.31- 8.33 (m, 1H), 8.07 (s, 1H), 7.88-7.96 (m, 3H), 7.57-7.67 (m, 2H), 7.22 (d, J = 8.0 Hz, 1H), 4.01 (s, 3H). DMSO 414.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1189

373.36 1H-NMR (400 MHz, DMSO-d6): 12.15 (s, 1H), 10.02 (s, 1H), 9.41 (d, J = 5.2 Hz, 1H), 8.94 (d, J = 7.6 Hz, 1H), 8.41 (m, 1H), 8.09 (d, J = 7.6 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.80 (t, J = 8.4 Hz, 1H), 7.60-7.62 (m, 2H), 7.25 (t, J = 7.6 Hz, 1H), 4.01 (s, 3H). DMSO 374.1, 376.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1190

398.25 1H-NMR (400 MHz, DMSO-d6): δ 9.95 (s, 1H), 9.54 (s, 1H), 8.81-8.32 (m, 1H), 8.74 (d, J = 2.0 Hz, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.06 (dd, J = 8.8, 2.4 Hz, 1H), 8.00 (d, J = 2.4 Hz, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.60 (dd, J = 8.8, 2.4 Hz, 1H), 3.40 (s, 3H). DMSO 397.9, 400.0, 401.9 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1191

381.79 1H-NMR (400 MHz, DMSO-d6): δ 9.90 (s, 1H), 9.52 (s, 1H), 8.81 (m, 1H), 8.73 (d, J = 2.4 Hz, 1H), 8.53 (dd, J = 6.8, 2.4 Hz, 1H, 7.98- 8.03 (m, 2H), 7.91 (d, J = 9.2 Hz, 1H), 7.59 (dd, J = 5.2, 2.4 Hz, 1H), 7.51 (t, J = 8.8 Hz, 1H), 3.40 (s, 3H). DMSO 382.0, 384.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1192

365.34 1H-NMR (400 MHz, DMSO-d6): δ 9.89 (s, 1H), 9.52-9.53 (m, 1H), 8.81-8.82 (m, 1H), 8.73 (d, J = 2.4 Hz, 1H), 8.45-8.51 (m, 1H), 7.98 (m, 1H), 7.90 (d, J = 9.2 Hz, 1H), 7.75-7.78 (m, 1H), 7.47-7.59 (m, 2H), 3.40 (s, 3H). DMSO 366.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1193

354.36 1H-NMR (400 MHz, DMSO-d6): δ 10.06 (s, 1H), 9.54 (s, 1H), 8.74-8.81 (m, 3H), 8.35 (d, J = 8.4 Hz, 1H), 8.04 (m, 1H), 7.92-7.95 (m, 1H), 7.59-7.69 (m, 3H), 3.40 (s, 3H). DMSO 355.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1194

398.25 1H-NMR (400 MHz, DMSO-d6): δ 9.91 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H), 8.81 (t, J = 2.0 Hz, 1H), 8.74 (d, J = 2.4 Hz, 1H), 8.39 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 2.8 Hz, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.59 (dd, J = 8.8, 2.4 Hz, 1H), 7.32 (t, J = 1.6 Hz, 1H), 3.40 (s, 3H). DMSO 398.0, 399.9, 402.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1195

395.36 1H-NMR (400 MHz, DMSO-d6): δ 9.91 (s, 1H), 9.55 (m, 1H), 8.74-8.79 (m, 2H), 8.25 (s, 1H), 8.03 (d, J = 2.4 Hz, 1H), 7.92 (d, J = 9.2 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.60 (dd, J = 9.2, 2.4 Hz, 1H), 7.48- 7.52 (m, 1H), 7.34 (t, J = 74.0 Hz, 1H), 6.96-6.98 (m, 1H), 3.40 (s, 3H). DMSO 396.1 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1196

377.78 1H-NMR (400 MHz, DMSO-d6): δ 12.26 (s, 1H), 9.94 (s, 1H), 9.41-9.42 (m, 1H), 8.75 (d, J = 8.0 Hz, 1H), 8.33-8.34 (m, 1H), 8.19 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 7.6 Hz, 1H), 7.93 (m, 1H), 7.75- 7.77 (m, 2H), 7.05- 7.30 (m, 2H). DMSO 378.0, 380.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1197

343.34 1H-NMR (400 MHz, DMSO-d6): δ 13.86 (s, 1H), 12.39 (s, 1H), 9.62 (d, J = 0.8 Hz, 1H), 9.29 (d, J = 8.0 Hz, 1H), 8.87 (s, 1H), 8.80 (d, J = 2.4 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.12 (dd, J = 8.0, 1.6 Hz, 1H), 7.97- 8.05 (m, 3H), 7.75- 7.79 (m, 2H), 7.24 (t, J = 7.6 Hz, 1H). DMSO 344.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1198

372.38 1H-NMR (400 MHz, DMSO-d6): δ 13.05 (s, 1H), 9.99 (s, 1H), 9.39 (d, J = 5.2 Hz, 1H), 9.05 (d, J = 8.4 Hz, 1H), 8.47 (s, 1H), 8.36-8.38 (m, 1H), 7.85-7.98 (m, 3H), 7.71 (t, J = 7.6 Hz, 1H), 7.46- 7.60 (m, 2H), 7.20 (t, J = 7.6 Hz, 1H), 3.95 (s, 3H). DMSO 373.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1199

376.8 1H-NMR (400 MHz, DMSO-d6): δ 13.15 (s, 1H), 10.00 (s, 1H), 9.44 (d, J = 4.2 Hz, 1H), 8.95 (d, J = 8.4 Hz, 1H), 8.49 (s, 1H), 8.40-8.42 (m, 1H), 8.15 (d, J = 9.2 Hz, 1H), 7.91- 7.97 (m, 3H), 7.80 (t, J = 7.6 Hz, 1H), 7.73 (t, J = 7.6 Hz, 1H), 7.25 (t, J = 7.2 Hz, 1H). DMSO 377.0, 379.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1200

399.78 1H-NMR (400 MHz, DMSO-d6): δ 12.29 (s, 1H), 9.98 (s, 1H), 9.42 (d, J = 5.2 Hz, 1H), 8.66 (d, J = 9.2 Hz, 1H), 8.36- 8.38 (m, 1H), 8.00 (d, J = 1.5 Hz, 1H), 7.89 (s, 1H), 7.79- 7.81 (m, 2H), 7.49- 7.57 (m, 1H), 7.31 (t, J = 74.0 Hz, 1H), 7.04 (dd, J = 8.0, 1.2 Hz, 1H). DMSO 400.0, 401.9 (M + 1) Method A (TFA) 95 Method D, G1 1201

386.21 1H-NMR (400 MHz, DMSO-d6): δ 9.94 (s, 1H), 9.43 (d, J = 5.2 Hz, 1H), 8.72 (d, J = 8.8 Hz, 1H), 8.33 (dd, J = 5.6, 2.4 Hz, 1H), 8.21 (dd, J = 6.4, 1.6 Hz, 1H), 7.93- 7.98 (m, 2H), 7.78 (dd, J = 8.8, 2.0 Hz, 1H), 7.54 (t, J = 9.2 Hz, 2H). DMSO 386.0 387.8 (M + 1) Method A (TFA) 95 Method D, G1 1202

369.76 1H-NMR (400 MHz, DMSO-d6): δ 10.28 (s, 1H), 9.95 (m, 1H), 9.44-9.45 (m, 1H), 8.60 (d, J = 8.8 Hz, 1H), 8.32-8.34 (m, 1H), 8.02-8.08 (m, 1H), 7.98 (d, J = 6.4 Hz, 1H), 7.79 (dd, J = 9.2, 2.4 Hz, 1H), 7.70-7.72 (m, 1H), 7.56 (q, J = 9.2 Hz, 1H). DMSO 369.9, 371.0 (M + 1) Method A (TFA) 95 Method D, G1 1203

358.78 1H-NMR (400 MHz, DMSO-d6): δ 10.36 (s, 1H), 9.92 (s, 1H), 9.42 (d, J = 4.8 Hz, 1H), 8.59 (d, J = 8.4 Hz, 1H), 8.23- 8.33 (m, 3H), 7.96 (d, J = 1.6 Hz, 1H), 7.65-7.79 (m, 3H). DMSO 359.0, 361.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1204

402.66 1H-NMR (400 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.96 (s, 1H), 9.44 (d, J = 5.2 Hz, 1H), 8.60 (d, J = 8.4 Hz, 1H), 8.28- 8.35 (m, 2H), 7.94- 7.99 (m, 2H), 7.79 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H). DMSO 401.9, 403.9, 405.9 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1205

402.66 1H-NMR (400 MHz, DMSO-d6): δ 9.90 (s, 1H), 9.42 (d, J = 4.8 Hz, 1H), 8.58 (d, J = 8.8 Hz, 1H), 8.27 (s, 1H), 8.07 (s, 2H), 7.92 (s, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H). DMSO 401.9, 403.9, 405.9 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1206

351.76 1H-NMR (400 MHz, DMSO-d6): δ 10.59 (s, 1H), 9.43 (m, 1H), 9.07 (d, J = 5.2 Hz, 1H), 8.71 (d, J = 8.4 Hz, 1H), 8.50 (dd, J = 6.4, 2.0 Hz, 1H), 8.31 (dd, J = 5.2, 0.8 Hz, 1H), 8.00-8.09 (m, 3H), 7.80 (t, J = 7.2 Hz, 1H), 7.53 (t, J = 9.2 Hz, 1H). DMSO 352.0, 354.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1207

342.35 1H-NMR (400 MHz, DMSO-d6): δ 13.31 (s, 1H), 9.38-9.43 (m, 2H), 9.05 (d, J = 5.2 Hz, 1H), 8.52 (s, 1H), 8.47 (d, J = 5.2 Hz, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.95-8.04 (m, 4H), 7.82 (t, J = 7.2 Hz, 1H), 7.70 (t, J = 7.6 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H). DMSO 343.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1208

365.34 1H-NMR (400 MHz, DMSO-d6): δ 10.13 (s, 1H), 9.37 (d, J = 1.2 Hz, 1H), 9.01 (d, J = 5.2 Hz, 1H), 8.68 (d, J = 8.4 Hz, 1H), 8.40 (dd, J = 5.2, 1.2 Hz, 1H), 8.28 (t, J = 1.2 Hz, 1H), 7.92-8.00 (m, 3H), 7.77-7.79 (m, 1H), 7.47-7.52 (m, 1H), 7.34 (t, J = 74.0 Hz, 1H), 6.97 (dd, J = 8.4, 2.4 Hz, 1H). DMSO 366.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1209

HCl (batch 02) 351.76 1H-NMR (400 MHz, DMSO-d6): δ 10.82 (s, 1H), 9.59 (s, 2H), 9.36 (s, 1H), 8.74 (d, J = 8.4 Hz, 1H), 8.22 (dd, J = 6.8, 2.4 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 8.00 (t, J = 7.6 Hz, 1H), 7.90-7.94 (m, 1H), 7.75 (t, J = 7.2 Hz, 1H), 7.56 (t, J = 9.2 Hz, 1H). DMSO 352.0, 354.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1210

342.35 1H-NMR (400 MHz, DMSO-d6): δ 13.17 (s, 1H), 9.65 (s, 2H), 9.36 (s, 1H), 8.93 (d, J = 8.0 Hz, 1H), 8.51 (s, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.92-8.02 (m, 4H), 7.72-7.79 (m, 2H), 7.26 (t, J = 7.6 Hz, 1H). DMSO 343.1 (M + 1) Method B (NH4HCO3) 95 Method D, G4 1211

365.34 1H-NMR (400 MHz, DMSO-d6): δ 10.15 (s, 1H), 9.62 (s, 2H), 9.32 (s, 1H), 8.63 (d, J = 8.0 Hz, 1H), 7.94-7.97 (m, 3H), 7.81 (dd, J = 8.4, 1.2 Hz, 1H), 7.69- 7.74 (m, 1H), 7.50-7.55 (m, 1H), 7.31 (t, J = 74.0 Hz, 1H), 7.01 (dd, J = 8.4, 2.4 Hz, 1H). DMSO 366.1 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1212

399.78 1H-NMR (400 MHz, DMSO-d6): δ 10.27 (s, 1H), 10.01-10.02 (m, 1H), 9.44-9.46 (m, 1H), 8.62 (d, J = 8.4 Hz, 1H), 8.40 (dd, J = 5.2, 2.0 Hz, 1H), 8.04 (t, J = 1.6 Hz, 1H), 8.00 (d, J = 3.2 Hz, 2H), 7.94 (m, 1H), 7.76- 7.80 (m, 1H), 7.38 (t, J = 73.8 Hz, 1H), 7.16 (t, J = 2.0 Hz, 1H). DMSO 400.0, 402.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1213

398.79 1H-NMR (400 MHz, DMSO-d6): δ 10.16 (s, 1H), 9.56 (m, 1H), 8.69-8.72 (m, 2H), 8.59 (d, J = 8.0 Hz, 1H), 8.08 (d, J = 1.6 Hz, 1H), 7.94- 7.97 (m, 2H), 7.69- 7.73 (m, 1H), 7.55- 7.58 (m, 1H), 7.36 (t, J = 73.6 Hz, 1H), 7.13 (t, J = 2.0 Hz, 1H). DMSO 399.0, 401.1 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1214

365.34 1H-NMR (400 MHz, DMSO-d6): δ 11.17 (s, 1H), 9.49 (s, 1H), 8.88-8.92 (m, 3H), 8.16 (d, J = 8.0 Hz, 1H), 8.07 (t, J = 7.6 Hz, 2H), 7.84 (t, J = 8.0 Hz, 2H), 7.57 (t, J = 8.0 Hz, 1H), 7.36 (t, J = 74.0 Hz, 1H), 7.10-7.12 (m, 1H). DMSO 366.1 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1215

368.22 1H-NMR (400 MHz, DMSO-d6): δ 10.23 (s, 1H), 10.00 (s, 1H), 9.44 (d, J = 5.2 Hz, 1H), 8.58 (d, J = 8.0 Hz, 1H), 8.38 (dd, J = 2.4, 5.2 Hz, 1H), 8.32 (d, J = 2.0 Hz, 1H), 7.96-8.00 (m, 3H) 7.73-7.77 (m, 2H). DMSO 367.8, 369.8, 371.8 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1216

351.76 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.99 (s, 1H), 9.43 (d, J = 5.2 Hz, 1H), 8.58 (d, J = 8.4 Hz, 1H), 8.38 (dd, J = 5.2, 2.0 Hz, 1H), 8.22 (dd, J = 7.0, 2.6 Hz, 1H), 7.89-7.93 (m, 3H), 7.68-7.72 (m, 1H), 7.55 (t, J = 8.6 Hz, 1H). DMSO 351.9, 353.8 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1217

324.34 1H-NMR (400 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.99 (dd, J = 2.0, 1.2 Hz, 1H), 9.44 (dd, J = 5.2, 0.8 Hz, 1H), 8.61 (d, J = 8.4 Hz, 1H), 8.38-8.40 (m, 2H), 8.28-8.31 (m, 1H), 7.99 (s, 1H), 7.97 (d, J = 3.6 Hz, 1H), 7.66-7.80 (m, 3H). DMSO 325.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1218

368.22 1H-NMR (400 MHz, DMSO-d6): δ 11.94 (s, 1H), 9.44 (d, J = 0.8 Hz, 1H), 9.06 (d, J = 8.0 Hz, 1H), 9.00 (d, J = 2.4 Hz, 1H), 8.97 (t, J = 1.8 Hz, 1H), 8.38 (d, J = 2.4 Hz, 1H), 8.38 (d, J = 2.4 Hz, 1H), 8.12 (t, J = 7.4 Hz, 1H), 8.00 (dd, J = 8.6, 2.2 Hz, 1H), 7.86 (t, J = 7.6 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H). DMSO 367.9, 369.9, 371.8 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1219

351.76 1H-NMR (400 MHz, DMSO-d6): δ 11.62 (s, 1H), 9.40 (d, J = 0.8 Hz, 1H), 8.60- 8.83 (m, 3H), 8.32 (dd, J = 6.6, 2.2 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 8.09 (t, J = 7.4 Hz, 1H), 7.95-8.00 (m, 1H), 7.85 (t, J = 7.8 Hz, 1H), 7.61 (t, J = 9.2 Hz, 1H). DMSO 352.0, 354.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1220

335.31 1H-NMR (400 MHz, DMSO-d6): δ 11.05 (s, 1H), 9.48 (d, J = 0.8 Hz, 1H), 8.91- 8.93 (m, 2H), 8.81 (d, J = 8.4 Hz, 1H), 8.28-8.33 (m, 1H), 8.14 (d, J = 8.4 Hz, 1H), 8.06 (t, J = 7.6 Hz, 1H), 7.77- 7.85 (m, 2H), 7.56- 7.63 (m, 1H) DMSO 336.1 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1221

324.34 1H-NMR (400 MHz, DMSO-d6): δ 12.09 (s, 1H), 9.40 (d, J = 1.6 Hz, 1H), 9.10 (d, J = 8.4 Hz, 1H), 9.00 (d, J = 2.0 Hz, 1H), 8.97 (t, J = 2.0 Hz, 1H), 8.49 (s, 1H), 8.26-8.30 (m, 2H), 8.12-8.06 (m, 1H), 7.87-7.91 (m, 1H), 7.76-7.84 (m, 2H) DMSO 324.9 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1222

368.22 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.59 (d, J = 1.2 Hz, 1H), 8.85 (t, J = 1.8 Hz, 1H), 8.78 (d, J = 2.0 Hz, 1H), 8.64 (d, J = 8.4 Hz, 1H), 8.42 (d, J = 1.6 Hz, 2H), 7.96-8.02 (m, 2H), 7.74-7.78 (m, 1H), 7.35 (d, J = 1.6 Hz, 1H). DMSO 368.0, 370.0, 372.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1223

368.22 1H-NMR (400 MHz, DMSO-d6): δ 10.26 (s, 1H), 10.00 (s, 1H), 9.45 (d, J = 5.2 Hz, 1H), 8.56 (d, J = 8.4 Hz, 1H), 8.38 (dd, J = 5.0, 1.8 Hz, 1H), 8.09 (s, 2H), 7.94 (s, 1H), 7.92 (d, J = 9.2 Hz, 1H), 7.70-7.74 (m, 1H), 7.35 (s, 1H). DMSO 368.1, 370.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1224

413.81 1H-NMR (400 MHz, DMSO-d6): δ 10.05 (s, 1H), 9.63 (s, 1H), 8.82 (s, 1H), 8.78 (s, 1H), 8.66 (s, 1H), 8.31 (s, 1H), 7.89- 7.91 (m, 2H), 7.49 (d, J = 8.0 Hz, 1H), 7.31 (t, J = 73.6 Hz, 1H), 6.96 (d, J = 7.6 Hz, 1H), 2.74 (s, 3H). DMSO 414.0 416.0 (M + 1) Method B (NH4HCO3) 95 Method C, G3 1225

400.24 1H NMR (400 MHz, DMSO-d6): δ 9.90 (s, 1H), 9.54 (s, 1H), 8.77-8.80 (m, 2H), 8.60 (s, 1H), 8.50 (s, 1H), 7.99 (s, 1H), 7.76 (8, 1H), 7.44 (s, 1H), 2.67 (s, 3H). DMSO 400.0 401.9 (M + 1) Method B (NH4HCO3) 95 Method C, G3 1226

390.83 1H-NMR (400 MHz, DMSO-d6): δ 13.33 (s, 1H), 9.67 (s, 1H), 9.38 (d, J = 8.0 Hz, 1H), 8.88 (s, 1H), 8.79 (s, 1H), 8.52 (s, 1H), 8.08 (s, 1H), 8.04 (s, 1H), 7.97 (d, J = 7.2 Hz, 1H), 7.88 (s, 1H), 7.69 (d, J = 7.2 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 2.75 (s, 3H). DMSO 391.0 392.0 (M + 1) Method A (TFA) 95 Method C, G3 1227

391.81 1H-NMR (400 MHz, DMSO-d6): δ 16.00 (s, 1H), 9.69 (s, 1H), 9.39 (d, J = 8.4 Hz, 1H), 8.90 (s, 1H), 8.79 (s, 1H), 8.29 (s, 1H), 8.13 (d, J = 7.6 Hz, 1H), 7.82 (s, 1H), 7.50 (s, J = 7.6 Hz, 1H), 7.06 (t, J = 7.2 Hz, 1H), 2.73 (s, 3H). DMSO 392.0 393.1 (M + 1) Method A (TFA) 95 Method C, G3 1228

372.81 1H-NMR (400 MHz, DMSO-d6): δ 10.07 (s, 1H), 9.57 (s, 1H), 8.82 (s, 2H), 8.76 (s, 1H), 8.57 (s, 1H), 8.32 (d, J = 7.6 Hz, 1H), 7.81 (s, 1H), 7.57-7.63 (m, 2H), 2.70 (s, 3H). DMSO 373.0 374.0 (M + 1) Method B (NH4HCO3) 95 Method C, G3 1229

416.69 1H-NMR (400 MHz, DMSO-d6): δ 10.09 (s, 1H), 9.63 (d, J = 1.2 Hz, 1H), 8.85 (dd, J = 2.4, 1.6 Hz, 1H), 8.78 (d, J = 2.4 Hz, 2H), 8.63 (d, J = 1.6 Hz, 1H), 8.45 (s, 2H), 7.34 (t, J = 2.0 Hz, 1H), 2.74 (s, 3H). DMSO 416.9 417.9 (M + 1) Method B (NH4HCO3) 95 Method C, G3 1230

HCl 351.76 1H-NMR (400 MHz, DMSO-d6): δ 10.42 (s, 1H), 9.60 (s, 2H), 9.34 (s, 1H), 8.64 (d, J = 8.4 Hz, 1H), 8.24 (dd, J = 8.4, 2.4 Hz, 1H), 7.98- 7.92 (m, 3H), 7.76- 7.71 (m, 1H), 7.56 (t, J = 8.8 Hz, 1H). DMSO 352.0, 354.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1231

HCl 383.33 1H-NMR (400 MHz, DMSO-d6): δ 10.58 (s, 1H), 9.61 (s, 2H), 9.34 (s, 1H), 8.71 (d, J = 8.4 Hz, 1H), 8.13 (s, 1H), 8.04- 7.93 (m, 3H), 7.78- 7.73 (m, 1H), 7.62 (t, J = 8.4 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H). DMSO 384.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1232

421.25 1H-NMR (400 MHz, DMSO-d6): δ 10.34 (s, 1H), 9.58 (s, 1H), 9.27-9.25 (m, 1H), 8.84-8.77 (m, 2H), 9.52 (s, 1H), 8.35 (s, 1H), 8.07-7.67 (m, 5H), 7.20 (t, J = 7.5 Hz, 1H). DMSO 421.0, 423.0 (M + 1) Method B (NH4HCO3) 95 Method C, G6 1233

1H-NMR (400 MHz, DMSO-d6): δ 13.15 (s, 1H), 10.00 (s, 1H), 9.44 (d, J = 5.2 Hz, 1H), 8.95 (d, J = 8.4 Hz, 1H), 8.48 (s, 1H), 8.42-8.40 (m, 1H), 8.16 (d, J = 9.2 Hz, 1H), 7.97- 7.91 (m, 3H), 7.81- 7.73 (m, 2H), 7.25 (t, J = 2.4 Hz, 1H). DMSO 377.0 (M + 1) Method B (NH4HCO3) 95 Method G 1234

1H-NMR (400 MHz, DMSO-d6): δ 9.95 (s, 1H), 9.54 (s, 1H), 8.82 (s, 1H), 8.74 (d, J = 2.0 Hz, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.07 (dd, J = 8.8, 2.4 Hz, 1H), 8.00 (d, J = 2.4 Hz, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.60 (dd, J = 8.8, 2.4 Hz, 1H), 4.00 (s, 3H). DMSO 397.9, 400.0 (M + 1) Method B (NH4HCO3) 95 Method G

Method C: 5-Nitro-2-(pyrazine-2-carboxamido)benzoic acid (Ii-a)

To a solution of pyrazine-2-carboxylic acid (1.36 g, 10.9 mmol, leq.) in SOCl₂ (20 mL) was added DMF (2 drops). The mixture was stirred at 60° C. for 2.0 min. The volatiles were removed in vacuo to give crude pyrazine-2-carbonyl chloride, which was used in the next step directly. TO a suspension of 2-amino-5-nitrobenzoic acid (2.00 g, 10.9 mmol, 1.0 eq.) in THF (50 mL) was added Et₃N (1.09 g) and pyrazine-2-carbonyl chloride in anhydrous THF (50 mL) dropwise. The resulting mixture was stirred at room temperature for 18 h. After the reaction was completed, the volatiles were removed. The residue was suspended in H₂O (10 mL) and the pH was adjusted to 5 by slow addition of 2N HCl in water. The resulting solid was collected and dried in vacuo to give 3.12 g of 5-nitro-2-(pyrazine-2-carboxamido)benzoic acid as a brown solid (99%). LCMS m/z=289.0 (M+1) (Method B) (retention time=1.24 min),

Method A: N-(2-carbamoyl-4-nitrophenyl)pyrazine-2-carboxamide (iii-d)

A mixture of 5-nitro-2-(pyrazine-2-carboxamido)benzoic acid (3.12 g, 10.8 mmol) in SOCl₂ (20 mL) was stirred at 80° C. for 2 h. After cooling, the volatiles were removed and the residue was suspended in DCM (150 mL), and a solution of NH₃.H₂O (25% by weight water, 40 mL) was added and stirred for 4 h. The resulting precipitate was collected and dried in vacuo to give 2.42 g of N-(2-carbamoyl-4-nitrophenyl)pyrazine-2-carboxamide as a dark red solid (74.6). LCMS m/z=288.0 (M+1) (Method B) (retention time=1.11 min).

Method E2: 6-nitro-2-(pyrazin-2-yl)quinazolin-4(1H)-one (iv-g)

To a mixture of N-(2-carbamoyl-4-nitrophenyl)pyrazine-2-carboxamide (2.42 g, 8.43 mmol, 1.0 eq.) in EtOH (60 mL) was added NaOH (198 g, 49.5 mmol, 5.0 eq.). The resulting mixture was stirred at room temperature for 18 h. After the reaction was completed, the volatiles were removed in vacuo. The residue was partitioned between H₂O (50 mL) and ethyl acetate (50 mL). The aqueous layer was neutralized to pH 5 by slow addition of aqueous citric acid. The resulting precipitate was collected and dried to give 2.00 g of 6-nitro-2-(pyrazin-2-yl)quinazolin-4(3H)-one as a yellow solid (88%), LCMS m/z=270.1 (M+1) (Method A) (retention time=1.36 min)

Method F2: 4-Chloro-6-nitro-2-(pyrazin-2-yl)quinazoline (v-g)

To a mixture of 6-nitro-2-(pyrazin-2-yl)quinazolin-4(3H)-one (1.00 g, 3.7 mmol) in POCl₃ (10 mL) was added N,N-dimethylbenzenamine (0.1 mL). The resulting mixture was stirred at 120° C. for 2 h. After the reaction was completed, POCl₃ was removed in vacuo, and the residue was co-evaporated with toluene twice to give a dark crude product, which was used for the next step without further purification.

Method G6: N-(3-(difluoromethoxy)phenyl)-6-nitro-2-(pyrazin-2-yl)quinazolin-4-amine (vi-s)

A mixture of 4-chloro-6-nitro-2-(pyrazin-2-yl)quinazoline (1.00 g, crude, 3.7 mmol, 1.0 eq.), 3-(difluoromethoxy)benzenamine (600 mg, 3.7 mmol, 1.0 eq.) and Et₃N (1.00 g, 10 mmol, 3.0 eq) in THF (80 mL) was stirred at 75° C. for 18 h. After cooling, the volatiles were removed in vacuo and the residue was washed with H₂O (100 mL×2). The solid was dried in vacuo to afford 1.40 g of N-(3-(difluoromethoxy)phenyl)-6-nitro-2-(pyrazin-2-yl)quinazolin-4-amine as a black solid (90.2% of two steps). LCMS m′ z=411.0 (M+1) (Method A) (retention time=1.61 min).

Method B: N⁴-(3-(difluoromethoxy)phenyl)-2-(pyrazin-2-yl)quinazoline-4,6-diamine (Iii-a)

To a mixture of N-(3-(difluoromethoxy)phenyl)-6-nitro-2-(pyrazin-2-yl) quinazolin-4-amine (1.40 g, 3.4 mmol, 1.0 eq.) in MeOH—H₂O (v/v, 3:1, 110 mL) was added NH₄Cl (1.80 g, 34 mmol, 10.0 eq.) and Fe (1.91 g, 34 mmol, 10.0 eq.). The resulting mixture was stirred at 60° C. for 3 h. After the reaction was completed, the mixture was cooled to room temperature, and the iron was filtered off. The filtrate was concentrated to 15 ml, and a precipitate formed and was collected and dried in vacuo to give 1.13 g of N⁴-(3-(difluoromethoxy)phenyl)-2-(pyrazin-2-yl)quinazoline-4,6-diamine as a pale yellow solid (87.5%). LCMS m/z=381.1 (M+1) (Method B) (retention time=1.60 min), ¹H-NMR (400 MHz, DMSO-d₆): δ 9.69 (s, 1H), 9.52 (d, J=1.2 Hz, 1H), 8.75 (d, J=2.4 Hz, 1H), 8.69 (d, J=2.4 Hz, 1H), 8.30 (s, 1H), 7.87 (dd, J=8.4, 0.8 Hz, 1H), 7.72 (d, J=8.8 Hz, 1H), 7.49-7.42 (m, 2H), 7.33-7.32 (m, 1H), 7.31 (t, J=74 Hz, 1H), 5.85 (s, 2H).

Method C: N-(4-(3-(difluoromethoxy)phenylamino)-2-(pyrazin-2-yl)quinazolin-6-yl)-6-methoxynicotinamide (liii-a)

To a solution of 6-methoxynicotinic acid (100 mg, 0.65 mmol) in SOCK, (2 mL) was added DMF (1 drop). The mixture was stirred at 60° C. for 20 min. The volatiles were removed in vacuo to give 6-methoxynicotinoyl chloride, which was used for the next step directly. To a suspension of N⁴-(3-(difluoromethoxy)phenyl)-2-(pyrazin-2-yl)quinazoline-4,6-diamine (130 mg, 0.34 mmol, 0.5 eq.) in THF (5 mL) and Et₃N (101 mg, 1 mmol, 3.0 eq) was added 6-methoxynicotinoyl chloride in anhydrous THF (5 mL) dropwise. The resulting mixture was stirred at room temperature for 18 h. The volatiles were removed in vacuo. The residue was washed with MeOH and re-crystallized from THF/MeOH twice, and purified by reverse phase chromatography PREP-HPLC (A=NH₄HCO₃—H₂O, 10 mmol/L, B=MeOH) to afford 33 mg of N-(4-(3-(difluoromethoxy)phenylamino)-2-(pyrazin-2-yl)quinazolin-6-yl)-6-methoxynicotinamide as a pale yellow solid (18.8%). LCMS m/z=516.1 (M+1), 258.6 (M/2+1) (Method A) (retention time=1.57 min), ¹H-NMR (400 MHz, DMSO-(d₆): δ 10.71 (s, 1H), 10.18 (s, 1H), 9.57 (d, J=1.6 Hz, 1H), 9.01 (d, J=1.6 Hz, 1H), 8.91 (d, J=2.4 Hz, 1H), 8.81 (t, J=2.0 Hz, 1H), 8.76 (d, J=2.4 Hz, 1H), 8.34 (dd, J=8.8, 2.8 Hz, 1H), 8.23 (s, 1H), 8.08 (dd, J=8.8, 2.0 Hz, 1H), 8.00 (d, J=9.2 Hz, 1H), 7.90 (d, J=9.2 Hz, 1H), 7.46-7.50 (m, 1H), 7.32 (t, J=74.4 Hz 1H), 7.02 (d, J=8.8 Hz, 1H), 6.95 (dd, J=8.0, 2.0 Hz, 1H), 3.97 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 67 (prepared according to method procedure A-G as designated).

TABLE 22 Molec- Salt ular Number PRODUCT type Mass ¹H-NMR 1242

422.39 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.10- 10.45 (m, 2H), 9.68 (s, 1H), 8.45-9.10 (m, 2H), 7.68-8.37 (m, 4H), 7.36-7.52 (m, 2H), 7.02- 7.08 (m, 1H), 2.21 (s, 3H). 1243

515.47 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.71 (s, 1H), 10.18 (s, 1H), 9.57 (d, J = 1.6 Hz, 1H), 9.01 (d, J = 1.6 Hz, 1H), 8.91 (d, J = 2.4 Hz, 1H), 8.81 (t, J = 2.0 Hz, 1H), 8.76 (d, J = 2.4 Hz, 1H), 8.34 (dd, J = 8.8, 2.8 Hz, 1H), 8.23 (s, 1H), 8.08 (dd, J = 8.8, 2.0 Hz, 1H), 8.00 (d, J = 9.2 Hz, 1H), 7.90 (d, J = 9.2 Hz, 1H), 7.46-7.50 (m, 1H), 7.32 (t, J = 74.4 Hz, 1H), 7.02 (d, J = 8.8 Hz, 1H), 6.95 (dd, J = 8.0, 2.0 Hz, 1H), 3.97 (s, 3H). 1244

514.48 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.56 (s, 1H), 10.16 (s, 1H), 9.57 (s, 1H), 9.00 (d, J = 1.6 Hz, 1H), 8.81(d, J = 2.4 Hz, 1H), 8.76 (d, J = 2.8 Hz, 1H), 8.23 (s, 1H), 8.07-8.12 (m, 3H), 7.99 (d, J = 9.2 Hz, 1H), 7.89 (d, J = 9.2 Hz, 1H), 7.46-7.50 (m, 1H), 7.32 (t, J = 72.8 Hz, 1H), 7.11- 7.13 (m, 2H), 6.95 (dd, J = 8.4, 2.4 Hz, 1H), 3.87 (s, 3H). 1245

520.53 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.30 (s, 1H), 10.16 (s, 1H), 9.54 (s, 1H), 8.89 (s, 1H), 8.79 (t, J = 2.4 Hz, 1H), 8.74 (d, J = 2.8 Hz, 1H), 8.20 (s, 1H), 7.93 (s, 2H), 7.87 (d, J = 8.4 Hz, 1H), 7.48 (dd, J = 10.0, 2.0 Hz, 1H), 7.31 (t, J = 74.0 Hz, 1H), 6.94 (dd, J = 8.4, 2.0 Hz, 1H), 3.26 (s, 3H), 3.18-3.22 (m, 1H), 1.91-1.96 (m, 2H), 1.66- 1.78 (m, 2H), 1.53-1.63 (m, 2H), 1.38-1.49 (m, 2H). 1246

492.48 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.35 (s, 1H), 10.15 (s, 1H), 9.54 (s, 1H), 8.90 (d, J = 2.0 Hz, 1H), 8.80 (dd, J = 2.4, 1.2 Hz, 1H), 8.75 (d, J = 2.4 Hz, 1H), 8.19 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.86-7.91 (m, 2H), 7.48 (dd, J = 10.8, 2.8 Hz, 1H), 7.31 (t, J = 74.4 Hz, 1H), 6.94 (dd, J = 7.6, 2.0 Hz, 1H), 3.94-3.97 (m, 2H), 3.40-3.43 (m, 2H), 2.70-2.73 (m, 1H), 1.65-1.78 (m, 4H). ¹H-NMR LCMS Purity Method for Number Solvent LCMS Protocol percent Coupling 1242 DMSO 423.0 (M + 1) Method A (TFA) 95 Method C, G4, C 1243 DMSO 516.2 (M + 1) Method B (NH4HCO3) 95 Method C, G4, C 1244 DMSO 515.2 (M + 1) Method B (NH4HCO3) 95 Method C, G4, C 1245 DMSO 521.2 (M + 1) Method B (NH4HCO3) 95 Method C, G4, C 1246 DMSO 493.2 (M + 1) Method B (NH4HCO3) 95 Method C, G4, C

Method BF 6-(3-methoxyphenyl)-N-methy-2-(pyrimidin-5-yl)quinazolin-4-amine (compound 1247)

In a 10 mL microwave vial was added 2-chloro-6-(3-methoxyphenyl)-N-methylquinazolin-4-amine (0.080 g, 0.267 mmol), pyrimidine-5-boronic acid (0.099 g, 0.801 mmol), dichlorobis(triphenylphosphine)palladium (II) (Pd(PPh₃)₂Cl₂) (9.37 mg, 0.013 mmol), and potassium carbonate (0.111 g, 0.801 mmol) in DME (3 mL), EtOH (1.286 mL), and water (0.857 mL) to give a yellow suspension. The vial was irradiated at 120° C. for 15 min under argon. Water (10 rill) was added to the mixture and extracted with ethyl acetate (2×10 mL). The organic layers were combined and washed with brine (1×20 mL) and then dried over MgSO₄, filtered and concentrated. The residue was washed with MeOH—CH₂Cl₂ and dried to give 35 mg of 6-(3-methoxyphenyl)-N-methyl-2-(pyrimidin-5-yl)quinazolin-4-amine as a white solid (38%). LCMS m/z=344 (M+1) (Method D) (retention time=1.78 min) ¹H NMR (300 MHz, DMSO) δ 9.79-9.59 (m, 2H), 9.30 (s, 1H), 8.72 (d, J=4.6 Hz, 1H), 8.59 (s, 8.16 (d, J=8.6 Hz, 1H), 7.85 (d, J=8.7 Hz, 1H), 7.53-7.28 (m, 3H), 7.00 (d, J=6.8 Hz, 1H), 3.86 (s, 3H), 3.18 (d, J=3.9 Hz, 3H).

In a 100 mL round-bottomed flask was added 6-iodo-2-(pyrazin-2-yl)quinazolin-4(3H)-one (0.500 g, 1.428 mmol), BOP (0.821 g, 1.857 mmol), and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.426 ml, 2.86 mmol) in DMT (10 mL) to give a colorless solution. Methylamine, 2M in THF (2.142 ml, 4.28 mmol) was added and stirred at room temperature overnight. The reaction mixture was diluted with water (50 mL) and then a precipitate formed. The resulting solid was collected by filtration and dried to give 0.515 g of 6-iodo-N-methyl-2-(pyrazin-2-yl)quinazolin-4-amine as a pale brown solid in a 99% yield. LCMS m/z=364 (M+1) (Method D) (retention time=1.25 min). ¹H NMR (300 MHz, DMSO) δ 9.60 (s, 1H), 8.89-8.65 (m, 3H), 8.65-8.48 (m, 1H), 8.06 (d, J=8.7 Hz, 1H), 7.59 (d, J=8.7 Hz, 1H), 3.11 (d, J=4.2 Hz, 3H).

In a 50 ml, round-bottomed flask was added 6-iodo-N-methyl-2-(pyrazin-2-yl)quinazolin-4-amine (0.100 g, 0.275 mmol), 3-methoxyphenylboronic acid (0.063 g, 0.413 mmol), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine) dichloropalladium(II) (0.016 g, 0.022 mmol), and potassium phosphate tribasic monohydrate (0.190 g, 0.826 mmol) in dioxane (5 mL) and water (0.5 mL) to give a brown suspension. The reaction mixture was heated at 80° C. overnight under argon. After cooling to room temperature, the reaction mixture was diluted with water (10 mL) and then a precipitate formed. The resulting solid was collected by filtration and washed with ethyl acetate and dried to give 25 mg of 6-(3-methoxyphenyl)-N-methyl-2-(pyrazin-2-yl)quinazolin-4-amine as a pale yellow solid in a 26% yield. LCMS m/z=344 (M+1) (Method D) (retention time=1.43 ruin). ¹H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.85-8.78 (m, 1H), 8.77-8.71 (m, 1H), 8.70-8.63 (m, 1H), 8.63-8.55 (m, 1H), 8.18 (d, J=8.8 Hz, 1H), 7.89 (d, J=8.9 Hz, 1H), 7.53-7.31 (m, 3H), 7.09-6.92 (m, 1H), 3.86 (5, 3H), 3.17 (d, J=3.6 Hz, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 69 (prepared according to method described for 6-(3-methoxyphenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine).

TABLE 23 Molec- Salt ular Number PRODUCT type Mass ¹H-NMR 1235

343.38 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.85-8.78 (m, 1H), 8.77-8.71 (m, 1H), 8.70-8.63 (m, 1H), 8.63- 8.55 (m, 1H), 8.18 (d, J = 0.8 Hz, 1H), 7.89 (d, J = 8.9 Hz, 1H), 7.53-7.31 (m, 3H), 7.09-6.92 (m, 1H), 3.86 (s, 3H), 3.17 (d, J = 3.6 Hz, 3H). 1236

338.37 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.87-8.61 (m, 4H), 8.24 (d, J = 8.8 Hz, 1H), 8.15-7.98 (m, 4H), 7.92 (d, J = 8.7 Hz, 1H), 3.17 (d, J = 4.0 Hz, 3H). 1237

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.17 (s, 1H), 9.54 (d, J = 5.2 Hz, 1H), 9.36 (s, 1H), 8.63 (s, 2H), 8.13- 8.06 (m, 2H), 7.58-7.51 (m, 2H), 7.43-7.38 (m, 1H), 3.23 (d, J = 4.0 Hz, 3H). 1238

2HCl ¹H-NMR (400 MHz, DMSO- 10.14 (s, 1H), 9.50 (d, J = 5.2 Hz, 1H), 9.24 (s, 1H), 8.60 (dd, J = 5.4, 1.8 Hz, 1H), 8.55 (s, 1H), 8.04 (q, J = 8.8 Hz, 2H), 7.76 (dd, J = 15.4, 9.0 Hz, 1H), 7.51-7.45 (m, 1H), 7.32 (dt, J = 8.4, 2.0 Hz, 1H), 3.23 (d, J = 4.4 Hz, 3H). 1239

¹H-NMR (400 MHz, DMSO-d₆): δ 9.73 (s, 1H), 9.32 (s, 1H), 8.74 (d, J = 4.4 Hz, 1H), 8.51 (s, 1H), 8.03 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.54- 7.49 (m, 2H), 7.42-7.37 (m, 1H), 4.12 (q, J = 5.2 Hz, 1H), 3.17 (t, J = 4.5 Hz, 3H). 1240

2HCl ¹H-NMR (400 MHz, CD3OD): δ 9.77 (s, 1H), 8.85 (d, J = 11.4 Hz, 2H), 8.42 (s, 1H), 8.19-8.03 (m, 2H), 7.60 (dd, J = 15.6, 7.8 Hz, 1H), 7.10 (t, J = 8.4 Hz, 2H), 3.38 (s, 3H). 1241

2HCl ¹H-NMR (400 MHz, DMSO): δ 10.84 (d, J = 1.8 Hz, 1H), 9.87 (s, 1H), 9.06 (d, J = 13.6 Hz, 2H), 8.90 (s, 1H), 8.32 (t, J = 9.8 Hz, 2H), 7.67-7.35 (m, 3H), 3.39 (s, 3H). ¹H-NMR LCMS Purity Method for Number Solvent LCMS Protocol percent Coupling 1235 DMSO 344 (M + 1) Method D 100 Method AP/AQ 1236 DMSO 339 (M + 1) Method D 100 Method C, G1 1237 DMSO 350.1, 351.1, (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 1238 DMSO 350.1, 351.1, (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 1239 DMSO 350.1 (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 1240 CD3OD 350.1 (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 1241 DMSO 349.9 (M + 1) Method B (NH₄HCO₃) 95 Method C, G1

Method B2: 2-Amino-3-methylbenzoic acid (Iv-a)

Pd/C catalyst (ISO mg) was suspended in a solution of 3-methyl-2-nitrobenzoic acid (1.50 g, 8.28 mmol, 1.0 eq) in THF (60 mL), the mixture was stirred under H₂ atmosphere at room temperature overnight. The Pd/C was removed by filtration over Celite and the THF was removed in vacuo to give 1.23 g of Iv-a as a white solid (yield 98%). LCMS m/z=152.1 (M+1) (Method B) (retention time=0.73 min). The product was used further without purification.

Method AZ: 2-Amino-5-bromo-3-methylbenzoic acid (Ivi-a)

To a solution of 2-amino-3-methylbenzoic acid (1.23 g, 8.14 mmol, 1.0 eq) in 15 mL of DMSO was added 40% HBr (6.00 mL, 44.7 mmol, 5 eq). The resulting mixture was stirred at room temperature overnight. A white precipitate formed during the course of the reaction. The reaction mixture was quenched with saturated aqueous NaHCO₃ resulting in a white solid that was filtered and dried in vacuo to yield 950 mg in 51% yield of Ivi-a as white solid. LCMS m/z=229.9 (M+1) (Method B) (retention time=1.20 min),

Method C: 2-Amino-5-bromo-3-methylbenzamide (ii-e)

A mixture of 2-amino-5-bromo-3-methylbenzoic acid (950 mg, 4.15 mmol) and SOCl₂ (20 mL) was stirred at 80° C. for 2 h. After the reaction was completed, the mixture was cooled to room temperature. The SOCl₂ was removed in vacuo and the residue was dissolved in anhydrous THF (10 mL). The THF solution was then added dropwise to a 28% by weight solution of NH₃—H₂O (10 mL). After 1 h, the resulting precipitate was collected and dried in vacuo to give 82.0 mg of ii-c as a yellow solid (87%). LCMS m/z=288.9, 230.9 (M+1) (Method B) (retention time=1.49 min).

Method G for Coupling Conditions

G1: i-PrOH/85-100° C.

G2: THF/heat

G3: i-AmOH/100-130° C.

G4: MeOH/microwave/150° C.

G5: i-AmOH/microwave/150° C.

G6: THF/Et₃N/reflux G7: THF—H₂O/NaOAc/rt-60° C. G8: NaH/THF

G9: n-BuLi/THF

G10: LHMDS/THF G11: LDA/THF G13: Cs₂CO₃/DMA/80° C. G14: NaOtBu/DMF/Microwave/100° C. Method AQ for Coupling Conditions AQ1: Pd(PPh₃)₂Cl₂/K₂CO₃/Dioxane-H₂O AQ2: Pd₂(APhos)₂Cl₂/K₃PO₄/Dioxane-H₂O AQ3: Pd(PPh₃)₄/K₃PO₄/Dioxane-H₂O AQ4: Pd(dppf)Cl₂—CH₂Cl₂/K₃PO₄/Dioxane-H₂O AQ5: Pd(OAc)₂Cl₂/S-Phos/K₃PO₄/Dioxane-H₂O AQ6: Pd(dppf)Cl₂—CH₂Cl₂/Na₂CO₃/Dioxane-H₂O

Method C: N-(4-bromo-2-carbamoyl-6-methylphenyl)nicotinamide (iii-e)

To a solution of 2-amino-5-bromo-3-methylbenzamide (820 mg, 3.55 mmol, 1.0 eq.) in THF (15 mL) and Et₃N (0.7 nit) was added nicotinoyl chloride (551 mg, 3.91 mmol, 1.1 eq.) in anhydrous THF (15 mL) dropwise. The resulting mixture was stirred at room temperature overnight. After the reaction was completed, the resultant precipitate was filtered and dried in vacuo to give 1.74 g of crude iii-e as a yellow solid. LCMS m/z=333.8, 335.8 (M+1) (Method B) (retention time=1.42 min).

Method E: 6-Bromo-8-methyl-2-(pyridin-3-yl)quinazolin-4-ol (iv-h)

A mixture of N-(4-bromo-2-carbamoyl-6-methylphenyl)nicotinamide (1.74 g salt, 5.22 mmol, 1.0 eq) in EtOH (50 mL) was treated with NaOH (1.04 g, 26.1 mmol, 5.0 eq). The resulting mixture was stirred at room temperature overnight. After the reaction was completed, the volatiles were removed in vacuo. Water (30 mL) was added to the residue and the mixture was adjusted to pH˜1 or 2 by slow addition of aqueous HCl. The resultant precipitate was collected and dried to give 870 mg of iv-h as a yellow solid (77% yield after two steps), LCMS m/z=315.7, 317.7 (M+1) (Method B) (retention time=1.74 min).

Method F5: 6-Bromo-4-chloro-8-methyl-2-(pyridin-3-yl)quinazoline (v-h)

6-Bromo-8-methyl-2-(pyridin-3-yl)quinazolin-4-ol (870 mg, 2.76 mmol) was added POCl₃ (10 mL). The resulting mixture was stirred at 120° C. overnight. After the reaction was completed, the mixture was carefully poured into ice-water. The pH was adjusted to 7 by slow addition of NH₄OH at 0° C. The resultant solid was collected to give 1.00 g of v-h as a beige solid (quantitative yield). LCMS m/z=333.9, 335.9 (M+1) (Method B) (retention time=2.23 min).

Method G6: 6-Bromo-N, 8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (vi-t)

A mixture of 6-bromo-4-chloro-8-methyl-2-(pyridin-3-yl)quinazoline (200 mg, 0.60 mmol, 1.0 eq.), methylamine (81 mg, 1.20 mmol, 2.0 eq.) and Et₃N (0.2 mL) in i-PrOH (10 mL) was stirred at 85° C. overnight. The resultant yellow precipitate was collected to afford 125 mg of vi-t as a beige solid (63.4%). LCMS m/z=328.8, 330.8 (M+1-1) (Method B) (retention time=1.95 min).

Method G2: 7-bromo-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (vi-u)

To a suspension of 7-bronco-4-chloro-2-(pyridin-3-yl)quinazoline (5.0 g, 0.0156 mol) in THF (100 mL) was added dropwise a methylamine solution (40 wt. % in H₂O) (24 ml, 0.272 mmol) with cooling. The suspension was stirred at 60° C. for 3 h, cooled, filtered, and dried to give the title compound. (3.62 g, 73.5%)

Method AQ1: 6-(3-Methoxyphenyl)-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (Iviii-a)

(This method is representative of method AQ2 and can be implemented in a similar way except for substitution of the appropriate catalyst and base) To a mixture of 6-bronco-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (130 mg, 0.396 mmol, 1.0 eq), 3-methoxyphenylboronic acid (60 mg, 0.396 mmol, 1.0 eq), K₂CO₃ (295 mg, 2.14 mmol, 5.4 eq.) in dioxane (8 mL) and H₂O (4 mL) was added Pd(PPh₃)₂Cl₂ (15 mg, 0.021 mmol, 0.054 eq) under N₂ atmosphere. The resulting mixture was stirred at 120° C. under N₂ atmosphere overnight. After the reaction was completed, the mixture was filtered, and the filtrate was concentrated in vacuo. The residue was purified by reverse phase HPLC column to afford 11 mg of Iviii-a as a white solid (yield 7.8%). LCMS m/z=357.2, (M+1) (Method B (retention time=2.11 min), ¹H NMR (400 MHz, DMSO-d₆): δ 9.68 (d, J=1.2 Hz, 1H), 8.75 (4, J=8.0 Hz, 1H), 8.62 (d, J=4.6 Hz, 1H), 8.49 (d, J=4.4 Hz, 1H), 8.35 (s, 1H), 7.97 (s, 1H), 7.49 (dd, J=7.8, 4.8 Hz, 7.44-7.29 (m, 3H), 6.93 (dd, J=6.8, 2.4 Hz, 1H), 3.81 (s, 3H), 3.12 (d, J=4.4 Hz, 3H), 2.68 (s, 3H).

Method AQ3: 6-(4-Fluorophenyl)-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (Iviii-h)

6-Bromo-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (340 mg, 1.03 mmol), 3-fluorobenzeneboronic acid (217 mg, 1.55 mmol), K₂PO₄ (658 mg, 3.10 mmol) and Pd(PPh₃)₄ (59.7 mg, 0.052 mmol) were dissolved in the mixed solvent of 1,4-dioxane (10 mL) and water (1 mL). The resulting mixture was stirred at 90° C. for 6 hours under a nitrogen atmosphere. After the reaction was completed, water was added to the mixture and stirred for 30 minutes. The resulting precipitate was collected by filtration and purified by column chromatography on NH-silica gel (eluted with THF) to give a yellow powder. The solid was suspended in ethanol and 5N HCl (1 mL) was added to the mixture. The mixture was sonicated for 10 min and the resulting precipitate was collected by filtration and dried to give 304 mg of 6-(3-fluorophenyl)-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4 amine dihydrochloride as a yellow powder in 71% yield.

Method AQ4: 6-(2,4-Difluorophenyl)-N,5-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine(lviii-c)

6-Bromo-N,5-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (350 mg, 1.06 mmol), 2,4-difluorophenylboronic acid (252 mg, 1.595 mmol), K₃PO₄ (677 mg, 3.19 mmol) and Pd(dppf)Cl₂—CH₂Cl₂ (87 mg, 0.106 mmol) were dissolved in the mixed solvent of 1,4-dioxane (10 mL) and water (1 mL). The resulting mixture was stirred at 90° C. for 2.5 hours under N₂. After the reaction was completed, water was added to the mixture and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over Na₂SO₄. After filtration and evaporation, the crude product was purified by column chromatography on NH-silica gel (eluted with isocratic 33% ethyl acetate/67% hexane) to give a white powder. The solid was suspended in ethanol and 5N HCl (1.0 mL) was added to the mixture. The mixture was sonicated for 10 min and the resultant precipitate was collected by filtration and dried to give 139 mg of 6-(2,4-difluorophenyl)-N,5-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride as a pale yellow powder in a 30% yield.

Method AQ5: 7-(3-fluorophenyl)-N,6-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (Iviii-d)

A mixture of 7-chloro-N,6-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (400 mg, 1.40 mmol), 3-fluorophenylboronic acid (294 g, 2.10 mmol), Pd(OAc) (15.8 mg, 0.070 mmol), 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (86.7 mg, 0.211 mmol), K₃PO₄ (900 mg, 4.23 mmol) in dioxane (10 mL) and water (2 mL) was stirred under reflux for 2.5 h. Ethyl acetate (2(1 mL) was added to the cooled mixture and a precipiate formed and was filtered. The solid was recrystallized from DMF and water to give the title compound as free form. The solid was suspended in ethyl acetate (10 mL) and 4N HCl in ethyl acetate (1.0 mL) was added. The resulting solid was subjected to sonication for 20 min, filtered and dried to give the title compound as the bis-110 salt (0.10 g, 18.7%).

Method AQ6:7-(3,4-difluorophenyl)-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (Iviii-e)

To a suspension of 3,4-difluorophenylboronic acid (389 mg, 2.46 mmol) and 7-bromo-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (395.4 mg, 1.201 mmol) in dioxane/H₂O (2/1) (30 mL) under a nitrogen atmosphere was added Na₂CO₃ (633.2 mg, 5.97 mmol) and (1,1′-bis(diphenylphosphino)ferrocene)-dichloropalladium(II) (98 mg, 0.120 mmol) at room temperature. The mixture was stirred at 100° C. for 1.5 h. Water was added to the reaction mixture and then a precipitate formed. The solid was filtered and washed with water and dried. The dried solid was then heated in a methanol/dioxane mixture to give a clear solution and filtered through Celite. The filtrate was concentrated to give the crude product. The crude product was sonicated in methanol/CH₂Cl₂ for ca. 15 min and filtered to give 305.2 mg of a pale brown solid as the parent compound. To a suspension of parent compound in methanol was added 4N HCl in ethyl acetate (ca. 4 mL) to give a clear solution. The solution was concentrated and recrystallized from ethanol to give the HCl salt. The salt was collected and dried in an oven at 60° C. to give 231.3 mg in a 44% yield as pale yellow solid. ¹H NMR (DMSO-d₆) δ 9.73 (s, 1H), 9.37 (brd, J=8.08 Hz, 1H), 8.97 (brd, J=5.24 Hz, 1H), 8.77 (brs, 1H), 8.20 (d, J=8.48 Hz, 1H), 8.10-8.07 (brm, 1H), 7.63-7.55 (brm, 2H), 7.47 (d, J=8.48 Hz, 1H), 7.32 (brm, 1H), 3.20 (d, J=4.20 Hz, 3H), 2.65 (s, 3H). The 1H of 2HCl was not observed.

Method AP: 6-bromo-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine (vi-u)

To a solution of 6-promo-2-(pyridin-3-yl)quinazolin-4(3H)-one (5.00 g, 16.6 mmol), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (9.52 g, 21.5 mmol), and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (4.94 ml, 33.1 mmol) in DMF (50 mL) was added methylamine, 2M in THF (16.6 mL, 33.1 mmol). The mixture was stirred overnight at room temperature. Water (100 mL) was added to the mixture and stirred. The resultant precipitate was collected by filtration and dried to give 5.15 g of 6-bromo-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine as pale yellow solid (99%) LCMS m/z=315 (M+1) (Method D) (retention time=1.34 min). ¹H NMR (300 MHz, DMSO) δ 9.60 (dd, J=2.1, 0.8 Hz, 1H), 8.79-8.70 (m, 1H), 8.67 (dd, J=4.8, 1.7 Hz, 1H), 8.57 (s, 1H), 8.51 (d, J=2.0 Hz, 1H), 7.90 (dd, J=8.9, 2.1 Hz, 1H), 7.71 (d, J=8.9 Hz, 1H) 7.52 (ddd, J=7.9, 4.8, 0.9 Hz, 1H), 3.13 (d, J=4.5 Hz, 3H).

Method AQ2: 6-(6-methoxypyridin-3-yl)-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine (lviii-f)

To a 1 dram reaction vial was added 6-bromo-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine (35 mg, 0.111 mmol), 6-methoxypyridin-3-ylboronic acid (20.4 mg, 0.133 mmol), Pd(APhos)₂Cl₂ (3.2 mg, 0.0041 mmol) and potassium phosphate monohydrate (77 mg, 0.33 mmol) in a mixture of dioxane-water (9:1, 2 mL). The reaction mixture was heated to 90° C. for 14 h after which it was cooled to room temperature and diluted with water (5 mL). The resultant precipitate was collected by filtration and recrystallized from methanol to give 6-(6-methoxypyridin-3-yl)-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine as a pale yellow solid (19.1 mg, 51%). LCMS m/z=344 (M+1) (Method C) (retention time=2.01 min) ¹H NMR (300 MHz, DMSO) f 9.64 (d, J=1.3 Hz, 1H), 8.84-8.74 (m, 1H), 8.68 (dd, J=6.2, 1.7 Hz, 2H), 8.57 (d, J=1.6 Hz, 2H), 8.16 (ddd, J=14.4, 8.7, 2.2 Hz, 2H), 7.85 (d, J=8.7 Hz, 1H), 7.54 (dd, J=7.9, 4.8 Hz, 1H), 7.00 (d, J=8.7 Hz, 1H), 3.93 (s, 3H), 3.18 (d, J=4.3 Hz, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 72 or 74, replacing methylamine with the appropriate amine and 6-methoxypyridin-3-ylboronic acid with the appropriate boronic acid.

TABLE 24 Method Molec- Reten- for ular ¹H-NMR tion LCMS Purity Cou- Number Product Salt Mass ¹H-NMR Solvent LCMS Time Protocol percent pling 1248

HCl 342.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.66 (s, 1H), 8.50-8.89 (m, 3H), 8.16 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.30-7.61 (m, 4H), 7.01 (d, J = 6.4 Hz, 1H), 3.88 (s, 3H), 3.32 (brs, 1H), 3.19 (s, 3H). DMSO 343.1 (M + 1) Method B (NH4HCO3) 95 Method AQ1 1249

372.4 1H-NMR (400 MHz, DMSO-d6): δ 9.63 (s, 1H), 8.77 (d, J = 7.9 Hz, 1H), 8.67 (d, J = 3.7 Hz, 1H), 8.50 (s, 1H), 8.11 (s, 1H), 7.56-7.53 (m, 2H), 7.48-7.40 (m, 3H), 7.01 (d, J = 3.9 Hz, 1H), 4.07 (s, 3H), 3.88 (s, 3H), 3.17 (d, J = 4.0 Hz, 3H). DMSO 372.9 (M + 1) Method B (NH4HCO3) 95 Method AQ1 1250

356.4 1H-NMR (400 MHz, DMSO-d6): δ 9.63 (s, 1H), 8.79-8.74 (m, 1H), 8.69 (d, J = 4.0 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.57-7.51 (m, 1H), 7.42 (t, J = 8.0 Hz, 1H), 7.37- 7.30 (m, 1H), 7.02-6.92 (m, 3H), 3.82 (s, 3H), 3.18 (d, J = 4.0 Hz, 3H), 2.69 (s, 3H). DMSO 357.1 (M + 1) Method B (NH4HCO3) 95 Method AQ1 1251

356.4 1H-NMR (400 MHz, DMSO-d6): δ 9.68 (d, J = 1.2 Hz, 1H), 8.75 (d, J = 8.0 Hz, 1H), 8.62 (d, J = 4.6 Hz, 1H), 8.49 (d, J = 4.4 Hz, 1H), 8.35 (s, 1H), 7.97 (s, 1H), 7.49 (dd, J = 7.8, 4.8 Hz, 1H), 7.44-7.29 (m, 3H), 6.93 (dd, J = 6.8, 2.4 Hz, 1H), 3.81 (s, 3H), 3.12 (d, J = 4.4 Hz, 3H), 2.68 (s, 3H). DMSO 357.2 (M + 1) Method B (NH4HCO3) 95 Method AQ1 1252

329.3 1H NMR (300 MHz, DMSO) δ 9.31 (s, 1H), 8.76 (d, J = 4.7 Hz, 1H), 8.51 (d, J = 8.0 Hz, 1H), 8.37 (d, J = 2.0 Hz, 1H), 8.18 (dd, J = 8.5, 2.2 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.59 (dd, J = 7.9, 4.8 Hz, 1H), 7.49-7.23 (m, 3H), 6.99 (d, J = 6.7 Hz, 1H), 3.85 (s, 3H). DMSO 330 (M + 1) 1.76 Method D 100 1253

HCl 342.4 1H NMR (300 MHz, DMSO) δ 10.11 (s, 1H), 9.63 (s, 1H), 9.07- 8.86 (m, 2H), 8.58 (s, 1H), 8.16 (s, 2H), 7.92-7.77 (m, 1H), 7.54- 7.36 (m, 2H), 7.20 (d, J = 8.6 Hz, 1H), 7.16-7.07 (m, 1H), 3.81 (s, 3H), 3.29 (d, J = 3.9 Hz, 3H). DMSO 343 (M + 1) 1.47 Method D 100 Method AQ2 1254

330.3 1H NMR (300 MHz, DMSO) δ 9.59 (s, 1H), 8.73 (d, J = 8.3 Hz, 1H), 8.65 (d, J = 4.7 Hz, 1H), 8.37-8.22 (m, 1H), 8.18-8.05 (m, 1H), 7.76 (d, J = 9.0 Hz, 1H), 7.71 (s, 1H), 7.56-7.43 (m, 2H), 4.58 (s, 2H), 3.14 (d, J = 4.4 Hz, 3H), 2.69 (d, J = 4.6 Hz, 3H). DMSO 331 (M + 1) 1.52 Method D 100 Method AQ2 1255

312.4 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.88-8.47 (m, 4H), 8.25-8.05 (m, 1H), 7.97-7.72 (m, 3H), 7.67-7.35 (m, 4H), 3.18 (d, J = 4.4 Hz, 3H). DMSO 313 (M + 1) 1.48 Method D 100 Method AQ2 1256

HCl 337.4 1H NMR (300 MHz, DMSO) δ 9.93 (s, 1H), 9.63 (s, 1H), 9.00 (d, J = 8.3 Hz, 1H), 8.95-8.82 (m, 2H), 8.46-8.32 (m, 2H), 8.25 (d, J = 7.0 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 7.2 Hz, 1H), 7.88-7.70 (m, 2H), 3.29 (d, J = 4.2 Hz, 3H). DMSO 338 (M + 1) 1.50 Method D 100 Method AQ2 1257

337.4 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.77 (d, J = 7.9 Hz, 1H), 8.73-8.59 (m, 3H), 8.21 (d, J = 8.8 Hz, 1H), 8.11-7.94 (m, 4H), 7.87 (d, J = 8.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 3.18 (d, J = 4.0 Hz, 3H). DMSO 338 (M + 1) 1.50 Method D 100 Method AQ2 1258

346.8 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.77 (d, J = 7.9 Hz, 1H), 8.72-8.52 (m, 3H), 8.14 (d, J = 8.7 Hz, 1H), 7.97- 7.74 (m, 3H), 7.68-7.45 (m, 3H), 3.18 (d, J = 4.0 Hz, 3H). DMSO 347 (M + 1) 1.60 Method D 100 Method AQ2 1259

346.8 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.78 (d, J = 8.0 Hz, 1H), 8.72-8.54 (m, 3H), 8.17 (d, J = 8.7 Hz, 1H), 7.94 (s, 1H), 7.90-7.78 (m, 2H), 7.61- 7.42 (m, 3H), 3.19 (d, J = 4.4 Hz, 3H). DMSO 347 (M + 1) 1.66 Method D 100 Method AQ2 1260

372.4 1H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 8.77 (dd, J = 7.9, 1.8 Hz, 1H), 8.67 (d, J = 4.7 Hz, 1H), 8.46 (d, J = 4.4 Hz, 1H), 8.26 (s, 1H), 7.95-7.84 (m, 1H), 7.75 (d, J = 8.6 Hz, 1H), 7.53 (dd, J = 7.9, 4.8 Hz, 1H), 7.35 (d, J = 8.3 Hz, 1H), 6.77- 6.60 (m, 2H), 3.80 (ss, 6H), 3.14 (d, J = 4.3 Hz, 3H). DMSO 373 (M + 1) 1.49 Method D 100 Method AQ2 1261

348.3 1H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 8.77 (dd, J = 8.0, 1.9 Hz, 1H), 8.68 (d, J = 4.6 Hz, 1H), 8.59 (s, 2H), 8.21-8.09 (m, 1H), 8.02-7.88 (m, 1H), 7.84 (d, J = 8.7 Hz, 1H), 7.71 (s, 1H), 7.67- 7.58 (m, 1H), 7.53 (dd, J = 7.6, 5.1 Hz, 1H), 3.18 (d, J = 4.4 Hz, 3H). DMSO 349 (M + 1) 1.61 Method D 100 Method AQ2 1262

313.4 1H NMR (300 MHz, DMSO) δ 9.65 (s, 1H), 9.09 (s, 1H), 8.78 (d, J = 8.0 Hz, 1H), 8.73-8.55 (m, 4H), 8.30-8.14 (m, 2H), 7.89 (d, J = 8.6 Hz, 1H), 7.63-7.47 (m, 2H), 3.19 (d, J = 4.3 Hz, 3H). DMSO 314 (M + 1) 1.70 Method C 96 Method AQ2 1263

343.4 1H NMR (300 MHz, DMSO) δ 9.64 (d, J = 1.3 Hz, 1H), 8.84- 8.74 (m, 1H), 8.68 (dd, J = 6.2, 1.7 Hz, 2H), 8.57 (d, J = 1.6 Hz, 2H), 8.16 (ddd, J = 14.4, 8.7, 2.2 Hz, 2H), 7.85 (d, J = 8.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.00 (d, J = 8.7 Hz, 1H), 3.93 (s, 3H), 3.18 (d, J = 4.3 Hz, 3H). DMSO 344.1 (M + 1) 1.94 Method C 95 Method AQ2 1264

356.4 1H NMR (300 MHz, DMSO) δ 10.76 (s, 1H), 9.75 (d, J = 1.6 Hz, 1H), 9.23 (d, J = 8.2 Hz, 1H), 9.05-8.86 (m, 2H), 8.41-8.24 (m, 2H), 8.24-8.05 (m, 2H), 7.96 (dd, J = 8.1, 5.2 Hz, 1H), 6.56 (d, J = 9.5 Hz, 1H), 4.81 (s, 2H), 3.34 (s, 3H), 3.29 (d, J = 4.3 Hz, 3H). DMSO 357.1 (M + 1) 2.13 Method C 100 Method AQ2 1265

342.4 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.78 (dd, J = 8.0, 1.9 Hz, 1H), 8.67 (dd, J = 6.3, 4.7 Hz, 2H), 8.58 (s, 1H), 8.17- 8.06 (m, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.79 (s, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.60-7.44 (m, 2H), 7.37 (d, J = 7.5 Hz, 1H), 5.31 (t, J = 5.4 Hz, 1H), 4.62 (d, J = 4.9 Hz, 2H), 3.18 (d, J = 4.4 Hz, 3H). DMSO 343.1 (M + 1) 1.78 Method C 99 Method AQ2 1266

344.4 1H NMR (300 MHz, DMSO) δ 9.65 (d, J = 2.1 Hz, 1H), 8.92- 8.59 (m, 3H), 8.59-8.47 (m, 1H), 8.40-8.11 (m, 2H), 8.04 (d, J = 8.5 Hz, 1H), 7.58 (dd, J = 7.9, 4.8 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 4.29 (s, 3H), 3.93 (s, 3H). DMSO 345.1 (M + 1) 2.32 Method C 100 Method AQ2 1267

329.4 1H NMR (300 MHz, DMSO) δ 12.77 (s, 1H), 9.33 (d, J = 1.7 Hz, 1H), 8.77 (dd, J = 4.7, 1.5 Hz, 1H), 8.60-8.46 (m, 1H), 8.23 (d, J = 8.3 Hz, 1H), 8.04 (d, J = 1.5 Hz, 1H), 7.87 (dd, J = 8.3, 1.8 Hz, 1H), 7.67-7.53 (m, 1H), 7.52-7.29 (m, 3H), 7.04 (ddd, J = 7.7, 2.4, 1.5 Hz, 1H), 3.57 (s, 3H). DMSO 330 (M + 1) 1.78 Method C 100 Method AQ2 1268

342.4 1H NMR (300 MHz, DMSO) δ 9.65 (dd, J = 2.1, 0.8 Hz, 1H), 8.84-8.74 (m, 1H), 8.68 (dd, J = 4.7, 1.7 Hz, 1H), 8.52 (d, J = 4.4 Hz, 1H), 8.30 (d, J = 8.6 Hz, 1H), 8.03 (d, J = 1.7 Hz, 1H), 7.85 (dd, J = 8.5, 1.8 Hz, 1H), 7.54 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.47-7.34 (m, 3H), 7.08-6.96 (m, 1H), 3.34 (s, 3H), 3.17 (d, J = 4.4 Hz, 3H). DMSO 343.3 (M + 1) 2.09 Method C Method AQ2 1269

342.4 1H NMR (300 MHz, DMSO) δ 9.53 (d, J = 2.0 Hz, 1H), 8.65 (dd, J = 5.9, 3.5 Hz, 2H), 8.51 (d, J = 4.2 Hz, 1H), 8.23 (d, J = 8.3 Hz, 1H), 7.84 (d, J = 7.3 Hz, 1H), 7.65-7.25 (m, 5H), 7.00 (dd, J = 8.1, 2.6 Hz, 1H), 3.33 (s, 3H), 3.17 (d, J = 4.2 Hz, 3H). DMSO 343.3 (M + 1) 2.16 Method C 100 Method AQ2 1270

2HCl 374.5 1H NMR (300 MHz, DMSO) δ 10.67 (s, 1H), 9.69 (s, 1H), 9.12 (d, J = 11.6 Hz, 2H), 8.97 (d, J = 5.0 Hz, 1H), 8.43 (d, J = 7.4 Hz, 1H), 8.31 (d, J = 8.6 Hz, 1H), 8.20 (s, 1H), 8.07 (s, 1H) 7.98-7.86 (m, 1H), 7.77 (s, 2H), 3.31 (d, J = 3.9 Hz, 3H), 2.90 (s, 3H). DMSO 375.1 (M + 1) 1.67 Method C 95 Method AQ2 1271

374.5 1H NMR (300 MHz, DMSO) δ 9.70-9.57 (m, 1H), 8.84-8.72 (m, 1H), 8.73-8.62 (m, 3H), 8.19 (dd, J = 8.7, 1.9 Hz, 1H), 8.06 (d, J = 8.4 Hz, 2H), 7.86 (dd, J = 10.6, 8.5 Hz, 3H), 7.60-7.49 (m, 1H), 3.19 (d, J = 4.4 Hz, 2H), 2.81 (s, 3H). DMSO 375.1 (M + 1) 1.64 Method C 95 Method AQ2 1272

2HCl 425.5 1H NMR (300 MHz, DMSO) δ 10.54 (s, 1H), 9.70 (d, J = 1.7 Hz, 1H), 9.12 (d, J = 8.1 Hz, 1H), 8.98 (dd, J = 5.5, 4.0 Hz, 2H), 8.37 (dd, J = 26.8, 7.9 Hz, 2H), 8.09-7.84 (m, 3H), 7.63 (t, J = 7.7 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 3.67 (bs, 8H), 3.31 (d, J = 4.3 Hz, 3H). DMSO 426.2 (M + 1) 1.72 Method C 95 Method AQ2 1273

HCl 342.4 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.77 (d, J = 7.9 Hz, 1H), 8.71-8.65 (m, 1H), 8.60 (s, 1H), 8.53 (s, 1H), 8.10 (d, J = 8.7 Hz, 1H), 7.87-7.77 (m, 3H), 7.59-7.49 (m, 1H), 7.10 (d, J = 8.7 Hz, 2H), 3.83 (d, J = 0.9 Hz, 3H), 3.19 (s, 3H). DMSO 343.1 (M + 1) 2.06 Method C 100 Method AQ2 1274

329.4 1H NMR (300 MHz, DMSO) δ 9.34 (d, J = 1.5 Hz, 1H), 8.74 (dd, J = 4.8, 1.6 Hz, 1H), 8.53 (d, J = 8.0 Hz, 1H), 8.32 (d, J = 2.1 Hz, 1H), 8.10 (dd, J = 8.5, 2.3 Hz, 1H), 7.79 (d, J = 8.6 Hz, 1H), 7.76 (s, 1H), 7.73 (s, 1H), 7.58 (dd, J = 8.0, 4.8 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 3.82 (s, 3H). DMSO 330.0 (M + 1) 1.75 Method C 100 Method AQ2 1275

343.4 1H NMR (300 MHz, DMSO) δ 9.65 (d, J = 1.5 Hz, 1H), 8.84- 8.65 (m, 4H), 8.31 (d, J = 5.4 Hz, 1H), 8.24 (dd, J = 8.7, 1.9 Hz, 1H), 7.87 (d, J = 8.7 Hz, 1H), 7.59-7.46 (m, 2H), 7.33 (d, J = 0.9 Hz, 1H), 3.93 (s, 3H), 3.20 (d, J = 4.4 Hz, 3H). DMSO 344.1 (M + 1) 1.95 Method C 95 Method AQ2 1276

331.3 1H NMR (300 MHz, DMSO) δ 9.63 (d, J = 1.4 Hz, 1H), 8.81- 8.74 (m, 1H), 8.73 (d, J = 2.3 Hz, 1H), 8.68 (dd, J = 4.7, 1.7 Hz, 1H), 8.66-8.56 (m, 2H), 8.44 (td, J = 8.2, 2.6 Hz, 1H), 8.18 (dd, J = 8.7, 2.0 Hz, 1H), 7.87 (d, J = 8.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.38 (dd, J = 8.5, 2.9 Hz, 1H), 3.18 (d, J = 4.4 Hz, 3H). DMSO 332.1 (M + 1) 1.89 Method C 100 Method AQ2 1277

425.5 1H NMR (300 MHz, DMSO) δ 9.63 (d, J = 1.4 Hz, 1H), 8.77 (d, J = 8.0 Hz, 1H), 8.70-8.59 (m, 3H), 8.15 (dd, J = 8.7, 1.6 Hz, 1H), 7.92 (d, J = 8.2 Hz, 2H), 7.85 (d, J = 8.7 Hz, 1H), 7.62- 7.48 (m, 3H), 3.62 (s, J = 54.7 Hz, 8H), 3.17 (d, J = 4.2 Hz, 3H). DMSO 426.2 (M + 1) 1.69 Method C 100 Method AQ2 1278

343.4 1H NMR (300 MHz, DMSO) δ 9.67 (d, J = 1.5 Hz, 1H), 8.86- 8.77 (m, 1H), 8.74 (dd, J = 4.7, 1.6 Hz, 1H), 8.37-8.25 (m, 2H), 8.06 (d, J = 8.7 Hz, 1H), 7.60 (dd, J = 7.9, 4.1 Hz, 1H), 7.50- 7.30 (m, 3H), 7.02 (dd, J = 7.9, 1.4 Hz, 1H), 4.31 (s, 3H), 3.87 (s, 3H). DMSO 344.2 (M + 1) 2.47 Method C 100 Method AQ2 Starting Starting Number Material 1 Material 2 Product 1279

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289

1290

1291

1292

1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

1319

1320

1321

1322

1323

1324

1325

1326

1327

1328

1329

1330

1331

1332

1333

1334

1335

1336

1337

1338

1339

1340

1341

1342

1343

1344

1345

1346

1347

1348

1349

1350

1351

1352

1353

1354

1355

1356

1357

1358

1359

1360

1361

1362

1363

1364

1365

1366

1367

1368

1369

1370

1371

1372

1373

1374

1375

1376

1377

1378

1379

1380

1381

1382

1383

1384

1385

1386

1387

1388

1389

1390

1391

1392

1393

1394

1395

1396

1397

1398

1399

1400

1401

1402

1403

1404

1405

1406

1407

1408

1409

1410

1411

1412

1413

1414

1415

1416

1417

1418

1419

1420

1421

1422

1423

1424

1425

1426

1427

1428

1429

1430

1431

1432

1433

1434

1435

1436

1437

1438

1439

1440

1441

1442

1443

1444

1445

1446

1447

1448

1449

1450

1451

1452

1453

1454

1455

1456

1457

1458

1459

1460

1461

1462

1463

1464

1465

1466

1467

1468

1469

1470

1471

1472

1473

1474

1475

1476

1477

1478

1479

1480

1481

1482

1483

1484

1485

1486

1487

1488

1489

1490

1492

1493

1494

1495

1496

1497

1498

1499

1500

1501

1502

1503

1504

1505

1506

1507

1508

1509

1510

1511

1512

1513

1514

1515

1516

1517

1518

1519

1520

1521

1522

1523

1524

1525

1526

1527

1528

1529

1530

1531

1532

1533

1534

1535

1536

1537

1538

1539

1540

1541

1542

1543

1544

1545

1546

1547

1548

1549

1550

1551

1552

1553

1554

1555

1556

1557

1558

1559

1560

1561

1562

1563

1564

1565

1566

1567

1568

1569

1570

1571

1572

1573

1574

1575

1576

1577

1578

1579

1580

1581

1583

1584

1585

1586

1587

1588

1589

1590

1591

1592

1593

1594

1595

1596

1597

1598

1599

1600

1601

1602

1603

1604

1605

1606

1607

1608

1609

1610

1611

1612

1613

1614

1615

1760

Salt ¹H NMR Purity Method of LCMS Number type ¹H NMR Solvent percent Coupling LCMS Method 1279 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.69 (d, J = 1.8 Hz, 1H), 9.40-9.33 (m, 1H), 9.03-8.93 (m, 2H), 8.64-8.59 (m, 1H), 8.18-8.14 (m, 1H), 8.13-8.05 (m, 3H), 8.04-7.97 (m, 2H), 3.21 (d, J = 4.4 Hz, 3H), 2.77 (s, 3H). DMSO >98 AQ3 1280 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.71- 9.65 (m, 1H), 9.44-9.36 (m, 1H), 9.06-8.94 (m, 2H), 8.59- 8.54 (m, 1H), 8.19-8.10 (m, 2H), 7.79-7.71 (m, 2H), 7.61- 7.54 (m, 1H), 7.29-7.22 (m, 1H), 3.21 (d, J = 3.9 Hz, 3H), 2.76 (s, 3H). DMSO >98 AQ3 1281 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.72- 9.65 (m, 1H), 9.43-9.36 (m, 1H), 9.04-8.91 (m, 2H), 8.63- 8.55 (m, 1H), 8.36-8.31 (m, 1H), 8.26-8.20 (m, 1H), 8.20- 8.11 (m, 2H), 7.91-7.85 (m, 1H), 7.78-7.70 (m, 1H), 3.22 (d, J = 4.2 Hz, 3H), 2.76 (s, 3H). DMSO >98 AQ3 1282 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.70- 9.65 (m, 1H), 9.37 (d, J = 8.2 Hz, 1H), 9.03-8.90 (m, 2H), 8.49-8.42 (m, 1H), 8.12 (dd, J = 8.1, 5.6 Hz, 1H), 8.08-8.03 (m, 1H), 7.88-7.78 (m, 2H), 7.15- 7.04 (m, 2H), 3.84 (s, 3H), 3.21 (d, J = 3.9 Hz, 3H), 2.76 (s, 3H). DMSO >98 AQ3 1283 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.73- 9.67 (m, 1H), 9.36 (d, J = 7.4 Hz, 1H), 9.02-8.96 (m, 1H), 8.82 (s, 1H), 8.26-8.19 (m, 1H), 8.15-8.07 (m, 1H), 7.89-7.83 (m, 1H), 7.47-7.38 (m, 2H), 7.21-7.15 (m, 1H), 7.14-7.06 (m, 1H), 3.81 (s, 3H), 3.19 (d, J = 4.5 Hz, 3H), 2.77 (s, 3H). DMSO >98 AQ3 1284 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.72 (d, J = 1.8 Hz, 1H), 9.34-9.28 (m, 1H), 8.95 (dd, J = 5.4, 1.4 Hz, 1H), 8.88-8.78 (m, 1H), 8.38 (d, J = 1.5 Hz, 1H), 8.07- 8.00 (m, 2H), 7.95-7.90 (m, 1H), 7.90-7.83 (m, 1H), 7.76 (dd, J = 7.8, 0.7 Hz, 1H), 7.68- 7.63 (m, 1H), 3.19 (d, J = 4.5 Hz, 3H), 2.77 (s, 3H). DMSO >98 AQ3 1285 ¹H NMR (400 MHz, DMSO) δ 9.63 (dd, J = 2.1, 0.8 Hz, 1H), 8.80- 8.75 (m, 1H), 8.69 (dd, J = 3.7, 1.8 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.58-7.49 (m, 2H), 7.46-7.40 (m, 1H), 7.39-7.32 (m, 1H), 7.28-7.18 (m, 1H), 3.18 (d, J = 4.4 Hz, 3H), 2.64 (s, 3H). DMSO >98 AQ4 1286 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.67- 9.60 (m, 1H), 9.06-8.88 (m, 3H), 8.12 (d, J = 8.8 Hz, 1H), 7.91-7.79 (m, 2H), 7.53-7.40 (m, 2H), 7.34-7.24 (m, 1H), 3.34 (d, J = 4.6 Hz, 3H), 2.66 (s, 3H). DMSO >98 AQ4 1287 HCl ¹H NMR (400 MHz, DMSO) δ 9.62- 9.57 (m, 1H), 8.94-8.86 (m, 2H), 8.62 (s, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.86-7.75 (m, 2H), 7.52-7.36 (m, 2H), 7.35-7.28 (m, 1H), 3.31 (d, J = 4.5 Hz, 3H), 2.67 (s, 3H). DMSO >98 AQ4 1288 HCl ¹H NMR (400 MHz, DMSO) δ 9.63- 9.58 (m, 1H), 8.95-8.86 (m, 2H), 8.73 (s, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.87-7.75 (m, 2H), 7.61-7.50 (m, 1H), 7.45-7.33 (m, 3H), 3.32 (d, J = 4.5 Hz, 3H), 2.66 (s, 3H). DMSO >98 AQ4 1289 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.64- 9.60 (m, 1H), 9.00-8.86 (m, 3H), 8.06 (d, J = 8.5 Hz, 1H), 7.91-7.79 (m, 2H), 7.65-7.55 (m, 1H), 7.37-7.29 (m, 1H), 7.29-7.22 (m, 2H), 3.35 (d, J = 4.6 Hz, 3H), 2.72 (s, 3H). DMSO >98 AQ4 1290 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.69- 9.64 (m, 1H), 9.14-8.99 (m, 2H), 8.96 (dd, J = 5.0, 1.5 Hz, 1H), 8.15 (d, J = 8.6 Hz, 1H), 7.90-7.81 (m, 2H), 7.50-7.34 (m, 4H), 3.35 (d, J = 4.6 Hz, 3H), 2.72 (s, 3H). DMSO >98 AQ4 1291 HCl ¹H NMR (300 MHz, CDCl₃) δ 9.63 (s, 2H), 8.96 (d, J = 8.2 Hz, 1H), 8.90 (d, J = 5.0 Hz, 1H), 8.50 (s, 1H), 8.16-7.99 (m, 2H), 7.82 (dd, J = 8.0, 4.9 Hz, 1H), 7.71- 7.62 (m, 1H), 7.61-7.47 (m, 3H), 3.26 (d, J = 4.5 Hz, 3H). DMSO >98 G2/AQ3 1292 2 HCl ¹H NMR (300 MHz, CDCl₃) δ 10.27 (s, 1H), 9.69 (s, 1H), 9.09 (d, J = 8.1 Hz, 1H), 8.97 (d, J = 5.0 Hz, 1H), 8.56 (s, 1H), 8.32 (d, J = 8.6 Hz, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.89 (dd, J = 8.0, 5.1 Hz, 1H), 7.45-7.26 (m, 4H), 3.29 (d, J = 4.2 Hz, 3H), 2.32 (s, 3H). DMSO >98 G2/AQ3 1293 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.40 (s, 1H), 9.73 (s, 1H), 9.15 (d, J = 7.9 Hz, 1H), 8.98 (d, J = 5.1 Hz, 1H), 8.67 (s, 1H), 8.33 (d, J = 8.6 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 7.91 (dd, J = 7.9, 5.2 Hz, 1H), 7.45 (m, 2H), 7.20 (d, J = 8.2 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 3.82 (s, 3H), 3.29 (d, J = 4.1 Hz, 3H). DMSO >98 G2/AQ3 1294 ¹H NMR (300 MHz, CDCl₃) δ 9.66 (s, 1H), 8.80 (d, J = 7.9 Hz, 1H), 8.74-8.67 (m, 1H), 8.60 (m, 1H), 8.49 (s, 1H), 8.00 (dd, J = 18.5, 10.4 Hz, 2H), 7.96-7.81 (m, 2H), 7.76 (d, J = 7.6 Hz, 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.56 (dd, J = 7.6, 5.0 Hz, 1H), 3.18 (d, J = 4.2 Hz, 3H). DMSO >98 G2/AQ3 1295 2 HCl ¹H NMR (300 MHz, CDCl₃) δ 9.88 (s, 1H), 9.66 (s, 1H), 9.01 (d, J = 8.3 Hz, 1H), 8.90 (d, J = 4.2 Hz, 1H), 8.70 (s, 1H), 8.27-8.08 (m, 2H), 7.81 (dd, J = 8.0, 5.1 Hz, 1H), 7.72 (t, J = 7.6 Hz, 1H), 7.60- 7.48 (m, 1H), 7.48-7.27 (m, 2H), 3.27 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1296 2 HCl ¹H NMR (300 MHz, CDCl₃) δ 9.63 (m, 2H), 8.93 (d, J = 7.7 Hz, 1H), 8.88 (d, J = 4.1 Hz, 1H), 8.76 (s, 1H), 8.29 (d, J = 8.4 Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.94 (dd, J = 8.6, 5.5 Hz, 2H), 7.82- 7.73 (m, 1H), 7.41 (t, J = 8.7 Hz, 2H), 3.28 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1297 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.82 (s, 1H), 9.64 (d, J = 1.7 Hz, 1H), 9.00 (d, J = 8.0 Hz, 1H), 8.95- 8.86 (m, 2H), 8.69 (t, J = 1.9 Hz, 1H), 8.51-8.34 (m, 2H), 8.30 (dd, J = 7.9, 1.8 Hz, 1H), 8.13 (d, J = 8.7 Hz, 1H), 7.93-7.76 (m, 2H), 3.30 (d, J = 4.5 Hz, 3H). DMSO >98 G2/AQ3 1298 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.30 (s, 1H), 9.70 (d, J = 2.1 Hz, 1H), 9.11 (d, J = 8.2 Hz, 1H), 9.04-8.83 (m, 1H), 8.56 (s, 1H), 8.26 (d, J = 8.6 Hz, 1H), 8.01- 7.80 (m, 3H), 7.78-7.64 (m, 1H), 7.60 (t, J = 7.2 Hz, 1H), 7.54 (d, J = 7.2 Hz, 1H), 3.29 (d, J = 4.4 Hz, 3H), 2.44 (s, 3H). DMSO >98 G2/AQ3 1299 ¹H NMR (300 MHz, DMSO) δ 10.50 (s, 1H), 9.66 (s, 1H), 9.09 (d, J = 8.2 Hz, 1H), 9.01 (s, 1H), 8.94 (d, J = 5.0 Hz, 1H), 8.40 (d, J = 8.7 Hz, 1H), 8.28 (d, J = 8.3 Hz, 1H), 8.13-8.00 (m, 4H), 7.88 (dd, J = 8.0, 5.2 Hz, 1H), 3.30 (d, J = 4.1 Hz, 3H), 2.62 (s, 3H). DMSO >98 G2/AQ3 1300 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.49 (s, 1H), 9.66 (s, 1H), 9.09 (d, J = 7.9 Hz, 1H), 9.01 (s, 1H), 8.95 (d, J = 5.0 Hz, 1H), 8.40 (d, J = 8.6 Hz, 1H), 8.29 (d, J = 8.7 Hz, 1H), 8.15-7.94 (m, 4H), 7.88 (dd, J = 7.9, 5.2 Hz, 1H), 3.31 (d, J = 4.1 Hz, 3H), 2.63 (s, 3H). DMSO >98 G2/AQ3 1301 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.97 (s, 1H), 9.71 (d, J = 2.0 Hz, 1H), 9.29 (s, 1H), 9.15 (d, J = 8.0 Hz, 1H), 8.98 (dd, J = 5.0, 1.3 Hz, 1H), 8.49-8.38 (m, 1H), 8.34 (d, J = 8.8 Hz, 1H), 8.21 (s, 1H), 7.92 (dd, J = 8.1, 5.1 Hz, 1H), 7.84 (s, 1H), 7.69-7.52 (m, 2H), 3.31 (d, J = 4.3 Hz, 3H), 3.23 (s, 6H). DMSO >98 G2/AQ3 1302 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.33 (s, 1H), 9.73 (d, J = 1.7 Hz, 1H), 9.20 (d, J = 8.0 Hz, 1H), 9.00 (d, J = 4.2 Hz, 1H), 8.68 (s, 1H), 8.32 (d, J = 8.6 Hz, 1H), 8.16 (d, J = 7.9 Hz, 1H), 8.01- 7.93 (m, 2H), 7.90 (t, J = 7.2 Hz, 1H), 7.74 (dd, J = 15.4, 7.7 Hz, 2H), 3.24 (t, J = 18.2 Hz, 3H). DMSO >98 G2/AQ3 1303 HCl ¹H NMR (300 MHz, DMSO) δ 10.46 (s, 1H), 9.76 (d, J = 2.1 Hz, 1H), 9.21 (d, J = 8.2 Hz, 1H), 9.00 (dd, J = 5.1, 1.2 Hz, 1H), 8.58 (d, J = 1.3 Hz, 1H), 8.41 (d, J = 8.6 Hz, 1H), 8.08-7.86 (m, 2H), 7.36-7.09 (m, 3H), 3.29 (d, J = 4.3 Hz, 3H), 2.33 (s, 3H), 2.17 (s, 3H). DMSO >98 G2/AQ3 1304 ¹H NMR (300 MHz, DMSO) δ 9.65 (d, J = 2.1 Hz, 1H), 8.79 (dt, J = 8.0, 1.9 Hz, 1H), 8.69 (dd, J = 4.7, 1.6 Hz, 1H), 8.46 (d, J = 4.5 Hz, 1H), 8.20 (d, J = 1.7 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.75 (dd, J = 8.5, 1.6 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.28- 7.02 (m, 3H), 3.33 (s, 6H), 3.15 (d, J = 4.4 Hz, 3H), 2.51 (dt, J = 3.6, 1.7 Hz, 1H), 2.35 (s, 3H), 2.27 (s, 3H). DMSO >98 G2/AQ3 1305 HCl ¹H NMR (300 MHz, DMSO) δ 10.48 (s, 1H), 9.70 (s, 1H), 9.11 (d, J = 7.8 Hz, 1H), 8.97 (d, J = 4.7 Hz, 1H), 8.90 (s, 1H), 8.36 (d, J = 8.6 Hz, 1H), 8.29 (d, J = 8.7 Hz, 1H), 7.98-7.80 (m, 1H), 7.74 (s, 1H), 7.65 (d, J = 7.5 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 3.32 (d, J = 4.0 Hz, 3H), 2.33 (d, J = 10.0 Hz, 3H), 2.29 (s, 3H). DMSO >98 G2/AQ3 1306 HCl ¹H NMR (300 MHz, DMSO) δ 10.45-10.35 (m, 1H), 9.69 (s, 1H), 9.09 (s, 1H), 8.99 (s, 1H), 8.88 (s, 1H), 8.37 (d, J = 8.6 Hz 1H), 8.28 (d, J = 8.7 Hz, 1H), 7.94 (s, 1H), 7.54 (s, 1H), 7.11 (s, 1H), 3.34 (d, J = 4.3 Hz, 3H), 2.40 (s, 3H). DMSO >98 G2/AQ3 1307 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.28 (s, 1H), 9.84-9.66 (m, 1H), 9.17 (d, J = 8.1 Hz, 1H), 8.99 (d, J = 5.0 Hz, 1H), 8.46 (s, 1H), 8.36 (d, J = 8.6 Hz, 1H), 7.98-7.80 (m, 2H), 7.41 (t, J = 8.4 Hz, 1H), 6.83 (d, J = 8.4 Hz, 2H), 3.71 (s, 6H), 3.29 (d, J = 4.2 Hz, 3H). DMSO >98 G2/AQ3 1308 HCl ¹H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.96-8.91 (m, 1H), 8.89- 8.83 (m, 2H), 8.41 (d, J = 9.1 Hz, 2H), 8.38-8.32 (m, 1H), 8.16 (d, J = 9.0 Hz, 2H), 8.02 (d, J = 9.1 Hz, 1H), 7.81-7.73 (m, 1H), 3.27 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1309 ¹H NMR (300 MHz, DMSO) δ 9.64 (d, J = 2.0 Hz, 1H), 8.78 (ddd, J = 14.6, 8.2, 6.5 Hz, 1H), 8.70 (dd, J = 4.7, 1.4 Hz, 1H), 8.56 (d, J = 4.3 Hz, 1H), 8.33 (d, J = 1.5 Hz, 1H), 8.06 (dd, J = 8.6, 1.4 Hz, 1H), 7.81 (d, J = 8.6 Hz, 1H), 7.56 (dd, J = 7.9, 4.8 Hz, 1H), 7.34 (t, J = 7.5 Hz, 2H), 7.20- 7.00 (m, 2H), 3.16 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1310 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.63 (s, 1H), 9.69 (s, 1H), 9.16 (s, 1H), 9.10 (d, J = 7.9 Hz, 1H), 8.97 (d, J = 5.0 Hz, 1H), 8.52 (s, 1H), 8.45 (d, J = 8.7 Hz, 1H), 8.29 (d, J = 8.7 Hz, 2H), 8.07 (d, J = 7.8 Hz, 1H), 8.01-7.84 (m, 2H), 7.63 (t, J = 7.8 Hz, 1H), 7.54 (s, 1H), 3.31 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1311 HCl ¹H NMR (300 MHz, DMSO) δ 10.20 (s, 1H), 9.65 (s, 1H), 9.02 (s, 1H), 8.95 (s, 2H), 8.43 (d, J = 8.7 Hz, 1H), 8.26-8.14 (m, 1H), 8.04 (dd, J = 18.8, 8.1 Hz, 4H), 7.88 (s, 1H), 7.47 (s, 1H), 3.32 (s, 3H), 3.17 (d, J = 1.8 Hz, 9H). DMSO >98 G2/AQ3 1312 HCl ¹H NMR (300 MHz, DMSO) δ 9.79 (s, 1H), 9.66 (d, J = 1.7 Hz, 1H), 9.02 (d, J = 8.1 Hz, 1H), 8.96- 8.86 (m, 1H), 8.57 (s, 1H), 8.18 (d, J = 8.7 Hz, 1H), 8.05 (dd, J = 8.7, 1.4 Hz, 1H), 7.82 (dd, J = 8.1, 5.0 Hz, 1H), 7.79-7.72 (m, 1H), 7.64-7.45 (m, 2H), 3.25 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1313 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.01 (s, 1H), 9.65 (s, 1H), 9.06 (d, J = 7.8 Hz, 1H), 8.95 (d, J = 4.8 Hz, 1H), 8.59 (s, 1H), 8.21 (d, J = 8.6 Hz, 1H), 8.07 (d, J = 9.1 Hz, 1H), 7.95-7.77 (m, 2H), 7.66-7.52 (m, 2H), 3.27 (d, J = 4.3 Hz, 3H), 3.17 (d, J = 0.7 Hz, 1H). DMSO >98 G2/AQ3 1314 HCl ¹H NMR (300 MHz, DMSO) δ 10.10 (s, 1H), 9.69 (s, 1H), 9.13 (d, J = 8.0 Hz, 1H), 8.98 (d, J = 5.1 Hz, 1H), 8.62 (s, 1H), 8.27 (d, J = 8.6 Hz, 1H), 8.13 (d, J = 8.3 Hz, 1H), 8.02-7.83 (m, 1H), 7.77-7.65 (m, 2H), 7.60 (d, J = 8.5 Hz, 1H), 3.29 (d, J = 3.9 Hz, 3H). DMSO >98 G2/AQ3 1315 HCl ¹H NMR (300 MHz, DMSO) δ 9.62 (s, 1H), 9.02-8.93 (m, 1H), 8.89 (d, J = 4.5 Hz, 1H), 8.80 (s, 1H), 8.35 (d, J = 8.7 Hz, 1H), 8.18 (s, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.96-7.75 (m, 2H), 3.29 (d, J = 4.2 Hz, 3H). DMSO >98 G2/AQ3 1316 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.36 (s, 1H), 9.67 (s, 1H), 9.13 (d, J = 8.2 Hz, 1H), 9.01-8.82 (m, 2H), 8.40 (d, J = 9.1 Hz, 1H), 8.26 (d, J = 8.7 Hz, 1H), 7.97 (s, 2H), 7.90 (dd, J = 8.0, 5.2 Hz, 1H), 7.65 (s, 1H), 3.31 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1317 ¹H NMR (300 MHz, DMSO) δ 9.65 (d, J = 1.9 Hz, 1H), 8.89-8.75 (m, 1H), 8.74-8.67 (m, 1H), 8.67-8.56 (m, 1H), 8.48 (s, 1H), 8.06-7.94 (m, 1H), 7.87 (d, J = 8.7 Hz, 1H), 7.68-7.51 (m, 2H), 7.46 (td, J = 9.6, 4.7 Hz, 1H), 7.39-7.21 (m, 1H), 3.18 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1318 HCl ¹H NMR (300 MHz, DMSO) δ 10.57 (s, 1H), 9.69 (d, J = 2.0 Hz, 1H), 9.15 (d, J = 8.0 Hz, 1H), 9.02 (s, 1H), 8.97 (d, J = 4.4 Hz, 1H), 8.40 (d, J = 8.8 Hz, 1H), 8.29 (d, J = 8.7 Hz, 1H), 7.91 (dd, J = 8.0, 5.2 Hz, 1H), 7.77- 7.63 (m, 2H), 7.37-7.18 (m, 1H), 3.29 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1319 ¹H NMR (300 MHz, CDCl₃) δ 9.58 (d, J = 2.0 Hz, 1H), 8.78-8.60 (m, 2H), 8.35 (d, J = 1.7 Hz, 1H), 8.11-7.84 (m, 3H), 7.78 (d, J = 8.6 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.48-7.34 (m, 2H), 7.17 (d, J = 8.1 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 3.81 (s, 3H). DMSO >98 G2/AQ3 1320 ¹H NMR (300 MHz, CDCl₃) δ 9.62 (d, J = 2.1 Hz, 1H), 8.82-8.72 (m, 1H), 8.72-8.66 (m, 1H), 8.30 (s, 1H), 7.93 (dd, J = 8.7, 1.2 Hz, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.50-7.33 (m, 2H), 7.18 (d, J = 8.3 Hz, 1H), 7.09 (t, J = 7.5 Hz, 1H), 3.82 (s, 3H), 3.46 (s, 6H). DMSO >98 G2/AQ3 1321 ¹H NMR (300 MHz, CDCl₃) δ 9.59 (d, J = 2.1 Hz, 1H), 8.76-8.66 (m, 2H), 8.50 (s, 2H), 8.06 (brs, 1H), 7.99 (dt, J = 8.6, 1.7 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.75-7.63 (m, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.52-7.44 (m, 1H), 7.44-7.32 (m, 2H). DMSO >98 G2/AQ3 1322 ¹H NMR (300 MHz, CDCl₃) δ 9.59 (d, J = 2.1 Hz, 1H), 8.79-8.62 (m, 3H), 8.21 (dd, J = 8.8, 1.9 Hz, 1H), 8.10 (brs, 2H), 7.86 (d, J = 8.7 Hz, 1H), 7.80-7.69 (m, 2H), 7.68-7.49 (m, 2H), 7.32- 7.20 (m, 1H). DMSO >98 G2/AQ3 1323 ¹H NMR (300 MHz, CDCl₃) δ 9.58 (d, J = 2.0 Hz, 1H), 8.80-8.64 (m, 2H), 8.62 (d, J = 1.8 Hz, 1H), 8.14 (dd, J = 8.7, 1.9 Hz, 1H), 8.07 (brs, 2H), 7.98-7.87 (m, 2H), 7.85 (d, J = 8.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.38 (t, J = 8.8 Hz, 2H). DMSO >98 G2/AQ3 1324 ¹H NMR (300 MHz, CDCl₃) δ 9.65- 9.57 (m, 1H), 8.82-8.70 (m, 1H), 8.70-8.63 (m, 1H), 8.36 (d, J = 1.8 Hz, 1H), 8.11 (dd, J = 8.7, 1.7 Hz, 1H), 7.89 (d, J = 8.7 Hz, 1H), 7.72-7.60 (m, 2H), 7.60-7.47 (m, 2H), 7.32-7.18 (m, 1H), 3.49 (s, 6H). DMSO >98 G2/AQ3 1325 ¹H NMR (400 MHz, DMSO) δ 9.64 (d, J = 1.4 Hz, 1H), 8.78 (dt, J = 8.3, 1.8 Hz, 1H), 8.69 (dd, J = 4.7, 1.8 Hz, 1H), 8.61-8.46 (m, 2H), 8.40 (d, J = 1.6 Hz, 1H), 7.99 (dd, J = 9.0, 1.8 Hz, 1H), 7.83 (d, J = 9.0 Hz, 1H), 7.54 (dd, J = 8.4, 4.5 Hz, 1H), 3.99 (d, J = 8.9 Hz, 6H), 3.17 (d, J = 4.6 Hz, 3H). DMSO >98 G2/AQ3 1326 ¹H NMR (300 MHz, DMSO) δ 9.64- 9.55 (m, 1H), 8.81-8.62 (m, 3H), 8.40 (s, 1H), 8.23 (dd, J = 8.8, 1.4 Hz, 1H), 8.13 (d, J = 7.7 Hz, 1H), 8.00 (d, J = 7.7 Hz, 2H), 7.89 (d, J = 8.7 Hz, 1H), 7.69 (t, J = 7.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 2.71 (s, 3H). DMSO >98 G2/AQ3 1327 ¹H NMR (300 MHz, DMSO) δ 9.58 (d, J = 2.1 Hz, 1H), 8.76-8.65 (m, 3H), 8.24 (dd, J = 8.7, 1.8 Hz, 1H), 8.19-7.93 (m, 6H), 7.88 (d, J = 8.8 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1HH), 2.65 (s, 3H). DMSO >98 G2/AQ3 1328 ¹H NMR (300 MHz, DMSO) δ 9.60 (d, J = 1.8 Hz, 1H), 8.73 (dt, J = 8.0, 1.8 Hz, 1H), 8.69 (dd, J = 4.8, 1.6 Hz, 1H), 8.37 (s, 1H), 7.99 (brs, 2H), 7.92-7.81 (m, 2H), 7.67-7.60 (m, 1H), 7.60- 7.52 (m, 2H), 7.52-7.43 (m, 2H). DMSO >98 G2/AQ3 1329 ¹H NMR (300 MHz, DMSO) δ 9.60 (d, J = 2.0 Hz, 1H), 8.77-8.65 (m, 3H), 8.19 (dd, J = 8.7, 1.8 Hz, 1H), 8.09 (brs, 2H), 7.99- 7.94 (m, 1H), 7.90-7.79 (m, 2H), 7.63-7.51 (m, 2H), 7.48 (d, J = 8.1 Hz, 1H). DMSO >98 G2/AQ3 1330 ¹H NMR (300 MHz, DMSO) δ 9.65 (s, 1H), 8.87-8.75 (m, 1H), 8.70 (s, 1H), 8.55 (s, 1H), 8.41 (s, 1H), 8.25 (s, 1H), 8.09-7.76 (m, 3H), 7.62-7.44 (m, 1H), 7.18 (s, 1H), 3.93 (s, 3H), 3.17 (s, 3H). DMSO >98 G2/AQ3 1331 ¹H NMR (300 MHz, DMSO) δ 9.61 (s, 1H), 8.75 (d, J = 7.6 Hz, 1H), 8.68 (s, 1H), 8.45 (s, 1H), 8.18 (d, J = 9.2 Hz, 1H), 8.07 (d, J = 8.2 Hz, 2H), 8.01-7.87 (m, 3H), 7.55 (s, 1H), 3.51 (s, 6H), 2.63 (s, 3H). DMSO >98 G2/AQ3 1332 ¹H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 8.83-8.72 (m, 1H), 8.70 (d, J = 3.3 Hz, 1H), 8.21 (s, 1H), 7.89 (q, J = 8.6 Hz, 2H), 7.74- 7.41 (m, 5H), 3.47 (s, 6H). DMSO >98 G2/AQ3 1333 ¹H NMR (300 MHz, DMSO) δ 9.62 (d, J = 2.0 Hz, 1H), 8.76 (dt, J = 7.9, 1.8 Hz, 1H), 8.70 (dd, J = 4.8, 1.6 Hz, 1H), 8.38 (d, J = 1.9 Hz, 1H), 8.13 (dd, J = 8.7, 1.9 Hz, 1H), 7.98-7.84 (m, 2H), 7.78 (d, J = 7.6 Hz, 1H), 7.66-7.41 (m, 3H), 3.51 (s, 6H). DMSO >98 G2/AQ3 1334 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.81- 9.63 (m, 1H), 9.18 (d, J = 8.4 Hz, 1H), 9.07-8.89 (m, 1H), 8.39 (d, J = 8.7 Hz, 1H), 8.31 (d, J = 1.7 Hz, 1H), 8.22-8.07 (m, 1H), 8.02 (dd, J = 8.7, 1.7 Hz, 1H), 7.98-7.91 (m, 1H), 7.91- 7.83 (m, 1H), 7.80-7.68 (m, 2H), 3.65 (s, 6H). DMSO >98 G2/AQ3 1335 ¹H NMR (300 MHz, DMSO) δ 9.65- 9.62 (m, 1H), 8.82-8.75 (m, 1H), 8.73-8.68 (m, 1H), 8.61- 8.56 (m, 1H), 8.50 (d, J = 2.0 Hz, 1H), 8.34-8.20 (m, 3H), 7.97 (d, J = 8.7 Hz, 1H), 7.82 (t, J = 8.0 Hz, 1H), 7.57 (dd, J = 8.3, 5.2 Hz, 1H), 3.54 (s, 6H). DMSO >98 G2/AQ3 1336 ¹H NMR (300 MHz, DMSO) δ 9.61 (d, J = 1.8 Hz, 1H), 8.80-8.72 (m, 1H), 8.72-8.67 (m, 1H), 8.47 (d, J = 1.6 Hz, 1H), 8.39- 8.29 (m, 2H), 8.19 (dd, J = 8.7, 1.8 Hz, 1H), 8.14-8.07 (m, 2H), 7.94 (d, J = 8.7 Hz, 1H), 7.55 (dd, J = 7.9, 4.8 Hz, 1H), 3.52 (s, 6H). DMSO >98 G2/AQ3 1337 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.67- 9.61 (m, 1H), 8.82-8.73 (m, 1H), 8.73-8.65 (m, 1H), 8.39 (s, 1H), 8.03-7.96 (m, 3H), 7.90- 7.72 (m, 2H), 7.72-7.60 (m, 1H), 7.56 (dd, J = 7.6, 5.1 Hz, 1H), 3.53 (s, 6H). DMSO >98 G2/AQ3 1338 ¹H NMR (300 MHz, DMSO) δ 9.65 (d, J = 2.1 Hz, 1H), 8.78 (dt, J = 8.1, 1.8 Hz, 1H), 8.71-8.59 (m, 3H), 8.19 (dd, J = 8.6, 1.7 Hz, 1H), 8.07-7.95 (m, 2H), 7.93- 7.81 (m, 2H), 7.54 (dd, J = 7.9, 4.7 Hz, 1H), 7.47-7.34 (m, 2H), 3.23-3.20 (m, 3H). DMSO >98 G2/AQ3 1339 ¹H NMR (300 MHz, DMSO) δ 9.68- 9.64 (m, 1H), 8.83-8.75 (m, 1H), 8.69 (d, J = 4.7 Hz, 1H), 8.56-8.45 (m, 2H), 8.17-8.05 (m, 1H), 8.05-7.87 (m, 4H), 7.58-7.40 (m, 3H), 3.18 (d, J = 4.1 Hz, 3H). DMSO >98 G2/AQ3 1340 ¹H NMR (300 MHz, DMSO) δ 9.67 (d, J = 1.5 Hz, 1H), 8.80 (dt, J = 7.9, 1.9 Hz, 1H), 8.69 (dd, J = 4.8, 1.7 Hz, 1H), 8.57-8.41 (m, 2H), 8.08 (dd, J = 6.1, 2.6 Hz, 1H), 7.99 (dd, J = 8.6, 1.8 Hz, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.84 (d, J = 5.6 Hz, 1H), 7.62- 7.44 (m, 4H), 3.17 (d, J = 4.5 Hz, 3H). DMSO >98 G2/AQ3 1341 ¹H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.5 Hz, 1H), 8.79 (dt, J = 7.9, 1.9 Hz, 1H), 8.68 (dd, J = 4.8, 1.7 Hz, 1H), 8.65 (d, J = 1.9 Hz, 1H), 8.61-8.53 (m, 1H), 8.35 (d, J = 1.6 Hz, 1H), 8.21 (dd, J = 8.7, 2.0 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.92-7.80 (m, 3H), 7.59-7.48 (m, 2H), 3.21 (d, J = 4.5 Hz, 3H). DMSO >98 G2/AQ3 1342 ¹H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.6 Hz, 1H), 8.79 (dt, J = 8.0, 1.9 Hz, 1H), 8.73-8.61 (m, 3H), 8.50 (s, 1H), 8.24 (dd, J = 8.7, 1.9 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.96-7.82 (m, 3H), 7.60-7.50 (m, 2H), 3.21 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1343 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.41 (brs, 1H), 9.75 (d, J = 1.7 Hz, 1H), 9.24-9.19 (m, 1H), 9.01 (dd, J = 5.2, 1.5 Hz, 1H), 8.90 (d, J = 1.5 Hz, 1H), 8.46 (d, J = 8.7 Hz, 1H), 8.39 (dd, J = 8.7, 1.7 Hz, 1H), 8.06-7.91 (m, 2H), 7.86 (d, J = 5.5 Hz, 1H), 7.66-7.52 (m, 3H), 3.29 (d, J = 4.5 Hz, 3H). DMSO >98 G2/AQ3 1344 HCl ¹H NMR (300 MHz, DMSO) δ 10.33 (brs, 1H), 9.78 (d, J = 2.0 Hz, 1H), 9.23 (d, J = 8.1 Hz, 1H), 9.01 (d, J = 5.0 Hz, 1H), 8.73 (s, 1H), 8.48 (d, J = 8.6 Hz, 1H), 8.14 (d, J = 8.6 Hz, 1H), 8.05 (d, J = 8.0 Hz, 2H), 7.95 (dd, J = 8.1, 5.2 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.72-7.50 (m, 4H), 3.27 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1345 ¹H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.4 Hz, 1H), 8.85-8.77 (m, 1H), 8.77-8.62 (m, 3H), 8.40 (s, 1H), 8.30 (dd, J = 8.7, 1.6 Hz, 1H), 8.14-7.95 (m, 4H), 7.91 (d, J = 8.7 Hz, 1H), 7.63- 7.50 (m, 3H), 3.22 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1346 ¹H NMR (300 MHz, DMSO) δ 9.67 (d, J = 2.0 Hz, 1H), 8.80 (dt, J = 8.0, 1.9 Hz, 1H), 8.69 (dd, J = 4.7, 1.7 Hz, 1H), 8.67-8.55 (m, 2H), 8.25 (dd, J = 8.7, 1.8 Hz, 1H), 8.13-8.09 (m, 1H), 7.92- 7.77 (m, 4H), 7.71 (d, J = 7.8 Hz, 1H), 7.67-7.47 (m, 4H), 7.47- 7.37 (m, 1H), 3.20 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1347 ¹H NMR (300 MHz, DMSO) δ 9.68- 9.65 (m, 1H), 8.79 (dt, J = 8.0, 1.9 Hz, 1H), 8.69 (dd, J = 4.8, 1.7 Hz, 1H), 8.68-8.60 (m, 2H), 8.20 (dd, J = 8.7, 1.9 Hz, 1H), 7.99-7.95 (m, 2H), 7.92-7.81 (m, 3H), 7.80-7.73 (m, 2H), 7.61-7.46 (m, 3H), 7.46-7.36 (m, 1H), 3.20 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1348 ¹H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.5 Hz, 1H), 8.80 (dt, J = 7.9, 1.9 Hz, 1H), 8.70 (dd, J = 4.7, 1.7 Hz, 1H), 8.55 (d, J = 4.6 Hz, 1H), 8.32 (d, J = 8.6 Hz, 1H), 8.04 (d, J = 1.8 Hz, 1H), 7.92- 7.84 (m, 3H), 7.60-7.50 (m, 3H), 7.50-7.42 (m, 1H), 3.18 (d, J = 4.5 Hz, 3H). DMSO >98 G2/AQ3 1349 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.23 (brs, 1H), 9.67 (d, J = 2.1 Hz, 1H), 9.04 (d, J = 7.7 Hz, 1H), 8.98-8.91 (m, 1H), 8.57 (d, J = 8.7 Hz, 1H), 8.43 (s, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.91-7.76 (m, 3H), 7.22-7.10 (m, 2H), 3.85 (s, 3H), 3.31 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1350 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.48 (brs, 1H), 9.74 (d, J = 1.9 Hz, 1H), 9.19 (d, J = 8.3 Hz, 1H), 9.07-8.97 (m, 1H), 8.71 (d, J = 8.8 Hz, 1H), 8.64 (s, 1H), 8.36 (s, 1H), 8.19 (d, J = 7.6 Hz, 1H), 8.16-8.06 (m, 2H), 7.95 (dd, J = 8.1, 5.0 Hz, 1H), 7.75 (t, J = 7.7 Hz, 1H), 3.31 (d, J = 4.4 Hz, 3H), 2.71 (s, 3H). DMSO >98 G2/AQ3 1351 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.47 (brs, 1H), 9.73 (d, J = 1.3 Hz, 1H), 9.19 (d, J = 8.3 Hz, 1H), 9.03-8.94 (m, 1H), 8.69-8.62 (m, 2H), 8.15-8.07 (m, 3H), 8.02-7.77 (m, 3H), 3.29 (d, J = 4.3 Hz, 3H), 2.65 (s, 3H). DMSO >98 G2/AQ3 1352 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.44 (brs, 1H), 9.74 (s, 1H), 9.19 (d, J = 7.3 Hz, 1H), 8.99 (d, J = 5.2 Hz, 1H), 8.68 (d, J = 8.4 Hz, 1H), 8.37 (s, 1H), 8.03-7.90 (m, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.72-7.62 (m, 1H), 7.53 (d, J = 9.6 Hz, 3H), 3.32 (d, J = 4.0 Hz, 3H). DMSO >98 G2/AQ3 1353 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.48 (brs, 1H), 9.77 (s, 1H), 9.29- 9.23 (m, 1H), 9.05-8.97 (m, 1H), 8.74-8.59 (m, 2H), 8.20- 8.08 (m, 1H), 8.02-7.95 (m, 1H), 7.90 (s, 1H), 7.84-7.79 (m, 1H), 7.68-7.57 (m, 2H), 3.35- 3.29 (m, 3H). DMSO >98 G2/AQ3 1354 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.35 (brs, 1H), 9.72 (d, J = 2.0 Hz, 1H), 9.21-9.11 (m, 1H), 8.98 (dd, J = 5.1, 1.4 Hz, 1H), 8.65 (d, J = 8.7 Hz, 1H), 8.59 (s, 1H), 8.09 (dd, J = 8.8, 1.7 Hz, 1H), 7.95-7.82 (m, 3H), 7.70- 7.60 (m, 2H), 3.30 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1355 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.51 (brs, 1H), 9.77 (d, J = 1.9 Hz, 1H), 9.22 (d, J = 8.2 Hz, 1H), 9.01 (dd, J = 5.1, 1.4 Hz, 1H), 8.69 (s, 1H), 8.40 (d, J = 8.7 Hz, 1H), 8.17 (dd, J = 8.7, 1.6 Hz, 1H), 7.96 (dd, J = 8.1, 5.2 Hz, 1H), 7.30-7.15 (m, 2H), 7.10 (dd, J = 7.3, 1.9 Hz, 1H), 3.89 (s, 3H), 3.59 (s, 3H), 3.30 (d, J = 4.5 Hz, 3H). DMSO >98 G2/AQ3 1356 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.42 (s, 1H), 9.71 (d, J = 1.8 Hz, 1H), 9.12 (d, J = 8.1 Hz, 1H), 8.97 (dd, J = 5.1, 1.5 Hz, 1H), 8.71 (s, 1H), 8.30 (d, J = 8.7 Hz, 1H), 8.19 (dd, J = 8.7, 1.6 Hz, 1H), 7.90 (dd, J = 7.9, 5.1 Hz, 1H), 7.18-7.06 (m, 2H), 7.01 (dd, J = 8.9, 3.1 Hz, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 3.30 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1357 HCl ¹H NMR (300 MHz, DMSO) δ 10.21 (brs, 1H), 9.63 (s, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.93 (d, J = 3.7 Hz, 1H), 8.87 (s, 1H), 8.37 (d, J = 8.9 Hz, 1H), 8.15 (d, J = 8.2 Hz, 1H), 7.91-7.78 (m, 1H), 7.05 (d, J = 2.1 Hz, 2H), 6.66- 6.58 (m, 1H), 3.87 (s, 6H), 3.31 (d, J = 4.2 Hz, 3H). DMSO >98 G2/AQ3 1358 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.43 (brs, 1H), 9.73 (d, J = 1.8 Hz, 1H), 9.17 (d, J = 8.2 Hz, 1H), 8.99 (dd, J = 5.0, 1.3 Hz, 1H), 8.69 (d, J = 8.6 Hz, 1H), 8.49 (s, 1H), 8.05-7.88 (m, 2H), 7.71 (t, J = 7.9 Hz, 1H), 7.64-7.50 (m, 1H), 7.50-7.33 (m, 2H), 3.32 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1359 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.29 (s, 1H), 9.70 (d, J = 1.7 Hz, 1H), 9.14 (d, J = 8.3 Hz, 1H), 8.97 (dd, J = 5.1, 1.3 Hz, 1H), 8.63 (d, J = 8.7 Hz, 1H), 8.58 (s, 1H), 8.15-8.04 (m, 1H), 7.90 (dd, J = 8.0, 5.1 Hz, 1H), 7.75- 7.57 (m, 3H), 7.43-7.30 (m, 1H), 3.30 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1360 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.41 (brs, 1H), 9.73 (d, J = 1.9 Hz, 1H), 9.16 (d, J = 8.3 Hz, 1H), 8.98 (dd, J = 5.1, 1.4 Hz, 1H), 8.65 (d, J = 8.8 Hz, 1H), 8.60 (s, 1H), 8.12-8.02 (m, 1H), 8.00- 7.84 (m, 3H), 7.49-7.33 (m, 2H), 3.30 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1361 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.39 (s, 1H), 9.71 (d, J = 1.8 Hz, 1H), 9.17-9.08 (m, 1H), 8.97 (dd, J = 5.1, 1.5 Hz, 1H), 8.64 (d, J = 8.7 Hz, 1H), 8.58 (s, 1H), 8.07 (dd, J = 8.6, 1.7 Hz, 1H), 7.88 (dd, J = 8.1, 5.2 Hz, 1H), 7.70-7.58 (m, 2H), 7.46 (t, J = 7.6 Hz, 1H), 7.33 (d, J = 7.4 Hz, 1H), 3.30 (d, J = 4.4 Hz, 3H), 2.43 (s, 3H). DMSO >98 G2/AQ3 1362 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.37 (brs, 1H), 9.70 (d, J = 1.7 Hz, 1H), 9.10 (d, J = 8.1 Hz, 1H), 8.96 (dd, J = 5.0, 1.4 Hz, 1H), 8.62 (d, J = 8.7 Hz, 1H), 8.58 (s, 1H), 8.08 (dd, J = 8.6, 1.6 Hz, 1H), 7.87 (dd, J = 7.9, 5.0 Hz, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 3.30 (d, J = 4.4 Hz, 3H), 2.40 (s, 3H). DMSO >98 G2/AQ3 1363 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.82 (brs, 1H), 9.65 (s, 1H), 9.14- 9.02 (m, 1H), 9.02-8.90 (m, 1H), 8.64-8.51 (m, 1H), 8.20 (s, 1H), 8.07 (d, J = 7.8 Hz, 1H), 8.00-7.85 (m, 3H), 7.85-7.66 (m, 2H), 3.30 (s, 3H). DMSO >98 G2/AQ3 1364 HCl ¹H NMR (300 MHz, DMSO) δ 9.83 (brs, 1H), 9.68-9.63 (m, 1H), 9.12-9.02 (m, 1H), 9.01-8.91 (m, 1H), 8.56 (d, J = 9.2 Hz, 1H), 8.42 (s, 1H), 8.35 (s, 1H), 8.19 (d, J = 8.7 Hz, 1H), 8.13 (d, J = 9.3 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.93-7.84 (m, 1H), 7.79 (t, J = 8.2 Hz, 1H), 3.28 (d, 4.5 Hz, 3H). DMSO >98 G2/AQ3 1365 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.27 (brs, 1H), 9.72 (s, 1H), 9.23- 9.10 (m, 1H), 8.98 (s, 1H), 8.77- 8.55 (m, 2H), 8.18-7.86 (m, 6H), 3.34-3.27 (m, 3H). DMSO >98 G2/AQ3 1366 ¹H NMR (300 MHz, DMSO) δ 9.66 (d, J = 2.0 Hz, 1H), 8.79 (dt, J = 7.9, 1.9 Hz, 1H), 8.69 (dd, J = 4.7, 1.6 Hz, 1H), 8.65-8.53 (m, 2H), 8.22-8.12 (m, 3H), 7.92 (dd, J = 8.8, 1.5 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 4.11 (s, 3H), 3.20 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1367 ¹H NMR (300 MHz, DMSO) δ 11.10 (s, 1H), 9.63 (d, J = 2.0 Hz, 1H), 8.85 (d, J = 1.7 Hz, 1H), 8.81-8.70 (m, 2H), 8.39 (dd, J = 8.9, 1.9 Hz, 1H), 8.15-8.02 (m, 5H), 7.60 (dd, J = 8.0, 4.8 Hz, 1H), 2.65 (s, 3H), 2.61 (s, 3H). 1368 HCl ¹H NMR (300 MHz, DMSO) δ 9.72 (d, J = 1.8 Hz, 1H), 9.27-9.21 (m, 1H), 8.97 (dd, J = 5.3, 1.4 Hz, 1H), 8.50 (dd, J = 8.8, 2.1 Hz, 1H), 8.34 (d, J = 1.9 Hz, 1H), 8.30 (d, J = 8.8 Hz, 1H), 8.15- 8.09 (m, 2H), 8.09-7.98 (m, 3H), 3.55 (s, 3H), 2.65 (s, 3H), 2.22 (s, 3H). DMSO >98 G2/AQ3 1369 HCl ¹H NMR (300 MHz, DMSO) δ 11.16 (s, 1H), 9.67 (s, 1H), 9.20 (d, J = 8.2 Hz, 1H), 8.97 (d, J = 4.3 Hz, 1H), 8.75 (s, 1H), 8.23 (d, J = 8.7 Hz, 1H), 8.14 (d, J = 8.8 Hz, 1H), 8.02 (dd, J = 8.0, 5.5 Hz, 1H), 7.66-7.47 (m, 2H), 7.47- 7.34 (m, 1H), 2.56 (s, 3H). DMSO >98 G2/AQ3 1370 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.17 (brs, 1H), 9.68 (d, J = 2.0 Hz, 1H), 9.06 (d, J = 8.0 Hz, 1H), 8.95 (dd, J = 5.0, 1.4 Hz, 1H), 8.77 (s, 1H), 8.31 (s, 2H), 8.16 (d, J = 2.1 Hz, 1H), 7.87 (dd, J = 7.8, 5.2 Hz, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.61-7.47 (m, 2H), 7.19 (d, J = 1.4 Hz, 1H), 3.31 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1371 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.28 (brs, 1H), 9.71 (s, 1H), 9.16 (d, J = 7.9 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.67 (d, J = 8.9 Hz, 1H), 8.45 (s, 1H), 8.01-7.83 (m, 2H), 7.68-7.50 (m, 2H), 7.50- 7.35 (m, 1H), 3.31 (d, J = 4.1 Hz, 3H). DMSO >98 G2/AQ3 1372 HCl ¹H NMR (300 MHz, DMSO) δ 9.72- 9.45 (m, 2H), 8.95 (d, J = 7.6 Hz, 1H), 8.88 (d, J = 3.8 Hz, 1H), 8.49 (d, J = 8.5 Hz, 1H), 8.13 (s, 1H), 7.91-7.75 (m, 3H), 7.53- 7.43 (m, 1H), 7.36-7.25 (m, 1H), 3.27 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1373 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.04 (brs, 1H), 9.70 (s, 1H), 9.22- 9.07 (m, 1H), 8.93 (s, 1H), 8.62 (d, J = 7.6 Hz, 1H), 8.55 (s, 1H), 8.06 (d, J = 8.9 Hz, 1H), 7.99- 7.79 (m, 2H), 7.79-7.55 (m, 2H), 3.33-3.27 (m, 3H). DMSO >98 G2/AQ3 1374 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 9.34 (brs, 1H), 9.06- 8.92 (m, 1H), 8.86 (s, 1H), 8.50- 8.37 (m, 1H), 8.25 (s, 1H), 8.11- 7.95 (m, 1H), 7.85-7.74 (m, 1H), 7.74-7.57 (m, 2H), 7.43- 7.29 (m, 1H), 3.28-3.21 (m, 3H). DMSO >98 G2/AQ3 1375 HCl ¹H NMR (300 MHz, DMSO) δ 9.63 (d, J = 1.6 Hz, 1H), 9.38 (brs, 1H), 9.01-8.91 (m, 1H), 8.84 (dd, J = 5.0, 1.6 Hz, 1H), 8.60 (s, 1H), 8.08 (s, 2H), 7.76 (dd, J = 7.9, 5.1 Hz, 1H), 7.64-7.38 (m, 2H), 3.26 (d, J = 3.7 Hz, 3H). DMSO >98 G2/AQ3 1376 HCl ¹H NMR (300 MHz, DMSO) δ 9.88 (brs, 1H), 9.65 (s, 1H), 9.18- 8.99 (m, 1H), 8.90 (s, 1H), 8.70 (s, 1H), 8.31-8.03 (m, 2H), 7.94- 7.77 (m, 2H), 7.77-7.57 (m, 1H), 3.28 (s, 3H). DMSO >98 G2/AQ3 1377 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.33 (s, 1H), 9.67 (s, 1H), 9.10 (d, J = 7.8 Hz, 1H), 9.02 (s, 1H), 8.92 (d, J = 5.0 Hz, 1H), 8.35 (d, J = 8.8 Hz, 1H), 8.25 (d, J = 8.8 Hz, 1H), 8.03-7.76 (m, 3H), 3.31 (s, 3H). DMSO >98 G2/AQ3 1378 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.7 Hz, 1H), 9.56-9.34 (m, 1H), 9.26-9.10 (m, 1H), 9.05 (d, J = 4.7 Hz, 1H), 8.44 (s, 1H), 8.19 (dd, J = 8.1, 5.7 Hz, 1H), 7.95 (d, J = 11.5 Hz, 1H), 7.63-7.45 (m, 2H), 7.45-7.26 (m, 1H), 3.19 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1379 HCl ¹H NMR (300 MHz, DMSO) δ 9.67- 9.59 (m, 1H), 9.38 (d, J = 8.3 Hz, 1H), 9.22-9.10 (m, 1H), 9.03 (d, J = 4.9 Hz, 1H), 8.37 (s, 1H), 8.16 (dd, J = 8.1, 5.6 Hz, 1H), 7.89 (d, J = 11.6 Hz, 1H), 7.78 (td, J = 8.9, 6.6 Hz, 1H), 7.54-7.36 (m, 1H), 7.30 (td, J = 8.3, 2.0 Hz, 1H), 3.18 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1380 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.72 (d, J = 1.6 Hz, 1H), 9.25-9.14 (m, 1H), 8.99 (dd, J = 5.2, 1.5 Hz, 1H), 8.51 (s, 1H), 8.44 (d, J = 8.7 Hz, 1H), 8.26-8.11 (m, 1H), 7.94 (dd, J = 8.0, 5.2 Hz, 1H), 7.65-7.49 (m, 2H), 7.49-7.29 (m, 1H), 3.69 (s, 6H). DMSO >98 G2/AQ3 1381 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.71 (s, 1H), 9.18 (d, J = 8.0 Hz, 1H), 8.98 (d, J = 5.1 Hz, 1H), 8.49- 8.36 (m, 2H), 8.16 (d, J = 8.8 Hz, 1H), 7.99-7.86 (m, 1H), 7.86- 7.72 (m, 1H), 7.46 (t, J = 10.2 Hz, 1H), 7.29 (t, J = 8.5 Hz, 1H), 3.69 (s, 6H). DMSO >98 G2/AQ3 1382 HCl ¹H NMR (300 MHz, DMSO) δ 10.25 (brs, 1H), 9.66 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 3.2 Hz, 1H), 8.94 (dd, J = 5.0, 1.6 Hz, 1H), 8.70 (s, 1H), 8.23 (d, J = 8.8 Hz, 1H), 8.16 (dd, J = 8.7, 1.5 Hz, 1H), 7.84 (dd, J = 8.0, 5.1 Hz, 1H), 7.71 (dd, J = 8.0, 1.4 Hz, 1H), 7.65-7.55 (m, 2H), 3.90 (s, 3H), 3.29 (d, J = 4.5 Hz, 3H), 2.64 (s, 3H). DMSO >98 G2/AQ3 1383 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.18 (brs, 1H), 9.68 (d, J = 1.8 Hz, 1H), 9.17 (d, J = 8.0 Hz, 1H), 8.99 (dd, J = 5.2, 1.4 Hz, 1H), 8.86 (s, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.22 (d, J = 8.8 Hz, 1H), 7.97 (dd, J = 8.0, 5.3 Hz, 1H), 7.64-7.49 (m, 2H), 7.49-7.34 (m, 1H), 4.06-3.92 (m, 2H), 3.73 (t, J = 5.5 Hz, 2H), 3.33 (s, 3H). DMSO >98 G2/AQ3 1384 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.18 (brs, 1H), 9.67 (d, J = 1.6 Hz, 1H), 9.14 (d, J = 3.1 Hz, 1H), 8.99 (dd, J = 5.2, 1.5 Hz, 1H), 8.80 (s, 1H), 8.29 (d, J = 8.7 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 7.95 (dd, J = 8.2, 5.2 Hz, 1H), 7.79 (td, J = 8.9, 6.6 Hz, 1H), 7.50 (ddd, J = 11.6, 9.3, 2.6 Hz, 1H), 7.33 (td, J = 8.3, 2.3 Hz, 1H), 4.08-3.94 (m, 3H), 3.73 (t, J = 5.5 Hz, 3H), 3.32 (s, 3H). DMSO >98 G2/AQ3 1385 2 HCl ¹H NMR (300 MHz, DMSO) δ 10.33 (brs, 1H), 9.70 (d, J = 1.7 Hz, 1H), 9.15 (d, J = 8.2 Hz, 1H), 8.99 (dd, J = 5.2, 1.5 Hz, 1H), 8.81 (s, 1H), 8.33 (d, J = 8.7 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 7.95 (dd, J = 8.1, 5.2 Hz, 1H), 7.81 (td, J = 8.9, 6.6 Hz, 1H), 7.49 (ddd, J = 11.5, 9.3, 2.5 Hz, 1H), 7.32 (td, J = 8.5, 2.2 Hz, 1H), 3.96-3.78 (m, 2H), 3.48 (t, J = 6.1 Hz, 2H), 3.27 (s, 3H), 2.14-1.93 (m, 2H). DMSO >98 G2/AQ3 1386 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.73 (s, 1H), 9.17 (d, J = 8.4 Hz, 1H), 8.99 (s, 1H), 8.52 (s, 1H), 8.43 (d, J = 8.8 Hz, 1H), 8.21 (d, J = 9.0 Hz, 1H), 8.02-7.90 (m, 1H), 7.87-7.78 (m, 1H), 7.57-7.38 (m, 1H), 7.38-7.24 (m, 1H), 4.31-4.18 (m, 4H), 2.08 (s, 4H). DMSO >98 G2/AQ3 1387 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.7 Hz, 1H), 9.17 (d, J = 8.3 Hz, 1H), 8.99 (dd, J = 5.2, 1.5 Hz, 1H), 8.34 (d, J = 8.6 Hz, 1H), 8.24-8.12 (m, 2H), 7.97 (dd, J = 8.0, 5.2 Hz, 1H), 7.81 (td, J = 8.9, 6.6 Hz, 1H), 7.49 (ddd, J = 11.6, 9.3, 2.5 Hz, 1H), 7.30 (td, J = 8.4, 2.1 Hz, 1H), 4.16 (brs, 4H), 1.80 (brs, 6H). DMSO >98 G2/AQ3 1388 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.70 (d, J = 1.7 Hz, 1H), 9.26 (d, J = 8.3 Hz, 1H), 9.01 (dd, J = 5.3, 1.4 Hz, 1H), 8.37-8.19 (m, 2H), 8.15 (d, J = 8.7 Hz, 1H), 8.02 (dd, J = 8.1, 5.3 Hz, 1H), 7.81 (td, J = 8.9, 6.5 Hz, 1H), 7.48 (ddd, J = 11.6, 9.3, 2.6 Hz, 1H), 7.30 (td, J = 8.4, 2.3 Hz, 1H), 4.23-4.12 (m, 4H), 3.90-3.80 (m, 4H). DMSO >98 G2/AQ3 1389 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.7 Hz, 1H), 9.17 (d, J = 8.2 Hz, 1H), 8.99 (dd, J = 5.2, 1.5 Hz, 1H), 8.34 (d, J = 8.7 Hz, 1H), 8.27-8.13 (m, 2H), 7.97 (dd, J = 8.1, 5.4 Hz, 1H), 7.67-7.48 (m, 2H), 7.41 (ddd, J = 14.7, 9.9, 4.9 Hz, 1H), 4.16 (brs, 4H), 1.80 (brs, 6H). DMSO >98 G2/AQ3 1390 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.70 (d, J = 1.8 Hz, 1H), 9.26 (d, J = 8.3 Hz, 1H), 9.01 (dd, J = 5.3, 1.4 Hz, 1H), 8.36-8.23 (m, 2H), 8.18 (d, J = 8.7 Hz, 1H), 8.03 (dd, J = 8.0, 5.4 Hz, 1H), 7.64- 7.46 (m, 2H), 7.46-7.29 (m, 1H), 4.23-4.16 (m, 4H), 3.35 (d, J = 4.7 Hz, 4H). DMSO >98 G2/AQ3 1391 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.7 Hz, 1H), 9.18 (d, J = 8.2 Hz, 1H), 9.00 (dd, J = 5.2, 1.2 Hz, 1H), 8.62 (s, 1H), 8.39 (d, J = 8.7 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 7.98 (dd, J = 8.0, 5.2 Hz, 1H), 7.64-7.47 (m, 2H), 7.46- 7.27 (m, 1H), 4.26 (t, J = 5.2 Hz, 2H), 3.85 (t, J = 5.3 Hz, 2H), 3.72 (s, 3H), 3.33 (s, 3H). DMSO >98 G2/AQ3 1392 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.67 (d, J = 1.7 Hz, 1H), 9.15 (d, J = 8.1 Hz, 1H), 8.99 (d, J = 4.1 Hz, 1H), 8.56 (s, 1H), 8.36 (d, J = 8.7 Hz, 1H), 8.17 (d, J = 8.7 Hz, 1H), 7.96 (dd, J = 8.1, 5.2 Hz, 1H), 7.86-7.70 (m, 1H), 7.55-7.40 (m, 1H), 7.30 (td, J = 8.5, 2.2 Hz, 1H), 4.36-4.18 (m, 2H), 3.88- 3.77 (m, 2H), 3.72 (s, 3H), 3.33 (s, 3H). DMSO >98 G2/AQ3 1393 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.70 (d, J = 3.7 Hz, 1H), 9.24-9.06 (m, 1H), 8.99 (dd, J = 5.1, 1.5 Hz, 1H), 8.52 (s, 1H), 8.40 (d, J = 8.7 Hz, 1H), 8.30-8.14 (m, 1H), 7.93 (dd, J = 8.0, 5.2 Hz, 1H), 7.63-7.46 (m, 2H), 7.46-7.25 (m, 1H), 4.22-4.11 (m, 2H), 3.73 (s, 3H), 3.59 (t, J = 5.9 Hz, 2H), 2.10-1.92 (m, 2H). DMSO >98 G2/AQ3 1394 2 HCl ¹H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.7 Hz, 1H), 9.11 (d, J = 8.3 Hz, 1H), 8.97 (dd, J = 5.1, 1.5 Hz, 1H), 8.46 (s, 1H), 8.36 (d, J = 8.7 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 7.90 (dd, J = 8.1, 5.2 Hz, 1H), 7.80 (td, J = 8.9, 6.6 Hz, 1H), 7.47 (ddd, J = 11.6, 9.3, 2.6 Hz, 1H), 7.29 (td, J = 8.4, 2.1 Hz, 1H), 4.22-4.08 (m, 2H), 3.72 (s, 3H), 3.59 (t, J = 5.9 Hz, 2H), 2.10- 1.94 (m, 2H). DMSO >98 G2/AQ3 1395 HCl ¹H NMR (300 MHz, DMSO) δ 9.97- 9.66 (m, 2H), 9.66-9.58 (m, 1H), 9.17-9.05 (m, 1H), 8.99 (dd, J = 5.2, 1.5 Hz, 1H), 8.66 (d, J = 8.6 Hz, 1H), 8.50 (s, 1H), 8.01-7.88 (m, 2H), 7.62 (ddd, J = 9.1, 6.1, 3.1 Hz, 1H), 7.58- 7.36 (m, 2H). DMSO >98 G2/AQ3 1396 HCl ¹H NMR (300 MHz, DMSO) δ 9.70 (d, J = 1.8 Hz, 1H), 9.16 (d, J = 8.3 Hz, 1H), 8.98 (d, J = 3.9 Hz, 1H), 8.58-8.42 (m, 2H), 8.00- 7.82 (m, 2H), 7.69-7.38 (m, 3H), 3.69 (s, 6H). DMSO >98 G2/AQ3 1397 HCl ¹H NMR (400 MHz, DMSO) δ 10.47 (s, 1H), 9.63 (d, J = 1.8 Hz, 1H), 9.11 (d, J = 3.0 Hz, 1H), 9.04 (s, 1H), 8.96 (dd, J = 5.1, 1.4 Hz, 1H), 8.41 (dd, J = 8.8, 1.6 Hz, 1H), 8.30 (d, J = 8.7 Hz, 1H), 8.14 (d, J = 3.2 Hz, 2H), 7.90 (d, J = 8.4 Hz, 3H), 3.34 (t, J = 17.1 Hz, 3H). DMSO >98 AQ4 1398 HCl ¹H NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 9.65 (d, J = 1.7 Hz, 1H), 9.06 (d, J = 7.9 Hz, 1H), 8.99-8.90 (m, 2H), 8.44 (d, J = 7.2 Hz, 1H), 8.23-8.17 (m, 3H), 7.94-7.76 (m, 3H), 3.32 (d, J = 4.5 Hz, 3H). DMSO >98 AQ4 1399 HCl ¹H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.65 (d, J = 2.1 Hz, 1H), 9.10-9.00 (m, 1H), 8.96 (dd, J = 5.1, 1.5 Hz, 1H), 8.65 (s, 1H), 8.26-8.17 (m, 1H), 8.16- 8.07 (m, 1H), 7.90 (dd, J = 7.8, 5.3 Hz, 1H), 7.77-7.69 (m, 1H), 7.68-7.55 (m, 3H), 3.29 (d, J = 4.6 Hz, 3H). DMSO >98 AQ4 1400 HCl ¹H NMR (400 MHz, DMSO) δ 9.77 (s, 1H), 9.63 (d, J = 1.7 Hz, 1H), 9.04-8.85 (m, 2H), 8.63 (s, 1H), 8.12 (q, J = 8.7 Hz, 2H), 7.83 (dd, J = 7.8, 4.9 Hz, 1H), 7.38- 7.25 (m, 2H), 7.25-7.17 (m, 1H), 3.92 (s, 3H). DMSO >98 AQ4 1401 HCl ¹H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.64 (d, J = 1.7 Hz, 1H), 9.04 (d, J = 7.6 Hz, 1H), 8.99-8.92 (m, 1H), 8.89 (s, 1H), 8.41 (d, J = 8.8 Hz, 1H), 8.33- 8.20 (m, 2H), 8.16 (d, J = 3.6 Hz, 1H), 7.94-7.84 (m, 1H), 7.81- 7.68 (m, 1H), 3.32 (d, J = 4.5 Hz, 3H). DMSO >98 AQ4 1402 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.30 (s, 1H), 9.68 (d, J = 1.8 Hz, 1H), 9.15-9.05 (m, 1H), 8.97 (dd, J = 5.1, 1.4 Hz, 1H), 8.52 (s, 1H), 8.10 (s, 1H), 7.96-7.82 (m, 1H), 7.67-7.55 (m, 1H), 7.42- 7.26 (m, 3H), 3.31 (d, J = 4.5 Hz, 3H), 2.40 (s, 3H). DMSO >98 AQ5 1403 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.87 (s, 1H), 9.59 (d, J = 1.5 Hz, 1H), 9.00-8.89 (m, 2H), 8.42 (s, 1H), 7.93-7.80 (m, 2H), 7.62-7.54 (m, 1H), 7.49-7.36 (m, 3H), 3.30 (d, J = 4.6 Hz, 3H), 2.32 (s, 3H). DMSO >98 AQ5 1404 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.19 (s, 1H), 9.68-9.61 (m, 1H), 9.05-8.98 (m, 1H), 8.94 (dd, J = 5.0, 1.6 Hz, 1H), 8.48 (d, J = 5.7 Hz, 1H), 8.02 (s, 1H), 7.91-7.82 (m, 1H), 7.59-7.50 (m, 2H), 7.43-7.36 (m, 2H), 3.31 (d, J = 4.6 Hz, 3H), 2.40 (s, 3H). DMSO >98 AQ5 1405 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.11 (s, 1H), 9.69-9.61 (m, 1H), 9.11-9.02 (m, 1H), 8.95 (dd, J = 5.1, 1.5 Hz, 1H), 8.52 (s, 1H), 8.05 (s, 1H), 7.89 (dd, J = 8.1, 5.1 Hz, 1H), 7.68-7.56 (m, 1H), 7.48-7.38 (m, 1H), 7.33- 7.25 (m, 1H), 3.31 (d, J = 4.6 Hz, 3H), 2.33 (s, 3H). DMSO >98 AQ5 1406 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.03 (s, 1H), 9.63 (dd, J = 2.2, 0.7 Hz, 1H), 9.09-9.00 (m, 1H), 8.95 (dd, J = 5.1, 1.6 Hz, 1H), 8.48 (s, 1H), 8.00 (s, 1H), 7.89 (dd, J = 7.9, 5.2 Hz, 1H), 7.54- 7.35 (m, 3H), 3.30 (d, J = 4.6 Hz, 3H), 2.33 (s, 3H). DMSO >98 AQ5 1407 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.08-8.98 (m, 1H), 8.95 (dd, J = 5.1, 1.5 Hz, 1H), 8.46 (s, 1H), 7.98 (s, 1H), 7.87 (dd, J = 8.1, 5.1 Hz, 1H), 7.64 (ddt, J = 16.8, 14.3, 5.3 Hz, 2H), 7.40- 7.30 (m, 1H), 3.30 (d, J = 4.6 Hz, 3H), 2.41 (s, 3H). DMSO >98 AQ5 1408 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.92 (s, 1H), 9.61 (d, J = 1.6 Hz, 1H), 9.03-8.97 (m, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.42 (s, 1H), 7.93 (s, 1H), 7.87 (dd, J = 8.1, 5.0 Hz, 1H), 7.44-7.36 (m, 1H), 7.33-7.23 (m, 2H), 3.29 (d, J = 4.6 Hz, 3H), 2.41 (s, 3H). DMSO >98 AQ5 1409 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.11 (s, 1H), 9.64 (d, J = 2.2 Hz, 1H), 9.10-9.03 (m, 1H), 8.96 (dd, J = 5.1, 1.5 Hz, 1H), 8.49 (s, 1H), 8.05-7.94 (m, 3H), 7.94- 7.88 (m, 1H), 7.88-7.82 (m, 1H), 7.77 (t, J = 7.7 Hz, 1H), 3.31 (d, J = 4.5 Hz, 3H), 2.40 (s, 3H). DMSO >98  AQ5 1410 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.22 (s, 1H), 9.67 (d, J = 1.6 Hz, 1H), 9.14-9.07 (m, 1H), 8.97 (dd, J = 5.1, 1.5 Hz, 1H), 8.52 (s, 1H), 8.10-8.00 (m, 3H), 7.91 (dd, J = 7.9, 5.3 Hz, 1H), 7.75- 7.67 (m, 2H), 3.31 (d, J = 4.5 Hz, 3H), 2.39 (s, 3H). DMSO >98 AQ5 1411 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.20-9.85 (m, 1H), 9.58 (s, 1H), 8.94-8.85 (m, 2H), 8.38 (s, 1H), 7.88-7.76 (m, 2H), 7.54- 7.44 (m, 1H), 7.24-7.16 (m, 2H), 7.12 (td, J = 7.4, 0.9 Hz, 1H), 3.76 (s, 3H), 3.31 (d, J = 4.5 Hz, 3H), 2.24 (s, 3H). DMSO >98% AQ5 1412 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.69-9.61 (m, 1H), 9.01 (d, J = 7.8 Hz, 1H), 8.93 (dd, J = 5.0, 1.6 Hz, 1H), 8.49 (s, 1H), 8.06 (s, 1H), 7.83 (dd, J = 8.0, 5.1 Hz, 1H), 7.51- 7.41 (m, 1H), 7.13-7.05 (m, 1H), 7.05-6.95 (m, 2H), 3.81 (d, J = 10.8 Hz, 3H), 3.31 (d, J = 4.6 Hz, 3H), 2.41 (s, 3H). DMSO >98% AQ5 1413 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.60 (s, 1H), 9.00- 8.88 (m, 2H), 8.42 (s, 1H), 7.94 (s, 1H), 7.86-7.78 (m, 1H), 7.48- 7.39 (m, 2H), 7.16-7.06 (m, 2H), 3.85 (s, 3H), 3.31 (d, J = 4.6 Hz, 3H), 2.43 (s, 3H). DMSO >98% AQ5 1414 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.02 (s, 1H), 9.63 (s, 1H), 9.05- 8.91 (m, 2H), 8.36 (s, 1H), 8.10- 7.99 (m, 1H), 7.91-7.80 (m, 1H), 7.59-7.50 (m, 2H), 7.44- 7.32 (m, 2H), 3.27 (d, J = 4.5 Hz, 3H), 2.45 (s, 3H). DMSO >98 AQ5 1415 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.01 (s, 1H), 9.65 (s, 1H), 9.10- 8.99 (m, 1H), 8.97 (d, J = 5.0 Hz, 1H), 8.41 (s, 1H), 8.09 (s, 1H), 7.97-7.83 (m, 1H), 7.61-7.41 (m, 2H), 7.31 (td, J = 8.4, 2.2 Hz, 1H), 3.26 (d, J = 4.5 Hz, 3H), 2.35 (s, 3H). DMSO >98 AQ5 1416 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.01-9.69 (m, 1H), 9.61 (s, 1H), 8.94 (m, J = 5.0 Hz, 2H), 8.36 (s, 1H), 7.99 (s, 1H), 7.92- 7.81 (m, 1H), 7.71-7.57 (m, 2H), 7.41-7.31 (m, 1H), 3.26 (d, J = 4.5 Hz, 3H), 2.47 (s, 3H). DMSO >98 AQ5 1417 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.90 (s, 1H), 9.63 (d, J = 1.8 Hz, 1H), 9.08-8.89 (m, 2H), 8.40 (s, 1H), 8.02 (s, 1H), 7.92-7.81 (m, 1H), 7.44-7.25 (m, 3H), 3.27 (d, J = 4.5 Hz, 3H), 2.49 (s, 3H). DMSO >98 AQ5 1418 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.99 (s, 1H), 9.62 (s, 1H), 8.95 (d, J = 5.0 Hz, 2H), 8.27 (s, 1H), 8.11- 7.99 (m, 1H), 7.89-7.80 (m, 1H), 7.53-7.45 (m, 1H), 7.24 (dd, J = 7.4, 1.7 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 7.12 (td, J = 7.4, 0.9 Hz, 1H), 3.74 (d, J = 8.9 Hz, 3H), 3.26 (d, J = 4.6 Hz, 3H), 2.28 (s, 3H). DMSO >98 AQ5 1419 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.30 (s, 1H), 9.72 (d, J = 1.6 Hz, 1H), 9.20-9.10 (m, 1H), 8.98 (dd, J = 5.1, 1.5 Hz, 1H), 8.45 (s, 1H), 8.21 (s, 1H), 7.91 (dd, J = 8.0, 5.1 Hz, 1H), 7.48-7.40 (m, 1H), 7.08-7.01 (m, 3H), 3.84 (s, 3H), 3.26 (d, J = 4.5 Hz, 3H), 2.45 (s, 3H). DMSO >98 AQ5 1420 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.08-9.71 (m, 1H), 9.58 (d, J = 2.0 Hz, 1H), 8.96-8.83 (m, 2H), 8.31 (s, 1H), 7.91 (s, 1H), 7.87- 7.79 (m, 1H), 7.47-7.39 (m, 2H), 7.10 (d, J = 8.8 Hz, 2H), 3.84 (s, 3H), 3.27 (d, J = 4.5 Hz, 3H), 2.47 (s, 3H). DMSO >98 AQ5 1421 2 HCl 1H NMR (400 MHz, DMSO) δ 9.69- 9.63 (m, 1H), 9.10-8.93 (m, 3H), 8.12 (d, J = 8.4 Hz, 1H), 7.90-7.82 (m, 2H), 7.63-7.58 (m, 1H), 7.56-7.43 (m, 1H), 7.30-7.22 (m, 1H), 3.35 (d, j = 4.6 Hz, 3H), 2.73 (s, 3H). DMSO >98 AQ4 1422 2 HCl 1H NMR (400 MHz, DMSO) δ 9.62 (s, 1H), 8.95 (d, J = 5.0 Hz, 3H), 8.03 (s, 1H), 7.85 (t, J = 9.9 Hz, 2H), 7.44-7.34 (m, 1H), 7.17 (dd, J = 8.2, 2.2 Hz, 2H), 3.34 (d, J = 4.5 Hz, 3H), 2.73 (s, 3H). DMSO >98 AQ4 1423 2 HCl 1H NMR (400 MHz, DMSO) δ 9.62 (d, J = 2.1 Hz, 1H), 9.00-8.75 (m, 3H), 8.08-7.99 (m, 1H), 7.99-7.93 (m, 1H), 7.93-7.79 (m, 3H), 7.79-7.73 (m, 2H), 3.34 (d, J = 4.5 Hz, 3H), 2.70 (s, 3H). DMSO >98 AQ4 1424 2 HCl 1H NMR (400 MHz, DMSO) δ 9.61 (s, 1H), 8.99-8.63 (m, 3H), 8.07- 7.98 (m, 3H), 7.89-7.78 (m, 2H), 7.65-7.59 (m, 2H), 3.33 (d, J = 4.5 Hz, 3H), 2.70 (s, 3H). DMSO >98 AQ4 1425 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.49 (s, 1H), 9.56 (s, 1H), 9.19 (s, 1H), 8.95 (d, J = 5.3 Hz, 1H), 8.83 (d, J = 5.5 Hz, 1H), 8.73 (d, J = 6.4 Hz, 1H), 8.41 (d, J = 5.6 Hz, 1H), 8.26 (s, 1H), 8.09 (s, 1H), 8.02-7.91 (m, 2H), 7.85 (s, 1H), 7.78-7.68 (m, 1H), 7.61- 7.51 (m, 1H), 7.48-7.36 (m, 2H), 5.36 (s, 2H). DMSO >98 Method AQ3 1426 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.53 (s, 1H), 9.67 (d, J = 1.8 Hz, 1H), 9.32 (dd, J = 5.8, 4.1 Hz, 1H), 8.97 (dd, J = 5.4, 1.4 Hz, 1H), 8.75 (d, J = 8.7 Hz, 1H), 8.35 (t, J = 7.9 Hz, 1H), 8.24 (d, J = 13.5 Hz, 1H), 8.03 (dd, J = 8.1, 5.4 Hz, 1H), 7.92 (dd, J = 13.5, 4.8 Hz, 2H), 7.85-7.73 (m, 2H), 7.53-7.43 (m, 1H), 7.36-7.25 (m, 1H), 5.40 (d, J = 5.6 Hz, 2H), 2.85 (s, 3H). DMSO >98 Method AQ3 1427 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.42 (s, 1H), 9.64 (d, J = 1.7 Hz, 1H), 9.26 (d,.J = 8.1 Hz, 1H), 8.95 (dd, J = 5.3, 1.4 Hz, 1H), 8.71 (d, J = 8.7 Hz, 1H), 8.30 (d, J = 18.0 Hz, 2H), 8.04-7.84 (m, 3H), 7.74 (dd, J = 7.8, 6.0 Hz, 2H), 7.62-7.33 (m, 3H), 5.38 (d, J = 5.5 Hz, 2H), 2.84 (s, 3H). DMSO >98 Method AQ3 1428 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.24 (d, J = 8.1 Hz, 1H), 8.95 (dd, J = 5.3, 1.4 Hz, 1H), 8.69 (d, J = 3.7 Hz, 1H), 8.41- 8.22 (m, 2H), 8.09 (dd, J = 8.7, 1.8 Hz, 1H), 8.01-7.84 (m, 4H), 7.74 (d, J = 7.8 Hz, 1H), 7.46- 7.33 (m, 2H), 5.36 (d, J = 5.5 Hz, 2H), 2.83 (s, 3H). DMSO >98 Method AQ3 1429 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.21 (s, 1H), 9.62 (s, 1H), 9.19 (d, J = 7.8 Hz, 1H), 8.93 (d, J = 4.6 Hz, 1H), 8.68 (d, J = 8.6 Hz, 1H), 8.26 (dd, J = 28.0, 20.1 Hz, 2H), 8.04-7.80 (m, 3H), 7.72 (d, J = 7.8 Hz, 1H), 7.64-7.50 (m, 2H), 7.46-7.33 (m, 1H), 5.33 (d, J = 5.3 Hz, 2H), 2.81 (s, 3H). DMSO >98 Method AQ3 1430 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.66 (d, J = 1.8 Hz, 1H), 9.31 (d, J = 8.2 Hz, 1H), 8.96 (dd, J = 5.4, 1.4 Hz, 1H), 8.73 (d, J = 8.7 Hz, 1H), 8.33 (t, J = 7.9 Hz, 1H), 8.23 (s, 1H), 8.03 (dd, J = 8.1, 5.4 Hz, 1H), 7.93 (dd, J = 11.7, 8.3 Hz, 2H), 7.76 (d, J = 7.9 Hz, 1H), 7.70-7.60 (m, 1H), 7.54-7.35 (m, 2H), 5.38 (d, J = 5.5 Hz, 2H), 2.85 (s, 3H). DMSO >98 Method AQ3 1431 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 9.61 (s, 1H), 9.22 (t, J = 7.3 Hz, 1H), 8.98-8.90 (m, 1H), 8.65 (dd, J = 8.6, 3.0 Hz, 1H), 8.36-8.26 (m, 2H), 8.13 (dd, J = 8.7, 1.9 Hz, 1H), 8.05-7.95 (m, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.76-7.64 (m, 3H), 7.43-7.33 (m, 1H), 5.33 (s, 2H), 2.82 (s, 3H). DMSO >98 Method AQ3 1432 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.26 (s, 1H), 9.62 (d, J = 1.8 Hz, 1H), 9.23 (d, J = 8.2 Hz, 1H), 8.94 (dd, J = 5.4, 1.5 Hz, 1H), 8.78 (s, 1H), 8.30 (t, J = 7.9 Hz, 1H), 8.20-8.15 (m, 1H), 8.10 (d, J = 8.7 Hz, 1H), 8.00 (dd, J = 7.9, 5.3 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.80-7.71 (m, 2H), 7.59-7.50 (m, 1H), 7.47-7.35 (m, 2H), 5.35 (d, J = 5.5 Hz, 2H), 2.82 (s, 3H). DMSO >98 Method AQ3 1433 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.39 (s, 1H), 9.61 (d, J = 1.7 Hz, 1H), 9.19 (d, J = 8.2 Hz, 1H), 9.01 (d, J = 1.8 Hz, 1H), 8.93 (dd, J = 5.3, 1.5 Hz, 1H), 8.38 (dd, J = 8.8, 1.9 Hz, 1H), 8.29 (t, J = 7.9 Hz, 1H), 8.09 (d, J = 8.7 Hz, 1H), 7.97 (dd, J = 8.1, 5.3 Hz, 1H), 7.92-7.80 (m, 3H), 7.72 (d, J = 7.3 Hz, 1H), 7.66-7.57 (m, 1H), 7.35-7.26 (m, 1H), 5.36 (d, J = 5.5 Hz, 2H), 2.81 (s, 3H). DMSO >98 Method AQ3 1434 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.45 (s, 1H), 9.60 (d, J = 1.9 Hz, 1H), 9.19 (d, J = 8.2 Hz, 1H), 9.01-8.89 (m, 2H), 8.36-8.25 (m, 2H), 8.10 (d, J = 8.7 Hz, 1H), 8.05-7.94 (m, 3H), 7.88 (dd, J = 12.8, 3.4 Hz, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.46-7.35 (m, 2H), 5.36 (d, J = 5.5 Hz, 2H), 2.32 (s, 3H). DMSO >98 Method AQ3 1435 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.28 (s, 1H), 9.63 (d, J = 1.8 Hz, 1H), 9.24 (d, J = 8.2 Hz, 1H), 8.95 (d, 1H), 8.83 (s, 1H), 8.30 (t, J = 7.9 Hz, 1H), 8.19 (dd, J = 8.7, 1.8 Hz, 1H), 8.11 (d, J = 8.7 Hz, 1H), 8.00 (dd, J = 8.1, 5.4 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.64- 7.51 (m, 2H), 7.46-7.37 (m, 1H), 5.36 (d, J = 5.5 Hz, 2H), 2.82 (s, 3H). DMSO >98 Method AQ3 1436 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.02 (s, 1H), 9.56 (d, J = 1.6 Hz, 1H), 9.06 (d, J = 8.0 Hz, 1H), 8.88 (dd, J = 5.2, 1.5 Hz, 1H), 8.75 (s, 1H), 8.25-8.13 (m, 2H), 8.04 (d, J = 8.7 Hz, 1H), 7.89 (dd, J = 7.8, 5.3 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.70-7.60 (m, 2H), 7.53-7.44 (m, 1H), 7.38 (ddd, J = 12.2, 8.4, 3.5 Hz, 1H), 5.27 (d, J = 5.3 Hz, 2H), 2.77 (s, 3H). DMSO >98 Method AQ3 1437 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.60 (d, J = 1.7 Hz, 1H), 9.19 (d, J = 8.1 Hz, 1H), 8.93 (dd, J = 5.4, 1.5 Hz, 1H), 8.75 (s, 1H), 8.29 (t, J = 7.9 Hz, 1H), 8.17-8.05 (m, 2H), 7.98 (dd, J = 8.0, 5.4 Hz, 1H), 7.83 (ddd, J = 15.5, 8.4, 6.0 Hz, 2H), 7.72 (d, J = 7.8 Hz, 1H), 7.54- 7.44 (m, 1H), 7.38-7.28 (m, 1H), 5.33 (d, J = 5.5 Hz, 2H), 2.81 (s, 3H). DMSO >98 Method AQ3 1438 4 HCl ¹H NMR (400 MHz, DMSO) δ 10.45 (s, 1H), 9.62 (d, J = 1.7 Hz, 1H), 9.21 (d, J = 8.1 Hz, 1H), 9.03 (d, J = 1.7 Hz, 1H), 8.93 (dd, J = 5.3, 1.4 Hz, 1H), 8.39- 8.26 (m, 2H), 8.15-8.04 (m, 2H), 8.00-7.81 (m, 3H), 7.76- 7.59 (m, 2H), 5.36 (d, J = 5.5 Hz, 2H), 2.82 (s, 3H). DMSO >98 Method AQ3 1439 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.29 (s, 1H), 9.53 (d, J = 1.8 Hz, 1H), 9.12 (d, J = 8.0 Hz, 1H), 8.93 (dd, J = 5.3, 1.4 Hz, 1H), 8.78 (d, J = 2.5 Hz, 2H), 8.31 (t, J = 7.8 Hz, 1H), 8.13 (q, J = 8.7 Hz, 2H), 8.04-7.89 (m, 2H), 7.87-7.68 (m, 2H), 7.50 (ddd, J = 11.6, 9.3, 2.6 Hz, 1H), 7.33 (td, J = 8.3, 1.9 Hz, 1H), 5.30 (d, J = 5.4 Hz, 2H). DMSO >98 Method AQ3 1440 2 HCl ¹H NMR (400 MHz, DMSO) 10.41 (s, 1H), 9.63 (d, J = 1.7 Hz, 1H), 9.15 (d, J = 8.1 Hz, 1H), 8.97 (dd, J = 5.2, 1.4 Hz, 1H), 8.83 (s, 1H), 8.20 (s, 2H), 7.97 (dd, J = 8.0, 5.3 Hz, 1H), 7.73- 7.56 (m, 2H), 7.54-7.28 (m, 4H), 5.03 (d, J = 5.7 Hz, 2H). DMSO >98 Method AQ3 1441 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.59 (d, J = 1.6 Hz, 1H), 9.07-8.94 (m, 2H), 8.84 (s, 1H), 8.76 (s, 1H), 8.22-8.13 (m, 2H), 7.96 (dd, J = 8.0, 5.3 Hz, 1H), 7.66 (ddd, J = 9.2, 6.1, 3.2 Hz, 1H), 7.53-7.32 (m, 2H), 1.69 (s, 9H). DMSO >98 Method AQ3 1442 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.93 (s, 1H), 9.62 (d, J = 1.6 Hz, 1H), 9.06-8.87 (m, 2H), 8.39 (s, 1H), 8.06-7.98 (m, 3H), 7.87 (dd, J = 8.0, 5.1 Hz, 1H), 7.77--7.67 (m, 2H), 3.26 (d, J = 4.6 Hz, 3H), 2.45 (s, 3H). DMSO >98 Method AQ3 1443 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.98 (s, 1H), 9.64 (s, 1H), 8.99 (dd, J = 27.3, 6.4 Hz, 2H), 8.41 (s, 1H), 8.10-7.93 (m, 3H), 7.88 (dd, J = 7.7, 6.0 Hz, 2H), 7.76 (t, J = 7.8 Hz, 1H), 3.27 (d, J = 4.5 Hz, 3H), 2.46 (s, 3H). DMSO >98 Method AQ3 1444 2 HCl ¹H NMR (400 MHz, DMSO) δ 9.76- 9.69 (m, 1H), 9.37 (t, J = 5.4 Hz, 1H), 8.99 (dd, J = 11.7, 7.5 Hz, 1H), 8.81 (dt, J = 7.9, 4.0 Hz, 1H), 8.70 (t, J = 7.3 Hz, 1H), 8.52 (d, J = 9.2 Hz, 1H), 8.35-8.27 (m, 1H), 8.10 (dd, J = 12.8, 7.3 Hz, 1H), 8.01-7.90 (m, 2H), 7.77-7.71 (m, 1H), 7.50-7.37 (m, 3H), 7.06-7.01 (m, 1H), 5.19 (t, J = 17.9 Hz, 2H), 3.88 (s, 3H). DMSO >98 Method AQ3, F, G2 (reflux) 1445 2 HCl 1H NMR (DMSO-d6) ppm 9.73 (s, 1H), 9.37 (brd, J = 8.08 Hz, 1H), 8.97 (brd, J = 5.24 Hz, 1H), 8.77 (brs, 1H), 8.20 (d, J = 8.48 Hz, 1H), 8.10-8.07 (brm, 1H), 7.63- 7.55 (brm, 2H), 7.47 (d, J = 8.48 Hz, 1H), 7.32 (brm, 1H), 3.20 (d, J = 4.20 Hz, 3H), 2.65 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 AQ6 1446 3 HCl 1H NMR (DMSO-d6) ppm 9.73 (d, J = 1.76 Hz, zH), 9.39 (brd, J = 8.16 Hz, 1H), 8.98 (dd, J = 5.44, 1.20 Hz, 1H), 8.80 (brs, 1H), 8.22 (d, J = 8.48 Hz, 1H), 8.12-8.08 (brm, 1H), 7.57-7.51 (m, 1H), 7.46-7.35 (m, 4H), 3.21 (d, J = 4.32 Hz, 3H), 2.55 (s, 3H). The 1H of 3HCl was not observed. DMSO >98 AQ6 1447 3 HCl 1H NMR (DMSO-d6) ppm 9.72 (d, J = 1.68 Hz, 1H), 9.26 (brd, J = 8.48 Hz, 1H), 8.91 (dd, J = 5.28, 1.40 Hz, 1H), 8.69 (brs, 1H), 8.18 (d, J = 8.56 Hz, 1H), 8.00-7.96 (brm, 1H), 7.53-7.49 (m, 2H), 7.44 (d, J = 8.56 Hz, 1H), 7.38- 7.33 (m, 2H), 3.20 (d, J = 4.40 Hz, 3H), 2.63 (s, 3H). The 1H of 3HCl was not observed. DMSO >98 AQ6 1448 2 HCl 1H NMR (DMSO-d6) ppm 9.73 (d, J = 1.44 Hz, 1H), 9.36 (brd, J = 7.88 Hz, 1H), 8.96 (d, J = 5.04 Hz, 1H), 8.77 (brs, 1H), 8.21 (d, J = 8.56 Hz, 1H), 8.07 (brm, 1H), 7.48 (d, J = 8.56 Hz, 1H), 7.38- 7.32 (m, 1H), 7.27-7.22 (m, 2H), 3.20 (d, J = 4.4 Hz, 3H), 2.65 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 AQ6 1449 3 HCl 1H NMR (DMSO-d6) ppm 9.73 (d, J = 1.72 Hz, 1H), 9.32 (brd, J = 7.56 Hz, 1H), 8.94 (brd, J = 5.48 Hz, 1H), 8.74 (brs, 1H), 8.20 (d, J = 8.56 Hz, 1H), 8.08-8.02 (m, 1H), 7.60-7.54 (m, 1H), 7.47 (d, J = 7.35-7.27 (m, 3H), 3.20 (d, J = 4.4 Hz, 3H), 2.65 (s, 3H). The 1H of 3HCl was not observed. DMSO >98 AQ6 1450 2 HCl 1H NMR (DMSO-d6) ppm 9.74 (d, J = 1.76 Hz, 1H), 9.37 (brd, J = 8.16 Hz, 1H), 8.97 (brdd, J = 5.44, 1.24 Hz, 1H), 8.79 (brs, 1H), 8.22 (d, J = 8.52 Hz, 1H), 8.10-8.06 (brm, 1H), 7.48-7.35 (m, 4H), 3.21 (d, J = 4.36 Hz, 3H), 2.56 (brs, 3H). The 1H of 2HCl was not observed. DMSO >98 AQ6 1451 3 HCl 1H NMR (DMSO-d6) ppm 9.74 (d, J = 1.52 Hz, 1H), 9.37 (d, J = 8.08 Hz, 1H), 8.97 (dd, J = 5.54, 1.16 Hz, 1H), 8.80 (brs, 1H), 8.23 (d, J = 8.52 Hz, 1H), 8.10- 8.07 (m, 1H), 7.60-7.53 (m, 1H), 7.48 (d, J = 8.52 Hz, 1H), 7.41- 7.36 (m, 1H), 7.30-7.26 (m, 1H), 3.21 (d, J = 4.36 Hz, 3H), 2.56 (s, 3H). The 1H of 3HCl was not observed. DMSO >98 AQ6 1452 3 HCl 1H NMR (DMSO-d6) ppm 9.73 (d, J = 1.68 Hz, 1H), 9.26 (brd, J = 7.8 Hz, 1H), 8.91 (brdd, J = 5.28, 1.36 Hz, 1H), 8.71 (brs, 1H), 8.21 (d, J = 8.52 Hz, 1H), 8.00 (d, J = 8.4 Hz, 2H), 7.99-7.95 (m, 1H), 7.69 (d, 8.4 Hz, 2H), 7.46 (d, J = 8.52 Hz, 1H), 3.20 (d, J = 4.4 Hz, 3H), 2.63 (s, 3H). The 1H of 3HCl was not observed. DMSO >98 AQ6 1453 2 HCl 1H NMR (DMSO-d6) ppm 9.73 (d, J = 1.72 Hz, 1H), 9.33 (brd, J = 7.64 Hz, 1H), 8.95 (brd, J = 5.28 Hz, 1H), 8.76 (brs, 1H), 8.22 (d, J = 8.48 Hz, 1H), 8.05 (brm, J = 7.64, 5.28 Hz, 1H), 7.98-7.93 (m, 2 H), 7.84-7.81 (m, 1H), 7.74 (dd, J = 7.84, 7.76 Hz, 1H), 7.49 (d, J = 8.84 Hz, 1H), 3.21 (d, J = 4.4 Hz, 3H), 2.63 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 AQ6 1454 2 HCl ¹H NMR (DMSO-d₆) ppm 9.72 (d, J = 1.76 Hz, 1H), 9.42 (brd, J = 8.00 Hz, 1H), 9.00 (d, J = 5.52 Hz, 1H), 8.83 (bsr, 1H), 8.22 (d, J = 8.56 Hz, 1H), 8.13 (brm, 1H), 7.55-7.51 (m, 2H), 7.48-7.43 (m, 4H), 3.21 (brd, J = 4.16 Hz, 3H), 2.64 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 AQ6 1455 2 HCl ¹H NMR (DMSO-d₆) ppm 9.72 (s, 1H), 9.33 (d, J = 8.24 Hz, 1H), 8.96 (d, J = 5.40 Hz, 1H), 8.75 (brs, 1H), 8.17 (d, J = 8.60 Hz, 1H), 8.06 (brm, 1H), 7.45 (d, J = 8.80 Hz, 1H), 7.40 (d, J = 8.64 Hz, 2H), 7.08 (d, J = 8.64 Hz, 2H), 3.84 (s, 3H), 3.20 (d, J = 4.20 Hz, 3H), 2.66 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 AQ6 1456 2 HCl ¹H NMR (DMSO-d₆) ppm 9.72 (d, J = 1.64 Hz, 1H), 9.38 (d, J = 8.04 Hz, 1H), 8.98 (dd, J = 5.48, 1.24 Hz, 1H), 8.79 (brs, 1H), 8.20 (d, J = 8.52 Hz, 1H), 8.12-8.09 (m, 1H), 7.48-7.42 (m, 2H), 7.04-6.97 (m, 3H), 3.82 (s, 3H), 3.21 (d, J = 4.28 Hz, 3H), 2.65 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 AQ6 1457 2 HCl ¹H NMR (DMSO-d₆) ppm 9.71 (d, J = 1.32 Hz, 1H), 9.40 (d, J = 7.64 Hz, 1H), 8.99 (dd, J = 5.52, 1.16 Hz, 1H), 3.32 (brs, 1H), 8.17 (d, J = 8.48 Hz, 1H), 8.13 (m, 1H), 7.47-7.43 (m, 1H), 7.37 (d, J = 8.48 Hz, 1H), 7.22-7.16 (m, 2H), 7.11-7.07 (m, 1H), 3.73 (s, 3H), 3.21 (d, J = 4.12 Hz, 3H), 2.47 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 AQ6 1458 2 HCl ¹H NMR (DMSO-d₆) ppm 9.57 (d, J = 1.88 Hz, 1H), 8.93 (dd, J = 4.88, 1.56 Hz, 1H), 8.87 (brd, J = 6.52 Hz, 1H), 7.95 (d, J = 8.36 Hz, 1H), 7.84 (d, J = 8.36 Hz, 1H), 7.81 (m, 1H), 7.34 (d, J = 8.72 Hz, 2H), 7.11 (d, J = 8.72 Hz, 2H), 3.84 (s, 3H), 3.34 (d, J = 4.56 Hz, 3H), 2.72 (s, 3H). The 1H of 2HCl and NH— were not observed. DMSO >98 AQ6 1459 2 HCl ¹H NMR (DMSO-d₆) ppm 9.59 (s, 1H), 8.94 (dd, J = 4.92, 1.48 Hz, 1H), 8.89 (br, 1H), 7.98 (d, J = 8.48 Hz, 1H), 7.86 (d, J = 8.48 Hz, 1H), 7.82 (m, 1H), 7.46 (t, J = 7.96 Hz, 1H), 7.06-7.03 (m, 1H), 6.98-6.94 (m, 2H), 3.83 (s, 3H), 3.34 (d, J = 4.56 Hz, 3H), 2.72 (s, 3H). The 1H of 2HCl and NH— were not observed. DMSO >98 AQ6 1460 ¹H NMR (300 MHz, DMSO) δ 9.60 (s, 1H), 8.84-8.57 (m, 3H), 8.30 (d, J = 7.0 Hz, 1H), 8.18 (d, J = 8.8 Hz, 1H), 8.12-7.93 (m, 4H), 7.85 (dd, J = 8.7, 1.5 Hz, 1H), 7.60-7.46 (m, 1H), 4.85-4.58 (m, 1H), 1.37 (d, J = 6.5 Hz, 6H). DMSO   100 AQ1 366 (M + 1) Method A (Formic acid) 1461 HCl 1H NMR (300 MHz, DMSO) δ 9.81 (s, 1H), 9.60 (s, 1H), 8.95 (s, 3H), 8.39 (d, J = 3.9 Hz, 1H), 8.19 (s, 1H), 7.96-7.73 (m, 3H), 7.68- 7.55 (m, 1H), 7.39-7.25 (m, 1H), 4.99-4.81 (m, 1H), 1.42 (d, J = 6.5 Hz, 6H). DMSO   100 AQ1 359 (M + 1) Method A (Formic acid) 1462 ¹H NMR (300 MHz, DMSO) δ 9.43 (s, 1H), 8.75-8.47 (m, 3H), 8.29 (d, J = 7.2 Hz, 1H), 7.79 (d, J = 7.1 Hz, 1H), 7.72-7.54 (m, 2H), 7.48 (dd, J = 7.8, 4.9 Hz, 1H), 7.44-7.32 (m, 1H), 7.30-7.12 (m, 1H), 3.32 (s, 3H), 3.16 (d, J = 4.3 Hz, 3H). DMSO 100 AQ1 349 (M + 1) Method A (Formic acid) 1463 1H NMR (300 MHz, DMSO) δ 9.68 (dd, J = 2.1, 0.8 Hz, 1H), 8.86- 8.78 (m, 1H), 8.74 (dd, J = 4.8, 1.7 Hz, 1H), 8.34-8.25 (m, 2H), 8.09-8.02 (m, 1H), 7.80 (d, J = 8.9 Hz, 2H), 7.60 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.09 (d, J = 8.9 Hz, 2H), 4.31 (s, 3H), 3.83 (s, 3H). DMSO    99 Method AQ2 344.0 (M + 1) Method C 1464 1H NMR (300 MHz, DMSO) δ 9.67 (d, J = 2.1 Hz, 1H), 8.82 (d, J = 7.9 Hz, 1H), 8.74 (dd, J = 4.8, 1.7 Hz, 1H), 8.46 (d, J = 1.7 Hz, 1H), 8.36 (dd, J = 8.8, 2.2 Hz, 1H), 8.15-7.94 (m, 5H), 7.60 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 4.31 (s, 3H). DMSO    99 Method AQ2 338.9 (M + 1) Method C 1465 2 HCl 1H NMR (300 MHz, DMSO) δ 9.71 (d, J = 1.8 Hz, 1H), 9.15 (d, J = 8.0 Hz, 1H), 8.90 (dd, J = 5.2, 1.4 Hz, 1H), 8.58 (s, J = 1.8 Hz, 1H), 8.48 (d, J = 1.6 Hz, 1H), 8.43 (dd, J = 8.7, 2.2 Hz, 1H), 8.32 (dd, J = 7.8, 0.9 Hz, 1H), 8.28 (dd, J = 8.2, 2.2 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 7.92 (dd, J = 8.0, 5.2 Hz, 1H), 7.81 (t, J = 8.0 Hz, 1H), 4.34 (s, 3H). DMSO    99 Method AQ2 359.0 (M + 1) Method C 1466 2 HCl 1H NMR (300 MHz, DMSO) δ 9.71 (d, J = 2.0 Hz, 1H), 9.12 (dd, J = 8.0, 1.4 Hz, 1H), 8.89 (dd, J = 5.2, 1.5 Hz, 1H), 8.49 (d, J = 1.6 Hz, 1H), 8.42 (dd, J = 8.8, 2.2 Hz, 1H), 8.34 (d, J = 9.0 Hz, 2H), 8.14 (dd, J = 9.2, 2.4 Hz, 3H), 7.88 (dd, J = 7.8, 5.5 Hz, 1H), 4.34 (s, 3H). DMSO    99 Method AQ2 359.0 (M + 1) Method C 1467 2 HCl 1H NMR (300 MHz, DMSO) δ 9.36 (s, 1H), 9.00 (d, J = 6.5 Hz, 2H), 8.78 (d, J = 4.5 Hz, 2H), 8.58 (s, 1H), 8.06 (s, 2H), 7.75 (dd, J = 15.6, 8.9 Hz, 1H), 7.47 (ddd, J = 11.7, 9.4, 2.6 Hz, 1H), 7.31 (td, J = 8.4, 2.7 Hz, 1H), 3.22 (d, J = 4.2 Hz, 3H). DMSO    99 Method AQ2 349.6 (M + 1) Method C 1468 3 HCl 1H NMR (300 MHz, DMSO) δ 9.97 (s, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 7.0 Hz, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.76 (d, J = 0.7 Hz, 1H), 8.41-8.05 (m, 4H), 7.89 (dd, J = 7.1, 4.8 Hz, 1H), 7.59 (ddd, J = 7.1, 4.9, 1.8 Hz, 1H), 3.27 (d, J = 4.3 Hz, 3H). DMSO    99 Method AQ2 332.4 (M + 1) Method C 1469 2 HCl 1H NMR (300 MHz, DMSO) δ 10.04 (s, 1H), 9.65 (d, J = 1.5 Hz, 1H), 9.06 (d, J = 7.3 Hz, 1H), 8.95 (dd, J = 5.1, 1.5 Hz, 1H), 8.71 (s, 1H), 8.19 (s, 2H), 7.89 (dd, J = 7.6, 5.1 Hz, 1H), 7.76- 7.61 (m, 2H), 7.42 (td, J = 7.9, 0.9 Hz, 1H), 3.27 (d, J = 4.4 Hz, 3H). DMSO    95 Method AQ2 365.3 (M + 1) Method C 1470 2 HCl 1H NMR (300 MHz, DMSO) δ 10.03 (s, 1H), 9.63 (d, J = 1.5 Hz, 1H), 9.04 (d, J = 7.9 Hz, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.68 (s, 1H), 8.16 (s, 2H), 7.88 (dd, J = 7.6, 5.1 Hz, 1H), 7.74 (t, J = 8.5 Hz, 1H), 7.67 (dd, J = 10.8, 2.0 Hz, 1H), 7.51 (dd, J = 8.3, 1.6 Hz, 1H), 3.27 (d, J = 4.4 Hz, 3H). DMSO    94 Method AQ2 365.3 (M + 1) Method C 1471 2 HCl 1H NMR (300 MHz, DMSO) δ 9.95 (s, 1H), 9.64 (d, J = 1.6 Hz, 1H), 9.07 (d, J = 7.9 Hz, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.75 (s, 1H), 8.18 (s, 2H), 8.09 (d, J = 11.1 Hz, 1H), 7.92 (d, J = 4.0 Hz, 3H), 3.27 (d, J = 4.4 Hz, 3H). DMSO    96 Method AQ2 356.4 (M + 1) Method C 1472 2 HCl 1H NMR (300 MHz, DMSO) δ 10.01 (s, 1H), 9.63 (d, J = 1.5 Hz, 1H), 9.03 (d, J = 7.8 Hz, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.73 (s, 1H), 8.25-8.12 (m, 3H), 7.93-7.76 (m, 4H), 7.63 (d, J = 0.8 Hz, 1H), 3.28 (d, J = 4.4 Hz, 3H). DMSO    95 Method AQ2 374.4 (M + 1) Method C 1473 2 HCl 1H NMR (300 MHz, DMSO) δ 9.97 (s, 1H), 9.61 (d, J = 2.1 Hz, 1H), 8.98 (d, J = 4.6 Hz, 1H), 8.93 (dd, J = 5.1, 1.5 Hz, 1H), 8.68- 8.60 (m, 1H), 8.13 (d, J = 6.1 Hz, 2H), 7.85 (dd, J = 7.7, 5.2 Hz, 1H), 7.63 (t, J = 8.3 Hz, 1H), 7.37- 7.23 (m, 2H), 3.27 (d, J = 4.5 Hz, 3H), 2.56 (s, J = 5.2 Hz, 3H). DMSO    95 Method AQ2 377.5 (M + 1) Method C 1474 2 HCl 1H NMR (300 MHz, DMSO) δ 9.98 (s, 1H), 9.64 (d, J = 1.6 Hz, 1H), 9.06 (d, J = 8.8 Hz, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.75 (s, 1H), 8.26-8.11 (m, 2H), 8.04- 7.85 (m, 5H), 3.35 (s, 3H), 3.27 (d, J = 4.1 Hz, 3H). DMSO    96 Method AQ2 409.5 (M + 1) Method C 1475 2 HCl 1H NMR (300 MHz, DMSO) δ 10.25 (s, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.00 (d, J = 7.1 Hz, 1H), 8.93 (dd, J = 5.0, 1.5 Hz, 1H), 8.79 (s, 1H), 8.31 (dd, J = 8.8, 1.5 Hz, 1H), 8.17 (d, J = 8.5 Hz, 1H), 7.84 (dd, J = 7.5, 4.3 Hz, 1H), 7.51 (d, J = 1.8 Hz, 1H), 7.40 (dd, J = 8.2, 1.9 Hz, 1H), 7.09 (d, J = 3.1 Hz, 1H), 6.10 (s, 2H), 3.29 (d, J = 4.3 Hz, 3H). DMSO    99 Method AQ2 357.5 (M + 1) Method C 1476 2 HCl 1H NMR (300 MHz, DMSO) δ 10.26 (s, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.01 (d, J = 3.6 Hz, 1H), 8.93 (dd, J = 5.0, 1.5 Hz, 1H), 8.77 (s, 1H), 8.31 (dd, J = 8.8, 1.4 Hz, 1H), 8.18 (d, J = 8.6 Hz, 1H), 7.84 (dd, J = 6.9, 5.8 Hz, 1H), 7.44 (d, J = 2.2 Hz, 1H), 7.39 (dd, J = 8.4, 2.3 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 4.30 (s, 4H), 3.29 (d, J = 4.4 Hz, 3H). DMSO    99 Method AQ2 371.5 (M + 1) Method C 1477 2 HCl 1H NMR (300 MHz, DMSO) δ 10.19 (s, 1H), 9.61 (d, J = 1.6 Hz, 1H), 8.98 (d, J = 8.8 Hz, 1H), 8.93 (dd, J = 5.0, 1.5 Hz, 1H), 8.82 (s, 1H), 8.35 (dd, J = 8.8, 1.3 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H), 7.85 (dd, J = 8.1, 5.2 Hz, 1H), 7.76-7.66 (m, 2H), 7.46 (t, J = 7.6 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 3.69 (t, J = 7.0 Hz, 2H), 3.31 (d, J = 4.4 Hz, 3H), 2.84 (t, J = 7.0 Hz, 2H). DMSO    99 Method AQ2 357.5 (M + 1) Method C 1478 2 HCl 1H NMR (300 MHz, DMSO) δ 10.11 (s, 1H), 9.60 (d, J = 1.9 Hz, 1H), 8.93 (dd, J = 10.3, 5.4 Hz, 2H), 8.80 (d, J = 0.6 Hz, 1H), 8.34 (dd, J = 8.0, 0.5 Hz, 1H), 8.10 (d, J = 8.3 Hz, 1H), 7.88- 7.75 (m, 3H), 7.40 (d, J = 8.3 Hz, 2H), 3.65 (t, J = 6.9 Hz, 2H), 3.30 (d, J = 4.4 Hz, 3H), 2.79 (t, J = 6.9 Hz, 2H). DMSO    99 Method AQ2 357.5 (M + 1) Method C 1479 2 HCl 1H NMR (300 MHz, DMSO) δ 10.27 (s, 1H), 9.62 (d, J = 1.5 Hz, 1H), 8.99 (s, 1H), 8.96-8.33 (m, 2H), 8.37 (d, J = 8.9 Hz, 1H), 8.18 (d, J = 8.6 Hz, 1H), 7.96 (d, J = 8.5 Hz, 2H), 7.85 (s, 1H), 7.70 (d, J = 8.5 Hz, 2H), 3.30 (d, J = 4.3 Hz, 3H), 1.74 (s, 6H). DMSO    99 Method AQ2 380.5 (M + 1) Method C 1480 2 HCl 1H NMR (300 MHz, DMSO) δ 10.23 (s, 1H), 9.62 (d, J = 1.8 Hz, 1H), 9.02 (d, J = 6.6 Hz, 1H), 8.93 (dd, J = 5.0, 1.5 Hz, 1H), 8.88 (d, J = 0.5 Hz, 1H), 8.33 (d, J = 8.5 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H), 7.99 (d, J = 1.7 Hz, 1H), 7.86 (dd, J = 7.4, 5.1 Hz, 1H), 7.75 (dd, J = 8.5, 1.8 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 3.29 (d, J = 4.3 Hz, 3H). DMSO    99 Method AQ2 393.4 (M + 1) Method C 1481 1H NMR (300 MHz, DMSO) δ 9.63 (d, J = 1.4 Hz, 1H), 8.81-8.73 (m, 1H), 3.68 (dd, J = 4.7, 1.7 Hz, 1H), 8.61 (d, J = 4.3 Hz, 1H), 8.45 (s, 1H), 7.97 (d, J = 8.6 Hz, 1H), 7.86 (d, J = 8.7 Hz, 2H), 7.77-7.61 (m, 3H), 7.53 (dd, J = 7.9, 4.8 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 3.15 (d, J = 4.3 Hz, 3H). DMSO    99 Method AQ2, followed by hydrolysis with 30% H₂O₂ and NaOH in ethanol 374.5 (M + 1) Method C 1482 2 HCl 1H NMR (300 MHz, DMSO) δ 10.60 (s, 1H), 10.29 (s, 1H), 9.62 (d, J = 1.5 Hz, 1H), 9.00 (d, J = 7.1 Hz 1H), 8.92 (dd, J = 4.9, 1.4 Hz, 1H), 8.76 (s, 1H), 8.29 (d, J = 8.9 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 7.84 (dd, J = 7.8, 4.8 Hz, 1H), 7.79-7.68 (m, 2H), 6.95 (d, J = 8.0 Hz, 1H), 3.57 (s, 2H), 3.29 (d, J = 4.3 Hz, 3H). DMSO    94 Method AQ1, except that dioxane water was replaced with DME/water/ EtOH in the microwave at 120° C. for 10 min 368.5 (M + 1) Method C 1483 2 HCl 1H NMR (300 MHz, DMSO) δ 10.67 (s, 1H), 9.60 (d, J = 2.4 Hz, 1H), 8.99-8.88 (m, 2H), 8.73 (d, J = 1.0 Hz, 1H), 8.27 (d, J = 9.2 Hz, 1H), 8.10 (d, J = 7.5 Hz, 1H), 7.83 (dd, J = 6.9, 4.3 Hz, 1H), 7.40 (q, J = 3.3 Hz, 2H), 7.20 (s, 1H), 3.56 (s, 2H), 3.29 (d, J = 4.1 Hz, 3H). DMSO    99 Method AQ1, except that dioxane water was replaced with DME/water/ EtOH in the microwave at 120° C. for 10 min 368.5 (M + 1) Method C 1484 2 HCl 1H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.61 (d, J = 1.9 Hz, 1H), 9.04-8.89 (m, 2H), 8.84 (d, J = 1.2 Hz, 1H), 8.36 (dd, J = 8.7, 1.3 Hz, 1H), 8.14 (d, J = 8.1 Hz, 1H), 7.94-7.78 (m, 3H), 7.50 (d, J = 8.3 Hz, 2H), 4.49 (s, 2H), 3.39-3.23 (m, 6H). DMSO    99 Method AQ1, except that dioxane water was replaced with DME/water/ EtOH in the microwave at 120° C. for 10 min 357.5 (M + 1) Method C 1485 1H-NMR (400 MHz, DMSO-d6): δ 9.63 (s, 1H), 8.76 (td, J = 8.0, 1.6 Hz, 1H), 871 (dd, J = 4.8, 1.6 Hz, 1H), 8.37 (s, 1H), 7.81 (d, J = 8.8 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.59-7.54 (m, 1H), 7.43 (t, J = 8.0 Hz, 1H), 7.06-6.98 (m, 3H), 3.82 (s, 3H). DMSO    95 Method G1, AQ1 377.0 379.0 (M + 1) Method B (NH₄HCO₃) 1486 2HCl 1H-NMR (400 MHz, DMSO-d6): δ 9.81 (s, 1H), 9.38 (d, J = 8.4 Hz, 1H), 9.15 (d, J = 5.2 Hz, 1H), 8.69 (d, J = 1.6 Hz, 1H), 8.41 (dd, J = 8.8, 2.0 Hz, 1H), 8.29- 8.26 (m, 1H), 8.14 (d, J = 8.8 Hz, 1H), 7.50-7.41 (m, 3H), 7.11- 7.08 (m, 1H), 4.80-4.76 (m, 1H), 3.66-3.57 (m, 2H), 3.50 (s, 3H), 3.44 (s, 3H), 1.35 (d, J = 6.4 Hz, 3H). DMSO    95 Method G1, AQ1 401.1 (M + 1) Method B (NH₄HCO₃) 1487 2HCl 1H-NMR (400 MHz, CD3OD): δ 9.55 (s, 1H), 8.92 (d, J = 4.9 Hz, 1H), 8.89 (dt, J = 8.2, 1.8 Hz, 1H), 8.62 (s, 1H), 8.37 (d, J = 8.8 Hz, 1H), 8.03 (d, J = 8.7 Hz, 1H), 7.83 (dd, J = 8.0, 5.0 Hz, 1H), 7.49 (t, J = 8.1 Hz, 1H), 7.43 (s, 2H), 7.10 (d, J = 7.6 Hz, 1H), 4.01 (s, 2H), 3.46 (s, 3H), 3.35 (s, 3H), 1.37 (s, 6H). MeOD    95 Method G1, AQ1 415.1 (M + 1) Method B (NH₄HCO₃) 1488 2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.34 (s, 1H), 9.65 (s, 1H), 9.04 (d, J = 6.9 Hz, 1H), 8.99-8.87 (m, 2H), 8.39 (d, J = 9.2 Hz, 1H), 8.24 (d, J = 8.2 Hz, 1H), 7.86 (s, 1H), 7.47-7.43 (m, 3H), 7.05 (d, J = 6.8 Hz, 1H), 4.26-4.22 (m, 2H), 3.77-3.73 (m, 2H), 3.56- 3.50 (m, 2H), 3.32 (d, J = 4.3 Hz, 3H), 1.15 (t, J = 7.0 Hz, 3H). DMSO    95 Method G1, AQ1 400.9 (M + 1) Method B (NH₄HCO₃) 1489 1H-NMR (400 MHz, DMSO-d6): δ 9.68 (s, 1H), 8.81-8.78 (m, 2H), 8.71 (d, J = 3.6 Hz, 1H), 8.54 (s, 1H), 8.32 (d, J = 1.2 Hz, 1H), 7.57 (dd, J = 7.6, 4.8 Hz, 1H), 7.46-7.42 (m, 3H), 7.04-7.01 (m, 1H), 3.88 (s, 3H), 3.19 (d, J = 4.0 Hz, 3H). DMSO    95 Method G1, AQ1 377.1, 379.1 (M + 1) Method B (NH₄HCO₃) 1490 2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.50 (brs, 1H), 9.68 (d, J = 2.0 Hz, 1H), 9.09 (d, J = 8.0 Hz, 1H), 8.96 (dd, J = 5.2, 1.2 Hz, 1H), 8.94 (s, 1H), 8.40 (d, J = 9.2 Hz, 1H), 8.29 (d, J = 8.8 Hz, 1H), 7.89 (dd, J = 8.0, 1.6 Hz, 1H), 7.48-7.43 (m, 3H), 7.03 (d, J = 7.2 Hz, 1H), 4.06-4.05 (m, 2H), 3.92 (d, J = 11.6 Hz, 1H), 3.69- 3.66 (m, 1H), 3.42-3.39 (m, 1H), 3.32 (d, J = 4.4 Hz, 3H), 1.86-1.83 (m, 1H), 1.69 (d, J = 12.4 Hz, 1H), 1.52-1.51 (m, 3H), 1.38-1.35 (m, 1H). DMSO    95 Method G1, AQ1 427.2 (M + 1) Method B (NH₄HCO₃) 1492 3HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.80 (s, 1H), 9.70 (s, 1H), 9.13 (d, J = 8.0 Hz, 1H), 9.07 (s, 1H), 8.97 (d, J = 4.4 Hz, 1H), 8.94 (s, 1H), 8.39 (d, J = 8.8 Hz, 1H), 8.32 (d, J = 8.8 Hz, 1H), 8.23 (d, J = 8.0 Hz, 1H), 7.98 (t, J = 8.0 Hz, 1H), 7.90 (t, J = 6.2 Hz, 1H), 7.68 (s, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 5.50 (s, 2H), 3.30 (d, J = 2.4 Hz, 3H). DMSO    95 Method G1, AQ1 488.0 (M + 1) Method B (NH₄HCO₃) 1493 2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.58 (s, 1H), 9.71 (s, 1H), 9.14 (d, J = 7.6 Hz, 1H), 8.98 (d, J = 8.0 Hz, 2H), 8.40 (d, J = 8.8 Hz, 1H), 8.31 (d, J = 8.8 Hz, 1H), 7.92 (t, J = 6.2 Hz, 1H), 7.81 (t, J = 7.6 Hz, 1H), 7.47-7.43 (m, 3H), 7.02 (d, J = 7.2 Hz, 1H), 4.10 (t, J = 6.0 Hz, 2H), 3.53 (d, J = 6.4 Hz, 1H), 3.32 (d, J = 2.4 Hz, 3H), 2.26 (t, J = 7.0 Hz, 2H), 2.00-1.93 (m, 2H), 1.73-1.63 (m, 4H), 1.55-1.51 (m, 1H), 1.28-1.02 (m, 5H). DMSO    95 Method G1, AQ1 496.2 (M + 1) Method B (NH₄HCO₃) 1494 2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.07 (s, 1H), 9.60 (s, 1H), 8.92 (d, J = 4.4 Hz, 2H), 876 (s, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.85-7.83 (m, 4H), 7.11 (d, J = 8.8 Hz, 2H), 4.04 (t, J = 6.4 Hz, 2H), 3.30 (d, J = 4.0 Hz, 3H), 2.58 (d, J = 4.0 Hz, 3H), 2.26 (t, J = 7.4 Hz, 2H), 2.00-1.93 (m, 2H). DMSO    95 Method G1, AQ1 428.1, 429.1, (M + 1) Method B (NH₄HCO₃) 1495 2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.63 (s, 1H), 9.73 (s, 1H), 9.17 (d, J = 7.6 Hz, 1H), 8.99 (s, 1H), 8.91 (s, 1H), 8.34 (s, 2H), 7.93 (t, J = 6.0 Hz, 1H), 7.88 (d, J = 7.2 Hz, 2H), 7.09 (d, J = 7.6 Hz, 2H), 4.08-4.06 (m, 2H), 3.32 (s, 3H), 2.98 (s, 3H), 2.84 (s, 3H), 2.47- 2.46 (m, 2H), 1.98-1.94 (m, 2H). DMSO    95 Method G1, AQ1 442.1, 443.1, (M + 1) Method B (NH₄HCO₃) 1496 2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.26 (s, 1H), 9.64 (s, 1H), 9.01 (d, J = 7.0 Hz, 1H), 8.94 (s, 1H), 8.89 (s, 1H), 8.39 (d, J = 8.2 Hz, 1H), 8.19 (d, J = 8.1 Hz, 1H), 7.85 (s, 1H), 7.47 (d, J = 5.8 Hz, 3H), 7.05 (d, J = 3.4 Hz, 1H), 4.21 (dt, J = 10.8, 5.5 Hz, 1H), 4.08 (qd, J = 10.1, 5.2 Hz, 2H), 3.82 (dd, J = 14.4, 7.0 Hz, 1H), 3.71 (dd, J = 14.1, 7.4 Hz, 1H), 3.31 (d, J = 4.2 Hz, 3H), 2.08- 2.00 (m, 1H), 1.98-1.79 (m, 2H), 1.72-1.68 (m, 1H). DMSO    95 Method G1, AQ1 413.1, 414.1, (M + 1) Method B (NH₄HCO₃) 1497 2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.53 (s, 1H), 9.68 (s, 1H), 9.09 (d, J = 7.7 Hz, 1H), 8.96 (d, J = 5.9 Hz, 2H), 8.39 (d, J = 8.7 Hz, 1H), 8.30 (d, J = 8.3 Hz, 1H), 7.94-7.79 (m, 1H), 7.48-7.45 (m, 3H), 7.04 (d, J = 7.5 Hz, 1H), 4.30-4.18 (m, 2H), 3.80-3.70 (m, 2H), 3.44 (t, J = 6.6 Hz, 2H), 3.31 (d, J = 4.2 Hz, 3H), 1.56- 1.54 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H). DMSO-d₆    95 Method G1, AQ1 415.1 (M + 1) Method B (NH₄HCO₃) 1498 2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.07 (s, 1H), 9.67 (s, 1H), 9.03 (d, J = 8.0 Hz, 1H), 8.95 (d, J = 4.5 Hz, 1H), 8.51 (s, 1H), 7.85 (s, 2H), 7.41 (t, J = 7.9 Hz, 1H), 7.18 (dd, J = 7.8, 5.1 Hz, 2H), 7.02 (dd, J = 8.2, 2.3 Hz, 1H), 3.97 (s, 3H), 3.84 (s, 3H). DMSO    95 Method G1, AQ1 373.1 (M + 1) Method B (NH₄HCO₃) 1499 2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.06 (s, 1H), 9.66 (s, 1H), 9.02 (d, J = 7.5 Hz, 1H), 8.95 (s, 1H), 8.89 (s, 1H), 8.39 (d, J = 8.5 Hz, 1H), 8.22 (d, J = 8.6 Hz, 1H), 7.85 (dd, J = 7.0, 5.4 Hz, 1H), 7.52-7.43 (m, 3H), 7.09-7.01 (m, 1H), 4.17-4.15 (m, 2H), 3.32-3.30 (m, 4H), 3.25 (s, 3H), 1.98-1.82 (m, 2H), 1.17 (d, J = 6.1 Hz, 3H). DMSO    95 Method G1, AQ1 415.1 (M + 1) Method B (NH₄HCO₃) 1500 2HCl 1H-NMR (400 MHz, CD3OD): δ 9.80 (s, 1H), 9.37 (d, J = 8.2 Hz, 1H), 9.13 (d, J = 5.3 Hz, 1H), 8.90 (s, 1H), 8.45 (d, J = 8.4 Hz, 1H), 8.25 (dd, J = 7.9, 5.6 Hz, 1H), 8.17 (d, J = 8.7 Hz, 1H), 7.64 (s, 1H), 7.54 (d, J = 5.1 Hz, 2H), 7.17 (dd, J = 7.5, 3.6 Hz, 1H), 4.70-4.62 (m, 2H), 4.42 (q, J = 9.0 Hz, 2H), 3.93-3.86 (m, 2H), 3.51 (s, 3H), 3.24 (s, 3H). CD₃OD    95 Method G1, AQ1 468.1 (M + 1) Method B (NH₄HCO₃) 1501 2HCl 1H-NMR (400 MHz, DMSO): δ 10.45 (brs, 1H), 9.72 (s, 1H), 9.12 (d, J = 7.6 Hz, 1H), 8.97 (d, J = 4.0 Hz, 1H), 8.70 (s, 1H), 8.35 (d, J = 8.8 Hz, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.90-7.87 (m, 2H), 7.49 (d, J = 7.2 Hz, 1H), 7.43 (t, J = 7.2 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.11 (t, J = 7.2 Hz, 1H), 4.03 (t, J = 6.4 Hz, 2H), 3.30 (d, J = 4.4 Hz, 3H), 2.54 (d, J = 4.0 Hz, 3H), 2.19 (t, J = 7.4 Hz, 2H), 1.93-1.86 (m, 2H). DMSO    95 Method G1, AQ1 428.1 (M + 1) Method B (NH₄HCO₃) 1502 1H-NMR (400 MHz, DMSO-d6): δ 9.65 (s, 1H). 8.88 (s, 1H), 8.81 (d, J = 8 Hz, 1H), 8.73 (s, 1H), 8.62 (s, 1H), 8.19 (d, J = 8 Hz, 1H), 7.88 (d, J = 9.2 Hz, 1H), 7.61- 7.58 (m, 1H), 7.47-7.44 (m, 3H), 7.06-7.04 (m, 1H), 4.56- 4.54 (m, 1H), 3.87 (dd, J = 11.2, 2.0 Hz, 1H), 3.68-3.64 (m, 1H), 3.56-3.53 (m, 2H), 3.21 (d, J = 4.4 Hz, 3H), 2.09-2.05 (m, 1H), 1.83-1.72 (m, 2H), 1.61-1.55 (m, 1H). DMSO    95 Method G1, AQ1 413.1 (M + 1) Method B (NH₄HCO₃) 1503 2HCl 1H-NMR (400 MHz, CD3OD): δ 9.77 (s, 1H), 9.43 (d, J = 8.1 Hz, 1H), 9.08 (d, J = 5.6 Hz, 1H), 8.46 (s, 1H), 8.34-8.25 (m, 1H), 8.20 (d, J = 8.7 Hz, 1H), 8.02 (d, J = 8.7 Hz, 1H), 7.37 (d, J = 7.5 Hz, 1H), 7.32 (t, J = 7.4 Hz, 1H), 7.05 (d, J = 8.3 Hz, 1H), 7.00 (t, J = 7.5 Hz, 1H), 3.98 (t, J = 6.1 Hz, 2H), 3.44 (t, J = 11.1 Hz, 1H), 3.35 (s, 3H), 2.17 (t, J = 7.3 Hz, 2H), 1.93-1.89 (m, 2H), 1.70- 1.53 (m, 4H), 1.48 (d, J = 12.5 Hz, 1H), 1.22-1.12 (m, 2H), 1.08-1.02 (m, 3H). CD₃OD    95 Method G1, AQ1 496.2 (M + 1) Method B (NH₄HCO₃) 1504 1H-NMR (400 MHz, DMSO-d6): δ 9.63 (s, 1H), 8.76 (d, J = 8.0 Hz, 1H), 8.67 (d, J = 3.6 Hz, 1H), 8.50 (d, J = 4.0 Hz, 1H), 8.10 (s, 1H), 7.56-7.53 (m, 2H), 7.46- 7.42 (m, 3H), 7.03-7.01 (m, 1H), 4.07 (s, 3H), 3.88 (s, 3H), 3.17 (d, J = 4.0 Hz, 1H). DMSO    95 Method G1, AQ1 372.9 (M + 1) Method B (NH₄HCO₃) 1505 1H-NMR (400 MHz, DMSO): δ 9.28 (s, 1H), 8.94 (t, J = 7.6 Hz, 1H), 8.62 (d, J = 4.2 Hz, 1H), 8.42 (s, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.73-7.71 (m, 1H), 7.46 (t, J = 10.0 Hz, 1H), 7.33-7.27 (m, 2H), 3.16 (d, J = 4.4 Hz, 3H). DMSO    95 Method G1, AQ1 367.0 (M + 1) Method B (NH₄HCO₃) 1506 1H-NMR (400 MHz, DMSO): δ 8.77 (s, 1H), 8.66 (t, J = 8.6 Hz, 1H), 8.52 (s, 1H), 8.44-8.31 (m, 1H), 8.03 (d, J= 8.6 Hz, 1H), 7.88 (d, J = 8.6 Hz, 1H), 7.62- 7.49 (m, 3H), 7.42-7.37 (m, 1H), 3.12 (d, J = 3.0 Hz, 3H). DMSO    95 Method G1, AQ1 366.9 (M + 1) Method B (NH₄HCO₃) 1507 1H-NMR (400 MHz, DMSO): δ 9.29 (d, J = 2.0 Hz, 1H), 8.95 (dt, J = 8.4, 2.4 Hz, 1H), 8.65 (d, J = 4.4 Hz, 1H), 8.49 (s, 1H), 7.94- 7.93 (m, 2H), 7.60-7.26 (m, 4H), 3.16 (d, J = 4.4 Hz, 3H). DMSO    95 Method G1, AQ1 367.1 (M + 1) Method B (NH₄HCO₃) 1508 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.46 (s, 1H), 8.77 (s, 1H), 8.65 (t, J = 8.5 Hz, 1H), 8.55 (s, 1H), 8.19 (d, J = 8.7 Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.79 (dd, J = 15.8, 7.8 Hz, 1H), 7.71-7.66 (m, 1H), 7.51 (t, J = 10.2 Hz, 1H), 7.34 (t, J = 8.5 Hz, 1H), 3.23 (d, J = 3.3 Hz, 3H). DMSO    95 Method G1, AQ1 367.0 (M + 1) Method B (NH₄HCO₃) 1509 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.98 (s, 1H), 9.55 (d, J = 1.3 Hz, 1H), 9.07 (d, J = 7.2 Hz, 1H), 8.67 (s, 1H), 8.16 (dd, J = 18.0. 8.4 Hz, 2H), 7.84 (d, J = 8.3 Hz, 1H), 7.78 (td, J = 8.9, 6.6 Hz, 1H), 7.55-7.45 (m, 1H), 7.33 (td, J = 8.4, 2.0 Hz, 1H), 3.28 (d, J = 4.4 Hz, 3H), 2.74 (s, 3H). DMSO    95 Method G1, AQ1 363.1 (M + 1) Method B (NH₄HCO₃) 1510 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.17 (s, 1H), 8.82 (dd, J = 7.9, 6.7 Hz, 2H), 8.65 (s, 1H), 8.21 (d, J = 8.5 Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.80 (s, 1H), 7.65-7.50 (m, 2H), 7.42 (dd, J = 12.7, 7.6 Hz, 1H), 3.20 (d, J = 4.4 Hz, 3H), 2.94 (s, 3H). DMSO    95 Method G1, AQ1 363.0 (M + 1) Method B (NH₄HCO₃) 1511 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.24 (s, 1H), 8.84 (d, J = 4.0 Hz, 1H), 8.77 (s, 1H), 8.64 (s, 1H), 8.18 (d, J = 8.6 Hz, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.79 (td, J = 8.9, 6.6 Hz, 2H), 7.57-7.46 (m, 1H), 7.34 (td, J = 8.5, 2.2 Hz, 1H), 3.20 (d, J = 4.5 Hz, 3H), 2.93 (s, 3H). DMSO    95 Method G1, AQ1 362.9 (M + 1) Method B (NH₄HCO₃) 1512 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.57 (s, 1H), 8.83 (dd, J = 8.0, 1.6 Hz, 1H), 8.63 (dd, J = 4.8, 2.0 Hz, 1H), 8.38 (s, 1H), 7.95-7.86 (m, 2H), 7.67-7.57 (m, 2H), 7.15-7.09 (m, 2H), 4.44 (brs, 1H), 2.17 (t, J = 7.6 Hz, 1H), 1.91-1.89 (m, 1H), 1.78 (d, J = 12.0 Hz, 1H), 1.56-1.48 (m, 4H), 1.32-1.28 (m, 1H). DMSO    95 Method G1, AQ1 417.1 (M + 1) Method B (NH₄HCO₃) 1513 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.55 (s, 1H), 8.94-8.89 (m, 2H), 8.58 (s, 1H), 8.23 (d, J = 8.8 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 7.85 (t, J = 6.8 Hz, 1H), 7.73 (dd, J = 14.4, 8.0 Hz, 1H), 7.25-7.19 (m, 2H), 4.01 (q, J = 7.2 Hz, 2H), 1.48 (t, J = 7.2 Hz, 3H). DMSO    95 Method G1, AQ1 363.1 (M + 1) Method B (NH₄HCO₃) 1514 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.71 (s, 1H), 9.21 (d, J = 8.4 Hz, 1H), 9.08 (d, J = 4.4 Hz, 1H), 8.68 (s, 1H), 8.30 (d, J = 8.8 Hz, 1H), 8.15-8.12 (m, 2H), 7.50- 7.38 (m, 3H), 4.04 (q, J = 7.2 Hz, 2H), 1.49 (t, J = 7.2 Hz, 3H). DMSO    95 Method G1, AQ1 363.1 (M + 1) Method B (NH₄HCO₃) 1515 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.67 (s, 1H), 9.25 (d, J = 8.0 Hz, 1H), 9.03 (d, J = 5.2 Hz, 1H), 8.60 (s, 1H), 8.21-8.14 (m, 2H), 8.06 (d, J = 8.4 Hz, 1H), 7.40- 7.26 (m, 3H), 4.26 (brs, 4H), 2.14 (brs, 4H). DMSO-d₆    95 Method G1, AQ1 389.1 (M + 1) Method B (NH₄HCO₃) 1516 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.60 (s, 1H), 9.14 (d, J = 8.0 Hz, 1H), 9.10 (d, J = 5.2 Hz, 1H), 8.69 (s, 1H), 8.19 (d, J = 8.4 Hz, 1H), 8.09 (dd, J = 8.0, 5.2 Hz, 1H), 8.03 (d, J = 8.8 Hz, 1H), 7.39-7.27 (m, 3H), 4.60-4.50 (m, 1H), 2.08 (d, J = 11.6 Hz, 2H), 1.84 (d, J = 12.0 Hz, 2H), 1.69 (d, J = 8.4 Hz, 1H), 1.57- 1.45 (m, 4H), 1.18-1.10 (m, 1H). DMSO    95 Method G1, AQ1 417.1 (M + 1) Method B (NH₄HCO₃) 1517 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.04 (brs, 1H), 9.58 (s, 1H), 9.38 (brs, 1H), 8.84 (d, J = 5.6 Hz, 2H), 8.72 (s, 1H), 8.28 (d, J = 9.2 Hz, 1H), 7.75 (t, J = 6.8 Hz, 1H), 7.51-7.41 (m, 3H), 7.07-7.03 (m, 1H), 3.88 (s, 3H), 3.80 (q, J = 5.6 Hz, 2H), 2.32 (t, J = 72 Hz, 2H), 1.86-1.74 (m, 2H), 1.73- 1.64 (m, 2H). DMSO    95 Method G1, AQ1 428.9 (M + 1) Method B (NH₄HCO₃) 1518 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.74 (td, J = 8.0, 1.6 Hz, 1H), 8.71-8.66 (m, 1H), 8.31 (d, J = 1.6 Hz, 1H), 8.08 (dd, J = 8.8, 2.0 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.87-7.81 (m, 2H), 7.58-7.49 (m, 1H), 7.39- 7.30 (m, 2H), 3.49 (s, 6H). DMSO    95 Method G1, AQ1 345.1 (M + 1) Method B (NH₄HCO₃) 1519 ¹H NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.74 (d, J = 7.2 Hz, 1H), 8.69 (d, J = 3.6 Hz, 1H), 8.32 (s, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.82 (d, J = 7.6 Hz, 2H), 7.62- 7.48 (m, 3H), 3.48 (s, 6H). DMSO    95 Method G1, AQ1 361.1 363.1 (M + 1) Method B (NH₄HCO₃) 1520 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.74 (td, J = 8.0, 1.6 Hz, 1H), 8.69 (dd, J = 4.8, 1.6 Hz, 1H), 8.42 (d, J = 2.0 Hz, 1H), 8.16 (dd, J = 8.8, 2.0 Hz, 1H), 8.04-7.89 (m, 5H), 7.54 (q, J = 5.2 Hz, 1H), 3.51 (s, 6H). DMSO    95 Method G1, AQ1 352.1 (M + 1) Method B (NH₄HCO₃) 1521 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.76 (d, J = 8.0 Hz, 1H), 8.68-8.60 (m, 2H), 8.15 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.56 (q, J = 4.8 Hz, 1H), 7.49-7.40 (m, 3H), 7.30 (s, 1H), 7.06-6.97 (m, 1H), 6.73 (s, 1H), 3.87 (s, 5H), 2.14 (t, J = 7.2 Hz, 2H), 1.80-1.71 (m, 2H), 1.71-1.62 (m, 2H). DMSO    95 Method G1, AQ1 428.1 (M + 1) Method B (NH₄HCO₃) 1522 2 HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.67 (s, 1H), 9.39 (d, J = 8.2 Hz, 1H), 9.02 (d, J = 5.3 Hz, 1H), 8.31 (d, J = 9.3 Hz, 2H), 8.24- 8.10 (m, 3H), 7.88 (d, J = 7.7 Hz, 1H), 7.72 (t, J = 7.8 Hz, 1H), 3.54 (s, 6H), 2.78 (s, 3H). DMSO    95 Method G1, AQ1 366.1 (M + 1) Method B (NH₄HCO₃) 1523 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.63 (d, J = 1.7 Hz, 1H), 8.88- 8.32 (m, 4H), 8.16 (dd, J = 8.7, 1.8 Hz, 1H), 7.86 (t, J = 9.2 Hz, 1H), 7.55 (dd, J = 7.9, 4.8 Hz, 1H), 7.50-7.34 (m, 3H), 7.01 (dt, J = 7.3, 2.1 Hz, 1H), 3.96- 3.84 (m, 5H), 2.78 (t, J = 6.9 Hz, 2H). DMSO    95 Method G1, AQ1 400.9 (M + 1) Method B (NH₄HCO₃) 1524 ¹H-NMR (400 MHz, DMSO-d₆): 9.63 (s, 1H), 8.77 (d, J = 8 Hz, 1H), 8.66-8.63 (m, 3H), 8.15 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.45-7.41 (m, 3H), 7.33 (s, 1H), 7.01 (d, J = 7.0 Hz, 1H), 6.79 (s, 1H), 3.88 (s, 3H), 3.72 (d, J = 6.0 Hz, 2H), 2.24 (t, J = 7.2 Hz, 2H), 2.04-1.94 (m, 2H). DMSO    95 Method G1, AQ1 414.1 (M + 1) Method B (NH₄HCO₃) 1525 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.58 (d, J = 1.2 Hz, 1H), 8.73- 8.68 (m, 3H), 8.37 (s, 1H), 8.27- 8.22 (m, 4H), 7.89-7.87 (m, 2H), 7.75 (t, J = 8.0 Hz, 1H), 7.55 (dd, J = 8.0, 5.2 Hz, 1H). DMSO    95 Method G1, AQ1 324.1 (M + 1) Method B (NH₄HCO₃) 1526 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.57 (d, J = 1.6 Hz, 1H), 8.72- 8.66 (m, 2H), 8.57 (d, J = 1.6 Hz, 1H), 8.19-7.91 (m, 3H), 7.83 (d, J = 8.0 Hz, 3H), 7.54 (dd, J = 7.6, 4.8 Hz, 1H), 7.10 (d, J = 8.4 Hz, 2H), 3.83 (s, 3H). DMSO    95 Method G1, AQ1 329.1 (M + 1) Method B (NH₄HCO₃) 1527 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.58 (s, 1H), 8.72-8.66 (m, 3H), 8.16 (d, J = 8.4 Hz, 3H), 7.91 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 8.4 Hz, 2H), 7.54 (dd, J = 7.6, 4.3 Hz, 1H). DMSO    95 Method G1, AQ1 333.1, 335.0 (M + 1) Method B (NH₄HCO₃) 1528 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.59 (s, 1H), 9.28 (d, J = 8.0 Hz, 1H), 9.01 (d, J = 5.6 Hz, 2H), 8.65 (s, 2H), 8.37 (s, 2H), 8.25 (d, J = 8.0 Hz, 1H), 8.22 (s, 1H), 8.13 (t, J = 6.8 Hz, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.74 (t, J = 8.0 Hz, 1H), 2.77 (s, 3H). DMSO    95 Method G1, AQ1 338.1 (M + 1) Method B (NH₄HCO₃) 1529 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.78 (s, 1H), 9.72 (d, J = 1.8 Hz, 1H), 9.18 (d, J = 8.1 Hz, 1H), 8.98 (dd, J = 5.1, 1.2 Hz, 1H), 8.78 (s, 1H), 8.29 (d, J = 8.6 Hz, 1H), 8,17 (d, J = 8.6 Hz, 1H), 7.95 (dd, J = 7.9, 5.3 Hz, 1H), 7.80 (td, J = 8.9, 6.6 Hz, 1H), 7.55-7.45 (m, 1H), 7.34 (td, J = 8.4, 2.3 Hz, 1H), 7.26 (s, 1H), 6.96 (s, 1H), 3.98 (d, J = 6.1 Hz, 2H), 1.24 (s, 6H). DMSO    95 Method G1, AQ1 434.1 (M + 1) Method B (NH₄HCO₃) 1530 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.58 (s, 1H), 9.04-8.89 (m, 2H), 8.71-8.66 (m, 1H), 8.15- 8.11 (m, 2H), 7.82-7.76 (m, 2H), 7.51 (t, J = 9.2 Hz, 1H), 7.34 (t, J = 8.8 Hz, 1H), 4.64 (s, 2H), 3.19 (s, 3H), 2.91 (s, 3H). DMSO    95 Method G1, AQ1 420.1 (M + 1) Method B (NH₄HCO₃) 1531 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.63 (s, 1H), 8.78 (d, J = 7.9 Hz, 1H), 8.72 (d, J = 3.2 Hz, 1H), 8.19 (s, 2H), 8.08-7.97 (m, 2H), 7.80 (dd, J = 15.5, 8.9 Hz, 1H), 7.58 (dd, J = 7.6, 4.9 Hz, 1H), 7.52-7.41 (m, 1H), 7.29 (td, J = 8.3, 1.9 Hz, 1H), 4.48 (s, 2H), 4.15 (s, 2H), 3.48 (s, 2H). DMSO    95 Method G1, AQ1 418.1 (M + 1) Method B (NH₄HCO₃) 1532 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.65 (s, 1H), 8.87 (s, 1H), 8.79 (d, J = 7.7 Hz, 1H), 8.70 (s, 1H), 8.59 (s, 1H), 8.23 (s, 1H), 8.05- 7.89 (m, 3H), 7.75 (dd, J = 15.1, 7.6 Hz, 1H), 7.56 (s, 1H), 7.48 (t, J = 9.9 Hz, 1H), 7.32 (t, J = 8.1 Hz, 1H), 4.46 (t, J = 13.4 Hz, 2H). DMSO    95 Method G1, AQ1 442.0 (M + 1) Method B (NH₄HCO₃) 1533 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.63 (s, 1H), 8.95-9.03 (m, 2H), 8.78 (s, 1H), 8.14-8.24 (m, 2H), 7.88 (t, J = 6.0 Hz, 1H), 7.79 (d, J = 8.8 Hz, 1H), 7.54-7.48 (m, 1H), 7.35-7.32 (m, 1H), 4.89 (m, 1H), 1.39 (d, J = 1.2 Hz, 6H). DMSO    95 Method G1, AQ1 377.1 (M + 1) Method B (NH₄HCO₃) 1534 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.69-8.74 (m, 2H), 8.59 (s, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.71-7.77 (m, 1H), 7.66 (s, 1H), 7.56-7.60 (m, 1H), 7.42-7.48 (m, 1H), 7.27-7.32 (m, 1H), 1.66 (s, 9H). DMSO    95 Method G1, AQ1 391.1 (M + 1) Method B (NH₄HCO₃) 1535 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.74 (s, 1H), 9.66 (s, 1H), 9.22 (d, J = 7.6 Hz, 1H), 8.99 (d, J = 4.8 Hz, 1H), 8.83 (s, 1H), 8.33 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 7.95 (t, J = 6.2 Hz, 1H), 7.58 (q, J = 8.6 Hz, 1H), 7.51 (t, J = 7.0 Hz, 1H), 7.46-7.41 (m, 1H), 7.25 (s, 1H), 6.72 (s, 1H), 5.13-5.06 (m, 1H), 3.21 (q, J = 7.3 Hz, 1H), 2.22-1.92 (m, 5H), 1.68-1.57 (m, 1H). DMSO    95 Method G1, AQ1 446.0 (M + 1) Method B (NH₄HCO₃) 1536 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.81 (s, 2H), 9.32 (d, J = 8.0 Hz, 1H), 9.02 (d, J = 5.2 Hz, 1H), 8.81 (s, 1H), 8.42 (d, J = 8.4 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.00 (dd, J = 7.8, 5.8 Hz, 1H), 7.76 (dd, J = 15.4, 3.6 Hz, 1H), 7.51 (t, J = 10.0 Hz, 1H), 7.35 (t, J = 8.2 Hz, 1H), 7.29 (s, 1H), 6.73 (s, 1H), 5.15-5.07 (m, 1H), 3.21 (q, J = 7.3 Hz, 1H), 2.23- 1.87 (m, 5H), 1.68-1.57 (m, 1H). DMSO    95 Method G1, AQ1 446.1 (M + 1) Method B (NH₄HCO₃) 1537 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.66 (s, 1H), 8.79 (d, J = 7.6 Hz, 1H), 8.69 (dd, J = 4.4, 1.2 Hz, 1H), 8.61 (d, J = 1.6 Hz, 1H), 8.40 (d, J = 7.2 Hz, 1H), 8.13 (dd, J = 8.6, 1.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.55 (dd, J = 7.6, 4.8 Hz, 1H), 7.49-7.40 (m, 3H), 7.11 (s, 1H), 7.02 (d, J = 7.2 Hz, 1H), 6.69 (s, 1H), 5.03-4.96 (m, 1H), 3.87 (s, 3H), 3.20 (dd, J = 15.0, 7.4 Hz, 1H), 2.22-1.88 (m, 5H), 1.70-1.56 (m, 1H). DMSO    95 Method G1, AQ1 Method B (NH₄HCO₃) 1538 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.60 (s, 1H), 8.86 (d, J = 7.7 Hz, 1H), 8.74 (d, J = 8.0 Hz, 1H), 8.69 (d, J = 3.3 Hz, 1H), 8.65 (s, 1H), 8.19 (d, J = 7.4 Hz, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.54 (dd, J = 7.8, 4.8 Hz, 1H), 7.50- 7.40 (m, 3H), 7.01 (dd, J = 7.3, 3.9 Hz, 1H), 4.85 (dd, J = 16.9, 8.7 Hz, 1H), 3.88 (s, 3H), 2.16 (s, 2H), 1.96 (s, 2H). DMSO    95 Method G1, AQ1 426.1, 427.1 (M + 1) Method B (NH₄HCO₃) 1539 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.34 (s, 1H), 9.67 (s, 1H), 9.07 (s, 1H), 8.97 (d, J = 5.0 Hz, 1H), 8.92 (s, 1H), 8.39 (d, J = 8.8 Hz, 1H), 8.25 (d, J = 7.4 Hz, 1H), 7.99 (s, 1H), 7.90 (s, 1H), 7.48 (d, J = 5.8 Hz, 3H), 7.09-6.99 (m, 1H), 4.03 (d, J = 6.1 Hz, 2H), 3.89 (s, 3H), 2.65 (t, J = 6.8 Hz, 2H), 2.56 (d, J = 4.4 Hz, 3H). DMSO    95 Method G1, AQ1 414.0, 415.0 (M + 1) Method B (NH₄HCO₃) 1540 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.48 (s, 1H), 9.64 (s, 1H), 9.05 (d, J = 7.9 Hz, 1H), 9.01-8.92 (m, 2H), 8.38 (d, J = 8.8 Hz, 1H), 8.28 (d, J = 8.6 Hz, 1H), 7.93- 7.83 (m, 1H), 7.55-7.43 (m, 3H), 7.08-6.98 (m, 1H), 4.04 (dd, J = 12.4, 6.6 Hz, 2H), 3.89 (s, 3H), 2.98 (s, 3H), 2.89 (t, J = 7.0 Hz, 2H), 2.34 (s, 3H). DMSO    95 Method G1, AQ1 428.1, 429.1 (M + 1) Method B (NH₄HCO₃) 1541 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.02 (brs, 1H), 9.75 (d, J = 1.6 Hz, 1H), 9.07 (dd, J = 8.0, 1.6 Hz, 1H), 8.83 (s, 1H), 8.35 (d, J = 9.2 Hz, 1H), 8.19 (d, J = 8.6 Hz, 1H), 8.14 (d, J = 8.8 Hz, 1H), 7.48-7.46 (m, 3H), 7.06-7.03 (m, 1H), 3.89 (s, 3H), 3.30 (d, J = 4.0 Hz, 3H). DMSO    95 Method G1, AQ1 411.1 (M + 1) Method B (NH₄HCO₃) 1542 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.22 (brs, 1H), 9.64 (s, 1H), 9.01 (d, J = 6.4 Hz, 1H), 8.95 (d, J = 4.0 Hz, 1H), 8.89 (s, 1H), 8.39 (d, J = 8.4 Hz, 1H), 8.23 (d, J = 8.0 Hz, 1H), 7.85 (t, J = 5.2 Hz, 1H), 7.52-7.42 (m, 4H), 7.08-7.05 (m, 1H), 6.89 (s, 1H), 3.89 (s, 4H), 3.83-3.76 (m, 2H), 2.83- 2.79 (m, 1H), 1.65-1.56 (m, 7H), 1.24-1.07 (m, 6H), 0.89- 0.81 (m, 2H). DMSO    95 Method G1, AQ1 510.2 (M + 1) Method B (NH₄HCO₃) 1543 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.67 (d, J = 1.6 Hz, 1H), 8.80 (dt, J = 8.0, 2.0 Hz, 1H), 8.70 (dd, J = 4.4, 2.0 Hz, 1H), 8.15 (s, 1H), 7.87 (s, 1H), 7.71-7.67 (m, 1H), 7.58-7.55 (m, 1H), 7.47 (d, J = 2.4 Hz, 1H), 7.34 (m, 2H), 3.45 (s, 6H), 2.76 (s, 3H). DMSO    95 Method G1, AQ1 359.1 (M + 1) Method B (NH₄HCO₃) 1544 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.66 (s, 1H), 8.82-8.79 (m, 1H), 8.70 (d, J = 4.0 Hz, 1H), 8.20 (d, J = 1.6 Hz, 1H), 8.02 (s, 1H), 7.86-7.84 (m, 2H), 7.58-7.55 (m, 3H), 3.48 (s, 6H), 2.77 (s, 3H). DMSO    95 Method G1, AQ1 375.1 (M + 1) Method B (NH₄HCO₃) 1545 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.68 (s, 1H), 9.01 (d, J = 8.0 Hz, 1H), 8.82 (d, J = 4.4 Hz, 1H), 8.18 (d, J = 1.6 Hz, 1H), 8.03 (s, 1H), 7.88-7.84 (m, 2H), 7.80- 7.77 (m, 1H), 7.37-7.33 (m, 2H), 3.50 (s, 6H), 2.78 (s, 3H). DMSO    95 Method G1, AQ1 359.1 (M + 1) Method B (NH₄HCO₃) 1546 ¹H-NMR (400 MHz, CD₃OD): δ 9.51 (s, 1H), 8.81 (d, J = 7.3 Hz, 1H), 8.54 (s, 1H), 8.35 (s, 1H), 8.02 (d, J = 8.3 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.50 (d, J = 7.2 Hz, 1H), 7.29 (dt, J = 11.2, 4.8 Hz, 3H), 6.88 (d, J = 7.5 Hz, 1H), 4.43 (dd, J = 7.1, 4.0 Hz, 1H), 4.16 (dd, J = 13.8, 4.0 Hz, 1H), 3.86 (dd, J = 13.7, 7.4 Hz, 1H), 3.80 (s, 3H). CD3OD    95 Method G1, AQ1 416.1 (M + 1) Method B (NH₄HCO₃) 1547 2HCl ¹H-NMR (400 MHz, CD₃OD): δ 9.74 (s, 1H), 9.44 (d, J = 8.2 Hz, 1H), 9.02 (d, J = 5.5 Hz, 1H), 8.50 (s, 1H), 8.24 (dd, J = 8.0, 5.9 Hz, 1H), 8.16 (q, J = 8.7 Hz, 2H), 7.70-7.58 (m, 1H), 7.12- 7.00 (m, 2H), 6.13 (s, 1H), 4.44- 4.41 (m, 1H), 4.29-4.27 (m, 1H), 2.37-2.16 (m, 3H), 2.09- 2.07 (m, 1H). CD₃OD    95 Method G1, AQ1 457.0 (M + 1) Method B (NH₄HCO₃) 1548 2HCl ¹H-NMR (400 MHz, CD₃OD): δ 9.85 (s, 1H), 9.57 (d, J = 8.0 Hz, 1H), 9.10 (d, J = 4.8 Hz, 1H), 8.64 (s, 1H), 8.34-8.22 (m, 3H), 7.51 (t, J = 6.9 Hz, 1H), 7.47- 7.33 (m, 2H), 6.23 (s, 1H), 4.53- 4.51 (m, 1H), 4.38-4.36 (m, 1H), 2.51-2.30 (m, 3H), 2.19- 2.18 (m, 1H). CD₃OD    95 Method G1, AQ1 457.1 (M + 1) Method B (NH₄HCO₃) 1549 2HCl ¹H-NMR (400 MHz, DMSO): δ 10.38 (brs, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.00 (d, J = 8.0 Hz, 1H), 8.95-8.94 (m, 2H), 8.39 (d, J = 9.2 Hz, 1H), 8.23 (d, J = 8.4 Hz, 1 H), 7.88-7.85 (m, 1 H), 7.49- 7.48 (m, 3H), 7.07-7.04 (m, 1H), 3.94-3.89 (m, 5H), 3.60- 3.57 (m, 2H), 1.96-1.93 (m, 2H). DMSO    95 Method G1, AQ1 387.1 (M + 1) Method B (NH₄HCO₃) 1550 ¹H-NMR (400 MHz, DMSO): δ 9.62 (s, 1H), 8.72-8.70 (m, 2H), 8.40 (s, 1H), 8.11-7.94 (m, 2H), 7.91-7.74 (m, 3H), 7.54 (dd, J = 7.6, 4.8 Hz, 1H), 7.09 (d, J = 8.6 Hz, 2H), 3.83 (s, 3H), 2.74 (s, 3H). DMSO    95 Method G1, AQ1 343.1 (M + 1) Method B (NH₄HCO₃) 1551 ¹H-NMR (400 MHz, DMSO): δ 9.64 (s, 1H), 8.76 (d, J = 8.0 Hz, 1H), 8.70 (d, J = 4.4 Hz, 1H), 8.46 (s, 1H), 8.12-7.83 (m, 5H), 7.57 (dd, J = 7.8, 4.8 Hz, 1H), 7.39 (t, J = 8.7 Hz, 2H), 2.84 (s, 3H). DMSO    95 Method G1, AQ1 331.1 (M + 1) Method B (NH₄HCO₃) 1552 1H-NMR (400 MHz, DMSO): δ 9.62 (s, 1H), 8.77 (d, J = 8.0 Hz, 1H), 8.71 (d, J = 4.4 Hz, 1H), 8.23 (s, 1H), 8.20 (s, 1H), 8.07- 8.00 (m, 2H), 7.60-7.50 (m, 3H), 7.40-7.37 (m, 1H), 4.48 (s, 2H), 4.12-4.10 (m, 2H), 3.48- 3.46 (m, 2H). DMSO    95 Method G1, AQ1 418.1 (M + 1) Method B (NH₄HCO₃) 1553 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.74 (s, 1H), 9.45 (s, 1H), 9.27 (d, J = 8.8 Hz, 1H), 8.97 (s, 1H), 8.69 (s, 1H), 8.12-8.00 (m, 3H), 7.83-7.76 (m, 1H), 7.51-7.32 (m, 2H), 480-4.64 (m, 2H). DMSO    95 Method G1, AQ1 417.1 (M + 1) Method B (NH₄HCO₃) 1554 2HCl ¹H-NMR (400 MHz, CD3OD): δ 9.86 (s, 1H), 9.48 (d, J = 8.8 Hz, 1H), 9.18 (d, J = 5.2 Hz, 1H), 8.72 (s1H), 8.92 (s, 1H), 8.37- 8.31 (m, 2H), 8.22 (d, J = 8.8 Hz, 1H), 7.80-7.55 (m, 1H), 7.26- 7.20 (m, 2H), 4.92 (d, J = 4.8 Hz, 1H), 4.81 (t, J = 4.8 Hz, 1H), 4.39-4.30 (m, 2H). CD3OD    95 Method G1, AQ1 380.9 (M + 1) Method B (NH₄HCO₃) 1555 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.62 (s, 1H), 8.7-8.68 (m, 2H), 8.32 (s, 1H), 7.97-7.93 (m, 2H), 7.91-7.36 (m, 5H), 347 (s, 6H). DMSO    95 Method G1, AQ1 345.1 (M + 1) Method B (NH₄HCO₃) 1556 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.75 (d, J = 8.0 Hz, 1H), 8.67 (d, J = 3.6 Hz, 2H), 8.48 (s, 1H), 8.13 (d, J = 8.8 Hz, 1H), 7.91 (d, J = 8.8 Hz, 1H), 7.59-7.49 (m, 3H), 7.45-7.30 (m, 5H), 7.02-6.92 (m, 1H), 4.50 (q, J = 3.2 Hz, 1H), 4.39- 4.20 (m, 2H), 4.14-4.09 (m, 1H), 3.98-3.83 (m, 1H), 3.38 (s, 3H), 2.49-2.40 (m, 1H), 2.35- 2.18 (m, 1H). DMSO    95 Method G1, AQ1 493.0 495.0 (M + 1) Method B (NH₄HCO₃) 1557 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.60 (s, 1H), 8.73 (dd, J = 7.6, 1.2 Hz, 1H), 8.67 (dd, J = 8.4, 1.2 Hz, 1H), 8.47 (s, 1H), 8.11 (dd, J = 8.4, 1.6 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.54-7.50 (m, 1H), 7.42 (t, J = 8.0 Hz, 1H), 7.38- 7.32 (m, 2H), 7.32-7.23 (m, 2H), 7.05 (d, J = 8.4 Hz, 1H), 7.00-6.92 (m, 2H), 4.45 (t, J = 8.4 Hz, 1H), 4.24 (s, 2H), 4.08- 3.95 (m, 1H), 3.88-3.80 (m, 7H), 2.44-2.33 (m, 1H), 2.29- 2.15 (m, 1H). DMSO    95 Method G1, AQ1 489.1 (M + 1) Method B (NH₄HCO₃) 1558 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.56 (s, 1H), 9.02 (s, 1H), 8.19 (d, J = 7.5 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.58 (dd, J = 7.7, 4.9 Hz, 1H), 7.52-7.37 (m, 3H), 7.37-7.24 (m, 3H), 7.12 (t, J = 8.8 Hz, 2H), 7.02 (d, J = 7.5 Hz, 1H), 6.84 (s, 1H), 3.89-3.78 (m, 4H), 3.72-3.66 (m, 1H), 3.13 (s, 1H), 2.97-2.90 (m, 1H), 2.86- 2.78 (m, 1H). DMSO    95 Method G1, AQ1 506.1 (M + 1) Method B (NH₄HCO₃) 1559 2 HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.48-10.00 (m, 1H), 9.70 (s, 1H), 9.12-8.77 (m, 3H), 8.42- 8.32 (m, 1H), 8.30-8.17 (m, 1H), 7.95-7.79 (m, 1H), 7.55- 7.44 (m, 6H), 7.26 (d, J = 7.2 Hz, 1H), 7.05 (s, 1H), 6.94 (S, 1H), 3.89 (s, 5H), 3.22 (s, 1H), 2.97- 2.81 (m, 2H). DMSO    95 Method G1, AQ1 558.1 560.0 562.0 (M + 1) Method B (NH₄HCO₃) 1560 2 HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.25 (s, 1H), 9.61 (d, J = 1.5 Hz, 1H), 8.96 (d, J = 4.0 Hz, 1H), 8.87 (s, 1H), 8.39 (d, J = 8.5 Hz, 1H), 8.25 (d, J = 7.7 Hz, 1H), 7.87 (s, 1H), 7.52-7.44 (m, 4H), 7.36 (t, J = 7.6 Hz, 1H), 7.28 (dd, J = 13.5, 6.0 Hz, 1H), 7.22-7.10 (m, 2H), 7.06 (d, J = 7.5 Hz, 1H), 6.89 (s, 1H), 3.95-3.81 (m, 5H), 3.21 (d, J = 9.0 Hz, 1H), 2.94 (d, J = 7.3 Hz, 2H). DMSO    95 Method G1, AQ1 508.2 (M + 1) Method B (NH₄HCO₃) 1561 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.64 (s, 1H), 8.71 (m, 2H), 8.69 (d, J = 3.5 Hz, 1H), 8.64 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.7 Hz, 1H), 7.58-7.49 (m, 1H), 7.43 (m, 4H), 7.28-7.18 (m, 4H), 7.15 (m, 1H), 7.01 (d, J = 7.2 Hz, 1H), 6.94 (s, 1H), 3.82- 3.73 (m, 5H), 2.90-2.87 (m. 1H), 2.68-2.65 (m, 2H), 1.89- 1.86 (m, 2H). DMSO    95 Method G1, AQ1 503.9 (M + 1) Method B (NH₄HCO₃) 1562 ¹H-NMR (400 MHz, DMSO-d₆): 9.85 (s, 1H), 8.76 (s, 1H), 8.65 (d, J = 3.6 Hz, 1H), 8.64 (s, 1H), 8.53 (d, J = 8.0 Hz, 1H), 8.14 (d, J = 8.6 Hz, 1H), 7.83 (d, J = 8.7 Hz, 1H), 7.51 (dd, J = 8.0, 4.7 Hz, 1H), 7.45 (d, J = 6.7 Hz, 2H), 7.40 (s, 1H), 7.31-7.27 (m, 5H), 7.24 (d, J = 6.6 Hz, 1H), 7.00 (d, J = 6.9 Hz, 1H), 6.80 (s, 1H), 3.77-3.70 (m, 5H), 3.17-3.15 (m, 1H), 2.98-2.81 (m, 2H). DMSO    95 Method G1, AQ1 489.9 (M + 1) Method B (NH₄HCO₃) 1563 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.57 (s, 1H), 8.74-8.68 (m, 2H), 8.21 (s, 1H), 8.15 (dd, J = 8.7, 1.6 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.56-7.52 (m, 2H), 7.46- 7.31 (m, 4H), 7.12 (d, J = 6.5 Hz, 2H), 6.95-6.93 (m, 1H), 5.16 (s, 2H), 3.78 (s, 3H), 3.53 (s, 3H). DMSO    95 Method G1, AQ1 467.1, 469.1 (M + 1) Method B (NH₄HCO₃) 1564 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.64 (d, J = 1.4 Hz, 1H), 8.75 (d, J = 7.9 Hz, 1H), 8.70 (d, J = 4.6 Hz, 1H), 8.32 (s, 1H), 8.12 (d, J = 8.7 Hz, 1H), 7.91 (d, J = 8.7 Hz, 1H), 7.55 (dd, J = 7.9, 4.8 Hz, 1H), 7.43 (t, J = 7.9 Hz, 1H), 7.36- 7.29 (m, 2H), 7.01-6.98 (m, 1H), 6.88 (s, 1H), 6.83 (s, 2H), 4.12-4.03 (m, 2H), 3.85 (s, 3H), 3.69 (s, 3H), 3.62 (s, 3H), 3.56 (d, J = 8.0 Hz, 3H), 3.15-3.02 (m, 2H). DMSO    95 Method G1, AQ1 507.2 (M + 1) Method B (NH₄HCO₃) 1565 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.64 (d, J = 2.0 Hz, 1H), 8.77- 8.69 (m, 2H), 8.68 (d, J = 1.6 Hz, 1H), 8.64 (d, J = 1.6 Hz, 1H), 8.16 (dd, J = 3.8, 1.6 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.55- 7.52 (m, 1H ), 7.46-7.41 (m, 4H), 7.29 (t, J = 7.2 Hz, 1H), 7.23- 7.19 (m, 1H), 7.14-7.06 (m, 2H), 7.01 (dt, J = 9.2 , 2.0 Hz, 1H), 6.96 (s, 1H), 3.87-3.76 (m, 5H), 2.94-2.93 (m, 1H), 2.68 (t, J = 7.8 Hz, 2H), 1.89- 1.83 (m, 2H). DMSO    95 Method G1, AQ1 522.3 (M + 1) Method B (NH₄HCO₃) 1566 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.59 (s, 1H), 8.76 (t, J = 5.2 Hz, 1H), 8.69 (dd, J = 4.4, 1.2 Hz, 1H), 8.63 (s, 1H), 8.56 (d, J = 8.4 Hz, 1H), 8.15 (dd, J = 8.8, 1.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.53-7.50 (m, 1H), 7.48-7.40 (m, 3H), 7.36-7.32 (m, 3H), 7.30-7.24 (m, 2H), 7.02-7.00 (m, 1H), 6.85 (s, 1H), 3.92-3.83 (m, 4H), 3.72-3.69 (m, 1H), 3.18-3.14 (m, 1H), 2.96-2.84 (m, 2H). DMSO    95 Method G1, AQ1 524.2, 526.2 (M + 1) Method B (NH₄HCO₃) 1567 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.64 (s, 1H), 9.08 (s, 1H), 8.79- 8.69 (m, 2H), 8.51 (s, 1H), 8.31 (s, 1H), 8.00-7.89 (m, 2H), 7.85- 7.69 (m, 1H), 7.67-7.42 (m, 2H), 7.30-7.21 (m, 2H), 5.00 (d, J = 5.1 Hz, 2H). DMSO    95 Method G1, AQ1 416.0 (M + 1) Method B (NH₄HCO₃) 1568 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.58 (s, 1H), 10.09 (d, J = 4.4 Hz, 1H), 9.65 (s, 1H), 9.05-9.02 (m, 2H), 8.95 (d, J = 4.4 Hz, 1H), 8.37 (d, J = 8.4 Hz, 1H), 8.30- 8.27 (m, 1H), 7.85 (t, J = 6.2 Hz, 1H), 7.59 (d, J = 8.0 Hz, 2H), 7.49-7.43 (m, 3H), 7.24 (t, J = 7.8 Hz, 2H), 7.03-6.97 (m, 2H), 3.89 (s, 3H), 3.86-3.84 (m, 2H), 2.44 (t, J = 7.0 Hz, 2H), 1.87- 1.77 (m, 4H). DMSO    95 Method G1, AQ1 504.1 (M + 1) Method B (NH₄HCO₃) 1569 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.62 (s, 1H), 9.67 (s, 1H), 9.08 (d, J = 7.2 Hz, 1H), 9.03 (s, 1H), 8.97 (d, J = 5.2 Hz, 1H), 8.44 (t, J = 5.6 Hz, 1H), 8.40 (dd, J = 8.8, 0.8 Hz, 1H), 8.32 (dd, J = 9.2, 2.8 Hz, 1H), 7.89 (t, J = 6.4 Hz, 1H), 7.50-7.44 (m, 3H), 7.25-7.14 (m, 5H), 7.03 (d, J = 7.2 Hz, 1H), 4.24 (d, J = 6.0 Hz , 2H), 3.89 (s, 3H), 3.87-3.82 (m, 2H), 2.26 (t, J = 7.0 Hz, 2H), 1.84-1.69 (m, 4H). DMSO    95 Method G1, AQ1 518.1 (M + 1) Method B (NH₄HCO₃) 1570 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.55 (s, 1H), 8.69 (dd, J = 11.3, 6.2 Hz, 2H), 8.23 (s, 1H), 8.15 (d, J = 8.7 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.59-7.50 (m, 2H), 7.44-7.26 (m, 3H), 7.23 (t, J = 7.5 Hz, 1H), 7.15 (s, 1H), 7.12 (d, J = 7.7 Hz, 1H), 6.95 (d, J = 8.1 Hz, 1H), 5.18 (s, 2H), 3.79 (s, 3H), 3.54 (s, 3H). DMSO    95 Method G1, AQ1 451.2, 452.2, 453.2 (M + 1) Method B (NH₄HCO₃) 1571 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.62 (s, 1H), 9.60 (s, 1H), 8.88 (d, J = 4.3 Hz, 1H), 8.82 (s, 1H), 8.78 (d, J = 8.1 Hz, 1H), 8.31 (d, J = 8.6 Hz, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.75 (dd, J = 7.8, 5.l Hz, 1H), 7.53-7.39 (m, 4H), 7.33 (dd, J = 14.3, 7.9 Hz, 1H), 7.12 (t, J = 7.8 Hz, 2H), 7.03 (dd, J = 11.0, 6.3 Hz, 2H), 6.90 (s, 1H), 3.97-3.90 (m, 4H), 3.82 (dd, J = 18.0, 9.5 Hz, 1H), 3.19 (dd, J = 13.4, 7.5 Hz, 1H), 2.98 (dd, J = 13.6, 7.9 Hz, 1H), 2.87 (dd, J = 13.6, 6.7 Hz, 1H). DMSO    95 Method G1, AQ1 508.1, 509.1, 510.1 (M + 1) Method B (NH₄HCO₃) 1572 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.20 (s, 1H), 9.61 (s, 1H), 8.94 (d, J = 4.8 Hz, 1H), 8.86 (s, 2H), 8.37 (d, J = 8.4 Hz, 1H), 8.22 (s, 1H), 7.83 (s, 1H), 7.56-7.32 (m, 6H), 7.31-7.19 (m, 2H), 7.06 (d, J = 7.2 Hz, 1H), 6.89 (s, 1H), 4.03-3.93 (m, 1H), 3.88 (s, 3H), 3.82 (dd, J = 14.4, 5.5 Hz, 1H), 3.22 (s, 1H), 3.02 (d, J = 7.2 Hz, 2H). DMSO    95 Method G1, AQ1 524.1, 525.1, 526.0 (M + 1) Method B (NH₄HCO₃) 1573 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.31 (s, 1H), 9.63 (s, 1H), 8.96 (d, J = 4.4 Hz, 1H), 8.90 (s, 1H), 8.84 (d, J = 7.7 Hz, 1H), 8.39 (d, J = 8.7 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 7.91-7.80 (m, 1H), 7.48 (dd, J = 15.6, 7.7 Hz, 3H), 7.36 (s, 1H), 7.24-7.03 (m, 5H), 6.85 (s, 1H), 4.03-3.93 (m, 1H), 3.88 (s, 3H), 3.83 (dd, J = 14.7, 7.6 Hz, 1H), 3.15 (s, 1H), 2.94 (dd, J = 13.8, 8.0 Hz, 1H), 2.84 (dd, J = 13.8, 6.6 Hz, 1H), 2.29 (s, 3H). DMSO    95 Method G1, AQ1 504.1, 505.2, 506.1 (M + 1) Method B (NH₄HCO₃) 1574 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.43 (s, 1H), 9.71 (s, 1H), 9.05 (d, J = 4.7 Hz, 1H), 9.01 (d, J = 7.6 Hz, 1H), 8.96 (s, 1H), 8.45 (d, J = 8.6 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 7.99-7.89 (m, 1H), 7.61-7.41 (m, 4H), 7.23 (d, J = 7.8 Hz, 2H), 7.13 (d, J = 7.6 Hz, 3H), 6.93 (s, 1H), 4.01-3.84 (m, 5H), 3.31-3.21 (m, 1H), 3.02- 2.97 (m, 7.5 Hz, 1H), 2.87-2.81 (m, 1H), 2.29 (s, 3H). DMSO    95 Method G1, AQ1 504.1 (M + 1) Method B (NH₄HCO₃) 1575 ¹H-NMR (400 MHz, CD₃OD): δ 9.39 (s, 1H), 8.69 (d, J = 8.0 Hz, 1H), 8.65 (s, 1H), 8.38 (s, 1H), 8.07 (d, J = 7.9 Hz, 1H), 7.85 (d, J = 8.6 Hz, 1H), 7.60-7.53 (m, 1H), 7.35-7.25 (m, 5H), 7.18 (dd, J = 13.6, 7.2 Hz, 2H), 7.12 (s, 1H), 6.88 (dd, J = 7.9, 2.1 Hz, 1H), 4.49 (dd, J = 11.3, 7.9 Hz, 1H), 4.36-4.17 (m, 2H), 4.04 (t, J = 10.4 Hz, 1H), 3.74 (s, 3H), 3.60-3.49 (m, 1H), 2.50-2.39 (m, 1H), 2.27-2.14 (m, 1H). CD3OD    95 Method G1, AQ1 459.0 (M + 1) Method B (NH₄HCO₃) 1576 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.67 (d, J = 1.7 Hz, 1H), 9.05 (s, 1H), 8.94 (d, J = 3.7 Hz, 1H), 8.59 (s, 1H), 8.40-8.22 (m, 2H), 7.85 (s, 1H), 7.79 (d, J = 1.9 Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.52-7.36 (m, 4H), 7.04 (d, J = 7.6 Hz, 1H), 4.74-4.72 (m, 2H), 4.48-4.43 (m, 3H), 3.85 (s, 3H), 3.74-3.60 (m, 1H), 2.25-2.23 (m, 1H). DMSO    95 Method G1, AQ1 527.0, 529.0 (M + 1) Method B (NH₄HCO₃) 1577 2HCl ¹H-NMR (400 MHz, DMSO): δ 9.69 (d, J = 1.6 Hz, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.79 (d, J = 1.6 Hz, 1H), 8.73 (s, 1H), 8.21 (d, J = 9.2 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.67 (dd, J = 7.6, 4.8 Hz, 1H), 7.56-7.38 (m, 7H), 7.05-7.02 (m, 1H), 5.59 (s, 4H), 3.89 (s, 3H). DMSO    95 Method G1, AQ1 431.1 (M + 1) Method B (NH₄HCO₃) 1578 ¹H-NMR (400 MHz, DMSO): δ 9.59 (d, J = 1.6 Hz, 1H), 8.81-8.64 (m, 2H), 8.28-8.10 (m, 2H), 7.96 (d, J = 8.6 Hz, 1H), 7.55 (td, J = 8.5, 5.0 Hz, 3H), 7.40-7.06 (m, 5H), 6.94 (dd, J = 8.2, 2.0 Hz, 1H), 5.15 (s, 2H), 3.78 (s, 3H), 3.51 (s, 3H). DMSO    95 Method G1, AQ1 451.2 (M + 1) Method B (NH₄HCO₃) 1579 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.61 (s, 1H), 9.66 (s, 1H), 9.00 (d, J = 13.5 Hz, 3H), 8.43-8.31 (m, 2H), 7.89 (s, 1H), 7.48 (dd, J = 14.6, 7.2 Hz, 3H), 7.33-7.22 (m, 4H), 7.21-7.14 (m, 1H), 7.05 (d, J = 7.2 Hz, 1H), 4.10- 3.85 (m, 2H), 3.90 (s, 3H), 3.37- 3.27 (m, 1H), 3.07-2.91 (m, 2H). DMSO    95 Method G1, AQ1 491.2 (M + 1) Method B (NH₄HCO₃) 1580 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.91 (s, 1H), 9.60 (s, 1H), 9.11 (s, 1H), 9.95 (s, 1H), 8.66 (s, 1H), 8.20-8.02 (m, 3H), 7.97 (s, 1H), 7.78 (dd, J = 13.3, 6.5 Hz, 1H), 7.50 (t, J = 11.3 Hz, 1H), 7.33 (t, J = 8.1 Hz, 1H), 7.21 (s, 1H), 5.08 (d, J = 3.8 Hz, 2H). DMSO    95 Method G1, AQ1 416.0 (M + 1) Method B (NH₄HCO₃) 1581 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.84 (s, 1H), 9.71 (s, 1H), 9.12 (d, J = 6.2 Hz, 1H), 8.96 (d, J = 4.8 Hz, 1H), 8.91 (s, 1H), 8.37 (d, J = 8.4 Hz, 1H), 8.30 (s, 1H), 7.88 (s, 1H), 7.57-7.38 (m, 3H), 7.24 (s, 1H), 7.08 (d, J = 7.9 Hz, 1H), 6.73 (s, 1H), 5.18-5.05 (m, 1H), 3.88 (s, 3H), 3.23 (dd, J = 14.8, 7.4 Hz, 1H), 2.31-2.17 (m, 1H), 2.15-1.89 (m, 4H), 1.71- 1.57 (m, 1H). DMSO    95 Method G1, AQ1 440.2 (M + 1) Method B (NH₄HCO₃) 1583 2HCl 1H-NMR (300 MHz, DMSO): δ 10.39 (s, 1H), 9.71 (s, 1H), 9.14 (d, J = 8.1 Hz, 1H), 8.98 (d, J = 4.0 Hz, 1H), 8.71 (s, 1H), 8.31 (d, J = 8.8 Hz, 1H), 8.25-8.19 (m, 1H), 7.96-7.89 (m, 1H), 7.38 (dd, J = 9.2, 3.0 Hz, 1H), 7.34- 7.14 (m, 2H), 3.81 (s, 4H), 3.30 (d, J = 4.4 Hz, 4H). DMSO    95 Method AQ2, AP 361.7 (M + 1) Method C 1584 2HCl 1H-NMR (300 MHz, DMSO): δ 10.84 (s, 1H), 9.01 (s, 1H), 8.95 (d, J = 3.9 Hz, 1H), 8.72 (d, J = 7.8 Hz, 1H), 8.50-8.40 (m, 1H), 8.33 (d, J = 8.8 Hz, 1H), 8.24 (td, J = 7.8, 1.7 Hz, 1H), 7.85 (dd, J = 6.5, 4.8 Hz, 1H), 7.57-7.43 (m, 3H), 7.09-7.02 (m, 1H), 3.90 (s, 3H), 3.38 (s, 3H) DMSO    95 Method AQ2, AP 343.5 (M + 1) Method C 1585 2HCl 1H-NMR (300 MHz, DMSO): δ 10.44-10.13 (m, 1H), 9.66 (s, 1H), 9.08 (d, J = 10.1 Hz, 2H), 8.96 (d, J = 3.7 Hz, 1H), 8.44 (d, J = 8.9 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 8.13 (dd, J = 13.3, 5.3 Hz, 2H), 8.00 (d, J = 8.2 Hz, 1H), 7.91 (s, 1H), 3.30 (d, J = 4.4 Hz, 3H). DMSO    95 Method AQ2, AP 356.4 (M + 1) Method C 1586 1H-NMR (300 MHz, DMSO): δ 9.64 (s, 1H), 8.78 (d, J = 8.0 Hz, 1H), 8.73-8.69 (m, 1H), 8.63 (s, 2H), 8.47-8.37 (m, 1H), 8.32- 8.25 (m, 1H), 8.23-8.12 (m, 1H), 7.87 (d, J = 8.6 Hz, 1H), 7.73 (t, J = 9.0 Hz, 1H), 7.55 (dd, J = 7.9, 4.7 Hz, 1H), 3.20 (d, J = 4.3 Hz, 3H). DMSO    95 Method AQ2, AP 356.4 (M + 1) Method C 1587 1H-NMR (300 MHz, DMSO): δ 9.65 (s, 1H), 8.79 (d, J = 8.0 Hz, 1H), 8.72-8.57 (m, 2H), 8.24 (d, J = 8.7 Hz, 1H), 7.88 (d, J = 8.7 Hz, 1H), 7.82 (d, J = 3.0 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.53 (t, J = 10.9 Hz, 2H), 7.45-7.36 (m, 1H), 3.99 (s, 3H), 3.94 (s, 3H), 3.21 (d, J = 4.1 Hz, 3H). DMSO    95 Method AQ2, AP 401.5 (M + 1) Method C 1588 2HCl 1H-NMR (300 MHz, DMSO): δ 10.77 (s, 1H), 9.66 (s, 1H), 9.06 (s, 2H), 8.95 (d, J = 3.8 Hz, 1H), 8.38 (d, J = 8.8 Hz, 1H), 8.26 (d, J = 8.8 Hz, 1H), 7.87 (s, 1H), 7.71 (d, J = 8.1 Hz, 1H), 7.38 (dd, J = 22.8, 11.6 Hz, 2H), 4.03 (s, 3H), 3.31 (d, J = 4.1 Hz, 3H). DMSO    95 Method AQ2, AP 361.5 (M + 1) Method C 1589 2HCl 1H-NMR (300 MHz, DMSO): δ 10.23-10.05 (m, 1H), 9.64 (s, 1H), 9.00 (s, 1H), 8.94 (s, 1H), 8.89 (s, 1H), 8.38 (d, J = 8.6 Hz, 1H), 8.14 (d, J = 8.5 Hz, 1H), 7.85 (s, 1H), 7.36 (d, J = 8.7 Hz, 2H), 6.95 (d, J = 10.9 Hz, 1H), 3.90 (s, 1H), 3.30 (d, J = 4.3 Hz, 3H). DMSO    95 Method AQ2, AP 361.5 (M + 1) Method C 1590 2HCl 1H-NMR (300 MHz, DMSO): δ 10.34 (s, 1H), 9.70 (s, 1H), 9.14 (d, J = 7.4 Hz, 1H), 8.98 (d, J = 3.9 Hz, 1H), 8.75 (s, 1H), 8.32 (d, J = 8.8 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 7.93 (d, J = 4.8 Hz, 1H), 7.27 (dd, J = 19.5, 6.3 Hz, 3H), 3.88 (s, 3H), 3.28 (d, J = 4.1 Hz, 3H). DMSO    95 Method AQ2, AP 361.3 (M + 1) Method C 1591 2HCl 1H-NMR (300 MHz, DMSO): δ 10.21 (s, 1H), 9.66 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 7.3 Hz, 1H), 8.96 (d, J = 3.5 Hz, 1H), 8.67 (s, 1H), 8.28-8.12 (m, 2H), 7.88 (s, 1H), 7.66 (t, J = 8.8 Hz, 1H), 7.11- 6.97 (m, 2H), 3.86 (s, 3H), 3.30 (d, J = 4.4 Hz, 3H). DMSO    95 Method AQ2, AP 361.3 (M + 1) Method C 1592 3HCl 1H-NMR (300 MHz, DMSO): δ 10.77 (s, 1H), 9.69 (s, 1H), 9.39 (s, 1H), 9.16 (d, J = 7.8 Hz, 1H), 9.04 (s, 1H), 8.97 (d, J = 3.6 Hz, 1H), 8.63 (d, J = 2.5 Hz, 1H), 8.53 (s, 2H), 8.31 (d, J = 8.5 Hz, 1H), 7.91 (d, J = 5.4 Hz, 1H), 4.11 (s, 3H), 3.30 (d, J = 4.4 Hz, 3H). DMSO    95 Method AQ2, AP 343.1 (M + 1) Method C 1593 2HCl DMSO    95 Method AQ2, AP 359.1 (M + 1) Method C 1594 1H-NMR (300 MHz, DMSO): δ 9.64 (d, J = 1.3 Hz, 1H), 8.82- 8.75 (m, 1H), 8.68 (dd, J = 4.8, 1.7 Hz, 1H), 8.60 (s, 1H), 8.53 (d, J = 1.7 Hz, 1H), 8.10 (dd, J = 8.7, 1.9 Hz, 1H), 7.86-7.77 (m, 4H), 7.58-7.48 (m, 2H), 7.09 (d, J = 8.8 Hz, 2H), 6.97 (d, J = 8.8 Hz, 1H), 3.99 (d, J = 6.0 Hz, 2H), 3.18 (d, J = 4.4 Hz, 3H), 1.82- 1.69 (m, 2H), 1.07 (d, J = 6.7 Hz, 3H). DMSO    95 Method AQ2, AP 371.1 (M + 1) Method C 1595 2HCl 1H-NMR (300 MHz, DMSO): δ 10.24-10.10 (bs, 1H), 9.65 (s, 1H), 9.02 (s, 1H), 8.96 (d, J = 3.8 Hz, 1H), 8.90 (s, 1H), 8.39 (s, 1H), 8.20 (s, 1H), 8.07 (s, 1H), 7.98 (s, 1H), 7.89 (s, 1H), 7.54 (t, J = 9.1 Hz, 1H), 3.70 (bs, 4H), 3.59 (bs, 4H), 3.32 (d, J = 4.4 Hz, 3H). DMSO    95 Method AQ2, AP 443.5 (M + 1) Method C 1596 2HCl 1H-NMR (300 MHz, DMSO): δ 10.37 (s, 1H), 9.69 (d, J = 1.7 Hz, 1H), 9.10 (d, J = 7.0 Hz, 1H), 9.03-8.93 (m, 2H), 8.42 (d, J = 8.6 Hz, 1H), 8.28 (d, J = 9.3 Hz, 1H), 8.05 (d, J = 3.5 Hz, 1H), 7.99 (dd, J = 6.2, 2.4 Hz, 2H), 7.52 (t, J = 9.1 Hz, 1H), 3.54- 3.43 (m, 4H), 3.30 (t, J = 10.4 Hz, 3H), 1.98-1.81 (m, 4H). DMSO    95 Method AQ2, AP 428.5 (M + 1) Method C 1597 2HCl 1H-NMR (300 MHz, DMSO): δ 10.71 (s, 1H), 8.96 (d, J = 3.9 Hz, 1H), 8.81 (s, 1H), 8.74 (d, J = 7.9 Hz, 1H), 8.36 (d, J = 8.7 Hz, 1H), 8.29-8.19 (m, 2H), 7.87 (dd, J = 6.5, 4.7 Hz, 1H), 7.80 (dd, J = 15.5, 8.9 Hz, 1H), 7.61-7.50 (m, 1H), 7.36 (d, J = 8.1 Hz, 1H), 3.37 (d, J = 4.5 Hz, 3H). DMSO    95 Method AQ2, AP 349.4 (M + 1) Method C 1598 1H-NMR (300 MHz, DMSO): δ 9.27 (d, J = 1.5 Hz, 1H), 8.61 (dd, J = 12.6, 3.0 Hz, 2H), 8.41 (d, J = 2.9 Hz, 1H), 8.34-8.27 (m, 1H), 8.16 (dd, J = 8.7, 1.9 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.45 (dd, J = 16.0, 9.2 Hz, 3H), 7.05-6.97 (m, 1H), 3.96 (s, 3H), 3.87 (s, 3H), 3.19 (d, J = 4.3 Hz, 3H). DMSO    95 Method AQ2, AP 373.4 (M + 1) Method C 1599 2HCl 1H-NMR (300 MHz, DMSO): δ 10.44-10.13 (m, 1H), 9.65 (s, 1H), 9.02 (s, 1H), 8.96 (d, J = 3.5 Hz, 1H), 8.87 (s, 1H), 8.37 (d, J = 9.1 Hz, 1H), 8.24 (s, 1H), 7.86 (s, 2H), 7.78 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.43 (d, J = 7.5 Hz, 1H), 4.64 (s, 2H), 3.33 (d, J = 4.2 Hz, 3H), 3.17 (s, 1H). DMSO    95 Method AQ2, AP 343.5 (M + 1) Method C 1600 MSA 1H-NMR (300 MHz, DMSO): δ 9.90 (s, 1H), 9.57 (d, J = 1.6 Hz, 1H), 8.93 (dd, J = 5.0, 1.5 Hz, 2H), 8.73 (s, 1H), 8.32 (d, J = 8.7 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.85 (dd, J = 10.1, 7.0 Hz, 2H), 7.73 (d, J = 7.5 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.42 (d, J = 7.5 Hz, 1H), 4.63 (s, 2H), 3.30 (d, J = 4.3 Hz, 3H), 2.32 (s, 3H). DMSO    95 Method AQ2, AP 343.5 (M + 1) Method C 1601 MsOH ¹H NMR (300 MHz, DMSO) δ 9.72 (brs, 1H), 9.58 (d, J = 1.6 Hz, 1H), 9.03-8.89 (m, 2H), 8.45 (d, J = 8.7 Hz, 1H), 8.11 (s, 1H), 7.99-7.84 (m, 2H), 7.64 (ddd, J = 9.2, 6.1, 3.1 Hz, 1H), 7.58- 7.31 (m, 2H), 3.28 (d, J = 4.5 Hz, 3H), 2.39 (s, 3H). DMSO    98 G2/AQ3 1602 ¹H NMR (300 MHz, DMSO) δ 9.59 (d, J = 2.0 Hz, 1H), 9.33 (s, 2H), 9.24 (s, 1H), 8.79 (d, J = 1.5 Hz, 1H), 8.76-8.64 (m, 2H), 8.30 (dd, J = 8.7, 1.5 Hz, 1H), 8.12 (brs, 2H), 7.91 (d, J = 8.7 Hz, 1H), 7.55 (dd, J = 7.9, 4.8 Hz, 1H). DMSO    98 G2/AQ3 1603 ¹H NMR (300 MHz, DMSO) δ 9.64- 9.53 (m, 1H), 8.77-8.53 (m, 2H), 8.53 (s, 1H), 8.43 (d, J = 1.5 Hz, 1H), 8.11 - 7.90 (m, 3H), 7.82 (d, J = 8.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 4.00 (s, 3H), 3.98 (s, 3H). DMSO    98 G2/AQ3 1604 ¹H NMR (300 MHz, DMSO) δ 9.59 (d, J = 2.0 Hz, 1H), 8.83-8.66 (m, 2H), 8.55 (s, 1H), 8.27-7.99 (m, 4H), 7.99-7.82 (m, 2H), 7.77 (d, J = 7.7 Hz, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.56 (dd, J = 7.9, 4.8 Hz, 1H). DMSO    98 G2/AQ3 1605 1H NMR (300 MHz, DMSO) δ 9.58 (d, J = 2.1 Hz, 1H), 8.80-8.64 (m, 2H), 8.25 (dd, J = 8.7, 1.6 Hz, 1H), 8.10 (d, J = 8.3 Hz, 2H), 8.02 (d, J = 8.3 Hz, 2H), 7.88 (d, J = 8.7 Hz, 1H), 7.55 (dd, J = 7.9, 4.8 Hz, 1H). DMSO    98 G2/AQ3 1606 2HCl ¹H NMR (300 MHz, DMSO) δ 9.95- 9.43 (m, 3H), 9.05 (d, J = 8.2 Hz, 1H), 8.99 (dd, J = 5.1, 1.5 Hz, 1H), 8.74 (s, 1H), 8.33 (d, J = 8.7 Hz, 1H), 8.21 (d, J = 8.7 Hz, 1H), 7.93 (dd, J = 8.0, 5.1 Hz, 1H), 7.79 (td, J = 8.9, 6.6 Hz, 1H), 7.51 (ddd, J = 11.5, 9.3, 2.6 Hz, 1H), 7.33 (td, J = 8.3, 1.9 Hz, 1H). DMSO    98 G2/AQ3 1607 3HCl ¹H NMR (300 MHz, DMSO) δ 11.88 (s, 1H), 9.77 (d, J = 1.7 Hz, 1H), 9.56-9.28 (rn, 1H), 9.19- 9.01 (m, 1H), 8.31-8.11 (m, 4H), 7.75-7.47 (m, 2H), 7.47- 7.23 (m, 1H), 4.83-4.67 (m, 2H), 3.96 (t, J = 12.2 Hz, 2H), 3.57 (d, J = 11.9 Hz, 2H), 3.46- 3.19 (m, 2H), 2.83 (d, J = 3.1 Hz, 3H). DMSO    98 G2/AQ3 1608 HCl ¹H NMR (300 MHz, DMSO) δ 14.45 (s, 1H), 10.36 (s, 1H), 9.31 (d, J = 2.2 Hz, 1H), 8.82 (s, 1H), 8.73 (ddd, J = 8.8, 2.5, 0.9 Hz, 1H), 8.36 (d, J = 9.0 Hz, 1H), 8.16 (d, J = 3.4 Hz, 1H), 7.56- 7.36 (m, 3H), 7.11 (d, J = 8.4 Hz, 1H), 7.03 (d, J = 7.1 Hz, 1H), 3.99 (s, 3H), 3.87 (s, 3H), 3.30 (d, J = 3.9 Hz, 3H). DMSO   100 Method AQ2/BF 1609 HCl ¹H NMR (300 MHz, DMSO) δ 10.97 (s, 1H), 9.56-9.35 (m, 2H), 9.04-8.81 (m, 2H), 8.66 (t, J = 7.7 Hz, 1H), 8.61-8.45 (m, 2H), 8.15 (d, J = 8.6 Hz, 1H), 8.10-7.96 (m, 1H), 7.77-7.58 (m, 1H), 3.25 (d, J = 4.1 Hz, 3H). DMSO   100 Method AQ2/BF 1610 2 MsOH ¹H NMR (300 MHz, CDCl₃) δ 9.93 (brs, 1H), 9.61 (d, J = 1.8 Hz, 1H), 9.10-8.96 (m, 2H), 8.64 (s, 1H), 8.21 (d, J = 8.7 Hz, 1H), 8.06 (d, J = 8.7 Hz, 1H), 7.99 (dd, J = 8.0, 5.3 Hz, 1H), 7.69- 7.47 (m, 2H), 7.47-7.34 (m, 1H), 3.30 (d, J = 4.5 Hz, 3H), 2.42 (s, 6H). DMSO >98 G2/AQ3 Method 3 1611 2HCl ¹H NMR (300 MHz, CDCl₃) δ 10.42 (brs, 1H), 9.71 (d, J = 1.9 Hz, 1H), 9.17 (d, J = 8.1 Hz, 1H), 8.99 (dd, J = 5.1, 1.3 Hz, 1H), 8.78 (s, 1H), 8.33 (d, J = 8.7 Hz, 1H), 8.17 (d, J = 8.7 Hz, 1H), 7.94 (dd, J = 8.1, 5.2 Hz, 1H), 7.79 (td, J = 8.9, 6.7 Hz, 1H), 7.55-7.37 (m, 1H), 7.31 (td, J = 3.4, 2.2 Hz, 1H), 3.29 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1612 HCl ¹H NMR (300 MHz, DMSO) δ 9.95 (brs, 1H), 9.65 (s, 1H), 9.18- 9.02 (m, 1H), 8.95 (d, J = 4.7 Hz, 1H), 8.58 (d, J = 8.7 Hz, 1H), 8.28 (s, 1H), 8.09-7.70 (m, 4H), 3.29 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1613 ¹H NMR (300 MHz, DMSO) δ 9.64 (d, J = 1.5 Hz, 1H), 8.77 (dt, J = 7.9, 1.9 Hz, 1H), 8.69 (dd, J = 4.8, 1.7 Hz, 1H), 8.61-8.48 (m, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.11 (d, J = 1.8 Hz, 1H), 8.00- 7.83 (m, 3H), 7.55 (dd, J = 7.9, 4.8 Hz, 1H), 3.17 (d, J = 4.4 Hz, 3H). DMSO >98 G2/AQ3 1614 ¹H NMR (300 MHz, DMSO) δ 9.65 (dd, J = 2.1, 0.8 Hz, 1H), 8.78 (dt, J = 8.0, 1.9 Hz, 1H), 8.69 (dd, J = 4.8, 1.7 Hz, 1H), 8.65- 8.50 (m, 1H), 8.33 (d, J = 8.6 Hz, 1H), 8.04-7.85 (m, 1H), 7.69 (dt, J = 8.5, 1.8 Hz, 1H), 7.65- 7.37 (m, 3H), 3.18 (d, J = 4.5 Hz, 3H). DMSO >98 G2/AQ3 Method 3 1615 ¹H NMR (300 MHz, DMSO) δ 9.65 (d, J = 1.7 Hz, 1H), 8.84-8.74 (m, 1H), 8.69 (dd, J = 4.7, 1.5 Hz, 1H), 8.65-8.52 (m, 1H), 8.34 (d, J = 8.6 Hz, 1H), 7.98 (s, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.69-7.43 (m, 3H), 3.18 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 Method 3 1760 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.04 (s, 1H), 9.65 (s, 1H), 9.11- 8.99 (m, 1H), 8.96 (dd, J = 5.0, 1.4 Hz, 1H), 8.41 (s, 1H), 8.13- 8.05 (m, 1H), 7.92-7.82 (m, 1H), 7.64-7.55 (m, 1H), 7.44- 7.26 (m, 3H), 3.27 (d, J = 4.6 Hz, 3H), 2.47 (s, 3H). DMSO >98 AQ5 ND 4

6-(3-methoxyphenyl)-2-(pyridine-3-yl)quinazoline-4-ol (lix-a)

6-(3-methoxyphenyl)-2-(pyridine-3-yl)quinazoline-4-ol was prepared from 6-bromo-2-(pyridin-3-yl)quinazolin-4-ol (synthesized following Scheme 70 substituting 2-amino-5-bromobenzamide for 2-amino-5-bromo-3-methylbenzamide) and 3-methoxylphenylboronic acid as described in Scheme 72 using method AQ2. The resultant product, 6-(6-methoxypyridin-3-yl)-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine, was a pale yellow solid (19.1 mg, 51%). LCMS m/z=344 (M+1) (Method C) (retention time=2.01 min). ¹H NMR (300 MHz, DMSO) d 9.64 (d, J=1.3 Hz, 1H), 8.84-8.74 (m, 1H), 8.68 (dd, J=6.2, 1.7 Hz, 2H), 8.57 (d, J=1.6 Hz, 2H), 8.16 (ddd, J=14.4, 8.7, 2.2 Hz, 2H), 7.85 (d, J=8.7 Hz, 1H), 7.54 (dd, J=7.9, 4.8 Hz, 1H), 7.00 (d, J=8.7 Hz, 1H), 3.93 (s, 3H), 3.18 (d, J=4.3 Hz, 3H).

Method AP: 6-(3-methoxyphenyl)-2-(pyridine-3-yl)-4-(pyrrolidin-1-yl)quinazoline (Iviii-g)

6-(3-methoxyphenyl)-2-(pyridine-3-yl)-4-(pyrrolidin-1-yl)quinazoline was prepared from 6-(3-methoxyphenyl)-2-(pyridine-3-yl)quinazoline-4-01 and pyrrolidine in a manner analogous to that described for 6-bromo-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine using Method AP in Scheme 72. 6-(3-methoxyphenyl)-2-(pyridine-3-yl)-4-(pyrrolidin-1-yl)quinazoline was a pale yellow solid (43 mg, 31%), LCMS m/z=383 (M+1) (Method C) (retention time=2.49 ruin). ¹H NMR (300 MHz, DMSO) δ 9.62 (s, 1H), 8.94 (d, J=5.0 Hz, 2H), 8.56 (s, 1H), 8.32 (dd, J=19.9, 8.5 Hz, 2H), 7.83 (s, 1H), 7.56-7.30 (m, 3H), 7.04 (d, J=6.8 Hz, 1H), 4.2.7 (s, 4H), 3.86 (s, 3H), 2.08 (s, 4H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 76, replacing pyrrolidine with the appropriate amine and 3-methoxyphenylboronic acid with the appropriate boronic acid.

TABLE 25 Meth- od for Num- ¹H—NMR Retention LCMS Purity Coup- ber Product Salt ¹H—NMR Solvent LCMS Time Protocol Percent ling 1616

HCl 1H NMR (300 MHz, DMSO) δ 9.82 (s, 1H), 9.59 (s, 1H), 9.08-8.81 (m, 3H), 8.36 (d, J = 8.8 Hz, 1H), 8.17 (d, J = 8.6 Hz, 1H), 7.95- 7.77 (rn, 1H), 7.58-7.37 (m, 3H), 7.05 (d, J = 6.5 Hz, 1 H), 5.01-4.79 (m, 1H), 3.87 (s, 3H), 1.42 (d, J = 6.5 Hz, 6H). DMSO 371   (M + 1) 2.36 Method C 100 Meth- od AP 1617

HCl 1H NMR (300 MHz, DMSO) δ 10.38 (s, 1H), 9.64 (s. 1H), 9.43 (s, 1H), 9.28 (s, 1H), 9.07 (d. J = 7.9 Hz, 1H), 9.00-8.76 (m, 3H), 8.48 (d, J = 7.5 Hz, 1H), 8.27 (d, J = 8.4 Hz, 1H), 8.08-7.95 (m, 1H), 7.94-7.81 (m, 1H), 3.97-3.74 (m, 2H), 1.38 (t, J = 7.2 Hz, 3H). DMSO 328   (M + 1) 1.82 Method C 100 Meth- od AP 1618

HCl 1H NMR (300 MHz, DMSO) δ 10.11 (s, 1H), 9.58 (s, 1H), 9.03-8.79 (m, 3H), 8.35 (d, J = 8.7 Hz, 1H), 8.23-8.09 (m, 1H), 7.90-7.75 (m, 1H), 7.58-7.36 (m, 3H), 7.04 (d, J = 3.3 Hz, 1H), 3.88 (s, 3H), 3.65 (t, J = 6.0 Hz, 2H), 2.29-2.09 (m, 1H), 1.02 (d, J = 6.7 Hz, 6H). DMSO 385   (M + 1) 1.76 Method D 100 Meth- od AP 1619

HCl 1H NMR (300 MHz, DMSO) δ 9.83-9.52 (m, 2H), 9.27 (d, J = 7.1 Hz, 1H), 8.95 (d, J = 5.1 Hz, 1H), 8.87 (s, 1H), 8.32 (d, J = 8.9 Hz, 1H), 8.15-7.92 (m, 2H), 7.59-7.33 (m, 3H), 7 04 (d, J = 3.4 Hz, 1H), 4.86-4.57 (m, 2H), 3.88 (s, 3H). DMSO 411   (M + 1) 1.99 Method D 100 Meth- od AP 1620

HCl 1H NMR (300 MHz, DMSO) δ 10.50 (s, 1H), 9.64 (d, J = 1.4 Hz, 1H), 9.12-8.85 (m, 3H), 8.46-8.33 (m, 1H), 8.27 (d, J = 8.9 Hz, 1H), 7.88 (dd, J = 7.9, 5.1 Hz, 1H), 7.57-7.37 (m, 3H), 7.11-6.94 (m, 1H), 4.00-3.76 (m, 5H), 1.37 (t, J = 7.2 Hz, 3H). DMSO MS not work 1.56 Method D 100 Meth- od AP 1621

1H NMR (300 MHz, DMSO) δ 9.57 (s, 1H), 8.78-8.50 (m, 3H), 8.33-7.89 (m, 3H), 7.83 (d, J = 8.7 Hz, 1H), 7.53 (dd, J = 7.9, 4.8 Hz, 1H), 7.47-7.32 (m, 3H), 7.04-6.91 (m, 1H), 3.86 (s, 3H). DMSO 329   (M + 1) 1.47 Method D 100 Meth- od AP 1622

HCl 1H NMR (300 MHz, DMSO) δ 9.65 (s, 1H), 9.14-8.87 (m, 2H), 8.50 (s, 1H), 8.33 (s, 2H), 7.94-7.77 (m, 1H), 7.52-7.25 (m, 3H), 7.02 (d, J = 7.9 Hz, 1H), 3.84 (s, 3H), 3.71 (s, 6H). DMSO 357   (M + 1) 1.55 Method D 100 Meth- od AP 1623

1H NMR (300 MHz, DMSO) δ 9.60 (d, J = 1.4 Hz, 1H), 8.81-8.55 (m, 3H), 8.42 (d, J = 1.8 Hz, 1H), 8.11 (ddd, J = 18.8, 8.7, 2.2 Hz, 2H), 7.86 (d, J = 8.7 Hz, 1H), 7.52 (dd, J = 7.9, 4.8 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 4.27 (s, 4H), 3.92 (s, 3H), 2.08 (s, 4H). DMSO 384.1 (M + 1) 2.33 Method C 100 Meth- od AP 1624

2HCl 1H NMR (300 MHz, DMSO) δ 9.62 (s, 1H), 8.94 (d, J = 5.0 Hz, 2H), 8.56 (s, 1H), 8.32 (dd, J = 19.9, 8.5 Hz, 2H), 7.83 (s, 1H), 7.56- 7.30 (m, 3H), 7.04 (d, J = 6.8 Hz, 1H), 4.27 (s, 4H), 3.86 (s, 3H), 2.08 (s, 4H). DMSO 383.2 (M + 1) 2.47 Method C 95 Meth- od AP 1625

1H NMR (300 MHz, DMSO) δ 9.70 (d, J = 1.4 Hz, 1H), 8.35 (d, J = 7.9 Hz, 1H), 8.80- 8.72 (m, 2H), 8.45 (d, J = 8.7 Hz, 1H), 8.27 (dd J = 14.9, 5.9 Hz. 3H), 7.63 (dd. J = 7.3, 4.8 Hz, 1H), 7.52-7.33 (m, 4H), 7.04 (d, J = 7.1 Hz, 1H), 3.88 (s, 3H). DMSO 380.1 (M + 1) 2.01 Method C 100 Meth- od AP 1626

HCl 1H NMR (300 MHz, DMSO) δ 9.61 (s, 1H), 8.75 (d, J = 7.7 Hz, 1H), 8.68 (d, J = 4.6 Hz, 1H), 8.30 (s, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.75 (d, J = 8.7 Hz, 2H), 7.54 (dd, J = 7.6, 5.0 Hz, 1H), 7.07 (d, J = 8.7 Hz, 2H), 3.82 (s, 4H), 3.49 (s, 7H). DMSO 358.0 (M + 1) 2.25 Method C 100 Meth- od AP 1627

HCl 1H NMR (300 MHz, DMSO) δ 9.52 (s, 1H), 8.76 (d, J = 7.9 Hz, 1H), 8.73-8.66 (m, 1H), 8.19-8.09 (m, 2H), 7.97 (d, J = 8.6 Hz, 1H), 7.82-7.73 (m, 2H), 7.61-7.52 (m, 1H), 7.14-7.05 (m, 2H), 3.94 (s, 5H), 3.89-3.80 (m, 9H). DMSO 399.2 (M + 1) 2.19 Method C 100 Meth- od AP 1628

1H NMR (300 MHz, DMSO) δ 9.55 (dd, J = 2.1, 0.8 Hz, 1H), 8.76-8.62 (m, 3H), 8.60 (d, J = 1.7 Hz, 1H), 8.24-8.10 (m, 2H), 8.02 (s, 2H), 7.83 (d, J = 8.7 Hz, 1H), 7.58-7.46 (m, 1H), 6.98 (d, J = 9.2 Hz, 1H), 3.91 (s, 3H). DMSO 330.1 (M + 1) 1.72 Method C 100 Meth- od AP 1629

1H NMR (300 MHz, DMSO) δ 9.65 (d, J = 2.1 Hz, 1H), 8.79 (d, J = 8.0 Hz, 1H), 8.73 (dd, J = 4.7, 1.6 Hz, 1H), 8.36-8.25 (m, 2H), 8.06 (d, J = 8.7 Hz, 1H), 7.59 (dd, J = 7.6, 4.4 Hz, 1H), 7.48-7.40 (m, 1H), 7.41-7.29 (m, 2H), 7.01 (dd, J = 8.0, 2.4 Hz, 1H), 4.80 (q, J = 7.1 Hz, 2H), 3.85 (s, 3H), 1.53 (t, J = 7.0 Hz, 3H). DMSO 358   (M + 1) Method C 99 Meth- od AP 1630

2 HCl 1H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.8 Hz, 1H), S.07 (d, J = 5.5 Hz, 1H), 8.96 (d, J = 3.5 Hz, 1H), 8.30 (s, 1H), 8.37 (d, J = 7.5 Hz, 1H), 8.22 (d, J = 8.3 Hz, 1H), 7.94-7.83 (m, 1H), 7.57-7,39 (m, 3H), 7.22 (d, J = 1.0 Hz, 1H), 7.08 (d, J = 7.3 Hz, 1H), 6.72 (s, 1H), 5.18-5.04 (m, 1H), 3.88 (s, J = 2.7 Hz, 3H), 3.23 (dd, J = 13.7, 6.1 Hz, 1H), 2.31- 2.17 (m, 1H), 2.17-1.88 (m, 4H), 1.74-1.55 (m, 1H). DMSO 440.6 (M + 1) Method C 99 Meth- od AP 1631

2 HCl 1H NMR (300 MHz, DMSO) δ 9.70 (d, J = 1.6 Hz, 1H), 9.24 (d, J = 7.4 Hz, 1H), 8.99 (dd, J = 5.3, 1.4 Hz, 1H), 8.34 (dd, J = 15.7, 6.1 Hz, 3H), 8.21 (d, J = 8.4 Hz, 1H), 8.01 (dd, J = 7.7, 5.1 Hz, 1H), 7.51-7.33 (m, 3H), 7.04 (dd, J = 7.8, 2.4 Hz, 1H), 4.67 (s, 2H), 4.33 (s, 2H), 3.87 (s, J = 3.6 Hz, 3H), 3.50 (s, 2H). DMSO 412.4 (M + 1) Method C 99 Meth- od AP 1632

2 HCl 1H NMR (300 MHz, DMSO) δ 9.00 (d, J = 6.5 Hz, 2H), 8.78 (d, J = 6.5 Hz, 2H), 8.46- 8.32 (m, 2H), 8.15 (d, J = 8.4 Hz, 1H), 7.53- 7.30 (m, 3H), 7.02 (d, J = 7.8 Hz, 1H), 4.34 (s, J = 2.4 Hz. 3H), 3.86 (s, J = 2.5 Hz, 3H). DMSO 344.4 (M + 1) Method C 99 Meth- od AP 1633

1H NMR (300 MHz, DMSO) δ 9.55 (dd, J = 2.1, 0.8 Hz, 1H), 8.76-8.62 (m, 3H), 8.60 (d, J = 1.7 Hz, 1H), 8.24-8.10 (m, 2H), 8.02 (s, 2H), 7.83 (d, J = 8.7 Hz, 1H), 7.56-7.46 (m, 1H), 6.98 (d, J = 9.2 Hz, 1H), 3.91 (s, 3H). DMSO 330.1 (M + 1) Method C 99 Meth- od AP ¹H Num- Starting Starting Salt NMR ber Material R¹ Material R³ Product Type ¹H NMR Solvent 1634

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 4.76 (d, 2H, J = 5.4 Hz), 6.58 (d, 1H, J = 1.1 Hz), 7.00-7.75 (m, 8H), 7.85 (d, 1H, J = 8.6 Hz), 8.64-8.97 (m, 4H), 9.64 (s, 1H) DMSO 1635

¹H NMR (DMSO-d₆) ppm 3.34- 3.95 (m, 11H), 7.01 (d, 1H, J = 8.1 Hz), 7.32- 7.45 (m, 3H), 7.56 (dd, 1H, J = 6.1, 8.1 Hz), 7.97 (d, 1H, J = 8.2 Hz), 8.16- 8.76 (m, 4H), 9.61 (s, 1H) DMSO 1636

¹H NMR (DMSO-d₆) ppm 2.23 (m, 2H), 3.85 (s, 3H), 4.71 (br s, 4H), 6.98 (dd, 1H, J = 2.1, 8.0 Hz), 7.31-7.55 (m, 4H), 7.87 (d, 1H, J = 8.2 Hz), 8.12- 8.74 (m, 4H), 9.59 (s, 1H) DMSO 1637

1H NMR (DMSO-d6) ppm 1.77 (br s, 6H), 3.86- 3.89 (br m, 7H), 6.99 (dd, 1H, J = 1.4, 8.6 Hz), 7.31-7.57 (m, 4H), 7.93 (d, 1H, J = 1.4, 8.6 Hz), 8.11-8.16 (m, 2H), 8.69-8.76 (m, 2H), 9.61 (s, 1H) DMSO 1638

1H NMR (DMSO-d6) ppm 2.18-2.22 (m, 1H), 3.00-3.09 (m, 1H), 3.11-3.22 (m, 2H), 3.31-3.34 (m, 1H), 3.86 (s, 3H), 6.29- 6.31 (m, 1H), 7.17- 8.82 (m, 14H), 9.63 (s, 1H) DMSO 1639

1H NMR (DMSO-d6) ppm 3.87 (s, 3H), 4.10-4.13 (m, 2H), 4.35-4.38 (m, 2H), 6.92-7.46 (m, 10H), 7.85 (d, 1H, J = 8.6 Hz), 8.16 (d, 1H, J = 8.6 Hz), 8.66- 8.75 (m, 4H), 3.61 (s, 1H) DMSO 1640

1H NMR (DMSO-d6) ppm 3.07 (t, 2H, J = 6.9 Hz), 3.87 (s, 3H), 3.92- 3.96 (m, 2H), 7.00- 7.58 (m, 10H), 7.84 (d, 1H, J = 8.6 Hz), 8.14 (d, 1H, J = 8.6 Hz), 8.59-8.78 (m, 4H), 9.64 (s, 1H) DMSO 1641

1H NMR (DMSO-d6) ppm 3.37 (s, 3H), 4.95 (d, 2H, J = 5.6 Hz), 7.01- 7.51 (m, 10H), 7.85 (d, 1H, J = 8.6 Hz), 8.16 (d, 1H, J = 8.6 Hz), 8.65-8.73 (m, 4H), 956 (s, 1H) DMSO 1642

1H NMR (DMSO-d6) ppm 1.66- 1.781 (m, 6H), 2.16-2.19 (m, 2H), 3.87 (s, 3H), 4.78 (br s, 1H), 7.00-7.55 (m, 5H), 7.83 (d, 1H, J = 8.6 Hz), 8.12 (d, 1H, J = 8.6 Hz), 8.29 (s, 1H), 8.67- 8.77 (m, 3H), 9.62 (s, 1H) DMSO 1643

HCl 1H NMR (DMSO-d6) ppm 0.81 (t, 3H, J = 7.4 Hz), 1.47- 1.54 (m, 2H), 2.00- 2.05 (m, 2H), 3.32- 3.37 (m, 4H), 3.86- 3.91 (m, 5H), 7.03- 7.80 (m, 5H), 8.16 (d, 1H, J = 8.7 Hz), 8.34 (d, 1H, J = 8.7 Hz), 8.86- 8.96 (m, 3H), 9.61 (s, 1H), 10.03 (s, 1H) DMSO 1644

1H NMR (DMSO-d6) ppm 0.38-0.54 (m, 4H), 1.30-1.32 (m, 1H), 3.58-3.62 (m, 2H), 3.87 (s, 3H), 7.00- 7.54 (m, 5H), 7.86 (d, 1H, J = 8.6 Hz), 8.14 (d, 1H, J = 8.6 Hz), 8.64-8.76 (m, 4H), 9.62 (s, 1H) DMSO 1645

1H NMR (DMSO-d6) ppm 1.83-1.88 (m, 2H), 2.21-2.27 (m, 2H), 2.43 (br s, 2H), 3.87 (s, 3H), 4.88-4.91 (m, 1H), 7.03-7.57 (m, 5H), 7.83 (d, 1H, J = 8.6 Hz), 8.13 (d, 1H, J = 8.6 Hz), 8.62-8.77 (m, 4H), 9.63 (s, 1H) DMSO 1646

1H NMR (DMSO-d6) ppm 3.21 (s, 1H), 3.88 (s, 3H), 4.52 (dd, 2H, J = 2.2, 5.2 Hz), 7.01- 7.58 (m, 5H), 7.88 (d, 1H, J = 8.7 Hz), 8.19 (d, 1H, J = 8.6 Hz), 8.64- 9.01 (m, 4H), 9.66 (s, 1H) DMSO 1647

1H NMR (DMSO-d6) ppm 3.87 (s, 3H), 4.37 (br s, 2H), 5.19 (dd, 1H, J = 1.5, 10.2 Hz), 5.31 (dd, 1H, J = 1.5, 17.2 Hz), 6.01- 6.22 (m, 1H), 7.00- 7.56 (m, 5H), 7.85 (d, 1H, J = 8.6 Hz), 8.16 (d, 1H, J = 8.6 Hz), 8.67-8.82 (m, 4H), 9.61 (s, 1H) DMSO 1648

1H NMR (DMSO-d6) ppm 0.94- 0.99 (t, 6H, J = 7.4 Hz), 1.68-1.80 (m, 4H), 3.87 (s, 3H), 4.49- 4.52 (m, 1H), 7.01- 7.47 (m, 5H), 7.83 (d, 1H, J = 8.6 Hz), 8.11-8.15 (m, 2H), 8.67-8.75 (m, 3H), 9.63 (s, 1H) DMSO 1649

1H NMR (DMSO-d6) ppm 1.68 (s, 9H), 3.87 (s, 3H), 7.01- 7.70 (m, 6H), 7.82 (d, 1H, J = 8.6 Hz), 8.11 (d, 1H, J = 8.6 Hz), 8.67- 8.74 (m, 3H), 9.60 (s, 1H) DMSO 1650

1H NMR (DMSO-d6) ppm 0.97 (t, 3H, J = 7.2 Hz), 1.44- 1.48 (m, 2H), 1.74- 1.78 (m, 2H), 3.71- 3.75 (m, 2H), 3.89 (s, 3H), 7.00- 7.56 (m, 5H), 7.83 (d, 1H, J = 8.6 Hz), 8.15 (d, 1H, J = 8.6 Hz), 8.59- 8.76 (m, 4H), 9.62 (s, 1H) DMSO 1651

1H NMR (DMSO-d6) ppm 3.87 (s, 3H), 4.98 (d, 2H, J = 5.6 Hz), 7.02-7.46 (m, 7H), 7.87 (d, 1H, J = 8.7 Hz), 8.51 (dd, 1H, J = 1.5, 4.5 Hz), 8.50-8.71 (m, 5H), 9.26 (s, 1H), 9.48 (s, 1H) DMSO 1652

1H NMR (DMSO-d6) ppm 3.87 (s, 3H), 4.93 (d, 2H, J = 5.5 Hz), 7.00- 7.46 (m, 6H), 7.86- 7.90 (m, 2H), 8.16 (d, 1H, J = 1.7 Hz), 8.46 (d, 1H, J = 1.7 Hz), 8.66-8.76 (m, 4H), 9.22 (s, 1H), 9.56 (s, 1H) DMSO 1653

1H NMR (DMSO-d6) ppm 3.22-3.27 (m, 2H), 3.87 (s, 3H). 4.04- 4.11 (m, 2H), 7.02- 7.46 (m, 8H), 7.83 (d, 1H, J = 8.6 Hz), 8.13 (d, 1H, J = 1.6 Hz), 8.67- 8.78 (m, 5H), 9.64 (s, 1H) DMSO 1654

1H NMR (DMSO-d6) ppm 1.76-1.88 (m, 4H), 2.66 (br s, 1H), 3.37- 3.48 (m, 2H), 3.86 (s, 3H), 4.39-4.47 (m, 2H), 6.95-7.57 (m, 7H), 7.95 (d, 1H, J = 8.7 Hz), 8.15- 8.19 (m, 2H), 8.69- 8.76 (m, 2H), 9,61 (s, 1H) DMSO 1655

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 4.97 (d, 2H, J = 5.6 Hz), 7.00-7.50 (m, 8H), 7.85 (d, 1H, J = 8.7 Hz), 8.16 (s, 1H), 8.66- 8.77 (m, 3H), 9.11 (s, 1H), 9.61 (s, 1H) DMSO 1656

¹H NMR (DMSO-d₆) ppm 2.28 (s, 3H), 3.87 (s, 3H), 4.91 (d, 2H, J = 5.5 Hz), 7.00-7.52 (m, 9H), 7.86 (d, 1H, J = 8.6 Hz), 8.17 (dd, 1H, J = 8.6, 1.8 Hz), 8.66-9.16 (m, 3H), 9.18-9.16 (m, 1H), 9.57 (s, 1H) DMSO 1657

¹H NMR (DMSO-d₆) ppm 3.71 (s, 3H), 3.87 (s, 3H), 4.91 (d, 2H, J = 5.7 Hz), 6.82-7.52 (m, 9H), 7.86 (d, 1H, J = 8.7 Hz), 8.17 (dd, 1H, J = 8.7, 1.8 Hz), 8.66-9.15 (m, 3H), 9.17-9.19 (m, 1H), 9.57 (s, 1H) DMSO 1658

¹H NMR (DMSO-d₆) ppm 2.25 (s, 3H), 3.87 (s, 3H), 4.91 (d, 2H, J = 5.7 Hz), 7.00-7.53 (m, 9H), 7.86 (d, 1H, J = 8.6 Hz), 8.17 (dd, 1H, J = 8.6, 1.8 Hz), 8.66-9.15 (m, 3H), 9.17-9.19 (m, 1H), 9.57 (s, 1H) DMSO 1659

¹H NMR (DMSO-d₆) ppm 2.44 (s, 3H), 3.86 (s, 3H), 4.95 (d, 2H, J = 5.7 Hz), 7.01-7.53 (m, 9H), 7.86 (d, 1H, J = 8.6 Hz), 8.17 (dd, 1H, J = 8.6, 1.8 Hz), 8.65-9.02 (m, 3H), 9.50-9.52 (m, 1H), 9.54 (s, 1H) DMSO 1660

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 7.03 (s, 1H), 7.44- 7.94 (m, 10H), 8.07- 8.70 (m, 4H), 9.41 (s, 1H) DMSO 1661

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 4.91 (d, 2H, J = 5.5 Hz), 7.00- 7.04 (m, 1H), 7.04-7.55 (m, 7H), 7.87 (d, 1H, J = 8.6 Hz), 8.18 (dd, 1H, J = 8.6, 1.8 Hz), 8.66- 9.18 (m, 3H), 9.18- 9.21 (m, 1H), 9.55 (s, 1H) DMSO 1662

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 4.99 (d, 2H, J = 5.5 Hz), 7.01- 7.05 (m, 2H), 7.15- 7.56 (m, 6H), 7.88 (d, 1H, J = 8.6 Hz), 8.20 (dd, 1H, J = 8.6, 1.8 Hz), 8.64- 9.18 (m, 3H), 9.19- 9.21 (m, 1H), 9.50 (s, 1H) DMSO 1663

¹H NMR (DMSO-d₆) ppm 3.49 (s, 3H), 3.74 (s, 3H), 5.15 (s, 2H), 6.90 (d, J = 8.2 Hz, 1H), 7.04- 7.29 (m, 2H), 7 33- 7.54 (m, 7H), 7.93 (d, 1H, J = 8.6 Hz), 8.15 (dd, 1H, J = 8.6, 1.8 Hz), 8.21 (s, 1H), 8.68- 8.75 (m, 2H), 9.59 (s, 1H) DMSO 1664

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 4.94 (d, 2H, J = 5.5 Hz), 7.01- 7.03 (m, 1H), 7.35- 7.57 (m, 7H), 7.88 (d, 1H, J = 8.6 Hz), 8.20 (dd, 1H, J = 8.6, 1.8 Hz), 8.66- 9.22 (m, 3H), 9.19- 9.21 (m, 1H), 9.50 (s, 1H) DMSO 1665

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 4.96 (d, 2H, J = 5.5 Hz), 7.00- 7.03 (m, 2H), 7.33- 7.52 (m, 7H), 7.88 (d, 1H, J = 8.6 Hz), 8.19 (dd, 1H, J = 8.6, 1.8 Hz), 8.65- 9.20 (m, 3H), 9.19- 9.21 (m, 1H), 9.54 (s, 1H) DMSO 1666

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 4.93 (d, 2H, J = 5.5 Hz), 7.00- 7.19 (m, 3H), 7.41- 7.55 (m, 6H), 7.88 (d, 1H, J = 8.6 Hz), 8.17 (dd, 1H, J = 8.6, 1.8 Hz), 8.65- 9.18 (m, 3H), 9.13- 9.21 (m, 1H), 9.57 (s, 1H) DMSO 1667

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 4.92 (d, 2H, J = 5.5 Hz), 7.01- 7.03 (d, 1H, J = 7.0 Hz), 7.37-7.53 (m, 6H), 7.72 (d, 1H, J = 8.6 Hz), 8.18 (dd, 1H, J = 8.6, 1.8 Hz), 8.66-9.19 (m, 3H), 9.20-9.23 (m, 1H), 9.56 (s, 1H) DMSO 1668

¹H NMR (DMSO-d₆) ppm 1.68 (d, 3H, J = 7.0 Hz), 3.87 (s, 3H), 4.92 (d, 2H, J = 5.5 Hz), 5.75-5.78 (m, 1H), 7.02 (d, 1H, J = 7.0 Hz), 7.32-7.56 (m, 9H), 7.84 (d, 1H, J = 8.6 Hz), 8.15 (dd, 1H, J = 8.6, 1.8 Hz), 8.64-8.84 (m, 4H), 9.51 (s, 1H) DMSO 1669

¹H NMR (DMSO-d₆) ppm 3.70 (s, 3H), 3.86 (s, 3H), 4.92 (d, J = 5.1 Hz, 2H), 6.89-7.01 (m, 3H), 7.41-7.54 (m, 6H), 7.85 (d, J = 8.6 Hz, 1H), 7.85 (d, J = 8.6 Hz, 1H), 8.67- 8.75 (m, 3H), 9.19 (s, 1H), 9.56 (s, 1H) DMSO 1670

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 3.91 (s, 3H), 4.92 (d, J = 5.0 Hz, 2H), 6.87-7.52 (m, 9H), 7.85 (d, J = 8.5 Hz, 1H), 8.17 (d, J = 8.5 Hz, 1H), 8.64-8.73 (m, 3H), 9.05 (s, 1H), 9.52 (s, 1H) DMSO 1671

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 4.93 (d, J = 5.6 Hz, 2H), 7.02 (s, 1H), 7.41-7.61 (m, 7H), 7.83 (d, J = 8.9 Hz, 1H), 8.18 (d, J = 8.9 Hz, 1H), 8.66-8.71 (m, 3H), 9.21 (s, 1H), 9.54 (s, 1H) DMSO 1672

¹H NMR (DMSO-d₆) ppm 3.69 (s, 6H), 3.87 (s, 3H), 4.93 (d, J = 5.6 Hz, 2H), 6.90 (s, 1H), 7.00- 7.54 (m, 7H), 7.85 (d, J = 8.6 Hz, 1H), 8.17 (d, J = 8.6 Hz, 1H), 8.66- 8.78 (m, 3H), 9.14 (s, 1H), 9.63 (s, 1H) DMSO 1673

— DMSO 1674

2HCl 1H—NMR (300 MHz, DMSO): δ 9.71 (d, J = 1.6 Hz, 1H), 9.16 (d, J = 8.2 Hz, 1H), 8.98 (dd, J = 5.1, 1,5 Hz, 1H), 8.58 (s, 1H), 8 48- 8.34 (m, 3H), 8.20 (ds J = 8.0 Hz, 1H), 7.98- 7.87 (m, 2H), 7.75 (t, J = 7.8 Hz, 1H), 3.73 (s, 6H). DMSO 1675

1H—NMR (300 MHz, DMSO): δ 9.59 (s, 1H), 8.78- 8.62 (m, 2H), 8.38 (s, 1H), 8.05 (dd, J = 8.6, 1.3 Hz, 1H), 7.34 (d, J = 8.7 Hz, 1H), 7.73 (d, J = 8.7 Hz, 2H), 7.52 (dd, J = 7.8, 4.7 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 4.04 (s, 4H), 3.82 (s, 3H), 2.02 (3, 4H). DMSO 1676

3HCl 1H—NMR (300 MHz, DMSO): δ 10.40 (s, 1H), 9.48 (d, J = 2.0 Hz, 1H), 8.95 (s, 2H), 3.88 (d, J = 5.2 Hz, 1H), 8.72 (d, J = 4.3 Hz, 1H), 8.35 (d, J = 8.9 Hz, 1H), 8.18 (s, 1H), 8.08 (d, J = 8.8 Hz, 1H), 7.94- 7.81 (m, 2H), 7.64 (s, 1H), 7.54-7.45 (m, 3H), 7.06-7.00 (m, 1H), 5.25 (d, J = 5.1 Hz, 2H), 3.88 (s, 3H). DMSO 1677

1H—NMR (300 MHz, DMSO): δ 12.83 (s, 1H), 9.32 (d, J = 2.2 Hz, 1H), 8.77 (dd, J = 4.8, 1.5 Hz, 1H), 8.63 (d, J = 2.5 Hz, 1H), 8.56- 8.49 (m, 1H), 8.37 (d, J = 2.2 Hz, 1H), 8.23-8.14 (m, 2H), 7.85 (d, J = 8.5 Hz, 1H), 7.60 (dd, J = 3.0, 4.8 Hz, 1H), 6.96 (d, J = 8.7 Hz, 1H), 3.92 (s, 3H). DMSO 1678 NH3

2HCl 1H NMR (300 MHz, DMSO) δ 9.79 (brs, 1H), 9,60 (s, 2H), 9.07 (d, J = 7.4 Hz, 1H), 9.00 (d, J = 4.5 Hz, 1H), 8.80 (s, 1H), 3.35 (d, J = 8.7 Hz, 1H), 8.26 (d, J = 8.6 Hz, 1H), 8.02- 7.88 (m, 1H), 7.67- 7.48 (m, 2H), 7.43-7.37 (m, 1H). DMSO Meth- od of Num- Purity Coup- ber percent ling 1634 >98 Meth- od AQ3, F5, G2 (re- flux) 1635 >98 Meth- od AQ3, F5, G2 (re- flux) 1636 >98 Meth- od AQ3, F5, G2 (re- flux) 1637 >98 Meth- od AQ3, F5, G2 (re- flux) 1638 >98 Meth- od AQ3, F5, G2 (re- flux) 1639 >98 Meth- od AQ3, F5, G2 (re- flux) 1640 >98 Meth- od AQ3, F5, G2 (re- flux) 1641 >98 Meth- od AQ3, F5, G2 (re- flux) 1642 >98 Meth- od AQ3, F5, G2 (re- flux) 1643 >98 Meth- od AQ3, F5, G2 (re- flux) 1644 >98 Meth- od AQ3, F5, G2 (re- flux) 1645 >98 Meth- od AQ3, F5, G2 (re- flux) 1646 >98 Meth- od AQ3, F5, G2 (re- flux) 1647 >98 Meth- od AQ3, F5, G2 (re- flux) 1648 >98 Meth- od AQ3, F5, G2 (re- flux) 1649 >98 Meth- od AQ3, F5, G2 (re- flux) 1650 >98 Meth- od AQ3, F5, G2 (re- flux) 1651 >98 Meth- od AQ3, F5, G2 (re- flux) 1652 >98 Meth- od AQ3, F5, G2 (re- flux) 1653 >98 Meth- od AQ3, F5, G2 (re- flux) 1654 >98 Meth- od AQ3, F5, G2 (re- flux) 1655 >98 Meth- od AQ3, F5, G2 (re- flux) 1656 >98 Meth- od AQ3, F5, G2 (re- flux) 1657 >98 Meth- od AQ3, F5, G2 (re- flux) 1658 >98 Meth- od AQ3, F5, G2 (re- flux) 1659 >98 Meth- od AQ3, F5, G2 (re- flux) 1660 >98 Meth- od AQ3, F5, G2 (re- flux) 1661 >98 Meth- od AQ3, F5, G2 (re- flux) 1662 >98 Meth- od AQ3, F5, G2 (re- flux) 1663 >98 Meth- od AQ3, F5, G2 (re- flux) 1664 >98 Meth- od AQ3, F5, G2 (re- flux) 1665 >98 Meth- od AQ3, F5, G2 (re- flux) 1666 >98 Meth- od AQ3, F5, G2 (re- flux) 1667 >98 Meth- od AQ3, F5, G2 (re- flux) 1668 >98 Meth- od AQ3, F5, G2 (re- flux) 1669 >98 Meth- od AQ3, F5, G2 (re- flux) 1670 >98 Meth- od AQ3, F5, G2 (re- flux) 1671 >98 Meth- od AQ3, F5, G2 (re- flux) 1672 >98 Meth- od AQ3, F5, G2 (re- flux) 1673 95 Meth- od AQ3, AP 1674 95 Meth- od AQ3, AP 1675 95 Meth- od AQ3, AP 1676 95 Meth- od AQ3, AP 1677 95 Meth- od AQ3, AP 1678 >98 Meth- od AQ3, F5, G2 (re- flux)

Method AT for Alkylation: Method AT1: NaOMe/MeOH/microwave/150° C. Method AT2: MeOH/microwave/150° C. Method AT3: DIPEA/KI/DMF/microwave/150° C.

Method AR: 3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenol (lxi-a)

To a suspension of 6-(3-methoxyphenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (prepared in a similar method described for 6-(3-methoxy phenyl)-2-(pyridine-3-yl)-4-(pyrrolidin-1-yl)quinazoline using Scheme 74, substituting N-methylamine for pyrrolidine) (1.00 g, 2.9 mmol) in CH₂Cl₂ (15 mL) and boron tribromide 1M solution in dichloromethane (8.76 ml, 8.76 mmol) was added at 0° C. The reaction mixture was stirred overnight at room temperature after which it was carefully poured into a vigorously stirring mixture of ice and saturated aqueous solution of NaHCO₃. The resultant solid was collected by filtration, dried and then dissolved in a mixture of K₂CO₃ (2 g) and methanol (50 mL). The solution was then acidified using aqueous NH₄Cl solution. (50 mL) and the precipitate which formed was collected by filtration and dried to give 0.95 g of 3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenol as pale yellow solid (99%). LCMS m/z=329 (M+1) (Method D) (retention time=1.30 min). ¹H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 9.60 (s, 1H), 8.77 (d, J=8.0 Hz, 1H), 8.74-8.59 (m, 2H), 8.54 (s, 1H), 8.05 (d, J=8.7 Hz, 1H), 7.83 (d, J=8.7 Hz, 1H), 7.54 (dd, J=7.9, 4.8 Hz, 1H), 7.38-7.12 (m, 3H), 6.82 (d, J=7.8 Hz, 1H), 3.17 (d, J=4.3 Hz, 3H).

Method AS: 6-(3-(2-chloroethoxy)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (lxii-a)

A suspension of 3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenol (0.30 g, 0.914 mmol), 1-bromo-2-chloroethane (0.38 ml, 4.57 mmol), and potassium carbonate (0.38 g, 2.74 mmol) in DMF (10 mL) was stirred for 2 days at room temperature. Water (10 mL) and ethyl acetate (10 mL) were added to the mixture and extracted. The organic layer was separated and concentrated in vacuo to leave a solid, which was collected by filtration and washed with hexane and dried to give 0.30 g of 6-(3-(2-chloroethoxy)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine as brown solid (83%). The product was used without further purification.

Method AT1: 6-(3-(2-methoxyethoxy)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (lxiii-a)

A solution of 6-(3-(2-chloroethoxy)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (70 mg, 0.18 mmol) and sodium methoxide (97 mg, 1.8 mmol) in methanol (3 mL) was placed in a microwave reaction vial. The mixture was heated under microwave irradiation conditions at 150° C. for 30 minutes after which the solvent was removed in vacuo. The crude product was obtained, which was purified by column chromatography on basic silica gel (eluted with hexane/ethyl acetate 3:1→1:4) to give 20 mg of 6-(3-(2-methoxyethoxy)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine as an off-white powder (29%). LCMS m/z=387 (M+1) (Method D) (retention time=1.49 min). ¹H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.77 (d, J=8.2 Hz, 1H), 8.73-8.51 (m, 3H), 8.16 (d, J=8.7 Hz, 1H), 7.84 (d, J=8.3 Hz, 1H), 7.60-7.32 (m, 4H), 7.01 (s, 1H), 4.21 (s, 2H), 3.70 (s, 2H), 3.33 (s, 3H), 3.19 (s, 3H),

Method AT2: N-Methyl-6-(4-(2-morpholinoethoxy)phenyl)-2-(pyridin-3-yl)quinazolin-4-amine (lxiii-b)

In a 10 mL microwave vial 6-(4-(2-chloroethoxy)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (70.0 mg, 0.179 mmol) and morpholine (0.155 ml, 1.791 mmol) were added in methanol (3 mL) to give a yellow suspension. The vial was irradiated at 150° C. in the microwave for 30 min. The volatiles were evaporated in vacuo. Water (10 mL) was added to the reaction mixture and extracted with ethyl acetate (2×10 mL). The organic layers were combined and washed with brine (1×20 mL), then dried over MgSO₄, filtered and concentrated. The residue was purified by column chromatography on basic silica gel (eluted with hexane/ethyl acetate 3:2 to 0:1). The product was obtained as the parent and converted to the HCl salt by addition of 4 M HCl-dioxane, then crystallized from EtOH—H2O to give 55 mg of N-methyl-6-(4-(2-morpholinoethoxy)phenyl)-2-(pyridin-3-yl)quinazolin-4-amine as a yellow powder (60% yield), LCMS m/z=442 (M+1) (Method D) (retention time=1.12 min). ¹H NMR (300 MHz, DMSO) δ 11.31 (s, 1H), 10.41 (s, 1H), 9.63 (s, 1H), 9.10-8.79 (m, 3H), 8.34 (d, J=8.2 Hz, 1H), 8.28-8.12 (m, 1H), 7.92 (d, J=8.0 Hz, 2H), 7.87-7.74 (m, 1H), 7.18 (d, J=8.0 Hz, 2H), 4.60-4.46 (m, 2H), 4.06-3.91 (m, 2H), 3.91-3.74 (m, 2H), 3.67-3.41 (m, 4H), 3.38-3.09 (m, J=10.1 Hz, 5H).

Method AT3: N-methyl-2-(pyridin-3-yl)-6-(3-(2-(2,2,2trifluoroethylamino)ethoxy)phenyl)quinazolin-4-amine (lxiii-c)

In a 10 mL microwave vial was added 6-(3-(2-chloroethoxy)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (50.0 mg, 0.128 mmol), 2,2,2-trifluoroethylamine (0.100 ml, 1.279 mmol), potassium iodide (42.5 mg, 0.256 mmol), and N,N′-diisopropylethylamine (0.045 ml, 0.256 mmol) in DMF (3 mL) to give a yellow suspension. The vial was irradiated at 150° C. in the microwave for 20 min. Water (10 mL) was added to the mixture and extracted with ethyl acetate (2×20 mL). The organic layers were combined and washed with water (1×20 mL) and brine (1×20 mL), dried over MgSO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted with (CH₂Cl₂/CH₂Cl₂-MeOH—NH₄OH=100:20:1 1:0 to 0:1). The product was converted to the HCl salt by addition of 4 M HCl-dioxane, then crystallization from IPA-H2O to give 30 mg of N-methyl-2-(pyridin-3-yl)-6-(3-(2-(2,2,2-trifluoroethylamino)ethoxy)phenyl)quinazolin-4-amine as a yellow powder (42%). LCMS m/z=454 (M+1) (Method C) (retention time=2.26 min). ¹H NMR (300 MHz, DMSO) δ 10.73-10.36 (m, 1H), 9.65 (s, 1H), 9.13-8.98 (m, 2H), 8.93 (d, J=5.0 Hz, 1H), 8.38 (d, J=8.4 Hz, 1H), 8.24 (d, J=7.7 Hz, 1H), 7.94-7.75 (m, 1H), 7.69-7.41 (m, 3H), 7.09 (d, J=8.1 Hz, 1H), 4.61-4.43 (m, 2H), 4.28-4.07 (m, 2H), 3.59-3.39 (m, 2H), 3.30 (d, J=2.8 Hz, 3H).

In a 50 mL round-bottomed flask was added 6-(4-(2-aminoethoxy)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (15.0 mg, 0.040 mmol) and triethylamine (0.017 ml, 0.121 mmol) in CH₂Cl₂ (5 mL) to give a yellow solution. Acetic anhydride (4.58 μl, 0.048 mmol) was added and the mixture was stirred for 2 h at room temperature. Water (10 mL) was added to the mixture and extracted with ethyl acetate (2×10 mL). The organic layers were combined and washed with brine (1×20 mL), dried over Mg₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted with CH₂Cl₂ MeOH 1:0 to 9:1), The product was converted to the HCl salt by addition of 4 M HCl-dioxane, then dissolved in a small amount of methanol, followed by ethyl acetate. The resulting solid was filtered and dried to give 10 mg of N-(2-(4-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenoxy)ethyl)acetamide as a HCl salt as a yellow solid in a 51% yield. LCMS m/z=414 (M+1) (Method C) (retention time=1.28 min). ¹H NMR (300 MHz, DMSO) δ 10.26 (s, 1H), 9.62 (s, 1H), 9.06-8.90 (m, 2H), 8.81 (s, 1H), 8.34 (d, J=9.0 Hz, 1H), 8.17 (d, J=6.6 Hz, 2H), 7.86 (d, J=8.0 Hz, 3H), 7.13 (d, J=7.91 Hz, 2H), 4.06 (t, J=5.4 Hz, 2H), 3.52-3.38 (m, 2H), 3.30 (d, J=4.1 Hz, 3H), 1.84 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 78, replacing 1-bromo-2-chloroethane with the corresponding alkyl halide.

TABLE 26 ¹H- Method NMR Retention LCMS Purity for Number PRODUCT Salt ¹H-NMR Solvent LCMS Time Protocol percent Coupling 1679

HCl 1H NMR (300 MHz, DMSO) δ 10.36 (s, 1H), 9.65 (s, 1H), 9.13-8.99 (m, 1H), 8.99-8.83 (m, 2H), 8.38 (d, J = 8.8 Hz, 1H), 8.30-8.16 (m, 1H), 7.94- 7.80 (m, 1H), 7.55-7.35 (m, 3H), 7.09-6.97 (m, 1H), 4.16 (q, J = 7.0 Hz, 2H), 3.31 (d, J = 4.3 Hz, 3H), 1.37 (t, J = 6.9 Hz, 3H). DMSO 357 (M + 1) 1.62 Method D 100 Method AR/AS/ AT1 1680

1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.77 (d, J = 8.2 Hz, 1H), 8.73-8.51 (m, 3H), 8.16 (d, J = 8.7 Hz, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.60-7.32 (m, 4H), 7.01 (s, 1H), 4.21 (s, 2H), 3.70 (s, 2H), 3.33 (s, 3H), 3.19 (s, 3H). DMSO 387 (M + 1) 1.49 Method D 100 Method AR/AS/ ATI 1681

1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.78 (d, J = 7.9 Hz, 1H), 8.72-8.49 (m, 3H), 8.22-8.01 (m, 2H), 7.85 (d, J = 8.6 Hz, 1H), 7.62-7.36 (m, 4H), 7.01 (s, 1H), 4.59 (s, 2H), 3.19 (d, J = 4.0 Hz, 3H), 2.68 (d, J = 4.5 Hz, 3H). DMSO 400 (M + 1) 1.31 Method D 100 Method AR/W with KI 1682

2HCl 1H NMR (300 MHz, DMSO) δ 10.47 (s, 1H), 9.65 (d, J = 1.7 Hz, 1H), 9.05 (d, J = 7.9 Hz, 1H), 9.01- 8.88 (m, 2H), 8.39 (m, 1H), 8.23 (d, J = 8.8 Hz, 1H), 7.87 (dd, J = 8.0, 5.3 Hz, 1H), 7.65-7.39 (m, 3H), 7.09 (m, 1H), 6.44 (m, 1H), 4.47 (td, J = 14.7, 3.4 Hz, 2H), 3.29 (d, J = 4.5 Hz, 3H). DMSO 393.4 (M + 1) Method C (NH4HCO3) 100 Method AR/AS (K2CO3, DMF- THF (1:1), 60° C.) then Method AT 1683

HCl ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.60 (s, 1H), 9.03-8.87 (m, 2H), 8.77 (s, 1H), 8.32 (d, J = 8.5 Hz, 1H), 8.21-8.02 (m, 1H), 7.92-7.69 (m, 3H), 7.20-7.02 (m, 2H), 4.93 (s, 2H), 3.70-3.40 (m, 8H), 3.29 (d, J = 3.5 Hz, 3H). DMSO 456 (M + 1) 1.73 Method B (Ammonium formate) 100 Method AR/W with KI 1684

HCl ¹H NMR (300 MHz, DMSO) δ 10.38 (s, 1H), 9.64 (s, 1H), 9.02 (d, J = 6.7 Hz, 1H), 8.93 (d, J = 4.9 Hz, 1H), 8.84 (s, 1H), 8.34 (d, J = 9.0 Hz, 1H), 8.22 (d, J = 8.7 Hz, 1H), 7.98-7.70 (m, 3H), 7.11 (d, J = 7.3 Hz, 2H), 4.26-4.05 (m, 2H), 3.78-3.57 (m, 2H), 3.45-3.19 (m, 6H). DMSO 387 (M + 1) 1.47 Method A (Formic acid) 100 Method AR/AS/ AT1 1685

HCl ¹H NMR (300 MHz, DMSO) δ 11.31 (s, 1H), 10.41 (s, 1H), 9.63 (s, 1H), 9.10-8.79 (m, 3H), 8.34 (d, J = 8.2 Hz, 1H), 8.28-8.12 (m, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.87-7.74 (m, 1H), 7.18 (d, J = 8.0 Hz, 2H), 4.60-4.46 (m, 2H), 4.06-3.91 (m, 2H), 3.91- 3.74 (m, 2H), 3.67-3.41 (m, 4H), 3.38-3.09 (m, J = 10.1 Hz, 5H). DMSO 442 (M + 1) 1.22 Method A (Formic acid) 100 Method AR/AS/ AT2 1686

HCl ¹H NMR (300 MHz, DMSO) δ 10.32-9.70 (m, 1H), 9.61 (s, 1H), 9.13-8.70 (m, 5H), 8.29 (d, J = 8.5 Hz, 1H), 8.20-8.01 (m, 1H), 7.89 (d, J = 8.6 Hz, 2H), 7.83-7.67 (m, 1H), 7.16 (d, J = 8.8 Hz, 2H), 4.38-4.27 (m, 2H), 3.43-3.32 (m, 2H), 3.27 (d, J = 3.7 Hz, 3H), 2.63 (t, J = 4.8 Hz, 3H). DMSO 386 (M + 1) 1.46 Method B (Ammonium formate) 100 Method AR/AS/ AT2 1687

HCl ¹H NMR (300 MHz, DMSO) δ 9.95 (s, 1H), 9.62 (s, 1H), 9.13-8.86 (m, J = 5.2 Hz, 3H), 8.39 (d, J = 8.7 Hz, 1H), 8.26 (s, 1H), 7.97-7.80 (m, 1H), 7.61- 7.37 (m, 3H), 7.14-6.98 (m, 1H), 5.01-4.81 (m, 1H), 4.31-4.13 (m, 2H), 3.79-3.63 (m, 2H), 1.42 (d, J = 6.5 Hz, 6H). DMSO 415 (M + 1) 1.65 Method A (Formic acid) 100 Method AR/AS/ AT1 1688

HCl ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.63 (s, 1H), 9.10-8.88 (m, 2H), 8.72 (s, 1H), 8.44 (d, J = 8.3 Hz, 1H), 8.14 (d, J = 8.3 Hz, 1H), 7.85 (dd, J = 7.6, 4.8 Hz, 1H), 7.52 (d, J = 6.3 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 7.22-7.04 (m, 2H), 4.97 (s, 2H), 3.30 (d, J = 4.1 Hz, 3H). 2.97 (s, 3H), 2.85 (s, 3H). DMSO 414 (M + 1) 1.28 Method A (Formic acid) 100 Method AR/W with KI 1689

HCl ¹H NMR (300 MHz, DMSO) δ 10.22 (s, 1H), 9.63 (s, 1H), 9.10-8.87 (m, 2H), 8.75 (s, 1H), 8.35 (d, J = 8.8 Hz, 1H), 8.15 (d, J = 8.7 Hz, 1H), 8.01 (d, J = 4.2 Hz, 1H), 7.93-7.77 (m, 1H), 7.51 (d, J = 7.3 Hz, 1H), 7.43 (t, J = 7.8 Hz, 1H), 7.16 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 8.5 Hz, 1H), 4.54 (s, 2H), 3.29 (d, J = 3.9 Hz, 3H), 2.64 (d, J = 4.4 Hz, 3H). DMSO 400 (M + 1) 1.33 Method A (Formic acid) 100 Method AR/W with KI 1690

HCl ¹H NMR (300 MHz, DMSO) δ 10.09 (s, 1H), 9.62 (s, 1H), 9.05-8.87 (m, 2H), 8.60 (s, 1H), 8.26 (d, J = 8.6 Hz, 1H), 8.13 (d, J = 3.8 Hz, 1H), 7.90-7.77 (m, 1H), 7.54-7.36 (m, 2H), 7.26-7.06 (m, 2H), 4.23-4.11 (m, 2H), 3.70-3.58 (m, 2H), 3.29 (d, J = 4.4 Hz, 3H), 3.24 (s, 3H). DMSO 387 (M + 1) 1.51 Method A (Formic acid) 100 Method AR/AS/ AT1 1691

HCl ¹H NMR (300 MHz, DMSO) δ 9.65 (s, 1H), 9.04 (d, J = 7.8 Hz, 1H), 8.94 (d, J = 5.0 Hz, 1H), 8.50 (s,1H), 8.39-8.22 (m, 2H), 7.97-7.80 (m, 1H), 7.53-7.31 (m, 3H), 7.03 (d, J = 6.8 Hz, 1H), 4.26-4.13 (m, 2H), 3.82-3.59 (m, 8H), 3.32 (s, 3H). DMSO 401 (M + 1) 1.47 Method A (Formic acid) 100 Method AR/AS/ AT1 1692

HCl ¹H NMR (300 MHz, DMS0) δ 9.83-9.26 (m, 3H), 9.00-8.76 (m, 3H), 8.40 (d, J = 8.8 Hz, 1H), 8.18 (d, J = 8.6 Hz, 1H), 7.89-7.72 (m, 1H), 7.58-7.36 (m, 3H), 7.04 (d, J = 3.4 Hz, 1H), 4.30-4.18 (m, 2H), 3.79-3.66 (m, 2H), 3.33 (s, 3H). DMSO 373 (M + 1) 1.42 Method A (Formic acid) 100 Method AR/AS/ AT1 1693

HCl ¹H NMR (300 MHz, DMSO) δ 10.73-10.36 (m, 1H), 9.65 (s, 1H), 9.13-8.98 (m, 2H), 8.93 (d, J = 5.0 Hz, 1H), 8.38 (d, J = 3.4 Hz, 1H), 8.24 (d, J = 7.7 Hz, 1H), 7.94-7.75 (m, 1H), 7.69-7.41 (m, 3H), 7.09 (d, J = 8.1 Hz, 1H), 4.61-4.43 (m, 2H), 4.28- 4.07 (m, 2H), 3.59-3.39 (m, 2H), 3.30 (d, J = 2.8 Hz, 3H). DMSO 454 (M + 1) 2.26 Method B (Ammonium formate) 100 Method AR/AS/ AT3 1694

HCl ¹H NMR (300 MHz, DMSO) δ 10.35 (s, 1H), 9.67 (s, 1H), 9.04 (d, J = 7.3 Hz, 1H), 8.94 (d, J = 5.0 Hz, 1H), 8.78 (s, 1H), 8.24 (s, 2H), 7.96-7.77 (m, 1H), 7.60-7.40 (m, 2H), 7.33-7.10 (m, 2H), 4.50-4.36 (m, 2H), 4.05-3.85 (m, 2H), 3.53-3.37 (m, 2H), 3.28 (d, J = 3.6 Hz, 3H), DMSO 454 (M + 1) 2.11 Method B (Ammonium formate) 100 Method AR/AS/ AT3 1695

¹H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.77 (d, J = 8.0 Hz, 1H), 8.73-8.50 (m, 3H), 8.14 (d, J = 8.7 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.48-7.34 (m, 3H), 6.96 (d, J = 3.2 Hz, 1H), 4.91 (s, 2H), 3.18 (d, J = 4.3 Hz, 3H), 3.03 (s, 3H), 2.86 (s, 3H). DMSO 414 (M + 1) 1.30 Method A (Formic acid) 100 Method AR/W with KI

Method AV: 1-(Benzyloxy)-7-bromo-3-chloroisoquinoline (lxv-a)

To 20 mL of benzyalcohol was slowly added Na (2.00 g, 86.9 mmol) at 0° C., the mixture was then stirred at room temperature for 4 h. 7-bromo-1,3-dichloroisoquinoline (2.00 g, 7.2 mmol) in toluene (50 mL) was added to the mixture with stirring. The reaction mixture was heated at 80° C. overnight. The solvent was removed under reduced pressure, the residue was purified with chromatography on silica gel (petroleum ether) to give 2.00 g xiv-a as a white solid (yield 80%) LCMS m/z=257.9, 259.9 (M+1) (Method B) (retention time=1.62 min).

Method AQ1: 1-(Benzyloxy)-3-chloro-7-(3-methoxyphenyl)isoquinoline (lxvi-a)

To a mixture of 1-(benzyloxy)-7-bromo-3-chloroisoquinoline (1.00 g, 2.86 mmol, 1.0 eq), 3-methoxyphenylboronic acid (435 mg, 2.86 mmol, 1.0 eq), K₂CO₃ (2.13 g, 15.4 mmol, 5.4 eq) in dioxane (10 mL) and H₂O (5 mL) was added Pd(PPh₃)₂Cl₂ (100 mg, 0.15 mmol, 0.05 eq) under N₂ atmosphere. The resulting mixture was stirred at 110° C. under N₂ atmosphere overnight. The solvent was removed in vacuo and the residue was purified with chromatography on silica gel (hexane/ethyl acetate 250:1) to give 550 mg of lxvi-a as white solid (yield 37%). LCMS m/z=376.0 (M+1) (Method B) (retention time=2.43 min).

Method AQ3: 1-(Benzyloxy)-7-(3-methoxyphenyl)-3-(pyridin-3-yl)isoquinoline (lxvii-a)

To a mixture of 1-(benzyloxy)-3-chloro-7-(3-methoxyphenyl)isoquinoline (150 mg, 0.40 mmol, 1.0 eq), pyridin-3-ylboronic acid (74 mg, 0.60 mmol, 1.5 eq), K₂CO₃ (166 mg, 1.20 mmol, 3.0 eq) in dioxane (2 ml) and H120 (1 mL) was added Pd(PPh₃)₂Cl₂ (14 mg, 0.02 mmol, 0.05 eq) under N₂ atmosphere. The sealed tube was irradiated in the CEM microwave at 130° C. for 1 h. After the reaction was completed, the volatiles were removed in vacuo and the residue was purified with chromatography on silica gel (hexane/ethyl acetate 50:1) to give 200 mg of crude lxvii-a as a brown oil, which was used directly in the next step without purification, LCMS m/z=419.0 (M+1) (Method B) (retention time=2.25 min).

Method AW: 7-(3-Methoxyphenyl)-3-(pyridin-3-yl)isoquinolin-1-ol (lxviii-a)

A mixture of 1-(benzyloxy)-7-(3-methoxyphenyl)-3-(pyridin-3-yl)isoquinoline (200 mg, 0.48 mmol), and concentrated HCl (10 mL) in ethanol (20 mL) was stirred at room temperature overnight. After the reaction was completed, the mixture was filtered and concentrated to afford 130 mg of lxviii-a as a yellow solid (yield 90% for two steps). LCMS m/z=329.0 (M+1) (Method B) (retention time=1.66 min).

Method AX: 1-Chloro-7-(3-methoxyphenyl)-3-(pyridin-3-yl)isoquinoline (lxix-a)

To a mixture of 7-(3-methoxyphenyl)-3-(pyridin-3-yl)isoquinolin-1-ol (130 mg, 0.395 mmol) in phenylphosphonic dichloride (5 mL) was stirred at 120° C. overnight. After the reaction was completed, the mixture was added to ice-water slowly. The pH was adjusted to 7 by slow addition of NH₃H₂O at 0° C. Then the mixture was extracted with dichloromethane (100 mL×3). The combined organic layer were dried over MgSO₄, filtered and concentrated in vacuo to give 130 mg of crude lxix-a as a white solid, which was used directly in the next step without purification. LCMS m/z=346.9 (M+1) (Method B) (retention time=1.80 min).

Method AY: 7-(3-Methoxyphenyl)-N-methyl-3-(pyridin-3-yl)isoquinolin-1-amine (lxx-a)

A mixture of 1-chloro-7-(3-methoxyphenyl)-3-(pyridin-3-yl)isoquinoline (90 mg, 0.26 mmol), methylamine hydrochloride (200 mg, 2.96 mmol, 10.0 eq) and Et₃ N (0.5 mL) was added to a sealed tube with i-AmOH (2 mL). The sealed tube was irradiated in the CEM microwave at 160° C. for 1 h. After the reaction was completed, the i-AmOH was removed in vacuo and the residue was dissolved in 10 mL of water and dichloromethane, the mixture was extracted with dichloromethane (3×50 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated in vacuo and the residue was washed with MeOH to give 5 mg of lxx-a as a brown solid (yield 6%). LCMS m/z=342.1 (M+1) (Method B) (retention time=2.02 min). ¹H NMR (400 MHz, DMSO-d₆): δ 9.40 (d, J=0.9 Hz, 1H), 8.67-8.47 (m, 3H), 8.08-7.95 (m, 1H), 7.89-7.84 (m, 2H), 7.66 (s, 1H), 7.57-7.49 (m, 1H), 7.46-7.42 (m, 3H), 7.08-6.95 (m, 1H), 3.88 (s, 3H), 3.14 (d, J=4.3 Hz, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 81, replacing with the appropriate isoquinoline and aniline.

TABLE 27 Molec- ¹H- Method Num- Salt ular NMR LCMS Purity for ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1697

341.41 1H-NMR (400 MHz, DMSO-d6): δ 9.40 (d, J = 0.9 Hz, 1H), 8.67- 8.47 (m, 3H), 8.08- 7.95 (m, 1H), 7.89- 7.84 (m, 2H), 7.66 (s, 1H), 7.57-7.49 (m, 1H), 7.46-7.42 (m, 3H), 7.08-6.95 (m, 1H), 3.88 (s, 3H), 3.14 (d, J = 4.3 Hz, 3H). DMSO 342.1 (M + 1) Method B (NH4HCO3) 95 Method AX, H1 1698

312.37 1H-NMR (400 MHz, DMSO-d6): δ 9.40 (d, J = 1.8 Hz, 1H), 9.12 (d, J = 2.1 Hz, 1H), 8.66 (s, 1H), 8.60 (m, 2H), 8.54 (dt, J = 8.0, 1.9 Hz, 1H), 8.29-8.23 (m, 1H), 8.08 (dd, J = 8.5, 1.6 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.87 (d, J = 4.5 Hz, 1H), 7.68 (s, 1H), 7.56 (dd, J = 7.8, 4.8 Hz, 1H), 7.51 (dd, J = 7.8, 4.8 Hz, 1H), 3.14 (d, J = 4.4 Hz, 3H). DMSO 312.9 ( M + 1) Method B (NH4HCO3) 95 Method AX, H1

Method BA: Synthesis of 5-[3-(4-Methylamino-2-pyridin-3-yl-quinazolin-6-yl)-phenoxymethyl]-oxazolidin-2-one (lxxi-a)

To 5-(chloromethyl)oxazolidin-2-one (45 μmol) was added the solution of 3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenol (30 μmol) in NMP (200 μL). PS-BEMP (90 μmol) was added to the vials by resin dispenser. After the reaction mixture was heated at 90° C. for 12 h, the residue was diluted with methanol and purified by PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 80, replacing 5-(chloromethyl)oxazolidin-2-one with the appropriate alkyl halide.

TABLE 28 Starting Starting Number Material 1 Material 2 1699

1700

1701

1702

1703

1704

1705

1706

1707

1708

1709

1710

1711

1712

1713

1714

1715

Number Product 1699

1700

1701

1702

1703

1704

1705

1706

1707

1708

1709

1710

1711

1712

1713

1714

1715

Exact Mass Found Number Salt Type Mass (M + 1) Purity (%) 1699 427 428 98 1700 421 422 98 1701 TFA 467 468 98 1702 515 516 98 1703 2TFA 468 469 98 1704 TFA 436 437 98 1705 455 456 98 1706 438 439 98 1707 421 422 98 1708 453 454 98 1709 TFA 467 468 98 1710 487 488 98 1711 TFA 515 516 98 1712 TFA 436 437 98 1713 TFA 422 423 98 1714 TFA 476 477 98 1715 2TFA 438 439 98

Method BB: Synthesis of 3-methyl-6-((3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin 6-yl)phenoxy)methyl)benzo[d]oxazol-2(3H)-one (lxxi-b)

To 6-(hydroxymethyl)-3-methylbenzo[d]oxazol-2(3H)-one (45.1 μmol) was added the solution of 3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenol (30 μmol) in THF (400 μL). After PS-triphenylphosphine (60 μmol) was added, the solution of DBAD (di-tert-butyl azodicarboxylate, 66 mmol) in THF was dispensed to the vials. The mixture was heated at 50° C. for 8 h. After the solvent was removed, the residue was diluted with methanol and purified by Mass triggered PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 85, replacing 6-(hydroxymethyl)-3-methylbenzo[d]oxazol-2(3H)-one with the appropriate alkyl alcohol.

TABLE 29 Starting Starting Number Material 1 Material 2 1716

1717

1718

1719

1720

1721

1722

1723

1724

1725

1726

1727

1728

1729

1730

1731

1732

1733

1734

1735

1736

1737

1738

Number Product 1716

1717

1718

1719

1720

1721

1722

1723

1724

1725

1726

1727

1728

1729

1730

1731

1732

1733

1734

1735

1736

1737

1738

Mass Salt Exact Found Number Type Mass (M + 1) Purity (%) 1716 TFA 489 490 100 1717 TFA 448 449 100 1718 TFA 422 423 100 1719 TFA 422 423 100 1720 TFA 472 473 100 1721 TFA 489 490 100 1722 TFA 489 490 100 1723 TFA 466 467 100 1724 TFA 425 426  94 1725 TFA 453 454 100 1726 TFA 489 490 100 1727 TFA 489 490 100 1728 TFA 448 449 100 1729 TFA 422 423 100 1730 TFA 504 505 100 1731 TFA 424 425 100 1732 TFA 433 434 100 1733 TFA 484 485 100 1734 TFA 466 467 100 1735 TFA 425 426 100 1736 TFA 464 465  95 1737 TFA 466 467 100 1738 TFA 489 490 100

Synthesis of N-(6-bromo-2-(pyridin-3-yl)quinazolin-4-yl)acetamide (lxxii-a)

A 100 mL round bottom flask was fitted with a reflux condenser and charged with 6-bromo-2-(pyridin-3-yl)quinazolin-4-amine (2.45 g, 8.14 mmol), acetic anhydride (5.81 g, 57.0 mmol) and acetic acid (30 mL). The reaction mixture was stirred at 90° C. for 20 min and then cooled to room temperature. A precipitate formed during the reaction and was collected by filtration and washed with water (100 mL). The solid was dried at 60° C. to give N-(6-bromo-2-(pyridin-3-yl)quinazolin-4-yl)acetamide as a white powder (1.83 g, 66%). ¹H NMR (300 MHz, CDCl₃) δ 9.72 (s, 1H), 8.84-8.69 (m, 3H), 8.22 (s, 1H), 8.02-7.90 (m, 2H), 7.53-7.41 (m, 1H), 2.83 (s, 3H).

Synthesis of N-(6-bromo-2-(pyridin-3-yl)quinazolin-4-yl)-N-methylacetamide (lxxiii-a)

To a solution of 6-bromo-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (1.20 g, 3.81 mmol) in acetic acid (10 mL) was added acetic anhydride (1.94 g, 19.0 mmol) and stirred at 195° C. using microwave for 6 h. The reaction mixture was checked by LC-MS, no starting material was observed, ice was added into the reaction. The precipitate was collected by filtration and washed with water. The product was dried at 60° C. to give N-(6-bromo-2-(pyridin-3-yl)quinazolin-4-yl)-N-methylacetamide (711 mg, 52%) as a light brown powder. ¹H NMR (300 MHz, CDCl₃) δ 9.76 (dd, J=2.2, 0.8 Hz, 1H), 8.85-8.79 (m, 1H), 8.76 (dd, J=4.8, 1.7 Hz, 1H), 8.09 (dd, J=1.8, 0.8 Hz, 1H), 8.05-8.01 (m, 2H), 7.46 (ddd, J=8.0, 4.8, 0.8 Hz, 1H), 3.52 (s, 3H), 2.11 (s, 3H).

Method BC: Synthesis of 6-(2,3-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (lxxv-a) (Compound 1742)

To a solution of the hydroxyl derivative (520 mg, 1.27 mmol) in DMF (20 mL) was added methyl iodide (262 mg, 1.84 mmol) and NaH (55% in oil; 69 mg, 1.9 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 h and the ice water was added into the reaction mixture. The resulting solution was extracted with ethyl acetate (3 times), dried over Na₂ SO₄, concentrated and purified by column chromatography (NH-silica gel, 50% hexane/50% ethyl acetate). The resulting product was dissolved in isopropyl alcohol and 1N—HCl (5 mL) was added and a precipitate formed which was collected by filtration and dried at 60° C. to give 6-(2,3-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride as an orange powder (130 mg, 21%). ¹H NMR (300 MHz, DMSO) δ 9.66 (d, J=1.6 Hz, 1H), 9.09 (d, J=8.1 Hz, 1H), 8.96 (dd, J=5.1, 1.5 Hz, 1H), 8.51 (s, 1H), 8.33 (d, J=8.7 Hz, 1H), 8.20 (d, J=8.8 z, 1H), 7.90 (dd, J=8.1, 5.1 Hz, 1H), 7.66-7.47 (m, 2H), 7.47-7.32 (m, 1H), 4.22-4.07 (m, 2H), 3.70 (s, 3H), 3.48 (t, J=5.8 Hz, 2H), 3.22 (s, 3H), 2.19-2.01 (m, 2H).

Method BD: 2-(3-(4-(dimethylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenyl)ethanol, 2HCl (lxxvi-a)

To a reaction vial containing 2-(3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenyl)ethanol (89.0 mg, 0.25 mmol) in DMF (1 ml) was added 60% sodium hydride (13 mg, 0.325 mmol) and iodomethane (0.02 mL, 0.325 mmol). The reaction mixture was allowed to stir at ambient temperature for 12 h. Water (20 ml) was added to the reaction mixture, and the crude product was extracted with ethyl acetate (4×15 nm i). The crude material was purified via ISCO (silica, 4 g column, 95% CH₂Cl₂—5% MeOH—0.1% NH₄OH) to give the product as an off-white solid. The free base was then converted to the HCl salt to yield the final product as a yellow solid (24.6 mg, 0.055 mmol, 22%). LC-MS m/z=371.5 (M+1) (retention time=1.86) ¹H NMR (300 MHz, DMSO) δ 9.61 (d, J=211 Hz, 1H), 8.99 (d, J=7.5 Hz, 1H), 8.93 (dd, J=5.0, 1.5 Hz, 1H), 8.48 (d, J=1.0 Hz, 1H), 8.28 (dd, J=17.4, 9.4 Hz, 2H), 7.84 (dd, J=7.7, 5.1 Hz, 1H), 7.69-7.60 (m, 2H), 7.44 (t, J=7.5 Hz, 1H), 7.30 (d, J=7.3 Hz, 1H), 3.78-3.61 (m, 9H), 2.82 (t, J=7.0 Hz, 2H).

Synthesis of 6-(2,4-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (lxxvii-a) (Compound 1744)

6-(2,4-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride was synthesized in a similar manner to that described for 6-(2,3-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride substituting the appropriate hydroxyl derivative. 6-(2,4-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine was obtained as the dihydrochloride salt ¹H NMR (300 MHz, DMSO) δ 9.69 (d, J=2.0 Hz, 1H), 9.14 (d, J=8.3 Hz, 1H), 8.97 (dd, J=5.1, 1.2 Hz, 1H), 8.45 (s, 1H), 8.39 (d, H=8.6 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 7.92 (dd, J=8.0, 5.2 Hz, 1H), 7.86-7.73 (m, 1H), 7.57-7.38 (m, 1H), 7.36-7.23 (m, 1H), 4.19-4.04 (m, 2H), 3.71 (s, 3H), 3.48 (t, J=5.7 Hz, 2H), 3.23 (s, 3H), 2.21-1.96 (m, 2H).

Method BE: 4-(3,4-dichlorophenyl)-1-(6-(3-methoxyphenyl)-2-(pyridin-3-yl)quinazolin-4-yl)pyrrolidin-2-one (lxxviii-a)

To a mixture of 4-chloro-6-(3-methoxyphenyl)-2-(pyridin-3-yl)quinazoline (40 mg, 0.12 mmol), 4-(3,4-dichlorophenyl)pyrrolidin-2-one (100 mg, 0.437 mmol) and Cs₂CO₃ (42 mg, 0.127 mmol) in dry toluene (6 mL) was added Pd(OAc)₂ (3 mg, 0.01 mmol) and Xantphos (10 mg, 0.02 mmol) under a nitrogen atmosphere. The resulting mixture was stirred at 100° C. for 12 h. After cooling, the mixture was filtered through a pad of celite. The residue was purified by silica gel chromatography, eluted with petroleum ether/ethyl acetate (5:4) to give the desired product as a yellow solid. 14 mg of the desired product was obtained in a 22.5% yield, LCMS: retention time=1.802 min, [MH]⁺=541.0, 543.0. ¹H-NMR (400 MHz, DMSO-d₆): δ 9.73 (s, 1H), 9.05-9.04 (m, 1H), 8.86-8.85 (m, 1H), 8.42-8.38 (m, 2H), 8.19 (d, J=8.8 Hz, 1H), 7.89 (d, J=1.6 Hz, 1H), 7.82-7.81 (m, 1H), 7.69 (d, J=8.0 Hz, 1H), 7.58 (dd, J=8.0, 1.6 Hz, 1H), 7.50 (t, J=8.0 Hz, 1H), 7.41-7.36 (m, 2H), 7.07 (dd, J=8.0, 2.0 Hz, 1H), 4.57-4.46 (m, 2H), 4.06-4.03 (m, 1H), 3.20-3.01 (m, 2H), 3.88 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 91, replacing 4-(3,4-dichlorophenyl)pyrrolidin-2-one with the appropriate amide

TABLE 30 ¹H-NMR Purity Method LCMS Number Product Salt type ¹H-NMR Solvent percent of Coupling LCMS Method 1745

¹H-NMR (400 MHz, DMSO-d₆): δ 9.75 (s, 1H), 8.90 (d, J = 8.0 Hz, 1H), 8.78 (d, J = 4.0 Hz, 1H), 8.35 (s, 1H), 8.28-8.19 (m, 2H), 7.92 (d, J = 7.6 Hz, 1H), 7.82 (d, J = 5.0 Hz, 2H), 7.73-7.70 (m, 1H), 7.68-7.61 (m, 2H), 7.52- 7.42 (m, 1H), 7.29 (t, J = 8.4 Hz, 1H), 5.61 (s, 2H). DMSO 95 Method BE 451.0 (M + 1) Method B (NH₄HCO₃) 1746

¹H-NMR (400 MHz, DMSO-d₆): δ 9.74 (s, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.77 (d, J = 3.8 Hz, 1H), 8.45 (s, 1H), 8.39 (d, J = 8.7 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 7.94 (d, J = 7.6 Hz, 1H), 7.83 (s, 2H), 7.72-7.56 (m, 2H), 7.52- 7.27 (m, 3H), 7.03 (d, J = 7.9 Hz, 1H), 5.60 (s, 2H), 3.85 (s, 3H). DMSO 95 Method BE 445.1 (M + 1) Method B (NH₄HCO₃) 1747

¹H-NMR (400 MHz, DMSO-d₆): δ 9.76 (s, 1H), 8.91 (d, J = 6.4 Hz, 1H), 8.79 (s, 1H), 8.41 (s, 1H), 8.30-8.23 (m, 2H), 7.92 (d, J = 8.0 Hz, 1H), 7.83 (s, 2H), 7.65 (d, J = 3.6 Hz, 2H), 7.55-7.49 (m, 2H), 7.40 (s, 1H), 5.61 (s, 2H). DMSO 95 Method BE 451.0, 452.0, (M + 1) Method B (NH₄HCO₃) 1748

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.73 (s, 1H), 9.05-9.04 (m, 1H), 8.36-8.85 (m, 1H), 8.42- 8.38 (m, 2H), 8.19 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.82-7.81 (m, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.58 (dd, J = 8.0, 1.6 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.41-7.36 (m, 2H), 7.07 (dd, J = 8.0, 2.0 Hz, 1H), 4.57-4.46 (m, 2H), 4.06-4.03 (m, 1H), 3.20-3.01 (m, 2H), 3.88 (s, 3H), DMSO 95 Method BE 541.0, 543.0 (M + 1) Method B (NH₄HCO₃) 1749

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.68 (s, 1H), 8.83 (d, J = 8.0 Hz, 1H), 8.76 (s, 1H), 8.39- 8.37 (m, 2H), 8.17 (d, J = 10.0 Hz, 1H), 7.63- 7.31 (m, 9H), 7.06 (dd, J = 8.4, 2.0 Hz, 1H), 4.56-4.45 (m, 2H), 4.03-3.99 (m, 1H), 3.88 (s, 3H), 3.19-2.97 (m, 2H). DMSO 95 Method BE 472.9 (M + 1) Method B (NH₄HCO₃) 1750

¹H-NMR (400 MHz, DMSO-d₆): δ 9.74 (d, J = 8.4 Hz, 1H), 8.89 (dt, J = 8.4, 1.6 Hz, 1H), 8.78 (dd, J = 4.4,1.2 Hz, 1H), 8.46 (d, J = 1.6 Hz, 1H), 8.41. (dd, J = 8.8, 1.6 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 7.97 (s, 1H), 7.88 (s, 2H), 7.65-7.62 (m, 1H), 7.48-7.44 (m, 1H),7.41-7.37 (m, 2H), 7.04 (dd, J = 8.0, 1.6 Hz, 1H), 5.59 (s, 2H), 3.86 (s, 3H). DMSO 95 Method BE 479.0 (M + 1) Method B (NH₄HCO₃) 1751

¹H-NMR (400 MHz, DMSO-d₆): δ 9.74 (s, 1H), 8.89 (d, J = 8.4 Hz, 1H), 8.78 (d, J = 4.4 Hz, 1H), 8.46 (s, 1H), 8.41 (d, J = 9.2 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 7.91-7.87 (m, 1H), 7.77-7.62 (m, 3H), 7.48-7.37 (m, 3H), 7.03 (d, J = 6.4 Hz, 1H), 5.58 (s, 2H), 3.86 (s, 3H). DMSO 95 Method BE 463.1 (M + 1) Method B (NH₄HCO₃)

N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (1.51 g, 3.87 mmol) was dissolved in CH₂ Cl₂/MeOH (20 mL/20 mL). Methanesulfonic acid (0.251 mL, 3.87 mmol) was added to the solution. The volatiles were evaporated in vacuo. The resultant residue was crystallized from EtOH (30 mL) to give 1.35 g of N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine methanesulfonate as a light yellow powder (72%), LCMS m/z=391 (M+1) (Method D) (Retention time=1.91 min). ¹H NMR (300 MHz, DMSO) δ 9.52 (s, 1H), 9.01-8.83 (m, 2H), 8.75 (s, 1H), 8.58 (s, 1H), 8.09 (d, J=7.2 Hz, 1H), 8.03-7.85 (m, 2H), 7.83-7.68 (m, 1H), 7.59-7.43 (m, 1H), 7.33 (t, J=7.91 Hz, 1H), 2.31 (s, 3H), 1.66 (s, 9H).

N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (1.22 g, 3.12 mmol) was dissolved in CH₂Cl₂ 1/MeOH (20 mL/20 mL). Fumaric acid (0.363 g, 3.12 mmol) was added to the solution. The mixture was sonicated until fumaric acid was dissolved. Then, the volatiles were evaporated in vacuo. The resultant solid was washed with MeOH and dried to give 1.28 g of N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine ½ fumarate as a light yellow powder (91%). LCMS m/z=391 (M+1) (Method D) (Retention time=1.95 min). ¹H NMR (300 MHz, DMSO) δ 13.14 (s, 1H), 9.59 (s, 1H), 8.82-8.65 (m, 2H), 8.57 (s, 1H), 7.89 (d, J=8.7 Hz, 1H), 7.82 (d, J=8.7 Hz, 1H), 7.79-7.62 (m, 2H), 7.61-7.52 (m, 1H), 7.51-7.38 (m, 1H), 7.28 (t, J=8.61 Hz, 1H), 6.61 (s, 1H), 1.64 (s, 9H).

N-methyl-6-(3-(2-propoxyethoxy)phenyl)-2-(pyridin-3-yl)quinazolin-4-amine fumarate was synthesized in a similar manner to that described N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine fumarate. LCMS m/z=415.5 (M+1) (Method C(NH₄ HCO₃) (Retention time=2.43 min). ¹H NMR (300 MHz, CD₃OD) δ 9.57 (s, 1H), 8.84 (m, 1H), 8.63 (s, 1H), 8.35 (m, 1H), 8.07 (m, 1H), 7.88 (d, J=8.7 Hz, 1H), 7.58 (m, 1H), 7.48-7.24 (m, 4H), 7.00 (m, 1H), 6.74 (s, 1H), 4.36-4.05 (m, 2H), 4.00-3.70 (m, 2H), 3.53 (t, J=6.6 Hz, 2H), 3.29-3.13 (m, 3H), 1.75-1.51 (m, 2H), 0.95 (t, J=7.4 Hz, 3H).

N-methyl-6-(3-(2-propoxyethoxy)phenyl)-2-(pyridin-3-yl)quinazolin-4-amine methanesulfonate was synthesized in a similar manner to that described N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine methanesulfonate. LCMS m/z=415.5 (M+1) (Method C(N_(H)4 HCO₃) (Retention time=2.43 min). ¹H NMR (300 MHz, CD₃OD) δ 9.49 (s, 1H), 9.00-8.72 (m, 1H), 8.53 (s, 1H), 8.29 (m, 1H), 7.99 (d, J=8.7 Hz, 1H), 7.80 (dd, J=8.0, 5.1 Hz, 1H), 7.52-7.25 (m, 3H), 7.02 (m, 1H), 4.38-4.06 (m, 2H), 3.98-3.72 (m, 2H), 3.61-3.48 (m, 2H), 3.42 (d, J=0.6 Hz, 3H), 3.34-3.26 (m, 2H), 2.71 (s, 3H), 1.80-1.47 (m, 2H), 0.96 (t, J=7.4 Hz, 3H).

Biological Testing: STEP46 Biochemical Assays

Serial dilutions of compounds were performed in 100% DMSO and 1 uL of compounds were dispensed into 384-well black polystyrene plates (Corning, N.Y.). Compounds were incubated with 24 uL of buffer containing 50 mM Hepes, 1 mM DTT, 0.02% Brij35, 1 ng/well purified STEP46 enzyme for 30 nm in at room temperature. The reaction was initiated by addition of 25 uL of DiFMUP (6,8-difluoro-4-methylumbelliferyl phosphate) (InVitrogen, CA) with a final concentration of 10 μM and incubated at 27° C. for 90 min. Final DMSO concentration is 2%. Plates were read with florescence intensity at excitation/emission of 360/460 nm using a PheraStar plate reader (BMG Labtech, NC).

Data Analysis

Data were expressed as percentage (%) inhibition of enzyme activity. 0% inhibition is defined as the RFUs (relative fluorescence units) in the absence of compounds and 100% inhibition is defined as RFUs in the absence of STEP46 enzyme. IC₅₀ values of compounds with inhibitory activity against STEP46 were determined by GraphPad Prism (version 4.03) using four parameter logistic equation. Some compounds act as activators. For compounds showing STEP46 enzymatic activation, data are represented as percentage of inhibition but with negative values at three representative concentrations (25, 50 and 100 uM).

Compounds 1-1760 show either inhibition or activation>50% at 100 uM, 50 or 25 uM.

STEP IC50 Number (μM) 73 ++ 296 ++ 297 + 300 + 303 ++ 306 + 309 ++ 312 +++ 313 +++ 314 ++ 315 ++ 316 +++ 317 ++ 318 ++ 320 ++ 322 + 325 +++ 326 ++ 327 ++ 329 +++ 330 ++ 332 +++ 333 +++ 334 ++ 335 +++ 336 +++ 337 +++ 339 ++ 341 ++ 342 ++ 343 + 344 ++ 346 ++ 348 ++ 352 ++ 390 ++ 391 ++ 392 ++ 393 ++ 396 ++ 399 +++ 400 ++ 403 ++ 407 ++ 412 +++ 415 ++ 416 +++ 418 ++ 419 +++ 421 + 423 ++ 424 ++ 425 ++ 426 + 427 ++ 428 ++ 429 +++ 430 +++ 431 +++ 433 ++ 434 ++ 435 +++ 436 ++ 437 ++ 439 +++ 440 ++ 441 ++ 442 +++ 443 +++ 444 +++ 445 +++ 446 ++ 447 ++ 448 +++ 449 ++ 451 +++ 452 +++ 453 +++ 454 ++ 455 ++ 456 +++ 457 ++ 458 +++ 459 +++ 460 ++ 461 ++ 463 ++ 466 ++ 467 ++ 468 +++ 470 ++ 471 ++ 472 ++ 473 ++ 474 ++ 629 ++ 630 ++ 631 ++ 632 +++ 633 ++ 634 ++ 635 +++ 636 + 637 ++ 638 ++ 639 +++ 640 ++ 641 +++ 642 +++ 643 +++ 644 ++ 645 ++ 647 ++ 648 ++ 649 ++ 650 +++ 651 +++ 652 +++ 653 +++ 655 +++ 656 +++ 657 +++ 658 ++ 660 +++ 661 +++ 662 +++ 663 +++ 664 ++ 665 ++ 666 +++ 667 +++ 668 +++ 669 +++ 670 +++ 671 ++ 672 ++ 673 ++ 674 ++ 675 +++ 676 +++ 677 + 678 ++ 679 +++ 680 ++ 681 ++ 682 ++ 683 ++ 684 ++ 685 +++ 686 +++ 687 +++ 688 +++ 689 +++ 690 ++ 691 +++ 692 +++ 693 +++ 694 +++ 695 +++ 696 +++ 697 ++ 698 +++ 699 +++ 700 +++ 701 ++ 702 +++ 703 +++ 704 +++ 705 +++ 706 +++ 707 +++ 708 ++ 709 +++ 846 ++ 847 +++ 884 + 888 + 889 ++ 896 + 899 ++ 900 ++ 901 ++ 923 ++ 932 ++ 933 ++ 934 +++ 962 +++ 1124 +++ 1125 ++ 1126 ++ 1140 +++ 1141 +++ 1142 ++ 1143 ++ 1144 ++ 1145 ++ 1146 ++ 1148 ++ 1150 + 1151 ++ 1152 ++ 1153 ++ 1155 ++ 1157 ++ 1158 ++ 1159 ++ 1160 ++ 1161 ++ 1165 +++ 1167 ++ 1168 ++ 1171 ++ 1172 ++ 1173 + 1176 ++ 1178 ++ 1180 ++ 1181 ++ 1182 ++ 1183 ++ 1184 ++ 1185 ++ 1186 ++ 1187 +++ 1188 ++ 1191 ++ 1192 ++ 1193 ++ 1194 +++ 1198 ++ 1200 ++ 1201 ++ 1202 ++ 1203 ++ 1204 + 1205 ++ 1206 ++ 1208 + 1211 + 1212 ++ 1213 ++ 1214 ++ 1215 +++ 1216 +++ 1217 ++ 1218 ++ 1219 ++ 1220 + 1221 + 1222 ++ 1223 +++ 1225 ++ 1226 ++ 1227 ++ 1228 ++ 1229 ++ 1230 ++ 1234 ++ 1237 ++ 1238 ++ 1239 ++ 1248 ++ 1279 ++ 1280 ++ 1281 +++ 1282 ++ 1283 + 1284 ++ 1285 + 1286 ++ 1324 ++ 1327 + 1328 + 1330 + 1332 ++ 1333 + 1334 + 1335 ++ 1336 ++ 1337 ++ 1339 ++ 1340 ++ 1341 ++ 1346 ++ 1348 + 1350 ++ 1351 ++ 1352 + 1353 ++ 1354 ++ 1356 ++ 1357 ++ 1358 ++ 1359 ++ 1360 ++ 1361 + 1362 ++ 1363 ++ 1364 ++ 1365 ++ 1366 ++ 1369 ++ 1370 ++ 1371 ++ 1372 ++ 1373 ++ 1374 ++ 1375 ++ 1376 ++ 1380 ++ 1381 ++ 1382 +++ 1391 + 1395 ++ 1396 ++ 1400 ++ 1401 ++ 1402 ++ 1403 + 1404 + 1406 ++ 1407 ++ 1408 ++ 1409 ++ 1410 ++ 1411 + 1412 ++ 1413 ++ 1414 ++ 1415 + 1416 ++ 1419 ++ 1420 ++ 1422 ++ 1423 + 1424 + 1425 ++ 1430 ++ 1437 ++ 1445 ++ 1446 ++ 1447 + 1448 ++ 1449 + 1450 ++ 1451 ++ 1452 +++ 1453 ++ 1454 + 1455 ++ 1456 ++ 1458 + 1467 ++ 1497 ++ 1516 + 1601 ++ 1611 ++ 1680 ++ Key + IC₅₀ > 10 uM ++ IC₅₀ 1-10 uM +++ IC₅₀ < 1 uM

Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the invention. Accordingly, the foregoing description and drawings are by way of example only. 

1. A compound of formula (I):

or a salt thereof, wherein: A is CR⁴ or N; B is aryl, cyclyl or a 5- or 6-membered heteroaryl; m is 0, 1, 2, 3, 4 or 5; E is aryl or a 5-membered heteroaryl; n is 0, 1, 2, 3 or when E is aryl, n is 0, 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3; L is NR⁵, S, O or a direct bond; one of X and Z is N and the other is CH; p is 0, 1, 2, 3 or 4; each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, silylalkoxy, silylalkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring; R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; R⁵ is hydrogen; or when nm is not 0, R⁵ and one R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring; each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁷; each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁹; each R⁹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); Y is O or S; q is 1 or 2 and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy or silylalkoxyalkyl; wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; and when B is phenyl, R² is not

a compound of formula (II):

or a salt thereof, wherein: L is CR⁴R⁵, O, C(O), NR⁶C(O) or NR⁷; A is N; each X¹, X², X³, X⁴ and X⁵ is independently CH or N, provided that at least two of X¹, X², X³, X⁴ and X⁵ are N; n is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl or heterocyclylalkyl, each of which is optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ is optionally taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached, to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰; each R² and R³ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each of which is optionally substituted with 1-3 R¹¹ each R⁴, R⁵, R⁶ and R⁷ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(Y)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein, two R⁹, two R¹⁰ or two R¹¹ is optionally taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring; R¹² is —OR^(d); Y is O or S; q is 1 or 2 and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl and a compound of formula (III):

or a salt thereof, wherein: A is CH or N; L is O, a direct bond or NR⁶; one of X¹, X², X³, X⁴ and X⁵ is N and the others are CH; m is 1, 2 or 3; n is 1, 2, 3 or 4; R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, heteroaryl, heteroarylalkyl, arylalkyl, —C(Y)R^(e), cyclyl, cyclylalkyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷; R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹; each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰; R⁶ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R¹¹; each R⁷, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷, two R⁹ or two R¹⁰ are optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring; each R¹¹ and R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR, —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹³; R¹³ is independently C₁-C₈ alkyl, haloalkyl, halo, heterocyclyl, cyclyl, oxo or —C(Y)NR^(b)R^(b′); Y is independently O or S; q is 1 or 2; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, haloalkyl alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; with proviso R⁹ is not


2. The compound according to claim 1 represented by general formula (I) or a salt thereof, wherein: A is CR⁴ or N; B is aryl, cyclyl or a 5- or 6-membered heteroaryl; m is 0, 1, 2, 3, 4 or 5; n is 0, 1, 2, 3 or 4; E is aryl or a 5-membered heteroaryl; when E is aryl, n is 0, 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3; L is NR⁵, S, O or a direct bond; one of X and Z is N and the other is CH; p is 0, 1, 2, 3 or 4; each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, silylalkoxy, silylalkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring; R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; R⁵ is hydrogen; or when nm is not 0, R⁵ and one R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring; each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁷; each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁹; each R⁹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); Y is O or S; q is 1 or 2; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy or silylalkoxyalkyl; wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; and when B is phenyl, R² is not


3. The compound according to claim 2 represented by general formula (I) or a salt thereof, wherein: A is CH or N; B is aryl, cyclyl or a 5- or 6-membered heteroaryl; m is 0, 1, 2, 3 or 4; E is aryl or a 5-membered heteroaryl; n is 0, 1 or 2; when E is aryl, n is 0, 1 or 2 and when E is a 5-membered heteroaryl, n is 0 or 1; p is 0, 1 or 2; each R¹, R² and R¹ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring; each R⁶ is independently C₁-C₈ alkyl, heterocyclyl, heterocyclylalkyl, hydroxyalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁷; each R¹ is oxo; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, haloalkyl, dialkylaminoalkyl, hydroxyalkyl or alkoxyalkyl.
 4. The compound according to claim 3 represented by general formula (I) or a salt thereof, wherein: B or two R¹ and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroquinoxalinyl, tetrahydroisoquinolinyl, tetrahydroquinoinolinyl, dihydroquinolinyl, quinolyl, isoquinolinyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, dihydroisobenzofuranyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, dihydrocyclopentathiophenyl, tetrahydrobenzothiophenyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyrrolyl or pyridyl; E is phenyl, thienyl or pyrrolyl; when E is phenyl, n is 1 or 2; and when E is thienyl, n is 0 or 1; each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyrrolyl, oxadiazolyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, oxazolyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidyl, pyrrolidinyl, morpholinyl, dioxolanyl, phenylalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperidylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, oxo, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; each R⁶ is independently C₁-C₈ alkyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, morpholinylalkyl, dialkylaminoalkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, oxo, —CN, —NO), —C(O)OR^(a), —NR^(c)C(Y)R^(c′), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), alkoxyalkyl, —OR^(d) or —C(Y)R^(e); and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, pyridyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, furylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, thiazolylalkyl, pyrazolylalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolylalkyl, dihydrobenzodioxinylalkyl, benzothienylalkyl, C₃-C₈ cycloalkylalkyl, oxazolidinylalkyl, haloalkyl or alkoxyalkyl.
 5. The compound according to claim 3 represented by general formula (I) or a salt thereof, wherein: B or two R¹ and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroquinoxalinyl, tetrahydroisoquinolyl, tetrahydroquinolinyl, dihydroquinolyl, quinolyl, isoquinolyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, dihydroisobenzofuranyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, dihydrocyclopentathiophenyl, tetrahydrobenzothienyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyrrolyl or pyridyl; E is phenyl, thienyl or pyrrolyl; when E is phenyl, n is 0, 1 or 2; and when E is thienyl, n is 0 or 1; each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidyl, pyrrolidinyl, morpholinyl, dioxolanyl, phenylalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperidyl alkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, oxo, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —OC(O)NR^(b)R^(b′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; each R⁶ is independently C₁-C₈ alkyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, morpholinylalkyl, dialkylaminoalkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, oxo, —CN, —NO₂—C(O)OR^(a), —NR^(c)C(Y)R^(c′), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), alkoxyalkyl, —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁷; R⁷ is oxo; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₁-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, pyridyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, furylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, thiazolylalkyl, pyrazolylalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolilalkyl, dihydrobenzodioxinylalkyl, benzothienylalkyl, C₃-C₈ cycloalkylalkyl, oxazolidinylalkyl, haloalkyl or alkoxyalkyl.
 6. The compound according to claim 5 represented by general formula (I) or a salt thereof, wherein: R¹ is C₁-C₈ alkyl, phenyl, thienyl, pyrrolyl, oxazolyl, C₃-C₈ cycloalkyl, dioxolanyl, phenylalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; R² is C₁-C₈ alkyl, C₁-C₈ alkynyl, phenyl, thienyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, pyrrolidinyl, morpholinyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperiridylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁶; R³ is C₁-C₈ alkyl, halo, haloalkyl, —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R⁶.
 7. The compound according to claim 4 or 6 represented by general formula (I) or a salt thereof, wherein: R¹ is C₁-C₈ alkyl, phenyl, thienyl, pyrolyl, oxazolyl, oxazolyl, C₃-C₈ cycloalkyl, dioxolanyl, phenylalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); R² is C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperiridinylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —OR^(d), —C(Y)R^(e) or —S(O)_(q)R^(f); R³ is C₁-C₈ alkyl, halo, haloalkyl, —NR^(b)R^(b′) or —OR^(d).
 8. The compound according to claim 7 represented by general formula (I) or a salt thereof, wherein: B or two R¹ and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroisoquinolyl, tetrahydroquinolinyl, dihydroquinolyl, quinolyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, tetrahydrobenzothienyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, thiadiazolyl or pyridyl; m is 1, 2, 3 or 4; R¹ is C₁-C₈ alkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), or —S(O)_(q)R^(f); R² is C₁-C₈ alkyl, C₃-C₈ cycloalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(Y)R^(e) or —S(O)_(q)R^(f); each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolilalkyl, dihydrobenzodioxinylalkyl, C₃-C₈ cycloalkylalkyl, haloalkyl or alkoxyalkyl.
 9. The compound according to claim 1 represented by general formula (II) or a salt thereof, wherein: L is CR⁴R⁵, O, C(O), NR⁶C(O) or NR⁷; A is N; each X¹, X², X³, X⁴ and X⁵ is independently CH or N, provided that at least two of X¹, X², X³, X⁴ and X⁵ are N; n is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl or heterocyclylalkyl, each of which is optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ is optionally taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰; each R² and R³ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹¹; each R⁴, R⁵, R⁶ and R⁷ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)N^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁸, two R⁹, two R¹⁰ or two R¹¹ is optionally taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring; R¹² is —OR^(d); Y is O or S; q is 1 or 2; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl.
 10. The compound according to claim 9 represented by general formula (II) or a salt thereof, L is NR⁷; n is 0, 1 or 2; p is 0; R¹ is C₁-C₈ alkyl, aryl or heteroaryl; each R² and R³ is independently hydrogen, C₁-C₈ alkyl, aryl, halo, heterocyclylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹; R⁷ is hydrogen; and each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, heterocyclyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e); Y is O; each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, cyclyl, heterocyclyl, aryl or heteroaryl.
 11. The compound according to claim 10 represented by general formula (II) or a salt thereof, wherein: R¹ is C₁-C₈ alkyl, phenyl or benzodioxolyl; each R² and R³ is independently hydrogen, C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c), —NR^(b)R^(b′) or —OR^(d); R⁹ is independently C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e); and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, tetrahydropyranyl, phenyl or pyridyl.
 12. The compound according to claim 10 represented by general formula (II) or a salt thereof, wherein: R¹ is C₁-C₈ alkyl, phenyl or benzodioxolyl; each R² and R³ is independently hydrogen, C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹; each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e); and each R^(a), R^(b)R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, tetrahydropyranyl, phenyl or pyridyl.
 13. The compound according to claim 12 represented by general formula (II) or a salt thereof, wherein: R² is C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹; R³ is hydrogen; R⁹ is halo, haloalkoxy, —CN, —C(O)OR^(a) or —C(Y)NR^(b)R^(b′); and R¹¹ is C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, —CN, —OR^(d) or —C(Y)R^(e);
 14. The compound according to claim 11 or 13 represented by general formula (II) or a salt thereof, wherein: R² is C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d); R³ is hydrogen; and R⁹ is halo, haloalkoxy, —CN, —C(O)OR^(a) or —C(Y)NR^(b)R^(b′).
 15. The compound according to claim 1 represented by general formula (III) or a salt thereof, wherein: A is CH or N; L is O, a direct bond or NH; one of X¹, X², X³, X⁴ and X⁵ is N and the others are CH; m is 1, 2 or 3; n is 1, 2, 3 or 4; R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, heteroaryl, heteroarylalkyl, arylalkyl, —C(Y)R^(e), cyclyl, cyclylalkyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷; R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹; each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰; each R⁷, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷ or two R⁹ are optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring; R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹³; R¹³ is independently C₁-C₈ alkyl, haloalkyl, halo, heterocyclyl, cyclyl, oxo or —C(Y)NR^(b)R^(b′); Y is O or S; q is 1 or 2; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, haloalkyl, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl.
 16. The compound according to claim 15 represented by general formula (III) or a salt thereof, wherein: m is 1; n is 1; R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, heteroaryl, heterocyclyl, arylalkyl, cyclylalkyl, heteroarylalkyl, alkoxyalkyl, hydroxyalkyl or —C(O)R^(e), each of which is optionally substituted with 1-3 R⁷; R² is aryl, heteroaryl or benzofuryl, each of which is optionally substituted with 1-5 R⁹; each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d); R⁶ is hydrogen or C₁-C₈ alkyl; each R⁷ and R⁹ is independently C₁-C₈ alkyl, aryl, heteroaryl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; R¹² is independently C₁-C₈ alkyl, oxo, halo, haloalkyl, —CN, —C(O)NR^(b)R^(b′) or —C(O)R^(e) each of which is optionally substituted with 1-3 R¹³; R¹³ is independently C₁-C₈ alkyl, halo or heterocyclyl; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, cyclyl, heterocyclyl, arylalkyl, alkoxyalkyl, heterocyclylalkyl, heteroarylalkyl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.
 17. The compound according to claim 16 represented by general formula (III) or a salt thereof, wherein: R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, thiazolidinyl isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷; R² is phenyl, naphthyl, benzofuryl, indazolyl, benzothienyl, pyridyl, pyrimidinyl, dihydrobenzodioxinyl, benzodioxolyl, benzoimidazolyl, isoxazolyl, pyrazolyl, indolinyl or benzoisoxazolyl, each of which is optionally substituted with 1-5 R⁹; each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d); R⁶ is hydrogen or C₁-C₈ alkyl; each R⁷ and R⁹ is independently C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.
 18. The compound according to claim 16 represented by general formula (III) or a salt thereof, wherein: R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, furylalkyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, thiazolidinyl, isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷; R² is phenyl, naphthyl, benzofuryl, indazolyl, benzothienyl, pyridyl, pyrimidinyl, dihydrobenzodioxinyl, benzodioxolyl, benzoimidazolyl, isoxazolyl, pyrazolyl, indolinyl or benzisoxazolyl, each of which is optionally substituted with 1-5 R⁹; each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d); R⁶ is hydrogen or C₁-C₈ alkyl; each R⁷ and R⁹ is independently C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; R¹² is independently C₁-C₈ alkyl, oxo, halo, haloalkyl, —CN, —C(O)NR^(b)R^(b′) or —C(O)R^(e), each of which is optionally substituted with 1-3 R¹³; R¹³ is independently C₁-C₈ alkyl, halo or pyrrolidinyl; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.
 19. The compound according to claim 18 represented by general formula (III) or a salt thereof, wherein: A is N; R³ is hydrogen, C₁-C₈ alkyl, halo, haloalkyl, or —OR^(d); R⁴ is hydrogen, C₁-C₈ alkyl, halo, or —OR^(d); R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d) each of which is optionally substituted with 1-3 R¹²; R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, tetrahydrofurylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.
 20. The compound according to claim 17 or 19 represented by general formula (III) or a salt thereof, wherein: A is N; R³ is hydrogen, C₁-C₈ alkyl, halo, haloalkyl, or —OR^(d); R⁴ is hydrogen, C₁-C₈ alkyl, halo, or —OR^(d); R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d); R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, dihydrobenzoxazinylalkyl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.
 21. The compound according to claim 20 represented by general formula (III) or a salt thereof, wherein: R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, furylalkyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷; R² is phenyl, which is optionally substituted with 1-5 R⁹; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, pyrrolidinyl, morpholinyl, tetrahydropyranyl, alkoxyalkyl, morpholinylalkyl, tetrahydropyranylalkyl, pyridylalkyl, thiazolylalkyl, pyrrolylalkyl, tetrahydrofuryl, alkylaminoalkyl or phenyl.
 22. A pharmaceutical composition comprising the compound according to any one of claims 1 to 21 or a salt thereof as an active ingredient and a pharmaceutically acceptable carrier.
 23. The pharmaceutical composition according to claim 22 for preventing or treating central nervous system diseases.
 24. The pharmaceutical composition according to claim 23 for treating or preventing central nervous system disorders selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar II type disorder; depression; endogenous depression; major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; agoraphobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; generalized anxiety disorder; acute stress disorder; hysteria; somatization disorder; conversion disorder; pain disorder; hypochondriasis; factitious disorder; dissociative disorder; sexual dysfunction; sexual desire disorder; sexual arousal disorder; erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep disorder; adjustment disorder; alcohol abuse; alcohol intoxication; drug addiction; stimulant intoxication; narcotism; anhedonia; iatrogenic anhedonia; anhedonia of a psychic or mental cause; anhedonia associated with depression; anhedonia associated with schizophrenia; delirium; cognitive impairment; cognitive impairment associated with Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases; cognitive impairment caused by Alzheimer's disease; Parkinson's disease and associated neurodegenerative diseases; cognitive impairment of schizophrenia; cognitive impairment caused by refractory, intractable or chronic schizophrenia; vomiting; motion sickness; obesity migraine; pain (ache); mental retardation; autism disorder (autism); Tourette's disorder; tic disorder; attention-deficit/hyperactivity disorder; conduct disorder; and Down's syndrome.
 25. A process for producing a pharmaceutical composition comprising mixing a compound of the formula (I), (II), or (III) or a salt thereof according to any one of claims 1 to 21 with a pharmaceutically acceptable carrier.
 26. Use of a compound of the formula (I), (II) or (III) or a salt thereof according to any one of claims 1 to 21 as a drug.
 27. Use of the compound according to any one of claims 1 to 21 represented by general formula (I), (II) or (III) or a salt thereof as a STEP inhibitor.
 28. A method of treating a disorder that would benefit by the modulation of STEP (e.g., by activation of inhibition of STEP) in a subject, the method comprising administering to a compound of formula (I), (II) or (III) or a salt thereof according to any one of claims 1 to
 21. 29. The method of claim 28, wherein the disorder is schizophrenia.
 30. The method of claim 28, wherein the disorder is cognitive deficit.
 31. The method of claim 28, wherein the compound of formula (I), (II) or (III) is administered in combination with an additional therapeutic agent.
 32. The method of claim 28, wherein the additional therapeutic agent is an atypical antipsychotic.
 33. The method of claim 28, wherein the additional therapeutic agent is selected from the group consisting of aripiprazole, clozapine, ziprasidone, risperidone, quetiapine, olanzapine, amisulpride, asenapine, iloperidone, melperone, paliperidone, perospirone, sertindole and sulpiride.
 34. The method of claim 28, wherein the additional therapeutic agent is a typical antipsychotic.
 35. The method of claim 28, wherein the additional therapeutic agent is selected from the group consisting of haloperidol, molindone, loxapine, thioridazine, molindone, thiothixene, pimozide, fluphenazine, trifluoperazine, mesoridazine, chlorprothixene, chlorpromazine, perphenazine, triflupromazine and zuclopenthixol.
 36. A kit comprising a composition comprising a compound of formula (I), (II), or (III) or a salt thereof according to anyone of claims 1 to 21 and an acceptable carrier.
 37. A kit comprising a pharmaceutical composition comprising a compound of formula (I), (II), or (III) or a salt thereof according to any one of claims 1 to 21 and a pharmaceutically acceptable carrier.
 38. A compound of formula (IV):

wherein: A is CH, CR⁴ or N; B is aryl or a 5- or 6-membered heteroaryl; m is 0, 1, 2, 3, 4 or 5; E is aryl or a 5-membered heteroaryl; when E is aryl, n is 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3; L is NR⁵ or O; one of X and Z is N and the other is CH; p is 0, 1, 2, 3 or 4; each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring; R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; R⁵ is hydrogen; or when m is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring; each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)N^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷; each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR, —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each Y is independently O or S; q is 1 or 2; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶, wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring; or a pharmaceutically acceptable derivative or prodrug thereof, wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; when B is phenyl, R² is not

and where in the compound is not:


39. A compound of formula (V):

wherein: L is CR⁴R⁵, O, C(O), NR⁶C(O), or NR⁷; A is CR⁸, CH or N; each X¹, X², X³, X⁴ and X⁵ is independently CH or N, provided that at least two of X¹, X², X³, X⁴ and X⁵ are N; n is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl or heterocyclylalkyl, each of which may be optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ may optionally be taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached, to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰; each R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each of which is optionally substituted with 1-3 R¹¹, each R⁴, R⁵, R⁶ and R⁷ is independently H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each R⁸, R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally further substituted; wherein two R⁸, two R⁹, two R¹⁰ or two R¹¹ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring; each Y is independently O or S; q is 1 or 2; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁸, or a pharmaceutically acceptable derivative or prodrug thereof.
 40. A compound of formula (VI):

wherein: A is CR⁵, CH or N; L is O or NR⁶; 1, 2 or 3 of X¹, X², X³, X⁴ and X⁵ are N and the others are CH; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷; or when L is NR⁶, R¹ or R⁷ may be taken together with R⁶ and the atoms to which they are attached to form a heterocyclyl or heteroaryl ring that is optionally substituted with 1-3 R⁸; R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹; each R³, R⁴ and R⁵ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹¹; R⁶ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R¹¹; each R⁷, R⁸, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷, two R⁸, two R⁹ or two R¹⁰ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring; each R¹¹ and R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), NR^(c)SO₂R^(c′), NR^(c)(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each Y is independently O or S; q is 1 or 2; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁷; or a pharmaceutically acceptable derivative or prodrug thereof, wherein when R¹ is cyclopropyl, R⁹ is not:


41. A compound described herein. 